var images_info;if (!images_info) images_info =[]; images_info["77"]={"77000":{"type":"graphic_diagnosticimage","displayName":"Tracheal wall involvement in GPA","title":"Tracheal wall involvement in granulomatosis with polyangiitis (Wegener's)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheal wall involvement in granulomatosis with polyangiitis (Wegener's)</div><div class=\"cntnt\"><img style=\"width:414px; height:243px;\" src=\"images/PULM/77000_Wegeners_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomographic scan shows narrowing and circumferential wall thickening of trachea as well as a left upper lobe pulmonary nodule.</div><div id=\"graphicVersion\">Graphic 77000 Version 4.0</div></div></div>"},"77001":{"type":"graphic_table","displayName":"Imaging studies shoulder","title":"Imaging studies for the evaluation of shoulder pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Imaging studies for the evaluation of shoulder pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Imaging modality</td> <td class=\"subtitle1\">Indications</td> <td class=\"subtitle1\">Limitations</td> </tr> <tr> <td>Plain film radiography</td> <td>First imaging modality for all shoulder pathology<br /> <br /> Often the only imaging modality needed for:<br /> Trauma<br /> Calcific tendonitis<br /> Arthritis</td> <td>Detection of:<br /> Bone bruise<br /> Subtle fractures<br /> Soft tissue pathology</td> </tr> <tr> <td>CT</td> <td>Preoperative evaluation of intra-articular fractures<br /> Post arthroplasty evaluation</td> <td>Limited soft tissue evaluation<br /> Detection of bone marrow edema</td> </tr> <tr> <td>MRI</td> <td>Best initial modality for evaluation of soft tissue of the shoulder (rotator cuff, biceps, tendons, bursa, labrum)<br /> Evaluation of bone marrow</td> <td>Lower sensitivity for evaluation of shoulder instability/labral tear compared to MRA</td> </tr> <tr> <td>Bone scan</td> <td>Infection after arthroplasty<br /> Suspected metastases</td> <td>Lack of anatomic localization and detail</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Arthrography</td> </tr> <tr> <td class=\"sublist1\">Conventional</td> <td class=\"sublist_other\">Diagnosis and treatment of frozen shoulder (adhesive capsulitis)</td> <td class=\"sublist_other\">Invasive</td> </tr> <tr> <td class=\"sublist1\">MR arthrography</td> <td class=\"sublist_other\">Procedure of choice for evaluating shoulder instability/labral tear<br /> High suspicion of rotator cuff tear with normal MRI</td> <td class=\"sublist_other\">Invasive</td> </tr> <tr> <td class=\"sublist1\">CT arthrography</td> <td class=\"sublist_other\">Rotator cuff tear, when MRI is not available or is contraindicated<br /> Shoulder instability/labral tear when MR arthrography is not available or is contraindicated</td> <td class=\"sublist_other\">Invasive<br /> Lower sensitivity for evaluation of shoulder instability/labral tear compared to MR arthrography</td> </tr> <tr> <td>Ultrasonography</td> <td>Evaluation of:<br /> Rotator cuff tendons<br /> Biceps tendon<br /> Calcific tendonitis<br /> Subacromial space<br /> Muscle<br /> <br /> Interventional therapeutic procedures</td> <td>Not widely used or readily available in the United States<br /> Highly operator dependent<br /> Limited evaluation of very small or very large (&#62;3 cm) tears and for partial thickness tears<br /> Limited evaluation of the labrum and bony structures</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; MR arthrography: magnetic resonance arthrography; CT arthrography: computed tomography arthrography.</div><div id=\"graphicVersion\">Graphic 77001 Version 2.0</div></div></div>"},"77002":{"type":"graphic_picture","displayName":"Disseminated granuloma annulare - annular lesions on leg","title":"Disseminated granuloma annulare","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disseminated granuloma annulare</div><div class=\"cntnt\"><img style=\"width:432px; height:376px;\" src=\"images/DERM/77002_Disseminated_granuloma_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 55-year-old patient presented with disseminated granuloma annulare in a brightly erythematous annular and arcuate pattern demonstrating complete central clearing. Scores of similar lesions were present on the trunk and extremities sparing the face, palms, and soles.</div><div id=\"graphicVersion\">Graphic 77002 Version 2.0</div></div></div>"},"77003":{"type":"graphic_diagnosticimage","displayName":"Tracheobronchopathia osteochondroplastica 1","title":"Tracheobronchopathia osteochondroplastica","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheobronchopathia osteochondroplastica</div><div class=\"cntnt\"><img style=\"width:408px; height:540px;\" src=\"images/PULM/77003_Tracheobronch_osteochondr_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The computed tomographic (CT) scan of the proximal mainstem bronchi demonstrates corrugation and polypoid projections into the airways lumen in a patient with tracheobronchopathia osteochondroplastica.</div><div id=\"graphicVersion\">Graphic 77003 Version 2.0</div></div></div>"},"77004":{"type":"graphic_figure","displayName":"Balamuthia life cycle","title":"<EM>Balamuthia </EM>life cycle","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\"><EM>Balamuthia </EM>life cycle</div><div class=\"cntnt\"><img style=\"width:622px; height:368px;\" src=\"images/ID/77004_Balamuthia_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Balamuthia mandrillaris</EM> has only recently been isolated from the environment and has also been isolated from autopsy specimens of infected humans and animals. <EM>B. mandrillaris</EM> has only two stages, cysts <STRONG>(1)</STRONG> and trophozoites <STRONG>(2)</STRONG>, in its life cycle. No flagellated stage exists as part of the life cycle. The trophozoites replicate by mitosis (nuclear membrane does not remain intact) <STRONG>(3)</STRONG>. The trophozoites are the infective forms, although both cysts and trophozoites gain entry into the body <STRONG>(4)</STRONG> through various means. Entry can occur through the nasal passages to the lower respiratory tract <STRONG>(5)</STRONG> or ulcerated or broken skin <STRONG>(6)</STRONG>. When <EM>B. mandrillaris</EM> enters the respiratory system or through the skin, it can invade the central nervous system by hematogenous dissemination, causing granulomatous amebic encephalitis <STRONG innerHtml>(7)</STRONG>, disseminated disease <STRONG>(8)</STRONG>, or skin lesions <STRONG>(9)</STRONG> in individuals who are immune competent as well as those with compromised immune systems. <EM>B. mandrillaris</EM> cysts and trophozoites are found in tissue.</div><div class=\"graphic_footnotes\">* Results in granulomatous amebic encephalitis <STRONG>(7)</STRONG>, disseminated disease <STRONG>(8)</STRONG>, or skin lesions <STRONG>(9)</STRONG> in individuals who are immune competent as well as those with compromised immune systems.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Parasites: Balamuthia. Available at: <a href=\"http://www.cdc.gov/parasites/balamuthia/biology.html\" target=\"_blank\">http://www.cdc.gov/parasites/balamuthia/biology.html</a>.</div><div id=\"graphicVersion\">Graphic 77004 Version 3.0</div></div></div>"},"77006":{"type":"graphic_diagnosticimage","displayName":"Extensive pulmonary TB","title":"Extensive pulmonary tuberculosis in a pre-adolescent child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extensive pulmonary tuberculosis in a pre-adolescent child</div><div class=\"cntnt\"><img style=\"width:372px; height:396px;\" src=\"images/ID/77006_Extensive_pulmonary_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive pulmonary tuberculosis in a pre-adolescent child. There is advanced disease in the left lung, with disease in the right lung occurring, perhaps, via lymphatic spread.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Starke, MD.</div><div id=\"graphicVersion\">Graphic 77006 Version 3.0</div></div></div>"},"77008":{"type":"graphic_picture","displayName":"Peau d orange pattern in NS","title":"Picture showing \"peau d'orange\" pattern in arm of patient with nephrogenic system fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Picture showing \"peau d'orange\" pattern in arm of patient with nephrogenic system fibrosis</div><div class=\"cntnt\"><img style=\"width:396px; height:260px;\" src=\"images/NEPH/77008_Peau_d_orange_pattern_in_NS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The arm from this patient with nephrogenic systemic fibrosis reveals thickening of the skin and erythematous plaques that have coalesced to form a \"peau d'orange\" pattern.</div><div class=\"graphic_reference\">With permission from: Shawn E Cowper, MD.</div><div id=\"graphicVersion\">Graphic 77008 Version 3.0</div></div></div>"},"77009":{"type":"graphic_table","displayName":"High calorie fortifiers PI","title":"Increasing caloric density of beverages and foods for toddlers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Increasing caloric density of beverages and foods for toddlers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Fortifier</td> <td class=\"subtitle1\">Calories</td> <td class=\"subtitle1\">Add to:</td> </tr> <tr> <td>Nonfat dry milk</td> <td>25 kcal/tablespoon</td> <td>Potatoes, ground meats, cereals, pudding, yogurt</td> </tr> <tr> <td>Cheese</td> <td>100 kcal/ounce</td> <td>Vegetables, casseroles, fish</td> </tr> <tr> <td>Sour cream</td> <td>30 kcal/tablespoon</td> <td>Beans, squash, potatoes, gravies, casseroles, salad dressing</td> </tr> <tr> <td>Whipping cream (also called heavy cream)</td> <td>60 kcal/tablespoon</td> <td>Gravies, casseroles, salad dressings, hot chocolate, cereal, potatoes, eggs</td> </tr> <tr> <td>Butter, margarine, oil</td> <td>40 kcal/teaspoon</td> <td>Gravies, mashed potatoes, cereal, rice, pasta, bread, muffins, tomato sauce</td> </tr> <tr class=\"divider_bottom\"> <td>Instant breakfast preparation</td> <td>130 kcal /packet</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Recipes</td> </tr> <tr> <td colspan=\"3\">One jar (4 ounces) strained fruit plus one scoop formula powder*</td> </tr> <tr> <td colspan=\"3\">8 ounces whole milk + 2 tablespoons nonfat dry milk powder = 24 kcal per ounce*</td> </tr> <tr> <td colspan=\"3\">8 ounces whole milk + 3 tablespoons nonfat dry milk powder = 28 kcal per ounce*</td> </tr> <tr> <td colspan=\"3\">4 cups whole milk + 1 cup nonfat dry milk powder = 28 kcal per ounce*<sup>&#182;</sup></td> </tr> <tr> <td colspan=\"3\">Mix 1 cup whole milk, 1 package instant breakfast and 1 cup ice cream in blender (430 kcal)*</td> </tr> <tr> <td colspan=\"3\">Mix one-half cup whole milk and one-half cup \"half-and-half\" to increase calories<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">1 kcal = 1 calorie.<br />* If making any of these changes causes your child to have diarrhea, stop and call your pediatrician.<br />&#182; Can be used in cooking (eg, mashed potatoes), baking (eg, muffins, waffles), desserts (eg, pudding, custard), etc.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bithoney WG, Dubowitz H, Egan H. Failure to thrive/growth deficiency. Pediatr Rev 1992; 13:453.</LI>&#xD;&#xA;<LI>Frank D. Failure to thrive. In: Behavioral and Developmental Pediatrics, 2nd ed, Parker S, Zuckerman B, Augustyn M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2005. p.183.</LI>&#xD;&#xA;<LI>Texas Children's Hospital high-calorie, high-protein diet.</LI></OL></div><div id=\"graphicVersion\">Graphic 77009 Version 5.0</div></div></div>"},"77010":{"type":"graphic_table","displayName":"Bow-legs red flags","title":"Clues to pathologic causes of bow-legs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clues to pathologic causes of bow-legs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Severe bowing (&#62;6 cm between the femoral condyles with patella facing forward and medial malleoli together)</td> </tr> <tr> <td>Progressive bowing</td> </tr> <tr> <td>Persistent bowing (after&nbsp;three years)</td> </tr> <tr> <td>Unilateral or asymmetric bowing</td> </tr> <tr> <td>Lateral thrust with ambulation</td> </tr> <tr> <td>Short stature</td> </tr> <tr> <td>History of metabolic disease, lower-extremity fracture, infection, or tumor</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77010 Version 2.0</div></div></div>"},"77013":{"type":"graphic_diagnosticimage","displayName":"Gastroduodenal Crohn UGI","title":"Crohn disease of the upper gastrointestinal tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Crohn disease of the upper gastrointestinal tract</div><div class=\"cntnt\"><img style=\"width:350px; height:288px;\" src=\"images/GAST/77013_Gastroduodenal_Crohns_UGI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper gastrointestinal series in a patient with gastroduodenal Crohn disease shows antral narrowing (small arrow) and two duodenal strictures (large arrows).</div><div class=\"graphic_reference\">Courtesy of the American Gastroenterological Association©. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1-800-432-8433.</div><div id=\"graphicVersion\">Graphic 77013 Version 5.0</div></div></div>"},"77015":{"type":"graphic_table","displayName":"Signs DDH","title":"Clinical findings in infants and children with developmental dysplasia of the hip","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical findings in infants and children with developmental dysplasia of the hip</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Birth to 3 months of age</td> <td class=\"subtitle1\">Unilateral<br /> </td> <td class=\"subtitle1\">Bilateral*</td> </tr> <tr> <td>Hip instability (demonstrated by positive Ortolani or Barlow tests)<sup>&#182;</sup></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Asymmetric leg creases (inguinal, gluteal, thigh, or popliteal)</td> <td class=\"centered\">Yes</td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr> <td>Apparent shortening of femur (Galeazzi, Allis, or Perkins sign)</td> <td class=\"centered\">Yes</td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr> <td class=\"subtitle1\">3 to 12 months of age</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Limitation of hip abduction in 90&#176; of flexion</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Apparent shortening of the femur (Galeazzi, Allis, or Perkins sign)</td> <td class=\"centered\">Yes</td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr> <td>Laterally rotated posture in prone position (ie, increased femoral anteversion)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Marked asymmetry of leg creases (inguinal, gluteal, thigh, or popliteal)</td> <td class=\"centered\">Yes</td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr> <td>Klisic test<sup>&#916;</sup></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td class=\"subtitle1\">After the child begins to walk</td> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>Excessive lordosis</td> <td class=\"centered\"><strong>No</strong></td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Prominent greater trochanter</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Gluteus medius lurch (Trendelenburg gait)</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Positive Trendelenburg sign</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td>Short leg limp, with toe-heel gait and out-toeing</td> <td class=\"centered\">Yes</td> <td class=\"centered\"><strong>No</strong></td> </tr> <tr> <td>Increasing adduction contracture of the hip, with compensatory genu valgum</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*&nbsp;Developmental dysplasia of the hip&nbsp;is bilateral in as many as 37% of&nbsp;cases.&nbsp;<br />&#182; Hip instability is a diagnostic finding.<br />&#916;&nbsp;The Klisic test is performed by placing the index finger on the anterior-superior iliac spine and the middle finger on the greater trochanter. An imaginary line between these points passes through or above the umbilicus in a child without developmental dysplasia of the hip (negative Klisic test). The line passes below the umbilicus if the hip is dislocated (positive Klisic test) because the greater trochanter is in a more superior position.</div><div class=\"graphic_reference\">Adapted from: The hip. In: Tachdjain MO. Clinical Pediatric Orthopedics. The Art of Diagnosis and Principles of Management. Appleton &amp; Lange, Stamford, CT 1997. p.167.</div><div id=\"graphicVersion\">Graphic 77015 Version 4.0</div></div></div>"},"77018":{"type":"graphic_waveform","displayName":"ECG prolonged QT interval tutorial","title":"Single-lead electrocardiogram (ECG) showing a prolonged QT interval","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Single-lead electrocardiogram (ECG) showing a prolonged QT interval</div><div class=\"cntnt\"><img style=\"width:341px; height:101px;\" src=\"images/CARD/77018_ProlongedQTintervaltutor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The corrected QT interval (QTc) is calculated by dividing the QT interval (0.60 seconds) by the square root of the preceding RR interval (0.92 seconds). In this case, the QTc is 0.625 seconds (625 milliseconds).</div><div id=\"graphicVersion\">Graphic 77018 Version 6.0</div></div></div>"},"77019":{"type":"graphic_picture","displayName":"Harvested STSG meshed","title":"Harvested split-thickness skin graft, meshed","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Harvested split-thickness skin graft, meshed</div><div class=\"cntnt\"><img style=\"width:432px; height:289px;\" src=\"images/SURG/77019_Harvested_STSG_meshed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The split-thickness skin graft has been meshed. Note the apertures for tissue expansion.</div><div class=\"graphic_reference\">Courtesy of Jorge Leon-Villapalos, MD, FRCS.</div><div id=\"graphicVersion\">Graphic 77019 Version 2.0</div></div></div>"},"77020":{"type":"graphic_picture","displayName":"Rosacea erythema","title":"Rosacea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rosacea</div><div class=\"cntnt\"><img style=\"width:432px; height:325px;\" src=\"images/DERM/77020_Rosaceaerythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Centrofacial redness with telangiectasias in rosacea.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77020 Version 5.0</div></div></div>"},"77021":{"type":"graphic_diagnosticimage","displayName":"Eumycetoma after treatment","title":"Mycetoma after two years of treatment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mycetoma after two years of treatment</div><div class=\"cntnt\"><img style=\"width:396px; height:323px;\" src=\"images/ID/77021_Eumycetoma_after_2_yrs_rx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">T1-weighted magnetic resonance imaging (MRI) with intravenous gadolinium and fat suppression of a pedal mycetoma after&nbsp;two years of treatment. Bone cavities are clearly delineated by areas of higher signal.</div><div class=\"graphic_reference\">Courtesy of Beatriz Bustamante, MD.</div><div id=\"graphicVersion\">Graphic 77021 Version 4.0</div></div></div>"},"77023":{"type":"graphic_figure","displayName":"Combined immunodeficiency gene defects and functional categories","title":"Human gene defects responsible for severe T cell deficiency","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Human gene defects responsible for severe T cell deficiency</div><div class=\"cntnt\"><img style=\"width:536px; height:758px;\" src=\"images/ALLRG/77023_CID_fxnl_categ_gene_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Genes with mutations that cause monogenic severe T cell immunodeficiency in humans can be intrinsic to the thymic epithelium or to T cells.<br />(A) Genetic defects that are intrinsic to thymic epithelial cells ultimately affect the antigen presentation pathway.<br />(B) Genetic defects that are intrinsic to T cells include those that affect T cell receptor (TCR) signaling, cytokine signaling, somatic recombination, or basic cellular processes. Other genes that are important to these pathways or processes, but have not been linked to severe T cell deficiency in humans are shown in gray.<br />(C) The pie chart shows the proportion of defective genes that affect each of these categories.</div><div class=\"graphic_footnotes\">ADA: adenosine deaminase; ATM: ataxia-telangiectasia mutated; CBL: casitas B-lineage lymphoma; CIITA: class II transactivator; DNMT3β: DNA cytosine-5 methyltransferase 3 beta; ER: endoplasmic reticulum; FOXN1: forkhead box N1; GADS: GRB2-related adaptor protein; IL-2Rγ: interleukin-2 receptor gamma-chain; IL-7: interleukin-7; IL-7Rα: IL-7 receptor alpha-chain; JAK: Janus kinase; LAT: linker for activation of T cells; LIG4: ligase IV; MRE11A: meiotic recombination 11 homologue A; Nibrin: Nijmegen breakage syndrome 1; PNP: purine nucleoside phosphorylase; CRACM1: calcium release-activated calcium modulator 1; RAG: recombination-activating gene; RFX5: regulatory factor X5; RFXANK: RFX-associated ankyrin-containing protein; RFXAP: RFX-associated protein; RMRP: RNA component of mitochondrial RNA-processing endoribonuclease; SLP76: SRC-homology-2-domain-containing leukocyte protein of 76 kDa; SMARCAL1: SWI/SNF-related matrix-associated actin-dependent regulator of chromatin a-like 1; SP110: SP110 nuclear body protein; STAT5B: signal transducer and activator of transcription 5B; TAP: transporter associated with antigen processing; TAPBP: TAP-binding protein; TSAD: T-cell-specific adaptor protein; ZAP70: zeta-chain-associated protein kinase of 70 kDa; DNAPKcs: DNA-dependent protein kinase, catalytic subunit; MST1: mammalian sterile 20-like protein kinase 1; DOCK8: dedicator of cytokinesis 8; MAGT1: magnesium transporter protein 1; STIM1: stromal interaction molecule 1; MHC: major histocompatibility complex; TCR: T cell receptor; ζζ: zeta-zeta chains; δεγ: delta-epsilon-gamma chains; LCK: lymphocyte cell-specific protein tyrosine kinase; VAV: Vav 1 guanine nucleotide exchange factor; CBL-B: casitas B-lineage lymphoma proto-oncogene B; V(D)J: variable, diversity, and joining segments; Cerunnos: also called XRCC4-like factor (XLF), encoded by nonhomologous end-joining factor 1 (NHEJ1); Artemis: encoded by DNA crosslink repair 1C; Ca<SUP>2+</SUP>: ionized calcium.</div><div class=\"graphic_reference\">Adapted by permission from: Macmillan Publishers Ltd: Liston A, Enders A, Siggs OM. Unravelling the association of partial T-cell immunodeficiency and immune dysregulation. Nat Rev Immunol 2008; 8:545. <a href=\"http://www.nature.com/nri/\" target=\"_blank\">www.nature.com/nri/</a>. Copyright &copy; 2008.</div><div id=\"graphicVersion\">Graphic 77023 Version 9.0</div></div></div>"},"77024":{"type":"graphic_picture","displayName":"Apply pin to foreskin2","title":"Apply pin to foreskin 2","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Apply pin to foreskin 2</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/OBGYN/77024_Apply_pin_to_foreskin2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 77024 Version 1.0</div></div></div>"},"77025":{"type":"graphic_figure","displayName":"Penile length of boys aged 0 to 5 years","title":"Penile length of boys aged 0 to 5 years","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Penile length of boys aged 0 to 5 years</div><div class=\"cntnt\"><img style=\"width:584px; height:587px;\" src=\"images/PEDS/77025_Penile_length_0_to_5yrs.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Camurdan AD, Oz MO, Ilhan MN, et al. Current stretched penile length: Cross-sectional study of 1040 healthy Turkish children aged 0 to 5 years. Urology 2007; 70:572. Copyright ©2007 Elsevier.</div><div id=\"graphicVersion\">Graphic 77025 Version 3.0</div></div></div>"},"77028":{"type":"graphic_table","displayName":"US findings antibiotic colitis","title":"Sonographic findings in patients with penicillin-induced segmental hemorrhagic colitis and antibiotic-related pseudomembranous colitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sonographic findings in patients with penicillin-induced segmental hemorrhagic colitis and antibiotic-related pseudomembranous colitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"30%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Segmental hemorrhagic colitis (n=9)</td> <td class=\"subtitle1\">Pseudomembranous colitis (n=10)</td> <td class=\"subtitle1\">p</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"4\">Distribution</td> </tr> <tr> <td class=\"sublist1\">Pancolitis</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">7/10 (70 percent)</td> <td class=\"sublist_other\">&#60;0.01</td> </tr> <tr> <td class=\"sublist1\">Terminal Ileum</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td class=\"sublist1\">Small intestine*</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">-</td> </tr> <tr> <td class=\"sublist1\">Ascending colon</td> <td class=\"sublist_other\">9/9 (100 percent)</td> <td class=\"sublist_other\">7/10 (70 percent)</td> <td class=\"sublist_other\">n.s.</td> </tr> <tr> <td class=\"sublist1\">Transverse colon</td> <td class=\"sublist_other\">3/9 (33 percent)</td> <td class=\"sublist_other\">7/10 (70 percent)</td> <td class=\"sublist_other\">n.s.</td> </tr> <tr> <td class=\"sublist1\">Sigmoid</td> <td class=\"sublist_other\">1/9</td> <td class=\"sublist_other\">10/10 (100 percent)</td> <td class=\"sublist_other\">&#60;0.001</td> </tr> <tr> <td>Bowel wall thickening [mm]</td> <td>8 &#177; 2 (6 - 12)</td> <td>8 &#177; 2 (4 - 10)</td> <td>n.s.</td> </tr> <tr> <td>Longitudinal bowel wall involvement [cm]</td> <td>20 &#177; 7 (15 - 35)</td> <td>all &#62;30 cm</td> <td>-</td> </tr> <tr> <td>Asymmetric bowel wall thickening</td> <td>9/9 (100 percent)</td> <td>0/10 (100 percent)</td> <td>&#60;0.01</td> </tr> <tr> <td>Thickening of the mesentery</td> <td>2/9 (22 percent)</td> <td>8/10 (80 percent)</td> <td>&#60;0.05</td> </tr> <tr> <td>Abscess</td> <td>0</td> <td>0</td> <td>n.s.</td> </tr> <tr> <td>Fistula</td> <td>0</td> <td>0 (82)</td> <td>n.s.</td> </tr> <tr> <td>Mesenteric lymphadenopathy<sup>&#182;</sup></td> <td>1/9</td> <td>6/10 (60 percent)</td> <td>&#60;0.05</td> </tr> <tr> <td>Ascites</td> <td>6/9 (66 percent)</td> <td>6/10 (60 percent)</td> <td>n.s.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">n.s.: not significant.<br />* Small intestine except terminal ileum.<br />¶ Defined as more than 2 mesenteric lymph nodes.</div><div class=\"graphic_reference\">Data from Dietrich, CF, Lembcke, B, Seifert, H, et al. Dtsch Med Wochenschr 2000; 125:755; Dietrich, CF, Zeuzem, S, Caspary, WF, et al. Ultraschall Med 1998; 19:265; Downey, DB, Wilson, SR. Radiology 1991; 180:61.</div><div id=\"graphicVersion\">Graphic 77028 Version 2.0</div></div></div>"},"77029":{"type":"graphic_figure","displayName":"Uterus didelphys normal vagina","title":"Uterus didelphys, bicollis, with normal vagina","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Uterus didelphys, bicollis, with normal vagina</div><div class=\"cntnt\"><img style=\"width:348px; height:284px;\" src=\"images/OBGYN/77029_Uterusdidelphysnormalvag.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright © 2012 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77029 Version 13.0</div></div></div>"},"77031":{"type":"graphic_diagnosticimage","displayName":"Malignant stenosis MRI","title":"Squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:340px; height:602px;\" src=\"images/PULM/77031_Malignant_stenosis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal and sagittal MR sequences of the chest demonstrate a mass in the lower trachea with near occlusion of the lumen and tumor extending into the surrounding mediastinum.</div><div id=\"graphicVersion\">Graphic 77031 Version 2.0</div></div></div>"},"77032":{"type":"graphic_figure","displayName":"Foot check diabetes PI","title":"Foot check for people with diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Foot check for people with diabetes</div><div class=\"cntnt\"><img style=\"width:425px; height:625px;\" src=\"images/PI/77032_Foot-check-diabetes-PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">People with diabetes should check both of their feet every day. It is important to check your feet all over, including in between your toes. If you can't see the bottom of your foot, use a mirror or ask another person to check for you. Let your doctor or nurse know if you find any:<br /><ul>&#xD;&#xA;    <li>Redness </li>&#xD;&#xA;    <li>Cuts or cracks in the skin </li>&#xD;&#xA;    <li>Blisters </li>&#xD;&#xA;    <li>Swelling </li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 77032 Version 3.0</div></div></div>"},"77033":{"type":"graphic_table","displayName":"Common agoraphobic situations","title":"Common agoraphobic situations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common agoraphobic situations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Waiting in line</td> </tr> <tr> <td>Crowds</td> </tr> <tr> <td>Being home alone</td> </tr> <tr> <td>Grocery stores</td> </tr> <tr> <td>Shopping malls</td> </tr> <tr> <td>Driving</td> </tr> <tr> <td>Restaurants</td> </tr> <tr> <td>Movie theaters</td> </tr> <tr> <td>Wide open spaces</td> </tr> <tr> <td>Hairdressing appointments</td> </tr> <tr> <td>Doctor or dentist appointments</td> </tr> <tr> <td>Being away from home</td> </tr> <tr> <td>Public transportation</td> </tr> <tr> <td>Flying</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77033 Version 1.0</div></div></div>"},"77034":{"type":"graphic_figure","displayName":"Operative approach for a preperitoneal inguinal hernia repair","title":"Operative approach for a preperitoneal inguinal hernia repair","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Operative approach for a preperitoneal inguinal hernia repair</div><div class=\"cntnt\"><img style=\"width:532px; height:380px;\" src=\"images/SURG/77034_Anatomy-Inguinal-preperitoneal-space.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the cross-sectional anatomy of the right lower abdominal wall showing the preperitoneal space. This approach can be used for repair of a primary inguinal hernia or recurrent inguinal hernia previously repaired by an anterior mesh repair or a failed posterior approach.</div><div id=\"graphicVersion\">Graphic 77034 Version 5.0</div></div></div>"},"77037":{"type":"graphic_table","displayName":"WHO diagnostic criteria for HTLV I associated myelopathy ","title":"World Health Organization diagnostic criteria for HTLV-I-associated myelopathy (tropical spastic paraparesis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">World Health Organization diagnostic criteria for HTLV-I-associated myelopathy (tropical spastic paraparesis)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Clinical Criteria</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Age and sex incidence</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Mostly sporadic and adult, but sometimes familial; occasionally seen in childhood; females predominant</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Onset</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Usually insidious but may be sudden</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Main neurological manifestations</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Chronic spastic paraparesis, which usually progresses slowly, sometime remains static after initial progression</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Weakness of the lower limbs, more marked proximally</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Bladder disturbance usually an early feature; constipation usually occurs later; impotence or decreased libido is common</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Sensory symptoms such as tingling, pins and needles, burning, etc., are more prominent than objective physical signs</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Low lumbar pain with radiation to the legs is common</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Vibration sense is frequently impaired; proprioception is less often affected</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hyperreflexia of the lower limbs, often with clonus and Babinski's sign</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Hyperreflexia of the upper limbs; positive Hoffman's and Tromner signs frequent; weakness may be absent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Exaggerated jaw jerk in some patients</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Less frequent neurological findings</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Cerebellar signs, optic atrophy, deafness, nystagmus, other\ncranial nerve deficits, hand tremor, absent or decreased ankle jerk.\nConvulsions, cognitive impairment, dementia or impaired consciousness\nare rare.</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Muscular atrophy, fasciculations (rare), polymyositis,\nperipheral neuropathy, polyradiculopathy, cranial neuropathy,\nmeningitis, encephalopathy</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_single\">Systemic non-neurological manifestations</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Pulmonary alveolitis, uveitis, Sjogren's syndrome,\narthropathy, vasculitis, ichthyosis, cryoglobulinemia, monoclonal\ngammopathy, adult T-cell leukemia/lymphoma</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Laboratory Diagnosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Presence of HTLV-1 antibodies or antigens in blood and CSF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>CSF may show mild lymphocyte pleiocytosis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Lobulated lymphocytes may be present in blood and/or CSF</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Mild to moderate increase of protein may be present in CSF</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77037 Version 2.0</div></div></div>"},"77038":{"type":"graphic_table","displayName":"Causes S2 abnormalities","title":"Abnormalities of the second heart sound (S2) and their mechanisms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Abnormalities of the second heart sound (S2) and their mechanisms</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Wide splitting of S2 with maintained inspiratory delay of P2</td> </tr> <tr> <td class=\"subtitle2_single\">Delayed activation and completion of right ventricular ejection</td> </tr> <tr> <td class=\"indent1\">Complete right bundle branch block</td> </tr> <tr> <td class=\"indent1\">Artificial left ventricular pacing </td> </tr> <tr> <td class=\"indent1\">Pre-excitation of the left ventricle (Wolff-Parkinson-White syndrome)</td> </tr> <tr> <td class=\"indent1\">Premature beats and idioventricular rhythm originating from the left ventricle</td> </tr> <tr> <td class=\"subtitle2_single\">Prolonged right ventricular ejection time</td> </tr> <tr> <td class=\"indent1\">Pulmonary hypertension with right heart failure</td> </tr> <tr> <td class=\"indent1\">Right ventricular outflow obstruction (eg, pulmonic stenosis, acute massive pulmonary embolus)</td> </tr> <tr> <td class=\"subtitle2_single\">Increased pulmonary hangout time</td> </tr> <tr> <td class=\"indent1\">Idiopathic dilatation of the pulmonary artery</td> </tr> <tr> <td class=\"indent1\">Mild pulmonic stenosis</td> </tr> <tr> <td class=\"indent1\">Postoperative atrial septal defect</td> </tr> <tr> <td class=\"subtitle2_single\">Decreased left ventricular ejection time (early A2)</td> </tr> <tr> <td class=\"indent1\">Mitral regurgitation</td> </tr> <tr> <td class=\"indent1\">Ventricular septal defect with low pulmonary vascular resistance</td> </tr> <tr> <td class=\"indent1\">Constrictive pericarditis</td> </tr> <tr> <td class=\"subtitle1_single\">Fixed splitting of S2</td> </tr> <tr> <td>Unchanged right ventricular stroke volume during respiration; severe right ventricular failure due to any cause</td> </tr> <tr> <td>Interatrial communication; atrial septal defect; common atrium</td> </tr> <tr> <td class=\"subtitle1_single\">Reversed splitting of S2</td> </tr> <tr> <td class=\"subtitle2_single\">Delayed left ventricular activation and completion of ejection</td> </tr> <tr> <td class=\"indent1\">Left bundle branch block</td> </tr> <tr> <td class=\"indent1\">Artificial right ventricular pacing</td> </tr> <tr> <td class=\"indent1\">Pre-excitation of the right ventricle (Wolff-Parkinson-White syndrome)</td> </tr> <tr> <td class=\"indent1\">Premature beats of right ventricular origin</td> </tr> <tr> <td class=\"subtitle2_single\">Prolonged left ventricular ejection time</td> </tr> <tr> <td class=\"indent1\">Increased resistance to left ventricular ejection (aortic stenosis, obstructive hypertrophic cardiomyopathy, hypertension)</td> </tr> <tr> <td class=\"indent1\">Isolated increase in left ventricular forward stroke volume (aortic regurgitation, patent ductus arteriosus)</td> </tr> <tr> <td class=\"indent1\">Myocardial dysfunction (mild to moderate left ventricular failure, myocardial ischemia or infarction)</td> </tr> <tr> <td class=\"subtitle2_single\">Increased aortic hangout time (not the sole cause)</td> </tr> <tr> <td class=\"indent1\">Aortic regurgitation</td> </tr> <tr> <td class=\"indent1\">Patent ductus arteriosus </td> </tr> <tr> <td class=\"indent1\">Aortic stenosis</td> </tr> <tr> <td class=\"subtitle1_single\">Single S2</td> </tr> <tr> <td><strong>Apparent:</strong> obesity, emphysema, pericardial effusion</td> </tr> <tr> <td><strong>Absent A2:</strong> severe aortic stenosis, severe aortic regurgitation</td> </tr> <tr> <td><strong>Absent P2:</strong> absent pulmonary valve, pulmonary atresia, tetralogy of Fallot, truncus arteriosus</td> </tr> <tr> <td><strong>Fusion of A2 and P2:</strong> Eisenmenger's ventricular septal defect, common ventricle</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77038 Version 2.0</div></div></div>"},"77039":{"type":"graphic_diagnosticimage","displayName":"Color flow Doppler severe MR","title":"Color flow Doppler of severe mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Color flow Doppler of severe mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:364px; height:277px;\" src=\"images/CARD/77039_Color_flow_Doppler_severe_M.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The color flow Doppler signal, as seen in the four chamber view, shows the typical features of severe mitral regurgitation: the first is a large proximal isovelocity surface area (PISA) and the second is a broad crossing jet from left ventricle (LV) into the left atrium (LA).</div><div id=\"graphicVersion\">Graphic 77039 Version 4.0</div></div></div>"},"77040":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound flattened adrenal and renal agenesis","title":"Prenatal ultrasound flattened adrenal with right renal agenesis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound flattened adrenal with right renal agenesis</div><div class=\"cntnt\"><img style=\"width:396px; height:313px;\" src=\"images/OBGYN/77040_Flattened_adrenal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flattened right adrenal gland seen on longitudinal view with right renal agenesis (arrow).</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 77040 Version 2.0</div></div></div>"},"77042":{"type":"graphic_table","displayName":"Retiform purpura histopathology","title":"Clinicopathological correlation for retiform purpura","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinicopathological correlation for retiform purpura</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Histopathological finding</td> <td class=\"subtitle1\">Diagnosis</td> </tr> <tr> <td>Thrombi in vessels with no inflammation or minimal inflammation</td> <td>APS, DIC, WISN, TTP, HIT, cryofibrinogenemia</td> </tr> <tr> <td>Prominent thrombosis with neutrophilic inflammation</td> <td>Septic emboli, bacterial endocarditis</td> </tr> <tr> <td>Inflammatory changes demonstrating:<br /> <ul> <li>Inflammatory invasion of vessel walls </li> <li>Fibrinoid necrosis </li> <li>Endothelial swelling </li> <li>Leukocytoclasis </li> </ul> </td> <td>Small and medium vessel vasculitides</td> </tr> <tr> <td>Eosinophilic plugging of small vessels</td> <td>Type 1 cryoglobulinemia</td> </tr> <tr> <td>Cholesterol clefts and fibrin clots in vessels</td> <td>Cholesterol emboli</td> </tr> <tr> <td>Vessel wall calcification</td> <td>Calciphylaxis</td> </tr> <tr> <td>Fibrin in vessel walls and vessel lumina</td> <td>Livedoid vasculopathy</td> </tr> <tr> <td>Myxomatous tissue plugging of vessels</td> <td>Atrial myxoma embolization</td> </tr> <tr> <td>Calcium and crystal deposition in vessel walls</td> <td>Oxalosis</td> </tr> <tr> <td>Non-specific inflammation with variable vascular involvement</td> <td>Pyoderma gangrenosum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">APS: antiphospholipid syndrome; DIC: disseminated intravascular coagulation; WISN: warfarin-induced skin necrosis; TTP: thrombotic thrombocytopenic purpura; HIT: heparin-induced thrombocytopenia.</div><div id=\"graphicVersion\">Graphic 77042 Version 1.0</div></div></div>"},"77043":{"type":"graphic_figure","displayName":"Porta hepatis","title":"Porta hepatis","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Porta hepatis</div><div class=\"cntnt\"><img style=\"width:541px; height:485px;\" src=\"images/SURG/77043_Porta_hepatis.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77043 Version 1.0</div></div></div>"},"77044":{"type":"graphic_diagnosticimage","displayName":"Perilunate dislocation","title":"Perilunate dislocation anterior posterior and lateral views","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Perilunate dislocation anterior posterior and lateral views</div><div class=\"cntnt\"><img style=\"width:514px; height:397px;\" src=\"images/EM/77044_Perilunate_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral view in particular provides a clear view of this dislocation. The normal juxtaposition of the proximal surface of the capitate and the concave distal surface of the lunate (arrow) is lost. The lunate lies anteriorly and distally displaced relative to the dorsally and proximally displaced capitate bone (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Patrice Eiff, MD.</div><div id=\"graphicVersion\">Graphic 77044 Version 4.0</div></div></div>"},"77045":{"type":"graphic_figure","displayName":"Ovarian anatomy","title":"Ovarian anatomy","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Ovarian anatomy</div><div class=\"cntnt\"><img style=\"width:566px; height:312px;\" src=\"images/PI/77045_Ovarian_cyst_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows the ovary, fallopian tube, and follicles (cysts).</div><div class=\"graphic_reference\">Reproduced with permission from: Anatomical Chart Company, General Anatomy. Copyright ©2008 Anatomical Chart Company.</div><div id=\"graphicVersion\">Graphic 77045 Version 5.0</div></div></div>"},"77048":{"type":"graphic_picture","displayName":"Comedo ductal carcinoma in situ","title":"Comedo ductal carcinoma in situ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comedo ductal carcinoma in situ</div><div class=\"cntnt\"><img style=\"width:360px; height:235px;\" src=\"images/ONC/77048_Comedo_ductal_CIS_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopic specimen of comedo ductal carcinoma in situ shows a large central area of necrosis that is focally calcified. The nuclei are poorly differentiated (high grade).</div><div class=\"graphic_reference\">Courtesy of Stuart Schnitt, MD.</div><div id=\"graphicVersion\">Graphic 77048 Version 2.0</div></div></div>"},"77050":{"type":"graphic_figure","displayName":"Two thumb technique","title":"Chest compression for infant resuscitation: Two thumb technique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chest compression for infant resuscitation: Two thumb technique</div><div class=\"cntnt\"><img style=\"width:388px; height:504px;\" src=\"images/PEDS/77050_Two_thumb_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thorax is encircled with the hands and cardiac compressions are performed with both thumbs. The compression site is approximately one finger's breadth below the intermammary line. The area over the xiphoid process should be avoided to prevent injury to the liver, spleen, or stomach.</div><div id=\"graphicVersion\">Graphic 77050 Version 2.0</div></div></div>"},"77051":{"type":"graphic_figure","displayName":"Time course of ARDS","title":"Time course of acute respiratory distress syndrome (ARDS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Time course of acute respiratory distress syndrome (ARDS)</div><div class=\"cntnt\"><img style=\"width:411px; height:278px;\" src=\"images/PULM/77051_Time_course_of_ARDS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the time course of the acute respiratory distress syndrome (ARDS). During the early (or exudative) phase, the lesion is characterized by high permeability pulmonary edema followed by the formation of hyaline membranes. After seven to ten days, a proliferative phase may develop, with marked interstitial inflammation, fibrosis, and disordered healing.</div><div class=\"graphic_reference\">Redrawn from Katzenstein AA, Askin FB. Surgical Pathology of Non-neoplastic Lung Disease. Saunders, Philadelphia, 1982.</div><div id=\"graphicVersion\">Graphic 77051 Version 2.0</div></div></div>"},"77052":{"type":"graphic_picture","displayName":"Skin changes post transplant","title":"Sclerodermatoid changes after bone marrow transplantation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sclerodermatoid changes after bone marrow transplantation</div><div class=\"cntnt\"><img style=\"width:396px; height:263px;\" src=\"images/RHEUM/77052_Skin_changes_post_transplan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with graft-versus-host disease after bone marrow transplantation with cutaneous manifestations similar to those observed in localized scleroderma.</div><div class=\"graphic_reference\">Courtesy of Carol M Black, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 77052 Version 1.0</div></div></div>"},"77053":{"type":"graphic_figure","displayName":"Sectional view of the abdominal wall musculature","title":"Sectional view of the abdominal wall musculature","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Sectional view of the abdominal wall musculature</div><div class=\"cntnt\"><img style=\"width:539px; height:687px;\" src=\"images/SURG/77053_Abdominal_wall_musculature_section.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77053 Version 4.0</div></div></div>"},"77054":{"type":"graphic_table","displayName":"Clin pulm infect score","title":"Clinical Pulmonary Infection Score (CPIS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical Pulmonary Infection Score (CPIS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Temperature</td> </tr> <tr> <td class=\"indent1\">&#8805;36.5 or &#8804;38.4 = 0 point</td> </tr> <tr> <td class=\"indent1\">&#8805;38.5 or &#8804;38.9 = 1 point</td> </tr> <tr> <td class=\"indent1\">&#8805;39 or &#60;36.5 = 2 points</td> </tr> <tr> <td class=\"subtitle1_single\">Blood leukocytes, microL</td> </tr> <tr> <td class=\"indent1\">&#8805;4000 or &#8804;11,000 = 0 points</td> </tr> <tr> <td class=\"indent1\">&#60;4000 or &#62;11,000 = 1 point</td> </tr> <tr> <td class=\"indent1\">Band forms &#8805;50 percent = add 1 point</td> </tr> <tr> <td class=\"subtitle1_single\">Tracheal secretions</td> </tr> <tr> <td class=\"indent1\">Absence of tracheal secretions = 0 point</td> </tr> <tr> <td class=\"indent1\">Presence of nonpurulent tracheal secretions = 1 point</td> </tr> <tr> <td class=\"indent1\">Presence of purulent tracheal secretions = 2 points</td> </tr> <tr> <td class=\"subtitle1_single\">Oxygenation</td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub>/FIO<sub>2</sub>, mmHg &#62;240 or ARDS (defined as PaO<sub>2</sub>/FIO<sub>2</sub> &#8804;200, PAWP &#8804;18 mmHg and acute bilateral infiltrates) = 0 points</td> </tr> <tr> <td class=\"indent1\">PaO<sub>2</sub>/FIO<sub>2</sub> &#8804;240 and no ARDS = 2 points</td> </tr> <tr> <td class=\"subtitle1_single\">Pulmonary radiography</td> </tr> <tr> <td class=\"indent1\">No infiltrate = 0 point</td> </tr> <tr> <td class=\"indent1\">Diffuse (patchy) infiltrate = 1 point</td> </tr> <tr> <td class=\"indent1\">Localized infiltrate = 2 points</td> </tr> <tr> <td class=\"subtitle1_single\">Progression of pulmonary infiltrate</td> </tr> <tr> <td class=\"indent1\">No radiographic progression = 0 point</td> </tr> <tr> <td class=\"indent1\">Radiographic progression (after HF and ARDS excluded) = 2 points</td> </tr> <tr> <td class=\"subtitle1_single\">Culture of tracheal aspirate</td> </tr> <tr> <td class=\"indent1\">Pathogenic bacteria cultured in rare or few quantities or no growth = 0 point</td> </tr> <tr> <td class=\"indent1\">Pathogenic bacteria cultured in moderate or heavy quantity = 1 point</td> </tr> <tr> <td class=\"indent1\">Same pathogenic bacteria seen on Gram stain, add 1 point</td> </tr> <tr> <td class=\"indent1\">Total (a score of &#62;6 was considered suggestive of pneumonia)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">An initial score is based upon the first five variables. The last two variables are assessed on day 2 or 3.</div><div class=\"graphic_footnotes\">ARDS: acute respiratory distress syndrome; HF: heart failure; PAWP: pulmonary arterial wedge pressure.</div><div class=\"graphic_reference\">Adapted with permission from: Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162:505. Copyright &copy; 2002 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 77054 Version 4.0</div></div></div>"},"77055":{"type":"graphic_picture","displayName":"Pigment from Pseudomonas aeruginosa","title":"Pigment produced by <EM>Pseudomonas aeruginosa</EM>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pigment produced by <EM>Pseudomonas aeruginosa</EM></div><div class=\"cntnt\"><img style=\"width:328px; height:240px;\" src=\"images/ID/77055_Gramstainsputum8Banswer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The green pigment produced by <EM>Pseudomonas aeruginosa </EM>is easily seen on Mueller-Hinton agar plate used for disk antimicrobial susceptibility testing.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 77055 Version 3.0</div></div></div>"},"77057":{"type":"graphic_table","displayName":"Heart rates in normal children","title":"Heart rates in normal children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Heart rates in normal children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">Awake rate</td> <td class=\"subtitle1\">Sleeping rate</td> </tr> <tr> <td>Neonate (28 days or younger)</td> <td>100-205</td> <td>90-160</td> </tr> <tr> <td>Infant (29 days to 1 year)</td> <td>100-180</td> <td>90-160</td> </tr> <tr> <td>Toddler (1 to &#60;3 years)</td> <td>98-140</td> <td>80-120</td> </tr> <tr> <td>Preschool (3 to 5 years)</td> <td>80-120</td> <td>65-100</td> </tr> <tr> <td>School-aged child&nbsp;(6 to 12 years)</td> <td>75-118</td> <td>58-90</td> </tr> <tr> <td>Adolescent (&#62;12 years)</td> <td>60-100</td> <td>50-90</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from Pediatric Advanced Life Support Provider Manual, American Heart Association, 2016. p. 48.</div><div id=\"graphicVersion\">Graphic 77057 Version 3.0</div></div></div>"},"77060":{"type":"graphic_table","displayName":"Rapid sequence intubation seven Ps timing","title":"Summary: The Seven Ps of rapid sequence intubation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary: The Seven Ps of rapid sequence intubation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Action</td> <td class=\"subtitle1\">Time</td> </tr> <tr> <td>Preparation</td> <td>10 minutes before intubation</td> </tr> <tr> <td>Preoxygenation</td> <td>5 minutes before intubation</td> </tr> <tr> <td>Pre-intubation optimization</td> <td>3&nbsp;minutes before intubation (may be longer depending on necessary interventions and time available)</td> </tr> <tr> <td>Paralysis with induction</td> <td>Induction</td> </tr> <tr> <td>Protection</td> <td>30 seconds after induction</td> </tr> <tr> <td>Placement (Intubation)</td> <td>45 seconds after induction</td> </tr> <tr> <td>Post-intubation management</td> <td>60 seconds after induction</td> </tr> </tbody></table></div><div class=\"graphic_reference\"><FONT size=1>&#xD;&#xA;<P>Used with permission from Brown III CA, Sakles JC, Mick N. The Walls Manual of Emergency Airway Management, 5th edition. 2018. Wolters Kluwer.</P></FONT></div><div id=\"graphicVersion\">Graphic 77060 Version 4.0</div></div></div>"},"77061":{"type":"graphic_picture","displayName":"Fistula closure clip endos","title":"Treatment of ileocolonic anastomosis fistula with endoclips","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of ileocolonic anastomosis fistula with endoclips</div><div class=\"cntnt\"><img style=\"width:289px; height:562px;\" src=\"images/GAST/77061_Fistula_closure_clip_endos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient developed ischemic colitis following an aspirin overdose and required a subtotal colectomy and temporary ileostomy. Following creation of an ileal-sigmoid anastomosis he developed a large abscess and was found the have a large post-operative fistula at the anastomotic site as shown above. In addition to percutaneous abscess drainage, twelve Resolution clips were placed during colonoscopy to close the defect. Subsequently, the abscess drainage subsided and the patient was able to tolerate refeeding within two weeks without the subsequent need for reoperation.</div><div class=\"graphic_reference\">Courtesy of Jonathan Cohen, MD.</div><div id=\"graphicVersion\">Graphic 77061 Version 3.0</div></div></div>"},"77062":{"type":"graphic_picture","displayName":"Ink stains at polypectomy","title":"India ink at polypectomy scar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">India ink at polypectomy scar</div><div class=\"cntnt\"><img style=\"width:312px; height:328px;\" src=\"images/GAST/77062_Ink_stains_at_polypectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">India ink staining is visible at the site of a polypectomy scar.</div><div class=\"graphic_reference\">Courtesy of Jerome D Waye, MD.</div><div id=\"graphicVersion\">Graphic 77062 Version 1.0</div></div></div>"},"77063":{"type":"graphic_table","displayName":"Causes of thrombocytopenia in adults","title":"Causes of thrombocytopenia in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of thrombocytopenia in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Falsely low platelet counts (pseudothrombocytopenia)</td> </tr> <tr> <td class=\"indent1\">In vitro platelet clumping caused by EDTA-dependent agglutinins (naturally occurring antibodies)</td> </tr> <tr> <td class=\"indent1\">In vitro platelet clumping caused by an insufficiently anticoagulated specimen</td> </tr> <tr> <td class=\"indent1\">In vitro platelet clumping caused by glycoprotein IIb/IIIa inhibitors (eg, abciximab) (NOTE: these can also cause true thrombocytopenia)</td> </tr> <tr> <td class=\"indent1\">Giant platelets counted by automated counter as white blood cells rather than platelets</td> </tr> <tr> <td class=\"subtitle1_single\">Common causes of thrombocytopenia</td> </tr> <tr> <td class=\"subtitle2_single\">Primary immune thrombocytopenia (ITP)</td> </tr> <tr> <td class=\"subtitle2_single\">Drug-induced immune&nbsp;thrombocytopenia (DITP)</td> </tr> <tr> <td class=\"indent1\">Heparin (NOTE: special case, also can cause thrombosis)</td> </tr> <tr> <td class=\"indent1\">Quinine (as in over-the-counter&nbsp;tablets for leg cramps; also in beverages)</td> </tr> <tr> <td class=\"indent1\">Sulfonamides (eg, trimethoprim-sulfamethoxazole [Bactrim; Septra])</td> </tr> <tr> <td class=\"indent1\">Acetaminophen (Tylenol, Panadol)</td> </tr> <tr> <td class=\"indent1\">Cimetidine (Tagamet)</td> </tr> <tr> <td class=\"indent1\">Ibuprofen (Advil, Motrin)</td> </tr> <tr> <td class=\"indent1\">Naproxen (Aleve, Midol)</td> </tr> <tr> <td class=\"indent1\">Ampicillin (Omnipen, Apo-Ampi)</td> </tr> <tr> <td class=\"indent1\">Piperacillin (Pipracil, Zosyn)</td> </tr> <tr> <td class=\"indent1\">Vancomycin (Vancocin)</td> </tr> <tr> <td class=\"indent1\">Glycoprotein IIb/IIIa inhibitors (abciximab [ReoPro], tirofiban [Aggrastat], eptifibatide [Integrilin])</td> </tr> <tr> <td class=\"subtitle2_single\">Food and beverages</td> </tr> <tr> <td class=\"indent1\">Quinine-containing beverages (tonic water, Schweppes bitter lemon)</td> </tr> <tr> <td class=\"indent1\">Walnuts</td> </tr> <tr> <td class=\"indent1\">Certain herbal teas&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Infections</td> </tr> <tr> <td class=\"indent1\">HIV</td> </tr> <tr> <td class=\"indent1\">Hepatitis C</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus (EBV; can be associated with infectious mononucleosis)</td> </tr> <tr> <td class=\"indent1\">H. pylori (suspected in patients with symptoms of dyspepsia or peptic ulcer disease)</td> </tr> <tr> <td class=\"indent1\">Sepsis with disseminated intravascular coagulation (DIC)</td> </tr> <tr> <td class=\"indent1\">Intracellular parasites (eg, malaria, babesia)&nbsp;</td> </tr> <tr> <td class=\"subtitle2_single\">Hypersplenism due to chronic liver disease</td> </tr> <tr> <td class=\"subtitle2_single\">Alcohol</td> </tr> <tr> <td class=\"subtitle2_single\">Nutrient deficiencies (eg, vitamin B12, folate, copper)</td> </tr> <tr> <td class=\"subtitle2_single\">Rheumatologic/autoimmune disorders (eg, systemic<span class=\"subtitle2_single\"></span><span class=\"subtitle2_single\"></span> lupus erythematosus, <span class=\"subtitle2_single\"></span><span class=\"sublist_other_start\"></span><span class=\"subtitle2_single\"></span><span class=\"subtitle3_left\"></span>rheumatoid arthritis)</td> </tr> <tr> <td class=\"subtitle2_single\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Gestational thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Preeclampsia</td> </tr> <tr> <td class=\"indent1\">HELLP syndrome (hemolysis, elevated liver function tests, low platelets)</td> </tr> <tr> <td class=\"subtitle1_single\">Other causes of thrombocytopenia</td> </tr> <tr> <td class=\"subtitle2_single\">Myelodysplasia</td> </tr> <tr> <td class=\"indent1\">Suspected in older patients, in whom a bone marrow biopsy may be appropriate</td> </tr> <tr> <td class=\"subtitle2_single\">Cancer with disseminated intravascular coagulation</td> </tr> <tr> <td class=\"subtitle2_single\">Cancer with bone marrow infiltration or suppression (eg, lymphoma, leukemia, some solid tumors)</td> </tr> <tr> <td class=\"subtitle2_single\">Paroxysmal nocturnal hemoglobinuria (PNH)</td> </tr> <tr> <td class=\"subtitle2_single\">Thrombotic microangiopathy (TMA)</td> </tr> <tr> <td class=\"indent1\">Thrombotic thrombocytopenic purpura (TTP) is manifested by thrombocytopenia and&nbsp;microangiopathic hemolytic anemia; fever, renal failure, and/or neurologic symptoms may or may not&nbsp;be present.</td> </tr> <tr> <td class=\"indent1\">Hemolytic uremic syndrome (HUS) is typically seen in children following infection with a Shiga-toxin producing organism (E. coli or Shigella).</td> </tr> <tr> <td class=\"indent1\">Drug-induced TMA may occur with quinine, certain&nbsp;cancer therapies,&nbsp;calcineurin inhibitors, and others</td> </tr> <tr> <td class=\"subtitle2_single\">Antiphospholipid syndrome (APS)</td> </tr> <tr> <td class=\"subtitle2_single\">Aplastic anemia</td> </tr> <tr> <td class=\"subtitle2_single\">Inherited thrombocytopenias</td> </tr> <tr> <td class=\"sublist2_start\">An important consideration, especially in young patients who do not respond to treatment. Some specific syndromes are listed. However, many patients appear to have autosomal dominant thrombocytopenia with no other clinical features.</td> </tr> <tr> <td class=\"sublist2\">Von Willebrand disease type 2B</td> </tr> <tr> <td class=\"sublist2\">Wiskott-Aldrich syndrome</td> </tr> <tr> <td class=\"sublist2\">Alport syndrome</td> </tr> <tr> <td class=\"sublist2\">May-Hegglin anomaly</td> </tr> <tr> <td class=\"sublist2\">Fanconi syndrome</td> </tr> <tr> <td class=\"sublist2\">Bernard-Soulier syndrome</td> </tr> <tr> <td class=\"sublist2\">Thrombocytopenia absent radius syndrome</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table lists possible causes of isolated thrombocytopenia. Refer to the UpToDate topics on&nbsp;thrombocytopenia, immune thrombocytopenia, heparin-induced thrombocytopenia, and drug-induced thrombocytopenia&nbsp;for further details and a more complete list of drugs that can cause drug-induced thrombocytopenia.</div><div id=\"graphicVersion\">Graphic 77063 Version 8.0</div></div></div>"},"77064":{"type":"graphic_table","displayName":"Criteria associated with RADS","title":"Criteria for diagnosis of reactive airways dysfunction syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for diagnosis of reactive airways dysfunction syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>A documented absence of previous respiratory complaints.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The onset of symptoms should occur after a single specific exposure.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The exposure should be to a gas, smoke, fume, or vapor with irritant qualities that was present in very high concentrations.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The onset of symptoms should occur within 24 hours of exposure and should persist for at least three months.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>The symptoms should simulate asthma with cough, wheezing, and dyspnea.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary function tests may or may not show airflow obstruction.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Methacholine challenge should be positive.</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Other types of pulmonary diseases should be ruled out.</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_reference\">Adapted from Brooks, SM, Weiss, MA, Bernstein, IL, Chest 1985; 88:376.</div><div id=\"graphicVersion\">Graphic 77064 Version 1.0</div></div></div>"},"77067":{"type":"graphic_picture","displayName":"Cocaine purpura on ear","title":"Purpura due to levamisole-contaminated cocaine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Purpura due to levamisole-contaminated cocaine</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/77067_Cocaine_purpura_ear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric lesions on the ear are common in toxicity due to levamisole-contaminated cocaine.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77067 Version 4.0</div></div></div>"},"77068":{"type":"graphic_figure","displayName":"Perineal proctosigmoidectomy","title":"Perineal proctosigmoidectomy","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Perineal proctosigmoidectomy</div><div class=\"cntnt\"><img style=\"width:467px; height:687px;\" src=\"images/SURG/77068_Perineal-proctosigmoidoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These figures depict the basic approach to the perineal proctosigmoidectomy, also known as the Altemeier procedure.<br />(Panel A) An incision is made through the seromuscular layer anteriorly, within 1 to 2 cm of the dentate line.<br />(Panel B) The incision is extended circumferentially.<br />(Panel C) The prolapsed rectum is everted and fully mobilized. The peritoneal reflexion is incised.<br />(Panel D) The mesorectum is divided. Full-thickness, nonabsorbable interrupted sutures are placed between the divided bowel and residual cuff.<br />(Panel E) The anastomosis is completed.</div><div id=\"graphicVersion\">Graphic 77068 Version 2.0</div></div></div>"},"77069":{"type":"graphic_diagnosticimage","displayName":"Normal sinus CT","title":"CT scan of normal paranasal sinuses","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">CT scan of normal paranasal sinuses</div><div class=\"cntnt\"><img style=\"width:586px; height:624px;\" src=\"images/ALLRG/77069_Normal_sinus_CT_SRC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This coronal CT image shows normal maxillary and ethmoid sinuses with the ostiomeatal complexes widely patent bilaterally.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Daniel Hamilos, MD.</div><div id=\"graphicVersion\">Graphic 77069 Version 5.0</div></div></div>"},"77070":{"type":"graphic_figure","displayName":"Ross River virus generalized rash ","title":"Generalized rash in Ross River virus infection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Generalized rash in Ross River virus infection</div><div class=\"cntnt\"><img style=\"width:244px; height:361px;\" src=\"images/ID/77070_Generalized_rash_in_RRV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Some patients with Ross River virus infection develop a more extensive, generalized rash, which can be vesicular or purpuric.</div><div class=\"graphic_reference\">Courtesy of Michael Richards, MB, BS, FRACP.</div><div id=\"graphicVersion\">Graphic 77070 Version 4.0</div></div></div>"},"77071":{"type":"graphic_diagnosticimage","displayName":"Miliary TB high resolution CT","title":"High resolution computed tomography of the chest in a patient with miliary tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">High resolution computed tomography of the chest in a patient with miliary tuberculosis</div><div class=\"cntnt\"><img style=\"width:360px; height:248px;\" src=\"images/ID/77071_Miliary_TB_high_resolution.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous 2 mm nodules and septal thickening are seen diffusely throughout the lung.</div><div class=\"graphic_reference\">Courtesy of Jo-Anne Shepard, MD, Massachusetts General Hospital, Boston.</div><div id=\"graphicVersion\">Graphic 77071 Version 2.0</div></div></div>"},"77074":{"type":"graphic_diagnosticimage","displayName":"Posterior cephalocele first trimester","title":"Posterior cephalocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior cephalocele</div><div class=\"cntnt\"><img style=\"width:261px; height:335px;\" src=\"images/OBGYN/77074_Postr_cephalocele_first_tri.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A sagittal view of a posterior encephalocele at 12<SUP>1/7th</SUP> weeks of gestation. Brain and&nbsp;covering membranes protrude through a cranial defect; arrows indicate the edge of the defect.</div><div id=\"graphicVersion\">Graphic 77074 Version 4.0</div></div></div>"},"77076":{"type":"graphic_figure","displayName":"ARF LIFT","title":"Ligation of the intersphincteric fistula (LIFT) procedure","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Ligation of the intersphincteric fistula (LIFT) procedure</div><div class=\"cntnt\"><img style=\"width:542px; height:328px;\" src=\"images/SURG/77076_ARFLIFT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This illustration shows the internal and external openings of the fistulous tract. A clamp is inserted under the tract and the fistula is ligated with a suture. The external opening is curetted and remains open. The lateral view shows the relationship of the ligated internal opening to the anatomy and external opening of the fistula.</div><div id=\"graphicVersion\">Graphic 77076 Version 4.0</div></div></div>"},"77077":{"type":"graphic_picture","displayName":"Bogota bag for managing open abdomen","title":"Bogota bag for managing open abdomen","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bogota bag for managing open abdomen</div><div class=\"cntnt\"><img style=\"width:334px; height:281px;\" src=\"images/SURG/77077_Bogota_bag_open_abdomen.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77077 Version 1.0</div></div></div>"},"77078":{"type":"graphic_diagnosticimage","displayName":"Chagas cardiomyopathy with late gadolinium enhancement","title":"Chagas cardiomyopathy with late gadolinium enhancement","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Chagas cardiomyopathy with late gadolinium enhancement</div><div class=\"cntnt\"><img style=\"width:547px; height:289px;\" src=\"images/CARD/77078_LV_fibr_paramagnetic_contr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiovascular magnetic resonance&nbsp;study of a 52-year-old man with Chagas cardiomyopathy&nbsp;who recovered from&nbsp;sudden cardiac arrest&nbsp;due to ventricular fibrillation. Arrows&nbsp;indicate late gadolinium enhancement consistent with focal&nbsp;fibrosis&nbsp;of the left ventricle.</div><div id=\"graphicVersion\">Graphic 77078 Version 4.0</div></div></div>"},"77079":{"type":"graphic_algorithm","displayName":"Initial management of undifferentiated shock in children ","title":"Initial management of undifferentiated shock in children receiving care in resource-rich settings","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Initial management of undifferentiated shock in children receiving care in resource-rich settings</div><div class=\"cntnt\"><img style=\"width:580px; height:970px;\" src=\"images/EM/77079_Intlmgmtshockchildedit2.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis.<br />* For possible cardiogenic shock with hypovolemia, give 5 to 10 mL/kg of isotonic fluids (eg, normal saline or Ringers lactate), infused over 10 to 20 minutes. Evaluate target endpoints and slowly give another 5 to 10 mL/kg if there has been improvement or no change. For patients with diabetic ketoacidosis, give 10 mL/kg of isotonic fluids over one hour.<br />¶ Such as inotropes or vasodilators. For newborns, prostaglandin E<SUB>1</SUB>. Refer to UpToDate topics on management of cardiogenic shock in children and management of neonates with cyanotic heart disease. <br />Δ For patients with DKA who do not improve with 20 mL/kg, look for another cause of shock before administering additional crystalloid. For possible cardiogenic shock, slowly give another 5 to 10 mL/kg if there has been improvement or no change.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate algorithms and topics on management of fluid-refractory septic shock. </div><div class=\"graphic_reference\">Adapted from: Carcillo JA, Fields AI. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365.</div><div id=\"graphicVersion\">Graphic 77079 Version 4.0</div></div></div>"},"77080":{"type":"graphic_table","displayName":"Signs symptoms allergic reaction during OFC","title":"Signs and symptoms of an allergic reaction to monitor for during an oral food challenge","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs and symptoms of an allergic reaction to monitor for during an oral food challenge</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Skin</td> </tr> <tr> <td class=\"indent1\">Feeling of warmth, flushing (erythema), itching (may begin on palms and soles), urticaria, angioedema, morbilliform rash, and \"hair standing on end\" (piloerection)</td> </tr> <tr> <td class=\"indent1\">Infants and children -&nbsp;Eczematous flare</td> </tr> <tr> <td class=\"subtitle1_single\">Oral</td> </tr> <tr> <td class=\"indent1\">Itching or tingling of lips, tongue, or palate</td> </tr> <tr> <td class=\"indent1\">Edema of lips, tongue, uvula, metallic taste</td> </tr> <tr> <td class=\"indent1\">Infants -&nbsp;Drooling</td> </tr> <tr> <td class=\"indent1\">Children -&nbsp;Rubbing tongue against pruritic palate, scratching tongue with hand</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Nausea, abdominal pain (colic, cramps), vomiting (large amounts of \"stringy\" mucus), and diarrhea</td> </tr> <tr> <td class=\"indent1\">Difficulty swallowing*</td> </tr> <tr> <td class=\"subtitle1_single\">Respiratory</td> </tr> <tr> <td class=\"indent1\">Laryngeal - Pruritus and \"tightness\" in the throat, dysphagia, dysphonia and hoarseness, and sensation of itching in the external auditory canals</td> </tr> <tr> <td class=\"indent1\">Lung - Shortness of breath, dyspnea, chest tightness, deep or repetitive cough, and wheezing</td> </tr> <tr> <td class=\"indent1\">Nose - Itching, congestion, rhinorrhea, and sneezing</td> </tr> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Feeling of faintness or dizziness; syncope, chest pain, palpitations, and/or hypotension (tunnel vision, difficulty hearing)</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Anxiety, apprehension, sense of impending doom, seizures, confusion</td> </tr> <tr> <td class=\"indent1\">Infants -&nbsp;Lethargy, hypotonia</td> </tr> <tr> <td class=\"indent1\">Children -&nbsp;Abrupt cessation of activity, fetal position</td> </tr> <tr> <td class=\"subtitle1_single\">Ocular</td> </tr> <tr> <td class=\"indent1\">Periorbital itching, erythema and edema, tearing, and conjunctival erythema </td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Lower back pain due to uterine cramping in women</td> </tr> <tr> <td class=\"indent1\">Children -&nbsp;Ear pulling as an indication of pruritus</td> </tr> <tr> <td class=\"subtitle1_single\">Vital signs/other objective measures</td> </tr> <tr> <td class=\"indent1\">Pulse oximetry, respiratory rate, peak flow, pulmonary function testing</td> </tr> <tr> <td class=\"indent1\">Pulse, blood pressure</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Often occurs in association with throat tightness and other upper airway symptoms.</div><div id=\"graphicVersion\">Graphic 77080 Version 4.0</div></div></div>"},"77081":{"type":"graphic_figure","displayName":"G6PD function","title":"Biochemical mechanism through which G6PD protects red blood cells against oxidant damage","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Biochemical mechanism through which G6PD protects red blood cells against oxidant damage</div><div class=\"cntnt\"><img style=\"width:354px; height:214px;\" src=\"images/HEME/77081_Physiology_of_G6PD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simplified schema of the mechanism by which G6PD protects red blood cells against oxidant injury. Oxidants generate hydrogen peroxide (H<SUB>2</SUB>O<SUB>2</SUB>) which is converted to water (H<SUB>2</SUB>O) in a reaction catalyzed by glutathione peroxidase (GSH Px) and associated with the conversion of reduced glutathione (GSH) to oxidized glutathione (GSSG). In red blood cells, GSH is regenerated in a reaction catalyzed by glutathione reductase (GSSG Red) and associated with the conversion of NADPH to NADP. NADPH is regenerated in a reaction catalyzed by G6PD in which glucose-6-phosphate (G-6-P)&nbsp;is converted to 6-phosphogluconate (6-PG). The last reaction (conversion of G-6-P to&nbsp;6-PG) is the initial step in the hexose monophosphate (or pentose phosphate) shunt.</div><div class=\"graphic_footnotes\">G6PD: glucose-6-phosphate dehydrogenase; GSH: reduced glutathione; GSSG: oxidized glutathione; GSSG red: glutathione reductase; NADP: nicotinamide adenine dinucleotide&nbsp;phosphate; NADPH: reduced form of nicotinamide adenine dinucleotide phosphate; G-6-P: glucose-6-phospate; 6-PG: 6-phosphogluconate.</div><div id=\"graphicVersion\">Graphic 77081 Version 3.0</div></div></div>"},"77085":{"type":"graphic_picture","displayName":"Diffuse alveolar damage","title":"Reparative phase of diffuse alveolar damage","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Reparative phase of diffuse alveolar damage</div><div class=\"cntnt\"><img style=\"width:358px; height:232px;\" src=\"images/PULM/77085_Diffuse_alveolar_damage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of matrix-containing active fibroblasts (staining brown for procollagen type I and purple for procollagen type IV) follows alveolar ducts in acute diffuse alveolar damage in a distribution similar to that of hyaline membranes.</div><div class=\"graphic_reference\">From Kuhn, C, III. Chest 1991; 99:11S.</div><div id=\"graphicVersion\">Graphic 77085 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal lung</div><div class=\"cntnt\"><img style=\"width:360px; height:330px;\" src=\"images/PULM/80140_Normal_lung_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumocytes (arrow) and smaller numbers of cuboidal type II pneumocytes (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Steven E Weinberger, MD.</div><div id=\"graphicVersion\">Graphic 80140 Version 2.0</div></div></div>"},"77086":{"type":"graphic_diagnosticimage","displayName":"Saprophytic aspergillus CT II","title":"Aspergilloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aspergilloma</div><div class=\"cntnt\"><img style=\"width:363px; height:350px;\" src=\"images/PULM/77086_Saprophytic_aspergillus_C1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small fungus ball due to saprophytic Aspergillus fumigatus. Incidental note is made of an aortic arch aneurysm. A prone CT scan shows the nodule to be mobile: it is located on the ventral aspect of the cavity.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77086 Version 3.0</div></div></div>"},"77087":{"type":"graphic_figure","displayName":"Plasmin and thrombolysis","title":"The genesis and function of plasmin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The genesis and function of plasmin</div><div class=\"cntnt\"><img style=\"width:362px; height:224px;\" src=\"images/CARD/77087_Plasmin_thrombolysis_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The inactive precursor, plasminogen, acted upon by intrinsic and extrinsic activators, is converted to the active enzyme, plasmin. Plasmin digests fibrin, the predominant structural component of most intravascular thrombi in the arterial circulatory system, and, to a lesser degree, circulating fibrinogen. The lysis of fibrin generates cross-linked fibrin degradation products (XLFDP) while fibrinogen breakdown yields fibrin(ogen) degradation products (FDP). Thrombin, a pivotal enzyme in hemostatic and pathologic thrombotic processes, converts fibrinogen to fibrin, activates factor XIII (responsible for fibrin monomer crosslinking), and is also a potent platelet activator.</div><div id=\"graphicVersion\">Graphic 77087 Version 3.0</div></div></div>"},"77089":{"type":"graphic_diagnosticimage","displayName":"Lung nodules in nocardiosis","title":"Pulmonary nodules in nocardiosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary nodules in nocardiosis</div><div class=\"cntnt\"><img style=\"width:250px; height:362px;\" src=\"images/ID/77089_Lung_nodules_in_nocardiosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple bilateral pulmonary nodules are seen on a chest radiograph in this patient with systemic lupus erythematosus on chronic corticosteroid therapy. The patient had cutaneous lesions as the initial manifestation of this disseminated infection.</div><div class=\"graphic_reference\">Courtesy of Stanley W Chapman, MD.</div><div id=\"graphicVersion\">Graphic 77089 Version 3.0</div></div></div>"},"77091":{"type":"graphic_movie","displayName":"Phonocardiogram bicusid AS at 2nd R ICS","title":"Carotid artery pulse tracing and phonocardiogram of aortic stenosis with bicuspid valve at the 2nd right intercostal space","html":"<div class=\"graphic normal\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Carotid artery pulse tracing and phonocardiogram of aortic stenosis with bicuspid valve at the 2nd right intercostal space</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77091_asb2ricsconv.mp4\" style=\"width:584px;height:390px\"></div><img style=\"width:563px; height:223px;\" src=\"images/CARD/77091_asb2rics.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid artery pulse tracing and phonocardiogram of aortic stenosis as heard at the second right intercostal space. S1 (mitral and tricuspid valve closure) is followed by an ejection click (opening of the stenotic aortic valve) and a mid systolic ejection murmur of aortic stenosis. A single S2 results from delayed closure of the aortic valve, which occurs simultaneously with pulmonic valve closure.</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 77091 Version 5.0</div></div></div>"},"77092":{"type":"graphic_figure","displayName":"Tension pneumothorax","title":"Tension pneumothorax","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Tension pneumothorax</div><div class=\"cntnt\"><img style=\"width:542px; height:455px;\" src=\"images/PEDS/77092_Tension_pneumothorax.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77092 Version 2.0</div></div></div>"},"77094":{"type":"graphic_picture","displayName":"Glomus tumor","title":"Glomus tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Glomus tumor</div><div class=\"cntnt\"><img style=\"width:319px; height:504px;\" src=\"images/DERM/77094_Glomus_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 13-year-old boy developed a painful nodule on his right great toe nail bed. Biopsy revealed a glomus tumor.</div><div class=\"graphic_reference\">Copyright © Brovedani Piergiorgio, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 77094 Version 3.0</div></div></div>"},"77096":{"type":"graphic_algorithm","displayName":"ED approach to the ventilated patient in respiratory distress","title":"Emergency department approach to the ventilated patient in respiratory distress","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Emergency department approach to the ventilated patient in respiratory distress</div><div class=\"cntnt\"><img style=\"width:600px; height:699px;\" src=\"images/EM/77096_EDvntltdptntrespdstrss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ETT: endotracheal tube; PEEP: peak end-expiratory pressure; ECG: electrocardiogram; ABG: arterial blood gas; ARDS: acute respiratory distress syndrome.</div><div id=\"graphicVersion\">Graphic 77096 Version 4.0</div></div></div>"},"77097":{"type":"graphic_figure","displayName":"Ligation infundibulopelvic ligm","title":"Suture ligation and placement of a suture tie on the infundibulopelvic ligament during gynecologic surgery","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Suture ligation and placement of a suture tie on the infundibulopelvic ligament during gynecologic surgery</div><div class=\"cntnt\"><img style=\"width:469px; height:456px;\" src=\"images/OBGYN/77097_Ligation_infundibulopelvic.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77097 Version 2.0</div></div></div>"},"77099":{"type":"graphic_diagnosticimage","displayName":"Echo endomyocardial fibrosis","title":"Echocardiogram of endomyocardial fibrosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram&nbsp;of endomyocardial fibrosis</div><div class=\"cntnt\"><img style=\"width:353px; height:288px;\" src=\"images/CARD/77099_LVendomyocardialfibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On two-dimensional echocardiography (panel A), typical apical obliteration (0) by a fibrocalcific process renders the left ventricular (LV) cavity very small. The net effect is a severe restrictive cardiomypathy with left atrial (LA) enlargement. The M-mode echocardiogram (panel B) shows the characteristic echoes arising from the apical mass and the very poor mitral valve (MV) opening motion associated with depressed stroke volume.</div><div class=\"graphic_footnotes\">S: interventricular septum; RA: right atrium.</div><div class=\"graphic_reference\">Courtesy of Dr. Harry Acquatella, del Hospital Universitario de Caracas, Venezuela.</div><div id=\"graphicVersion\">Graphic 77099 Version 5.0</div></div></div>"},"77100":{"type":"graphic_figure","displayName":"Water soluble vitamins A","title":"Chemical structure of vitamins B1, B2, B6 and B12","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Chemical structure of vitamins B1, B2, B6 and B12</div><div class=\"cntnt\"><img style=\"width:531px; height:579px;\" src=\"images/PC/77100_Water_soluble_vitamins_A.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77100 Version 2.0</div></div></div>"},"77101":{"type":"graphic_table","displayName":"Epworth Sleepiness Scale","title":"Epworth Sleepiness Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epworth Sleepiness Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td colspan=\"2\">How likely are you to doze off or fall asleep in the following situations in contrast to just feeling tired? This refers to your usual way in recent times. Even if you have not done some of these things recently, try to work out how they would have affected you. Use the following scale to choose the most appropriate number for each situation.</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">0 = Would never doze</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">1 = Slight chance of dozing</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">2 = Moderate chance of dozing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">3 = High chance of dozing</td> </tr> <tr> <td class=\"subtitle1\">Situation</td> <td class=\"subtitle1\">Chance of dozing</td> </tr> <tr> <td>Sitting and reading</td> <td class=\"centered\">__________</td> </tr> <tr> <td>Watching TV</td> <td class=\"centered\">__________</td> </tr> <tr> <td>Sitting inactive in a public place (eg, a theater or meeting)</td> <td class=\"centered\">__________</td> </tr> <tr> <td>As passenger in a car for an hour without break</td> <td class=\"centered\">__________</td> </tr> <tr> <td>Lying down to rest during the day when circumstances permit</td> <td class=\"centered\">__________</td> </tr> <tr> <td>Sitting and talking to someone</td> <td class=\"centered\">__________</td> </tr> <tr> <td>Sitting quietly after lunch without alcohol</td> <td class=\"centered\">__________</td> </tr> <tr> <td>In a car, while stopped for a few minutes in traffic</td> <td class=\"centered\">__________</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Redrawn from: Johns MW. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep 1991; 14:540.</div><div id=\"graphicVersion\">Graphic 77101 Version 3.0</div></div></div>"},"77104":{"type":"graphic_table","displayName":"Microbiology of preseptal and orbital cellulitis","title":"Microbiology of preseptal and orbital cellulitis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology of preseptal and orbital cellulitis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup span=\"7\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Preseptal cellulitis</td> <td class=\"subtitle1\" colspan=\"5\">Orbital cellulitis</td> </tr> <tr> <td class=\"subtitle2\">Chaudhry, et al<sup>[1]</sup></td> <td class=\"subtitle2\">Botting, et al<sup>[2]</sup></td> <td class=\"subtitle2\">McKinley, et al<sup>[3]</sup></td> <td class=\"subtitle2\">Seltz, et al<sup>[4]</sup></td> <td class=\"subtitle2\">Nageswaran, et al<sup>[5]</sup></td> <td class=\"subtitle2\">Botting, et al<sup>[2]</sup></td> <td class=\"subtitle2\">Goytia, et al<sup>[6]</sup></td> </tr> <tr> <td>Number of patients</td> <td>104</td> <td>227</td> <td>38</td> <td>94</td> <td>41</td> <td>35</td> <td>85</td> </tr> <tr class=\"divider_bottom\"> <td>Number of patients with a positive culture (except<sup>&#182;</sup>)</td> <td>36</td> <td>53<sup>&#182;</sup></td> <td>24</td> <td>29</td> <td>20</td> <td>11<sup>&#182;</sup></td> <td>29<sup>&#182;</sup></td> </tr> <tr> <td class=\"sublist1_start\"><em>Staphylococcus aureus</em></td> <td class=\"sublist1_start\">&#916;</td> <td class=\"sublist1_start\">32</td> <td class=\"sublist1_start\">11</td> <td class=\"sublist1_start\">8</td> <td class=\"sublist1_start\">3</td> <td class=\"sublist1_start\">7</td> <td class=\"sublist1_start\">14</td> </tr> <tr> <td class=\"sublist1\">MSSA</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">3</td> <td class=\"sublist_other\">7</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">7</td> </tr> <tr> <td class=\"sublist1\">MRSA</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">8</td> <td class=\"sublist_other\">1</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">NR</td> <td class=\"sublist_other\">7</td> </tr> <tr> <td>Alpha-hemolytic streptococci (including <em>S. pneumoniae</em>) or non-hemolytic streptococci</td> <td>&#916;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>4</td> <td>7</td> <td>&nbsp;</td> <td>15</td> </tr> <tr> <td>Beta-hemolytic streptococci (including <em>S. pyogenes</em>)</td> <td>&#916;</td> <td>7</td> <td>13</td> <td>6</td> <td>5</td> <td>3</td> <td>10</td> </tr> <tr> <td><em>Streptococcus anginosus</em> (formerly <em>S. milleri</em>)</td> <td>&nbsp;</td> <td>2</td> <td>&nbsp;</td> <td>14</td> <td>&nbsp;</td> <td>2</td> <td>&nbsp;</td> </tr> <tr> <td><em>Rothia mucilaginosa</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td><em>Haemophilus influenzae</em></td> <td>8</td> <td>5</td> <td>3</td> <td>3</td> <td>3</td> <td>&nbsp;</td> <td>5</td> </tr> <tr> <td><em>Haemophilus parainfluenzae</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td><em>Klebsiella pneumoniae</em></td> <td>3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1</td> </tr> <tr> <td><em>Moraxella catarrhalis</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><em>Arcanobacterium</em> spp</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1</td> <td>1</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td><em>Eikenella corrodens</em></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>1</td> <td>2</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Anaerobes</td> <td>&nbsp;</td> <td>2</td> <td>&nbsp;</td> <td>2</td> <td>8</td> <td>&nbsp;</td> <td>4</td> </tr> <tr> <td>Skin flora/contaminant</td> <td>&nbsp;</td> <td>5</td> <td>11<sup>&#9674;</sup></td> <td>12<sup>&#9674;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Possible pathogen<sup>&#167;</sup></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>10</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Sites of culture</td> <td>Blood, wound, abscess</td> <td>NR</td> <td>Blood, orbital abscess, eye, sinus, epidural abscess, nose</td> <td>Blood, sinus/orbit, subdural space</td> <td>Orbital abscess, subperiostial abscess, sinus</td> <td>NR</td> <td>Blood, endoscopic sinus, subperiosteal, intraorbital</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <EM>Staphylococcus aureus</EM>; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>; NR: not reported.<br />* Results are reported as the number of cultures that grew a given organism. Some cultures grew &gt;1 organism and some patients had &gt;1 positive culture.<br />¶ Results are reported as number of positive cultures (rather than number of patients with a positive culture); some patients may have had &gt;1 positive culture.<br />Δ <EM>Staphylococcus</EM> spp and <EM>Streptococcus</EM> spp were recovered from 26 (72 percent) of cultures, but the authors did not report the number of positive cultures for individual species.<br /><FONT class=lozenge>◊</FONT> In McKinley, et al<SUP>[3]</SUP>, coagulase-negative <EM>Staphylococcus</EM> spp was reported as a recovered organism, but in Seltz, et al<SUP>[4]</SUP>, this organism was classified as a contaminant. We have classified it as a contaminant for both studies.<br />§ The authors of this study classifed some (but not all) sinus/orbit cultures as possible pathogens rather than true pathogens.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Chaudhry IA, Shamsi FA, Elzaridi E, et al. Inpatient preseptal cellulitis: experience from a tertiary eye care centre. Br J Ophthalmol 2008; 92:1337. </LI>&#xD;&#xA;<LI>Botting AM, McIntosh D, Mahadevan M. Paediatric pre- and post-septal peri-orbital infections are different diseases. A retrospective review of 262 cases. Int J Pediatr Otorhinolaryngol 2008; 72:377. </LI>&#xD;&#xA;<LI>McKinley SH, Yen MT, Miller AM, Yen KG. Microbiology of pediatric orbital cellulitis. Am J Ophthalmol 2007; 144:497. </LI>&#xD;&#xA;<LI>Seltz LB, Smith J, Durairaj VD, et al. Microbiology and antibiotic management of orbital cellulitis. Pediatrics 2011; 127:e566. </LI>&#xD;&#xA;<LI>Nageswaran S, Woods CR, Benjamin DK Jr, et al. Orbital cellulitis in children. Pediatr Infect Dis J 2006; 25:695. </LI>&#xD;&#xA;<LI>Goytia VK, Giannoni CM, Edwards MS. Intraorbital and intracranial extension of sinusitis: comparative morbidity. J Pediatr 2011; 158:486. </LI></OL></div><div id=\"graphicVersion\">Graphic 77104 Version 3.0</div></div></div>"},"77105":{"type":"graphic_figure","displayName":"WBC differential CD4000","title":"WBC differential as obtained on an Abbott CD 4000 automated cell counter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">WBC differential as obtained on an Abbott CD 4000 automated cell counter</div><div class=\"cntnt\"><img style=\"width:354px; height:333px;\" src=\"images/HEME/77105_WBC_differential_CD4000.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a computer printout of a portion of a CBC as obtained on an Abbott CD 4000 automated cell counter. In this plot, white blood cells are separated by size (Y axis) and complexity (X axis). Shown here is the separation for neutrophils (orange), lymphocytes (light blue), and monocytes (purple). This CBC was obtained from a patient with a low total white blood cell count (3340 cells/microL), 16 percent neutrophils, 45 percent lymphocytes, and 38 percent monocytes.</div><div id=\"graphicVersion\">Graphic 77105 Version 2.0</div></div></div>"},"77108":{"type":"graphic_picture","displayName":"Diabetic nephropathy EM","title":"Basement membrane thickening in diabetic nephropathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basement membrane thickening in diabetic nephropathy</div><div class=\"cntnt\"><img style=\"width:378px; height:243px;\" src=\"images/NEPH/77108_Diabetic_nephropathy_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in diabetic nephropathy shows a 2 to 3 fold increase in the thickness of the glomerular basement membrane (GBM). Although not seen, the mesangium is also expanded by basement membrane-like material, a process that contributes to nodule formation and glomerulosclerosis.</div><div class=\"graphic_footnotes\">Mes: mesangium; Ep: epithelial cell.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 77108 Version 1.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"77112":{"type":"graphic_picture","displayName":"Wound repigmentation","title":"Wound repigmentation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Wound repigmentation</div><div class=\"cntnt\"><img style=\"width:504px; height:403px;\" src=\"images/SURG/77112_Wound_repigmentation_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Repigmentation of healed wounds occurs as melanocytes migrate from the epidermal appendages across the wound bed. Skin color in a healed wound is difficult to predict. Exposure to ultraviolet radiation can permanently increase the pigmentation. Bleaching agents are discouraged because of the risk of further tissue damage.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77112 Version 1.0</div></div></div>"},"77113":{"type":"graphic_diagnosticimage","displayName":"MRI findings in copper deficiency","title":"MRI findings in copper deficiency","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">MRI findings in copper deficiency</div><div class=\"cntnt\"><img style=\"width:470px; height:358px;\" src=\"images/NEURO/77113_MRI_find_copper_deficiency.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal (A) and axial (B) T2-weighted magnetic resonance images in a patient with copper deficiency showing increased signal in the paramedian aspect of the dorsal cervical cord.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Neeraj Kumar, MD.</div><div id=\"graphicVersion\">Graphic 77113 Version 3.0</div></div></div>"},"77114":{"type":"graphic_figure","displayName":"Interphalangeal finger joint anatomy and dislocation","title":"Interphalangeal finger joint anatomy and dislocation","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Interphalangeal finger joint anatomy and dislocation</div><div class=\"cntnt\"><img style=\"width:560px; height:468px;\" src=\"images/EM/77114_DIPPIPligaments.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic (A, B) and schematic (C) representation of an interphalangeal joint dislocation.</div><div class=\"graphic_reference\">Reproduced with permission from: Johnson FC, Okada PJ. Reduction of common joint dislocations and subluxations. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77114 Version 10.0</div></div></div>"},"77116":{"type":"graphic_picture","displayName":"Finger clubbing cyanosis","title":"Clubbing and cyanosis in Eisenmenger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Clubbing and cyanosis in Eisenmenger</div><div class=\"cntnt\"><img style=\"width:329px; height:216px;\" src=\"images/CARD/77116_Finger_clubbing_cyanosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clubbing and cyanosis of the fingers in a patient with Eisenmenger syndrome due to an atrial septal defect.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD.</div><div id=\"graphicVersion\">Graphic 77116 Version 2.0</div></div></div>"},"77117":{"type":"graphic_picture","displayName":"Test of shoulder external rotation strength","title":"Testing of shoulder external rotation strength","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Testing of shoulder external rotation strength</div><div class=\"cntnt\"><img style=\"width:444px; height:344px;\" src=\"images/EM/77117_Isometric_test_infraspinatu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">External rotation of the shoulder is performed primarily by the infraspinatus. The maneuver shown is used to assess the strength of the infraspinatus tendon. The patient's elbow is flexed to 90 degrees and held against the patient's body by the examiner's hand. The patient actively rotates the arm externally against the resistance of the examiner's other hand, placed at the wrist.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 77117 Version 3.0</div></div></div>"},"77118":{"type":"graphic_picture","displayName":"Acute rejection airway I","title":"Airway pattern of acute lung transplant rejection","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Airway pattern of acute lung transplant rejection</div><div class=\"cntnt\"><img style=\"width:360px; height:239px;\" src=\"images/PULM/77118_Acute_rejection_airway_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph demonstrating a lymphocytic inflammatory response surrounding the airway.</div><div class=\"graphic_reference\">Courtesy of L Kobzik, MD.</div><div id=\"graphicVersion\">Graphic 77118 Version 1.0</div></div></div>"},"77119":{"type":"graphic_diagnosticimage","displayName":"Fibrous pleural tumor II PA","title":"Fibrous tumor of the pleura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fibrous tumor of the pleura</div><div class=\"cntnt\"><img style=\"width:307px; height:324px;\" src=\"images/PULM/77119_FibrouspleuraltumorIIPA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest frontal radiograph shows a large mass blending with the left mediastinal contour and projecting into the left hemithorax.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77119 Version 3.0</div></div></div>"},"77121":{"type":"graphic_table","displayName":"Diseases assoc with cryos I","title":"Types of cryoglobulinemia and their clinical associations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Types of cryoglobulinemia and their clinical associations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Idiopathic</td> </tr> <tr> <td class=\"subtitle1_single\">Familial</td> </tr> <tr> <td>C4 deficiency</td> </tr> <tr> <td>C3 deficiency</td> </tr> <tr> <td>Factor XIII deficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"subtitle2_single\">Viral</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> </tr> <tr> <td class=\"indent1\">Hantavirus</td> </tr> <tr> <td class=\"indent1\">Hepatitis viruses: A, B, C</td> </tr> <tr> <td class=\"sublist2_start\">Herpes viruses</td> </tr> <tr> <td class=\"sublist2\">Epstein-Barr</td> </tr> <tr> <td class=\"sublist2\">Varicella-Zoster</td> </tr> <tr> <td class=\"indent1\">Human T cell leukemia virus (HTLV)-I</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV)</td> </tr> <tr> <td class=\"indent1\">Influenza virus</td> </tr> <tr> <td class=\"indent1\">Parvovirus B19</td> </tr> <tr> <td class=\"indent1\">Rubella virus</td> </tr> <tr> <td class=\"subtitle2_single\">Bacterial</td> </tr> <tr> <td class=\"indent1\">Brucella</td> </tr> <tr> <td class=\"indent1\">Infective endocarditis</td> </tr> <tr> <td class=\"indent1\">Postintestinal bypass arthritis</td> </tr> <tr> <td class=\"indent1\">Leprosy</td> </tr> <tr> <td class=\"indent1\">Lyme disease</td> </tr> <tr> <td class=\"indent1\">Rickettsia, including coxiella burnetii (Q fever)</td> </tr> <tr> <td class=\"indent1\">Poststreptococcal disease</td> </tr> <tr> <td class=\"indent1\">Syphilis</td> </tr> <tr> <td class=\"subtitle2_single\">Fungal</td> </tr> <tr> <td class=\"indent1\">Coccidiomycosis</td> </tr> <tr> <td class=\"subtitle2_single\">Parasitic</td> </tr> <tr> <td class=\"indent1\">Echinococcosis</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Malaria</td> </tr> <tr> <td class=\"indent1\">Schistosomiasis</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis</td> </tr> <tr> <td class=\"indent1\">Tropical splenomegaly syndrome</td> </tr> <tr> <td class=\"indent1\">Trypanasomiasis</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune</td> </tr> <tr> <td class=\"subtitle2_single\">Connective tissue diseases</td> </tr> <tr> <td class=\"indent1\">Drug-induced lupus</td> </tr> <tr> <td class=\"indent1\">Polymyositis</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Sj&#246;gren's syndrome</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Systemic sclerosis</td> </tr> <tr> <td class=\"sublist2_start\">Systemic vasculitis</td> </tr> <tr> <td class=\"sublist2\">Beh&#231;et's syndrome</td> </tr> <tr> <td class=\"sublist2\">Henoch-Sch&#246;nlein purpura</td> </tr> <tr> <td class=\"sublist2\">Kawasaki disease</td> </tr> <tr> <td class=\"sublist2\">Polyarteritis nodosa (+/- hepatitis B)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Dispenzieri, A, Gorevic, PD. Cryoglobulinemia. Hematology-Oncology Clinics of North America 1999; 42:2507. Copyright © 1999 W.B. Saunders Company.</div><div id=\"graphicVersion\">Graphic 77121 Version 3.0</div></div></div>"},"77122":{"type":"graphic_waveform","displayName":"Basic case 15 with answer","title":"Late evolution of anterior MI","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Late evolution of anterior MI</div><div class=\"cntnt\"><img style=\"width:540px; height:277px;\" src=\"images/CARD/77122_Basic_case_15_with_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Later stage in the evolution of an acute anterior ST-elevation/Q wave myocardial infarction. There is a QS pattern in leads V1 to V3 and T wave inversion in leads V2 to V4. The ST segment elevations in these leads have almost resolved.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 77122 Version 4.0</div></div></div>"},"77123":{"type":"graphic_diagnosticimage","displayName":"TB arthritis of the wrist","title":"Tuberculosis arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis arthritis</div><div class=\"cntnt\"><img style=\"width:338px; height:285px;\" src=\"images/ID/77123_TB_arthritis_of_the_wrist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tuberculous arthritis of the left wrist with destructive changes in the carpal bones (arrow) and radius and prominent soft tissue swelling (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Charles E Putnam, MD.</div><div id=\"graphicVersion\">Graphic 77123 Version 3.0</div></div></div>"},"77125":{"type":"graphic_table","displayName":"Cutaneous features","title":"Cutaneous features of urticarial vasculitis versus common urticaria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous features of urticarial vasculitis versus common urticaria</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Urticarial vasculitis</td> <td class=\"subtitle1\">Common urticaria</td> </tr> <tr> <td>Description</td> <td>Painful, tender, burning, and/or pruritic</td> <td>Mainly pruritic</td> </tr> <tr> <td>Persistence</td> <td>Between 24 and 72 hours</td> <td>Between 8&nbsp;and 24 hours</td> </tr> <tr> <td>Residual effects</td> <td>Purpura or hyperpigmentation</td> <td>None</td> </tr> <tr> <td>Predilection</td> <td>Anywhere</td> <td>Anywhere</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77125 Version 3.0</div></div></div>"},"77126":{"type":"graphic_diagnosticimage","displayName":"UGI duodenal bulb","title":"Upper gastrointestinal contrast studies demonstrating the duodenal bulb","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Upper gastrointestinal contrast studies demonstrating the duodenal bulb</div><div class=\"cntnt\"><img style=\"width:472px; height:216px;\" src=\"images/PEDS/77126_UGI_duodenal_bulb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the image on the left, the duodenal bulb is to left of the spine. In the image on the right, with malrotation, the duodenal bulb is overlying spine.</div><div class=\"graphic_reference\">Reproduced with permission from Carlo Buonomo, MD, Children's Hospital-Boston. Copyright © Carlo Buonomo, MD.</div><div id=\"graphicVersion\">Graphic 77126 Version 2.0</div></div></div>"},"77128":{"type":"graphic_diagnosticimage","displayName":"Thyrocervical collateral","title":"Thyrocervical collateral","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thyrocervical collateral</div><div class=\"cntnt\"><img style=\"width:199px; height:290px;\" src=\"images/SURG/77128_Thyrocervical_collateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The distal vertebral and basilar artery fed by thyrocervical collateral in patient with proximal vertebral artery occlusion.</div><div id=\"graphicVersion\">Graphic 77128 Version 1.0</div></div></div>"},"77129":{"type":"graphic_figure","displayName":"Direct laryngoscopy straight blade","title":"Direct laryngoscopy with a straight blade","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Direct laryngoscopy with a straight blade</div><div class=\"cntnt\"><img style=\"width:454px; height:608px;\" src=\"images/EM/77129_DLstraightblade.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Direct laryngoscopy using a straight blade.<br> (A) The head is positioned with the right hand, and the mouth is opened using the fifth finger of the left hand (if necessary).<br> (B) Alternately, the mouth may be opened with the thumb and index finger of the right hand using a &quot;scissor&quot; technique.<br> (C) The laryngoscope blade is inserted under direct vision over the tongue and into the vallecula. One attempt may be made at this point to elevate the epiglottis by lifting upward on the laryngoscope handle at a 45-degree angle.<br> (D) If unsuccessful, the tip of the blade is used to directly retract the epiglottis, revealing the vocal cords and glottic opening.</div><div class=\"graphic_reference\">Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77129 Version 12.0</div></div></div>"},"77130":{"type":"graphic_picture","displayName":"Lens trauma","title":"Lens trauma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lens trauma</div><div class=\"cntnt\"><img style=\"width:336px; height:259px;\" src=\"images/EM/77130_Lens_trauma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A photograph of a patient following blunt trauma. The lens is laterally dislocated (subluxed) as evidenced by the visible lens edge in this photograph.</div><div class=\"graphic_reference\">Photo courtesy of Kathryn A. Colby, MD, PhD, Massachusetts Eye and Ear Infirmary, Boston.</div><div id=\"graphicVersion\">Graphic 77130 Version 2.0</div></div></div>"},"77131":{"type":"graphic_picture","displayName":"Facial lipoatrophy","title":"HIV-associated facial lipoatrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HIV-associated facial lipoatrophy</div><div class=\"cntnt\"><img style=\"width:261px; height:172px;\" src=\"images/ENDO/77131_Fat_atrophy_in_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the hollow cheeks.</div><div class=\"graphic_reference\">Courtesy of AW Karchmer, MD, C Mantzoros, MD, and S Tsiodras, MD.</div><div id=\"graphicVersion\">Graphic 77131 Version 3.0</div></div></div>"},"77132":{"type":"graphic_diagnosticimage","displayName":"Fibroid embolization 4c","title":"Left uterine angiogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left uterine angiogram</div><div class=\"cntnt\"><img style=\"width:420px; height:275px;\" src=\"images/OBGYN/77132_Fibroid_embolization_4c.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left uterine angiogram after uterine artery embolization demonstrates successful occlusions of the left uterine artery and its branches (arrow).</div><div id=\"graphicVersion\">Graphic 77132 Version 2.0</div></div></div>"},"77133":{"type":"graphic_table","displayName":"Diagnostic tests for PCD","title":"Diagnostic tests for primary ciliary dyskinesia (PCD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for primary ciliary dyskinesia (PCD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Test </td> <td class=\"subtitle1\">Comments </td> <td class=\"subtitle1\">Disadvantages </td> </tr> <tr> <td>Nasal Nitric Oxide (nNO)</td> <td>Screening test that is easy to set up; becoming less expensive to set up.</td> <td>Both false positive and false negative results reported; depends somewhat on cut-off levels.</td> </tr> <tr> <td>Electron microscopy of nasal or bronchial biopsy</td> <td>Confirmation test. Somewhat painful. Requires experienced lab and interested pathologist.</td> <td>False negative in about 20 percent. Only available at specialized centers.</td> </tr> <tr> <td>High-speed videomicroscopy analysis (HSVA)</td> <td>Confirmation test. Requires nasal brush biopsy or nasal/bronchial biopsy, which may be painful. Must be performed on fresh specimen. Requires experienced lab.</td> <td>Seldom false negative. False positive results occur, so a positive test needs to be repeated. Only available at specialized centers.</td> </tr> <tr> <td>Cell culture of ciliated cells</td> <td>Confirmation test when other test-results are equivocal.</td> <td>Complicated, time consuming and available at few centers.</td> </tr> <tr> <td>Sperm motility</td> <td>Additional test when other test-results are equivocal.</td> <td>False negative as well as false positive results are reported.</td> </tr> <tr> <td>Genetic testing</td> <td>Mainly a research tool, but developing rapidly. Expensive.</td> <td>Identifies only 50 to 60 percent of patients.</td> </tr> <tr> <td>Inhalation of colloid albumin tagged with 99Tc</td> <td>So far mainly a \"research tool\" but entering into clinical practice in a few centers. Could be a useful test in the future.</td> <td>Exposure to radiation. Indirect test measuring mucociliary clearance. A high specificity and sensitivity for PCD is reported but number of reports is still limited.</td> </tr> <tr> <td>Saccharin test</td> <td>Screening test. Not recommended as false positive as well as false negative results are quite common. Easy to set up.</td> <td>False positive as well as false negative results are quite common. As a screening test, quite time consuming.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77133 Version 3.0</div></div></div>"},"77137":{"type":"graphic_diagnosticimage","displayName":"Lung gangrene","title":"Sequestrum of necrotic lung tissue","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sequestrum of necrotic lung tissue</div><div class=\"cntnt\"><img style=\"width:432px; height:318px;\" src=\"images/PULM/77137_Lung_gangrene_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic lung ball in a patient with pulmonary gangrene due to Klebsiella pneumonia. The CT scan demonstrates a large cavity replacing the right lower lobe. The central solid mass is surrounded by gas and transfixed to the lateral wall of the cavity: it represents a sequestrum composed of devascularized, necrotic lung tissue.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 77137 Version 4.0</div></div></div>"},"77138":{"type":"graphic_picture","displayName":"Inflammatory cells displacing myofibers in IBM","title":"Inflammatory cells displacing myofibers in IBM","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Inflammatory cells displacing myofibers in IBM</div><div class=\"cntnt\"><img style=\"width:480px; height:349px;\" src=\"images/RHEUM/77138_Imflam_displace_IBM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammatory cells invading necrotic myofibers and displacing other myofibers in inclusion body myositis.</div><div class=\"graphic_reference\">Courtesy of Steven A Greenberg, MD.</div><div id=\"graphicVersion\">Graphic 77138 Version 2.0</div></div></div>"},"77142":{"type":"graphic_table","displayName":"Standard assessment of concussion SAC","title":"Standardized assessment of concussion (SAC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Standardized assessment of concussion (SAC)</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Orientation (1 point each)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Month</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Date</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Day of week</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Year</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Time (within 1 hr)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Orientation score: 5</strong></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Immediate memory (1 point for each correct, total over 3 trials)</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Trial 1</td> <td class=\"subtitle2\">Trial 2</td> <td class=\"subtitle2\">Trial 3</td> </tr> <tr> <td class=\"indent1\">Word 1</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Word 2</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Word 3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Word 4</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Word 5</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>Immediate memory score: 15</strong></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Concentration</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"4\">Reverse digits (Go to next string length if correct on first trial. Stop if incorrect on both trials. 1 point each for each string length.)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">3-8-2</td> <td colspan=\"2\">5-1-8</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">2-7-9-3</td> <td colspan=\"2\">2-1-6-8</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">5-1-8-6-9</td> <td colspan=\"2\">9-4-1-7-5</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">6-9-7-3-5-1</td> <td colspan=\"2\">4-2-8-9-3-7</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"4\">Months of the year in reverse order (1 point for entire sequence correct)</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Dec-Nov-Oct-Sep-Aug-Jul</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Jun-May-Apr-Mar-Feb-Jan</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Concentration score: 5</strong></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Delayed recall (Approximately 5 minutes after Immediate memory. 1 point each.)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Word 1</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Word 2</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Word 3</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Word 4</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Word 5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\"><strong>Delayed recall score: 5</strong></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Summary of total scores:</td> </tr> <tr> <td class=\"indent1\">Orientation</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Immediate memory</td> <td class=\"centered\">15</td> </tr> <tr> <td class=\"indent1\">Concentration</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Delayed recall</td> <td class=\"centered\">5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Total score</strong></td> <td class=\"centered\"><strong>30</strong></td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"2\">The following may be performed between the Immediate memory and Delayed recall portions of this assessment when appropriate:</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Neurologic screening</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Recollection of the injury</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Strength</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Coordination</td> </tr> <tr> <td class=\"subtitle2_single\" colspan=\"2\">Exertional maneuvers</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">1 40-yard sprint</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">5 sit-ups</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">5 push-ups</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">5 knee bends</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: McCrea M, Kelly JP, Kluge J, et al. Standardized assessment of concussion in football players. Neurology 1997; 48:586. Copyright © 1997 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77142 Version 14.0</div></div></div>"},"77143":{"type":"graphic_picture","displayName":"UPJ obstruction","title":"Ureteropelvic junction obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ureteropelvic junction obstruction</div><div class=\"cntnt\"><img style=\"width:421px; height:336px;\" src=\"images/PEDS/77143_UPJ_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of: Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 77143 Version 2.0</div></div></div>"},"77147":{"type":"graphic_algorithm","displayName":"Acute pelvic pain in the postmenarchal adolescent female","title":"Acute pelvic pain in the postmenarchal adolescent female who is not pregnant","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Acute pelvic pain in the postmenarchal adolescent female who is not pregnant</div><div class=\"cntnt\"><img style=\"width:614px; height:912px;\" src=\"images/EM/77147_Pelvic_pain_adol_post_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RLQ: right lower quadrant; CVA: costovertebral angle; STD: sexually transmitted diseases; PID: pelvic inflammatory disease; DNA: deoxyribonucleic acid.<br />* Pelvic examination is suggested for sexually active patients.<br />&#182; Refer to UpToDate topics on Causes of abdominal pain in children and adolescents.<br />&Delta; Insterstitial cystitis, voiding dysfunction.</div><div id=\"graphicVersion\">Graphic 77147 Version 5.0</div></div></div>"},"77149":{"type":"graphic_diagnosticimage","displayName":"Brain MRI postpartum angiopathy","title":"Brain MRI of a 33-year-old woman with postpartum angiopathy (reversible cerebral vasoconstriction syndrome)","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Brain MRI of a 33-year-old woman with postpartum angiopathy (reversible cerebral vasoconstriction syndrome)</div><div class=\"cntnt\"><img style=\"width:525px; height:335px;\" src=\"images/NEURO/77149_Brain_MRI_33_W_postpart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Head MRI axial cuts: FLAIR (A, B, E, F) and apparent diffusion coefficient map (C, D, G, H) sequences.<br />Upper panel MRI, performed on admission, showed FLAIR hyperintensities and diffusion restriction in the right parietal lobe and in the splenium of the corpus callosum (arrows). Lower panel, done on hospital day 3 when the patient deteriorated, showed worsening bilateral lesions involving the cortex and subcortical white matter of the parietal, posterior frontal, and occipital lobes (arrows).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery.</div><div class=\"graphic_reference\">Reproduced with permission from: Maalouf N, Harik SI. Clinical reasoning: A 33-year-old woman with severe postpartum occipital headaches. Neurology 2012; 78:366. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77149 Version 7.0</div></div></div>"},"77150":{"type":"graphic_diagnosticimage","displayName":"Metastasis small intestine US","title":"Metastasis to the small intestine on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metastasis to the small intestine on ultrasound</div><div class=\"cntnt\"><img style=\"width:407px; height:249px;\" src=\"images/GAST/77150_Metastasis_small_intestine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An echopoor region (met) is visible adjacent to the jejunum in a patient later confirmed to have metastatic meloma. The lesion was confirmed to be melanoma.</div><div class=\"graphic_reference\">Courtesy of Christoph F Dietrich, MD.</div><div id=\"graphicVersion\">Graphic 77150 Version 3.0</div></div></div>"},"77152":{"type":"graphic_algorithm","displayName":"Evaluation and initial therapy cirrhosis ascites","title":"Evaluation and initial therapy of a patient with cirrhosis and ascites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation and initial therapy of a patient with cirrhosis and ascites</div><div class=\"cntnt\"><img style=\"width:376px; height:433px;\" src=\"images/GAST/77152_Eval_ther_cirrhosis_ascites.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">ACE: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers; NSAID: non-steroidal anti-inflammatory drug.</div><div class=\"graphic_reference\">Source: Runyon B. Management of adult patients with ascites due to cirrhosis: Update of 2012. AASLD Practice Guideline (February, 2013). Available at: <a href=\"http://www.aasld.org/practiceguidelines/Pages/default.aspx\" target=\"_blank\">http://www.aasld.org/practiceguidelines/Pages/default.aspx</a>.</div><div id=\"graphicVersion\">Graphic 77152 Version 4.0</div></div></div>"},"77154":{"type":"graphic_waveform","displayName":"ECG blocked APB","title":"Electrocardiogram (ECG) strips showing a blocked atrial premature beat (APB)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) strips showing a blocked atrial premature beat (APB)</div><div class=\"cntnt\"><img style=\"width:379px; height:199px;\" src=\"images/CARD/77154_Blocked_atrial_premature_be.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous electrocardiographic leads V1, II, and V5 show an atrial premature beat (red arrow) that is blocked within the atrioventricular node and not conducted to the ventricle. The P wave of the atrial premature beats alters the terminal portion of preceding T wave, seen in leads V1 and II, but not in lead V5.</div><div id=\"graphicVersion\">Graphic 77154 Version 3.0</div></div></div>"},"77155":{"type":"graphic_table","displayName":"Strep bovis susceptibilities I","title":"Representative susceptibilities of <EM>Streptococcus bovis </EM>to antibiotics*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Representative susceptibilities of <EM>Streptococcus bovis </EM>to antibiotics*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Antimicrobial</td> <td class=\"subtitle1\">MIC range, mcg/mL<sup>&#182;</sup></td> <td class=\"subtitle1\">MIC50 range, mcg/mL<sup>&#916;</sup></td> <td class=\"subtitle1\">MIC90 range, mcg/mL<sup>&#916;</sup></td> <td class=\"subtitle1\">References </td> </tr> <tr> <td>Penicillin</td> <td>&#8804;0.008 to 2</td> <td>0.03 to 0.09</td> <td>0.06 to 1</td> <td>Pfaller, 1997; Eggers, 1992; Thornsberry, 1974; Mouton, 1997; Kerawala, 2000; Hoogkamp-Korstanje, 2000; Streit, 2005; Moet, 2007</td> </tr> <tr> <td>Ampicillin</td> <td>&#8804;0.015 to 0.25</td> <td>0.03 to 0.25</td> <td>0.25</td> <td>Eggers, 1992; Fass, 1991</td> </tr> <tr> <td>Amoxicillin</td> <td>0.06 to 8</td> <td>0.06</td> <td>0.25</td> <td>Mouton, 1997</td> </tr> <tr> <td>Piperacillin</td> <td>0.125 to 0.5</td> <td>0.25</td> <td>0.25</td> <td>Etienne, 1988</td> </tr> <tr> <td>Cefuroxime</td> <td>&#8804;0.01 to 2</td> <td>0.125</td> <td>0.12 to 0.25</td> <td>Mouton, 1997; Fass, 1990; Fass, 1993</td> </tr> <tr> <td>Cefotaxime</td> <td>0.016 to 0.25</td> <td>0.063 to 0.125 </td> <td>0.25</td> <td>Eggers, 1992; Mouton, 1997</td> </tr> <tr> <td>Ceftriaxone</td> <td>0.03 to 0.38</td> <td>0.125</td> <td>0.125</td> <td>Pfaller, 1997; Etienne, 1988</td> </tr> <tr> <td>Ceftazidime</td> <td>0.25 to 1</td> <td>0.5</td> <td>1.0</td> <td>Etienne, 1988</td> </tr> <tr> <td>Oxacillin</td> <td>&#8804;0.015 to 0.5</td> <td>0.13</td> <td>0.25</td> <td>Fass, 1991</td> </tr> <tr> <td>Imipenem</td> <td>0.007 to 0.25</td> <td>&#8804;0.008 to 0.12 </td> <td>&#8804;0.008 to 0.25</td> <td>Eggers, 1992; Etienne, 1988; Schouten, 1997; Hoogkamp-Korstanje, 2000</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MIC: minimum inhibitory concentration.<br />* Compilations of susceptibility data for <EM>S. bovis </EM>need to be viewed with caution because they were generated by different methods from various geographically disparate collections over a number of years. Inaccuracies in speciation were also possible in these studies. Thus, direct comparisons of antimicrobial potencies should not be made.<br />¶&nbsp;Minimum and maximum values of MIC ranges given.<br />Δ Range of concentrations inhibiting 50 percent (MIC50) and 90 percent (MIC90) of isolates.</div><div id=\"graphicVersion\">Graphic 77155 Version 4.0</div></div></div>"},"77156":{"type":"graphic_table","displayName":"Treatment results NPC","title":"Survival rates for nasopharyngeal cancer in an endemic population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Survival rates for nasopharyngeal cancer in an endemic population</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Stage\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Percent of patients\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Five-year OS, percent\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>I</td>\r\n  \r\n   <td>7</td>\r\n  \r\n   <td>90</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>II</td>\r\n  \r\n   <td>41</td>\r\n  \r\n   <td>84</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>III</td>\r\n  \r\n   <td>25</td>\r\n  \r\n   <td>75</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>IVA-B</td>\r\n  \r\n   <td>28</td>\r\n  \r\n   <td>58</td>\r\n  \r\n   </tr>\r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=48478&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Treatment_results_NPC.htm</title></head></div><div class=\"graphic_footnotes\">OS: overall survival.</div><div class=\"graphic_reference\">Data from: Lee AW, Sze WM, Au JS, et al. Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys 2005; 61:1107.</div><div id=\"graphicVersion\">Graphic 77156 Version 2.0</div></div></div>"},"77157":{"type":"graphic_picture","displayName":"Normal cervix PI","title":"Picture of a normal cervix","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Picture of a normal cervix</div><div class=\"cntnt\"><img style=\"width:530px; height:424px;\" src=\"images/PI/77157_Normal_cervix_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: O'Connor DM, Brotzman GL, Apgar BS. Glossary. In: Colposcopy Principles and Practice, Apgar BS, Brotzman GL, Spitzer M (Eds), W.B. Saunders Company, Philadelphia 2002. p.137. Copyright &copy; 2002 Elsevier.</div><div id=\"graphicVersion\">Graphic 77157 Version 3.0</div></div></div>"},"77160":{"type":"graphic_picture","displayName":"Mantle cell lymphoma Light","title":"Mantle cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mantle cell lymphoma</div><div class=\"cntnt\"><img style=\"width:438px; height:287px;\" src=\"images/GAST/77160_Mantle_cell_lymphoma_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a mantle cell lymphoma shows diffuse proliferation of small to medium-sized lymphoid cells with slight nuclear irregularity. A residual naked germinal center is seen in the upper left-hand corner (400x).</div><div class=\"graphic_reference\">Courtesy of Paul C Schroy, III, MD.</div><div id=\"graphicVersion\">Graphic 77160 Version 1.0</div></div></div>"},"77161":{"type":"graphic_diagnosticimage","displayName":"Endometrioma sonogram","title":"Endometrioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endometrioma</div><div class=\"cntnt\"><img style=\"width:432px; height:343px;\" src=\"images/OBGYN/77161_Endometrioma_sonogram.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of the right adnexa showing an endometrioma of the right ovary. The homogeneous echo pattern of the cyst contents (ie, \"ground-glass\" appearance) is characteristic of an endometrioma (short arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright © Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 77161 Version 3.0</div></div></div>"},"77164":{"type":"graphic_diagnosticimage","displayName":"US megaureter transverse","title":"Transverse ultrasonographic view of a megaureter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse ultrasonographic view of a megaureter</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PEDS/77164_US_megaureter_transverse.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77164 Version 2.0</div></div></div>"},"77165":{"type":"graphic_table","displayName":"Interventional therapies for low back pain","title":"Interventional therapies for low back pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interventional therapies for low back pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Net benefit*</td> <td class=\"subtitle1\">Graded recommendation<sup>&#182;</sup></td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Epidural steroid injection</td> <td>Sciatica or prolapsed lumbar disc with radiculopathy</td> <td>Moderate (short-term only)</td> <td>Suggested <strong>(2B)</strong></td> <td>Some higher-quality trials found no benefits.</td> </tr> <tr> <td>Intradiscal corticosteroid injection</td> <td>Sciatica or prolapsed lumbar disc with radiculopathy</td> <td>No effect (versus chemonucleolysis)</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Local injections</td> <td>Sciatica or prolapsed lumbar disc with radiculopathy</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Radiofrequency denervation</td> <td>Sciatica or prolapsed lumbar disc with radiculopathy</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Facet joint (intraarticular) injection</td> <td>Presumed facet joint pain</td> <td>No effect</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Medial branch block (therapeutic)</td> <td>Presumed facet joint pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Radiofrequency denervation</td> <td>Presumed facet joint pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Intradiscal corticosteroid injection</td> <td>Presumed discogenic low back pain</td> <td>No effect</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Intradiscal electrothermal therapy</td> <td>Presumed discogenic low back pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Intradiscal anti-TNF injections</td> <td>Presumed discogenic low back pain</td> <td>No effect</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Intradiscal methylene blue injection</td> <td>Presumed discogenic low back pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Percutaneous intradiscal radiofrequency thermocoagulation</td> <td>Presumed discogenic low back pain</td> <td>No effect</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Radiofrequency denervation</td> <td>Presumed discogenic low back pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Epidural steroid injection</td> <td>Spinal stenosis</td> <td>No effect</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Epidural steroid injection</td> <td>Nonspecific low back pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Botulinum toxin injection</td> <td>Nonspecific low back pain</td> <td>Moderate (short-term only)</td> <td>Suggest not using <strong>(2C)</strong></td> <td>&nbsp;</td> </tr> <tr> <td>Local injections</td> <td>Nonspecific low back pain</td> <td>Unable to determine</td> <td>Suggest not using <strong>(2C)</strong></td> <td> <p>Interventions varied substantially between trials.</p> No higher-quality trials, all trials had small sample sizes.</td> </tr> <tr> <td>Prolotherapy</td> <td>Nonspecific low back pain</td> <td>No effect</td> <td>Suggest not using <strong>(2B)</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TNF: tumor necrosis factor.<br />* Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5 to 10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1 to 2 points on the Roland Morris Disability Questionnaire (RDQ), 10 to 20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2 to 0.5. Moderate benefit defined as 10 to 20 points on a VAS for pain, 2 to 5 points on the RDQ, 10 to 20 points on the ODI, or a SMD of 0.5 to 0.8. Large benefit defined as &gt;20 points on a 100-point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.<br />¶ Grading:<br /><STRONG>1A</STRONG> - Strong recommendation. High quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.<br /><STRONG>1B</STRONG> - Strong recommendation. Moderate quality evidence. Strong recommendation, likely to apply to most patients.<br /><STRONG>1C</STRONG> - Strong recommendation. Low quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.<br /><STRONG>2A</STRONG> - Weak recommendation. High quality evidence. Weak recommendation, best action may differ depending on circumstances or patients or societal values.<br /><STRONG>2B</STRONG> - Weak recommendation. Moderate quality evidence. Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.<br /><STRONG>2C</STRONG> - Weak recommendation. Low quality evidence. Very weak recommendation; other alternatives may be equally reasonable.</div><div id=\"graphicVersion\">Graphic 77165 Version 7.0</div></div></div>"},"77166":{"type":"graphic_picture","displayName":"Microinjection into fert egg","title":"Microinjection into fertilized egg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microinjection into fertilized egg</div><div class=\"cntnt\"><img style=\"width:360px; height:288px;\" src=\"images/PC/77166_Microinjection_into_fert_eg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph showing microinjection of DNA into fertilized egg.</div><div class=\"graphic_reference\">Reproduced with permission from: Transgenic mouse and gene targeting core. Http://cancer.ucsd.edu/tgm/ genetargeting.html/#injection. Copyright © 2002 University of California, San Diego.</div><div id=\"graphicVersion\">Graphic 77166 Version 2.0</div></div></div>"},"77170":{"type":"graphic_table","displayName":"Hib schedule US","title":"Recommended routine schedule of administration of conjugate <em>Haemophilus influenzae</em> type b vaccine for children in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommended routine schedule of administration of conjugate <em>Haemophilus influenzae</em> type b vaccine for children in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Primary series<br /> (&#60;12 months of age)</td> <td class=\"subtitle1\">Booster<br /> (&#8805;12 months of age)</td> </tr> <tr> <td>2, 4, and 6 months for ActHIB, Hiberix, or DTaP-IPV/PRP-T</td> <td rowspan=\"2\"> <p>12 through 15 months for PRP-OMP, ActHIB, and Hiberix</p> 15 through 18 months for DTaP-IPV/PRP-T*</td> </tr> <tr> <td>2 and 4 months for PRP-OMP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DTaP: diphtheria tetanus-toxoid-acellular pertussis vaccine; IPV: inactivated polio vaccine; PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; PRP-OMP: polyribosylribitol phosphate conjugated to the outer membrane protein complex of <EM>Neisseria meningitidis</EM>.<br />* May be given as early as age 12 months of age, provided at least six months have elapsed since the third dose of DTaP.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). <A spellcheck=true href=\"http://www.cdc.gov/mmwr/pdf/rr/rr6301.pdf\" target=_blank>MMWR Recomm Rep 2014; 63:1</A>.</LI>&#xD;&#xA;<LI>Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2018. Available at: <A spellcheck=true href=\"http://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html\" target=_blank>www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html</A> (Accessed on February 14, 2018).</LI></OL></div><div id=\"graphicVersion\">Graphic 77170 Version 19.0</div></div></div>"},"77171":{"type":"graphic_table","displayName":"Beta blockers drug interactions","title":"Major drug interactions with beta blockers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major drug interactions with beta blockers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Possible effects</td> <td class=\"subtitle1\">Precautions</td> </tr> <tr> <td>Aluminum hydroxide gel</td> <td>Decreased beta-blocker adsorption and therapeutic effect</td> <td>Avoid&nbsp;beta-blocker-aluminum hydroxide combination</td> </tr> <tr> <td>Aminophylline</td> <td>Mutual inhibition</td> <td>Observe patient's response</td> </tr> <tr> <td>Amiodarone</td> <td>May induce cardiac arrest</td> <td>Combination should be used with extreme caution</td> </tr> <tr> <td>Antidiabetic agents</td> <td>Enhanced hypoglycemia; hypertension</td> <td>Monitor for altered diabetic response</td> </tr> <tr> <td>Calcium channel inhibitors (verapamil, diltiazem)</td> <td>Potentiation of bradycardia, myocardial depression, and hypotension</td> <td>Avoid use, although few patients show ill effects</td> </tr> <tr> <td>Cimetidine</td> <td>Prolongs half-life of propranolol</td> <td>Combination should be used with caution</td> </tr> <tr> <td>Clonidine</td> <td>Hypertension during clonidine withdrawal</td> <td>Monitor for hypertensive response; withdraw&nbsp;beta-blocker before withdrawing clonidine</td> </tr> <tr> <td>Digitalis glycosides</td> <td>Potentiation of bradycardia</td> <td>Observe patient's response; interactions may benefit angina patients with abnormal ventricular function</td> </tr> <tr> <td>Epinephrine</td> <td>Hypertension; bradycardia</td> <td>Administer epinephrine cautiously; cardioselective&nbsp;beta-blocker may be safer</td> </tr> <tr> <td>Ergot alkaloids</td> <td>Excessive vasoconstriction</td> <td>Observe patient's response; few patients show ill effects</td> </tr> <tr> <td>Glucagon</td> <td>Inhibition of hyperglycemic effect</td> <td>Monitor for reduced response</td> </tr> <tr> <td>Halofenate</td> <td>Reduced&nbsp;beta-blocking activity; induction of propranolol withdrawal rebound</td> <td>Observe for impaired response to&nbsp;beta-blockade</td> </tr> <tr> <td>Indomethacin</td> <td>Inhibition of antihypertensive response to&nbsp;beta-blockade</td> <td>Observe patient's response</td> </tr> <tr> <td>Isoproterenol</td> <td>Mutual inhibition</td> <td>Avoid concurrent use or choose cardiac-selective beta-blocker</td> </tr> <tr> <td>Levodopa</td> <td>Antagonism of levodopa's hypotensive and positive inotropic effects</td> <td>Monitor for altered response; interaction may have favorable results</td> </tr> <tr> <td>Lidocaine</td> <td>Propranolol pretreatment increases lidocaine levels with potential toxicity</td> <td>Combination should be used with caution; use lower doses of lidocaine</td> </tr> <tr> <td>Methyldopa</td> <td>Hypertension during stress</td> <td>Monitor for hypertensive episodes</td> </tr> <tr> <td>MAO inhibitors</td> <td>Uncertain, theoretical</td> <td>Manufacturer of propranolol considers concurrent use contraindicated</td> </tr> <tr> <td>Phenothazines</td> <td>Additive hypotensive effects</td> <td>Monitor for altered response, especially with high doses of phenothiazines</td> </tr> <tr> <td>Phenylpropranolamine</td> <td>Severe hypertensive reaction</td> <td>&nbsp;</td> </tr> <tr> <td>Phenytoin</td> <td>Additive cardiac depressant effects</td> <td>Administer IV phenytoin with great caution</td> </tr> <tr> <td>Quinidine</td> <td>Additive cardiac depressant effects</td> <td>Observe patient's response; few patient show ill effects</td> </tr> <tr> <td>Reserpine</td> <td>Excessive sympathetic blockade</td> <td>Observe patient's response</td> </tr> <tr> <td>Rifampin</td> <td>Increased metabolism of&nbsp;beta-blockers</td> <td>Observe patient's response</td> </tr> <tr> <td>Smoking</td> <td>Increased metabolism of&nbsp;beta-blockers</td> <td>Observe patient's response</td> </tr> <tr> <td>Tricyclic antidepressants</td> <td>Inhibits negative inotropic and chronotropic effects of&nbsp;beta-blockers</td> <td>Observe patient's response</td> </tr> <tr> <td>Tubocurarine</td> <td>Enhanced neuromuscular blockade</td> <td>Observe response in surgical patients, especially after high doses of propranolol</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77171 Version 2.0</div></div></div>"},"77173":{"type":"graphic_table","displayName":"Desensitiz for chemo hypersens","title":"Premedication regimens","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Premedication regimens</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Intravenous premedication regimen\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Premedications (last dose immediately prior to infusion of chemotherapy)\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Dexamethasone, 10-20 mg iv every 6 hours for 4 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Cimetidine, 300 mg iv every 8 hours for 3 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Diphenhydramine hydrochloride, 25-50 mg iv every 6 hours for 4 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Optional\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Ondansetron hydrochloride (Zofran), 8 mg iv every 6 hours for 4 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Albuterol nebulizer, 2.5 mg every 6 hours for 4 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\">\r\n  \r\n   Oral premedication regimen\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Premedications\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Dexamethasone, 20 mg po every 6 hours for 4 to 8 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Cimetidine, 300-600 mg po every 8 hours for 3 to 6 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Diphenhydramine hydrochloride, 25-50 mg every 6 hours for 4 to 8 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Optional\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Albuterol multidose inhaler, two puffs administered every 6 hours for 8 doses\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Immediately prior to infusion of chemotherapy\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Dexamethasone, 20 mg iv\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Cimetidine, 300-600 mg iv\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Diphenhydramine hydrochloride, 25-50 mg iv\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\">\r\n  \r\n   Optional\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Lorazepam, 0.5 mg iv\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   Ondansetron hydrochloride, 8 mg iv\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent1\">\r\n  \r\n   May continue dexamethasone, cimetidine, diphenhydramine during infusion\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_footnotes\">Note: Patients with delayed reactions may continue dexamethasone, 8 mg po every 12 hours for 5 days as outpatients.</div><div class=\"graphic_reference\">Reproduced with permission from: Robinson, JB, Singh, D, Bodurka-Bevers, DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecologic Oncol 2001; 82:555. Copyright &#169; 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 77173 Version 1.0</div></div></div>"},"77175":{"type":"graphic_picture","displayName":"Esophageal adenocarcinoma endosc","title":"Endoscopic appearance of an esophageal adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic appearance of an esophageal adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:252px; height:258px;\" src=\"images/GAST/77175_Esoph_adenoca_CPC_Endosc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopy revealed a fungating mass in the distal esophagus extending from the gastroesophageal junction with complete obstruction of the distal esophageal lumen.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.</div><div id=\"graphicVersion\">Graphic 77175 Version 3.0</div></div></div>"},"77177":{"type":"graphic_figure","displayName":"Closure outer myometrium","title":"Closure of the outer myometrium during myomectomy","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Closure of the outer myometrium during myomectomy</div><div class=\"cntnt\"><img style=\"width:526px; height:364px;\" src=\"images/OBGYN/77177_Closure_outer_myometrium.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 77177 Version 2.0</div></div></div>"},"77180":{"type":"graphic_table","displayName":"Muscles involved in thumb movement","title":"Muscles involved in thumb movement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscles involved in thumb movement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Function</td> </tr> <tr> <td>Extensor pollicis longus (EPL)</td> <td>Extends IP joint</td> </tr> <tr> <td>Flexor pollicis longus (FPL)</td> <td>Flexes IP joint</td> </tr> <tr> <td>Extensor pollicis brevis (EPB)</td> <td>Extends MCP joint</td> </tr> <tr> <td>Flexor pollicis brevis (FPB)</td> <td>Flexes MCP joint</td> </tr> <tr> <td> <p>Abductor pollicis longus (APL)</p> <p>Abductor pollicis brevis (APB)</p> </td> <td>Abducts thumb metacarpal</td> </tr> <tr> <td>Adductor pollicis (AP)</td> <td>Adducts thumb metacarpal</td> </tr> <tr> <td>Opponens pollicis (OP)</td> <td>Flexes and abducts thumb metacarpal (pinch with little finger isolates OP)</td> </tr> <tr> <td>First interosseus</td> <td>Works with OP to enable pinch against index finger</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IP: interphalangeal; MCP: metacarpophalangeal.</div><div id=\"graphicVersion\">Graphic 77180 Version 3.0</div></div></div>"},"77183":{"type":"graphic_waveform","displayName":"Pulsatile GnRH and LH release","title":"Relationship between GnRH pulses and LH release","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Relationship between GnRH pulses and LH release</div><div class=\"cntnt\"><img style=\"width:464px; height:266px;\" src=\"images/ENDO/77183_Pulsatile_GnRH_and_LH_relea.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Concentrations of gonadotropin-releasing hormone in hypophysial portal plasma and luteinizing hormone in jugular venous plasma in five ovariectomized ewes during estrogen-induced LH surges. Each pulse of LH measured in the peripheral blood corresponded to a hypothalamic pulse of GnRH into the portal system in a one-to-one relationship.</div><div class=\"graphic_reference\">Data from Clarke, IJ, Endocrinology 1993; 133:1624.</div><div id=\"graphicVersion\">Graphic 77183 Version 2.0</div></div></div>"},"77184":{"type":"graphic_figure","displayName":"Lymph nodes female PI","title":"Lymph node groups in women","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Lymph node groups in women</div><div class=\"cntnt\"><img style=\"width:528px; height:584px;\" src=\"images/PI/77184_Lymph_nodes_female_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The green dots indicate the location of lymph nodes, which are found throughout the body.</div><div id=\"graphicVersion\">Graphic 77184 Version 4.0</div></div></div>"},"77185":{"type":"graphic_table","displayName":"Classification of deficient response to pneumococcal vaccination","title":"Classification of deficient response to pneumococcal vaccination","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of deficient response to pneumococcal vaccination</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Severity of deficiency</td> <td class=\"subtitle1\" colspan=\"2\">IgG antipneumococcal antibodies</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Postimmunization</td> </tr> <tr> <td class=\"subtitle3\">2 to 5 years of age</td> <td class=\"subtitle3\">&#8805;6 years of age</td> </tr> <tr> <td>Severe</td> <td>Protective antibody levels for &#8804;2 serotypes</td> <td>Protective antibody levels for &#8804;2 serotypes</td> </tr> <tr> <td>Moderate</td> <td>Protective antibody levels for &#60;50% of serotypes administered</td> <td>Protective antibody levels for &#60;70% of serotypes administered</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A protective antibody concentration is defined as ≥1.3 micrograms/mL, based on response to polysaccharide vaccine serotypes in patients &gt;2 years of age.<br />If a patient previously received the conjugate pneumococcal vaccine and had protective titers to those serotypes, then an adequate response would be expected to the age-appropriate percentage (50 or 70%) of those serotypes exclusive to the polysaccharide vaccine.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G.</div><div class=\"graphic_reference\">Adapted from: Sorensen RU, Moore C. Peds Clin N A 2000; 42:1225.</div><div id=\"graphicVersion\">Graphic 77185 Version 6.0</div></div></div>"},"77187":{"type":"graphic_table","displayName":"Medical eval IEI","title":"Medical evaluation for patients with symptoms of idiopathic environmental intolerance","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical evaluation for patients with symptoms of idiopathic environmental intolerance</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n  <td>1. Complete medical and environmental history; medication history. Focus on exposures at home and in the workplace</td>\n </tr>\n <tr>\n  <td>2. Thorough physical examination, including neurologic examination</td>\n </tr>\n <tr>\n  <td>3. Mental status examination and formal psychiatric evaluation</td>\n </tr>\n <tr>\n  <td>4. Routine laboratory studies, which may include:</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Complete blood count, with differential</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Serum electrolytes</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Serum glucose</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Blood urea nitrogen</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Creatinine</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Liver function tests</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Thyroid function tests</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Urinalysis</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Electrocardiogram</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Chest x-ray</td>\n </tr>\n <tr>\n  <td>5. Neuropsychological testing for patients with cognitive complains (eg, memory impairment), or to rule out alternate diagnoses (eg, dementia)</td>\n </tr>\n <tr>\n  <td>6. Immunologic tests for patients reporting allergies or immune dysfunction</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Skin tests or in vitro assays with common allergens</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Immunoglobulin levels</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Complement levels</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Selected auto-antibody assays</td>\n </tr>\n <tr>\n  <td class=\"sublist2\">Simple T- and B-cell assays</td>\n </tr>\n <tr>\n  <td>7. Other tests will be guided by the patient's complaints (eg, spirometry for patients whose primary complaints are respiratory, nerve conduction tests for patients with persistent numbness and tingling in the extremities)</td>\n </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">16.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=59788&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Medical_eval_IEI.htm</title></head></div><div id=\"graphicVersion\">Graphic 77187 Version 1.0</div></div></div>"},"77189":{"type":"graphic_table","displayName":"Bootzins stimulus control","title":"Stimulus control therapy rules","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stimulus control therapy rules</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Go to bed only when sleepy.</td> </tr> <tr> <td>2. Do not watch television, read, eat, or worry while in bed. Use bed only for sleep and sex.</td> </tr> <tr> <td>3. Get out of bed if unable to fall asleep within&nbsp;20 minutes and go to another room. Return to bed only when sleepy. Repeat this step as many times as necessary throughout the night.</td> </tr> <tr> <td>4. Set an alarm clock to wake up at a fixed time each morning, including weekends.</td> </tr> <tr> <td>5. Do not take a nap during the day.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Bootzin RR, Perlis ML. Nonpharmacologic treatments of insomnia. J Clin Psychiatry 1992; 53:37.</div><div id=\"graphicVersion\">Graphic 77189 Version 3.0</div></div></div>"},"77191":{"type":"graphic_diagnosticimage","displayName":"Echo image abdominal aorta","title":"Echocardiographic image of the abdominal aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiographic image of the abdominal aorta</div><div class=\"cntnt\"><img style=\"width:413px; height:258px;\" src=\"images/CARD/77191_Echo_image_abdominal_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The abdominal (Ab) aorta (Ao) is seen from the subcostal long axis (panel A) and short axis views (panel B). In this thin patient the neural canal (NC) is seen through the intervertegral disc in the short axis view.</div><div class=\"graphic_footnotes\">RA: right atrium.</div><div id=\"graphicVersion\">Graphic 77191 Version 3.0</div></div></div>"},"77192":{"type":"graphic_picture","displayName":"Carcinoid heart disease","title":"Carcinoid heart disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Carcinoid heart disease</div><div class=\"cntnt\"><img style=\"width:301px; height:559px;\" src=\"images/ONC/77192_Carcinoid_heart_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Pulmonary valve (autopsy specimen, viewed from above). Diffuse carcinoid plaques have caused thickening and retraction of all three cusps and appreciable constriction of the annulus (valve ring). The result is a small fixed triangular orifice that was both stenotic and regurgitant clinically. B) Normal pulmonary valve, for comparison with (A) (autopsy specimen, viewed from above). All three cusps are thin and coapt (come together) centrally, and the annulus (valve ring) is neither constricted or dilated.</div><div class=\"graphic_reference\">Courtesy of Dr. William D. Edwards, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.</div><div id=\"graphicVersion\">Graphic 77192 Version 2.0</div></div></div>"},"77193":{"type":"graphic_picture","displayName":"Coccidioidomycosis silver stain","title":"Coccidioidomycosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Coccidioidomycosis</div><div class=\"cntnt\"><img style=\"width:284px; height:188px;\" src=\"images/PULM/77193_Coccidioidomycosis_silver_s.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph of a silver stained slide showing multiple organisms of <EM>Coccidioides</EM> spp. Some spherules contain multiple small endospores (arrow). Large empty spherules can resemble the round yeast of <EM>Blastomyces dermatitidis</EM>, but the spherules of coccidioides tend to be larger, lack basophilic nuclei, and do not bud.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 77193 Version 3.0</div></div></div>"},"77194":{"type":"graphic_figure","displayName":"Patient position and catheter","title":"Patient position and the pulmonary artery catheter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patient position and the pulmonary artery catheter</div><div class=\"cntnt\"><img style=\"width:363px; height:370px;\" src=\"images/PULM/77194_Patient_position_and_cathet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic illustration of the phlebostatic level. As the patient moves from the flat to the upright position, the phlebostatic level rotates on the axis and remains horizontal.</div><div class=\"graphic_reference\">Redrawn from Bridges, EJ, Woods, SL, Heart Lung 1993; 22:99.</div><div id=\"graphicVersion\">Graphic 77194 Version 1.0</div></div></div>"},"77195":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM PA gram V","title":"Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PULM/77195_Pulm_AVM_PA_gram_V.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pulmonary venous phase shows abnormally dilated distorted pulmonary veins, but no right-to-left shunt.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77195 Version 2.0</div></div></div>"},"77196":{"type":"graphic_table","displayName":"Immunologic sys drug rxns","title":"Comparison of systemic immunologic drug reactions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of systemic immunologic drug reactions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of immunologic drug reaction</td> <td class=\"subtitle1\">Incidence</td> <td class=\"subtitle1\">Signs and symptoms</td> <td class=\"subtitle1\">Timing</td> <td class=\"subtitle1\">Common culprit drugs</td> <td class=\"subtitle1\">Diagnostic testing available?</td> </tr> <tr class=\"divider_bottom\"> <td> <p>IgE, mast cell and basophil mediated</p> Type I Gell and Coombs</td> <td>Common</td> <td>Urticaria/angioedema, bronchospasm, laryngeal edema, nausea, vomiting, hypotension, shock</td> <td> <p>Immediate - Seconds to one hour after last dose</p> <p>May be slightly more delayed if drug slowly absorbed</p> Faster and more severe upon reexposure</td> <td>Beta-lactam antibiotics (penicillins and cephalosporins), muscle relaxants, foreign proteins (eg, cetuximab, rituximab), platinum-based chemotherapy (eg, carboplatin, cisplatin)</td> <td> <p>YES</p> <p>At time of reaction - Serum tryptase</p> Later - Skin prick and intradermal testing</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Antibody-mediated (IgG and IgM) cell destruction</p> Type II Gell and Coombs</td> <td>Uncommon</td> <td> <p>Hemolytic anemia</p> <p>Thrombocytopenia</p> Neutropenia or agranulocytosis</td> <td> <p>Delayed - Days to weeks after beginning therapy</p> <p>May occur months into long-term treatments</p> Faster upon reexposure</td> <td>Beta-lactam antibiotics, NSAIDs, quinidine, methyldopa, ticlopidine</td> <td> <p>YES</p> <p>Direct Coombs</p> <p>Tests for antiplatelet antibodies</p> Tests for antineutrophil antibodies</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Immune complex-mediated tissue damage</p> Type III Gell and Coombs</td> <td>Uncommon</td> <td> <p>Serum sickness, serum-sickness like reactions</p> <p>Vasculitis (eg, cutaneous)</p> <p>Drug fever</p> Acute glomerulonephritis</td> <td> <p>Delayed - Weeks to months after beginning therapy</p> Faster on reexposure</td> <td>Beta-lactam antibiotics, sulfonamide antibiotics, sirolimus/tacrolimus</td> <td> <p>No direct diagnostic testing available. Diagnosis is based on patterns of clinical and laboratory findings.</p> Biopsy of affected tissue is sometimes helpful.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Mediated by T cells</p> <p>+/&ndash; other cell types (esp eosinophils, neutrophils)</p> Type IV Gell and Coombs</td> <td>Common</td> <td> <p>Prominent skin findings +/&ndash; other organ involvement - Exanthematous (morbilliform) eruption</p> <p>DRESS/DiHS</p> <p>AGEP</p> Exfoliative dermatoses (SJS/TEN)</td> <td>Delayed at least 24 to 48 hours after beginning therapy and may begin weeks to months after treatment began</td> <td>Beta-lactam antibiotics, sulfonamide antibiotics and sulfasalazine, minocycline, phenytoin, carbamazepine, lamotrigine, allopurinol, abacavir, nevirapine</td> <td> <p>VARIABLE</p> <p>Although testing is not standardized and is considered investigational in most cases, some centers perform skin and in vitro testing for type IV reactions. For example, DiHS/DRESS reactions can be evaluated with in vitro lymphocyte activation, and tests have good specificity.</p> ANY form of reexposure to the culprit drug is CONTRAINDICATED in patients with past severe or exfoliative reactions, including DRESS/DiHS and SJS/TEN.</td> </tr> <tr> <td>Unclassified</td> <td>&nbsp;</td> <td> <p>Drug-induced lupus</p> Fixed drug eruption</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Patch testing at affected area may be useful in fixed drug eruption.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; IgG: immunoglobulin G; IgM: immunoglobulin M; NSAIDs: nonsteroidal antiinflammatory drugs; DRESS/DiHS: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome; AGEP: acute generalized exanthematous pustulosis; SJS/TEN: Stevens-Johnson syndrome/toxic epidermal necrolysis.</div><div id=\"graphicVersion\">Graphic 77196 Version 6.0</div></div></div>"},"77197":{"type":"graphic_diagnosticimage","displayName":"Osteoarthritis of the elbow","title":"Osteoarthritis of the elbow","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis of the elbow</div><div class=\"cntnt\"><img style=\"width:540px; height:472px;\" src=\"images/EM/77197_Osteoarthritis_of_the_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe joint space narrowing and sclerosis of the articular bone surfaces (arrow) is evident.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 77197 Version 2.0</div></div></div>"},"77200":{"type":"graphic_picture","displayName":"Reed Sternberg variants","title":"Variants of classic Reed-Sternberg cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Variants of classic Reed-Sternberg cells</div><div class=\"cntnt\"><img style=\"width:289px; height:287px;\" src=\"images/HEME/77200_Reed_Sternberg_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left panel: two binucleated diagnostic Reed-Sternberg cells are seen in this field. Right upper panel: two uninucleate cells are shown. Right lower panel: multilobated nuclei or multinucleated cells are seen. Note the nuclear similarities in all three fields (ie, prominent central nucleolus with surrounding clear area).</div><div class=\"graphic_reference\">From Warnke, RA, Weiss, LM, Chan, JK, Cleary, ML, Dorfman, RF. Tumors of the lymph nodes and spleen. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 14, 1995, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 77200 Version 1.0</div></div></div>"},"77201":{"type":"graphic_picture","displayName":"Nerve biopsy","title":"Neuronal loss in vasculitic neuropathy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Neuronal loss in vasculitic neuropathy</div><div class=\"cntnt\"><img style=\"width:432px; height:219px;\" src=\"images/RHEUM/77201_Nerve_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nerve infarction in vasculitic neuropathy leads to dropout of neural axons. The biopsy on the left is from a normal nerve. The biopsy on the right shows extensive neuronal loss.</div><div class=\"graphic_reference\">Courtesy of John H Stone, MD, MPH.</div><div id=\"graphicVersion\">Graphic 77201 Version 1.0</div></div></div>"},"77205":{"type":"graphic_figure","displayName":"Deep fascial spaces of the hand","title":"Deep fascial spaces of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep fascial spaces of the hand</div><div class=\"cntnt\"><img style=\"width:439px; height:602px;\" src=\"images/SURG/77205_Deep_fascial_spaces_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The palm has three potential closed spaces with well-defined anatomical borders; the thenar, the midpalmar, and the hypothenar space. These spaces are deep to the flexor tendons but superficial to the interosseous muscles. Infections in these spaces occur following a penetrating injury in most cases and occasionally as an extension from a subcutaneous abscess or adjacent pyogenic flexor tenosynovitis.<br />(A) The deep spaces of the palmar aspect of the hand.<br />(B) The extent of the deep palmar spaces of the hand.</div><div id=\"graphicVersion\">Graphic 77205 Version 3.0</div></div></div>"},"77206":{"type":"graphic_picture","displayName":"Lentigo maligna periocular","title":"Lentigo maligna","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lentigo maligna</div><div class=\"cntnt\"><img style=\"width:448px; height:504px;\" src=\"images/DERM/77206_Lentigo_maligna.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77206 Version 1.0</div></div></div>"},"77207":{"type":"graphic_figure","displayName":"Antioxidants and mortality MI","title":"Antioxidants do not reduce mortality or major coronary events after a myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Antioxidants do not reduce mortality or major coronary events after a myocardial infarction</div><div class=\"cntnt\"><img style=\"width:520px; height:361px;\" src=\"images/CARD/77207_Antixdnts_and_mrtality_Edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kaplan-Meier estimates of total and cardiac mortality fail to show a benefit from supplemental therapy with alpha-tocopherol or beta-carotene in men with a previous myocardial infarction. Compared with placebo, there was a significant increase in cardiac mortality among patients treated with beta-carotene (p = 0.007) and those treated with both beta-carotene and alpha-tocopherol (p = 0.03).</div><div class=\"graphic_reference\">Data from: Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997; 349:1715.</div><div id=\"graphicVersion\">Graphic 77207 Version 2.0</div></div></div>"},"77208":{"type":"graphic_diagnosticimage","displayName":"CPA radiographs","title":"Chronic pulmonary aspergillosis","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Chronic pulmonary aspergillosis</div><div class=\"cntnt\"><img style=\"width:484px; height:472px;\" src=\"images/ID/77208_CPA_radiograph_3_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph in 1969 in a patient aged 24 with asthma with bronchiectasis showing mild left mid-zone shadows consistent with bronchiectasis and a small area of opacification in the left base, with left apical scarring. New streaky shadowing is projected over the left heart border.<br />(B) Chest radiograph in same patient in 1981 (aged 36) following first radiological feature of allergic bronchopulmonary aspergillosis (ABPA; clearance of the left upper lobe shadowing after physiotherapy and corticosteroids). Compared with 1969, there is now extensive bronchiectasis in the left lower and right lower lobes.<br />(C) Chest radiograph in same patient in 1985 (aged 40), with first clue of chronic cavitary pulmonary aspergillosis. The chest radiograph shows development of right upper pleural thickening with further volume loss, without extensive fibrotic disease. There is more obvious new cavity formation in the left upper lobe with unchanged thickened bronchi in the left mid zone. A mild scoliosis has developed.<br />(D) Chest radiograph in same patient in 1995 (aged 50), showing interval development of scoliosis with bilateral upper lobe pleural thickening, worse on the right, with cavities in the left upper lobe and fullness of the right upper mediastinum. The features of central bronchiectasis, so characteristic of ABPA, are very prominent. She is significantly disabled by her disease now.</div><div class=\"graphic_reference\">Reproduced with permission from:The Aspergillus Website (http://www.aspergillus.org.uk/). Copyright © 2010.</div><div id=\"graphicVersion\">Graphic 77208 Version 5.0</div></div></div>"},"77210":{"type":"graphic_table","displayName":"Chemotherapy radiation sensitizers","title":"Cytotoxic chemotherapy agents associated with radiation enhancement and radiation recall","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cytotoxic chemotherapy agents associated with radiation enhancement and radiation recall</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Radiation enhancement</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> </tr> <tr> <td class=\"indent1\">Doxorubicin</td> </tr> <tr> <td class=\"indent1\">Fluorouracil with and without cisplatin</td> </tr> <tr> <td class=\"indent1\">Hydroxyurea</td> </tr> <tr> <td class=\"indent1\">Mercaptopurine</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Paclitaxel</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> </tr> <tr> <td class=\"indent1\">Chlorambucil</td> </tr> <tr> <td class=\"indent1\">Capecitabine</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Radiation recall</td> </tr> <tr> <td class=\"indent1\">Arsenic trioxide</td> </tr> <tr> <td class=\"indent1\">Bleomycin</td> </tr> <tr> <td class=\"indent1\">Capecitabine</td> </tr> <tr> <td class=\"indent1\">Cyclophosphamide</td> </tr> <tr> <td class=\"indent1\">Cytarabine</td> </tr> <tr> <td class=\"indent1\">Dactinomycin</td> </tr> <tr> <td class=\"indent1\">Daunorubicin</td> </tr> <tr> <td class=\"indent1\">Docetaxel</td> </tr> <tr> <td class=\"indent1\">Doxorubicin (free and liposomal)</td> </tr> <tr> <td class=\"indent1\">Etoposide</td> </tr> <tr> <td class=\"indent1\">Fluorouracil</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> </tr> <tr> <td class=\"indent1\">Hydroxyurea</td> </tr> <tr> <td class=\"indent1\">Idarubicin</td> </tr> <tr> <td class=\"indent1\">Lomustine</td> </tr> <tr> <td class=\"indent1\">Melphalan</td> </tr> <tr> <td class=\"indent1\">Methotrexate</td> </tr> <tr> <td class=\"indent1\">Paclitaxel</td> </tr> <tr> <td class=\"indent1\">Pemetrexed</td> </tr> <tr> <td class=\"indent1\">Tamoxifen</td> </tr> <tr> <td class=\"indent1\">Vinblastine</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Localized reactions typically involving areas of occluded skin (ifosfamide, topical carmustine, docetaxel, thiotepa) or the infusion site.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Susser WS, Whitaker-Worth DL, Grant-Kels JM. Mucucutaneous reactions to chemotherapy. J Am Acad Dermatol 1999; 40:367.</LI>&#xD;&#xA;<LI>Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002; 14:212.</LI>&#xD;&#xA;<LI>Keung YK, Lyerly ES, Powell BL. Radiation recall phenomenon associated with arsenic trioxide. Leukemia 2003; 17:1417.</LI></OL></div><div id=\"graphicVersion\">Graphic 77210 Version 6.0</div></div></div>"},"77211":{"type":"graphic_picture","displayName":"Typical carcinoid gross app","title":"Typical carcinoid gross appearance","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Typical carcinoid gross appearance</div><div class=\"cntnt\"><img style=\"width:360px; height:237px;\" src=\"images/ONC/77211_Typical_carcinoid_gross_app.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The gross appearance of the tumor depicted radiographically and subsequently resected is a pale-tan, solid mass filling the bronchus intermedius. Histologically, the tumor was designated a typical carcinoid.</div><div class=\"graphic_reference\">Courtesy of Charles F Thomas, Jr, MD.</div><div id=\"graphicVersion\">Graphic 77211 Version 4.0</div></div></div>"},"77212":{"type":"graphic_table","displayName":"Evaluation hearing loss","title":"Evaluation in childhood hearing loss","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation in childhood hearing loss</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp; </td> <td class=\"subtitle1\">Potential diagnosis </td> <td class=\"subtitle1\">Yield </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Laboratory evaluation </td> </tr> <tr> <td class=\"indent1\" rowspan=\"3\">CBC </td> <td>Anemia</td> <td rowspan=\"3\">Low </td> </tr> <tr> <td>Leukemia</td> </tr> <tr> <td>Fechner syndrome</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Antinuclear antibody, erythrocyte sedimentation rate, rheumatoid factor </td> <td>Systemic lupus erythematosus</td> <td rowspan=\"2\">Low </td> </tr> <tr> <td>Autoimmune disorders</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Thyroid function studies </td> <td>Hypothyroidism</td> <td rowspan=\"2\">Low </td> </tr> <tr> <td>Pendred syndrome</td> </tr> <tr> <td class=\"indent1\">BUN, creatinine, urinalysis </td> <td>Alport syndrome</td> <td>Low</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Serum glucose </td> <td>Diabetes mellitus</td> <td rowspan=\"2\">Very low </td> </tr> <tr> <td>Alstrom syndrome</td> </tr> <tr> <td class=\"indent1\">FTA, RPR</td> <td>Syphilis</td> <td>Low</td> </tr> <tr> <td class=\"indent1\">TORCH titers</td> <td>Congenital infection</td> <td>Depends upon timing</td> </tr> <tr> <td class=\"indent1\">Transaminases </td> <td>Liver abnormalities</td> <td>Very low</td> </tr> <tr> <td class=\"indent1\">Connexin 26 </td> <td>Recessive SNHL</td> <td>High</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Radiologic evaluation </td> </tr> <tr> <td class=\"indent1\">High-resolution computed tomography of temporal bone </td> <td>Pathology of the temporal bone, inner-ear bony dysplasia, otosclerosis, erosive and destructive lesions</td> <td>High</td> </tr> <tr> <td class=\"indent1\">Magnetic resonance imaging </td> <td>Retrocochlear pathology including abnormalities of the membranous labyrinth, central auditory pathway, cerebellopontine angle, brainstem, or cerebral cortex</td> <td>Medium</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other evaluation </td> </tr> <tr> <td class=\"indent1\">ECG </td> <td>Jervell and Lange-Nielsen syndrome</td> <td>Very low</td> </tr> <tr> <td class=\"indent1\">Genetics consultation </td> <td>Genetic SNHL</td> <td>Variable</td> </tr> <tr> <td class=\"indent1\">Ophthalmology consultation </td> <td>Retinitis pigmentosa, congenital infection</td> <td>Low in infants unless they have congenital infection</td> </tr> <tr> <td class=\"indent1\">Neurology consultation </td> <td>Associated diseases</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; BUN: blood urea nitrogen; FTA: fluorescent treponemal antibody; RPR: rapid plasma reagin; TORCH titers: toxoplasmosis, rubella, cytomegalovirus, and herpes simplex virus; SNHL: sensorineural hearing loss; ECG: electrocardiogram.</div><div class=\"graphic_reference\">Adapted from Billings, KR, Kenna, MA. Arch Otolaryngol Head Neck Surg 1999; 125:517 and Mafong, DD, Shin, EJ, Lalwani, AK. Laryngoscope 2002; 112:1.</div><div id=\"graphicVersion\">Graphic 77212 Version 2.0</div></div></div>"},"77213":{"type":"graphic_table","displayName":"Examination findings of opioid toxicity","title":"Physical examination findings of opioid toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination findings of opioid toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n\t\t<tr>\r\n\t\t\t<td class=\"subtitle1_single\">Vital Signs</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Heart rate decreased or unchanged</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Blood pressure decreased or unchanged</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Respiratory rate decreased</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Temperature decreased or unchanged</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td class=\"subtitle1_single\">Gastrointestinal</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Decreased bowel sounds</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td class=\"subtitle1_single\">Neurological</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Sedation or coma</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Seizure (Meperidine, Propoxyphene, Tramadol, or as a result of hypoxia)</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td class=\"subtitle1_single\">Ophthalmologic</td>\r\n\t\t</tr>\r\n\t\t<tr>\r\n\t\t\t<td>Miosis</td>\r\n\t\t</tr>\r\n\t\t</table>\r\n\t\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12453&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Opioid_tox_exam_findings.htm</title></head></div><div id=\"graphicVersion\">Graphic 77213 Version 3.0</div></div></div>"},"77215":{"type":"graphic_table","displayName":"Complications of pulmonary AVM","title":"Complications of pulmonary AVMs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of pulmonary AVMs</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Seizure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Migraine headache</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transient ischemic attack</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerebrovascular accident</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Brain abscess</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hypoxemia/orthodeoxia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Exercise intolerance</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemothorax</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Hemoptysis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Catamennial hemoptysis</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pulmonary hypertension</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Heart failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Polycythemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Anemia</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Infectious endocarditis</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77215 Version 1.0</div></div></div>"},"77217":{"type":"graphic_diagnosticimage","displayName":"Enchondroma knee Xray","title":"Enchondroma of the proximal tibia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enchondroma of the proximal tibia</div><div class=\"cntnt\"><img style=\"width:252px; height:396px;\" src=\"images/RHEUM/77217_Enchondroma_knee_Xray_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frontal radiograph of the knee shows stippled calcifications in the proximal tibial metaphysis, consistent with an enchondroma (arrow).</div><div class=\"graphic_reference\">Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.</div><div id=\"graphicVersion\">Graphic 77217 Version 3.0</div></div></div>"},"77218":{"type":"graphic_waveform","displayName":"12-lead ECG right lateral WPW","title":"12-lead electrocardiogram (ECG) of a right lateral accessory AV pathway","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">12-lead electrocardiogram (ECG) of a right lateral accessory AV pathway</div><div class=\"cntnt\"><img style=\"width:535px; height:254px;\" src=\"images/CARD/77218_Right_lateral_WPW.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Electrocardiogram in sinus rhythm from a patient with Wolff-Parkinson-White syndrome shows classic preexcitation with a short PR interval, delta wave, and widened QRS complex with a left bundle branch block morphology. The delta wave is positive in the lateral leads 1, aVL, and V6, it is negative in lead III and isoelectric in lead aVF. The QRS axis of &lt;30L distinguishes this pathway from an anteroseptal accessory AV pathway.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 77218 Version 3.0</div></div></div>"},"77219":{"type":"graphic_picture","displayName":"Renal pathology of early diffuse mesangial sclerosis","title":"Renal pathology of early diffuse mesangial sclerosis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Renal pathology of early diffuse mesangial sclerosis</div><div class=\"cntnt\"><img style=\"width:540px; height:346px;\" src=\"images/PEDS/77219_Renal_patho_mesangial_scler.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathologic specimen from a patient with diffuse mesangial sclerosis demonstrating the fibrillar increase in mesangial matrix. The capillary walls are lined by hypertrophied podocytes.</div><div id=\"graphicVersion\">Graphic 77219 Version 2.0</div></div></div>"},"77220":{"type":"graphic_table","displayName":"Muscles of the anterior compartment of the forearm","title":"Muscles of the anterior compartment of the forearm","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Muscles of the anterior compartment of the forearm</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Proximal attachment</td> <td class=\"subtitle1\">Distal attachment</td> <td class=\"subtitle1\">Innervation*</td> <td class=\"subtitle1\">Main action</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Superficial (first) layer</td> </tr> <tr> <td class=\"indent1\">Pronator teres</td> <td>&nbsp;</td> <td rowspan=\"3\">Middle of convexity of lateral surface of radius</td> <td rowspan=\"4\">Median nerve (C6, <strong>C7</strong>)</td> <td rowspan=\"3\">Pronates and flexes forearm (at elbow)</td> </tr> <tr> <td class=\"indent2\">Ulnar head</td> <td>Coronoid process</td> </tr> <tr> <td class=\"indent2\">Humeral head</td> <td rowspan=\"5\">Medial epicondyle of humerus (common flexor origin)</td> </tr> <tr> <td class=\"indent1\">Flexor carpi radialis (FCR)</td> <td>Base of second metacarpal</td> <td>Flexes and abducts hand (at wrist)</td> </tr> <tr> <td class=\"indent1\">Palmaris longus</td> <td rowspan=\"2\">Distal half of flexor retinaculum and apex of palmar aponeurosis</td> <td rowspan=\"2\">Median nerve (C7, C8)</td> <td>Flexes hand (at wrist) and tenses palmar aponeurosis</td> </tr> <tr> <td class=\"indent1\">Flexor carpi ulnaris (FCU)</td> <td>Flexes and adducts hand (at wrist)</td> </tr> <tr> <td class=\"indent2\">Humeral head</td> <td rowspan=\"2\">Pisiform, hook of hamate, fifth metacarpal</td> <td rowspan=\"2\">Ulnar nerve (C7, <strong>C8</strong>)</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent2\">Ulnar head</td> <td>Olecranon and posterior border (via aponeurosis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Intermediate (second) layer</td> </tr> <tr> <td class=\"indent1\">Flexor digitorum superficialis (FDS)</td> <td rowspan=\"2\">Medial epicondyle (common flexor origin and coronoid process)</td> <td rowspan=\"3\">Shafts (bodies) of middle phalanges of medial four fingers</td> <td rowspan=\"3\">Median nerve (C7, C8, T1)</td> <td rowspan=\"3\">Flexes middle phalanges at proximal interphalangeal joints of middle four fingers; acting more strongly, it also flexes proximal phalanges at metacarpophalangeal joints</td> </tr> <tr> <td class=\"indent1\">Humeroulnar head</td> </tr> <tr> <td class=\"indent1\">Radial head</td> <td>Superior half of anterior border</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Deep (third) layer</td> </tr> <tr> <td class=\"indent1\">Flexor digitorum profundus (FDP)</td> <td rowspan=\"3\">Proximal three quarters of medial and anterior surfaces of ulna and interosseous membrane</td> <td rowspan=\"3\">Bases of distal phalanges of fourth and fifth fingers</td> <td rowspan=\"2\">Ulnar nerve (C8, <strong>T1</strong>)</td> <td rowspan=\"2\">Flexes distal phalanges four and five at distal interphalangeal joints</td> </tr> <tr> <td class=\"indent1\">Medial part</td> </tr> <tr> <td class=\"indent1\">Lateral part</td> <td rowspan=\"2\">Anterior interosseous nerve, from median nerve (<strong>C8</strong>, T1)</td> <td>Flexes distal phalanges two and three at distal interphalangeal joints</td> </tr> <tr> <td class=\"indent1\">Flexor pollicis longus (FPL)</td> <td>Anterior surface of radius and adjacent interosseous membrane</td> <td>Base of distal phalanx of thumb</td> <td>Flexes phalanges of first digit (thumb)</td> </tr> <tr> <td class=\"indent1\">Pronator quadratus</td> <td>Distal quarter of anterior surface of ulna</td> <td>Distal quarter of anterior surface of radius</td> <td>&nbsp;</td> <td>Pronates forearm; deep fibers bind radius and ulna together</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (eg, &quot;C6, <strong>C7</strong>&quot; means that the nerves supplying the pronator teres are derived from the sixth and seventh cervical segments of the spinal cord). Numbers in boldface (<strong>C7</strong>) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77220 Version 13.0</div></div></div>"},"77221":{"type":"graphic_picture","displayName":"Condylomata lata","title":"Condylomata lata, penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Condylomata lata, penis</div><div class=\"cntnt\"><img style=\"width:337px; height:244px;\" src=\"images/ID/77221_Condylomata_lata.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. STD Picture Cards. Available at: <A href=\"http://www.cdc.gov/std/training/picturecards.htm\">http://www.cdc.gov/std/training/picturecards.htm</A></div><div id=\"graphicVersion\">Graphic 77221 Version 2.0</div></div></div>"},"77222":{"type":"graphic_figure","displayName":"KtV URR and dialysis survival","title":"Relative risk of mortality by dialysis dose","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Relative risk of mortality by dialysis dose</div><div class=\"cntnt\"><img style=\"width:395px; height:317px;\" src=\"images/NEPH/77222_KtV_URR_and_dialysis_surviv.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The relative risk of mortality by delivered dose of dialysis as measured by quintiles of Kt/V (top panel) or&nbsp;URR (bottom panel, in percent) among a random sample of 2311 patients on dialysis for more than one year at the end of 1990. Increasing the dialysis dose improved survival with apparent maximum benefit at a Kt/V of 1.3 and URR of 70.</div><div class=\"graphic_footnotes\">URR: Urea reduction ratio.</div><div class=\"graphic_reference\">Data from Held PJ, Port FK, Wolfe RA. The dose of hemodialysis and patient mortality.&nbsp;Kidney Int 1996; 50:550.</div><div id=\"graphicVersion\">Graphic 77222 Version 3.0</div></div></div>"},"77224":{"type":"graphic_figure","displayName":"Complete breech presentation","title":"Complete breech presentation","html":"<div class=\"graphic\"><div style=\"width: 527px\" class=\"figure\"><div class=\"ttl\">Complete breech presentation</div><div class=\"cntnt\"><img style=\"width:507px; height:578px;\" src=\"images/OBGYN/77224_Complete_breech_presentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Both hips and both knees are flexed.</div><div id=\"graphicVersion\">Graphic 77224 Version 3.0</div></div></div>"},"77225":{"type":"graphic_table","displayName":"Breast ca surveillance PI","title":"Watching for cancer return after breast cancer treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Watching for cancer return after breast cancer treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type of monitoring</td> <td class=\"subtitle1\">What experts recommend</td> </tr> <tr> <td><strong>Regular doctor visits</strong></td> <td> <p>For the first three years after being treated for breast cancer, see your doctor or nurse every 3 to 6 months. During the 4th and 5th year after treatment, see your doctor or nurse every 6 to 12 months. After that, see your doctor or nurse once a year. Having these regular check-ups will give your doctor or nurse a chance to check for any signs of returning cancer.</p> <p>After treatment, it's good to have a doctor who is familiar with monitoring patients for cancer recurrence. If your primary care physician takes over monitoring, make sure he or she is in touch with your cancer specialists.</p> </td> </tr> <tr> <td><strong>Symptom checks</strong></td> <td>If you notice any symptoms that might signal the return of cancer, tell your doctor or nurse. Symptoms to look for include new lumps in the breast, bone pain, chest pain, belly pain, trouble breathing, or persistent headaches.</td> </tr> <tr> <td><strong>Genetic counseling or testing</strong></td> <td> <p>If you are at higher-than-average risk for a second breast cancer, consider genetic counseling or testing. High-risk groups include women with:</p> <ul> <li>Ashkenazi Jewish heritage </li> <li>A personal or family history of ovarian cancer </li> <li>A daughter, sister, or mother who was diagnosed with breast cancer before the age of 50 </li> <li>Two or more relatives diagnosed with breast cancer at any age </li> <li>Breast cancer in both breasts or a relative who had breast cancer in both breasts </li> <li>A male relative with breast cancer </li> </ul> </td> </tr> <tr> <td><strong>Mammograms</strong></td> <td>After you have been treated, have a mammogram 1 year after the mammogram that led to the diagnosis but no earlier than 6 months after radiation therapy. You may also need other subsequent mammograms, depending on your individual situation. (Note that experts do not recommend breast MRI as a routine part of post-treatment monitoring.)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77225 Version 7.0</div></div></div>"},"77226":{"type":"graphic_table","displayName":"Exam childhood cataracts","title":"Important aspects of the physical examination in children with cataracts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the physical examination in children with cataracts</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">Feature</td>\r\n            <td class=\"subtitle1\">Potential clinical implications</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Growth parameters</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle3_left\" colspan=\"2\">Birth weight</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">&#62;4 kg</td>\r\n            <td>Maternal diabetes</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle3_left\" colspan=\"2\">Weight</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Failure to thrive</td>\r\n            <td>Chondrodysplasia punctata (Conradi-Hunermann syndrome), galactosemia, Lowe syndrome, Refsum disease (infantile form), Smith-Lemli-Opitz syndrome, Wolf-Hirschhorn syndrome, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Obesity</td>\r\n            <td>Bardet-Biedl syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle3_left\" colspan=\"2\">Length/stature</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Short stature</td>\r\n            <td>Cockayne syndrome, Down syndrome, chondrodysplasia punctata, Hallermann-Streiff syndrome, incontinentia pigmenti, Lowe syndrome, Marinesco-Sjogren syndrome, Marshall syndrome, nail-patella syndrome, Rothmund-Thomson syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, Turner syndrome, Werner syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle3_left\" colspan=\"2\">Head Circumference</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Microcephaly</td>\r\n            <td>Cockayne syndrome, cri-du-chat syndrome, Hallermann-Streiff syndrome, incontinentia pigmenti, intrauterine infection, Marinesco-Sjogren syndrome, Meckel-Gruber syndrome, Norrie disease, oculodentodigital dysplasia, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, Walker-Warburg syndrome, Wolf-Hirschhorn syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent2\">Macrocephaly</td>\r\n            <td>Mannosidosis, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Skin</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Sebaceous cysts</td>\r\n            <td>Lowe syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Subcutaneous nodules</td>\r\n            <td>Lowe syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Hyperpigmented whorls</td>\r\n            <td>Incontinentia pigmentii</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Telangectasias</td>\r\n            <td>Rothmund-Thomson syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Angiokeratomas</td>\r\n            <td>Fabry disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Jaundice</td>\r\n            <td>Galactosemia, intrauterine infection, maternal diabetes</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Scaly skin</td>\r\n            <td>Alport syndrome, ichthyosis, chondrodysplasia punctata, Refsum disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Rash</td>\r\n            <td>Intrauterine infection</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Decreased/absent sweating</td>\r\n            <td>Anhidrotic and hypohidrotic ectodermal dysplasia, Cockayne syndrome, Fabry disease</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Nails</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Hypoplastic, dysplastic or absent</td>\r\n            <td>Hidrotic ectodermal dysplasia, incontinentia pigmenti, nail-patella syndrome, Rothmund-Thomson syndrome, trisomy 18</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Head</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Craniosynostosis</td>\r\n            <td>Apert syndrome, Crouzon syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Micrognathia</td>\r\n            <td>Cri-du-chat syndrome, Hallermann-Streiff syndrome, Marshall syndrome, Meckel-Gruber syndrome, Pierre-Robin syndrome, progeria, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, Stickler syndrome, trisomy 18, Wolf-Hirschhorn syndrome, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Sparse hair or alopecia</td>\r\n            <td>Anhidrotic and hypohidrotic ectodermal dysplasia, chondrodysplasia punctata, Hallermann-Streiff syndrome incontinentia pigmenti, oculodentodigital dysplasia, progeria, Rothmund-Thomson syndrome, Werner syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Hypertrichosis</td>\r\n            <td>Mannosidosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Ears</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Small ears</td>\r\n            <td>Down syndrome, Walker-Warburg syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Low set ears</td>\r\n            <td>Cri-du-chat syndrome, Hallermann-Streiff syndrome, Meckel-Gruber syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 18</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Conductive hearing loss</td>\r\n            <td>Apert syndrome, Down syndrome, oculodentodigital dysplasia</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Sensorineural deafness</td>\r\n            <td>Alport syndrome, Cockayne syndrome, congenital cytomegalovirus, congenital rubella, mannosidosis, Marshall syndrome, Refsum disease, Stickler syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Oropharynx</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Cleft palate</td>\r\n            <td>Marshall syndrome, Meckel-Gruber syndrome, nail-patella syndrome, oculodentodigital dysplasia, Pierre-Robin syndrome, Smith-Lemli-Opitz syndrome, Stickler syndrome, trisomy 13, Walker-Warburg syndrome, Wolf-Hirschhorn syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Gingival hypertrophy</td>\r\n            <td>Mannosidosis</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Hepatomegaly</td>\r\n            <td>Cockayne syndrome, congenital cytomegalovirus, congenital rubella, congenital syphilis, congenital toxoplasmosis, galactosemia, mannosidosis, Refsum disease, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Cardiac</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Cardiac malformations</td>\r\n            <td>Apert syndrome, Bardet-Biedl syndrome, congenital rubella, Down syndrome, Meckel-Gruber syndrome, Refsum disease (infantile form), Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, trisomy 18, Turner syndrome, Wolf-Hirschhorn syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Conduction disturbance</td>\r\n            <td>Myotonic dystrophy</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Musculoskeletal</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Transverse palmar crease</td>\r\n            <td>Down syndrome, trisomy 13, Wolf-Hirschhorn syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Absent or hypoplastic patella; radial head subluxation </td>\r\n            <td>Nail-patella syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Joint contractures</td>\r\n            <td>Chondrodysplasia punctata, Marinesco-Sjogren syndrome, Walker-Warburg syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Broad thumbs</td>\r\n            <td>Rubinstein-Taybi syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Polydactyly</td>\r\n            <td>Bardet-Beidl syndrome, Meckel-Gruber syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, Wolf-Hirschhorn syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Syndactyly</td>\r\n            <td>Apert syndrome (mitten hand), Meckel-Gruber syndrome, Smith-Lemli-Opitz syndrome&nbsp;(2nd and 3rd toes)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Talipes equinovarus (club feet)</td>\r\n            <td>Chondrodysplasia punctata, nail-patella syndrome, Rothmund-Thomson syndrome, Wolf-Hirschhorn syndrome, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Rocker bottom feet</td>\r\n            <td>Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Hypotonia</td>\r\n            <td>Cri-du-chat syndrome, Down syndrome, galactosemia, Lowe syndrome (neonatal), mannosidosis, Marinesco-Sjogren syndrome, myotonic dystrophy, Refsum disease, Smith-Lemli-Opitz syndrome (early infancy), Walker-Warburg syndrome, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Seizures</td>\r\n            <td>Cockayne syndrome, congenital cytomegalovirus, congenital herpes simplex virus, congenital toxoplasmosis, hypoparathyroidism, incontinentia pigmenti, Lowe syndrome, Smith-Lemli-Opitz syndrome, Walker-Warburg syndrome, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Decreased/absent reflexes</td>\r\n            <td>Lowe syndrome, Refsum disease (infantile form), Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Increased reflexes</td>\r\n            <td>Mannosidosis, oculodentodigital dysplasia</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Mental retardation</td>\r\n            <td>Cockayne syndrome, chondrodysplasia punctata, cri-du-chat syndrome, Down syndrome, Hallermann-Streiff syndrome, incontinentia pigmenti, Lowe syndrome, Marinesco-Sjogren syndrome, oculodentodigital dysplasia, Refsum disease (infantile form), Smith-Lemli-Opitz syndrome, Zellweger syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Weakness</td>\r\n            <td>Myotonic dystrophy, Marinesco-Sjogren syndrome</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2_left\" colspan=\"2\">Genitourinary</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"indent1\">Cryptorchidsim and/or hypogonadism</td>\r\n            <td>Apert syndrome, Bardet-Biedl syndrome, Cockayne syndrome, Hallermann-Streiff syndrome, Lowe syndrome, Meckel-Gruber syndrome, myotonic dystrophy, Refsum disease, Rothmund-Thomson syndrome, Rubinstein-Taybi syndrome, Smith-Lemli-Opitz syndrome, trisomy 13, trisomy 18, Wolf-Hirschhorn syndrome</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div id=\"graphicVersion\">Graphic 77226 Version 2.0</div></div></div>"},"77227":{"type":"graphic_figure","displayName":"Mean weight change orlistat","title":"Orlistat promotes weight loss and limits weight regain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Orlistat promotes weight loss and limits weight regain</div><div class=\"cntnt\"><img style=\"width:414px; height:334px;\" src=\"images/ENDO/77227_Mean_weight_change_orlistat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean body weight change during two years of&nbsp;treatment with orlistat or placebo in patients with type 2 diabetes. The patients initially received a reduced energy diet, and at one year, a weight maintenance diet. Orlistat therapy was associated with more weight loss and less weight regain. Although not shown, the orlistat group was randomly assigned to continued orlistat or placebo during the weight maintenance phase. Continued orlistat therapy was associated with less weight regain than in the two placebo groups (35 versus 51 and 63 percent).</div><div class=\"graphic_reference\">Data from: Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235.</div><div id=\"graphicVersion\">Graphic 77227 Version 3.0</div></div></div>"},"77228":{"type":"graphic_table","displayName":"Grading of esophageal burn","title":"Grading of esophageal burns from caustic injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of esophageal burns from caustic injury</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Injury</td> <td class=\"subtitle1\">Findings</td> </tr> <tr> <td>Grade 0</td> <td>Normal mucosa</td> </tr> <tr> <td>Grade 1 (superficial)</td> <td>Mucosal edema and hyperemia</td> </tr> <tr> <td class=\"sublist1_start\">Grade 2 (transmucosal)</td> <td class=\"sublist_other_start\">Friability, hemorrhages, erosions, blisters, whitish membranes, and superficial ulcerations</td> </tr> <tr> <td class=\"sublist1\">Grade 2A</td> <td class=\"sublist_other\">No deep focal or circumferential ulcers</td> </tr> <tr> <td class=\"sublist1\">Grade 2B</td> <td class=\"sublist_other\">Deep focal or circumferential ulcers</td> </tr> <tr> <td class=\"sublist1_start\">Grade 3</td> <td class=\"sublist_other_start\">Areas of multiple ulceration and areas of brown-black or greyish discoloration suggesting necrosis</td> </tr> <tr> <td class=\"sublist1\">Grade 3A</td> <td class=\"sublist_other\">Small scattered areas of focal necrosis</td> </tr> <tr> <td class=\"sublist1\">Grade 3B</td> <td class=\"sublist_other\">Extensive necrosis</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This scheme for grading of esophageal burns was described by Zargar and colleagues in 1991. In a study of 81 patients (primarily adults) with corrosive esophageal burns, this scheme helped to predict complications. Early major complications occurred only in patients with grade 3 injury. Late complications including esophageal strictures were limited to patients with grade 2B or 3 injuries.</div><div class=\"graphic_reference\">Reference: Zargar SA, Kochhar R, Mehta S, Mehta SK. The role of fiberoptic endoscopy in the management of corrosive ingestion and modified endoscopic classification of burns. Gastrointest Endosc 1991; 37:165.</div><div id=\"graphicVersion\">Graphic 77228 Version 2.0</div></div></div>"},"77229":{"type":"graphic_table","displayName":"Return to play guidelines B","title":"Recommendations for participation in contact sports in certain cervical spine conditions, part B","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recommendations for participation in contact sports in certain cervical spine conditions, part B</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\t<tbody><tr>\n\t\t\t\t<td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">Condition</td><td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">Contraindication to play</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr><td class=\"subtitle2\">Absolute</td><td class=\"subtitle2\">Relative*</td><td class=\"subtitle2\">None*</td></tr><tr>\n\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Ligamentous injuries</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Mild ligamentous sprain with no laxity</td><td>&nbsp;</td><td>&nbsp;</td><td>X</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Ligamentous sprain with mild laxity (&#60;3.5 mm anteroposterior displacement and 11 degrees rotation)</td><td>&nbsp;</td><td>X</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Ligamentous laxity (&#62;3.5 mm anteroposterior displacement or 11 degrees rotation)</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Fractures</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Acute cervical fracture</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Vertebral body fracture with a sagittal component</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Vertebral body fracture with associated posterior arch fractures and/or ligamentous laxity</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Vertebral body fracture with displacement into the spinal canal</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed fractures with associated neurologic findings or symptoms, pain, or limitation of cervical range of motion</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed, stable, mildly displaced vertebral body fracture without a sagittal component or neural ring involvement</td><td>&nbsp;</td><td>X</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed, stable, end-plate fracture</td><td>&nbsp;</td><td>&nbsp;</td><td>X</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed stable compression fracture of vertebral body</td><td>&nbsp;</td><td>&nbsp;</td><td>X</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed \"clay-shoveler's\" fracture</td><td>&nbsp;</td><td>&nbsp;</td><td>X</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed, nondisplaced Jefferson fracture</td><td>&nbsp;</td><td>X</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed, stable neural ring fractures</td><td>&nbsp;</td><td>X</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Spinal fusion</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Stable, one-level anterior or posterior surgical fusion</td><td>&nbsp;</td><td>&nbsp;</td><td>X</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Stable, two-level anterior or posterior surgical fusion</td><td>&nbsp;</td><td>X</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Anterior or posterior fusion of three or more levels</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">Cervical disk conditions</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed intervertebral disk bulge</td><td>&nbsp;</td><td>&nbsp;</td><td>X</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Healed intervertebral disk herniation</td><td>&nbsp;</td><td>X</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n\t\t\t<tr>\n\t\t\t\t<td class=\"indent1\">Intervertebral disk herniation with neurologic signs or symptoms, pain, or limitation of cervical range of motion</td><td>X</td><td>&nbsp;</td><td>&nbsp;</td>\n\t\t\t\t\n\t\t\t\t\n\t\t\t</tr>\n</tbody></table></div><div class=\"graphic_footnotes\">* Provided individual is asymptomatic and neurologically normal and has full range of pain-free cervical motion. </div><div class=\"graphic_reference\">Adapted from Torg, JS, Ramsey-Emrhein, JA. Cervical spine and brachial plexus injuries: Return-to-play recommendations. Phys Sportsmed 1997;25.</div><div id=\"graphicVersion\">Graphic 77229 Version 1.0</div></div></div>"},"77231":{"type":"graphic_picture","displayName":"Fungal keratitis","title":"Fungal keratitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fungal keratitis</div><div class=\"cntnt\"><img style=\"width:324px; height:219px;\" src=\"images/PC/77231_Fungal_keratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With satellite lesions and hypopyon (layering of white blood cells in anterior chamber).</div><div id=\"graphicVersion\">Graphic 77231 Version 2.0</div></div></div>"},"77232":{"type":"graphic_diagnosticimage","displayName":"Jefferson C1 arch fracture open mouth xray","title":"C1 arch fractures: Jefferson fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">C1 arch fractures: Jefferson fracture</div><div class=\"cntnt\"><img style=\"width:360px; height:308px;\" src=\"images/EM/77232_Jeffersonfxopenmouth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This odontoid or open-mouth view shows a Jefferson fracture. Note the step-off of the lateral masses (arrows), which normally are in alignment.</div><div class=\"graphic_reference\">Courtesy of Mary Hochman, MD.</div><div id=\"graphicVersion\">Graphic 77232 Version 4.0</div></div></div>"},"77233":{"type":"graphic_diagnosticimage","displayName":"Oblique foot x-ray with metatarsal shaft fracture","title":"Oblique foot x-ray with metatarsal shaft fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Oblique foot x-ray with metatarsal shaft fracture</div><div class=\"cntnt\"><img style=\"width:206px; height:432px;\" src=\"images/EM/77233_Oblique_metatars_shaft_frac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A&nbsp;fracture of the third metatarsal shaft is indicated by the arrow.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH and James R Clugston, MD, MS.</div><div id=\"graphicVersion\">Graphic 77233 Version 2.0</div></div></div>"},"77234":{"type":"graphic_picture","displayName":"Buruli ulcer foot","title":"Buruli ulcer on the foot","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Buruli ulcer on the foot</div><div class=\"cntnt\"><img style=\"width:456px; height:287px;\" src=\"images/ID/77234_Buruli_ulcer_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Tjip van der Werf, MD, PhD.</div><div id=\"graphicVersion\">Graphic 77234 Version 2.0</div></div></div>"},"77236":{"type":"graphic_picture","displayName":"Electron micrograph type 3 MPGN","title":"Electron micrograph type 3 membranoproliferative glomerulonephritis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electron micrograph type 3 membranoproliferative glomerulonephritis</div><div class=\"cntnt\"><img style=\"width:378px; height:270px;\" src=\"images/NEPH/77236_MPGN_EM_Type_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph in type 3 membranoproliferative glomerulonephritis (MPGN) shows marked thickening (more than three times normal) of the glomerular capillary wall and complex disruption of the glomerular basement membrane with large lucent areas (arrows) and variable decrease in thickness of the lamina densa (LD). A red cell is present in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut Rennke, MD.</div><div id=\"graphicVersion\">Graphic 77236 Version 3.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Electron micrograph of a normal glomerulus</div><div class=\"cntnt\"><img style=\"width:377px; height:266px;\" src=\"images/NEPH/50018_Normal_glomerulus_EM_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron-dense deposits are present. Two normal platelets are seen in the capillary lumen.</div><div class=\"graphic_reference\">Courtesy of Helmut G Rennke, MD.</div><div id=\"graphicVersion\">Graphic 50018 Version 7.0</div></div></div>"},"77237":{"type":"graphic_picture","displayName":"Lymphohistiocytic villitis 2","title":"Lymphohistiocytic (chronic) villitis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Lymphohistiocytic (chronic) villitis</div><div class=\"cntnt\"><img style=\"width:540px; height:384px;\" src=\"images/OBGYN/77237_Chronic_villitis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrow points to a mononuclear inflammatory infiltrate in a term placenta. Pregnancy was complicated by fetal growth restriction. Arrowhead shows avascular villi presumably due to the vascular damage from the lymphohistiocytic villitis \"upstream.\"</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 77237 Version 4.0</div></div></div>"},"77241":{"type":"graphic_table","displayName":"Radionuclide yields fission","title":"Yields of radionuclides from nuclear fission","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Yields of radionuclides from nuclear fission</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Radionuclide</td>\n\n      <td class=\"subtitle1\">Half-life</td>\n\n      <td class=\"subtitle1\">Yield (MCi per megaton)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Iodine-131</td>\n\n      <td>8 days</td>\n\n      <td>125</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerium-131</td>\n\n      <td>1 year </td>\n\n      <td>39 </td>\n\n    </tr>\n\n    <tr>\n\n      <td>Zirconium-95 </td>\n\n      <td>65 days</td>\n\n      <td>25</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Strontium-89</td>\n\n      <td>53 days</td>\n\n      <td>20</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ruthenium-103</td>\n\n      <td>40 days</td>\n\n      <td>18</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cerium-144</td>\n\n      <td>33 days</td>\n\n      <td>4</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Ruthenium-106</td>\n\n      <td>1 year </td>\n\n      <td>0.3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cesium-137 </td>\n\n      <td>30 years</td>\n\n      <td>0.2</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Strontium-90</td>\n\n      <td>28 years</td>\n\n      <td>0.1</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_lgnd\">This table shows some of the most important radionuclides produced during explosion of a nuclear fission device. Yields are expressed as millicuries (MCi) per megaton.</div><div class=\"graphic_reference\">From The Medical NBC Battlebook United States Army CHPPM, Technical Guide 244, August, 2002.</div><div id=\"graphicVersion\">Graphic 77241 Version 1.0</div></div></div>"},"77243":{"type":"graphic_picture","displayName":"Inflamed pterygium extending toward visual axis","title":"Inflamed pterygium extending toward visual axis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Inflamed pterygium extending toward visual axis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/77243_Vasc_ptery_iris_visual_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77243 Version 5.0</div></div></div>"},"77244":{"type":"graphic_picture","displayName":"Parabasal cells","title":"Parabasal cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Parabasal cells</div><div class=\"cntnt\"><img style=\"width:366px; height:546px;\" src=\"images/OBGYN/77244_Parabasal_cells.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (A) and high (B) power microscopy of vaginal discharge reveals parabasal cells and a marked increase in inflammatory cells (primarily polymorphonuclear leukocytes).</div><div id=\"graphicVersion\">Graphic 77244 Version 1.0</div></div></div>"},"77245":{"type":"graphic_picture","displayName":"Anatomy of the popliteal fossa","title":"Anatomy of the popliteal fossa","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Anatomy of the popliteal fossa</div><div class=\"cntnt\"><img style=\"width:497px; height:532px;\" src=\"images/EM/77245_Knee_post_neurovasc_anat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep dissection of the popliteal fossa reveals the important neurovascular structures of this region. Observe the thickness of the various muscles. Observe also the popliteal artery lying on the floor of the fossa.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Dalley AF II. Clinical Oriented Anatomy, 4th Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright © 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77245 Version 3.0</div></div></div>"},"77246":{"type":"graphic_diagnosticimage","displayName":"Gestational sac empty","title":"Gestational sac without yolk sac or embryo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gestational sac without yolk sac or embryo</div><div class=\"cntnt\"><img style=\"width:354px; height:298px;\" src=\"images/OBGYN/77246_Gestational_sac_empty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse view of the uterus shows an abnormally shaped intrauterine gestational sac with mean sac diameter of 31 mm. At this sac size, a yolk sac and embryo should be seen but were not. Findings represent early pregnancy failure. Arrows indicate the empty amnion.</div><div class=\"graphic_reference\">Courtesy of Tejas S Mehta, MD, MPH.</div><div id=\"graphicVersion\">Graphic 77246 Version 2.0</div></div></div>"},"77248":{"type":"graphic_table","displayName":"Homesickness resources for families","title":"Homesickness resources for families","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Homesickness resources for families</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>American Camp Association Website. Available at: <a href=\"http://www.acacamps.org/\" spellcheck=\"true\" target=\"_blank\">www.acacamps.org</a>.</td> </tr> <tr> <td>Pravda M, Weiland J. Off to Camp, JSP Publishing, Cincinnati, OH 1990.</td> </tr> <tr> <td>Thorn C. Second Home: Life in a Boarding School, Avocus Publishing, Gilsum, NH 2003.</td> </tr> <tr> <td>Thurber CA. The Secret Ingredients of Summer Camp Success: How to Have the Most Fun With the Least Homesickness [DVD/CD], American Camp Association, Martinsville, IN 2006.</td> </tr> <tr> <td>Thurber CA, Malinowski JC. The Summer Camp Handbook: Everything You Need to Know to Find, Choose, and Get Ready for Overnight Camp &#8212; and Skip the Homesickness, Everything Summer Camp, Boyd,&nbsp;WI 2016.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from Pediatrics, Vol. 119, Pages 192-201, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 77248 Version 18.0</div></div></div>"},"77249":{"type":"graphic_figure","displayName":"CDC stature for age girls 2 to 20 years","title":"Stature-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Stature-for-age percentiles, girls, 2 to 20 years, CDC growth charts: United States</div><div class=\"cntnt\"><img style=\"width:547px; height:670px;\" src=\"images/PEDS/77249_Stature_for_age_girls_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CDC: Centers for Disease Control and Prevention.</div><div class=\"graphic_reference\">From National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion (2000).</div><div id=\"graphicVersion\">Graphic 77249 Version 4.0</div></div></div>"},"77252":{"type":"graphic_picture","displayName":"Pulmonary LAM microscopy High","title":"Microscopic features of lymphangioleiomyomatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Microscopic features of lymphangioleiomyomatosis</div><div class=\"cntnt\"><img style=\"width:250px; height:228px;\" src=\"images/PULM/77252_Pulmonary_LAM_High.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High magnification photomicrograph showing the abnormal spindle cells that characterize lymphangioleiomyomatosis. The proliferating spindle cells have many characteristics of modified smooth muscles cells and frequently stain for smooth muscle-associated intermediate filaments using immunohistochemistry.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 77252 Version 2.0</div></div></div>"},"77253":{"type":"graphic_table","displayName":"Factors associated with Raynaud phenomenon","title":"Disorders and factors associated with Raynaud phenomenon","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders and factors associated with Raynaud phenomenon</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Autoimmune rheumatic&nbsp;diseases</td> </tr> <tr> <td>Scleroderma</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Polymyositis/dermatomyositis</td> </tr> <tr> <td>Sj&#246;gren's syndrome</td> </tr> <tr> <td>Undifferentiated connective tissue disease</td> </tr> <tr> <td>Mixed connective disease</td> </tr> <tr> <td class=\"subtitle1_single\">Hematologic/oncologic</td> </tr> <tr> <td>Paraneoplastic syndrome</td> </tr> <tr> <td>Cryoglobulinemia</td> </tr> <tr> <td>Cryofibrinogenemia</td> </tr> <tr> <td>Cold agglutinin</td> </tr> <tr> <td>Paraproteinemia</td> </tr> <tr> <td>POEMS syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Endocrine</td> </tr> <tr> <td>Hypothyroidism</td> </tr> <tr> <td class=\"subtitle1_single\">Vascular</td> </tr> <tr> <td>Thoracic outlet syndrome</td> </tr> <tr> <td>Emboli</td> </tr> <tr> <td>Vasculitis</td> </tr> <tr> <td>Prinzmetal angina</td> </tr> <tr> <td>Atherosclerosis</td> </tr> <tr> <td>Thromboangiitis obliterans</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic</td> </tr> <tr> <td>Carpal tunnel syndrome</td> </tr> <tr> <td>Migraine headache</td> </tr> <tr> <td class=\"subtitle1_single\">Environmental</td> </tr> <tr> <td>Vibration injury</td> </tr> <tr> <td>Frost bite</td> </tr> <tr> <td>Emotional stress</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs/toxins</td> </tr> <tr> <td>Sympathomimetic drugs</td> </tr> <tr> <td>Chemotherapeutic drugs</td> </tr> <tr> <td>Interferons</td> </tr> <tr> <td>Nicotine</td> </tr> <tr> <td>Cocaine</td> </tr> <tr> <td>Ergotamines</td> </tr> <tr> <td>Polyvinyl chloride</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Fibromyalgia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">POEMS: polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes.</div><div class=\"graphic_reference\">Adapted with permission from: Block JA, Sequiera W. Lancet 2001; 357:2042. Copyright © 2001 The Lancet, Ltd.</div><div id=\"graphicVersion\">Graphic 77253 Version 7.0</div></div></div>"},"77258":{"type":"graphic_figure","displayName":"Sciatic notch","title":"Anatomy involved in piriformis syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy involved in piriformis syndrome</div><div class=\"cntnt\"><img style=\"width:406px; height:435px;\" src=\"images/PC/77258_Sciatic_notch.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77258 Version 3.0</div></div></div>"},"77260":{"type":"graphic_algorithm","displayName":"Acute ataxia in children","title":"Algorithmic approach to acute ataxia in children*","html":"<div class=\"graphic\"><div style=\"width: 1564px\" class=\"figure\"><div class=\"ttl\">Algorithmic approach to acute ataxia in children*</div><div class=\"cntnt\"><img style=\"width:1544px; height:940px;\" src=\"images/EM/77260_Acuteataxiainchildren.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; ICP: intracranial pressure; MRI: magnetic resonance imaging; CT: computed tomography; ADEM: acute demyelinating encephalomyelitis; LP: lumbar puncture; CSF: cerebrospinal fluid.<br />* Refer to the UpToDate topics on the approach to acute ataxia in children for further details.<br />¶ MRI is preferred over CT if available in a timely fashion.<br />Δ Signs of increased ICP include papilledema, headache, and/or vomiting.<br /><FONT class=lozenge>◊</FONT> Acute stroke may be present despite normal CT. If suspected, MRI should be performed.<br />§ Acute cerebellar ataxia is a diagnosis of exclusion. Additional evaluation (eg, neuroimaging and/or CSF examination) may be warranted in some cases. Refer to the UpToDate topics on the approach to ataxia in children and acute cerebellar ataxia in children for further details.<br />¥ Conversion disorder is a diagnosis of exclusion. Additional evaluation is generally warranted. Refer to UpToDate content on evaluation and diagnosis of conversion disorder for further details.</div><div id=\"graphicVersion\">Graphic 77260 Version 6.0</div></div></div>"},"77261":{"type":"graphic_picture","displayName":"Moon facies in Cushings","title":"Moon facies and increased supraclavicular fat pads in Cushing's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Moon facies and increased supraclavicular fat pads in Cushing's syndrome</div><div class=\"cntnt\"><img style=\"width:249px; height:288px;\" src=\"images/ENDO/77261_Moon_facies_in_Cushings.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">30-year-old woman with Cushing's disease showing round, plethoric &quot;moon&quot; face, facial hirsutism, and increased supraclavicular fat pads.</div><div class=\"graphic_reference\">Reprinted with permission from: Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.</div><div id=\"graphicVersion\">Graphic 77261 Version 3.0</div></div></div>"},"77263":{"type":"graphic_figure","displayName":"High resolution manometry","title":"High resolution manometry","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">High resolution manometry</div><div class=\"cntnt\"><img style=\"width:574px; height:423px;\" src=\"images/GAST/77263_High_resolution_manometry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown is a wet swallow captured by high resolution manometry. The colors represent pressure in the esophagus as shown on the y-axis. The x-axis is time. There are simultaneous contractions in the body of the esophagus. The&nbsp;lower esophageal sphincter relaxes incompletely. These findings are consistent with a diagnosis of achalasia.</div><div class=\"graphic_reference\">Courtesy of Anthony J Lembo, MD.</div><div id=\"graphicVersion\">Graphic 77263 Version 2.0</div></div></div>"},"77264":{"type":"graphic_figure","displayName":"Use of platelet transfusions","title":"Indications for inpatient platelet transfusions","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Indications for inpatient platelet transfusions</div><div class=\"cntnt\"><img style=\"width:479px; height:275px;\" src=\"images/HEME/77264_Use_of_platelet_transfusion.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The total usage of platelet transfusions (random donor platelet concentrates, single donor apheresis units, and HLA-matched single donor apheresis units) was estimated for all inpatient admissions for the years 1993-1995 in the United States for each recipient's DRG classification. The individual DRG classifications were combined into ten general disease groupings and the relative use of all platelet products (measured in &quot;single donor apheresis unit equivalents&quot;) in these groups calculated. A &quot;single donor apheresis unit equivalent&quot; is appoximately 3 x 10<sup>11</sup> platelets; six random donor platelet concentrates equal one &quot;single donor apheresis unit equivalent.&quot;</div><div class=\"graphic_reference\">Data from: Kuter, DJ. The use of PEG-rhuMGDF in platelet apheresis. Stem cells 1998; 16 Suppl 2:231.</div><div id=\"graphicVersion\">Graphic 77264 Version 1.0</div></div></div>"},"77265":{"type":"graphic_figure","displayName":"MRS at rest in HF","title":"Impaired muscle metabolism in HF","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Impaired muscle metabolism in HF</div><div class=\"cntnt\"><img style=\"width:284px; height:383px;\" src=\"images/CARD/77265_MRS_at_rest_in_HF.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance spectropscopy (MRS) performed at rest in normal controls and patients with heart failure (HF). The inorganic phosphate (Pi), phosphocreatine (PCr), and three adenosine triphosphate (ATP) peaks are identified; the pH is determined by the chemical shift between the PCr and Pi peak. Using the observed values, the concentrations of PCr and Pi and the Pi/PCr ratio of the areas under the Pi and PCr peaks are calculated; this ratio provides an estimation of the high energy phosphate supply available for utilization. An increase in the Pi/PCr ratio, as seen in HF, suggests a reduction in energy supply and is an useful indicator of the rate of energy utilization during exercise.</div><div class=\"graphic_reference\">Data from: Massie, B, Conway, M, Yonge, R, et al, Am J Cardiol 1987; 60:309.</div><div id=\"graphicVersion\">Graphic 77265 Version 1.0</div></div></div>"},"77266":{"type":"graphic_table","displayName":"Drug and toxin related pulmonary edema or pneumonitis","title":"Agents associated with noncardiogenic pulmonary edema","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents associated with noncardiogenic pulmonary edema</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"sublist1_start\">Irritant gases</td> </tr> <tr> <td class=\"sublist1\">Ammonia</td> </tr> <tr> <td class=\"sublist1\">Chlorine</td> </tr> <tr> <td class=\"sublist1\">Hydrogen sulfide</td> </tr> <tr> <td class=\"sublist1\">Nitrogen oxides</td> </tr> <tr> <td class=\"sublist1\">Phosgene</td> </tr> <tr> <td class=\"sublist1\">Smoke</td> </tr> <tr> <td class=\"sublist1\">Sulfur dioxide</td> </tr> <tr> <td class=\"sublist1\">Metal oxides</td> </tr> <tr> <td class=\"sublist1\">Acid and alkaline gases</td> </tr> <tr> <td class=\"sublist1\">Aldehydes</td> </tr> <tr> <td class=\"sublist1\">Isocyanates</td> </tr> <tr> <td class=\"sublist1\">Polymers</td> </tr> <tr> <td class=\"sublist1_start\">Volatile inhalants (hydrocarbons)</td> </tr> <tr> <td class=\"sublist1\">Gasoline</td> </tr> <tr> <td class=\"sublist1\">Kerosene</td> </tr> <tr> <td class=\"sublist1\">Butane</td> </tr> <tr> <td>Beryllium</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"sublist1_start\">Opiates</td> </tr> <tr> <td class=\"sublist1\">Heroin</td> </tr> <tr> <td class=\"sublist1\">Methadone</td> </tr> <tr> <td class=\"sublist1_start\">Sedative-hypnotics</td> </tr> <tr> <td class=\"sublist1\">Ethchlorvynol</td> </tr> <tr> <td class=\"sublist1_start\">Cellular asphyxiants</td> </tr> <tr> <td class=\"sublist1\">Cyanide</td> </tr> <tr> <td class=\"sublist1\">Carbon monoxide</td> </tr> <tr> <td>Salicylates</td> </tr> <tr> <td>Organophosphates</td> </tr> <tr> <td>Phencyclidine</td> </tr> <tr> <td>Paraquat</td> </tr> <tr> <td>Ethylene glycol</td> </tr> <tr> <td>Heavy metals</td> </tr> <tr> <td>Sympathomimetics</td> </tr> <tr> <td>Beta blockers</td> </tr> <tr> <td>Calcium-channel blockers</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Any agent that causes prolonged hypoxia or hypotension may result in the acute respiratory distress syndrome.</div><div id=\"graphicVersion\">Graphic 77266 Version 5.0</div></div></div>"},"77267":{"type":"graphic_table","displayName":"Management of localized scleroderma in children","title":"Management of localized scleroderma in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of localized scleroderma in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Circumscribed (plaque) morphea</td> <td class=\"subtitle1\">Generalized morphea</td> <td class=\"subtitle1\">Linear morphea</td> <td class=\"subtitle1\">En coup de sabre</td> </tr> <tr> <td><strong>Clinical features</strong></td> <td>One or a few circumscribed sclerotic plaques with hypo- or hyperpigmentation and an inflamed violaceous border.</td> <td>Individual plaques (four or more and larger than 3 cm) that become confluent and involve at least two anatomic sites.</td> <td>Linear induration involving dermis, subcutaneous tissue, and sometimes muscle and underlying bone, and affecting the limbs and/or the trunk.</td> <td>Linear morphea affecting the face or scalp, involving underlying subcutaneous tissues, muscles, and bone. Underlying cerebral abnormalities have been reported.</td> </tr> <tr class=\"divider_top\"> <td><strong>Treatment</strong></td> <td>Often unnecessary. Topical corticosteroids for active lesions.</td> <td>Suppress inflammation with oral or IV glucocorticoids for three months&nbsp;in addition to methotrexate (15 mg/m<sup>2</sup>/week) for&nbsp;24 months. Mycophenolate mofetil can be used in methotrexate-refractory cases.</td> <td>Suppress inflammation with oral or IV glucocorticoids for three&nbsp;months&nbsp;in addition to methotrexate (15 mg/m<sup>2</sup>/week) for&nbsp;24 months.&nbsp;Mycophenolate mofetil can be used in methotrexate-refractory cases.</td> <td>Suppress inflammation with oral or IV glucocorticoids for three months&nbsp;in addition to methotrexate (15 mg/m<sup>2</sup>/week) for&nbsp;24 months.&nbsp;Mycophenolate mofetil can be used in methotrexate-refractory cases.</td> </tr> <tr class=\"divider_top\"> <td><strong>Prognosis</strong></td> <td>Good prognosis lesions less active within&nbsp;three years, but pigmentary changes often persist.</td> <td>Generally improves within&nbsp;five years of onset, although textural and pigmentary changes can remain.</td> <td>Long-term effects of childhood onset form minimized by effective suppression of inflammatory process. Ultimately the disease tends to resolve, but it can remain active for many years.</td> <td>Scarring, growth defects, and alopecia persist, but inflammatory component usually resolves.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.</div><div id=\"graphicVersion\">Graphic 77267 Version 7.0</div></div></div>"},"77268":{"type":"graphic_figure","displayName":"Prevalence of atrial fibrillation with age","title":"Prevalence of atrial fibrillation with age","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Prevalence of atrial fibrillation with age</div><div class=\"cntnt\"><img style=\"width:525px; height:260px;\" src=\"images/CARD/77268_Prevalence_atrial_fibrillat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a cross-sectional study of almost 1.9 million men and women, the prevalence of atrial fibrillation increases with age, ranging from 0.1 for those &lt;55 years of age to over 9 percent in those ≥85 years of age. At all ages, the prevalence is higher in men than women.</div><div class=\"graphic_reference\">Data from Go AS, Hylek EM, Phillips K, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285:2370.</div><div id=\"graphicVersion\">Graphic 77268 Version 5.0</div></div></div>"},"77269":{"type":"graphic_figure","displayName":"Causes of seasonal allergies PI","title":"Common causes of seasonal allergies","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Common causes of seasonal allergies</div><div class=\"cntnt\"><img style=\"width:497px; height:457px;\" src=\"images/PI/77269_Causes_seas_allerg_PI_edt2.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77269 Version 3.0</div></div></div>"},"77270":{"type":"graphic_picture","displayName":"Keratosis pilaris rubra faciei","title":"Keratosis pilaris rubra faciei","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Keratosis pilaris rubra faciei</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77270_Keratosis_pilaris_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small, follicularly-based, rough, keratotic papules are present on the cheeks. As shown here, background erythema may also be present in patients with this condition.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77270 Version 4.0</div></div></div>"},"77271":{"type":"graphic_figure","displayName":"Tendon sheath anatomy","title":"Flexor tendons, common flexor sheath, fibrous digital sheaths, and synovial sheaths of the digits","html":"<div class=\"graphic\"><div style=\"width: 492px\" class=\"figure\"><div class=\"ttl\">Flexor tendons, common flexor sheath, fibrous digital sheaths, and synovial sheaths of the digits</div><div class=\"cntnt\"><img style=\"width:472px; height:526px;\" src=\"images/ID/77271_Tendon_sheath_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection of the palm of the hand illustrating the tendons and fibrous digital tendon sheaths. The fibrous sheaths of the digits are strong coverings of the flexor tendons, which extend from the heads of the metacarpals to the base of the distal phalanges. They prevent the tendons from pulling away from the bones of the digits. They attach along the borders of the proximal and middle phalanges, to capsules of the interphalangeal joints, and to the surface of the distal phalanx.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, PhD, FRSM, FIAC &amp; Dalley AF II, PhD. Clinical Oriented Anatomy (4th ed.). Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &#169;1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77271 Version 1.0</div></div></div>"},"77274":{"type":"graphic_table","displayName":"Pneumococcal vaccines","title":"Comparison of serotypes in pneumococcal vaccines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of serotypes in pneumococcal vaccines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Conjugate vaccines</td> <td class=\"subtitle1\" colspan=\"2\">Polysaccharide vaccine</td> </tr> <tr> <td class=\"subtitle2\"> <p>PCV7</p> <p>(Prevnar 7)</p> </td> <td class=\"subtitle2\"> <p>PCV10*</p> <p>(Synflorix)</p> </td> <td class=\"subtitle2\"> <p>PCV13</p> <p>(Prevnar 13)</p> </td> <td class=\"subtitle2\">PCV15<sup>&#182;</sup></td> <td class=\"subtitle2\" colspan=\"2\"> <p>PPSV23</p> <p>(Pneumovax 23)</p> </td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">4</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">6B</td> <td class=\"centered\">6B</td> <td class=\"centered\">6B</td> <td class=\"centered\">6B</td> <td class=\"centered\">6B</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"centered\">9V</td> <td class=\"centered\">9V</td> <td class=\"centered\">9V</td> <td class=\"centered\">9V</td> <td class=\"centered\">9V</td> <td class=\"centered\">9N</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">14</td> <td class=\"centered\">14</td> <td class=\"centered\">14</td> <td class=\"centered\">14</td> <td class=\"centered\">10A</td> </tr> <tr> <td class=\"centered\">18C</td> <td class=\"centered\">18C</td> <td class=\"centered\">18C</td> <td class=\"centered\">18C</td> <td class=\"centered\">18C</td> <td class=\"centered\">11A</td> </tr> <tr> <td class=\"centered\">19F</td> <td class=\"centered\">19F</td> <td class=\"centered\">19F</td> <td class=\"centered\">19F</td> <td class=\"centered\">19F</td> <td class=\"centered\">12F</td> </tr> <tr> <td class=\"centered\">23F</td> <td class=\"centered\">23F</td> <td class=\"centered\">23F</td> <td class=\"centered\">23F</td> <td class=\"centered\">23F</td> <td class=\"centered\">15B</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">17F</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">20</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> <td class=\"centered\">5</td> <td class=\"centered\">22F</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">3</td> <td class=\"centered\">33F</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">7F</td> <td class=\"centered\">7F</td> <td class=\"centered\">7F</td> <td class=\"centered\">7F</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">19A</td> <td class=\"centered\">19A</td> <td class=\"centered\">19A</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">6A</td> <td class=\"centered\">6A</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">22F</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">33F</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCV7: 7-valent pneumococcal conjugate vaccine; PCV10: 10-valent pneumococcal conjugate vaccine; PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine.<br />* Not available in the United States.<br />&para; In development.</div><div id=\"graphicVersion\">Graphic 77274 Version 6.0</div></div></div>"},"77276":{"type":"graphic_algorithm","displayName":"P wave before QRS I","title":"P wave before each QRS complex with constant PR relationship","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">P wave before each QRS complex with constant PR relationship</div><div class=\"cntnt\"><img style=\"width:551px; height:446px;\" src=\"images/CARD/77276_P_wave_before_QRS_I.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77276 Version 2.0</div></div></div>"},"77282":{"type":"graphic_figure","displayName":"Rabies in the US","title":"Terrestrial rabies virus variants in the United States and Puerto Rico","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Terrestrial rabies virus variants in the United States and Puerto Rico</div><div class=\"cntnt\"><img style=\"width:635px; height:491px;\" src=\"images/ID/77282_RabiesUS20092015.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of major rabies virus variants among mesocarnivores in the United States and Puerto Rico, 2008 through 2015.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention (CDC). Rabies: Wild Animals. Available at: <A href=\"https://www.cdc.gov/rabies/resources/publications/2015-surveillance/2015-us-map.html\" target=_blank>https://www.cdc.gov/rabies/resources/publications/2015-surveillance/2015-us-map.html</A> (Accessed on January 2, 2018).</div><div id=\"graphicVersion\">Graphic 77282 Version 4.0</div></div></div>"},"77283":{"type":"graphic_table","displayName":"Zoonoses causing encephalitis","title":"Important viral zoonoses that cause encephalitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important viral zoonoses that cause encephalitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Family/virus</td> <td class=\"subtitle1\">Vector</td> <td class=\"subtitle1\">Vertebrate host</td> <td class=\"subtitle1\">Ecology</td> <td class=\"subtitle1\">Geographic distribution</td> <td class=\"subtitle1\">Epidemics</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Togaviridae</td> </tr> <tr> <td class=\"indent1\">Eastern equine encephalitis</td> <td>Mosquitoes</td> <td>Birds</td> <td>R</td> <td>Americas</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Western equine encephalitis</td> <td>Mosquitoes</td> <td>Birds, rabbits</td> <td>R</td> <td>Americas</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Venezuelan equine encephalitis</td> <td>Mosquitoes</td> <td>Rodents</td> <td>R</td> <td>Americas</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Flaviviridae</td> </tr> <tr> <td class=\"indent1\">Dengue</td> <td>Mosquitoes</td> <td>Humans</td> <td>R, S, U</td> <td>Americas, Africa, Asia</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Japanese encephalitis</td> <td>Mosquitoes</td> <td>Birds</td> <td>R, S</td> <td>Asia</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Murray Valley encephalitis</td> <td>Mosquitoes</td> <td>Birds</td> <td>R</td> <td>Australia</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">St. Louis encephalitis</td> <td>Mosquitoes</td> <td>Birds</td> <td>R, S, U</td> <td>Americas</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">West Nile encephalitis</td> <td>Mosquitoes</td> <td>Birds</td> <td>R, S, U</td> <td>Asia, Africa, North America,</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\">Powassan</td> <td>Ticks</td> <td>&nbsp;</td> <td>R, S</td> <td>Europe, Northern United States, Canada</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Tick-borne encephalitis</td> <td>Ticks</td> <td>Rodents</td> <td>R</td> <td>Europe, Asia</td> <td>No</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Bunyaviridae</td> </tr> <tr> <td class=\"indent1\">La Crosse encephalitis</td> <td>Mosquitoes</td> <td>Rodents</td> <td>R, S</td> <td>North America</td> <td>No</td> </tr> <tr> <td class=\"indent1\">California encephalitis</td> <td>Mosquitoes</td> <td>Rodents</td> <td>R</td> <td>North America, Europe, Asia</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Reoviridae</td> </tr> <tr> <td class=\"indent1\">Colorado tick fever</td> <td>Ticks</td> <td>Rodents, small mammals</td> <td>R</td> <td>Western United States, Canada</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">R: rural; S: suburban; U: urban.</div><div id=\"graphicVersion\">Graphic 77283 Version 3.0</div></div></div>"},"77288":{"type":"graphic_diagnosticimage","displayName":"Acute pancreatitis with pseudocyst formation","title":"Acute pancreatitis with pseudocyst formation","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Acute pancreatitis with pseudocyst formation</div><div class=\"cntnt\"><img style=\"width:500px; height:389px;\" src=\"images/SURG/77288_Acute_pancreat_pseudocyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral and intravenous contrast enhanced CT scan of the upper abdomen demonstrates an enlarged pancreas containing multiple cystic lesions within it. The findings are consistent with acute pancreatitis with pseudocyst formation.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of J Pierre Sasson, MD.</div><div id=\"graphicVersion\">Graphic 77288 Version 3.0</div></div></div>"},"77290":{"type":"graphic_figure","displayName":"Brow presentation","title":"Brow presentation","html":"<div class=\"graphic\"><div style=\"width: 550px\" class=\"figure\"><div class=\"ttl\">Brow presentation</div><div class=\"cntnt\"><img style=\"width:530px; height:441px;\" src=\"images/OBGYN/77290_Brow_presentation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fetus in the brow presentation occupies a longitudinal axis with the fetal neck extended, but not to the degree in face presentation. The area presenting in the birth canal typically extends from the anterior fontanelle to the brow (orbital ridge).</div><div id=\"graphicVersion\">Graphic 77290 Version 6.0</div></div></div>"},"77293":{"type":"graphic_figure","displayName":"Front view knee PI","title":"Front view of the knee","html":"<div class=\"graphic\"><div style=\"width: 513px\" class=\"figure\"><div class=\"ttl\">Front view of the knee</div><div class=\"cntnt\"><img style=\"width:493px; height:506px;\" src=\"images/PI/77293_Front_view_knee_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing shows the inner parts of the knee as seen from the front. A small bone (called the patella or the \"knee cap\") that sits in front of the knee has been removed so that you can see what is under that bone. The anterior cruciate ligament (ACL) is in the middle in white. It connects the thigh bone (called the \"femur\") to the shin bone (called the \"tibia\"). The meniscus is a cushion of rubbery material (cartilage) between the thigh bone and the shin bone.</div><div id=\"graphicVersion\">Graphic 77293 Version 5.0</div></div></div>"},"77294":{"type":"graphic_figure","displayName":"TR beta molecule","title":"Location of mutations in the TR<sub> β </sub> molecule causing RTH","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Location of mutations in the TR<sub> β </sub> molecule causing RTH</div><div class=\"cntnt\"><img style=\"width:577px; height:499px;\" src=\"images/PEDS/77294_TR_beta_molecule.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Schematic representation of the thyroid hormone receptor beta&nbsp;(TR<SUB> β</SUB>)<SUB> </SUB>and its functional domains for interaction with TREs (DNA-binding), with hormone (T3-binding), with activating and repressing cofactors, and with nuclear receptor partners (dimerization). Note their relationship to the three clusters of natural mutations. B) The T3-binding domain and distal end of the hinge region, which contain the three mutation clusters, are expanded and show the positions of CpG dinucleotide, which are mutational \"hot spots\" in the RT<SUB> β </SUB>gene. <br />The location of 124 different mutations detected in 343 unrelated families (published and our unpublished data) are each indicated by a symbol. Identical mutations in members of unrelated families are indicated vertically by the same color and symbol. \"Cold regions\" are areas devoid of mutations associated with RTH. Amino acids are numbered consecutively starting at the amino terminus of the TR<SUB> β </SUB>1 molecule according to the consensus statement of the First International Workshop on RTH [Beck-Peccoz 1993]. TR<SUB> β </SUB>2 has 15 additional residues at the amino terminus.</div><div class=\"graphic_footnotes\">RTH: resistance to thyroid hormone; AF2: hormone-dependent activation function (12th amphipatic helix); RBE: corepressor-binding enhancer; RBI: corepressor-binding inhibitor; SSD: silencing subdomain; NucL: nuclear localization; SigM: signature motif; TRE: thyroid hormone response element.</div><div class=\"graphic_reference\">Reproduced with permission from: WWW.THYROIDMANAGER.ORG, the comprehensive free on-line web textbook, Chapter 16d, by Samuel Refetoff, MD, version 7 June 2008.</div><div id=\"graphicVersion\">Graphic 77294 Version 11.0</div></div></div>"},"77298":{"type":"graphic_table","displayName":"Treatment for bartonellosis","title":"Antimicrobial therapy for treatment of South American bartonellosis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial therapy for treatment of South American bartonellosis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Notes</td> <td class=\"subtitle1\">Adult dose</td> <td class=\"subtitle1\">Pediatric dose</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Oroya fever<br /> (Carrion's disease)</td> <td>Ciprofloxacin</td> <td>Treatment of choice for uncomplicated Oroya fever in adults.</td> <td>500 mg orally twice daily for 14 days</td> <td>20 mg/kg orally in two divided doses for 14 days (max 1 g/day)<sup>&#182;</sup></td> </tr> <tr> <td>Chloramphenicol</td> <td>Alternative treatment choice for treatment of Oroya fever; recurrence has been described. Administered in combination with ceftriaxone.</td> <td> <p>50 to 75 mg/kg/day (up to 3 g/day) orally or intravenously in four divided doses for 10 to 14 days</p> Following defervescence, may be reduced to 25 mg/kg orally or intravenously in four divided doses</td> <td> <p>50 to 75 mg/kg/day (up to 2 g/day) orally or intravenously in four divided doses for 10 to 14 days<sup>&#182;</sup></p> Following defervescence, may be reduced to 25 mg/kg orally or intravenously in four divided doses</td> </tr> <tr> <td>Ceftriaxone</td> <td> <p>Administered in combination with chloramphenicol.</p> Administered in combination with ciprofloxacin for treatment of severe disease.</td> <td>1 g intravenously once daily for 10 to 14 days</td> <td>50 to 75 mg/kg intravenously once daily for 10 to 14 days (maximum 1 g/day)</td> </tr> <tr class=\"divider_bottom\"> <td>Amoxicillin-clavulanic acid</td> <td>Treatment of choice for uncomplicated Oroya fever in children and pregnant women.</td> <td>1 g (based on amoxicillin) orally twice daily for 14 days</td> <td>40 mg/kg (based on amoxicillin) orally in three divided doses for 14 days (maximum 2 g/day)</td> </tr> <tr> <td rowspan=\"3\">Verruga peruana<br /> (Peruvian wart)</td> <td>Azithromycin</td> <td>Treatment of choice in adults, children, and pregnant women.</td> <td>500 mg orally once daily for 7 days</td> <td>10 mg/kg orally once daily for 7 days (maximum 500 mg/day)</td> </tr> <tr> <td>Rifampin</td> <td>Treatment failures have been reported; alternate treatment choice.</td> <td>600 mg orally once daily for 14 to 21 days</td> <td>10 mg/kg orally once daily for 14 to 21 days (maximum 600 mg/day)</td> </tr> <tr> <td>Ciprofloxacin</td> <td>Alternate treatment choice.</td> <td>500 mg orally twice daily for 7 to 10 days</td> <td>20 mg/kg orally in two divided doses for 14 days (max 1 g/day)<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to Lexicomp drug monographs for further information.</div><div class=\"graphic_footnotes\">* See text for discussion of approach to antibiotic selection.<br />&para; Chloramphenicol may cause bone marrow depression and aplastic anemia; dose adjustments are required for renal or hepatic impairment. Optimally, serum concentration should be monitored if chloramphenicol is employed. The risk of toxicity due to chloramphenicol may exceed that of ciprofloxacin.<br />&Delta; Ciprofloxacin is not a drug of first choice in children due to reported adverse events related to joints and/or surrounding tissues. In some pediatric studies, an increased risk of reversible adverse events involving joints or surrounding tissues, often due to reports of arthralgia, has been observed. However, no compelling published evidence supports the occurrence of sustained injury to developing bones or joints in children treated with available fluoroquinolone agents<sup>[1]</sup>. The risks and benefits should be considered if a fluoroquinolone is prescribed in a child younger than 18 years of age.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Bradley JS, Jackson MA, Committee on Infectious Diseases, American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 2011; 128:e1034.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 77298 Version 5.0</div></div></div>"},"77302":{"type":"graphic_diagnosticimage","displayName":"TVUS ovary gonadotroph adenoma","title":"Transvaginal ultrasound examination of the ovary (A) and uterus (B) of a 39-year-old woman with a gonadotroph adenoma and FSH hypersecretion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transvaginal ultrasound examination of the ovary (A) and uterus (B) of a 39-year-old woman with a gonadotroph adenoma and FSH hypersecretion</div><div class=\"cntnt\"><img style=\"width:504px; height:248px;\" src=\"images/ENDO/77302_U-S_ovary_gonadotroph_adeno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Multiple cysts (arrows) within the substance of the ovary.<br />(B) In a coronal view of the uterus (outlined by narrow arrows), a markedly thickened, echogenic endometrial stripe (wide arrows) is shown.<br />Scale: distance between open arrows = 10 mm.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone.</div><div class=\"graphic_reference\">Reproduced with permission from: Djerassi A, Coutifaris C, West VA. Gonadotroph adenoma in a premenopausal woman secreting follicle-stimulating hormone and causing ovarian hyperstimulation. J Clin Endocrinol Metab 1995; 80:591. http://jcem.endojournals.org/. Copyright © 1995 The Endocrine Society.</div><div id=\"graphicVersion\">Graphic 77302 Version 8.0</div></div></div>"},"77303":{"type":"graphic_diagnosticimage","displayName":"EHL for entrapped basket","title":"Electrohydraulic lithotripsy of a common bile duct stone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Electrohydraulic lithotripsy of a common bile duct stone</div><div class=\"cntnt\"><img style=\"width:324px; height:313px;\" src=\"images/GAST/77303_EHL_for_entrapped_basket.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fluoroscopic view demonstrating a basket containing a gallstone (arrow), which has become entrapped in the bile duct. A daughter scope has been advanced into the bile duct (arrowhead) permitting fragmentation of the stone using electrohydraulic lithotripsy (EHL). Following EHL, both the basket and the stone were removed and the bile duct cleared of stones.</div><div class=\"graphic_reference\">Courtesy of Isaac Raijman, MD and Susana Escalante, MD.</div><div id=\"graphicVersion\">Graphic 77303 Version 4.0</div></div></div>"},"77304":{"type":"graphic_table","displayName":"History taking in women with pseudocyesis","title":"Psychological themes relevant to pseudocyesis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Psychological themes relevant to pseudocyesis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Psychological themes</td> <td class=\"subtitle1\">Relevant questions</td> </tr> <tr> <td>Pressure to be pregnant</td> <td>How do significant others feel about the patient's pregnancy?</td> </tr> <tr> <td>Fear of pregnancy</td> <td>Does the patient have concerns/fears about pregnancy?</td> </tr> <tr> <td>Coping style characterized by somatization and/or denial</td> <td>How does the patient characteristically manage difficult emotions?</td> </tr> <tr> <td>Loneliness</td> <td>Does the patient have adequate social support?</td> </tr> <tr> <td>Loss</td> <td>Is there a history of loss (eg, pregnancy loss, deaths, loss of custody of a child, loss of reproductive capacity)?</td> </tr> <tr> <td>Rejection</td> <td>Has the patient been rejected by her partner or someone else important to her?</td> </tr> <tr> <td>Self-identity</td> <td>What role does fertility and pregnancy play?</td> </tr> <tr> <td>Trauma</td> <td>Is there a history of abuse (physical, sexual)?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77304 Version 2.0</div></div></div>"},"77305":{"type":"graphic_figure","displayName":"Pathophysiology of aortic regurgitation with VSD","title":"Pathophysiology of aortic regurgitation with VSD","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Pathophysiology of aortic regurgitation with VSD</div><div class=\"cntnt\"><img style=\"width:586px; height:200px;\" src=\"images/CARD/77305_Patho_aortic_regurg_VSD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pathophysiology of aortic regurgitation. In early systole (A), ejected blood from the left ventricle (LV) will be shunted through the ventricular septal defect. As a result, the anatomically unsupported coronary cusp and aortic sinus are driven into the right ventricle (RV) (B) (Venturi effect). In diastole (C), the intra-aortic pressure forces the aortic valve leaflet to close, but the unsupported cusp (right or noncoronary) is pushed down into the left ventricular outflow tract away from the opposed coronary cusp, resulting in regurgitation.</div><div class=\"graphic_footnotes\">AR: aortic regurgitation; IVS: interventricular septum; PA: pulmonary artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Tatsuno K, Konno S, Ando M, et al. Pathogenetic mechanisms of prolapsing aortic valve and aortic regurgitation associated with ventricular septal defect. Anatomical, angiographic, and surgical considerations. Circulation 1973; 48:1028. Copyright © 1973 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77305 Version 8.0</div></div></div>"},"77306":{"type":"graphic_figure","displayName":"Implant breast reconstruction","title":"Implant breast reconstruction","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Implant breast reconstruction</div><div class=\"cntnt\"><img style=\"width:510px; height:347px;\" src=\"images/SURG/77306_Implant-breast-reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The placement of a reconstructive implant is preceded by tissue expansion (&quot;secondary&quot; or two-stage implant/expander reconstruction), in order to grow additional soft tissue covering (mainly skin) for the new breast.</div><div id=\"graphicVersion\">Graphic 77306 Version 3.0</div></div></div>"},"77307":{"type":"graphic_picture","displayName":"Multicentric reticulohistiocytosis","title":"Multicentric reticulohistiocytosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multicentric reticulohistiocytosis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/77307_Multi_reticulohistiocytosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules are present on the hand of this patient with multicentric reticulohistiocytosis. Note the small papules involving the proximal and lateral nail folds.</div><div id=\"graphicVersion\">Graphic 77307 Version 1.0</div></div></div>"},"77308":{"type":"graphic_picture","displayName":"Psoriasis legs","title":"Plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77308_Psoriasis_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well demarcated, erythematous, and scaly&nbsp;plaques on the legs of a patients with psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77308 Version 4.0</div></div></div>"},"77309":{"type":"graphic_diagnosticimage","displayName":"Reduced overlapping fracture","title":"Anatomic reduction and long arm cast","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomic reduction and long arm cast</div><div class=\"cntnt\"><img style=\"width:412px; height:484px;\" src=\"images/EM/77309_Reduced_overlapping_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Paula Schweich, MD.</div><div id=\"graphicVersion\">Graphic 77309 Version 2.0</div></div></div>"},"77310":{"type":"graphic_picture","displayName":"Incomplete gastric intestinal metaplasia","title":"Incomplete gastric intestinal metaplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Incomplete gastric intestinal metaplasia</div><div class=\"cntnt\"><img style=\"width:396px; height:294px;\" src=\"images/ONC/77310_Incomplete_metaplasia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incomplete intestinal metaplasia with colonic epithelium, multiple, irregular goblet cells without a brush border.</div><div id=\"graphicVersion\">Graphic 77310 Version 2.0</div></div></div>"},"77311":{"type":"graphic_table","displayName":"Stage group head and neck CA","title":"American Joint Committee on Cancer TNM stage groupings for head and neck sites, not including the nasopharynx.","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Joint Committee on Cancer TNM stage groupings for head and neck sites, not including the nasopharynx.</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td    rowspan=\"1\" colspan=\"4\" class=\"subtitle1\">\r\n  \r\n   Stage groupings of TNM subsets\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stage 0</td>\r\n  \r\n   <td>Tis</td>\r\n  \r\n   <td>N0</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stage I</td>\r\n  \r\n   <td>T1</td>\r\n  \r\n   <td>N0</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stage II</td>\r\n  \r\n   <td>T2</td>\r\n  \r\n   <td>N0</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td    rowspan=\"2\">\r\n  \r\n   Stage III\r\n  \r\n   </td>\r\n  \r\n   <td>T3</td>\r\n  \r\n   <td>N0</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>T1-T3</td>\r\n  \r\n   <td>N1</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td    colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Stage IVA\r\n  \r\n   </td>\r\n  \r\n   <td>T4a</td>\r\n  \r\n   <td>N0-N1</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>T1-T4a</td>\r\n  \r\n   <td>N2</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td    colspan=\"1\" rowspan=\"2\">\r\n  \r\n   Stage IVB\r\n  \r\n   </td>\r\n  \r\n   <td>T4b</td>\r\n  \r\n   <td>Any N</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Any T</td>\r\n  \r\n   <td>N3</td>\r\n  \r\n   <td>M0</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Stage IVC</td>\r\n  \r\n   <td>Any T</td>\r\n  \r\n   <td>Any N</td>\r\n  \r\n   <td>M1</td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.</div><div id=\"graphicVersion\">Graphic 77311 Version 1.0</div></div></div>"},"77312":{"type":"graphic_table","displayName":"APC initial settings","title":"Guidelines for the flexible bronchoscope and accessories using argon plasma coagulation*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for the flexible bronchoscope and accessories using argon plasma coagulation*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">APC pulsed effect 1, monopolar non-contact<sup>&#182;</sup></td> <td class=\"subtitle1\">APC pulsed effect 2, monopolar non-contact<sup>&#182;</sup></td> <td class=\"subtitle1\">APC forced, monopolar non-contact<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Obstruction</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Argon plasma coagulation</td> <td>15 watts</td> <td>15 watts</td> <td>15 watts</td> </tr> <tr> <td>Gas 0.3 L/m</td> <td>Gas 0.3 L/m</td> <td>Gas 0.3 L/m</td> </tr> <tr> <td>Slow pulses</td> <td>Fast pulses</td> <td>Continuous output</td> </tr> <tr> <td>Deeper coagulation</td> <td>Superficial coagulation</td> <td class=\"divider_bottom\" rowspan=\"2\">Superficial to deep thermal insult depending on: a) time/length of activation and b) power setting</td> </tr> <tr class=\"divider_bottom\"> <td>Active regulation (ie, elastic plasma)</td> <td>Active regulation (ie, elastic plasma)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Hemostasis</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Argon plasma coagulation</td> <td>15 watts (above)</td> <td>15 watts (above)</td> <td>15 watts (above)</td> </tr> <tr> <td>Gas 0.3 L/m</td> <td>Gas 0.3 L/m</td> <td>Gas 0.3 L/m</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This is a synthesis of literature and manufacturer information.<br />¶ Wattage and Gas Flow is recommended as a starting point. Physicians may adjust parameters based upon manufacturer recommendations, tissue effect objectives intraoperatively, and anatomic presentation pre- and intraoperatively.</div><div class=\"graphic_reference\">Reproduced with permission from: Turner JF, Wang KP. Endobronchial laser therapy. Clin Chest Med 1999; 20:107. Copyright &copy; 1999 Elsevier.</div><div id=\"graphicVersion\">Graphic 77312 Version 8.0</div></div></div>"},"77313":{"type":"graphic_table","displayName":"Causes alveolar proteinosis","title":"Pulmonary alveolar proteinosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary alveolar proteinosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Disruption of GM-CSF signalling (autoimmune and hereditary PAP)</td> </tr> <tr> <td class=\"indent1\">Anti-GM-CSF antibodies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recessive variants of gene for GM-CSF receptor alpha and beta subunits (CSF2RA and CSF2RB)</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders of surfactant production (congenital PAP)</td> </tr> <tr> <td class=\"indent1\">Variants of surfactant proteins B and C (SFTPB, SFTPC)</td> </tr> <tr> <td class=\"indent1\">Variants of ATP-binding cassette, subfamily A (ABCA3)</td> </tr> <tr> <td class=\"indent1\">Variant of NK2 homeobox-1 (NKX2.1) that encodes thyroid transcription factor-1 (TTF1), which in turn regulates transcription of SFTP-C and ABCA3</td> </tr> <tr> <td class=\"indent1\">Variants of SLC7A7/y+LAT1, which causes lysinuric protein intolerance (LPI). Patients with LPI have defective cationic amino acid transport (y+L transport) and defective expression of y+LAT in alveolar macrophages</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Methionyl-tRNA synthetase (MARS) variants: Compound heterozygosity associated with liver failure, PAP, anemia, delays in motor development; exact mechanism of PAP uncertain</td> </tr> <tr> <td class=\"subtitle1_single\">Secondary: Underlying disorder secondarily affects alveolar macrophages</td> </tr> <tr> <td class=\"indent1\">Hematologic malignancy (eg, myelodysplastic syndrome, multiple myeloma, chronic myelocytic leukemia, Waldenstr&#246;m macroglobulinemia)</td> </tr> <tr> <td class=\"indent1\">Myelodysplastic syndromes (eg, GATA2 deficiency)</td> </tr> <tr> <td class=\"indent1\">Hematopoietic cell transplantation for myeloid malignancy</td> </tr> <tr> <td class=\"indent1\">Immune defects (eg, Fanconi syndrome, agammaglobulinemia, severe combined immunodeficiency <span style=\"color: black;\">(especially adenosine deaminase deficiency)</span><span style=\"color: black;\">, </span>Beh&#231;et disease, juvenile dermatomyositis, renal tubular acidosis, GATA2 deficiency)</td> </tr> <tr> <td class=\"indent1\">Infections (eg, <em>Nocardia</em>, <em>Pneumocystis jirovecii</em>, cytomegalovirus)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inhalational exposures <ul class=\"decimal_heading\"> <li>Inorganic dust inhalation (silica, aluminum, titanium, tin-oxide) </li> <li>Organic dust inhalation (agricultural, bakery flour, fertilizer, sawdust) </li> <li>Fume inhalation (chlorine, gasoline/petroleum, nitrogen dioxide, paint/varnish, plastic) </li> </ul> </td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\"><strong>Unclassified</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GM-CSF: granulocyte macrophage-colony stimulating factor.</div><div id=\"graphicVersion\">Graphic 77313 Version 3.0</div></div></div>"},"77315":{"type":"graphic_picture","displayName":"In situ hybridization","title":"Representative example of in situ hybridization of nasal biopsy specimens in allergic rhinitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Representative example of in situ hybridization of nasal biopsy specimens in allergic rhinitis</div><div class=\"cntnt\"><img style=\"width:393px; height:261px;\" src=\"images/RHEUM/77315_In_situ_hybridization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Expression of IL-4 mRNA after antigen challenge (A) and diluent challenge (B). Expression of IL-14 mRNA after allergen challenge and (C) colocalization of IL-4 and IL-13 mRNA after allergen challenge (D).</div><div class=\"graphic_footnotes\">IL: interleukin; mRNA: messenger RNA.</div><div class=\"graphic_reference\">Reproduced with permission from: Christodoulopoulos P, Cameron L Durham S, Hamid Q. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol 2000; 105(2 Pt 1):211. Copyright © 2000 Elsevier.</div><div id=\"graphicVersion\">Graphic 77315 Version 4.0</div></div></div>"},"77319":{"type":"graphic_diagnosticimage","displayName":"Megaureter natural course","title":"Megaureter: Natural course","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Megaureter: Natural course</div><div class=\"cntnt\"><img style=\"width:536px; height:373px;\" src=\"images/PEDS/77319_Megaureter_natural_course.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Series of imaging studies that demonstrate spontaneous resolution of a left megaureter without surgical intervention: The imaging studies are intravenous pyelograms (IVPs) as a neonate (panel A) and at 10-year follow-up (F/U, panel C), and a diuretic renogram at two years F/U (panel B). The second image of the renogram shows a delay in washout. The diuretic renogram image is taken from back to front of the patient reserving the position of the left and right kidney and ureter from the IVPs images, which are taken from front to back.</div><div class=\"graphic_reference\">Courtesy of Laurence Baskin, MD.</div><div id=\"graphicVersion\">Graphic 77319 Version 3.0</div></div></div>"},"77320":{"type":"graphic_figure","displayName":"Drug-metabolizing enzymes","title":"Drug-metabolizing enzymes exhibiting clinically relevant genetic polymorphisms","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Drug-metabolizing enzymes exhibiting clinically relevant genetic polymorphisms</div><div class=\"cntnt\"><img style=\"width:585px; height:349px;\" src=\"images/PC/77320_Known_drug_metab_enzymes.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most drug-metabolizing enzymes exhibit clinically relevant genetic polymorphisms. Essentially all of the major human enzymes responsible for modification of functional groups [classified as phase I reactions (Panel A)] or conjugation with endogenous substituents [classified as phase II reactions (Panel B)] exhibit common polymorphisms at the genomic level; those enzyme polymorphisms that have already been associated with changes in drug effects are separated from the corresponding pie charts. The percentage of phase I and phase II metabolism of drugs that each enzyme contributes is estimated by the relative size of each section of the corresponding chart.</div><div class=\"graphic_footnotes\">ADH: alcohol dehydrogenase; ALDH: aldehyde dehydrogenase; CYP: cytochrome P450; DPD: dihydropyrimidine dehydrogenase; NQO1: NADPH:quinone oxidoreductase or DT diaphorase; COMT: catechol O-methyltransferase; GST: glutathione S-transferase; HMT: histamine methyltransferase; NAT: N-acetyltransferase; STs: sulfotransferases; TPMT: thiopurine methyltransferase; UGTs: uridine 5'-triphosphate glucuronosyltransferases.</div><div class=\"graphic_reference\">From: Evans WE, Relling MV. Pharmacogenetics: Translating functional geneomics into rational therpaeutics. Science 1999; 286:487. Reprinted with permission from AAAS. Copyright © 1999. Readers may view, browse, and/or download material for temporary copying purposes only, provided these uses are for noncommercial personal purposes. Except as provided by law, this material may not be further reproduced, distributed, transmitted, modified, adapted, performed, displayed, published, or sold in whole or in part, without prior written permission from the publisher.</div><div id=\"graphicVersion\">Graphic 77320 Version 3.0</div></div></div>"},"77321":{"type":"graphic_table","displayName":"MD responsibilities LTOT","title":"Responsibilities of physicians prescribing long-term oxygen therapy (LTOT)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Responsibilities of physicians prescribing long-term oxygen therapy (LTOT)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Document the need for LTOT in the medical record*</td> </tr> <tr> <td>Select a qualified oxygen equipment supplier</td> </tr> <tr> <td class=\"sublist1_start\">Complete certificate of medical necessity form, CMS 484, in the United States and specify:</td> </tr> <tr> <td class=\"sublist1\">1. Oxygen flow at rest, during exercise, and during sleep, where appropriate</td> </tr> <tr> <td class=\"sublist1\">2. Oxygen delivery systems, including:</td> </tr> <tr> <td class=\"sublist2\">A. Stationary unit</td> </tr> <tr> <td class=\"sublist2\">B. Portable or ambulatory equipment</td> </tr> <tr> <td class=\"sublist2\">C. Oxygen-conserving device, if desired</td> </tr> <tr> <td class=\"sublist2\">D. Nasal cannula or transtracheal catheter</td> </tr> <tr> <td class=\"sublist1\">3. Justification for portable or ambulatory oxygen, if requested</td> </tr> <tr> <td class=\"sublist1\">4. Verify that the supplier has correctly restated the prescription before signing</td> </tr> <tr> <td>Monitor use and environment (with home oxygen supplier)</td> </tr> <tr> <td>Reevaluate for possible changes in the prescription</td> </tr> <tr> <td>Renew LTOT,&nbsp;as required</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Please see UpToDate topic on long term oxygen therapy.</div><div id=\"graphicVersion\">Graphic 77321 Version 4.0</div></div></div>"},"77322":{"type":"graphic_table","displayName":"BTM assays","title":"Bone turnover markers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bone turnover markers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Formation </td> <td class=\"subtitle1\">Assay </td> <td class=\"subtitle1\">Circadian rhythm </td> <td class=\"subtitle1\">LSC </td> <td class=\"subtitle1\">Comments </td> </tr> <tr> <td>OC</td> <td>S*</td> <td>Y</td> <td>21%</td> <td>Lack of standardization, rapidly degraded in serum, requires collection on ice</td> </tr> <tr> <td>BSAP</td> <td>S*</td> <td>N</td> <td>28%</td> <td>Cross-reactivity with liver isoform (15 to 20%)</td> </tr> <tr> <td>PINP/PICP</td> <td>S*</td> <td>Y</td> <td>21%/24%</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Resorption </td> </tr> <tr> <td class=\"indent1\">NTX </td> <td>U*,S</td> <td>Y</td> <td>35% (S), 70% (U)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">CTX </td> <td>U,S*</td> <td>Y</td> <td>30% (S), 80% (U)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">D-PYR </td> <td>U</td> <td>Y</td> <td>26%</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">PYD </td> <td>U*</td> <td>Y</td> <td>36%</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">HYP </td> <td>U</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Reflects bone resorption and dietary intake</td> </tr> <tr> <td class=\"indent1\">TRACP5b </td> <td>S</td> <td>Y</td> <td>17%</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LSC: least significant change; OC: osteocalcin; S: serum, collection of serum should be performed in the morning after an overnight fast; BSAP: bone-specific alkaline phosphatase;&nbsp;PINP: N-terminal propeptide of type I procollagen; PICP: C-terminal propeptide of type&nbsp;I procollagen;&nbsp;NTX: N-telopeptide of type&nbsp;I collagen; U: urinary excretion, collection of urine should be performed in the morning (usually second AM void, fasting);&nbsp;CTX: C-telopeptide of type&nbsp;I collagen;&nbsp;D-PYR: free deoxypyridinoline;&nbsp;PYD: free pyridinoline; HYP: hydroxyproline; TRACP5b: isoform 5b of tartrate resistant acid phosphatase;&nbsp;circadian rhythm: higher in the early morning.<br />* Automated technology for measurement is available.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<OL>&#xD;&#xA;<LI>Bergmann P, Body JJ, Boonen S, et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: A consensus document of the Belgian Bone Club. Int J Clin Pract 2009; 63:19.</LI>&#xD;&#xA;<LI>Scariano JK, Garry PJ, Montoya GD, et al. Critical differences in the serial measurement of three biochemical markers of bone turnover in the sera of pre-and postmenopausal women. Clin Biochem 2001; 34:639.</LI>&#xD;&#xA;<LI>Baim S, Miller PD. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res 2009; 24:561.</LI>&#xD;&#xA;<LI>Hannon R, Blumsohn A, Naylor K, Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability. J Bone Miner Res 1998; 13:1124.</LI>&#xD;&#xA;<LI>Rosen HN, Parker RA, Greenspan SL, et al. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcif Tissue Int 2004; 74:415.</LI>&#xD;&#xA;<LI>Miller PD, Baran DT, Bilezikian JP, et al.&nbsp;Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Denistom 1999; 2:323.</LI></OL></div><div id=\"graphicVersion\">Graphic 77322 Version 6.0</div></div></div>"},"77323":{"type":"graphic_table","displayName":"Conditions associated with a high serum lipase","title":"Conditions associated with a high serum lipase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with a high serum lipase</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td>Acute pancreatitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Chronic pancreatitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Renal failure</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Acute cholecystitis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Bowel obstruction or infarction</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Duodenal ulceration</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pancreatic calculus</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Pancreatic tumors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Diabetic ketoacidosis</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>HIV disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Macrolipasemia</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Post-ERCP/trauma</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Celiac disease</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Idiopathic</td>\r\n                </tr>\r\n                <tr>\r\n                    <td>Drugs</td>\r\n                </tr>\r\n            </tbody>\r\n        </table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; ERCP: endoscopic retrograde cholangiopancreatography.</div><div id=\"graphicVersion\">Graphic 77323 Version 3.0</div></div></div>"},"77324":{"type":"graphic_figure","displayName":"Perfusion scan chest pain ER","title":"A positive rest perfusion scan predicts outcome in patients with chest pain","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">A positive rest perfusion scan predicts outcome in patients with chest pain</div><div class=\"cntnt\"><img style=\"width:533px; height:245px;\" src=\"images/CARD/77324_Perfusion_scan_chest_pain_E.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a study of 532 patients with chest pain seen in the emergency room, those with a positive rest perfusion scan had a higher incidence of myocardial infarction (MI); MI or need for revascularization (R); and MI, revascularization, and a diagnosis of significant coronary disease (S) when compared to patients with a normal perfusion scan (P&lt;0.0001).</div><div class=\"graphic_reference\">Redrawn from: Kontos ML, Jesse ML, Schmidt KL, et al. J Am Coll Cardiol 1997; 30:976.</div><div id=\"graphicVersion\">Graphic 77324 Version 2.0</div></div></div>"},"77325":{"type":"graphic_table","displayName":"Dx neuropsychiatric lupus","title":"Diagnostic approach to manifestations of neuropsychiatric lupus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic approach to manifestations of neuropsychiatric lupus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Sequential evaluation</td> </tr> <tr> <td class=\"indent1\">Confirm diagnosis of lupus according to American College of Rheumatology criteria</td> </tr> <tr> <td class=\"indent1\">Careful history and physical examination - Exclude systemic illness and medications as confounding variables</td> </tr> <tr> <td class=\"sublist2_start\">For specific symptoms or signs:</td> </tr> <tr> <td class=\"sublist2\">Stroke - CT scan, blood tests for coagulopathy (including lupus anticoagulant), MRI, echocardiogram, carotids ultrasonography</td> </tr> <tr> <td class=\"sublist2\">Seizures - EEG</td> </tr> <tr> <td class=\"sublist2\">Neuropathy - EMG</td> </tr> <tr> <td class=\"sublist2\">Psychosis - MRI, EEG, lumbar puncture</td> </tr> <tr> <td class=\"sublist2\">Cognitive abnormalities - Psychometric testing (to differentiate organic from psychosocial disease), MRI, EEG, blood tests for coagulopathy, antibrain antibody</td> </tr> <tr> <td class=\"sublist2\">Anxiety or depression - Psychometric testing (to differentiate organic from psychosocial disease)</td> </tr> <tr> <td class=\"sublist2\">Meningitis/fever - Lumbar puncture</td> </tr> <tr> <td class=\"subtitle1_single\">Monitoring</td> </tr> <tr> <td class=\"indent1\">If patient improves: Monitor history and physical examination</td> </tr> <tr> <td class=\"indent1\">If patient gets no better or worse: MRI, LP</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77325 Version 3.0</div></div></div>"},"77326":{"type":"graphic_table","displayName":"Side effects pharmacologic stress agents","title":"Frequency of side effects (percent) with pharmacologic stress agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Frequency of side effects (percent) with pharmacologic stress agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dipyridamole</td> <td class=\"subtitle1\">Adenosine</td> <td class=\"subtitle1\">Regadenoson</td> <td class=\"subtitle1\">Dobutamine</td> </tr> <tr> <td>Chest pain</td> <td>20</td> <td>34</td> <td>7</td> <td>11</td> </tr> <tr> <td>Headache</td> <td>12</td> <td>21</td> <td>26</td> <td>2</td> </tr> <tr> <td>Dizziness</td> <td>1</td> <td>7</td> <td>8</td> <td>0.3</td> </tr> <tr> <td>Nausea</td> <td>5</td> <td>5</td> <td>6</td> <td>4</td> </tr> <tr> <td>Hypotension</td> <td>5</td> <td>3</td> <td>2</td> <td>5</td> </tr> <tr> <td>Flushing</td> <td>3.4</td> <td>35</td> <td>16</td> <td>0.3</td> </tr> <tr> <td>Palpitations</td> <td>3.2</td> <td>&ndash;</td> <td>&#182;</td> <td>49*</td> </tr> <tr> <td>Dyspnea</td> <td>2.6</td> <td>19</td> <td>28</td> <td>0.3</td> </tr> <tr> <td>Paresthesias</td> <td>1.3</td> <td>&ndash;</td> <td>&#182;</td> <td>12</td> </tr> <tr> <td>ST segment changes</td> <td>7.5</td> <td>12.5</td> <td>12</td> <td>50</td> </tr> <tr> <td class=\"sublist1_start\">Major event</td> <td class=\"sublist_other_start\">0.3</td> <td class=\"sublist_other_start\">0.2</td> <td class=\"sublist_other_start\">0</td> <td class=\"sublist_other_start\">0.4</td> </tr> <tr> <td class=\"sublist1\">Fatal MI</td> <td class=\"sublist_other\">0.05</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> </tr> <tr> <td class=\"sublist1\">Nonfatal MI</td> <td class=\"sublist_other\">0.05</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0</td> <td class=\"sublist_other\">0.2</td> </tr> <tr> <td class=\"sublist1\">Bronchospasm</td> <td class=\"sublist_other\">0.15</td> <td class=\"sublist_other\">0.16</td> <td class=\"sublist_other\">&#182;</td> <td class=\"sublist_other\">NA</td> </tr> <tr> <td>Any side effect</td> <td>47</td> <td>79</td> <td>73</td> <td>76</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MI: myocardial infarction; NA: not applicable.<br />* Any cardiac arrhythmia as a consequence of dobutamine infusion.<br />¶ Data not available.</div><div class=\"graphic_reference\">Adapted from: Mahmarian JJ, Verani MS. Cardiol Clin 1994; 12:223.</div><div id=\"graphicVersion\">Graphic 77326 Version 6.0</div></div></div>"},"77327":{"type":"graphic_picture","displayName":"Bullae caused by Fusarium spp","title":"Bullae caused by <EM>Fusarium</EM> spp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullae caused by <EM>Fusarium</EM> spp</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/ID/77327_Bullae_fusarium_spp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous skin lesions of the lower extremities caused by <EM>Fusarium</EM> spp in a 15-year-old girl with aplastic anemia. The patient presented with <EM>Fusarium</EM> sinusitis with subsequent development of cutaneous nodules on the face, extremities, and chest and bullous lesions on the lower extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: Nucci M, Spector N, Lucena S, et al. Three cases of infection with Fusarium species in neutropenic patients. Eur J Clin Microbiol Infect Dis 1992; 11:1160. Copyright © 1992 Springer Science and Business Media. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77327 Version 3.0</div></div></div>"},"77328":{"type":"graphic_figure","displayName":"Regional auricular block","title":"Regional auricular block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Regional auricular block</div><div class=\"cntnt\"><img style=\"width:312px; height:618px;\" src=\"images/EM/77328_RegionalauricularblockPR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A regional auricular block is indicated for repair of extensive auricular lacerations or to avoid local tissue distortion when cosmetic alignment is important.&nbsp;This&nbsp;technique provides anesthesia to the auricle with the exception of the concha and meatus. After cleansing the ear and surrounding skin with antiseptic solution,&nbsp;anesthetize with&nbsp;buffered lidocaine 1 percent <STRONG>with </STRONG>epinephrine using a long (1.5 inch), small gauge (25 or 27 gauge) needle&nbsp;and injecting along&nbsp;a straight track&nbsp;within the skin covering the mastoid and temporal bone anterior and behind the auricle as shown in the figure. The total dose of buffered lidocaine administered should not exceed&nbsp;7 mg/kg (0.7 mL/kg) of lidocaine 1 percent. Lidocaine <STRONG>with</STRONG> epinephrine should be <STRONG>avoided</STRONG>&nbsp;when directly infiltrating the ear itself.</div><div class=\"graphic_reference\">Reproduced with permission from: Martinez NR, Friedman MJ. External ear procedures. In: Textbook of Pediatric Emergency Procedures, 2nd Edition. King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77328 Version 9.0</div></div></div>"},"77329":{"type":"graphic_diagnosticimage","displayName":"Intraarticular fracture of the great toe proximal phalanx","title":"Intraarticular fracture of the great toe: AP and oblique","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intraarticular fracture of the great toe: AP and oblique</div><div class=\"cntnt\"><img style=\"width:442px; height:454px;\" src=\"images/EM/77329_IA_fx_1st_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the image to the right, the oblique fracture line can be seen extending into the interphalangeal joint. The triangular-shaped fracture fragment contains 80 to 90 percent&nbsp;of the articular surface of the joint.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Robert L Hatch, MD, MPH.</div><div id=\"graphicVersion\">Graphic 77329 Version 5.0</div></div></div>"},"77331":{"type":"graphic_waveform","displayName":"EP study tracings bundle branch reentrant VT","title":"Intracardiac and surface ECG recordings during electrophysiologic study of bundle branch reentrant ventricular tachycardia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Intracardiac and surface ECG recordings during electrophysiologic study of bundle branch reentrant ventricular tachycardia</div><div class=\"cntnt\"><img style=\"width:540px; height:379px;\" src=\"images/CARD/77331_Bundle_branch_reentrant_VT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shown are five surface ECG leads (I, II, aVF, V1, V6) and intracardiac recordings from the high right atrium (HRA3-4), His bundle region (HBE1-2), and the right ventricular apex (RVA3-4). The atrial and ventricular (V) electrograms are dissociated, confirming a ventricular tachycardia; however, a His bundle depolarization (H) precedes each ventricular electrogram. Further testing confirmed the diagnosis of bundle branch reentrant ventricular tachycardia (BBRVT), a macroreentrant ventricular tachycardia involving the left and right bundle branches. During typical BBRVT, the wavefront goes down the right bundle, across the interventricular septum, and then retrograde up the left bundle, with passive retrograde activation of the His bundle. Since both bundle branches are necessary parts of the macroreentry circuit, catheter ablation of the right bundle branch is curative.</div><div id=\"graphicVersion\">Graphic 77331 Version 4.0</div></div></div>"},"77332":{"type":"graphic_figure","displayName":"Sentinel lymph node sampling","title":"Pathologic processing of sentinel lymph node","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Pathologic processing of sentinel lymph node</div><div class=\"cntnt\"><img style=\"width:535px; height:316px;\" src=\"images/ONC/77332_Sentinel_lymph_node_samplin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the selection of tissue sections for processing within a 1 to 2 mm thick sample of a sentinel lymph node. Laboratories vary in technical protocol and in choice of immunohistochemical markers.</div><div id=\"graphicVersion\">Graphic 77332 Version 2.0</div></div></div>"},"77333":{"type":"graphic_figure","displayName":"C2 pedicle fracture","title":"Pedicle fracture of C2 (axis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pedicle fracture of C2 (axis)</div><div class=\"cntnt\"><img style=\"width:371px; height:441px;\" src=\"images/EM/77333_C2_pedicle_fx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77333 Version 6.0</div></div></div>"},"77334":{"type":"graphic_figure","displayName":"Insulin response IV glucose","title":"Acute insulin responses to IV glucose and isoproterenol","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acute insulin responses to IV glucose and isoproterenol</div><div class=\"cntnt\"><img style=\"width:284px; height:594px;\" src=\"images/ENDO/77334_Ins_response_gluc_nongluc.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Robertson RP, Porte D, Jr. The glucose receptor: A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin Invest 1973; 52:870. Copyright © 1973 American Society for Clinical Investigation.</div><div id=\"graphicVersion\">Graphic 77334 Version 2.0</div></div></div>"},"77335":{"type":"graphic_figure","displayName":"rHuTPO intensive chemotherapy","title":"Use of recombinant human thrombopoietin after intensive chemotherapy","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Use of recombinant human thrombopoietin after intensive chemotherapy</div><div class=\"cntnt\"><img style=\"width:478px; height:277px;\" src=\"images/HEME/77335_rHuTPO_intensive_chemothera.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patients with gynecologic malignancy were treated with high-dose carboplatin on day 1 of cycles 1 (red columns) and 2 (blue columns). In cycle 1 rHuTPO was not administered. In cycle 2 rHuTPO was administered daily. The administration of rHuTPO significantly increased the nadir platelet count, decreased the duration of thrombocytopenia, and reduced the need for platelet transfusion.</div><div class=\"graphic_reference\">Data from Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132:364.</div><div id=\"graphicVersion\">Graphic 77335 Version 4.0</div></div></div>"},"77336":{"type":"graphic_diagnosticimage","displayName":"CT scan acute calculous cholecystitis","title":"Computed tomographic (CT) scan from a patient with acute cholecystitis","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Computed tomographic (CT) scan from a patient with acute cholecystitis</div><div class=\"cntnt\"><img style=\"width:597px; height:249px;\" src=\"images/RADIOL/77336_Acute_cholecystitis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan shows a distended gallbladder with an edematous and hyperemic wall (thick arrow) and inflammatory induration in the fat surrounding the gallbladder (arrowheads). A calcified stone is visible lying dependently at the base of the gallbladder (thin arrow).</div><div id=\"graphicVersion\">Graphic 77336 Version 3.0</div></div></div>"},"77337":{"type":"graphic_table","displayName":"Hepatocellular causes jaundice","title":"Some hepatocellular conditions that can produce jaundice","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Some hepatocellular conditions that can produce jaundice</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Viral hepatitis</td> </tr> <tr> <td class=\"sublist1\">Hepatitis A, B, C, D, and E</td> </tr> <tr> <td class=\"sublist1\">Epstein-Barr virus</td> </tr> <tr> <td class=\"sublist1\">Cytomegalovirus</td> </tr> <tr> <td>Alcohol</td> </tr> <tr> <td class=\"sublist1_start\">Drugs</td> </tr> <tr> <td class=\"sublist1\">Predictable, dose-dependent (eg, acetaminophen)</td> </tr> <tr> <td class=\"sublist1\">Unpredictable, idiosyncratic (many drugs)</td> </tr> <tr> <td class=\"sublist1_start\">Environmental toxins</td> </tr> <tr> <td class=\"sublist1\">Vinyl chloride</td> </tr> <tr> <td class=\"sublist1\">Jamaica bush tea - pyrrolizidine alkaloids</td> </tr> <tr> <td class=\"sublist1\">Wild mushrooms - Amanita phalloides or verna</td> </tr> <tr> <td>Autoimmune hepatitis</td> </tr> <tr> <td>Wilson disease</td> </tr> <tr> <td>Ischemia (eg, Budd-Chiari syndrome, ischemic hepatitis)</td> </tr> <tr> <td>Congestive hepatopathy (eg, from right-sided heart failure)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77337 Version 5.0</div></div></div>"},"77338":{"type":"graphic_table","displayName":"Treatment of deep neck space infections","title":"Usual causative organisms and initial empiric antimicrobial regimens for suppurative peripharyngeal infections in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual causative organisms and initial empiric antimicrobial regimens for suppurative peripharyngeal infections in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Infection</td> <td class=\"subtitle1\" rowspan=\"2\">Usual causative organisms</td> <td class=\"subtitle1\" colspan=\"2\">Antimicrobial regimens</td> </tr> <tr> <td class=\"subtitle2\">Normal host</td> <td class=\"subtitle2\">Immunocompromised host<sup>&#916;</sup></td> </tr> <tr> <td colspan=\"4\"><strong>NOTE:</strong> Coverage for methicillin-resistant <em>Staphylococcus aureus </em>(MRSA) should be included for those with risk factors<sup>&#9674;</sup></td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Peritonsillar abscess (Quinsy)</td> <td rowspan=\"3\">Group A <em>Streptococcus </em>(<em>S. pyogenes</em>), <em>Fusobacterium </em>spp, <em>Peptostreptococcus </em>spp, and other oral anaerobes<sup>&#916;</sup></td> <td class=\"centered\"> <p>Ampicillin-sulbactam 3 g IV Q 6 h</p> <strong>OR</strong></td> <td rowspan=\"3\"> <p>Cefepime 2 g IV Q 12 h <strong>PLUS</strong> metronidazole 500 mg IV Q 6-8 h</p> <strong>OR monotherapy with:</strong> <ul> <li>Imipenem 500 mg IV Q 6 h <strong>or</strong> </li> <li>Meropenem 1 g IV Q 8 h <strong>or</strong> </li> <li>Piperacillin-tazobactam 4.5 g IV Q 6 h </li> </ul> </td> </tr> <tr> <td class=\"centered\"> <p>Penicillin G 2-4 MU IV Q 4-6 h</p> <p><strong>plus</strong></p> <p>Metronidazole 500 mg IV Q 6-8 h</p> <strong>OR</strong></td> </tr> <tr> <td class=\"centered\">Clindamycin 600 mg IV Q 6-8 h</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Suppurative parotitis</td> <td rowspan=\"3\"><em>Staphylococcus aureus</em>, viridans and other streptococci, <em>Bacteroides </em>spp, <em>Peptostreptococcus </em>spp, and other oral anaerobes<sup>&#916;</sup></td> <td class=\"centered\"> <p>Nafcillin 1.5 g IV Q 4 h<sup>&#9674;</sup></p> <p><strong>or</strong></p> <p>Vancomycin 15-20 mg/kg IV Q 8-12 h<sup>&#167;</sup></p> <p><strong>or</strong></p> Linezolid 600 mg orally or IV Q 12 h</td> <td rowspan=\"3\">Vancomycin 15-20 mg/kg IV Q 8-12 h<sup>&#167;</sup> or linezolid 600 mg orally or IV Q 12 h <strong>PLUS</strong> one of the following regimens: <ul> <li>Cefepime 2 g IV Q 12 h <strong>PLUS</strong> metronidazole 500 mg IV Q 6-8 h <strong>or</strong> </li> <li>Imipenem 500 mg IV Q 6 h <strong>or</strong> </li> <li>Meropenem 1 g IV Q 8 h <strong>or</strong> </li> <li>Piperacillin-tazobactam 4.5 g IV Q 6 h </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"centered\"> <p>Either metronidazole 500 mg IV Q 6-8 h</p> <p><strong>or</strong></p> Clindamycin 600 mg IV Q 6-8 h</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Submandibular space infections (Ludwig's angina)</td> <td rowspan=\"3\">Viridans and other streptococci, <em>Staphylococcus </em>spp, <em>Peptostreptococcus </em>spp, <em>Bacteroides </em>spp, and other oral anaerobes<sup>&#916;</sup></td> <td class=\"centered\"> <p>Ampicillin-sulbactam 3 g IV Q 6 h</p> <strong>OR</strong></td> <td rowspan=\"3\"> <p>Cefepime 2 g IV Q 12 h <strong>PLUS</strong> metronidazole 500 mg IV Q 6-8 h</p> <strong>OR monotherapy with:</strong> <ul> <li>Imipenem 500 mg IV Q 6 h <strong>or</strong> </li> <li>Meropenem 1 g IV Q 8 h <strong>or</strong> </li> <li>Piperacillin-tazobactam 4.5 g IV Q 6 h </li> </ul> </td> </tr> <tr> <td class=\"centered\"> <p>Penicillin G 2-4 MU IV Q 4-6 h</p> <p><strong>plus</strong></p> <p>Metronidazole 500 mg IV Q 6-8 h</p> <strong>OR</strong></td> </tr> <tr> <td class=\"centered\">Clindamycin 600 mg IV Q 6-8 h</td> </tr> <tr class=\"divider_top\"> <td colspan=\"4\">Parapharyngeal or retropharyngeal space infections</td> </tr> <tr> <td class=\"indent2\" rowspan=\"3\">Odontogenic</td> <td rowspan=\"3\">Viridans and other streptococci, <em>Staphylococcus </em>spp, <em>Peptostreptococcus </em>spp, <em>Bacteroides </em>spp, and other oral anaerobes<sup>&#916;</sup></td> <td class=\"centered\"> <p>Ampicillin-sulbactam 3 g IV Q 6 h</p> <strong>OR</strong></td> <td rowspan=\"3\"> <p>Cefepime 2 g IV Q 12 h <strong>PLUS</strong> metronidazole 500 mg IV Q 6-8 h</p> <strong>OR monotherapy with:</strong> <ul> <li>Imipenem 500 mg IV Q 6 h <strong>or</strong> </li> <li>Meropenem 1 g IV Q 8 h <strong>or</strong> </li> <li>Piperacillin-tazobactam 4.5 g IV Q 6 h </li> </ul> </td> </tr> <tr> <td class=\"centered\"> <p>Penicillin G 2-4 MU IV Q 4-6 h</p> <p><strong>plus</strong></p> <p>Metronidazole 500 mg IV Q 6-8 h</p> <strong>OR</strong></td> </tr> <tr> <td class=\"centered\">Clindamycin 600 mg IV Q 6-8 h</td> </tr> <tr> <td class=\"indent2\" rowspan=\"3\">Rhinogenic</td> <td rowspan=\"3\"><em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, viridans and other streptococci, <em>Bacteroides </em>spp, <em>Peptostreptococcus </em>spp, and other oral anaerobes<sup>&#916;</sup></td> <td class=\"centered\"> <p>Ampicillin-sulbactam 3 g IV Q 6 h</p> <strong>OR</strong></td> <td rowspan=\"3\">Same as for odontogenic space infections</td> </tr> <tr> <td class=\"centered\"> <p>Ceftriaxone 1 g IV Q 24 h</p> <p><strong>plus</strong></p> <p>Metronidazole 500 mg IV Q 6-8 h</p> <strong>OR</strong></td> </tr> <tr> <td class=\"centered\"> <p>Doxycycline 200 mg IV per day in one to two divided doses</p> </td> </tr> <tr> <td class=\"indent2\">Otogenic</td> <td>Same as for rhinogenic space infections</td> <td>Same as for rhinogenic space infections</td> <td>Same as for odontogenic space infections</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Septic jugular thrombophlebitis (Lemierre syndrome)</td> <td rowspan=\"3\"><em>Fusobacterium necrophorum</em>; same as for peritonsillar abscess or odontogenic space infections<sup>&#916;</sup></td> <td class=\"centered\"> <p>Ampicillin-sulbactam 3 g IV Q 6 h</p> <strong>OR</strong></td> <td rowspan=\"3\">Same as for odontogenic space infections</td> </tr> <tr> <td class=\"centered\"> <p>Penicillin G 2-4 MU IV Q 4-6 h</p> <p><strong>plus</strong></p> <p>Metronidazole 500 mg IV Q 6-8 h</p> <strong>OR</strong></td> </tr> <tr> <td class=\"centered\">Clindamycin 600 mg IV Q 6-8 h</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Prevertebral space infection</td> <td rowspan=\"3\"><em>Staphylococcus aureus</em>,<sup>&#9674;</sup> facultative gram-negative bacilli<sup>&#916;</sup></td> <td class=\"centered\"> <p>Nafcillin 1.5 g IV Q 4 h<sup>&#9674;</sup></p> <p><strong>or</strong></p> <p>Vancomycin 15-20 mg/kg IV Q 8-12 h<sup>&#167;</sup></p> <p><strong>or</strong></p> Linezolid 600 mg orally or IV Q 12 h</td> <td rowspan=\"3\"> <p>Vancomycin 15-20 mg/kg IV Q 8-12 h<sup>&#167;</sup> or linezolid 600 mg orally or IV Q 12 h <strong>PLUS</strong> one of the following regimens:</p> <strong>Combination therapy with:</strong> <ul> <li>Cefepime 2 g IV Q 12 h <strong>PLUS</strong> metronidazole 500 mg IV Q 6-8 h </li> </ul> <br /> <strong>OR monotherapy with:</strong> <ul> <li>Imipenem 500 mg IV Q 6 h <strong>or</strong> </li> <li>Meropenem 1 g IV Q 8 h <strong>or</strong> </li> <li>Piperacillin-tazobactam 4.5 g IV Q 6 h </li> </ul> </td> </tr> <tr> <td class=\"centered\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"centered\"> <p><strong>Either</strong> gentamicin or tobramycin 1.7 mg/kg IV Q 8 h <strong>or</strong> 5 mg/kg IV Q 24 h</p> <p><strong>or</strong></p> <p>Ciprofloxacin 400 mg IV Q 12 h</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The doses recommended in this table are intended for patients with normal renal and hepatic function.<br />Δ Immunocompromised hosts are at increased risk for facultative gram-negative bacilli, including extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae and <EM>Pseudomonas aeruginosa</EM>.<br /><FONT class=lozenge>◊</FONT> In patients with risk factors for MRSA infection, vancomycin 15-20 mg/kg IV Q 8-12 h or linezolid 600 mg orally or IV Q 12 h should be added, or substituted for nafcillin. Risk factors for MRSA infection include a history of intravenous drug use, comorbid disease (eg, diabetes mellitus), or residing in a community or hospital where there is a substantial incidence of MRSA.<br />§ Not to exceed 2 g per dose.</div><div id=\"graphicVersion\">Graphic 77338 Version 14.0</div></div></div>"},"77342":{"type":"graphic_figure","displayName":"Transperineal fistula repair5","title":"Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located about the sphincter complex</div><div class=\"cntnt\"><img style=\"width:348px; height:384px;\" src=\"images/OBGYN/77342_Transperineal_fistula_rep4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The second layer of closure is placed into the muscularis of the rectum in the same direction as the first layer, thus imbricating the first layer and reinforcing the closure</div><div id=\"graphicVersion\">Graphic 77342 Version 1.0</div></div></div>"},"77343":{"type":"graphic_figure","displayName":"Age \"choking game\" versus suicide","title":"Age distribution of deaths attributed to the \"choking game\" versus suicide by hanging or suffocation","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Age distribution of deaths attributed to the \"choking game\" versus suicide by hanging or suffocation</div><div class=\"cntnt\"><img style=\"width:502px; height:406px;\" src=\"images/PEDS/77343_Age_choking_game_vs_suicide.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age distribution of youths aged 6 to 19 years whose deaths were attributed to the \"choking game\" (n = 82) during 1995-2007, compared with youths whose deaths were attributed to suicide by hanging/suffocation (n = 5101) during 1999-2005 - United States.</div><div class=\"graphic_reference\">Data from: Unintentional strangulation deaths from the \"choking game\" among youths aged 6-19 years - United States, 1995-2007. MMWR 2008; 57:141.</div><div id=\"graphicVersion\">Graphic 77343 Version 4.0</div></div></div>"},"77345":{"type":"graphic_algorithm","displayName":"Classification diffuse lung disease","title":"Diffuse parenchymal lung diseases","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse parenchymal lung diseases</div><div class=\"cntnt\"><img style=\"width:384px; height:356px;\" src=\"images/PULM/77345_Classific_diffuse_lung_dz.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse parenchymal lung diseases consist of disorders of known causes (rheumatic disease, environmental or drug related) as well as disorders of unknown cause. The latter include idiopathic interstitial pneumonias, granulomatous lung disorders (eg, sarcoidosis), and other forms of interstitial lung disease including lymphangioleiomyomatosis, pulmonary Langerhans cell histiocytosis/histiocytosis X, and eosinophilic pneumonia. The interstitial pneumonias are further categorized as chronic fibrosing, acute or subacute fibrosing, or smoking related. Lymphoid interstitial pneumonia is typically associated with other disease processes, such as rheumatic disease or immunosuppression; idiopathic lymphoid interstitial&nbsp;pneumonia is rare.</div><div class=\"graphic_footnotes\">DPLD: diffuse parenchymal lung disease; IIP: idiopathic interstitial pneumonia; LAM: lymphangioleiomyomatosis; PLCH: pulmonary Langerhans cell histiocytosis/histiocytosis X.</div><div id=\"graphicVersion\">Graphic 77345 Version 10.0</div></div></div>"},"77346":{"type":"graphic_diagnosticimage","displayName":"Med bronchogen cyst CXR IV","title":"Paratracheal bronchogenic cyst","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Paratracheal bronchogenic cyst</div><div class=\"cntnt\"><img style=\"width:360px; height:280px;\" src=\"images/PULM/77346_Med_bronchogen_cyst_CXR_IV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows a right paratracheal mass.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77346 Version 2.0</div></div></div>"},"77347":{"type":"graphic_picture","displayName":"FAST suprapubic probe position transverse","title":"FAST: Suprapubic probe position in transverse orientation","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">FAST: Suprapubic probe position in transverse orientation</div><div class=\"cntnt\"><img style=\"width:504px; height:333px;\" src=\"images/EM/77347_FAST_suprapubic_probe_trans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows probe position for obtaining a transverse view of the bladder and retrovesical structures.</div><div class=\"graphic_reference\">Courtesy of Manoj Pariyadath, MD.</div><div id=\"graphicVersion\">Graphic 77347 Version 1.0</div></div></div>"},"77348":{"type":"graphic_figure","displayName":"Flow cytometry DLBCL","title":"Flow cytometry diffuse large B-cell lymphoma","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Flow cytometry diffuse large B-cell lymphoma</div><div class=\"cntnt\"><img style=\"width:536px; height:362px;\" src=\"images/HEME/77348_FlowcytomDLBCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flow cytometry histograms show positive CD19, CD20, K, and FMC-7 but negative CD5, CD23, and lambda reactions.</div><div class=\"graphic_footnotes\">SS: side scatter; PC5: phycoerythrin-cyanin 5; FITC: fluorescein isothiocyanate; ECD: phycoerythrin-Texas Red; PE: phycoerythrin.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun T. Clinical application. In: Flow Cytometry and Immunochemistry for Hematologic Neoplasms, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright © 2007 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77348 Version 9.0</div></div></div>"},"77349":{"type":"graphic_table","displayName":"Sensitivity of tests for MG","title":"Approximate sensitivity of the confirmatory tests for myasthenia gravis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approximate sensitivity of the confirmatory tests for myasthenia gravis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Generalized myasthenia percent positive</td> <td class=\"subtitle1\">Ocular myasthenia percent positive</td> </tr> <tr> <td><strong>AChR antibodies</strong></td> <td class=\"centered\">80 to 90</td> <td class=\"centered\">40 to 55</td> </tr> <tr> <td><strong>MuSK antibodies (in AChR Ab negative patients)</strong></td> <td class=\"centered\">40 to 50</td> <td class=\"centered\">&#60;10</td> </tr> <tr> <td><strong>Repetitive nerve stimulation</strong></td> <td class=\"centered\">75</td> <td class=\"centered\">&#60;50</td> </tr> <tr> <td><strong>Single fiber electromyography</strong></td> <td class=\"centered\">92 to 99</td> <td class=\"centered\">80 to 95</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MG: myasthenia gravis; AChR: acetylcholine receptor; MuSK: muscle-specific kinase.</div><div id=\"graphicVersion\">Graphic 77349 Version 7.0</div></div></div>"},"77350":{"type":"graphic_table","displayName":"Cardiac defects causing hydrops","title":"Structural cardiac abnormalities associated with hydrops fetalis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Structural cardiac abnormalities associated with hydrops fetalis</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td>Ventricular hypoplasia</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cardiomyopathy</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Aortic or pulmonary stenosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Valvular insufficiency</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Single ventricle</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Atrial or ventricular septal defect</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Closure of the foramen ovale</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Transposition of the great arteries</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Tetralogy of Fallot</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Ebstein's anomaly</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Truncus arteriosus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Rhabdomyoma</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Premature closure of the ductus arteriosus</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Cardiosplenic syndromes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Endocardial fibroelastosis</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>&nbsp;</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 77350 Version 1.0</div></div></div>"},"77352":{"type":"graphic_diagnosticimage","displayName":"US normal T cervix","title":"Ultrasound normal T cervix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound normal T cervix</div><div class=\"cntnt\"><img style=\"width:450px; height:397px;\" src=\"images/OBGYN/77352_US_normal_T_cervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal cervix, no funneling (\"T-shaped\"). Note prominent endocervical mucus, small Nabothian cyst near external os. Lower uterine segment thick and not developed.</div><div class=\"graphic_reference\">Courtesy of Jeffrey R Johnson, MD.</div><div id=\"graphicVersion\">Graphic 77352 Version 4.0</div></div></div>"},"77353":{"type":"graphic_table","displayName":"Molecular classification of CRC","title":"Molecular classification of colorectal carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular classification of colorectal carcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\">Chromosomal instability pathway (APC)</td> <td class=\"subtitle1\">Mismatch repair pathway</td> <td class=\"subtitle1\" colspan=\"2\">Serrated pathway</td> </tr> <tr> <td class=\"subtitle2\">Hereditary (FAP) and sporadic</td> <td class=\"subtitle2\">Hereditary</td> <td class=\"subtitle2\">Hereditary</td> <td class=\"subtitle2\">Sporadic</td> </tr> <tr> <td>CIMP status</td> <td>Negative</td> <td>Negative</td> <td>High</td> <td>High</td> </tr> <tr> <td>MSI status</td> <td>MSS</td> <td>MSI-H</td> <td>MSI-H</td> <td>MSI-L</td> </tr> <tr> <td>Chromosomal instability</td> <td>+++</td> <td>---</td> <td>---</td> <td>---</td> </tr> <tr> <td>KRAS mutation</td> <td>+++</td> <td>+/-</td> <td>---</td> <td>---</td> </tr> <tr> <td>BRAF mutation</td> <td>---</td> <td>---</td> <td>+++</td> <td>+++</td> </tr> <tr> <td>MLH1 status</td> <td>Normal</td> <td>Mutation</td> <td>Methylated</td> <td>Partial methylation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CIMP: CpG island methylator phenotype; MSS: microsatellite stability; MSI: microsatellite instability; MSI-H: high-level microsatellite instability; MSI-L: low-level microsatellite instability; +++: present; +/-: might or might not be present; ---: absent.</div><div class=\"graphic_reference\">Reproduced from: Cunningham, D, Atkins, W, Lenz, HJ, et al. Colorectal cancer. Lancet 2010; 375:1030. Copyright &#169; 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77353 Version 5.0</div></div></div>"},"77354":{"type":"graphic_picture","displayName":"Prostate adenocarcinoma3 light","title":"Prostate cancer and prominent nucleoli","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prostate cancer and prominent nucleoli</div><div class=\"cntnt\"><img style=\"width:373px; height:274px;\" src=\"images/ONC/77354_Prostate_adenocarcinoma3_li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power photomicrograph of an hematoxylin- and eosin-stained prostate gland demonstrating prostate adenocarcinoma. The prominent nucleoli and amphophilic cytoplasm of adenocarcinoma (arrows) can be compared to the large adjacent benign gland taking up the entire right half of the tissue section.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 77354 Version 2.0</div></div></div>"},"77357":{"type":"graphic_table","displayName":"Clinical features of tonic pupil","title":"Clinical features of the tonic pupil","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of the tonic pupil</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Poor pupillary light reaction</td>\n</tr>\n<tr>\n<td>Segmental palsy of the sphincter</td>\n</tr>\n<tr>\n<td>Tonic pupillary near response with light-near dissociation</td>\n</tr>\n<tr>\n<td>Cholinergic supersensitivity of the denervated muscles</td>\n</tr>\n<tr>\n<td>Accommodation paresis (that tends to recover)</td>\n</tr>\n<tr>\n<td>Induced astigmatism at near and tonicity of accommodation</td>\n</tr>\n<tr>\n<td>Occasional \"ciliary cramp\" (accommodative spasm) with near work</td>\n</tr>\n<tr>\n<td>Occasionally regional corneal anesthesia (trigeminal fibers in ciliary ganglion damaged)</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Thompson HS. Adie's syndrome: Some new observations. Trans Am Ophthalmol Soc 1977; 75:587. Copyright &copy; 1977 American Ophtalmalogic Society.</div><div id=\"graphicVersion\">Graphic 77357 Version 3.0</div></div></div>"},"77358":{"type":"graphic_diagnosticimage","displayName":"MRI left traumatic EDH","title":"MRI of the brain demonstrates a traumatic epidural hematoma in the left parieto-occipital region","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI of the brain demonstrates a traumatic epidural hematoma in the left parieto-occipital region</div><div class=\"cntnt\"><img style=\"width:396px; height:533px;\" src=\"images/NEURO/77358_MRI_left_traumatic_EDH.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Neuroradiology Department, Thomas Jefferson University, Philadelphia, PA.</div><div id=\"graphicVersion\">Graphic 77358 Version 3.0</div></div></div>"},"77359":{"type":"graphic_table","displayName":"Patch efficacy","title":"Efficacy of the transdermal contraceptive patch*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Efficacy of the transdermal contraceptive patch*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Cycles</td> <td class=\"subtitle1\">Pregnancies</td> <td class=\"subtitle1\">Perfect use<sup>&#182;</sup></td> <td class=\"subtitle1\">Typical use<sup>&#916;</sup></td> </tr> <tr> <td>Non-comparative trial</td> <td>10,994</td> <td>6</td> <td>0.59</td> <td>0.71</td> </tr> <tr> <td>Oral contraceptive, comparative trial</td> <td>5921</td> <td>4</td> <td>0.66</td> <td>0.88</td> </tr> <tr class=\"divider_bottom\"> <td>Oral contraceptive, comparative trial</td> <td>5240</td> <td>5</td> <td>0.99</td> <td>1.24</td> </tr> <tr> <td><strong>Combined total</strong></td> <td><strong>22,155</strong></td> <td><strong>15</strong></td> <td><strong>0.7</strong></td> <td><strong>0.88</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Pregnancies per 100 women-years.<br />¶ Failure (pregnancy) when taking correctly.<br />Δ Perfect use failure plus user failure.</div><div class=\"graphic_reference\">Adapted with permission from: Burkman, RT. The transdermal contraceptive patch: a new approach to hormonal contraception. Int J Fertil Womens Med. 2002; 47(2): 69-76. Copyright &copy;2002 MSP International, Inc.</div><div id=\"graphicVersion\">Graphic 77359 Version 2.0</div></div></div>"},"77360":{"type":"graphic_table","displayName":"Back pain clinical features","title":"Clinical and radiographic features of selected causes of back pain in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and radiographic features of selected causes of back pain in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Musculoskeletal causes</td> <td class=\"subtitle1\">Typical age group/risk groups</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Features on plain films</td> </tr> <tr> <td>Spondylolysis</td> <td> <p>Early adolescence</p> <p>Inuit &#62; whites &#62; blacks</p> <p>Boys &#62; girls</p> <p>Associated with Scheuermann (juvenile)&nbsp;kyphosis</p> Associated with gymnastics, dance/ballet, diving, weight lifting, figure skating, volleyball, soccer, football (linemen), racquet sports, throwing sports</td> <td> <p>Lumbosacral pain (usually L5)</p> <p>Pain with extension</p> Hamstring tightness</td> <td> <p>Lateral view: healing defect of pars interarticularis</p> <p>(MRI and SPECT scan are more sensitive)</p> </td> </tr> <tr> <td>Spondylolisthesis</td> <td>As for spondylolysis</td> <td> <p>Lumbosacral pain (usually L5)</p> <p>Pain with extension</p> <p>Hamstring tightness</p> <p>Prominent spinous process</p> <p>Flattening of normal lumbar lordosis</p> Knee-flexed, hip-flexed gait (Phalen-Dickson sign)</td> <td> <p>Lateral view: anterior slippage of vertebral body</p> <p>Oblique view: stepladder sign*</p> <p>PA view: inverted Napoleon hat sign<sup>&#182;</sup></p> </td> </tr> <tr> <td>Idiopathic scoliosis</td> <td>Adolescents</td> <td>Lateral spinal curvature</td> <td> <p>Full length (C7 to the sacrum/iliac crest)</p> <p>PA view: lateral curvature</p> </td> </tr> <tr> <td>Scheuermann (juvenile) kyphosis</td> <td> <p>Early adolescence</p> <p>Boys &#62; girls</p> Tall boys</td> <td> <p>Subacute/chronic thoracic or thoracolumbar pain</p> <p>Increased pain with flexion</p> <p>Rigid thoracic kyphosis</p> <p>Increased lumbar lordosis</p> Hamstring tightening</td> <td> <p>Lateral view: anterior wedging of &#8805;5&#176; in &#8805;3 adjacent vertebral bodies</p> <p>Degeneration of vertebral end-plates (Schmorl nodes)</p> <p>Herniation of intervertebral disc material into vertebral body end-plate </p> <p>May be associated with spondylolysis</p> </td> </tr> <tr> <td>Intervertebral disc herniation</td> <td> <p>Adolescents</p> <p>Acute trauma</p> <p>Scheuermann (juvenile)&nbsp;kyphosis</p> <p>Family history of intervertebral disc herniation</p> <p>Obesity/overweight</p> Associated with weight lifting, wrestling, gymnastics, collision sports</td> <td> <p>Lumbar pain</p> <p>Sciatica</p> <p>Limited spinal flexibility</p> Limited passive straight-leg raising</td> <td> <p>Usually normal</p> <p>May show slight posterior calcification</p> (MRI is preferred imaging modality)</td> </tr> <tr class=\"divider_bottom\"> <td>Intervertebral disc calcification</td> <td> <p>Preadolescents</p> Ochronosis<sup>&#916;</sup></td> <td> <p>Generally affects cervical and/or thoracic discs</p> Torticollis</td> <td>Intervertebral disc calcification</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Infectious causes</td> </tr> <tr> <td class=\"indent1\">Discitis</td> <td>0 to 5 years</td> <td> <p>Generally affects lower lumbar spine</p> <p>Gradual onset of back pain or irritability, refusal to crawl or walk</p> Minimal systemic toxicity</td> <td> <p>Narrowing of intervertebral joint space after two to three weeks of symptoms, followed by destruction of vertebral end-plates and disc herniation</p> Diagnosis is best made by MRI</td> </tr> <tr> <td class=\"indent1\">Vertebral osteomyelitis</td> <td>Adolescents</td> <td> <p>Fever</p> Ill appearance</td> <td>Destructive changes of vertebral bodies (after two to three weeks of symptoms)</td> </tr> <tr> <td class=\"indent1\">Sacroiliac joint infection</td> <td>Late childhood</td> <td> <p>Pain over sacrum</p> <p>Fever</p> Pain with maneuvers that twist the pelvis (eg, the FABERE test)</td> <td> <p>May demonstrate sclerosis of the sacroiliac joint</p> <p>Widening of the joint space</p> Blurring of subchondral plate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Epidural abscess</td> <td>&nbsp;</td> <td> <p>Fever</p> <p>Spinal pain</p> Neurologic deficit</td> <td>MRI is preferred imaging modality</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Inflammatory arthritis</strong></td> <td>Family history of inflammatory spondylitis</td> <td> <p>Chronic pain</p> <p>Morning stiffness</p> <p>Sacroiliac joint tenderness (eg, positive FABERE test)</p> </td> <td> <p>Erosion or sclerosis at anterior vertebral corners</p> <p>Vertebral squaring</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Tumors</td> </tr> <tr> <td class=\"indent1\">Osteoid osteoma</td> <td>Second decade of life</td> <td> <p>Nocturnal pain</p> <p>Prompt relief with NSAIDs</p> May be associated with scoliosis</td> <td> <p>Osteoid nidus with or without calcification (osteoid nidus may be obscured by dense sclerosis)</p> Sclerosis of posterior elements</td> </tr> <tr> <td class=\"indent1\">Malignant tumors (eg, leukemia, lymphoma, Ewing sarcoma, etc)</td> <td>&nbsp;</td> <td> <p>Nighttime pain</p> <p>Constant pain (unchanged by activity)</p> <p>Pain &#60;3 months duration</p> Systemic symptoms (eg, fever, weight loss)</td> <td> <p>Bony destruction</p> Subtle signs of space-occupying lesion (separation or thinning of the pedicles)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; SPECT scan: single photon emission computed tomography scan;&nbsp;PA: posteroanterior; FABERE: <STRONG>F</STRONG>lexion of the hip and knee, <STRONG>AB</STRONG>duction and <STRONG>E</STRONG>xternal <STRONG>R</STRONG>otation of the hip, <STRONG>E</STRONG>xtension of the opposite hip (also called the \"figure of four\" test; see UpToDate graphic on the FABERE test); NSAIDS: nonsteroidal anti-inflammatory drugs.<br />* The stepladder sign of spondylolisthesis: The alignment of the facet joints changes abruptly at the level of slippage.<br />¶ The inverted Napoleon hat sign of high grade spondylolisthesis of L5&nbsp;on S1: The dome of the hat is formed by the body of L5 and the brim by the downward rotation of the transverse processes.<br />Δ Ochronosis: Exogenously deposited or medication-induced pigmentation of the connective tissue.</div><div id=\"graphicVersion\">Graphic 77360 Version 7.0</div></div></div>"},"77362":{"type":"graphic_figure","displayName":"Possible pathologic cascade ALS and FTLD-linked molecules","title":"Possible pathologic cascade of amyotrophic lateral sclerosis (ALS)/frontotemporal lobar degeneration (FTLD)-linked molecules","html":"<div class=\"graphic\"><div style=\"width: 609px\" class=\"figure\"><div class=\"ttl\">Possible pathologic cascade of amyotrophic lateral sclerosis (ALS)/frontotemporal lobar degeneration (FTLD)-linked molecules</div><div class=\"cntnt\"><img style=\"width:589px; height:441px;\" src=\"images/NEURO/77362_Possible_path_casc_ALS_FTLD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TAR DNA-binding protein (TDP-43) and fused in sarcoma (FUS) induce a conjoint pathologic cascade of neurodegeneration that leads to ALS/FTLD with ubiquitin-positive inclusions. Ataxin-2 possibly promotes this cascade. Recent pathologic and biochemical evidence indicates that valosin containing protein (VCP) and progranulin (PGRN) may be located upstream of TDP-43 in the pathologic cascade. Cu/Zn SOD1 may contribute to an independent pathologic process or join the pathologic cascade downstream of TDP-43/FUS. The role of optineurin in the pathologic cascade remains to be elucidated.</div><div class=\"graphic_reference\">Reproduced with permission from: Ito D, Suzuki N. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 2011; 77:1636. Copyright © 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77362 Version 4.0</div></div></div>"},"77363":{"type":"graphic_figure","displayName":"Subtotal stomach preserving pancreaticoduodenectomy","title":"Subtotal stomach-preserving pancreaticoduodenectomy","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Subtotal stomach-preserving pancreaticoduodenectomy</div><div class=\"cntnt\"><img style=\"width:541px; height:352px;\" src=\"images/SURG/77363_Subtotal-stomach-preserving-Whipple.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subtotal stomach preserving Whipple with end-to-side (left panel) and end-to-end pancreato-jejunostomy (right panel).</div><div id=\"graphicVersion\">Graphic 77363 Version 2.0</div></div></div>"},"77364":{"type":"graphic_figure","displayName":"Cheek structure lacerations","title":"The parotid gland and facial nerve underlie the zygomatic and cheek areas","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">The parotid gland and facial nerve underlie the zygomatic and cheek areas</div><div class=\"cntnt\"><img style=\"width:491px; height:517px;\" src=\"images/EM/77364_Cheek_structure_lacerations.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The parotid gland and facial nerve branches are superficial to the masseter muscle and can be damaged in lacerations to the cheek and zygoma that are anterior to the ear.</div><div id=\"graphicVersion\">Graphic 77364 Version 2.0</div></div></div>"},"77366":{"type":"graphic_picture","displayName":"Sickle cell scanning EM","title":"Sickle cell by scanning electron micrography (scanning EM)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sickle cell by scanning electron micrography (scanning EM)</div><div class=\"cntnt\"><img style=\"width:365px; height:288px;\" src=\"images/HEME/77366_Sickle_cell_scanning_EM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scanning electron micrograph of a single red blood cell from a patient with sickle cell disease, illustrating the classical &quot;sickle&quot; shape.</div><div class=\"graphic_reference\">Courtesy of RL Nagel, MD.</div><div id=\"graphicVersion\">Graphic 77366 Version 4.0</div></div></div>"},"77367":{"type":"graphic_table","displayName":"Usual doses of antileukotriene agents","title":"Usual doses of antileukotriene agents in the management of persistent asthma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Usual doses of antileukotriene agents in the management of persistent asthma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Preparations</td> <td class=\"subtitle1\">Infant and small child</td> <td class=\"subtitle1\">Pediatric</td> <td class=\"subtitle1\">Adolescent and adult</td> </tr> <tr class=\"divider_bottom\"> <td>Montelukast</td> <td> <p>Granules: 4 mg per packet</p> <p>Chewable tablets: 4 mg, 5 mg</p> Tablet: 10 mg</td> <td>12 months* to 5 years: 4 mg granules or chewable tablet once daily in evening</td> <td>6 to 14 years: 5 mg chewable tablet once daily in evening</td> <td>&#8805;15 years and adult: 10 mg tablet once daily in evening</td> </tr> <tr class=\"divider_bottom\"> <td>Zafirlukast<sup>&#182;</sup></td> <td>Tablets: 10 mg, 20 mg</td> <td>(Not studied)</td> <td>5 to 11 years: 10 mg twice per day</td> <td>&#8805;12 years and adult: 20 mg twice per day</td> </tr> <tr class=\"divider_bottom\"> <td>Zileuton<sup>&#182;</sup></td> <td> <p>Immediate-release tablet: 600 mg</p> Extended-release tablet: 600 mg</td> <td>(Not studied)</td> <td>(Not studied)</td> <td>&#8805;12 years and adult:<br /> <ul class=\"decimal_heading\"> <li>Immediate release: 600 mg four times per day </li> <li>Extended release: 1200 mg twice per day </li> </ul> </td> </tr> <tr> <td>Pranlukast<sup>&#916;</sup></td> <td> <p>Capsules: 112.5 mg, 225 mg</p> Granules: 50 mg, 70 mg, 100 mg per packet</td> <td>24 months to 5 years: 7 to 10 mg/kg granules per day in two divided doses</td> <td>6 to 11 years: 7 to 10 mg/kg per day granules in two divided doses (maximum 225 mg twice per day)</td> <td>&#8805;12 years and adult: 225 mg twice per day</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Approved for use in infants ≥6 months in some countries other than United States.<br />¶&nbsp;Elevated transaminases and severe hepatoxicity have been reported.<br />Δ&nbsp;Not available in United States. Available in Japan and some countries of Central and South America.</div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;    <li>US Food &amp; Drug Administration approved prescribing information. Available at <a href=\"http://dailymed.nlm.nih.gov/dailymed/about.cfm\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/about.cfm</a> (Accessed April 15, 2014).</li>&#xD;&#xA;    <li>Bisgaard H, et al. Pediatric Pulmonol 2009; 44:568.</li>&#xD;&#xA;    <li>Keam SJ, et al. Drugs 2003; 63:991.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 77367 Version 4.0</div></div></div>"},"77368":{"type":"graphic_table","displayName":"Characteristics TEC","title":"Characteristics of thymic epithelial cells (TEC)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of thymic epithelial cells (TEC)</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1_single\">Growth factors for TECs:</td>\n</tr>\n<tr>\n<td>IL-1, EGF, beta-FGF</td>\n</tr>\n<tr>\n<td class=\"subtitle1_single\">Secreted products of TECs</td>\n</tr>\n<tr>\n<td>Cortical TEC: IL-1, IL-7</td>\n</tr>\n<tr>\n<td>Medullary and subcapsular TEC (also called \"giant\" or \"nurse\" cells): IL-1, IL-6, IL-8, G-CSF, M-CSF, TGF-beta, alpha and beta thymosins, thymulin, neuropeptides</td>\n</tr>\n\n<tr>\n<td class=\"subtitle1_single\">Adhesion molecules expressed by TECs</td>\n</tr>\n<tr>\n<td>LFA-3 (CD58), ligand CD2; ICAM-1 (CD54), ligand LFA-1 (CD11a/CD18)</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_footnotes\">CSF: colony stimulating factor; EGF: epidermal growth factor; FGF: fibroblast growth factor; G: granulocyte; ICAM: intercellular adhesion molecule; IL: interleukin; LFA: leukocyte function antigen; M: monocyte; TGF: transforming growth factor.</div><div class=\"graphic_reference\">Data from Bodey, B, Jr., Siegel, SE, Kaiser, HE. Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment. In Vivo 1999; 13:267. and Hadden, JW. Thymic endocrinology. Ann N Y Acad 1998; 840:352.</div><div id=\"graphicVersion\">Graphic 77368 Version 1.0</div></div></div>"},"77369":{"type":"graphic_figure","displayName":"TEP access balloon dissector","title":"TEP access balloon dissector","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">TEP access balloon dissector</div><div class=\"cntnt\"><img style=\"width:500px; height:499px;\" src=\"images/SURG/77369_TEP_access_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Maithel SK, Schneider BE. Atlas of minimally invasive surgery. Ciné-Med, Woodbury, CT 2006. Copyright © 2006 Ciné-Med, Inc.</div><div id=\"graphicVersion\">Graphic 77369 Version 10.0</div></div></div>"},"77371":{"type":"graphic_table","displayName":"Barthel Index","title":"Barthel Index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Barthel Index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Activity</td> <td class=\"subtitle1_single\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Feeding</td> </tr> <tr> <td class=\"indent1\">0 = Unable</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Needs help cutting, spreading butter, etc, or requires modified diet</td> </tr> <tr> <td class=\"indent1\">10 = Independent</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Bathing</td> </tr> <tr> <td class=\"indent1\">0 = Dependent</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Independent (or in shower)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Grooming</td> </tr> <tr> <td class=\"indent1\">0 = Needs to help with personal care</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Independent face/hair/teeth/shaving (implements provided)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Dressing</td> </tr> <tr> <td class=\"indent1\">0 = Dependent</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Needs help but can do about half unaided</td> </tr> <tr> <td class=\"indent1\">10 = Independent (including buttons, zips, laces, etc)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Bowels</td> </tr> <tr> <td class=\"indent1\">0 = Incontinent (or needs to be given enemas)</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Occasional accident</td> </tr> <tr> <td class=\"indent1\">10 = Continent</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Bladder</td> </tr> <tr> <td class=\"indent1\">0 = Incontinent, or catheterized and unable to manage alone</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Occasional accident</td> </tr> <tr> <td class=\"indent1\">10 = Continent</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Toilet use</td> </tr> <tr> <td class=\"indent1\">0 = Dependent</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Needs some help, but can do something alone</td> </tr> <tr> <td class=\"indent1\">10 = Independent (on and off, dressing, wiping)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Transfers (bed to chair and back)</td> </tr> <tr> <td class=\"indent1\">0 = Unable, no sitting balance</td> <td rowspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Major help (one or two people, physical), can sit</td> </tr> <tr> <td class=\"indent1\">10 = Minor help (verbal or physical)</td> </tr> <tr> <td class=\"indent1\">15 = Independent</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Mobility (on level surfaces)</td> </tr> <tr> <td class=\"indent1\">0 = Immobile or &#60;50 yards</td> <td rowspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Wheelchair independent, including corners, &#62;50 yards</td> </tr> <tr> <td class=\"indent1\">10 = Walks with help of one person (verbal or physical) &#62;50 yards</td> </tr> <tr> <td class=\"indent1\">15 = Independent (but may use any aid; for example, stick) &#62;50 yards</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"2\">Stairs</td> </tr> <tr> <td class=\"indent1\">0 = Unable</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">5 = Needs help (verbal, physical, carrying aid)</td> </tr> <tr> <td class=\"indent1\">10 = Independent</td> </tr> <tr class=\"divider_top\"> <td align=\"right\"><strong>Total (0-100):</strong></td> <td>&nbsp;</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">10</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=98922&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_lgnd\">The Barthel ADL Index: Guidelines<br> <ul> <li>The index should be used as a record of what a patient does, not as a record of what a patient could do </li> <li>The main aim is to establish degree of independence from any help, physical or verbal, however minor and for whatever reason </li> <li>The need for supervision renders the patient not independent </li> <li>Patient performance should be established using the best available evidence provided by the patient, family, friends and caregivers; direct observation and common sense are also important, but direct testing is not needed </li> <li>Usually the patient's performance over the preceding 24 to 48 hours is important, but occasionally longer periods will be relevant </li> <li>Middle categories imply that the patient supplies over 50 percent of the effort </li> <li>Use of aids to be independent is allowed </li> </ul></div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Mahoney FI, Barthel D. Functional evaluation: The Barthel Index. Maryland State Medical Journal 1965; 14:56. Used with permission. </LI>&#xD;&#xA;<LI>Loewen SC, Anderson BA. Predictors of stroke outcome using objective measurement scales. Stroke 1990; 21:78. </LI>&#xD;&#xA;<LI>Gresham GE, Phillips TF, Labi ML. ADL status in stroke: Relative merits of three standard indexes. Arch Phys Med Rehabil 1980; 61:355. </LI>&#xD;&#xA;<LI>Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index:&nbsp;A reliability study. Int Disability Study 1988; 10:61. </LI></OL></div><div id=\"graphicVersion\">Graphic 77371 Version 2.0</div></div></div>"},"77372":{"type":"graphic_figure","displayName":"Wireless motility capsule studies","title":"Wireless motility capsule studies","html":"<div class=\"graphic\"><div style=\"width: 830px\" class=\"figure\"><div class=\"ttl\">Wireless motility capsule studies</div><div class=\"cntnt\"><img style=\"width:810px; height:813px;\" src=\"images/GAST/77372_Wireless_motility_cap_stud.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative results of wireless motility capsule studies in patients with (A) normal intestinal transit, (B) delayed gastric emptying, and (C) delayed colonic transit.</div><div class=\"graphic_footnotes\">GET: gastric emptying time; SBTT: small bowel transit time; CTT: colon transit time.</div><div class=\"graphic_reference\">Courtesy of Braden Kuo, MD.</div><div id=\"graphicVersion\">Graphic 77372 Version 2.0</div></div></div>"},"77373":{"type":"graphic_table","displayName":"High risk sports spine injury","title":"Sports with high risk for head and spine injury","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sports with high risk for head and spine injury</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Auto racing</td>\n\n\n</tr>\n<tr>\n<td>Motorcycling</td>\n\n\n</tr>\n<tr>\n<td>Cycling</td>\n\n\n</tr>\n<tr>\n<td>Football</td>\n\n\n</tr>\n<tr>\n<td>Lacrosse</td>\n\n\n</tr>\n<tr>\n<td>Ice hockey</td>\n\n\n</tr>\n<tr>\n<td>Rugby</td>\n\n\n</tr><tr><td>Boxing</td></tr><tr><td>Wrestling</td></tr><tr><td>Martial arts</td></tr><tr><td>Diving</td></tr><tr><td>Gymnastics</td></tr><tr><td>Trampolining</td></tr><tr><td>Soccer (goalie)</td></tr><tr><td>Hang gliding</td></tr><tr><td>Parachuting</td></tr><tr><td>Sky diving</td></tr><tr><td>Skating/rollerblading</td></tr><tr><td>Skiing</td></tr><tr><td>Track (pole vaulting)</td></tr><tr><td>Equestrian sports</td></tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Adapted with permission from: Cantu, RC. Head and spine injuries in youth sports. Clin Sports Med 1995; 14:517. Copyright &#169; 1995 Elsevier.</div><div id=\"graphicVersion\">Graphic 77373 Version 1.0</div></div></div>"},"77374":{"type":"graphic_diagnosticimage","displayName":"Large vestibular aqueduct","title":"Patent vestibular aqueduct","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Patent vestibular aqueduct</div><div class=\"cntnt\"><img style=\"width:399px; height:281px;\" src=\"images/PEDS/77374_Large_vestibular_aqueduct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This child with an enlarged vestibular aqueduct (*) developed progressive sensory-neural hearing loss after mild head trauma.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 77374 Version 2.0</div></div></div>"},"77375":{"type":"graphic_figure","displayName":"TAPVC anatomic variants","title":"Diagram of common types of totally anomalous pulmonary venous connection (TAPVC)","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Diagram of common types of totally anomalous pulmonary venous connection (TAPVC)</div><div class=\"cntnt\"><img style=\"width:461px; height:612px;\" src=\"images/PEDS/77375_TAPVRanatomicvariants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Supracardiac TAPVC to the left innominate vein. The individual pulmonary veins form a horizontal pulmonary venous confluence (HVC) that connects to the left innominate vein by way of a vertical vein. <br />(B) Infradiaphragmatic TAPVC to the portal vein. The pulmonary veins form a vertical confluence that descends below the diaphragm and typically joins the portal vein (PV). Pulmonary venous blood then drains into the inferior vena cava (IVC) via the ductus venosus or the hepatic sinusoids. The individual pulmonary veins may join the vertical vein at different levels. <br />(C) TAPVC to the coronary sinus (CS). <br />(D) Mixed-type TAPVC. In the example shown, the left pulmonary veins (LPV) connect to the left innominate vein (LIV), and the right pulmonary veins (RPV) connect with the CS. <br />(E) Total anomalous pulmonary venous drainage owing to malposition of septum primum. The pulmonary veins connect normally to the back wall of the atria, but pulmonary venous drainage is to the right of the malattached septum primum (arrow) (in atrial situs solitus).</div><div class=\"graphic_footnotes\">HV: hepatic vein; LA: left atrium; RA: right atrium; SMV: superior mesenteric vein; SV: splenic vein.</div><div class=\"graphic_reference\">Reproduced with permission from: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF. Moss and Adams' Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult, 7<SUP>th</SUP> ed, Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77375 Version 13.0</div></div></div>"},"77376":{"type":"graphic_table","displayName":"Complications of central venous catheterization","title":"Complications of central venous catheterization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications of central venous catheterization</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Immediate</td> </tr> <tr> <td>Bleeding</td> </tr> <tr> <td>Arterial puncture</td> </tr> <tr> <td>Arrhythmia</td> </tr> <tr> <td>Air embolism</td> </tr> <tr> <td>Thoracic duct injury (with left SC or left IJ approach)</td> </tr> <tr> <td>Catheter malposition</td> </tr> <tr> <td>Pneumothorax or hemothorax</td> </tr> <tr> <td class=\"subtitle1_single\">Delayed</td> </tr> <tr> <td>Infection</td> </tr> <tr> <td>Venous thrombosis, pulmonary emboli</td> </tr> <tr> <td>Venous stenosis</td> </tr> <tr> <td>Catheter migration</td> </tr> <tr> <td>Catheter embolization</td> </tr> <tr> <td>Myocardial perforation</td> </tr> <tr> <td>Nerve injury</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SC: subclavian; IJ: internal jugular.</div><div id=\"graphicVersion\">Graphic 77376 Version 4.0</div></div></div>"},"77380":{"type":"graphic_table","displayName":"Prev venous cath infection","title":"Prevention of infection with peripheral venous catheters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevention of infection with peripheral venous catheters</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Replacement and relocation of catheter</td> </tr> <tr> <td>In adults patients,&nbsp;leave peripheral venous catheters in place until intravenous therapy is completed, unless a complication occurs.</td> </tr> <tr> <td>In pediatric patients, leave peripheral venous catheters in place until intravenous therapy is completed, unless a complication occurs.</td> </tr> <tr> <td>For catheters inserted under emergency conditions, insert a new catheter at a different site within 24 hours.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of catheter-site dressing</td> </tr> <tr> <td>Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.</td> </tr> <tr> <td>There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.</td> </tr> <tr> <td class=\"subtitle1_single\">Replacement of administration sets</td> </tr> <tr> <td>Replace administration sets, including secondary sets and add-on devices, no more frequently than at 96-hour intervals, unless clinically indicated.</td> </tr> <tr> <td>Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion. <strong>No recommendation*</strong> for replacement of tubing used for intermittent infusions.</td> </tr> <tr> <td>Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.</td> </tr> <tr> <td class=\"subtitle1_single\">Hang time for parenteral fluids</td> </tr> <tr> <td>Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.</td> </tr> <tr> <td>Complete infusion of blood or blood products within four hours of hanging the blood.</td> </tr> <tr> <td><strong>No recommendation*</strong> for the hang time of intravenous fluids, including nonlipid-containing parenteral nutrition fluids.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* No recommendation is made when there is insufficient data in the literature.</div><div id=\"graphicVersion\">Graphic 77380 Version 4.0</div></div></div>"},"77382":{"type":"graphic_table","displayName":"Causes of lymphadenopathy","title":"Causes of peripheral lymphadenopathy*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of peripheral lymphadenopathy*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Cause </td> <td class=\"subtitle1\">Examples </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Infections </td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Bacterial </td> </tr> <tr> <td class=\"sublist2\">Localized </td> <td class=\"sublist_other\">Streptococcal pharyngitis; skin infections; tularemia; plague; cat scratch disease; diphtheria; chancroid; rat bite fever </td> </tr> <tr> <td class=\"sublist2\">Generalized </td> <td class=\"sublist_other\">Brucellosis; leptospirosis; lymphogranuloma venereum; typhoid fever </td> </tr> <tr> <td class=\"indent1\">Viral </td> <td>Human immunodeficiency virus; Epstein-Barr virus; herpes simplex virus; cytomegalovirus; mumps; measles; rubella; hepatitis B; dengue fever</td> </tr> <tr> <td class=\"indent1\">Mycobacterial </td> <td><em>Mycobacterium tuberculosis</em>; atypical mycobacteria</td> </tr> <tr> <td class=\"indent1\">Fungal </td> <td>Histoplasmosis; coccidioidomycosis; cryptococcosis</td> </tr> <tr> <td class=\"indent1\">Protozoal </td> <td>Toxoplasmosis; leishmaniasis</td> </tr> <tr> <td class=\"indent1\">Spirochetal </td> <td>Secondary syphilis; Lyme disease</td> </tr> <tr> <td class=\"subtitle2_left\">Cancer </td> <td>Squamous cell cancer head and neck; metastatic; lymphoma; leukemia</td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"4\">Lymphoproliferative </td> <td>Angioimmunoblastic lymphadenopathy with dysproteinemia</td> </tr> <tr> <td>Autoimmune lymphoproliferative disease</td> </tr> <tr> <td>Rosai-Dorfman disease</td> </tr> <tr> <td>Hemophagocytic lymphohistiocytosis</td> </tr> <tr> <td class=\"subtitle2_left\">Immunologic </td> <td>Serum sickness; drug reactions (phenytoin); IgG4-related disease</td> </tr> <tr> <td class=\"subtitle2_left\">Endocrine </td> <td>Addison's disease</td> </tr> <tr> <td class=\"subtitle2_left\">Miscellaneous </td> <td>Sarcoidosis; lipid storage diseases; amyloidosis; histiocytosis; chronic granulomatous diseases; Castleman disease; Kikuchi disease; Kawasaki disease; inflammatory pseudotumor; systemic lupus erythematosus; rheumatoid arthritis; Still's disease; dermatomyositis; eosinophilic granulomatosis with polyangiitis (Churg-Strauss)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG4: Immunoglobulin G4.<br />* Note: This is a partial list and is not meant to be all-inclusive.</div><div id=\"graphicVersion\">Graphic 77382 Version 8.0</div></div></div>"},"77383":{"type":"graphic_picture","displayName":"Gonioscopy","title":"Gonioscopy","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Gonioscopy</div><div class=\"cntnt\"><img style=\"width:502px; height:221px;\" src=\"images/PC/77383_Gonioscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left: Patient undergoing gonioscopy. Right: Anterior chamber angle as viewed on gonioscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Alward, WLM. Color Atlas of Gonioscopy. Foundation of the American Academy of Ophthalmology 2001.</div><div id=\"graphicVersion\">Graphic 77383 Version 1.0</div></div></div>"},"77384":{"type":"graphic_table","displayName":"Heliox ventilator calibration","title":"Correction factors for inspiratory and expiratory volumes during use of Heliox","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Correction factors for inspiratory and expiratory volumes during use of Heliox</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">FiO<sub>2</sub> set</td> <td class=\"subtitle1\" colspan=\"2\">Veolar FT</td> <td class=\"subtitle1\" colspan=\"2\">Galileo</td> <td class=\"subtitle1\" colspan=\"2\">Servo 900C</td> <td class=\"subtitle1\" colspan=\"2\">Servo 300</td> </tr> <tr> <td class=\"subtitle2\">VFi</td> <td class=\"subtitle2\">VFe</td> <td class=\"subtitle2\">VFi</td> <td class=\"subtitle2\">VFe</td> <td class=\"subtitle2\">VFi</td> <td class=\"subtitle2\">VFe</td> <td class=\"subtitle2\">VFi</td> <td class=\"subtitle2\">VFe</td> </tr> <tr> <td>0.21</td> <td>1.68</td> <td>1.70</td> <td>1.68</td> <td>1.70</td> <td>1.38</td> <td>1.34</td> <td>1.00</td> <td>1.34</td> </tr> <tr> <td>0.25</td> <td>1.60</td> <td>1.60</td> <td>1.60</td> <td>1.60</td> <td>1.36</td> <td>1.34</td> <td>1.00</td> <td>1.34</td> </tr> <tr> <td>0.30</td> <td>1.51</td> <td>1.50</td> <td>1.51</td> <td>1.50</td> <td>1.35</td> <td>1.33</td> <td>1.00</td> <td>1.33</td> </tr> <tr> <td>0.35</td> <td>1.44</td> <td>1.47</td> <td>1.44</td> <td>1.47</td> <td>1.33</td> <td>1.23</td> <td>1.00</td> <td>1.33</td> </tr> <tr> <td>0.40</td> <td>1.37</td> <td>1.40</td> <td>1.37</td> <td>1.40</td> <td>1.31</td> <td>1.22</td> <td>1.00</td> <td>1.22</td> </tr> <tr> <td>0.45</td> <td>1.31</td> <td>1.33</td> <td>1.31</td> <td>1.33</td> <td>1.29</td> <td>1.20</td> <td>1.00</td> <td>1.20</td> </tr> <tr> <td>0.50</td> <td>1.28</td> <td>1.30</td> <td>1.28</td> <td>1.30</td> <td>1.26</td> <td>1.17</td> <td>1.00</td> <td>1.17</td> </tr> <tr> <td>0.60</td> <td>1.20</td> <td>1.26</td> <td>1.20</td> <td>1.26</td> <td>1.24</td> <td>1.13</td> <td>1.00</td> <td>1.13</td> </tr> <tr> <td>1.00</td> <td>0.97</td> <td>1.01</td> <td>0.97</td> <td>1.01</td> <td>0.97</td> <td>1.09</td> <td>0.99</td> <td>1.09</td> </tr> <tr> <td class=\"subtitle1\" rowspan=\"2\">FiO<sub>2</sub> set</td> <td class=\"subtitle1\" colspan=\"2\">Evita 2</td> <td class=\"subtitle1\" colspan=\"2\">Evita 4</td> <td class=\"subtitle1\" colspan=\"4\">7200 series</td> </tr> <tr> <td class=\"subtitle2\">VFi</td> <td class=\"subtitle2\">VFe</td> <td class=\"subtitle2\">VFi</td> <td class=\"subtitle2\">VFe</td> <td class=\"subtitle2\" colspan=\"2\">VFi</td> <td class=\"subtitle2\" colspan=\"2\">VFe</td> </tr> <tr> <td>0.21</td> <td>1.83</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.10</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.25</td> <td>1.75</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.14</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.30</td> <td>1.73</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.19</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.35</td> <td>1.66</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.25</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.40</td> <td>1.60</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.30</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.45</td> <td>1.55</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.35</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.50</td> <td>1.48</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.40</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>0.60</td> <td>1.40</td> <td>Inop</td> <td>NL</td> <td>Inop</td> <td colspan=\"2\">0.50</td> <td colspan=\"2\">Inop</td> </tr> <tr> <td>1.00</td> <td>0.986</td> <td>1.093</td> <td>0.99</td> <td>1.093</td> <td colspan=\"2\">1.05</td> <td colspan=\"2\">1.05</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Inop: inoperative; NL: nonlinear relationship; VFe: expiratory volume correction factor (VTe = VTe meas x VFe); VFi: inspiratory volume correction factor (VTdel = VTset x VFi).</div><div class=\"graphic_reference\">Reproduced with permission from: Tassaux D, Jolliet P, Thouret J, et al. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures. Am J Respir Crit Care Med 1999; 160:22. Copyright &#169;1999 American Lung Association.</div><div id=\"graphicVersion\">Graphic 77384 Version 2.0</div></div></div>"},"77385":{"type":"graphic_figure","displayName":"Conceptual model for chronic kidney disease","title":"Conceptual model for chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Conceptual model for chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:546px; height:262px;\" src=\"images/NEPH/77385_Concept_model_kidney_3.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram presents the continuum of development, progression and complications of chronic kidney disease (CKD) and strategies to improve outcomes. Green circles represent stages of CKD; aqua circles represent potential antecedents of CKD, lavender circles represent consequences of CKD; and thick arrows between circles represent the development, progression and remission of CKD. &quot;CKD&quot; is defined as the presence of either kidney damage or decreased kidney function for three or more months, irrespective of cause (underlying illness and pathology). &quot;Complications&quot; refers to all complications of CKD, including complications of decreased GFR, albuminuria and cardiovascular disease. Complications may also arise from adverse effects of interventions to prevent or treat the disease. The horizontal arrows pointing from left to right emphasize the progressive nature of CKD. Dashed arrowheads pointing from right to left signify that remission is less frequent than progression.</div><div class=\"graphic_reference\">Original figure modified for this publication. From: Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. Am J Kidney Dis 2009; 53:S4. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77385 Version 1.0</div></div></div>"},"77386":{"type":"graphic_picture","displayName":"Atopic dermatitis infant 2","title":"Atopic dermatitis - infantile","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis - infantile</div><div class=\"cntnt\"><img style=\"width:325px; height:432px;\" src=\"images/DERM/77386_Atopicderminfant2PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, lichenified patches are present on the face of this infant with atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77386 Version 10.0</div></div></div>"},"77387":{"type":"graphic_algorithm","displayName":"Abnormal adult behavior diagnosis algorithm","title":"Diagnostic approach to the adult with altered mental status","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the adult with altered mental status</div><div class=\"cntnt\"><img style=\"width:289px; height:386px;\" src=\"images/EM/77387_AbnormadultbehavrDxalgo.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77387 Version 3.0</div></div></div>"},"77388":{"type":"graphic_table","displayName":"Motor function score","title":"Motor function score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motor function score</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Score</td>\n<td class=\"subtitle1\">Response</td>\n</tr>\n\n<tr>\n<td>0</td>\n<td>No contraction</td>\n</tr>\n\t\n<tr>\n<td>1</td>\n<td>Flicker or trace of contraction</td>\n</tr>\n\n<tr>\n<td>2</td>\n<td>Active movement with gravity eliminated</td>\n</tr>\n\n<tr>\n<td>3</td>\n<td>Active movement against gravity</td>\n</tr>\n\n<tr>\n<td>4</td>\n<td>Active movement against gravity and resistance</td>\n</tr>\n\n<tr>\n<td>5</td>\n<td>Normal power</td>\n</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">3.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">1/23/2010--Requested permission (JD).\r\n2/2/2010--Permission granted, awaiting formal invoice; figure to Terrence (JD).\r\n2/4/2010--Formal invoice received, paid on my AMEX (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=12275&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Motor_exam_score.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Brain Journal. Aids to the Examination of the Peripheral Nervous System, WB Saunders, 2000. Illustration used with permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77388 Version 2.0</div></div></div>"},"77389":{"type":"graphic_picture","displayName":"Passive wrist flexion","title":"Passive wrist flexion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Passive wrist flexion</div><div class=\"cntnt\"><img style=\"width:432px; height:335px;\" src=\"images/EM/77389_Wrist_passive_flexion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pain with passive terminal wrist flexion with the elbow in full extension occurs with lateral epicondylitis.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 77389 Version 2.0</div></div></div>"},"77390":{"type":"graphic_diagnosticimage","displayName":"Trucut apparatus seen by EUS","title":"Distinct echo features of trucut apparatus","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Distinct echo features of trucut apparatus</div><div class=\"cntnt\"><img style=\"width:540px; height:400px;\" src=\"images/GAST/77390_Trucut_apparatus_seen_by_EU.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic image showing distinct patterns of the components of the trucut apparatus.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Mauritis J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 77390 Version 2.0</div></div></div>"},"77391":{"type":"graphic_table","displayName":"Modes of mechanical ventilation","title":"Modes of mechanical ventilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modes of mechanical ventilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Mode</td> <td class=\"subtitle1\" rowspan=\"2\">Breath strategy<br /> (target)</td> <td class=\"subtitle1\" colspan=\"2\">Trigger</td> <td class=\"subtitle1\" rowspan=\"2\">Cycle<br /> (breath termination)</td> <td class=\"subtitle1\" colspan=\"3\">Types of breaths</td> </tr> <tr> <td class=\"subtitle2\">Ventilator</td> <td class=\"subtitle2\">Patient</td> <td class=\"subtitle2\">Mandatory</td> <td class=\"subtitle2\">Assisted</td> <td class=\"subtitle2\">Spontaneous</td> </tr> <tr> <td rowspan=\"2\">CMV</td> <td>Volume-limited</td> <td>Yes</td> <td>No</td> <td>Volume</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td>Pressure-limited</td> <td>Yes</td> <td>No</td> <td>Time</td> <td>Yes</td> <td>No</td> <td>No</td> </tr> <tr> <td rowspan=\"2\">AC</td> <td>Volume-limited</td> <td>Yes</td> <td>Yes</td> <td>Volume</td> <td>Yes</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>Pressure-limited</td> <td>Yes</td> <td>Yes</td> <td>Time</td> <td>Yes</td> <td>Yes</td> <td>No</td> </tr> <tr> <td rowspan=\"2\">IMV</td> <td>Volume-limited</td> <td>Yes</td> <td>Yes</td> <td>Volume</td> <td>Yes</td> <td>Yes*</td> <td>Yes*</td> </tr> <tr> <td>Pressure-limited (also called APRV)</td> <td>Yes</td> <td>Yes</td> <td>Time</td> <td>Yes</td> <td>Yes*</td> <td>Yes*</td> </tr> <tr> <td>PSV</td> <td>Pressure-limited</td> <td>No</td> <td>Yes</td> <td>Flow, pressure, or time</td> <td>No</td> <td>Yes</td> <td>No</td> </tr> <tr> <td>CPAP</td> <td>&nbsp;</td> <td>No</td> <td>No</td> <td>Flow</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr> <td>Tube compensation</td> <td>&nbsp;</td> <td>No</td> <td>Yes</td> <td>Flow</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"8\">Types of breaths:</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Mandatory: Breaths are initiated by the ventilator and the ventilator performs the work of inspiration during those breaths</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Assisted: Breaths are initiated by the patient, but the ventilator performs at least some of the work of inspiration for those patient initiated breaths</td> </tr> <tr> <td class=\"indent1\" colspan=\"8\">Spontaneous: Breaths are initiated by the patient and the patient performs the entire work of inspiration for those patient initiated breaths</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: controlled mechanical ventilation; AC: assist control; IMV: intermittent mandatory ventilation; PSV: pressure support ventilation; CPAP: continuous positive airway pressure; APRV: airway pressure release ventilation; BPAP: bilevel positive airway pressure.<br />* Note that there is overlap between the types of breaths that can be generated during various modes of ventilation. This overlap is dependent on the ventilator settings. As examples, APRV and IMV are capable of assisted breaths (pressure support added) or spontaneous breaths (no pressure support added). Both assisted and spontaneous breaths depend on the patient's ability to trigger the ventilator.</div><div id=\"graphicVersion\">Graphic 77391 Version 4.0</div></div></div>"},"77392":{"type":"graphic_diagnosticimage","displayName":"Progressive fibrosis CXR","title":"Progressive massive fibrosis (PMF)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Progressive massive fibrosis (PMF)</div><div class=\"cntnt\"><img style=\"width:396px; height:357px;\" src=\"images/PULM/77392_Progressive_fibrosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with end-stage silicosis complicated by respiratory failure. There is upward retraction of hila, and the lower zones are hyperinflated.</div><div class=\"graphic_reference\">Courtesy of Dr. J. Parker.</div><div id=\"graphicVersion\">Graphic 77392 Version 2.0</div></div></div>"},"77394":{"type":"graphic_movie","displayName":"Thoracic ultrasound - Absence of lung sliding","title":"Thoracic ultrasound: Absence of lung sliding","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic ultrasound: Absence of lung sliding</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/PULM/77394_ThoracUSlungslideconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:324px; height:272px;\" src=\"images/PULM/77394_ThoracicUSlungslide.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77394 Version 2.0</div></div></div>"},"77395":{"type":"graphic_diagnosticimage","displayName":"Normal thymus in an infant","title":"Radiographic appearance of a normal thymus gland in an infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiographic appearance of a normal thymus gland in an infant</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/PEDS/77395_Normal_thymus_infant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior (PA) view of the chest in a healthy infant. The radioopaque paraspinal density just above the heart (arrows) represents the normal infant thymus gland. The right margin is slightly undulating, characteristic of the thymus, which is indented by adjacent costochondral cartilages (thymic wave sign).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77395 Version 3.0</div></div></div>"},"77396":{"type":"graphic_diagnosticimage","displayName":"ECD x-ray","title":"Osteosclerosis and osteolysis in Erdheim-Chester disease","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Osteosclerosis and osteolysis in Erdheim-Chester disease</div><div class=\"cntnt\"><img style=\"width:464px; height:486px;\" src=\"images/HEME/77396_ECD_xray_PR2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">X-ray of left femur revealed diffuse osteosclerosis with focal osteolysis in the diaphysis and metaphysis of the left distal femur.</div><div class=\"graphic_reference\">Reproduced with permission from: Kim MS, Kim CH, Choi SJ, et al. Erdheim-Chester disease. Ann Dermatol 2010; 22:439. Copyright © 2010 Korean Dermatological Association.</div><div id=\"graphicVersion\">Graphic 77396 Version 2.0</div></div></div>"},"77401":{"type":"graphic_table","displayName":"Meta anal surveillance CRC surg","title":"Meta-analyses of intensive versus less intensive surveillance after potentially curative therapy for colon and rectum cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Meta-analyses of intensive versus less intensive surveillance after potentially curative therapy for colon and rectum cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Author; year</td> <td class=\"subtitle1\" colspan=\"2\">Pooled number of patients in randomized trials</td> <td class=\"subtitle1\" rowspan=\"2\">Relative risk for mortality<br /> (95% CI)</td> </tr> <tr> <td class=\"subtitle2\">Intensive</td> <td class=\"subtitle2\">Less intensive</td> </tr> <tr> <td>Renehan A; 2002</td> <td class=\"centered\">666</td> <td class=\"centered\">676</td> <td class=\"centered\">0.81 (0.70-0.94)</td> </tr> <tr> <td>Figueredo A; 2003</td> <td class=\"centered\">858</td> <td class=\"centered\">821</td> <td class=\"centered\">0.80 (0.70-0.91)</td> </tr> <tr> <td>Jeffery G; 2007</td> <td class=\"centered\">793</td> <td class=\"centered\">808</td> <td class=\"centered\">0.73 (0.59-0.91)</td> </tr> <tr> <td>Tijandra J; 2007</td> <td class=\"centered\">1474</td> <td class=\"centered\">1449</td> <td class=\"centered\">0.74 (0.59-0.93)</td> </tr> <tr> <td>Pita-Hernandez S; 2015</td> <td class=\"centered\">2000</td> <td class=\"centered\">2055</td> <td class=\"centered\">0.75 (0.66-0.86)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77401 Version 7.0</div></div></div>"},"77403":{"type":"graphic_table","displayName":"CO2 waveform diagnostics","title":"Waveform diagnostics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Waveform diagnostics</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Waveform</td> <td class=\"subtitle1\">Chest wall movement</td> <td class=\"subtitle1\">Breath sounds</td> </tr> <tr> <td>Central apnea</td> <td>-</td> <td>-</td> <td>-</td> </tr> <tr> <td>Upper airway obstruction</td> <td>-</td> <td>+</td> <td>-</td> </tr> <tr> <td>Laryngospasm</td> <td>-</td> <td>+</td> <td>-</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">+: Present.<br> -: Absent.</div><div id=\"graphicVersion\">Graphic 77403 Version 2.0</div></div></div>"},"77404":{"type":"graphic_diagnosticimage","displayName":"Middle phalanx fracture involving DIP joint","title":"Middle phalanx fracture involving DIP joint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Middle phalanx fracture involving DIP joint</div><div class=\"cntnt\"><img style=\"width:432px; height:182px;\" src=\"images/EM/77404_Mid_phalanx_fx_dip_lat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative lateral radiograph demonstrating a displaced neck fracture of the ring finger's middle phalanx.</div><div class=\"graphic_footnotes\">DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Reproduced with permission from: Strickland JW, Graham TJ. Master Techniques in Orthopeadic Surgery: The Hand, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77404 Version 4.0</div></div></div>"},"77409":{"type":"graphic_table","displayName":"Meds for treatment of generalized anxiety disorder","title":"Pharmacology of medicines for treatment of adults with generalized anxiety disorder (GAD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacology of medicines for treatment of adults with generalized anxiety disorder (GAD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"12%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Initial daily oral dose (mg)*</td> <td class=\"subtitle1\">Daily oral dose range (mg)*</td> <td class=\"subtitle1\">Primary metabolism<sup>&#916;</sup></td> <td class=\"subtitle1\">Effect on metabolism of other drugs<sup>&#916;</sup></td> <td class=\"subtitle1\">Selected characteristics relevant to treatment of adults with GAD</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Selective serotonin reuptake inhibitor (SSRI) antidepressants</strong><br /> Applies to all SSRIs: Onset of effect may be delayed 2 to 4 weeks or more. Adverse effects among the SSRIs include: Nausea, diarrhea, insomnia/agitation, somnolence, impaired sexual function, and hyponatremia. Adverse effects of individual agents are presented in a separate table in UpToDate.</td> </tr> <tr> <td class=\"indent1\">Citalopram</td> <td>10</td> <td>10 to 40</td> <td>CYP3A4, 2C19</td> <td>None</td> <td> <ul> <li>Lower risk of insomnia/agitation </li> <li>Few drug interactions </li> <li>Can&nbsp;prolong QT interval with increasing blood levels </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Escitalopram</td> <td>5 to 10</td> <td>10 to 20</td> <td>CYP3A4, 2C19</td> <td>None</td> <td> <ul> <li>Lower risk of insomnia/agitation </li> <li>Few drug interactions </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sertraline</td> <td>25 to 50</td> <td>50 to 150</td> <td>Limited (minor CYP2C9, 2D6, and 3A4)</td> <td>Inhibits CYP2B6, 2C19, 2D6</td> <td> <ul> <li>Greater risk of insomnia/agitation </li> <li>More frequent diarrhea and other gastrointestinal complaints </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Paroxetine</td> <td>20</td> <td>20 to 50</td> <td>CYP2D6</td> <td>Inhibits CYP2B6, 2D6</td> <td> <ul> <li>Mildly sedating </li> <li>Weakly anticholinergic </li> <li>Lower risk of insomnia/agitation </li> <li>Withdrawal symptoms if not tapered </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluoxetine</td> <td>20</td> <td>20 to 60</td> <td>CYP2D6, 2C9, and several minor</td> <td>Inhibits CYP2D6, 2C19</td> <td> <ul> <li>Greater risk of insomnia/agitation </li> <li>No withdrawal symptoms if not tapered </li> <li>Takes weeks to reach steady blood levels due to long half-life </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fluvoxamine</td> <td>50</td> <td>100 to 300</td> <td>CYP1A2, 2D6</td> <td>Inhibits CYP1A2, 2C19</td> <td> <ul> <li>Lower risk of insomnia/agitation </li> <li>Withdrawal symptoms if not tapered </li> <li>Significant drug interactions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants</strong><br /> Onset of effect and adverse effects of the SNRIs are similar to the SSRIs (see above). Adverse effects of individual agents are presented in a separate table in UpToDate.</td> </tr> <tr> <td class=\"indent1\">Duloxetine</td> <td>30</td> <td>60 to 120</td> <td>CYP1A2, 2D6</td> <td>Inhibits CYP2D6</td> <td> <ul> <li>Greater risk of insomnia/agitation </li> <li>Useful for treatment of comorbid painful conditions </li> <li>Withdrawal symptoms if not tapered </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Venlafaxine (extended-release)</td> <td>75</td> <td>75 to 225</td> <td>CYP2D6, 3A4</td> <td>None</td> <td> <ul> <li>Greater risk of insomnia/agitation </li> <li>Increased blood pressure (primarily diastolic) and heart rate with increasing doses </li> <li>Useful for treatment of comorbid painful conditions </li> <li>Few drug interactions </li> <li>Withdrawal symptoms if not tapered </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\"><strong>Other</strong></td> </tr> <tr> <td class=\"indent1\">Buspirone</td> <td>10 mg in divided doses</td> <td>10 to 60 mg in divided doses</td> <td>CYP3A4</td> <td>None</td> <td> <ul> <li>A nonbenzodiazepine anxiolytic </li> <li>Augmentation choice for partial response to antidepressant </li> <li>Slow onset and modest efficacy </li> <li>Lacks tolerance, dependence, and withdrawal </li> <li>Ineffective for comorbid major depression </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pregabalin</td> <td>50 mg in divided doses</td> <td>50 to 300 mg in divided doses</td> <td>Dependent on renal function for clearance</td> <td>None</td> <td> <ul> <li>A GABA analog calcium-channel modulator anticonvulsant </li> <li>Onset within days of starting treatment </li> <li>Approved for treatment of anxiety in some countries (not United States) </li> <li>Sedation and dizziness </li> <li>Tolerance, dependence, and withdrawal possible </li> <li>Schedule V controlled substance in United States </li> <li>Many patients require&nbsp;&#62;150 mg/day, up to 300 mg/day </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Mirtazapine</td> <td>15</td> <td>15 to 60</td> <td>CYP1A2, 2D6, 3A4</td> <td>None</td> <td> <ul> <li>An atypical antidepressant </li> <li>Alternate or augmentation choice for anxiety with insomnia </li> <li>Sedating; notably increases appetite </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Quetiapine</td> <td>25 to 50</td> <td>50 to 300</td> <td>CYP3A4</td> <td>None</td> <td> <ul> <li>A second generation antipsychotic (SGA) </li> <li>Potential augmentation choice for partial response to antidepressant or alternate as monotherapy </li> <li>Sedation, extrapyramidal effects, weight gain, and metabolic side effects (see separate table on SGA adverse effects) </li> <li>Rarely tardive dyskinesia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hydroxyzine</td> <td>50 mg at bedtime</td> <td>25 to 50 mg three to four times per day as needed</td> <td>None</td> <td>None</td> <td> <ul> <li>A sedating antihistamine with anxiolytic properties </li> <li>Augmentation option for treatment of insomnia </li> <li>Anticholinergic side-effects with increasing doses </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Imipramine</td> <td>75 mg in divided doses</td> <td>75 to 200 mg in divided doses</td> <td>CYP2C19, 2D6</td> <td>Inhibits CYP2D6</td> <td> <ul> <li>A tricyclic antidepressant </li> <li>Anticholinergic side effects </li> <li>Cardiotoxic in overdose </li> <li>May be poorly tolerated relative to SSRI and SNRI antidepressants </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The pharmacology of benzodiazepines used for treatment of adults with generalized anxiety disorder is presented in a separate table in UpToDate.</div><div class=\"graphic_footnotes\">CYP: cytochrome P450; GABA: gamma aminobutyric acid.<br />* A 50% dose reduction and gradual titration is suggested for older adults and individuals sensitive to adverse effects such as nausea, dizziness, headache, and initial insomnia/agitation due to some antidepressants.<br />&Delta; Data provided on drug metabolism are included to assess the potential for drug interactions. Only strong or moderate effects on other drugs are listed. Specific drug interactions and management suggestions may be determined by use of Lexi-Interact, the drug interactions program included with UpToDate.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>World Federation of Societies of Biological Psychiatry (WFSBP), \"Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, First Revision,\" World J Biol Psychiatry. 2008; 9(4):248-312.</li>&#xD;&#xA;    <li>Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiat Clin, 2012; 16:77.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 77409 Version 17.0</div></div></div>"},"77410":{"type":"graphic_table","displayName":"Switching between different methods of contraception","title":"Switching between different methods of contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Switching between different methods of contraception</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Pill</td> <td class=\"subtitle1\">Patch</td> <td class=\"subtitle1\">Ring</td> <td class=\"subtitle1\">Progestin shot<br /> (\"Depo\")</td> <td class=\"subtitle1\">Progestin implant</td> <td class=\"subtitle1\">Hormone IUD</td> <td class=\"subtitle1\">Copper IUD</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pill</strong></td> <td><strong>No gap:</strong> take 1st pill of new pack the day after taking any pill in old pack</td> <td>Start patch <strong>1 day before</strong> stopping pill</td> <td><strong>No gap:</strong> insert ring the day after taking any pill in pack</td> <td>First shot <strong>7 days before</strong> stopping pill</td> <td>Insert implant <strong>4 days before</strong> stopping pill</td> <td>Insert hormone IUD <strong>7 days before</strong> stopping pill</td> <td>Can insert copper IUD <strong>up to 5 days after</strong> stopping pill</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Patch</strong></td> <td>Start pill <strong>1 day before</strong> stopping patch</td> <td>&nbsp;</td> <td><strong>No gap:</strong> insert ring and remove patch on the same day</td> <td>First shot <strong>7 days before</strong> stopping patch</td> <td>Insert implant <strong>4 days before</strong> stopping patch</td> <td>Insert hormone IUD <strong>7 days before</strong> stopping patch</td> <td>Can insert copper IUD <strong>up to 5 days after</strong> stopping patch</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ring</strong></td> <td>Start pill <strong>1 day before</strong> stopping ring</td> <td>Start patch <strong>2 days before</strong> stopping ring</td> <td>&nbsp;</td> <td>First shot <strong>7 days before</strong> stopping ring</td> <td>Insert implant <strong>4 days before</strong> stopping ring</td> <td>Insert hormone IUD <strong>7 days before</strong> stopping ring</td> <td>Can insert copper IUD <strong>up to 5 days after</strong> stopping ring</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Progestin shot<br /> (\"Depo\")</strong></td> <td>Can take 1st pill <strong>up to 15 weeks after</strong> the last shot</td> <td>Can start patch <strong>up to 15 weeks after</strong> the last shot</td> <td>Can insert ring <strong>up to 15 weeks after</strong> the last shot</td> <td>&nbsp;</td> <td>Can insert implant <strong>up to 15 weeks after</strong> the last shot</td> <td>Can insert hormone IUD <strong>up to 15 weeks after</strong> the last shot</td> <td>Can insert copper IUD <strong>up to 16 weeks after</strong> the last shot</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Progestin implant</strong></td> <td>Start pill <strong>7 days before</strong> implant is removed</td> <td>Start patch <strong>7 days before</strong> implant is removed</td> <td>Start ring <strong>7 days before</strong> implant is removed</td> <td>First shot <strong>7 days before</strong> implant is removed</td> <td>&nbsp;</td> <td>Insert hormone IUD <strong>7 days before</strong> implant is removed</td> <td>Can insert copper IUD <strong>up to 5 days after</strong> implant is removed</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hormone IUD</strong></td> <td>Start pill <strong>7 days before</strong> IUD is removed</td> <td>Start patch <strong>7 days before</strong> IUD is removed</td> <td>Start ring <strong>7 days before</strong> IUD is removed</td> <td>First shot <strong>7 days before</strong> IUD is removed</td> <td>Insert implant <strong>4 days before</strong> IUD is removed</td> <td>&nbsp;</td> <td>Can insert copper IUD <strong>right after</strong> hormone IUD is removed</td> </tr> <tr> <td><strong>Copper IUD</strong></td> <td>Start pill <strong>7 days before</strong> IUD is removed</td> <td>Start patch <strong>7 days before</strong> IUD is removed</td> <td>Start ring <strong>7 days before</strong> IUD is removed</td> <td>First shot <strong>7 days before</strong> IUD is removed</td> <td>Insert implant <strong>4 days before</strong> IUD is removed</td> <td>Insert hormone IUD <strong>right after</strong> copper IUD is removed and use back-up method for <strong>7 days</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: the Reproductive Health Access Project (<a href=\"http://www.reproductiveaccess.org/\" target=\"_blank\">http://www.reproductiveaccess.org</a>). Accessed March 29th, 2011.</div><div id=\"graphicVersion\">Graphic 77410 Version 4.0</div></div></div>"},"77411":{"type":"graphic_picture","displayName":"Acropustulosis of infancy 1","title":"Acropustulosis of infancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acropustulosis of infancy</div><div class=\"cntnt\"><img style=\"width:432px; height:328px;\" src=\"images/DERM/77411_Acropustulosisofinfancy1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small pustules are present on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77411 Version 6.0</div></div></div>"},"77412":{"type":"graphic_table","displayName":"Signs of autism spectrum disorder PI","title":"Signs of autism spectrum disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Signs of autism spectrum disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">A child with autism spectrum disorder might:</td> </tr> <tr> <td class=\"indent1\">Not point at objects to show interest (point at an airplane flying over)</td> </tr> <tr> <td class=\"indent1\">Not look at objects when another person points at them</td> </tr> <tr> <td class=\"indent1\">Have trouble relating to others or not have an interest in other people at all</td> </tr> <tr> <td class=\"indent1\">Avoid eye contact and want to be alone</td> </tr> <tr> <td class=\"indent1\">Have trouble understanding other people's feelings or talking about their feelings&nbsp;</td> </tr> <tr> <td class=\"indent1\">Prefer not to be held or cuddled or might cuddle only when they want to</td> </tr> <tr> <td class=\"indent1\">Appear to be unaware when other people talk to them but respond to other sounds</td> </tr> <tr> <td class=\"indent1\">Be very interested in people, but not know how to talk, play, or relate to them</td> </tr> <tr> <td class=\"indent1\">Repeat or echo words or phrases said to them, or repeat words or phrases in place of normal language (echolalia)</td> </tr> <tr> <td class=\"indent1\">Have trouble expressing their needs using typical words or motions</td> </tr> <tr> <td class=\"indent1\">Not play \"pretend\" games (pretend to feed a doll)</td> </tr> <tr> <td class=\"indent1\">Repeat actions over and over again</td> </tr> <tr> <td class=\"indent1\">Have trouble adapting when a routine changes</td> </tr> <tr> <td class=\"indent1\">Have unusual reactions to the way things smell, taste, look, feel, or sound</td> </tr> <tr> <td class=\"indent1\">Lose skills they once had (for instance, stop saying words they were once using)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Centers for Disease Control and Prevention.&nbsp;Autism spectrum disorder (ASD). Facts about ASD.&nbsp;Available at: <A spellcheck=true href=\"http://www.cdc.gov/ncbddd/autism/facts.html\" target=_blank>www.cdc.gov/ncbddd/autism/facts.html</A>.</div><div id=\"graphicVersion\">Graphic 77412 Version 4.0</div></div></div>"},"77414":{"type":"graphic_diagnosticimage","displayName":"Upper airway size during tidal breathing","title":"Upper airway size during tidal breathing","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Upper airway size during tidal breathing</div><div class=\"cntnt\"><img style=\"width:517px; height:578px;\" src=\"images/PEDS/77414_Cxs_xsection-midtonsillar_l.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic changes in cross-sectional area at midtonsillar level (level 2) during tidal breathing of control subjects (top panels); and in subjects with obstructive sleep apnea&nbsp;(bottom panels), with 5-vol increments of inspiration (Ins) and 5-vol increments of expiration (Exp). Note the differences in anteroposterior (A-P) and lateral airway dimension.</div><div class=\"graphic_footnotes\">%: percent; Ins: inspiration; Exp: expiration.</div><div class=\"graphic_reference\">Reproduced with permission from: Arens R, Sin S, McDonough J, et al. Changes in upper airway size during tidal breathing in children with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2005; 171:1298. Official Journal of the American Thoracic Society. Copyright © 2005 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 77414 Version 3.0</div></div></div>"},"77415":{"type":"graphic_diagnosticimage","displayName":"Hilar lymph nodes CT I","title":"Hilar node involvement in lung cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hilar node involvement in lung cancer</div><div class=\"cntnt\"><img style=\"width:275px; height:245px;\" src=\"images/PULM/77415_Hilar_lymph_nodes_CT_I.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan in a patient with a right bronchogenic carcinoma and right hilar lymph node enlargement (arrow). This represents N1 disease.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77415 Version 3.0</div></div></div>"},"77416":{"type":"graphic_picture","displayName":"Mucosal telangiectasias in HHT","title":"Mucosal telangiectasias in hereditary hemorrhagic telangectasia (Osler Weber Rendu syndrome)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mucosal telangiectasias in hereditary hemorrhagic telangectasia (Osler Weber Rendu syndrome)</div><div class=\"cntnt\"><img style=\"width:360px; height:219px;\" src=\"images/PULM/77416_Mucosal_telangiectasias_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superficial telangectasias are seen on the lips of a man with hereditary hemorrhagic telangectasia syndrome who had a solitary pulmonary arteriovenous malformation.</div><div class=\"graphic_reference\">Reproduced with permission from Gossage JR, Kanj G, Am J Respir Crit Care Med 1998; 158:643</div><div id=\"graphicVersion\">Graphic 77416 Version 4.0</div></div></div>"},"77417":{"type":"graphic_diagnosticimage","displayName":"Proximal PA interrupt III","title":"Proximal interruption of the right pulmonary artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Proximal interruption of the right pulmonary artery</div><div class=\"cntnt\"><img style=\"width:360px; height:528px;\" src=\"images/PULM/77417_Proximal_PA_interrupt_III.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An internal thoracic arteriogram displays the systemic vascular supply to the right lung.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77417 Version 2.0</div></div></div>"},"77418":{"type":"graphic_table","displayName":"SBP variants","title":"Spontaneous bacterial peritonitis and its variants that do not require surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spontaneous bacterial peritonitis and its variants that do not require surgery</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">Variant</td>\n\n      <td class=\"subtitle1\">Ascitic fluid culture</td>\n\n      <td class=\"subtitle1\">Absolute PMN per mm3</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Spontaneous bacterial peritonitis</td>\n\n      <td>Positive</td>\n\n      <td>&#8805;250</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Culture-negative neutrocytic ascites</td>\n\n      <td>No growth</td>\n\n      <td>&#8805;250</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Monomicrobial non-neutrocytic bacterascites (single\norganism)</td>\n\n      <td>Positive</td>\n\n      <td>&#60;250</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Polymicrobial bacterascites</td>\n\n      <td>Positive</td>\n\n      <td>&#60;250</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77418 Version 1.0</div></div></div>"},"77419":{"type":"graphic_table","displayName":"Abx therapy pyomyositis","title":"Empiric antimicrobial therapy for pyomyositis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Empiric antimicrobial therapy for pyomyositis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\"> <p>Regimens for beta-hemolytic streptococci and staphylococci (including activity against MRSA)</p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Preferred therapy </td> </tr> <tr> <td class=\"indent1\">Vancomycin </td> <td>30 mg/kg intravenously every 24 hours in&nbsp;two equally divided doses; not to exceed 2 g/24 hours unless concentrations in serum are inappropriately low</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Alternative agents </td> </tr> <tr> <td class=\"indent1\">Daptomycin </td> <td>4 mg/kg intravenously once daily</td> </tr> <tr> <td class=\"indent1\">Linezolid </td> <td>600 mg intravenously twice daily</td> </tr> <tr> <td class=\"indent1\">Ceftraoline</td> <td>600 mg intravenously every 12 hours&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tigecycline </td> <td>100 mg intravenously once, thereafter 50 mg intravenously every 12 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.</div><div id=\"graphicVersion\">Graphic 77419 Version 5.0</div></div></div>"},"77424":{"type":"graphic_picture","displayName":"Cystocele and rectocele","title":"Cystocele and rectocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cystocele and rectocele</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/OBGYN/77424_Cystocele_and_rectocele.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77424 Version 2.0</div></div></div>"},"77425":{"type":"graphic_picture","displayName":"T2 oral tongue SCC","title":"Stage T2 oral tongue squamous cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stage T2 oral tongue squamous cell carcinoma</div><div class=\"cntnt\"><img style=\"width:396px; height:297px;\" src=\"images/ONC/77425_T2_oral_tongue_SCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Neil D Gross, MD.</div><div id=\"graphicVersion\">Graphic 77425 Version 2.0</div></div></div>"},"77426":{"type":"graphic_diagnosticimage","displayName":"Choledochocele","title":"Choledochocele","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Choledochocele</div><div class=\"cntnt\"><img style=\"width:360px; height:311px;\" src=\"images/PEDS/77426_Choledochocele.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Moises Guelrud, MD.</div><div id=\"graphicVersion\">Graphic 77426 Version 2.0</div></div></div>"},"77432":{"type":"graphic_table","displayName":"CAP diagnostic testing","title":"Clinical indications for diagnostic testing for community-acquired pneumonia*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical indications for diagnostic testing for community-acquired pneumonia*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Blood culture</td> <td class=\"subtitle1\">Sputum culture</td> <td class=\"subtitle1\"><em>Legionella</em> UAT</td> <td class=\"subtitle1\">Pneumococcal UAT</td> <td class=\"subtitle1\">Multiplex PCR<sup>&#182;</sup></td> <td class=\"subtitle1\">Other</td> </tr> <tr> <td>Intensive care unit admission</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X<sup>&#916;</sup></td> </tr> <tr> <td>Failure of outpatient antibiotic therapy</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Cavitary infiltrates</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X<sup>&#9674;</sup></td> </tr> <tr> <td>Leukopenia</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Active alcohol abuse</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Chronic severe liver disease</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Severe obstructive/structural lung disease</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Asplenia (anatomic or functional)</td> <td>X</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>X</td> <td>&nbsp;</td> </tr> <tr> <td>Recent travel (within past two weeks)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>X</td> <td>&nbsp;</td> <td>X</td> <td>X<sup>&#167;</sup></td> </tr> <tr> <td>Positive <em>Legionella</em> UAT result</td> <td>&nbsp;</td> <td>X<sup>&#165;</sup></td> <td>NA</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Positive pneumococcal UAT result</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>NA</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Pleural effusion</td> <td>X</td> <td>X</td> <td>X</td> <td>X</td> <td>&nbsp;</td> <td>X<sup>&#135;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UAT: urinary antigen test; PCR: polymerase chain reaction; NA: not applicable.<br />* During outbreaks, testing for specific pathogens (eg, Middle East respiratory syndrome coronavirus, novel influenza viruses [H7N9 influenza], <EM>Legionella</EM>, <EM>Mycoplasma pneumoniae</EM>, <EM>Chlamydophila pneumoniae</EM>) may be necessary. As an example, patients presenting with community-acquired pneumonia who have traveled to the Middle East within 14 days before onset of illness should be tested for Middle East respiratory syndrome coronavirus. In patients who have traveled to or lived in regions that are endemic for tuberculosis, testing for tuberculosis is indicated.<br />¶ A multiplex PCR assay, the FilmArray Respiratory Panel, that can detect multiple respiratory viruses, <EM>Mycoplasma pneumoniae</EM>, <EM>Chlamydophila pneumoniae</EM>, and <EM>Bordetella pertussis</EM> is available. The use of this assay may be limited by cost and/or availability.<br />Δ Endotracheal aspirate if intubated, possibly bronchoscopy or nonbronchoscopic bronchoalveolar lavage.<br /><FONT class=lozenge>◊</FONT> Fungal and tuberculosis cultures.<br />§ Refer to the UpToDate topic&nbsp;and table on the&nbsp;risk factors for CAP pathogens for details.<br />¥ Selective media for <EM>Legionella </EM>spp.<br />‡ Thoracentesis and pleural fluid cultures.</div><div class=\"graphic_reference\">Adapted with permission from: Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007; 44:S27. Copyright &copy;2007 University of Chicago.</div><div id=\"graphicVersion\">Graphic 77432 Version 5.0</div></div></div>"},"77433":{"type":"graphic_diagnosticimage","displayName":"Enchondroma hand","title":"Solitary enchondroma of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Solitary enchondroma of the hand</div><div class=\"cntnt\"><img style=\"width:363px; height:520px;\" src=\"images/PEDS/77433_Enchondroma_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postero-anterior radiograph of the hand. Observe the large geographic area of radiolucency within the mid-diaphysis of the fifth metacarpal. Significant expansion, endosteal scalloping, bone deformity, and pathologic fracture are noted (arrows). Matrix calcification is evident.</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77433 Version 2.0</div></div></div>"},"77436":{"type":"graphic_table","displayName":"Rheumatoid pleural effusion","title":"Chronic rheumatoid pleural effusion: Typical abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic rheumatoid pleural effusion: Typical abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_left\">Size</td> <td>Small to moderate; unilateral</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Appearance</td> <td>Milky-green, serous, or hemorrhagic</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Protein</td> <td>&#62;3 g/dL (&#62;30 g/L), consistent with an exudate</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Glucose</td> <td>&#60;29 mg/dL (&#60;1.6 mmol/L)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Lactic dehydrogenase (LDH)</td> <td>&#62;700 U/L, consistent with an exudate</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Cholesterol</td> <td>&#62;200 mg/dL (5.18 mmol/L), cholesterol crystals may be present under polarizing light</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">pH</td> <td>&#60;7.20</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Rheumatoid factor</td> <td>&#62;240 IU/mL (&#62;1:320)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\">Complement</td> <td>Low</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" rowspan=\"4\">Cytology</td> <td class=\"sublist1_start\">Cell number:</td> </tr> <tr> <td class=\"indent1\">&#60;5000/mm<sup>3</sup></td> </tr> <tr> <td class=\"sublist1_start\">Cell type:</td> </tr> <tr> <td class=\"indent1\">Lymphocytes (neutrophils and eosinophils acutely)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Bouros D, Pneumatikos I, Tzouvelekis A. Pleural involvement in systemic autoimmune disorders. Respiration 2008; 75:361 and Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65:Suppl 2:ii4.</div><div id=\"graphicVersion\">Graphic 77436 Version 4.0</div></div></div>"},"77437":{"type":"graphic_table","displayName":"Causes of vitamin B12 deficiency","title":"Causes of vitamin B12 deficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of vitamin B12 deficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gastric abnormalities</td> </tr> <tr> <td class=\"indent1\">Autoantibodies to intrinsic factor or gastric parietal cells (ie, pernicious anemia)</td> </tr> <tr> <td class=\"indent1\">Gastrectomy/bariatric surgery</td> </tr> <tr> <td class=\"indent1\">Gastritis</td> </tr> <tr> <td class=\"indent1\">Autoimmune metaplastic atrophic gastritis</td> </tr> <tr> <td class=\"subtitle1_single\">Small bowel disease</td> </tr> <tr> <td class=\"indent1\">Malabsorption syndrome</td> </tr> <tr> <td class=\"indent1\">Ileal resection or bypass</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease (eg, Crohn disease)</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Bacterial overgrowth</td> </tr> <tr> <td class=\"indent1\">Blind loop</td> </tr> <tr> <td class=\"indent1\">Diphyllobothrium latum (fish tapeworm)</td> </tr> <tr> <td class=\"subtitle1_single\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Pancreatic insufficiency</td> </tr> <tr> <td class=\"subtitle1_single\">Diet</td> </tr> <tr> <td class=\"indent1\">Breastfed infant of a mother with vitamin B12 deficiency</td> </tr> <tr> <td class=\"indent1\">Strict vegan diet</td> </tr> <tr> <td class=\"indent1\">Vegetarian diet in pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Agents that block or impair absorption</td> </tr> <tr> <td class=\"indent1\">Neomycin</td> </tr> <tr> <td class=\"indent1\">Biguanides (eg, metformin)</td> </tr> <tr> <td class=\"indent1\">Proton pump inhibitors (eg, omeprazole)</td> </tr> <tr> <td class=\"indent1\">Histamine 2 receptor antagonists (eg, cimetidine)</td> </tr> <tr> <td class=\"indent1\">Nitrous oxide (N<sub>2</sub>O) gas, used for anesthesia or recreationally</td> </tr> <tr> <td class=\"subtitle1_single\">Inherited transcobalamin II deficiency</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on vitamin B12 and folate deficiency for further information on evaluation and management.</div><div id=\"graphicVersion\">Graphic 77437 Version 5.0</div></div></div>"},"77438":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of tracheoesophageal fistula","title":"Ultrasound of fetus with esophageal atresia and tracheoesophageal fistula","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound of fetus with esophageal atresia and tracheoesophageal fistula</div><div class=\"cntnt\"><img style=\"width:302px; height:577px;\" src=\"images/OBGYN/77438_US_missed_atresia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Esophageal atresia with tracheoesophageal fistula at 22 weeks of gestation. The diagnosis was missed prenatally.<br />(A) Axial ultrasound demonstrates a normal-sized stomach. Amniotic fluid was high normal.<br />(B) Postnatally, esophageal atresia was discovered when the nasogastric tube (arrow) could not be advanced into the stomach. Note the large amount of air in the stomach and small bowel due to the tracheoesophageal fistula.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 77438 Version 7.0</div></div></div>"},"77440":{"type":"graphic_movie","displayName":"Nexplanon insertion","title":"Nexplanon insertion","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Nexplanon insertion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/77440_Nexplanoninsertionvideo.mp4\" style=\"width:480px;height:368px\"></div><img style=\"width:504px; height:378px;\" src=\"images/OBGYN/77440_Nexplanoninsertionimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission of MSD Oss B.V., a subsidiary of Merck &amp; Co., Inc., Whitehouse Station, New Jersey, USA. All rights reserved. NEXPLANON is a registered trademark of MSD Oss B.V. All requests to reproduce this copyrighted material should be directed to MSD Oss B.V.</div><div id=\"graphicVersion\">Graphic 77440 Version 4.0</div></div></div>"},"77441":{"type":"graphic_table","displayName":"Aortic dissection anatomy based clinical findings  ","title":"Presentations of aortic dissection based on affected structures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presentations of aortic dissection based on affected structures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Artery or structure involved</td> </tr> <tr> <td>Aortic insufficiency or heart failure</td> <td>Aortic valve</td> </tr> <tr> <td>Myocardial infarction</td> <td>Coronary artery (often right)</td> </tr> <tr> <td>Cardiac tamponade</td> <td>Pericardium</td> </tr> <tr> <td>Hemothorax</td> <td>Thorax</td> </tr> <tr> <td>Horner syndrome (ptosis, miosis, anhidrosis)</td> <td>Superior cervical sympathetic ganglion</td> </tr> <tr> <td>Stroke or syncope</td> <td>Brachiocephalic, common carotid, or left subclavian arteries</td> </tr> <tr> <td>Upper extremity pulselessness, hypotension pain</td> <td>Subclavian artery</td> </tr> <tr> <td>Paraplegia</td> <td>Intercostal arteries (give off spinal and vertebral arteries)</td> </tr> <tr> <td>Back or flank pain; renal failure</td> <td>Renal artery</td> </tr> <tr> <td>Abdominal pain; mesenteric ischemia</td> <td>Celiac or mesenteric arteries</td> </tr> <tr> <td>Lower extremity pain, pulselessness, weakness</td> <td>Common iliac artery</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77441 Version 4.0</div></div></div>"},"77442":{"type":"graphic_picture","displayName":"Sweat bee","title":"Sweat bee","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sweat bee</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ALLRG/77442_Sweat_bee.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 77442 Version 1.0</div></div></div>"},"77443":{"type":"graphic_figure","displayName":"Developing vesicouterine fold","title":"Developing the vesicouterine fold during hysterectomy","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Developing the vesicouterine fold during hysterectomy</div><div class=\"cntnt\"><img style=\"width:503px; height:428px;\" src=\"images/OBGYN/77443_Developing_vesicouterine_fo.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77443 Version 2.0</div></div></div>"},"77445":{"type":"graphic_figure","displayName":"Decision tree for thrombolysis","title":"Decision tree for thrombolysis in the elderly (example data for decision analysis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Decision tree for thrombolysis in the elderly (example data for decision analysis)</div><div class=\"cntnt\"><img style=\"width:381px; height:401px;\" src=\"images/PC/77445_Decision_tree_for_thromboly.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MI: myocardial infarction.</div><div class=\"graphic_reference\">Created with data from: Krumholz HM, Pasternak RC, Weinstein MC, et al, N Engl J Med 1992; 327:7.</div><div id=\"graphicVersion\">Graphic 77445 Version 3.0</div></div></div>"},"77446":{"type":"graphic_diagnosticimage","displayName":"2D TTE parasternal long axis","title":"Two-dimensional transthoracic echocardiogram (2D TTE) parasternal long axis view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) parasternal long axis view</div><div class=\"cntnt\"><img style=\"width:394px; height:278px;\" src=\"images/CARD/77446_Long_axis_view_normal_LV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This parasternal long axis echocardiogram was obtained in systole; the aortic valve is open and the mitral is closed.</div><div class=\"graphic_footnotes\">RV: right ventricle; IL: inferolateral left ventricular wall; IVS: interventricular septum; NCC: noncoronary cusp of the aortic valve; RCC: right coronary cusp of the aortic valve; aML: anterior mitral valve leaflet; pML: posterior mitral valve leaftlet; dAo: descending aorta.</div><div id=\"graphicVersion\">Graphic 77446 Version 4.0</div></div></div>"},"77449":{"type":"graphic_figure","displayName":"Clinical manifestations of sarcoidosis in different groups","title":"Clinical manifestations of sarcoidosis in different groups","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Clinical manifestations of sarcoidosis in different groups</div><div class=\"cntnt\"><img style=\"width:458px; height:333px;\" src=\"images/PULM/77449_Sx_sarcoid_in_diff_ed.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of proportion of organ involvement in which there was a significant difference between groups on the basis of race, sex, or age.</div><div class=\"graphic_footnotes\">* Other than erythema nodosum.</div><div class=\"graphic_reference\">Reproduced with permission from: Baughman, RP, Teirstein, AS, Judson, MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885. Official Journal of the American Thoracic Society. Copyright &#169; 2001 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 77449 Version 4.0</div></div></div>"},"77450":{"type":"graphic_picture","displayName":"Suction irrigator","title":"Suction irrigator for laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suction irrigator for laparoscopy</div><div class=\"cntnt\"><img style=\"width:374px; height:273px;\" src=\"images/OBGYN/77450_Suction_irrigator.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This combination suction and irrigating device is used for laparoscopic surgery.</div><div id=\"graphicVersion\">Graphic 77450 Version 2.0</div></div></div>"},"77451":{"type":"graphic_figure","displayName":"Formation of porphobilinogen","title":"Enzymatic formation of porphobilinogen","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Enzymatic formation of porphobilinogen</div><div class=\"cntnt\"><img style=\"width:501px; height:253px;\" src=\"images/HEME/77451_Formation_of_porphobilinoge.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This schematic diagram shows the enzymatic formation of one molecule of the monopyrrole porphobilinogen (PBG, in black) from two molecules of 5-aminolevulinic acid (ALA, in blue), under the catalytic direction of the enzyme ALA dehydratase (ALAD). Bond lengths are not to scale.</div><div class=\"graphic_footnotes\">Ac: acetyl; Pr: propionyl.</div><div id=\"graphicVersion\">Graphic 77451 Version 2.0</div></div></div>"},"77452":{"type":"graphic_picture","displayName":"Popliteal angle","title":"Popliteal angle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Popliteal angle</div><div class=\"cntnt\"><img style=\"width:415px; height:259px;\" src=\"images/EM/77452_Popliteal_angle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The popliteal angle is a measure of hamstring flexibility. With the patient relaxed and supine, flex the&nbsp;hip to 90 degrees, then gently extend the knee by raising the lower leg until you appreciate resistance. The angle of the leg at this point is the popliteal angle.</div><div id=\"graphicVersion\">Graphic 77452 Version 3.0</div></div></div>"},"77453":{"type":"graphic_picture","displayName":"Toddler with CHH","title":"Toddler with cartilage-hair hypoplasia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toddler with cartilage-hair hypoplasia</div><div class=\"cntnt\"><img style=\"width:335px; height:452px;\" src=\"images/ALLRG/77453_ToddlerwithCHH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) An 18-month-old child with McKusick-type metaphyseal chondrodysplasia. Notice the characteristic light, sparse hair, disproportionate short stature, pectus excavatum, and varus deformities of the lower extremities. B) Mildly increased lumbar lordosis, flexion contractures of the elbows, and expansion of the wrists are also part of the deformity.</div><div class=\"graphic_reference\">Reproduced with permission from: Sponseller PD, Ain MC. The Skeletal Dysplasias. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77453 Version 13.0</div></div></div>"},"77457":{"type":"graphic_picture","displayName":"Infantile atopic dermatitis widespread","title":"Atopic dermatitis: Infantile","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis: Infantile</div><div class=\"cntnt\"><img style=\"width:327px; height:419px;\" src=\"images/ALLRG/77457_Atopicdermatitisinfantile.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent erythema, microvesiculation, scaling, and crusting on the face, with similar involvement (to a lesser degree) on the trunk and arms.</div><div class=\"graphic_reference\">Reproduced with permission from: Fitzpatrick TB, Johnson RA, Wolff K, et al (Eds). Color Atlas and Synopsis of Clinical Dermatology, 3rd ed, McGraw-Hill, New York, 1997. Copyright © McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 77457 Version 6.0</div></div></div>"},"77460":{"type":"graphic_table","displayName":"Antibiotics for treatment of tularemia","title":"Antibiotics for treatment of tularemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antibiotics for treatment of tularemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><strong></strong>Drug</td> <td class=\"subtitle1\">Adult dosing</td> <td class=\"subtitle1\">Pediatric dosing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Moderate to severe illness</td> </tr> <tr> <td class=\"indent1\">Streptomycin</td> <td>10 mg/kg intramuscularly every 12 hours for 7 to 10 days.* The daily dose should not exceed 2 g.</td> <td>30-40&nbsp;mg/kg per day intramuscularly, in divided doses&nbsp;every 12 hours for 7 to 10 days. The daily dose should not exceed 2 g.</td> </tr> <tr> <td class=\"indent1\">Gentamicin</td> <td>5 mg/kg intramuscularly or intravenously daily&#182;, divided every 8 hours for 7 to 10 days.</td> <td> <p>5 mg/kg intramuscularly or intravenously daily, divided every 8 or 12 hours for 7 to 10 days.</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Chloramphenicol<sup>&#916;</sup></p> <p>(for use in the setting of meningitis, in combination with an aminoglycoside)</p> </td> <td>15 to 25 mg/kg intravenously four times daily for 14 to 21 days. The daily dose should not exceed 4 g.</td> <td>15 mg/kg intravenously four times daily for 14 to 21 days. The daily dose should not exceed 4 g.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Mild illness</td> </tr> <tr> <td class=\"indent1\">Doxycycline</td> <td>100 mg orally twice daily for 14 days.</td> <td> <p>Doxycycline should be administered to children &#60;8 years of age only if the benefits outweigh the risks.</p> <p>2 to 4 mg/kg per day orally divided in one or two doses for 14 days. The daily dose should not exceed 200 mg.</p> </td> </tr> <tr> <td class=\"indent1\">Ciprofloxacin</td> <td>500 to 750 mg orally twice daily for 14 days.</td> <td>The fluoroquinolones have not been&nbsp;recommended in the United States because of limited experience&nbsp;in children &#60;18 years of age.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Streptomycin is the drug of choice for adults; gentamicin is the drug of choice for children. Dosing for streptomycin and gentamicin must be adjusted according to serum concentrations for individuals with renal insufficiency, individuals over age 50, and for pediatric patients. Target serum streptomycin concentrations for IM administration are trough &lt;10 mcg/mL and peak up to 20 to 25 mcg/mL. Streptomycin is more ototoxic than other aminoglycosides and audiometric testing is warranted for situations in which serum concentration monitoring is warranted. For obese patients dosing should be determined based on adjusted weight (See \"Calculator: Ideal Body Weight (method of Devine) and Dosing Weight\"). For select patients with mild illness, oral antibiotic regimens&nbsp;can be used.&nbsp;</div><div class=\"graphic_footnotes\">*For patients who are very ill, streptomycin 15 mg/kg every 12 hours may be administered.<br />¶&nbsp;For adults with normal renal function, once-daily dosing of&nbsp;gentamicin is also acceptable.<br />Δ&nbsp;Intravenous chloramphenicol may not be available in a timely fashion. </div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Dennis, DT, Inglesby, TV, Henderson, DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001; 285:2763.</LI>&#xD;&#xA;<LI>American Academy of Pediatrics.&nbsp;Tularemia In: Red Book: 2015 Report of the Committee on Infectious Diseases, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.839.</LI></OL></div><div id=\"graphicVersion\">Graphic 77460 Version 11.0</div></div></div>"},"77462":{"type":"graphic_picture","displayName":"Pemphigus vulgaris oral lesions","title":"Pemphigus vulgaris","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus vulgaris</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/77462_Pemph_vulgaris_oral_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions on the tongue and lips are present in this patient with pemphigus vulgaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77462 Version 4.0</div></div></div>"},"77463":{"type":"graphic_picture","displayName":"DLBCL Ki-67 staining","title":"Diffuse large B-cell lymphoma Ki-67 staining","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Diffuse large B-cell lymphoma Ki-67 staining</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/HEME/77463_DLBCLKi67staining.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse large B-cell lymphoma with a majority of cells staining for the Ki-67 proliferative index, indicative of rapid growth. Ki67/peroxidase stain.</div><div class=\"graphic_reference\">Reproduced with permission from: Ioachim HL, Medeiros LJ. Diffuse large B-cell lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77463 Version 6.0</div></div></div>"},"77464":{"type":"graphic_table","displayName":"Causes of metabolic acidosis","title":"Major causes of metabolic acidosis according to mechanism and anion gap","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of metabolic acidosis according to mechanism and anion gap</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mechanism of acidosis</td> <td class=\"subtitle1\">Increased AG</td> <td class=\"subtitle1\">Normal AG</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"14\">Increased acid production</td> <td>Lactic acidosis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Ketoacidosis</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Diabetes mellitus</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Starvation</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Alcohol associated</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Ingestions</td> <td class=\"sublist_other_start\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Methanol</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Ethylene glycol</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Aspirin</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Toluene (if early or if kidney function is impaired)</td> <td class=\"sublist_other\">Toluene ingestion (if late and if renal function is preserved; due to excretion of sodium and potassium hippurate in the urine)</td> </tr> <tr> <td class=\"sublist1\">Diethylene glycol</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Propylene glycol</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td>D-lactic acidosis</td> <td><span class=\"sublist1\">A component of non-AG metabolic acidosis may coexist due to urinary excretion of D-lactate as Na and K salts (which represents potential HCO<sub>3</sub>)</span></td> </tr> <tr class=\"divider_bottom\"> <td>Pyroglutamic acid (5-oxoproline)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Loss of bicarbonate or bicarbonate precursors</td> <td class=\"divider_bottom\" rowspan=\"5\">&nbsp;</td> <td>Diarrhea or other intestinal losses (eg, tube drainage)</td> </tr> <tr> <td>Type 2 (proximal) RTA</td> </tr> <tr> <td>Posttreatment of ketoacidosis</td> </tr> <tr> <td>Carbonic anhydrase inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td>Ureteral diversion (eg, ileal loop)</td> </tr> <tr> <td rowspan=\"3\">Decreased renal acid excretion</td> <td rowspan=\"3\">Chronic kidney disease</td> <td>Chronic kidney disease and tubular dysfunction (but relatively preserved glomerular filtration rate)</td> </tr> <tr> <td>Type 1 (distal) RTA</td> </tr> <tr> <td>Type 4 RTA (hypoaldosteronism)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AG: anion gap; RTA: renal tubular acidosis.</div><div id=\"graphicVersion\">Graphic 77464 Version 12.0</div></div></div>"},"77465":{"type":"graphic_figure","displayName":"Th1 and Th2 cells","title":"Schematic representation showing cytokines released by Th1 and Th2 cells","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Schematic representation showing cytokines released by Th1 and Th2 cells</div><div class=\"cntnt\"><img style=\"width:544px; height:339px;\" src=\"images/NEPH/77465_Th1_Th2_in_transplantation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Advanced T cells secrete an extraordinary array of cytokines with a bewildering number of functions. Such cytokines have been divided into two general groups according to their general mode of action, Th1 and Th2. In general, allograft rejection is mediated by T cells that produce Th1 cytokines. In contrast, transplantation tolerance has been associated with T cells that produce Th2 cytokines; however, the casual link between such cytokine production and the induction and maintenance of the tolerant state remains controversial.</div><div class=\"graphic_footnotes\">Th1: T helper cell type 1; Th2: T helper cell type 2; IL: interleukin; IFN-gamma: interferon-gamma; TNF-beta: tumor necrosis factor-beta; IgE: immunoglobulin E; IgG: immunoglobulin G.</div><div id=\"graphicVersion\">Graphic 77465 Version 3.0</div></div></div>"},"77466":{"type":"graphic_picture","displayName":"Nonpupil-sparing 3rd nerve palsy","title":"Nonpupil-sparing third nerve palsy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nonpupil-sparing third nerve palsy</div><div class=\"cntnt\"><img style=\"width:432px; height:207px;\" src=\"images/NEURO/77466_Nonpupil-sparing_3rd_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right mydriasis in a patient with a right third nerve palsy secondary to a posterior communicating aneurysm. The patient also had a mild ptosis and complained of diplopia with reduced adduction, elevation, and depression of the right eye. Abduction and intorsion were normal in the right eye.</div><div id=\"graphicVersion\">Graphic 77466 Version 1.0</div></div></div>"},"77467":{"type":"graphic_picture","displayName":"Gomco clamp with safety pin","title":"Safety pin on foreskin and Gomco clamp in position prior to excision","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Safety pin on foreskin and Gomco clamp in position prior to excision</div><div class=\"cntnt\"><img style=\"width:468px; height:305px;\" src=\"images/OBGYN/77467_Gomco_clamp_with_safety_pin.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of David G Weismiller, MD.</div><div id=\"graphicVersion\">Graphic 77467 Version 1.0</div></div></div>"},"77468":{"type":"graphic_figure","displayName":"Torsion of spermatic cord","title":"Torsion of spermatic cord","html":"<div class=\"graphic\"><div style=\"width: 519px\" class=\"figure\"><div class=\"ttl\">Torsion of spermatic cord</div><div class=\"cntnt\"><img style=\"width:499px; height:319px;\" src=\"images/PEDS/77468_Torsion_of_spermatic_cord.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abnormality of testicular fixation permits torsion of spermatic vessels with subsequent infarction of the gonad.</div><div id=\"graphicVersion\">Graphic 77468 Version 2.0</div></div></div>"},"77469":{"type":"graphic_table","displayName":"Lower extremity vein list","title":"Lower extremity (CEAP) vein list","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lower extremity (CEAP) vein list</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Superficial veins</td> <td class=\"subtitle1\">Deep veins</td> <td class=\"subtitle1\">Perforator veins</td> </tr> <tr> <td> <p>Telangiectasias or reticular veins</p> <p>Great saphenous vein above the knee</p> <p>Great saphenous vein below the knee</p> <p>Small saphenous vein</p> <p>Nonsaphenous veins</p> </td> <td> <p>Inferior vena cava</p> <p>Common iliac vein</p> <p>Internal iliac vein</p> <p>External iliac vein</p> <p>Pelvic: gonadal, broad ligament veins, other</p> <p>Common femoral vein</p> <p>Deep femoral vein</p> <p>Femoral vein*</p> <p>Popliteal vein</p> <p>Crural: anterior tibial, posterior tibial, peroneal veins (all paired)</p> <p>Muscular: gastrocnemial, soleal veins, other</p> </td> <td> <p>Thigh</p> <p>Calf</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CEAP: Clinical-Etiology-Anatomy-Pathophysiology classification of lower extremity chronic venous disorders.<br />* Formerly referred to as the superficial femoral vein, a misnomer since it is a deep vein.</div><div id=\"graphicVersion\">Graphic 77469 Version 4.0</div></div></div>"},"77473":{"type":"graphic_figure","displayName":"Sciatic nerve anatomy","title":"Sciatic nerve anatomy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Sciatic nerve anatomy</div><div class=\"cntnt\"><img style=\"width:540px; height:720px;\" src=\"images/SURG/77473_Sciatic_nerve_anatomy_edt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77473 Version 3.0</div></div></div>"},"77474":{"type":"graphic_figure","displayName":"US meningococcal disease incidence","title":"Meningococcal disease incidence*, by year - United States, 1984 to 2014","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Meningococcal disease incidence*, by year - United States, 1984 to 2014</div><div class=\"cntnt\"><img style=\"width:730px; height:488px;\" src=\"images/ID/77474_US_mening_disease_incd_2014.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In 2014, meningococcal disease incidence remained at a historic low in the United States. However, <EM>Neisseria meningitidis</EM> remains an important cause of bacterial meningitis and sepsis in the United States.</div><div class=\"graphic_footnotes\">* Per 100,000 population.</div><div class=\"graphic_reference\">Reproduced from: Adams DA, Thomas KR, Jajosky RA, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2014. MMWR Morb Mortal Wkly Rep 2016; 63:1.</div><div id=\"graphicVersion\">Graphic 77474 Version 5.0</div></div></div>"},"77476":{"type":"graphic_picture","displayName":"Balantidium microscopy","title":"<EM>Balantidium</EM> microscopy","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\"><EM>Balantidium</EM> microscopy</div><div class=\"cntnt\"><img style=\"width:514px; height:257px;\" src=\"images/ID/77476_Balantidium_microsc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) <em>B. coli</em> trophozoite in a Mann's hematoxylin-stained smear, 500x magnification. Note the cytosome (black arrow) and the bean-shaped macronucleus.<br> (B) <em>B. coli</em> trophozoite in a wet mount, 1000x magnification. Note the visible cilia on the cell surface.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Balantidiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/balantidiasis/index.html\">http://www.cdc.gov/dpdx/balantidiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 77476 Version 3.0</div></div></div>"},"77477":{"type":"graphic_picture","displayName":"Endosc gastric carcinoids","title":"Gastric carcinoids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gastric carcinoids</div><div class=\"cntnt\"><img style=\"width:432px; height:370px;\" src=\"images/GAST/77477_Endosc_gastric_carcinoids.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastric carcinoids in the proximal gastric body.</div><div class=\"graphic_reference\">Courtesy of Akira Horiuchi, MD.</div><div id=\"graphicVersion\">Graphic 77477 Version 1.0</div></div></div>"},"77478":{"type":"graphic_table","displayName":"Lifestyle changes in CVS","title":"Lifestyle changes in CVS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lifestyle changes in CVS</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n            <tbody>\r\n                <tr>\r\n                    <td class=\"subtitle1_single\">Lifestyle changes (for one to two months or one to two cycles)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\"><strong>Reassurance</strong> (eg, episodes are not self-induced) and anticipatory guidance (eg, natural history)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\"><strong>Avoidance of triggers</strong></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Keep a \"vomiting diary\" of potential precipitating factors</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Avoid fasting</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Recognize the potential role of excitement as a trigger (eg, downplay big events)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Maintain good sleep hygiene (eg, avoid sleep deprivation)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Avoid triggering foods: chocolate, cheese, monosodium glutamate, antigenic foods</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Avoid excessive energy output</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\"><strong>Supplemental carbohydrate: for fasting-induced episodes</strong></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Provide fruit juices, other sugar-containing drinks</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Provide extra snacks between meals, before exertion, or at bedtime</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"sublist1_start\"><strong>Migraine headache lifestyle interventions</strong></td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Regular aerobic exercise (avoid overexercising)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Regular meal schedules (ie, avoid skipping meals)</td>\r\n                </tr>\r\n                <tr>\r\n                    <td class=\"indent1\">Moderation in consuming or avoidance of caffeine</td>\r\n                </tr>\r\n            </tbody>\r\n        </table>\r\n        <!--[if gte mso 9]><xml>\r\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">6</mso:Specialty>\r\n<mso:Media_Notes msdt:dt=\"string\">10/2/2008--Requested permission (JD). 10/2/2008--Permission granted; figures to Terrence (JD). 9/11/2009--Permission granted via Rightslink (JD).</mso:Media_Notes>\r\n<mso:Edit_Table msdt:dt=\"string\">&#60;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=19541&#38;amp;Mode=Edit&quot;&#62;&#60;/a&#62;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\r\n</xml><![endif]--></div><div class=\"graphic_reference\">Reproduced with permission from: Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition consensus statement on the diagnosis and management of cyclic vomiting syndrome. J Pediatr Gastroenterol Nutr 2008; 47:379. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77478 Version 10.0</div></div></div>"},"77479":{"type":"graphic_algorithm","displayName":"Diagnosis of polyneuropathy","title":"Diagnostic approach to polyneuropathy","html":"<div class=\"graphic\"><div style=\"width: 877px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to polyneuropathy</div><div class=\"cntnt\"><img style=\"width:857px; height:652px;\" src=\"images/NEURO/77479_DXpolyneuropathyed1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive diagnostic testing is probably not necessary in a patient with mild symptoms who has a known underlying cause of neuropathy (eg, diabetes mellitus, alcohol abuse, or chemotherapy). However, a diagnostic evaluation is warranted in patients with no clear etiology or in whom symptoms are severe or rapidly progressive. In addition, a full diagnostic evaluation should be pursued in patients with atypical features, including asymmetry, non-length dependence, motor predominance, acute onset, or prominent autonomic involvement.</div><div class=\"graphic_footnotes\">EMG: electromyography; ESR: erythrocyte sedimentation rate; SPEP: serum protein electrophoresis; TSH: thyroid stimulating hormone; ANA: antinuclear antibodies; UPEP: urine protein electrophoresis; HIV: human immunodeficiency virus; CIDP: chronic inflammatory demyelinating polyneuropathy; IVIG: intravenous immune globulin.<br />* Including sympathetic skin response, tilt table, R-R interval testing, valsalva maneuver.<br />¶ In patients with borderline normal serum B12.</div><div id=\"graphicVersion\">Graphic 77479 Version 8.0</div></div></div>"},"77480":{"type":"graphic_figure","displayName":"3D airway anatomy MRI","title":"Volumetric reconstruction of axial MR images in a normal subject and patient with sleep apnea","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Volumetric reconstruction of axial MR images in a normal subject and patient with sleep apnea</div><div class=\"cntnt\"><img style=\"width:458px; height:357px;\" src=\"images/PULM/77480_3D_airway_anatomy_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The mandible is depicted in white, the tongue in red, the soft palate in blue, the lateral parapharyngeal fat pads in yellow, and the lateral/posterior pharyngeal walls in green. The airway is depicted in gray/white. The normal subject has a larger airway than the patient with sleep apnea. The tongue, soft palate, parapharyngeal fat pads, and lateral pharyngeal walls of the patient with sleep apnea are all larger than in the normal subject.</div><div class=\"graphic_reference\">Courtesy of Richard J Schwab, MD.</div><div id=\"graphicVersion\">Graphic 77480 Version 2.0</div></div></div>"},"77483":{"type":"graphic_picture","displayName":"Conjunctivitis and uveitis","title":"Conjunctivitis and anterior uveitis in reactive arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conjunctivitis and anterior uveitis in reactive arthritis</div><div class=\"cntnt\"><img style=\"width:432px; height:432px;\" src=\"images/RHEUM/77483_Conjunctivitis_and_uveitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Conjunctival injection and anterior uveitis (iritis) with hypopyon are noted in the photograph of the eye of a patient with reactive arthritis (formerly Reiter's Syndrome).</div><div class=\"graphic_reference\">Courtesy of Filip de Keyser.</div><div id=\"graphicVersion\">Graphic 77483 Version 2.0</div></div></div>"},"77485":{"type":"graphic_table","displayName":"PNS manifestations Lyme","title":"Peripheral nervous system manifestations of neuroborreliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Peripheral nervous system manifestations of neuroborreliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Manifestation</td> </tr> <tr> <td rowspan=\"6\">Mononeuropathy multiplex</td> <td>Cranial neuritis</td> </tr> <tr> <td>Radiculoneuritis</td> </tr> <tr> <td>Mononeuropathy</td> </tr> <tr> <td>Mononeuropathy multiplex</td> </tr> <tr> <td>Plexopathy (brachial, lumbosacral)</td> </tr> <tr> <td>Confluent mononeuropathy multiplex, simulating diffuse polyneuropathy</td> </tr> <tr> <td>Demyelinating</td> <td>Rarely reported, questionable causality</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77485 Version 2.0</div></div></div>"},"77488":{"type":"graphic_diagnosticimage","displayName":"MRI osteophyte L3","title":"Lumbar spine MRI showing an osteophyte abutting the exiting L3 nerve root","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Lumbar spine MRI showing an osteophyte abutting the exiting L3 nerve root</div><div class=\"cntnt\"><img style=\"width:504px; height:319px;\" src=\"images/NEURO/77488_Osteophyte_L3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal T1-weighted MRI of the lumbar spine shows facet hypertrophic changes with osteophytes (arrow) abutting the exiting L3 nerve root (arrowhead) in the right L3-4 neural foramen. Note the lack of facet hypertrophic changes at the level below, L4-5, where the exiting nerve root is surrounded by hyperintense fat.<br />(B) Axial T2-weighted images show the facet osteophytes (arrow) encroaching on the posterior aspect of the neural foramen, adjacent to the exiting L3 nerve root (arrowhead).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Eric D. Schwartz, MD.</div><div id=\"graphicVersion\">Graphic 77488 Version 4.0</div></div></div>"},"77489":{"type":"graphic_figure","displayName":"VF congr incompl HH","title":"Visual fields: Congruous incomplete homonymous hemianopia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Visual fields: Congruous incomplete homonymous hemianopia</div><div class=\"cntnt\"><img style=\"width:504px; height:400px;\" src=\"images/NEURO/77489_VF_congr_incompl_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humphrey visual field (24-2) showing a right congruous incomplete homonymous hemianopia.</div><div id=\"graphicVersion\">Graphic 77489 Version 1.0</div></div></div>"},"77492":{"type":"graphic_diagnosticimage","displayName":"CT scan SMA syndrome","title":"CT scan of the abdomen in a patient with SMA Syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan of the abdomen in a patient with SMA Syndrome</div><div class=\"cntnt\"><img style=\"width:218px; height:148px;\" src=\"images/GAST/77492_CT_scan_SMA_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a distended, contrast-filled stomach (closed arrowhead) and a dilated, contrast-filled proximal duodenum (open arrowhead). The duodenum can be seen narrowing as it approaches the aorta where it is compressed between the aorta and the SMA.</div><div class=\"graphic_footnotes\">CT: computed tomography; SMA: superior mesenteric artery.</div><div class=\"graphic_reference\">Reprinted from Ross J Bellavia, MD and Sheila Berlin, MD from Rainbow Babies and Children's Hospital in Cleveland, OH (uhrad.com). Reprinted with permission from Sheila Berlin, MD.</div><div id=\"graphicVersion\">Graphic 77492 Version 3.0</div></div></div>"},"77494":{"type":"graphic_picture","displayName":"Apert syndrome dental features","title":"Dental features of Apert syndrome","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Dental features of Apert syndrome</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/PEDS/77494_Apert_syndr_dental_feat_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In patients with Apert syndrome, the maxillary dental arch is V shaped, and a class 3 malocclusion (prognathism, or underbite) with an associated open bite is nearly universal.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77494 Version 7.0</div></div></div>"},"77495":{"type":"graphic_picture","displayName":"Posterior lenticonus","title":"Posterior lenticonus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Posterior lenticonus</div><div class=\"cntnt\"><img style=\"width:396px; height:272px;\" src=\"images/PEDS/77495_Posterior_lenticonus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior lenticonus. There is a larger than typical, relatively clear protrusion.</div><div class=\"graphic_reference\">Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77495 Version 2.0</div></div></div>"},"77496":{"type":"graphic_picture","displayName":"Chigger bites C","title":"Chigger bites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chigger bites</div><div class=\"cntnt\"><img style=\"width:432px; height:453px;\" src=\"images/DERM/77496_Chigger_bites_C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin lesions on a patient who sustained over 1000 chigger bites. Note the erythematous papules clustered along the waistline, a common location for chigger bites.</div><div class=\"graphic_reference\">Courtesy of JF Butler, Professor Emeritus, University of Florida.</div><div id=\"graphicVersion\">Graphic 77496 Version 2.0</div></div></div>"},"77497":{"type":"graphic_table","displayName":"Differential diagnosis of tremor","title":"Differential diagnosis of tremor","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of tremor</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Tremor</td> <td class=\"subtitle1\">Description</td> </tr> <tr> <td>Essential tremor</td> <td>Bilateral postural or kinetic tremor of the hands and forearms (&#8805;4 Hz; usually&nbsp;6 to&nbsp;12 Hz) or isolated head tremor without evidence of dystonia. Absence of other neurologic signs or recent trauma preceding the onset of tremor.</td> </tr> <tr> <td>Physiologic tremor</td> <td>Enhanced physiologic tremor. High frequency (10 to 12 Hz), presence of known cause (eg, medications, hyperthyroidism, hypoglycemia).</td> </tr> <tr> <td>Parkinson disease</td> <td>Mixture of rest and action tremors; occasionally action tremor alone. Leg or foot tremor more common than with essential tremor, usually does not produce head tremor. Frequency 4 to 6 Hz.</td> </tr> <tr> <td>Orthostatic tremor</td> <td>Postural tremor in the torso and lower limbs while standing; may also occur in the upper limbs. Suppressed by walking. Tremor is high frequency (14 to&nbsp;20 Hz) and synchronous among ipsilateral and contralateral muscles.</td> </tr> <tr> <td>Cerebellar tremor</td> <td>Postural, intention, or action tremor. Relatively low frequency (3 to 4 Hz). Associated with ataxia and dysmetria.</td> </tr> <tr> <td>Neuropathic tremor</td> <td>Variable tremor type and frequency, usually postural and kinetic tremor in the involved extremities. Other signs of peripheral neuropathy present.</td> </tr> <tr> <td>Rubral or midbrain tremor</td> <td>Mixture of rest, postural, and intention tremor with frequency of 2 to 5 Hz. Always associated with signs of brainstem or cerebellar damage.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Elble RJ. Diagnostic criteria for essential tremor and differential diagnosis. Neurology 2000; 54(11 Suppl 4):S2.</LI>&#xD;&#xA;<LI>Louis ED. Essential tremors: a family of neurodegenerative disorders? Arch Neurol 2009; 66:1202.</LI>&#xD;&#xA;<LI>Hassan A, Ahlskog JE, Matsumoto JY, et al. Orthostatic tremor: Clinical, electrophysiologic, and treatment findings in 184 patients. Neurology 2016; 86:458.</LI></OL></div><div id=\"graphicVersion\">Graphic 77497 Version 5.0</div></div></div>"},"77498":{"type":"graphic_table","displayName":"Dosing, side effects, drug interactions of lipid-lowering drugs","title":"Adult dosing, side effects, and drug interactions of lipid-lowering drugs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adult dosing, side effects, and drug interactions of lipid-lowering drugs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug class</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Major side effects and drug interactions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Statins</td> </tr> <tr> <td class=\"indent1\">Atorvastatin</td> <td>10 to 80 mg/day</td> <td>&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"9\">Headache; nausea; sleep disturbance; elevations in hepatocellular enzymes and alkaline phosphatase. Myositis and rhabdomyolysis, primarily when given with gemfibrozil or cyclosporine; myositis is also seen with severe renal insufficiency (CrCl &#60;30 mL/min). Lovastatin, atorvastatin, rosuvastatin, and simvastatin potentiate effect of warfarin; this interaction is not seen with pravastatin, fluvastatin, or pitavastatin. Most statins can also affect digoxin metabolism and levels.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Fluvastatin</td> <td>IR: 20 to 80 mg/day</td> <td>IR take in the evening. Divide dose twice per day (morning and evening) if dose &#62;40 mg/day.</td> </tr> <tr> <td>XR: 80 mg/day</td> <td>XR take any time</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Lovastatin</td> <td>IR: 20 to 80 mg/day</td> <td>IR take with evening meal. Divide dose twice per day with meals if dose &#62;20 mg/day.</td> </tr> <tr> <td>XR: 20 to 60 mg/day</td> <td>XR take any time</td> </tr> <tr> <td class=\"indent1\">Pitavastatin</td> <td>1 to 4 mg/day</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pravastatin</td> <td>10 to 80 mg/day</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Rosuvastatin</td> <td>5 to 40 mg/day</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Simvastatin</td> <td>5 to 40 mg/day</td> <td>Take in the evening</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">PCSK9 inhibitors</td> </tr> <tr> <td class=\"indent1\">Alirocumab</td> <td>75 to 150 mg every two weeks</td> <td class=\"divider_bottom\" rowspan=\"2\">Subcutaneous injections</td> <td class=\"divider_bottom\" rowspan=\"2\">Injection site reactions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Evolocumab</td> <td> <p>140 mg every two weeks or 420 mg every month</p> Homozygous familial hypercholesterolemia: 420 mg every month to 420 mg every two weeks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Fibric acid derivatives</td> </tr> <tr> <td class=\"indent1\">Fenofibrate</td> <td> <p>Nanocrystal 145 mg/day</p> Micronized 160 to 200 mg/day</td> <td>Micronized taken with meals. Use lower doses with renal insufficiency.</td> <td>Skin rash, gastrointestinal (nausea, bloating, cramping) myalgia; lowers blood cyclosporine levels; potentially nephrotoxic in cyclosporine treated patients. Avoid in patients with CrCl &#60;30 mL/min.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gemfibrozil</td> <td>600 mg twice per day</td> <td>30 to 60 minutes before meals</td> <td>Potentiates warfarin action. Absorption of gemfibrozil diminished by bile acid sequestrants.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Nicotinic acid (niacin)</strong></td> <td>IR: 1 to 6 g/day</td> <td>IR: Taken with meals. Start with 100 mg twice per day and titrate to 500 mg three times per day. After six weeks, check lipids, glucose, liver function, and uric acid. Increase dose as needed.</td> <td class=\"divider_bottom\" rowspan=\"2\">Prostaglandin-mediated cutaneous flushing, headache, warm sensation, and pruritus; hyperpigmentation (particularly in intertriginous regions); acanthosis nigricans; dry skin; nausea; vomiting; diarrhea; and myositis</td> </tr> <tr class=\"divider_bottom\"> <td>XR (Niaspan): 0.5 to 2 g/day</td> <td>XR: Taken at bedtime; adjust dose every four weeks as needed.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Bile acid sequestrants</td> </tr> <tr> <td class=\"indent1\">Cholestyramine</td> <td>4 to 24 g/day</td> <td rowspan=\"2\">Take within 30 minutes of a meal. A double dose with dinner produces same lipid-lowering effect as twice per day dosing.</td> <td rowspan=\"2\">Nausea, bloating, cramping, and constipation; elevations in hepatic transaminases and alkaline phosphatase. Impaired absorption of fat soluble vitamins and coadministered medications including: Amiodarone, digoxin, warfarin, thiazides, beta blockers, levothyroxine, others; interaction can be minimized by taking other medications at least&nbsp;one hour before or&nbsp;four hours after bile acid sequestrant.</td> </tr> <tr> <td class=\"indent1\">Colestipol</td> <td>5 to 30 g/day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Colesevelam</td> <td>3.75 g/day</td> <td>Take with meals once daily or in two divided doses.</td> <td>Similar</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cholesterol absorption inhibitors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ezetimibe</td> <td>10 mg/day</td> <td>&nbsp;</td> <td>Increased transaminases in combination with statins</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neomycin</strong></td> <td>1 g twice per day</td> <td>&nbsp;</td> <td>Ototoxicity; nephrotoxicity</td> </tr> <tr> <td><strong>Probucol</strong> (not available in United States)</td> <td>500 mg twice per day</td> <td>&nbsp;</td> <td>Loose stools; eosinophilia; QT prolongation; angioneurotic edema</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Doses shown are for oral administration (except PCSK9 inhibitors) in adult patients with normal organ function. A reduced initial and maximum dose is recommended for fibric acid derivatives and some statins in the setting of reduced renal function. For specific recommendations, refer to the Lexicomp drug information monographs included within UpToDate.</div><div class=\"graphic_footnotes\">IR: immediate release; XR: extended release; CrCl: creatinine clearance; PCSK9 inhibitors: proprotein convertase subtilisin kexin type 9 inhibitors.</div><div id=\"graphicVersion\">Graphic 77498 Version 13.0</div></div></div>"},"77501":{"type":"graphic_picture","displayName":"Acral erythema","title":"Acral erythema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acral erythema</div><div class=\"cntnt\"><img style=\"width:432px; height:306px;\" src=\"images/ONC/77501_Acralerythema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acral erythema of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: Payne AS, James WD, Weiss RB. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 2006; 33:86. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77501 Version 5.0</div></div></div>"},"77502":{"type":"graphic_table","displayName":"Renal cell CA UISS categories","title":"Prognosis of renal cell carcinoma according to University of California Los Angeles Integrated Staging System (UISS) categorization","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognosis of renal cell carcinoma according to University of California Los Angeles Integrated Staging System (UISS) categorization</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\">UISS stage</td>\r\n            <td class=\"subtitle1\">1997 TNM stage</td>\r\n            <td class=\"subtitle1\">Furman's grade</td>\r\n            <td class=\"subtitle1\">ECOG PS</td>\r\n            <td class=\"subtitle1\">Two-year survival (percent)</td>\r\n            <td class=\"subtitle1\">Five-year survival (percent)</td>\r\n        </tr>\r\n        <tr>\r\n            <td>I</td>\r\n            <td>I</td>\r\n            <td>1, 2</td>\r\n            <td>0</td>\r\n            <td>96 </td>\r\n            <td>94</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"5\">II</td>\r\n            <td>I</td>\r\n            <td>1, 2</td>\r\n            <td>1 or more</td>\r\n            <td rowspan=\"5\">89</td>\r\n            <td rowspan=\"5\">67</td>\r\n        </tr>\r\n        <tr>\r\n            <td>I </td>\r\n            <td>3, 4</td>\r\n            <td>Any</td>\r\n        </tr>\r\n        <tr>\r\n            <td>II</td>\r\n            <td>Any</td>\r\n            <td>Any</td>\r\n        </tr>\r\n        <tr>\r\n            <td>III</td>\r\n            <td>Any</td>\r\n            <td>0</td>\r\n        </tr>\r\n        <tr>\r\n            <td>III</td>\r\n            <td>1</td>\r\n            <td>1 or more</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">III</td>\r\n            <td>III</td>\r\n            <td>2 to 4</td>\r\n            <td>1 or more</td>\r\n            <td rowspan=\"2\">66</td>\r\n            <td rowspan=\"2\">39</td>\r\n        </tr>\r\n        <tr>\r\n            <td>IV</td>\r\n            <td>1, 2</td>\r\n            <td>0</td>\r\n        </tr>\r\n        <tr>\r\n            <td rowspan=\"2\">IV</td>\r\n            <td rowspan=\"2\">IV</td>\r\n            <td>3, 4</td>\r\n            <td>0</td>\r\n            <td rowspan=\"2\">42</td>\r\n            <td rowspan=\"2\">23</td>\r\n        </tr>\r\n        <tr>\r\n            <td>1 to 3</td>\r\n            <td>1 or more</td>\r\n        </tr>\r\n        <tr>\r\n            <td>V</td>\r\n            <td>IV</td>\r\n            <td>4</td>\r\n            <td>1 or more</td>\r\n            <td>9 </td>\r\n            <td>0</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_footnotes\">ECOG PS: Eastern Cooperative Oncology Group performance status.</div><div class=\"graphic_reference\">Modified with permission from: Zisman A, Pantuck A, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649. Copyright &#169;2001 American Society of Clinical Oncology.</div><div id=\"graphicVersion\">Graphic 77502 Version 2.0</div></div></div>"},"77503":{"type":"graphic_table","displayName":"Initial ventilator settings for pediatric status asthmaticus","title":"Initial ventilator settings in children with status asthmaticus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial ventilator settings in children with status asthmaticus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Recommended initial setting</td> <td class=\"subtitle1\">Maximum recommended setting</td> </tr> <tr> <td>Tidal volume</td> <td>8 to 10 mL/kg</td> <td>12 mL/kg</td> </tr> <tr> <td>Respiratory rate</td> <td>8 to 12 breaths/minute</td> <td>16 breaths/minute</td> </tr> <tr> <td>Inspiratory time</td> <td>0.75 to 1 second</td> <td>1.5 seconds</td> </tr> <tr> <td>I:E ratio</td> <td>1:3 to 1:5</td> <td>&#62;1:3</td> </tr> <tr> <td>Inspiratory flow</td> <td>4 to 10 L/kg/minute</td> <td>4 to 10 L/kg/minute</td> </tr> <tr> <td>Minute ventilation</td> <td>&#60;115 mL/kg/minute</td> <td>&#60;115 mL/kg/minute</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">I:E ratio: the ratio of inspiratory to expiratory time.</div><div id=\"graphicVersion\">Graphic 77503 Version 5.0</div></div></div>"},"77504":{"type":"graphic_table","displayName":"Valvular heart disease prevalence by age","title":"Valvular heart disease prevalence by age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Valvular heart disease prevalence by age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">&#60;45 yrs<br /> (percent)</td> <td class=\"subtitle1\">45 to 54 yrs<br /> (percent)</td> <td class=\"subtitle1\">55 to 64 yrs<br /> (percent)</td> <td class=\"subtitle1\">65 to 74 yrs<br /> (percent)</td> <td class=\"subtitle1\">&#62;75 yrs<br /> (percent)</td> </tr> <tr> <td class=\"centered\"><strong>AS</strong>*</td> <td class=\"centered\">0.02</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.2</td> <td class=\"centered\">1.3</td> <td class=\"centered\">2.8</td> </tr> <tr> <td class=\"centered\"><strong>AR</strong>*</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.7</td> <td class=\"centered\">1.0</td> <td class=\"centered\">2.0</td> </tr> <tr> <td class=\"centered\"><strong>MS</strong>*</td> <td class=\"centered\">0.0</td> <td class=\"centered\">0.1</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.2</td> <td class=\"centered\">0.2</td> </tr> <tr> <td class=\"centered\"><strong>MR</strong>*</td> <td class=\"centered\">0.5</td> <td class=\"centered\">0.1</td> <td class=\"centered\">1.0</td> <td class=\"centered\">6.4</td> <td class=\"centered\">9.3</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AS: aortic stenosis; AR: aortic regurgitation; MS: mitral stenosis; MR: mitral regurgitation.</div><div class=\"graphic_reference\">Original figure modified for this publication. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368:1005. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77504 Version 3.0</div></div></div>"},"77505":{"type":"graphic_diagnosticimage","displayName":"Hashimotos goiter echo","title":"Focal lesion in Hashimoto's goiter","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Focal lesion in Hashimoto's goiter</div><div class=\"cntnt\"><img style=\"width:318px; height:214px;\" src=\"images/ENDO/77505_Hashimotos_goiter_Echo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sonogram of the right thyroid lobe in the longitudinal plane of a large multinodular goiter due to Hashimoto's disease. The lobe had a firm prominence at its lower pole on physical examination. This photograph demonstrates an electronic assembly of two adjacent images; the seam is in the projection of the arrow. There is a complex hypoechogenic nodule (N) that expands the lower end of a 33 mm wide and 88 mm long lobe (+ + and x x). The nodule was suspicious of cancer on biopsy.</div><div class=\"graphic_reference\">Courtesy of Manfred Blum, MD.</div><div id=\"graphicVersion\">Graphic 77505 Version 3.0</div></div></div>"},"77506":{"type":"graphic_picture","displayName":"Urticaria 4","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:247px; height:345px;\" src=\"images/ALLRG/77506_Urticaria_4_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77506 Version 3.0</div></div></div>"},"77508":{"type":"graphic_figure","displayName":"Sensory nerves in females","title":"Sensory nerves in females","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Sensory nerves in females</div><div class=\"cntnt\"><img style=\"width:557px; height:555px;\" src=\"images/OBGYN/77508_Peripheral_nerves_female.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77508 Version 3.0</div></div></div>"},"77509":{"type":"graphic_table","displayName":"Tx autoimmune hepatitis","title":"Oral treatment regimens for autoimmune hepatitis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Oral treatment regimens for autoimmune hepatitis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Prednisone only*&#182;, mg/day</td> <td class=\"subtitle1\" colspan=\"2\">Combination&#182;</td> </tr> <tr> <td class=\"subtitle2\">Prednisone*, mg/day</td> <td class=\"subtitle2\">Azathioprine<sup>&#916;</sup>, mg/day</td> </tr> <tr> <td>Week 1</td> <td>60</td> <td>30</td> <td>50</td> </tr> <tr> <td>Week 2</td> <td>40</td> <td>20</td> <td>50</td> </tr> <tr> <td>Week 3</td> <td>30</td> <td>15</td> <td>50</td> </tr> <tr> <td>Week 4</td> <td>30</td> <td>15</td> <td>50</td> </tr> <tr> <td>Maintenance until end point</td> <td>20<sup>&#9674;</sup></td> <td>10<sup>&#167;</sup></td> <td>50</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Reasons for preference:</td> </tr> <tr> <td rowspan=\"7\">&nbsp;</td> <td>Cytopenia</td> <td colspan=\"2\">Postmenopausal state</td> </tr> <tr> <td>Thiopurine methyltransferase (TPMT) deficiency</td> <td colspan=\"2\">Osteoporosis</td> </tr> <tr> <td>Pregnancy</td> <td colspan=\"2\">Brittle diabetes</td> </tr> <tr> <td>Malignancy</td> <td colspan=\"2\">Obesity</td> </tr> <tr> <td>Short course (&#8804;6 months)</td> <td colspan=\"2\">Acne</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td colspan=\"2\">Emotional lability</td> </tr> <tr> <td colspan=\"2\">Hypertension</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Orally administered prednisolone can be used in place of prednisone at the same doses. For patients with mild disease (eg, asymptomatic patients with aminotransferase levels &lt;10 times the upper limit of normal), lower dose prednisone monotherapy (20 mg per day) is an alternative.&nbsp;<br />¶ In patients at increased risk of side effects from glucocorticoids, a lower dose of prednisone monotherapy (eg, 30 mg daily) or combination therapy may be preferable to prednisone monotherapy at a dose of 60 mg daily.<br />Δ TPMT phenotyping should be obtained before initiating azathioprine. In Europe, an azathioprine&nbsp;dose of 1 to 2 mg/kg/day is often used.<br />◊ Prednisone may be further tapered to an individual dose that maintains remission. A 10 mg/day maintenance dose may be achieved by tapering the dose by 5 mg every week. A maintenance dose of 5 mg/day may be considered; in that case, the&nbsp;dose is tapered by 2.5 mg every week. The maintenance prednisone regimen is continued until resolution of the disease, treatment failure, or drug-intolerance.<br />§ Prednisone may be further tapered to an individual dose that maintains remission by increments of 2.5 mg/day each week down to a dose of 5 mg/day. Dose adjustment recommendations for maintenance with either azathioprine or glucocorticoids alone are provided in the topic and accompanying algorithm. </div><div class=\"graphic_reference\">Adapted from: Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.</div><div id=\"graphicVersion\">Graphic 77509 Version 9.0</div></div></div>"},"77510":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound of normal fetal kidneys transverse","title":"Prenatal ultrasound, transverse view, bilateral normal kidneys in the second trimester","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound, transverse view, bilateral normal kidneys in the second trimester</div><div class=\"cntnt\"><img style=\"width:425px; height:299px;\" src=\"images/OBGYN/77510_Normal_kidneys_transverse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral normal kidneys (arrows) in the second trimester on transverse view. Note that the echogenicity is similar to other abdominal tissue.</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 77510 Version 2.0</div></div></div>"},"77512":{"type":"graphic_picture","displayName":"Kwashiorkor dermatosis","title":"Dermatosis of Kwashiorkor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatosis of Kwashiorkor</div><div class=\"cntnt\"><img style=\"width:274px; height:228px;\" src=\"images/PEDS/77512_Kwashiorkor_dermatos.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The desquamating dermatosis and subcutaneous edema in a young infant with edematous malnutrition (kwashiorkor).</div><div class=\"graphic_reference\">Courtesy of Dr. Buford Nichols.</div><div id=\"graphicVersion\">Graphic 77512 Version 3.0</div></div></div>"},"77514":{"type":"graphic_figure","displayName":"ECT stimulating electrodes","title":"Electrode placement for electroconvulsive therapy (ECT)","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Electrode placement for electroconvulsive therapy (ECT)</div><div class=\"cntnt\"><img style=\"width:476px; height:598px;\" src=\"images/PSYCH/77514_ECT_stimulating_electrodes.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77514 Version 2.0</div></div></div>"},"77515":{"type":"graphic_table","displayName":"Air embolism during ERCP","title":"Cases of air embolism during endoscopic retrograde cholangiopancreatography (ERCP) reported in the literature","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cases of air embolism during endoscopic retrograde cholangiopancreatography (ERCP) reported in the literature</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5.5%\"></colgroup><colgroup span=\"7\" width=\"13.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Reference/year</td> <td class=\"subtitle1\">Age/sex</td> <td class=\"subtitle1\">Underlying disease</td> <td class=\"subtitle1\">Endoscopic procedures</td> <td class=\"subtitle1\">Complications</td> <td class=\"subtitle1\">Diagnostic findings and imaging</td> <td class=\"subtitle1\">Outcome</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td>Simmons et al, 1988</td> <td>23/F</td> <td>Bile duct stone</td> <td>ES</td> <td>Portal venous gas</td> <td>Radiographs during ERCP</td> <td>Uneventful</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td>Merine et al, 1989</td> <td>39/F</td> <td>Papillary stenosis</td> <td>ES</td> <td> <p>Retroperitoneal perforation</p> <p>Pancreatitis</p> Portal venous gas</td> <td>Abdominal CT</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td>Blind et al, 1991</td> <td>60/M</td> <td>Bile duct stone</td> <td>ES</td> <td> <p>Moderate bleeding</p> Portal venous gas</td> <td>Radiographs during ERCP</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">4</td> <td>Barthet et al, 1994</td> <td>31/M</td> <td>Bile duct stenosis</td> <td>ES</td> <td> <p>Mild bleeding</p> Portal venous gas</td> <td>Radiographs during ERCP</td> <td>Uneventful</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">5</td> <td>Herman et al, 1995</td> <td>46/M</td> <td>Liver transplant for cirrhosis</td> <td>ES</td> <td> <p>Moderate bleeding</p> Portal venous gas</td> <td>Radiographs during ERCP</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">6</td> <td>Tighe et al, 1996</td> <td>31/M</td> <td>Cirrhosis and portal cavernoma</td> <td> <p>ES</p> Balloon dilation</td> <td> <p>Moderate bleeding</p> Portal venous gas and opacification</td> <td>Radiographs during ERCP</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">7</td> <td>Kennedy et al, 1997</td> <td>63/F</td> <td>Bile duct stone</td> <td> <p>ES</p> Stone extraction</td> <td> <p>Mild bleeding</p> <p>Venous air embolism</p> Cardiorespiratory arrest</td> <td>Radiographs during ERCP and post-mortem</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">8</td> <td>Nayagam et al, 2004</td> <td>56/M</td> <td>Malignant bile duct stenosis</td> <td>Biliary stent</td> <td> <p>Venous and arterial air embolism</p> Cerebral ischemia</td> <td> <p>Echocardiography</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">9</td> <td>Giuly et al, 2005</td> <td>60/F</td> <td> <p>Bile duct stenosis</p> Myeloma multiple</td> <td>Biliary stent</td> <td> <p>Venous air embolism</p> Hypoxemia and shock</td> <td>Echocardiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">10</td> <td>Siddiqui et al, 2005</td> <td>43/F</td> <td> <p>Recent liver biopsy</p> Ampullary adenoma</td> <td> <p>ES</p> Brushing and biopsy</td> <td> <p>Venous air embolism</p> Cardiorespiratory arrest</td> <td> <p>Radiographs during ERCP (post-mortem review)</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">11</td> <td>Mohammedi et al, 2005</td> <td>27/M</td> <td> <p>Hepatic trauma</p> Biliary fistula</td> <td>ES</td> <td> <p>Venous air embolism</p> Hypoxemia and shock</td> <td>Cardiac auscultation</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">12</td> <td>Stabile et al, 2006</td> <td>65/M</td> <td> <p>Previous PTBD and ES</p> Biliary colic and icterus</td> <td>Cholangiography</td> <td> <p>Venous and arterial air embolism</p> Cerebral ischemia</td> <td> <p>Thoracoabdominal and head CT</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">13</td> <td>Rabe et al, 2006</td> <td>87/M</td> <td> <p>Benign biliary stricture</p> Patent foramen ovale</td> <td>Disobstruction of metal biliary stent</td> <td> <p>Venous and arterial air embolism</p> Unconsciousness and hemiparesis</td> <td>Head CT</td> <td>Hemiparesis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">14</td> <td>Rabe et al, 2006</td> <td>54/M</td> <td> <p>Portal vein cavernoma</p> Patent foramen ovale</td> <td>Balloon revision of obstructed metal biliary stent</td> <td> <p>Brisk bleeding</p> <p>Venous air embolism</p> Cardiorespiratory arrest</td> <td> <p>Echocardiography</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">15</td> <td>Tan et al, 2008</td> <td>82/F</td> <td>Ampullary adenoma</td> <td>Metal biliary stent</td> <td> <p>Venous and arterial air embolism</p> <p>Cardiorespiratory arrest</p> Cerebral ischemia</td> <td>Thoracoabdominal and head CT</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">16</td> <td>Bisceglia et al, 2009</td> <td>78/M</td> <td> <p>Bile duct stone</p> <p>Cholangitis and liver abscesses</p> Biliary-duodenal fistula</td> <td>Stone extraction</td> <td> <p>Veno-biliary fistula</p> <p>Venous and arterial air embolism</p> Cardiorespiratory arrest</td> <td> <p>Thoracoabdominal and head CT</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">17</td> <td>Romberg, 2009</td> <td>53/M</td> <td>Bile duct stone</td> <td>Mechanical lithotripsy</td> <td> <p>Moderate bleeding</p> <p>Porto-biliary fistula</p> <p>Venous and arterial air embolism</p> Hypoxemia, shock, and unconsciousness</td> <td>Transesophageal echocardiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">18</td> <td>Rangappa et al, 2009</td> <td>50/F</td> <td> <p>Bile duct stone</p> <p>Cholecystectomy</p> Patent foramen ovale</td> <td> <p>Widening of sphincterotomy</p> Stone extraction</td> <td>Venous and arterial air embolism</td> <td> <p>Head CT</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">19</td> <td>Cha et al, 2010</td> <td>50/F</td> <td> <p>Bile duct stones</p> <p>Choledocoduodenostomy</p> Liver abscesses</td> <td>Stone extraction</td> <td> <p>Venous air embolism</p> Cardiorespiratory arrest</td> <td> <p>Chest radiograph</p> Abdominal CT</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">20</td> <td>Going et al, 2010</td> <td>72/F</td> <td>Cholangiocarcinoma</td> <td>Cholangioscopy ERCP</td> <td> <p>Venous air embolism</p> <p>Cardiorespiratory arrest</p> Cerebral ischemia</td> <td> <p>Abdominal radiograph</p> <p>Transesophageal echocardiography</p> Head MRI</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">21</td> <td>Arguelles Garcia et al, 2010</td> <td>82/M</td> <td> <p>Previous ES</p> <p>Cholangitis</p> Bile duct stones</td> <td> <p>Balloon dilatation</p> Stone extraction</td> <td> <p>Venous and arterial air embolism</p> <p>Hypoxemia, shock and hemiparesis</p> Cerebral ischemia</td> <td>Head CT</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">22</td> <td>Van Boxel et al, 2010</td> <td>82/M</td> <td> <p>Bile duct stones</p> Bile duct stent</td> <td>Removal of bile duct stent</td> <td> <p>Venous and arterial air embolism</p> Myocardial and cerebral ischemia</td> <td> <p>Electrocardiogram</p> Head CT</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">23</td> <td>Finsterer et al, 2010</td> <td>59/F</td> <td> <p>Choledochojejunostomy</p> Recurrent cholangitis and liver abscesses</td> <td>Removal of bile duct stent</td> <td> <p>Venous and arterial air embolism</p> Hypoxemia and shock</td> <td>Thoracoabdominal and head CT</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">24</td> <td>Mal et al, 2010</td> <td>78/F</td> <td> <p>Cholangitis</p> Bilio-digestive anastomosis</td> <td>Dilatation of bilio-digestive</td> <td> <p>Mild bleeding</p> Venous air embolism</td> <td> <p>Echocardiography</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">25</td> <td>Di Pisa et al, 2011</td> <td>8/M</td> <td> <p>Portal cavernoma</p> Post-sphincterotomy bleeding</td> <td>Removal of covered metal stent</td> <td> <p>Moderate bleeding</p> <p>Venous air embolism</p> Cardiorespiratory arrest</td> <td>Transesophageal echocardiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">26</td> <td>Jow et al, 2011</td> <td>65/M</td> <td> <p>Chronic pancreatitis</p> Pancreatic pseudocyst</td> <td> <p>Pancreatic sphincterotomy</p> <p>Pancreatic stent</p> EUS-guided cyst-gastrostomy</td> <td> <p>Venous air embolism</p> Cardiorespiratory arrest</td> <td> <p>Radiographs post-mortem</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">27</td> <td>Bechi et al, 2011</td> <td>79/F</td> <td>Bile duct stones</td> <td>ES</td> <td>Venous air embolism</td> <td>Echocardiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">28</td> <td>Maccarone et al, 2011</td> <td>45/M</td> <td> <p>Bile duct stones</p> Patent foramen ovale</td> <td>Rendez-vous technique</td> <td> <p>Venous and arterial air embolism</p> Shock and cerebral ischemia</td> <td> <p>Transesophageal echocardiography</p> Head MRI</td> <td>Residual neurologic deficit</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">29</td> <td>Nern et al, 2012</td> <td>58/F</td> <td> <p>Suspected Klatskin tumor</p> <p>Echinococcus of the liver</p> Patent foramen ovale</td> <td> <p>Liver biopsy</p> Biliary stent</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarctions</td> <td> <p>Thoracoabdominal and head CT</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">30</td> <td>Chavalitdhamrong and Draganov, 2013</td> <td>66/M</td> <td> <p>Bile duct stricture</p> Patent foramen ovale</td> <td>Stent exchange</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarctions</td> <td> <p>Echocardiography</p> Thoracoabdominal and head CT</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">31</td> <td>Chavalitdhamrong and Draganov, 2013</td> <td>51/F</td> <td>Recurrent pancreatitis post-pancreaticodudenectomy</td> <td>Diagnostic ERCP</td> <td> <p>Venous and arterial air embolism</p> Cerebral and spinal cord infarctions</td> <td>Head and spinal MRI</td> <td>Residual neurologic deficits</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">32</td> <td>Vachalova et al, 2013</td> <td>45/M</td> <td> <p>Liver cirrhosis</p> <p>Chronic pancreatitis</p> <p>Bile duct stenosis</p> Bile duct stones</td> <td> <p>ES</p> <p>Removal of bile duct stones</p> <p>Biliary stent</p> Second EGD</td> <td> <p>Venous and arterial air embolism</p> Right-sided brain infarction</td> <td> <p>Head CT</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">33</td> <td>Arora et al, 2013</td> <td>74/F</td> <td> <p>Gallbladder carcinoma</p> Cholangitis</td> <td>7-Fr biliary stent</td> <td>Portal venous air</td> <td>Radiographs during ERCP</td> <td>Uneventful</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">34</td> <td>Merini et al, 2014</td> <td>42/F</td> <td> <p>Choledocoduodenal anastomosis</p> Bile duct stones</td> <td> <p>Cholangiography</p> Diagnostic ERCP</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarction</td> <td> <p>Echocardiography</p> Head MRI</td> <td>Hemiparesis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">35</td> <td>Athauda et al, 2014</td> <td>36/M</td> <td> <p>Gallstone pancreatitis</p> <p>Third ERCP</p> Previous PTBD</td> <td>Stent removal</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarction</td> <td>Head CT and MRI</td> <td>Hemiparesis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">36</td> <td>Duburque et al, 2014</td> <td>45/M</td> <td> <p>Chronic pancreatitis</p> <p>Cholestasis</p> <p>Abdominal pain</p> Patent foramen ovale</td> <td> <p>ES</p> <p>Metal biliary stent</p> Metal pancreatic stent</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarction</td> <td> <p>Echocardiography</p> <p>Coronary angiography</p> Head MRI</td> <td>Quadraparesis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">37</td> <td>Duburque et al, 2014</td> <td>87/M</td> <td>Bile duct stone</td> <td> <p>ES</p> <p>Removal of bile duct stone</p> Biliary stent</td> <td> <p>Venous air embolism</p> Cardiac arrest</td> <td>Echocardiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">38</td> <td>Bastovansky et al, 2014</td> <td>59/F</td> <td> <p>Bile duct stone</p> <p>Cholangitis and liver abscesses</p> <p>Bilio-enteric anastomosis</p> Patent foramen ovale</td> <td>Removal of metal biliary stent</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarction</td> <td> <p>Cerebral CT</p> <p>Brain MRI</p> <p>Transesophageal echocardiography</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">39</td> <td>Hauser et al, 2014</td> <td>56/F</td> <td> <p>Non-Hodgkin lymphoma</p> Bile duct stones</td> <td> <p>ES</p> Removal of stones</td> <td> <p>Venous air embolism</p> Ventricular fibrillation</td> <td>Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">40</td> <td>Wills-Sanin et al, 2014</td> <td>55/F</td> <td> <p>Liver transplant for Budd-Chiari syndrome</p> <p>Biliary strictures</p> Bile duct stones</td> <td> <p>Biliary stent migration</p> Removal of stones</td> <td> <p>Venous air embolism</p> Cardiac arrest</td> <td>CT angiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">41</td> <td>Markin et al, 2015</td> <td>66/M</td> <td> <p>Bile duct stones</p> <p>Portal vein thrombosis</p> Patent foramen ovale</td> <td>Replacement of biliary stent</td> <td> <p>Venous and arterial air embolism</p> Cardiac and cerebral ischemia</td> <td> <p>Transesophageal echocardiography</p> <p>Cerebral CT</p> Brain MRI</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">42</td> <td>Marchesi et al, 2015</td> <td>51/F</td> <td> <p>Bile duct stones</p> <p>Recent ESWL and ES</p> <p>Biliary-vascular fistula</p> Patent foramen ovale</td> <td>Attempted removal of large bile duct stone</td> <td> <p>Venous and arterial air embolism</p> Cardiac arrest</td> <td> <p>Thoracoabdominal and cerebral CT post-mortem</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">43</td> <td>Mathew Jr et al, 2015</td> <td>55/M</td> <td>Bile duct stones</td> <td> <p>ES</p> <p>Removal of stones</p> Choledochoscopy</td> <td> <p>Venous air embolism</p> Cardiac arrest</td> <td> <p>Explolatory laparotomy</p> <p>Left ventricular aspiration</p> Autopsy</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">44</td> <td>Park et al, 2016</td> <td>69/M</td> <td>Bile duct stones</td> <td> <p>EPBD</p> <p>Removal of stones</p> CMS</td> <td> <p>Venous air embolism</p> Cardiac arrest</td> <td> <p>Cerebral CT</p> Brain MRI</td> <td>Hemiparesis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">45</td> <td>Cooper JS et al, 2016</td> <td>75/M</td> <td> <p>Hilar stricture </p> <p>Brushing and plastic biliary stent</p> Cholangitis</td> <td> <p>Removal of biliary stent with biliary balloon and snare</p> Mild bleeding</td> <td> <p>Venous and arterial air embolism</p> Ventricular tachycardia</td> <td>Echocardiography</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">46</td> <td>Maggino et al, 2016</td> <td>24/M</td> <td>Blunt traumatic pancreatic transection</td> <td> <p>Plastic pancreatic stent</p> Bleeding</td> <td>Portal air embolism</td> <td>Abdominal CT</td> <td>Recovered</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">47</td> <td>Fernandez et al, 2016</td> <td>85/M</td> <td>Distal cholangiocarcinoma</td> <td>Replacement of biliary stent</td> <td>Venous and arterial air embolism</td> <td>Cerebral CT</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">48</td> <td>Sisk et al, 2016</td> <td>37/M</td> <td> <p>Recurrent pancreatitis</p> <p>Common bile duct obstruction</p> Post-kidney transplant</td> <td>Replacement of biliary stent</td> <td>Venous and arterial air embolism</td> <td> <p>Transesophageal echocardiography</p> Brain MRI</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">49</td> <td>Sisk et al, 2016</td> <td>79/F</td> <td>Cholangitis</td> <td>Replacement of biliary stent</td> <td> <p>Venous air embolism</p> Cardiac arrest</td> <td>Transesophageal echocardiography</td> <td><strong>Death</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">50</td> <td>Trabanco et al, 2017</td> <td>85/M</td> <td> <p>Cholangiocarcinoma</p> Cholangitis</td> <td>Biopsy and replacement of biliary stent</td> <td> <p>Venous and arterial air embolism</p> Cerebral infarction</td> <td>Cerebral CT</td> <td><strong>Death</strong></td> </tr> <tr> <td class=\"centered\">51</td> <td>Barbeiro et al, 2017</td> <td>72/F</td> <td> <p>Jaundice</p> Dilation of the bile ducts</td> <td>Precut papillotomy</td> <td>Portal air embolism</td> <td>Radiographs during ERCP abdominal CT</td> <td>Recovered</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ES: endoscopic sphincterotomy; ERCP: endoscopic retrograde cholangiopancreatography; CT: computed tomography; PTBD: percutaneous transhepatic biliary drainage; MRI: magnetic resonance imaging; EGD: esophagogastroduodenoscopy; EPBD: endoscopic papillary ballon dilation; CMS: covered metal stent; ESWL: extracorporeal shockwave lithotripsy; M: male; F: female.</div><div id=\"graphicVersion\">Graphic 77515 Version 17.0</div></div></div>"},"77517":{"type":"graphic_picture","displayName":"Malaria trophozoites","title":"Malaria: Red cell containing intraerythrocytic ring forms (trophozoites)","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Malaria: Red cell containing intraerythrocytic ring forms (trophozoites)</div><div class=\"cntnt\"><img style=\"width:430px; height:284px;\" src=\"images/HEME/77517_Malaria_trophozoites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral smear from a patient with malaria shows intraerythrocytic ring forms (trophozoites) (arrows).</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 77517 Version 4.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal peripheral blood smear</div><div class=\"cntnt\"><img style=\"width:393px; height:257px;\" src=\"images/HEME/59683_Normal_blood_smear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view of a normal peripheral blood smear. Several platelets (arrows) and a normal lymphocyte (arrowhead) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (dashed arrow) should equal one-third of its diameter.</div><div class=\"graphic_reference\">Courtesy of Carola von Kapff, SH (ASCP).</div><div id=\"graphicVersion\">Graphic 59683 Version 4.0</div></div></div>"},"77518":{"type":"graphic_movie","displayName":"IVUS in patient with CAV","title":"Intravascular ultrasound images in a patient with cardiac allograft vasculopathy","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Intravascular ultrasound images in a patient with cardiac allograft vasculopathy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77518_IVUSCAVconv2.mp4\" style=\"width:384px;height:368px\"></div><img style=\"width:370px; height:369px;\" src=\"images/CARD/77518_IVUSpatientwithCAV.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe intimal thickening (green line indicates maximal intimal thickness).</div><div class=\"graphic_reference\">Courtesy of Dr. Finn Gustafsson.</div><div id=\"graphicVersion\">Graphic 77518 Version 3.0</div></div></div>"},"77519":{"type":"graphic_table","displayName":"Hamstring injury rehabilitation program","title":"Hamstring injury rehabilitation program","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hamstring injury rehabilitation program</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Phase 1</td> </tr> <tr> <td class=\"subtitle2_single\">Goals</td> </tr> <tr> <td> <ol> <li>Protect scar development </li> <li>Minimize atrophy </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Protection</td> </tr> <tr> <td class=\"indent1\">Avoid excessive active or passive lengthening of the hamstrings</td> </tr> <tr> <td class=\"subtitle2_single\">Ice</td> </tr> <tr> <td class=\"indent1\">2 to 3 times per day</td> </tr> <tr> <td class=\"subtitle2_single\">Therapeutic exercise (performed daily)</td> </tr> <tr> <td> <ol> <li>Stationary bike x 10 minutes </li> <li>Side-step x 10 meters, 3 x 1 minute, low to moderate intensity, pain-free speed and stride </li> <li>Grapevine x 10 meters, 3 x 1 minute, low to moderate intensity, pain-free speed and stride </li> <li>Fast feet stepping in place, 2 x 1 min </li> <li>Prone body bridge, 5 x 10 seconds </li> <li>Side body bridge, 5 x 10 seconds </li> <li>Supine bent knee bridge, 10 x 5 seconds </li> <li>Single-limb balance progressing from eyes open to closed, 4 x 20 seconds </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Criteria for progression to next phase</td> </tr> <tr> <td> <ol> <li>Normal walking stride without pain </li> <li>Very low-speed jog without pain </li> <li>Pain-free isometric contraction against submaximal (50-70 percent) resistance during prone knee flexion (90&#176;) manual strength test </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2</td> </tr> <tr> <td class=\"subtitle2_single\">Goals</td> </tr> <tr> <td> <ol> <li>Regain pain-free hamstring strength, beginning in mid-range and progressing to a longer hamstring length </li> <li>Develop neuromuscular control of trunk and pelvis with progressive increase in movement speed </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Protection</td> </tr> <tr> <td class=\"indent1\">Avoid end-range lengthening of hamstrings while hamstring weakness is present</td> </tr> <tr> <td class=\"subtitle2_single\">Ice</td> </tr> <tr> <td class=\"indent1\">Post-exercise, 10-15 minutes</td> </tr> <tr> <td class=\"subtitle2_single\">Therapeutic exercise (performed 5-7 d/wk)</td> </tr> <tr> <td> <ol> <li>Stationary bike x 10 min </li> <li>Side-shuffle x 10 meters, 3 x 1 minute, moderate to high intensity, pain-free speed and stride </li> <li>Grapevine jog x 10 meters, 3 x 1 minute, moderate to high intensity, pain-free speed and stride </li> <li>Boxer shuffle x 10 meters, 2 x 1 minute, low to moderate intensity, pain-free speed and stride </li> <li>Rotating body bridge, 5 second hold each side, 2 x 10 reps </li> <li>Supine bent knee bridge with walk-outs, 3 x 10 reps </li> <li>Single-limb balance windmill touches without weight, 4 x 8 reps per arm each limb </li> <li>Lunge walk with trunk rotation, opposite hand-toe touch and T-lift, 2 x 10 steps per limb </li> <li>Single-limb balance with forward trunk lean and opposite hip extension, 5 x 10 seconds per limb </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Criteria for progression to next phase</td> </tr> <tr> <td> <ol> <li>Full strength (5/5) without pain during prone knee flexion (90&#176;) manual strength test </li> <li>Pain-free forward and backward jog, moderate intensity </li> </ol> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 3</td> </tr> <tr> <td class=\"subtitle2_single\">Goals</td> </tr> <tr> <td> <ol> <li>Symptom-free (eg, pain and tightness) during all activities </li> <li>Normal concentric and eccentric hamstring strength through full range of motion and speeds </li> <li>Improve neuromuscular control of trunk and pelvis </li> <li>Integrate postural control into sport-specific movements </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Protection</td> </tr> <tr> <td class=\"indent1\">Avoid full intensity if pain/tightness/stiffness is present</td> </tr> <tr> <td class=\"subtitle2_single\">Ice</td> </tr> <tr> <td class=\"indent1\">Post-exercise, 10-15 minutes, as needed</td> </tr> <tr> <td class=\"subtitle2_single\">Therapeutic exercise (performed 4-5 d/wk)</td> </tr> <tr> <td> <ol> <li>Stationary bike x 10 min </li> <li>Side-shuffle x 30 meters, 3 x 1 minute, moderate to high intensity, pain-free speed and stride </li> <li>Grapevine jog x 30 meters, 3 x 1 minute moderate to high intensity, pain-free speed and stride </li> <li>Boxer shuffle x 10 meters, 2 x 1 minute moderate to high intensity, pain-free speed and stride </li> <li>A and B skips, starting at low knee height and progressively increasing, pain-free <ul> <li>a. A skip is a hop-step forward movement that alternates from leg to leg and couples with arm opposition (similar to running). During the hop, the opposite knee is lifted in a flexed position and then the knee and hip extend together to make the next step </li> <li>b. B skip is a progression of the A skip; however, the opposite knee extends prior to the hip extending recreating the terminal swing phase of running. The leg is then pulled backward in a pawing type action. The other components remain the same as the A skip. </li> </ul> </li> <li>Forward-backward accelerations, 3 x 1 minute; start at 5 meters, progress to 10 m, then 20 m </li> <li>Rotating body bridge with dumbbells, 5 seconds hold each side, 2 x 10 reps </li> <li>Supine single-limb chair-bridge, 3 x 15 reps, slow to fast speed </li> <li>Single-limb balance windmill touches with dumbbells, 4 x 8 reps per arm for each leg </li> <li>Lunge walk with trunk rotation, opposite hand dumbbell toe touch and T-lift, 2 x 10 steps per limb </li> <li>Sport-specific drills that incorporate postural control and progressive speed </li> </ol> </td> </tr> <tr> <td class=\"subtitle2_single\">Criteria for return to sport</td> </tr> <tr> <td> <ol> <li>Full strength without pain <ul> <li>a. 4 consecutive repetitions of maximum effort manual strength test in each prone knee flexion position (90&#176; and 15&#176;) </li> <li>b. Less than 5 percent bilateral deficit in eccentric hamstrings (30&#176;/second): concentric quadriceps (240&#176;/second) ratio during isokinetic testing </li> <li>c. Bilateral symmetry in knee flexion angle of peak isokinetic concentric knee flexion torque at 60&#176;/second </li> </ul> </li> <li>Full range of motion without pain </li> <li>Replication of sport specific movements near maximal speed without pain (eg, incremental sprint test for running athletes) </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Proposed guide for the rehabilitation of acute hamstring strain injuries. Suggested exercises, including sets and repetitions, should be individualized. Progression through the 3-phase program is estimated to take from 2 to 6 weeks but should be adjusted to the patient.</div><div class=\"graphic_reference\">Appendix reproduced from: Heiderscheit BC, Sherry MA, Silder A, Chumanov ES, Thelen DG. Hamstring strain injuries: recommendations for diagnosis, rehabilitation, and injury prevention. J Orthop Sports Phys Ther 2010; 40(2):67-81. doi:10.2519/jospt.2010.3047, with permission of JOSPT and the Orthopaedic and Sports Physical Therapy Sections of the American Physical Therapy Association.</div><div id=\"graphicVersion\">Graphic 77519 Version 2.0</div></div></div>"},"77520":{"type":"graphic_diagnosticimage","displayName":"The tubing from gastric banding causing abdominal pain","title":"The tubing from gastric banding causing abdominal pain","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">The tubing from gastric banding causing abdominal pain</div><div class=\"cntnt\"><img style=\"width:545px; height:302px;\" src=\"images/SURG/77520_Disconn_tubing_abdom_pain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal pain after gastric banding can be caused by the tubing causing obstruction or pressure.<br> (A) This plain film shows the tubing being pulled down out of position, which caused abdominal pain.<br> (B) This computed tomography (CT) scan shows the tubing around the hilum of the spleen. At surgery, the tubing was wrapped around the hilum of the spleen and the colon.</div><div id=\"graphicVersion\">Graphic 77520 Version 8.0</div></div></div>"},"77521":{"type":"graphic_figure","displayName":"Rhomboid flap ","title":"Rhomboid flap","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Rhomboid flap</div><div class=\"cntnt\"><img style=\"width:539px; height:262px;\" src=\"images/SURG/77521_Rhomboidflapsurg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A single rhomboid flap is very useful for defects that cannot be closed directly and abut an area of laxity. The orientation of the rhomboid is designed so that the flap donor site will close easily once the flap is transposed. Each rhomboid offers the possibility of four flap choices, each arising from the short axis of the rhomboid.</div><div id=\"graphicVersion\">Graphic 77521 Version 7.0</div></div></div>"},"77522":{"type":"graphic_picture","displayName":"Palpable purpura","title":"Palpable purpura in cutaneous small vessel vasculitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palpable purpura in cutaneous small vessel vasculitis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77522_Palpable_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palpable purpura are present in this patient with cutaneous small vessel vasculitis secondary to Henoch-Schönlein purpura (IgA vasculitis).</div><div id=\"graphicVersion\">Graphic 77522 Version 2.0</div></div></div>"},"77526":{"type":"graphic_diagnosticimage","displayName":"UIP IPF radiographs","title":"Idiopathic pulmonary fibrosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Idiopathic pulmonary fibrosis</div><div class=\"cntnt\"><img style=\"width:504px; height:184px;\" src=\"images/PULM/77526_UIP_IPF_radiographs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest radiograph shows typical peripheral reticular opacity, most marked at the bases, with honeycombing. Lower lobe volume loss (not present in this case) is also common. Chest radiographs may occasionally be normal in patients with IPF. (B and C) CT images show basal predominant, peripheral predominant reticular abnormality with traction bronchiectasis and honeycombing, typical of IPF.</div><div id=\"graphicVersion\">Graphic 77526 Version 2.0</div></div></div>"},"77527":{"type":"graphic_figure","displayName":"Flexion hip deformity in AS II","title":"Unmasking of flexion hip deformity in ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unmasking of flexion hip deformity in ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:360px; height:258px;\" src=\"images/RHEUM/77527_Flexion_hip_deformity_in_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To correct for excess lordosis masking flexion hip deformity in ankylosing spondylitis, have the patient lie supine maximally flex one of the hips. This obliterates any possible exaggeration of the lumbar lordosis and allows flexion deformity of the contralateral hip to become apparent.</div><div class=\"graphic_reference\">Courtesy of Craig W Wiesenhutter, MD.</div><div id=\"graphicVersion\">Graphic 77527 Version 3.0</div></div></div>"},"77528":{"type":"graphic_figure","displayName":"Absorption of laser and light by various tissues","title":"Absorption of laser and light by various tissues","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Absorption of laser and light by various tissues</div><div class=\"cntnt\"><img style=\"width:529px; height:436px;\" src=\"images/SURG/77528_Absorption_of_laser_and_light.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77528 Version 1.0</div></div></div>"},"77529":{"type":"graphic_figure","displayName":"Rate of AAA repair over time","title":"The need for surgical repair of an abdominal aortic aneurysm increases over time","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">The need for surgical repair of an abdominal aortic aneurysm increases over time</div><div class=\"cntnt\"><img style=\"width:392px; height:343px;\" src=\"images/CARD/77529_Rate_of_AAA_repair_over_tim.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the US ADAM trial of 1136 patients with a moderate sized abdominal aortic aneurysm, the need for surgical repair in those randomized to initial surveillance increased over time.</div><div class=\"graphic_reference\">Data from Lederle, FA, Wilson, SE, Johnson, GR et al, N Engl J Med 2002: 346:1437.</div><div id=\"graphicVersion\">Graphic 77529 Version 2.0</div></div></div>"},"77532":{"type":"graphic_table","displayName":"Episiotomy complications","title":"Complications attributed to episiotomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complications attributed to episiotomy</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td>Infection</td>\n</tr>\n<tr>\n<td>Hematoma</td>\n</tr>\n<tr>\n<td>Third and fourth degree extension</td>\n</tr>\n<tr>\n<td>Cellulitis</td>\n</tr>\n<tr>\n<td>Dehiscence</td>\n</tr>\n<tr>\n<td>Abscess</td>\n</tr>\n<tr>\n<td>Dyspareunia</td>\n</tr>\n<tr>\n<td>Altered sexual function</td>\n</tr>\n<tr>\n<td>Perineal pain</td>\n</tr>\n<tr>\n<td>Incontinence: urinary, fecal, flatus</td>\n</tr>\n<tr>\n<td>Rectovaginal fistula</td>\n</tr>\n<tr>\n<td>Impaired pudendal nerve conduction</td>\n</tr>\n<tr>\n<td>Necrotizing fasciitis</td>\n</tr>\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=42727&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Episiotomy_complications.htm</title></head></div><div class=\"graphic_reference\">Data from: Ramin SM, Gilstrap LC. Episiotomy and early repair of dehiscence. Clin Obstet Gynecol 1994; 37:816.</div><div id=\"graphicVersion\">Graphic 77532 Version 2.0</div></div></div>"},"77533":{"type":"graphic_table","displayName":"NCI CTCAE v5 hepatobiliary toxicity","title":"NCI CTCAE v5.0 hepatobiliary toxicity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hepatobiliary toxicity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr class=\"divider_bottom\"> <td>Alkaline phosphatase increased</td> <td>&#62;ULN to 2.5 x ULN if baseline was normal; 2 to 2.5 x baseline if baseline was abnormal</td> <td>&#62;2.5 to 5 x ULN if baseline was normal; &#62;2.5 to 5 x baseline if baseline was abnormal</td> <td>&#62;5 to 20 x ULN if baseline was normal; &#62;5 to 20 x baseline if baseline was abnormal</td> <td>&#62;20 x ULN if baseline was normal; &#62;20 x baseline if baseline was abnormal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Alanine aminotransferase increased</td> <td>&#62;ULN to 3 x ULN if baseline was normal; 1.5 to 3 x baseline if baseline was abnormal</td> <td>&#62;3 to 5 x ULN if baseline was normal; &#62;3 to 5 x baseline if baseline was abnormal</td> <td>&#62;5 to 20 x ULN if baseline was normal; &#62;5 to 20 x baseline if baseline was abnormal</td> <td>&#62;20 x ULN if baseline was normal; &#62;20 x baseline if baseline was abnormal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Aspartate aminotransferase increased</td> <td>&#62;ULN to 3 x ULN if baseline was normal; 1.5 to 3 x baseline if baseline was abnormal</td> <td>&#62;3 to 5 x ULN if baseline was normal; &#62;3 to 5 x baseline if baseline was abnormal</td> <td>&#62;5 to 20 x ULN if baseline was normal; &#62;5 to 20 x baseline if baseline was abnormal</td> <td>&#62;20 x ULN if baseline was normal; &#62;20 x baseline if baseline was abnormal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Blood bilirubin increased</td> <td>&#62;ULN to 1.5 x ULN if baseline was normal; &#62;1 to 1.5 x baseline if baseline was abnormal</td> <td>&#62;1.5 to 3 x ULN if baseline was normal; &#62;1.5 to 3 x baseline if baseline was abnormal</td> <td>&#62;3 to 10 x ULN if baseline was normal; &#62;3 to 10 x baseline if baseline was abnormal</td> <td>&#62;10 x ULN if baseline was normal; &#62;10 x baseline if baseline was abnormal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>GGT increased</td> <td>&#62;ULN to 2.5 x ULN if baseline was normal; 2 to 2.5 x baseline if baseline was abnormal</td> <td>&#62;2.5 to 5 x ULN if baseline was normal; &#62;2.5 to 5 x baseline if baseline was abnormal</td> <td>&#62;5 to 20 x ULN if baseline was normal; &#62;5 to 20 x baseline if baseline was abnormal</td> <td>&#62;20 x ULN if baseline was normal; &#62;20 x baseline if baseline was abnormal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Hepatic failure</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Asterixis; mild encephalopathy; drug-induced liver injury (DILI); limiting self-care ADL*</td> <td>Life-threatening consequences; moderate to severe encephalopathy; coma</td> <td>Death</td> </tr> <tr> <td>Portal hypertension</td> <td>&nbsp;</td> <td>Decreased portal vein flow</td> <td>Reversal/retrograde portal vein flow associated with varices and/or ascites</td> <td>Life-threatening consequences; urgent intervention needed</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The laboratory findings (ie, increased alkaline phosphatase, bilirubin, GGT, aspartate aminotransferase [also called AST or SGOT], and alanine aminotransferase [also called ALT or SGPT]) are graded separately under \"Investigations\" in the source document. Hepatic failure, characterized by the inability of the liver to metabolize chemicals in the body, and portal hypertension, characterized by an increase in blood pressure in the portal venous system, are graded under hepatobiliary disorders.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; ULN: upper limit of normal; GGT: gamma-glutamyl transpeptidase (also called gamma-glutamyl transferase); DILI: drug-induced liver injury; ADL: activities of daily living.<br />* DILI is defined by Hy's law; refer to text for details. Self-care ADLs include bathing, dressing/undressing, using the toilet, taking medications, and not bedridden.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 77533 Version 12.0</div></div></div>"},"77534":{"type":"graphic_diagnosticimage","displayName":"MRI of nerve sheath A","title":"MRI of lumbar intradural nerve sheath tumor","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">MRI of lumbar intradural nerve sheath tumor</div><div class=\"cntnt\"><img style=\"width:542px; height:270px;\" src=\"images/ONC/77534_MRI_of_nerve_sheath_A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">33-year-old presented with a three-month history of biologic pain and progressive perineal numbness. MRI T1-weighted contrast image revealed a heterogeneously enhancing lesion at L2-3; Sagittal (a) and Axial (b) images show the lesion filling the thecal sac. The tumor was approached via an L2-3 laminectomy with intradural exploration. The tumor was debulked followed by sacrifice of the sensory roots from which it arose. Patient had increased perineal numbness postoperatively which completely resolved at one month.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div id=\"graphicVersion\">Graphic 77534 Version 5.0</div></div></div>"},"77536":{"type":"graphic_picture","displayName":"Hb H inclusions","title":"Hemoglobin H inclusions","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemoglobin H inclusions</div><div class=\"cntnt\"><img style=\"width:397px; height:296px;\" src=\"images/HEME/77536_HgbHinclusions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Red cells from a patient with acquired hemoglobin H disease were incubated in vitro with new methylene blue. Multiple (&quot;golf ball-like&quot;) small inclusions due to precipitation of hemoglobin H are seen as a result of interaction with this dye.</div><div class=\"graphic_reference\">Kindly provided by Dr. German Pihan, Pathology Department, Beth Israel Deaconess Medical Center, Boston.</div><div id=\"graphicVersion\">Graphic 77536 Version 2.0</div></div></div>"},"77537":{"type":"graphic_table","displayName":"ATRA plus chemotherapy for APL","title":"ATRA plus daunorubicin plus cytarabine with arsenic trioxide consolidation for acute promyelocytic leukemia [1]","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ATRA plus daunorubicin plus cytarabine with arsenic trioxide consolidation for acute promyelocytic leukemia [1]</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Induction therapy</td> </tr> <tr> <td class=\"indent1\">ATRA 45 mg/m<sup>2</sup> PO per day in two divided doses until CR <strong>plus</strong> an anthracycline (eg, daunorubicin or idarubicin) with or without added cytarabine. The optimal dose of daunorubicin in this setting has not been clarified (see text).</td> </tr> <tr> <td class=\"subtitle2_single\">Consolidation</td> </tr> <tr> <td class=\"indent1\">Two 25-day cycles of arsenic trioxide (0.15 mg/kg IV per day for five days each week for five weeks each) followed by two cycles of the combination of daunorubicin (50 mg/m<sup>2</sup> IV daily for three days) plus ATRA (45 mg/m<sup>2</sup> per day orally days 1 through 7).</td> </tr> <tr> <td class=\"subtitle2_single\">Maintenance</td> </tr> <tr> <td class=\"indent1\">ATRA 45 mg/m<sup>2</sup> PO daily on an intermittent schedule (eg, 15 days every three months or 7 days every two weeks) for one year.</td> </tr> <tr> <td class=\"subtitle2_single\">Follow-up</td> </tr> <tr> <td class=\"indent1\">PCR for the PML/RARa fusion gene on a bone marrow specimen every three months for one year. Monitoring of peripheral blood may be a reasonable alternative. Relapses can occur between scheduled bone marrow studies and late relapses (ie, &#62;4 years) may be observed.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These recommendations are for patients with t(15;17) or the PML/RAR-alpha fusion gene only.</div><div class=\"graphic_footnotes\">ATRA: all-trans retinoic acid; CR: complete remission; PCR: polymerase chain reaction; 6-MP: 6-mercaptopurine; MTX: methotrexate; HCT: hematopoietic cell transplantation.</div><div class=\"graphic_reference\">Reference:<br> <ol> <li>Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2011; 116:3751. </li> </ol></div><div id=\"graphicVersion\">Graphic 77537 Version 8.0</div></div></div>"},"77539":{"type":"graphic_picture","displayName":"Echinostomiasis egg","title":"Echinostomiasis egg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echinostomiasis egg</div><div class=\"cntnt\"><img style=\"width:300px; height:300px;\" src=\"images/ID/77539_Echinostomiasis_egg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Egg of <em>Echinostoma</em> spp in an unstained wet mount of stool.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Echinostomiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/echinostomiasis/index.html\">http://www.cdc.gov/dpdx/echinostomiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 77539 Version 5.0</div></div></div>"},"77540":{"type":"graphic_figure","displayName":"BMD bone markers and hip fx","title":"BMD and bone turnover markers are independent predictors of hip fracture risk","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">BMD and bone turnover markers are independent predictors of hip fracture risk</div><div class=\"cntnt\"><img style=\"width:449px; height:343px;\" src=\"images/ENDO/77540_BMD_bone_markers_and_hip_fx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low BMD was defined according to the WHO guidelines, ie, by a value 2.5 SD or more below the young-adult mean (T-score ≤2.5). High bone resorption was defined by CTX or free D-Pyr values higher than the upper limit (mean +2 SD) of the premenopausal range. Women with both low hip BMD and high bone resorption were at a higher risk of hip fracture than women with either low hip BMD or high bone resorption.</div><div class=\"graphic_footnotes\">BMD: bone mineral density; CTX: C-telopeptide; D-Pyr: free deoxypyridinoline; SD: standard deviation; WHO: World Health Organization.</div><div class=\"graphic_reference\">Reproduced with permission from: Garnero, P, Hausherr, E, Chapuy, MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11:1531. Copyright ©1996 American Society for Bone and Mineral Research.</div><div id=\"graphicVersion\">Graphic 77540 Version 2.0</div></div></div>"},"77541":{"type":"graphic_figure","displayName":"Metabolism of tryptophan","title":"Metabolism of tryptophan to melatonin in the pineal gland","html":"<div class=\"graphic\"><div style=\"width: 565px\" class=\"figure\"><div class=\"ttl\">Metabolism of tryptophan to melatonin in the pineal gland</div><div class=\"cntnt\"><img style=\"width:545px; height:487px;\" src=\"images/ENDO/77541_Metabolism_of_tryptophan.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Zhdanova, IV, Wurtman, RJ. In: Endocrinology: Basic and Clinical Principles, PM, Conn, S, Melmed (Eds), Humana Press, Inc, Totowa, NJ, 1997. p. 281. Copyright &#169; 1997 Humana Press.</div><div id=\"graphicVersion\">Graphic 77541 Version 1.0</div></div></div>"},"77542":{"type":"graphic_picture","displayName":"Barretts esophagus Low","title":"Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:413px; height:252px;\" src=\"images/GAST/77542_Barretts_esophagus_Low.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a biopsy specimen from a patient with Barrett's esophagus shows predominantly columnar-lined surface epithelium. Gastric-type pits, mucous glands, and occasional intestinalized crypts are also visible.</div><div class=\"graphic_reference\">From: Lewin KJ, Appelman HD. Tumors of the esophagus and stomach. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 18, 1996, Washington, DC. Armed Forces Institute of Pathology.</div><div id=\"graphicVersion\">Graphic 77542 Version 3.0</div></div></div>"},"77543":{"type":"graphic_diagnosticimage","displayName":"Tubo-ovarian abscess ultrasound","title":"Tubo-ovarian abscess","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tubo-ovarian abscess</div><div class=\"cntnt\"><img style=\"width:432px; height:390px;\" src=\"images/OBGYN/77543_Tuboovarian_abscess_ultraso.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound image of the left adnexa showing a tubo-ovarian abscess. A complex solid and cystic mass is identified in the left adnexa. The tubo-ovarian abscess is seen as a complex cyst (large arrow) and fluid-filled tube (short arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Thomas D Shipp, MD. Copyright © Thomas D Shipp, MD.</div><div id=\"graphicVersion\">Graphic 77543 Version 4.0</div></div></div>"},"77545":{"type":"graphic_picture","displayName":"Retinal vasculitis sarcoid","title":"Retinal vasculitis in sarcoidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Retinal vasculitis in sarcoidosis</div><div class=\"cntnt\"><img style=\"width:398px; height:300px;\" src=\"images/RHEUM/77545_Retinal_vasculitis_sarcoid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Vascular occlusion and hemorrhage from a patient with ocular sarcoidosis. Ophthalmologists would describe this lesion as indicative of retinal vasculitis.</div><div class=\"graphic_reference\">Courtesy of James T Rosenbaum, MD.</div><div id=\"graphicVersion\">Graphic 77545 Version 1.0</div></div></div>"},"77546":{"type":"graphic_table","displayName":"Symptoms in patients with CFS, also known as SEID","title":"Symptoms in patients with chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms in patients with chronic fatigue syndrome (CFS), also known as systemic exertion intolerance disease (SEID)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">%&nbsp;of patients</td> </tr> <tr> <td>Easy fatigability</td> <td>100</td> </tr> <tr> <td>Difficulty concentrating</td> <td>90</td> </tr> <tr> <td>Headache</td> <td>90</td> </tr> <tr> <td>Sore throat</td> <td>85</td> </tr> <tr> <td>Tender lymph nodes</td> <td>80</td> </tr> <tr> <td>Muscle aches</td> <td>80</td> </tr> <tr> <td>Joint aches</td> <td>75</td> </tr> <tr> <td>Feverishness</td> <td>75</td> </tr> <tr> <td>Difficulty sleeping</td> <td>70</td> </tr> <tr> <td>Psychiatric problems</td> <td>65</td> </tr> <tr> <td>Allergies</td> <td>55</td> </tr> <tr> <td>Abdominal cramps</td> <td>40</td> </tr> <tr> <td>Weight loss</td> <td>20</td> </tr> <tr> <td>Rash</td> <td>10</td> </tr> <tr> <td>Rapid pulse</td> <td>10</td> </tr> <tr> <td>Weight gain</td> <td>5</td> </tr> <tr> <td>Chest pain</td> <td>5</td> </tr> <tr> <td>Night sweats</td> <td>5</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Straus SE. J Infect Dis 1988; 157:405.</div><div id=\"graphicVersion\">Graphic 77546 Version 3.0</div></div></div>"},"77547":{"type":"graphic_algorithm","displayName":"Approach to the child with pseudovertigo","title":"Approach to the child with pseudovertigo","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Approach to the child with pseudovertigo</div><div class=\"cntnt\"><img style=\"width:480px; height:454px;\" src=\"images/EM/77547_Apprchildpseudovertigo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EKG: electrocardiogram.</div><div class=\"graphic_reference\">Reproduced with permission from: Teach SJ. Dizziness. In: Textbook of Pediatric Emergency Medicine, 6th ed, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77547 Version 8.0</div></div></div>"},"77548":{"type":"graphic_figure","displayName":"Adolescent HIV cases by race and ethnicity","title":"Diagnoses of HIV infection and population among adolescents aged 13 to 19 years, by race/ethnicity, 2013 - United States","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Diagnoses of HIV infection and population among adolescents aged 13 to 19 years, by race/ethnicity, 2013 - United States</div><div class=\"cntnt\"><img style=\"width:581px; height:441px;\" src=\"images/PEDS/77548_Adlscnt_HIV_cs_rc_ethnc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data include persons with a diagnosis of HIV infection regardless of stage of disease at diagnosis. All displayed data have been statistically adjusted to account for reporting delays, but not for incomplete reporting. </div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.<br />* Hispanics/Latinos can be of any race.</div><div class=\"graphic_reference\">Reproduced from: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV surveillance&mdash;Adolescents and young adults. Centers for Disease Control and Prevention. Available at: <a href=\"http://www.cdc.gov/hiv/pdf/statistics_surveillance_Adolescents.pdf\" spellcheck=\"true\" target=\"_blank\">http://www.cdc.gov/hiv/pdf/statistics_surveillance_Adolescents.pdf</a> (Accessed on July 30, 2015).</div><div id=\"graphicVersion\">Graphic 77548 Version 5.0</div></div></div>"},"77549":{"type":"graphic_figure","displayName":"Infraorbital nerve block","title":"Infraorbital nerve block (intraoral approach)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infraorbital nerve block (intraoral approach)</div><div class=\"cntnt\"><img style=\"width:393px; height:587px;\" src=\"images/EM/77549_Infraorbitalnerveblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The infraorbital nerve block anesthetizes the upper lip, lateral nose, lower eyelid, and medial cheek as shown in A. To perform, locate the infraorbital foramen with the middle finger and lift the upper lip with the index finger and thumb as shown in B. Numb the upper gum line near the second bicuspid using topical anesthetic (eg, 2 percent viscous lidocaine on a Q-tip). Insert a small needle (gauge 25 or 27) through the gum line and at the second bicuspid as shown until the needle is palpated at the infraorbital foramen (approximately 2 cm in the adolescent or adult).&nbsp;If the patient reports paresthesias, withdraw the needle until paresthesias resolve. Inject one to two mL of buffered lidocaine 1 percent with epinephrine. Allow 5-10 minutes for complete anesthesia to occur.</div><div class=\"graphic_reference\">Reproduced with permission from: Cimpello LB, Deutsch RJ, Dixon C, et al. Illustrated techniques of pediatric emergency procedures. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77549 Version 8.0</div></div></div>"},"77551":{"type":"graphic_table","displayName":"Lymphatic drainage of the head and neck ","title":"Lymphatic drainage of the head and neck","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lymphatic drainage of the head and neck</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Lymph node group\r\n  \r\n   </td>\r\n  \r\n   <td  class=\"subtitle1\">\r\n  \r\n   Anatomic areas drained\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Occipital</td>\r\n  \r\n   <td>Posterior scalp</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Postauricular</td>\r\n  \r\n   <td>Temporal and parietal scalp</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Preauricular</td>\r\n  \r\n   <td>Anterior and temporal scalp, midface, nose, anterior ear canal and pinna, lateral conjunctivae</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Parotid</td>\r\n  \r\n   <td>Forehead and temporal scalp, midface, nose, external ear canal, middle ear, gums, parotid gland</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Submandibular (submaxillary)</td>\r\n  \r\n   <td>Cheek, nose, lips, anterior tongue, submandibular gland, buccal mucosa</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Submental</td>\r\n  \r\n   <td>Central lower lip, floor of mouth, tongue</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Superficial cervical</td>\r\n  \r\n   <td>Skin, lower larynx, lower ear canal, parotid</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Superior deep cervical</td>\r\n  \r\n   <td>Tonsil, adenoid, posterior scalp and neck, tongue, larynx, hypopharynx, thyroid, palate, nose, esophagus, paranasal sinuses, nasopharynx, other cervicofacial nodes</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td>Inferior deep cervical</td>\r\n  \r\n   <td>Dorsal scalp and neck, nasopharynx, superficial pectoral region of the arm, superior deep cervical</td>\r\n  \r\n   </tr>\r\n </table></div><div id=\"graphicVersion\">Graphic 77551 Version 2.0</div></div></div>"},"77552":{"type":"graphic_picture","displayName":"Sebaceous cell carcinoma eyelid","title":"Sebaceous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sebaceous carcinoma</div><div class=\"cntnt\"><img style=\"width:380px; height:268px;\" src=\"images/PC/77552_Sebaceous_cell_carcinoma_ey.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules that originally resemble chalazia then cause loss of lashes and destruction of the meibomian gland orifices.</div><div class=\"graphic_reference\">With permission from Slomovits TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 77552 Version 2.0</div></div></div>"},"77553":{"type":"graphic_table","displayName":"Agents for which activated charcoal is not recommended","title":"Agents for which activated charcoal is not recommended","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents for which activated charcoal is not recommended</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1_single\">Heavy metals</td></tr>\n\t\t\t\t\t\t<tr><td>Arsenic</td></tr>\n\t\t\t\t\t\t<tr><td>Lead</td></tr>\n\t\t\t\t\t\t<tr><td>Mercury</td></tr>\n\t\t\t\t\t\t<tr><td>Iron</td></tr>\n\t\t\t\t\t\t<tr><td>Zinc </td></tr>\n\t\t\t\t\t\t<tr><td>Cadmium</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Inorganic ions</td></tr>\n\t\t\t\t\t\t<tr><td>Lithium</td></tr>\n\t\t\t\t\t\t<tr><td>Sodium</td></tr>\n\t\t\t\t\t\t<tr><td>Calcium</td></tr>\n\t\t\t\t\t\t<tr><td>Potassium</td></tr>\n\t\t\t\t\t\t<tr><td>Magnesium</td></tr>\n\t\t\t\t\t\t<tr><td>Fluoride</td></tr>\n\t\t\t\t\t\t<tr><td>Iodide</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Boric acid</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Corrosives</td></tr>\n\t\t\t\t\t\t<tr><td>Acids</td></tr>\n\t\t\t\t\t\t<tr><td>Alkali</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Hydrocarbons</td></tr>\n\t\t\t\t\t\t<tr><td>Alkanes </td></tr>\n\t\t\t\t\t\t<tr><td>Alkenes</td></tr>\n\t\t\t\t\t\t<tr><td> Alkyl halides</td></tr>\n\t\t\t\t\t\t<tr><td> Aromatic hydrocarbons</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Alcohols</td></tr>\n\t\t\t\t\t\t<tr><td>Acetone</td></tr>\n\t\t\t\t\t\t<tr><td>Ethanol</td></tr>\n\t\t\t\t\t\t<tr><td>Ethylene glycol </td></tr>\n\t\t\t\t\t\t<tr><td>Isopropanol </td></tr>\n\t\t\t\t\t\t<tr><td>Methanol</td></tr>\n\t\t\t\t\t\t<tr><td class=\"subtitle1_single\">Essential oils</td></tr>\n\n    \n\n   \n    \n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77553 Version 2.0</div></div></div>"},"77554":{"type":"graphic_picture","displayName":"Chronic eosinophilic pneumonia biopsy","title":"Chronic eosinophilic pneumonia histopathology","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic eosinophilic pneumonia histopathology</div><div class=\"cntnt\"><img style=\"width:289px; height:189px;\" src=\"images/PULM/77554_Chronic_eosinophilic_pneu_L.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intermediate power photomicrograph showing a combination of air space filling and interstitial thickening in a patient with chronic eosinophilic pneumonia. The air space exudate&nbsp;is a&nbsp;combination of histiocytes and eosinophils. A similar inflammatory infiltrate is responsible for the associated alveolar septal thickening.</div><div class=\"graphic_reference\">Courtesy of Jeffrey L Myers, MD.</div><div id=\"graphicVersion\">Graphic 77554 Version 2.0</div></div></div>"},"77555":{"type":"graphic_figure","displayName":"M mode aortic stenosis","title":"Aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic stenosis</div><div class=\"cntnt\"><img style=\"width:297px; height:523px;\" src=\"images/CARD/77555_Mmodeaorticstenosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">M-mode echocardiogram and carotid pulse (CP) tracings show aortic stenosis of various severity. Panel A: Mild aortic stenosis. There is increased density in region of the aortic valve (AV) but preservation of the rapid movement of one leaflet. The carotid pulse tracing shows an upstroke time of 17 msec and an ejection time of 35 msec. Panel B: Critical aortic stenosis. There are dense echoes through the leaflets, which are uninterupted by leaflet motion. The carotid upstroke time is prolonged to 25 msec.</div><div class=\"graphic_footnotes\">Ao: aortic root; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 77555 Version 2.0</div></div></div>"},"77561":{"type":"graphic_table","displayName":"Brain mets prognosis RTOG RPA","title":"Prognostic groups for outcome after palliative treatment of brain metastases by recursive partitioning analysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prognostic groups for outcome after palliative treatment of brain metastases by recursive partitioning analysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class</td> <td class=\"subtitle1\">Prognostic factors</td> <td class=\"subtitle1\">Median survival (months)</td> </tr> <tr> <td class=\"centered divider_bottom\" rowspan=\"4\">I</td> <td>KPS &#8805;70 percent</td> <td class=\"centered divider_bottom\" rowspan=\"4\">7.1</td> </tr> <tr> <td>Age &#60;65 years</td> </tr> <tr> <td>Controlled primary site</td> </tr> <tr class=\"divider_bottom\"> <td>No extracranial metastases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">III</td> <td>KPS &#60;70</td> <td class=\"centered\">2.3</td> </tr> <tr> <td class=\"centered\">II</td> <td>All others</td> <td class=\"centered\">4.2</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KPS: Karnofsky performance status.</div><div class=\"graphic_reference\">Gaspar L, et al. Int J Radiat Oncol Biol Phys 1997; 37:745.</div><div id=\"graphicVersion\">Graphic 77561 Version 3.0</div></div></div>"},"77562":{"type":"graphic_figure","displayName":"Tropocollagen synthesis","title":"Tropocollagen synthesis","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Tropocollagen synthesis</div><div class=\"cntnt\"><img style=\"width:502px; height:280px;\" src=\"images/ENDO/77562_Tropocollagen_synthesis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first step in the synthesis of type I collagen in bone is the production of alpha-1 and alpha-2 polypeptides. After many of the prolines and lysines in the collagen chains are hydroxylated to hydroxyproline and hydroxylysine, one alpha-2 (shown in red) and two alpha-1 polypeptides (shown in blue) wind around each other to form a helical structure known as procollagen (top). Amino- and carboxy-terminal propeptides of type I collagen are cleaved off the procollagen molecule, resulting in the formation of tropocollagen (bottom).</div><div id=\"graphicVersion\">Graphic 77562 Version 2.0</div></div></div>"},"77563":{"type":"graphic_table","displayName":"Conditions leading to lymphoma","title":"Conditions associated with the development of lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with the development of lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Inherited immunodeficiency states </td> </tr> <tr> <td>Klinefelter syndrome</td> </tr> <tr> <td>Chediak-Higashi syndrome</td> </tr> <tr> <td>Ataxia telangiectasia syndrome</td> </tr> <tr> <td>Wiscott-Aldrich syndrome</td> </tr> <tr> <td>Common variable immunodeficiency disease</td> </tr> <tr> <td>X-linked lymphoproliferative disease</td> </tr> <tr> <td>Autoimmune lymphoproliferative syndrome</td> </tr> <tr> <td>Bloom syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Acquired immunodeficiency states </td> </tr> <tr> <td>Iatrogenic immunosuppression (eg, treatment of autoimmune disease or malignancy, organ transplantation)</td> </tr> <tr> <td>HIV-1 infection</td> </tr> <tr> <td>Acquired agammaglobulinemia</td> </tr> <tr> <td>Multicentric Castleman's disease</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune disorders </td> </tr> <tr> <td>Autoimmune hemolytic anemia</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Sj&#246;gren's syndrome (sicca complex)</td> </tr> <tr> <td>Hashimoto's thyroiditis</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory disorders </td> </tr> <tr> <td>Acquired angioedema (acquired C1 esterase inhibitor deficiency)</td> </tr> <tr> <td>Celiac disease, dermatitis herpetiformis</td> </tr> <tr> <td>Inflammatory bowel disease treated with azathioprine/6-MP</td> </tr> <tr> <td class=\"subtitle1_single\">Chemicals and drugs </td> </tr> <tr> <td>Phenytoin</td> </tr> <tr> <td>Dioxin, phenoxy-herbicides (Agent Orange), agricultural pesticides</td> </tr> <tr> <td>Ionizing radiation</td> </tr> <tr> <td>Chemotherapy, radiation therapy</td> </tr> <tr> <td>Tumor necrosis factor antagonists</td> </tr> <tr> <td>Hair dyes</td> </tr> <tr> <td class=\"subtitle1_single\">Infectious agents (other than HIV) </td> </tr> <tr> <td>Epstein-Barr virus</td> </tr> <tr> <td>Human T cell leukemia/lymphoma virus (HTLV)-I</td> </tr> <tr> <td>Human herpesvirus type 8 (HHV-8, primary effusion lymphoma)</td> </tr> <tr> <td>Helicobacter pylori</td> </tr> <tr> <td>Campylobacter jejuni (Mediterranean lymphoma)</td> </tr> <tr> <td>Chlamydia psittaci (ocular adnexal lymphoma)</td> </tr> <tr> <td>Borrelia afzelii (cutaneous B cell lymphoma)</td> </tr> <tr> <td>Hepatitis C virus (mixed cryoglobulinemia, splenic marginal zone lymphoma)</td> </tr> <tr> <td>Mycobacterium tuberculosis, EBV (pyothorax-associated lymphoma)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Freedman AS, Nadler LM. Malignancies of lymphoid cells. In: Harrison's Principles of Internal Medicine, 14th ed, Fauci AS, Braunwald E, Isselbacher KJ, et al. (Eds), McGraw-Hill, New York 1998. Copyright © 1998 McGraw-Hill.</div><div id=\"graphicVersion\">Graphic 77563 Version 2.0</div></div></div>"},"77564":{"type":"graphic_diagnosticimage","displayName":"LCH spine","title":"Langerhans cell histiocytosis of bone","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Langerhans cell histiocytosis of bone</div><div class=\"cntnt\"><img style=\"width:293px; height:358px;\" src=\"images/HEME/77564_Eos_granuloma_spine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T1 weighted magnetic resonance imaging of the upper spine shows a severe flattening of the C6 vertebral body with preservation of adjacent intervertebral discs (vertebra plana deformity, short red arrow). In addition, a soft tissue mass extending into the paracervical region (short yellow arrow) with resulting spinal cord compression (long red arrow) can be identified.</div><div id=\"graphicVersion\">Graphic 77564 Version 3.0</div></div></div>"},"77565":{"type":"graphic_picture","displayName":"SLN melanoma metastasis HandE","title":"Sentinel lymph node metastasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sentinel lymph node metastasis</div><div class=\"cntnt\"><img style=\"width:371px; height:273px;\" src=\"images/ONC/77565_SLN_melanoma_meta_Han_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power light photomicrograph of a section from a sentinel lymph node. In contrast to the surrounding lymphocytes, melanoma cells have large nuclei and prominent nucleoli. Arrows point to aggregates of melanoma cells.</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 77565 Version 4.0</div></div></div>"},"77566":{"type":"graphic_table","displayName":"Dentin dysplasia","title":"Heritable conditions of dentin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Heritable conditions of dentin</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Radiographic features</td> <td class=\"subtitle1\">Molecular defect</td> </tr> <tr> <td>DI type 1 (occurs in some forms of osteogenesis imperfecta) (MIM #<a href=\"http://omim.org/entry/125490\" target=\"_blank\">125490</a>)</td> <td>Variable blue-gray to yellow-brown teeth, enamel fracturing, excessive wear, primary teeth usually more affected than permanent</td> <td>Variable pulp obliteration, bulbous crowns, altered root morphology, increased risk for dentigerous cysts</td> <td>Mutations of collagen type 1 genes (<em>COL1A1</em> and <em>COL1A2</em>)</td> </tr> <tr class=\"divider_top\"> <td>DI type 2<br /> (MIM #<a href=\"http://omim.org/entry/125490\" target=\"_blank\">125490</a>)</td> <td>Same appearance and variability as in DI type 1, often similar severity in primary and permanent dentitions</td> <td>Pulp chamber obliteration that can begin before tooth eruption, abnormal crown and root morphology</td> <td>Mutations&nbsp;of dentin sialophosphoprotein gene (<em>DSPP</em>) at 4q22.1</td> </tr> <tr class=\"divider_top\"> <td>DI type 3<br /> (MIM #<a href=\"http://omim.org/entry/125500\" target=\"_blank\">125500</a>)</td> <td>Similar clinical phenotype as DI types 1 and 2 although typically severe expression with enamel loss and extensive wear occurring early</td> <td>Large pulp chambers, very thin dentin, bulbous crowns, diminished root structure</td> <td>Mutations&nbsp;of dentin sialophosphoprotein gene (<em>DSPP</em>) at 4q22.1</td> </tr> <tr class=\"divider_top\"> <td>Dentin dysplasia type 1<br /> (MIM #<a href=\"http://omim.org/entry/125400\" target=\"_blank\">125400</a>)</td> <td>Normal clinical crown morphology and coloration in primary and permanent dentitions, malaligned teeth, frequent dental abscess</td> <td>Pulp obliteration and short blunt roots in both primary and permanent dentitions</td> <td>Mutations&nbsp;of SPARC-related modular calcium-binding protein 2 gene&nbsp;(<em>SMOC2</em>) at 6q27</td> </tr> <tr class=\"divider_top\"> <td>Dentin dysplasia type 2<br /> (MIM #<a href=\"http://omim.org/entry/125420\" target=\"_blank\">125420</a>)</td> <td>Primary dentition has same phenotype as DI, permanent dentition has normal to slight blue-gray discoloration</td> <td>Pulp obliteration in primary dentition, abnormal pulp morphology, pulp stones in permanent dentition</td> <td>Mutations&nbsp;of dentin sialophosphoprotein&nbsp;gene(<em>DSPP</em>) at&nbsp;4q22.1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DI: dentinogenesis imperfecta; SPARC: secreted protein acidic and rich in cysteine.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Online Mendelian Inheritance in Man. Available at <A style=\"FONT-STYLE: italic\" href=\"http://www.omim.org/\" target=_blank>www.omim.org</A>. Accessed on December 4, 2013.</LI></OL>Original figure modified for this publication.&nbsp;Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77566 Version 8.0</div></div></div>"},"77568":{"type":"graphic_diagnosticimage","displayName":"Asbestosis CT","title":"Asbestosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Asbestosis</div><div class=\"cntnt\"><img style=\"width:373px; height:246px;\" src=\"images/PULM/77568_Asbestosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan in asbestosis shows bibasal opacities which are difficult to differentiate from gravitational changes without a prone scan. Several small cystic, honeycomb-like changes at the left lung base as well as a pleural plaque in the right anterior hemithorax are findings which make the diagnosis of asbestosis likely.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77568 Version 4.0</div></div></div>"},"77569":{"type":"graphic_figure","displayName":"Home sleep apnea test tracing","title":"Home sleep apnea test tracing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Home sleep apnea test&nbsp;tracing</div><div class=\"cntnt\"><img style=\"width:450px; height:372px;\" src=\"images/SLEEP/77569_Home_sleep_tracing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical tracing from a four-channel cardiopulmonary recording performed at home. The parameters measured include pulse rate, chest wall impedance, airflow, and oxygen saturation. Obstructive apneas are denoted by the letter \"A.\"</div><div class=\"graphic_footnotes\">BPM: beats per minute.</div><div id=\"graphicVersion\">Graphic 77569 Version 3.0</div></div></div>"},"77570":{"type":"graphic_diagnosticimage","displayName":"Type II supracondylar fracture 2","title":"Gartland type II supracondylar fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gartland type II supracondylar fracture</div><div class=\"cntnt\"><img style=\"width:291px; height:432px;\" src=\"images/EM/77570_Type_II_supracondylar_fx_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Type II extension supracondylar humeral fracture (left elbow). Lateral radiograph. Note the positive fat pad sign (arrows) and how the anterior humeral line does not intersect with the capitellar epiphysis (black vertical line). A, ulna; B, humerus; C, capitellar epiphysis; D, radial head.</div><div class=\"graphic_reference\">Reproduced with permission from: Koval KJ, Zuckerman JD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &#169; 2004 Lippincott Williams &amp; Wilkins.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 77570 Version 4.0</div></div></div>"},"77571":{"type":"graphic_table","displayName":"Indications for liver biopsy","title":"Indications for liver biopsy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for liver biopsy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Diagnosis, grading, and staging of alcoholic liver disease, nonalcoholic steatohepatitis, and autoimmune hepatitis</td> </tr> <tr> <td>Grading and staging of chronic hepatitis B and C*</td> </tr> <tr> <td class=\"sublist1_start\">Diagnosis of:</td> </tr> <tr> <td> <ul> <li>Hemochromatosis (quantitative estimation of hepatic iron) </li> <li>Wilson disease (quantitative hepatic copper) </li> <li>Focal liver lesions </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\">Evaluation of:</td> </tr> <tr> <td> <ul> <li>Cholestatic liver disease: primary biliary cholangitis, primary sclerosing cholangitis </li> <li>Abnormal liver biochemical tests in a patient with a negative or inconclusive serologic work-up </li> <li>Treatment efficacy </li> <li>Side effects of treatment regimens (such as methotrexate for rheumatoid arthritis) </li> <li>Post-liver transplant by protocol or for evaluation of abnormal liver biochemical tests </li> <li>Donor liver </li> <li>Fever of unknown origin </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Because of the development of newer hepatitis C treatments that are effective and tolerable, staging of liver disease prior to hepatitis C treatment may not be necessary. Refer to UpToDate topics on the treatment of hepatitis C for details.</div><div class=\"graphic_reference\">Adapted from: Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.</div><div id=\"graphicVersion\">Graphic 77571 Version 8.0</div></div></div>"},"77572":{"type":"graphic_waveform","displayName":"ECG in pericarditis","title":"Electrocardiogram (ECG) in pericarditis","html":"<div class=\"graphic normal\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram (ECG) in pericarditis</div><div class=\"cntnt\"><img style=\"width:538px; height:322px;\" src=\"images/CARD/77572_ECG_in_pericarditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram in acute pericarditis showing diffuse upsloping ST segment elevations seen best here in leads II, III, aVF, and V2 to V6. There is also subtle PR segment deviation (positive in aVR, negative in most other leads). ST segment elevation is due to a ventricular current of injury associated with epicardial inflammation; similarly, the PR segment changes are due to an atrial current of injury which, in pericarditis, typically displaces the PR segment upward in lead aVR and downward in most other leads.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 77572 Version 3.0</div></div><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Normal ECG</div><div class=\"cntnt\"><img style=\"width:594px; height:337px;\" src=\"images/CARD/76183_Normal_ECG.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75°.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 76183 Version 3.0</div></div></div>"},"77573":{"type":"graphic_figure","displayName":"Predictive model for outcome after CABG","title":"Predictive model for outcome after CABG","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Predictive model for outcome after CABG</div><div class=\"cntnt\"><img style=\"width:505px; height:789px;\" src=\"images/CARD/77573_Predct_modl_outcm_aftr_CABG.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative factors can be used to predict in-hospital mortality and morbidity in patients who are undergoing coronary artery bypass graft surgery (CABG). These factors are given a risk score value (panel B). Based upon the total risk score, which varies from 0 to 73, patients can be stratified in deciles of risk (panel A). The predicted probability of a major adverse event correlates closely with the observed incidence.</div><div class=\"graphic_reference\">Data from Fortescue EB, Kahn K, Bates DW. Development and validation of a clinical prediction rule for major adverse outcomes in coronary bypass grafting. Am J Cardiol 2001; 88:1251.</div><div id=\"graphicVersion\">Graphic 77573 Version 4.0</div></div></div>"},"77575":{"type":"graphic_diagnosticimage","displayName":"Hepatic hemangioma US","title":"Hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:363px; height:282px;\" src=\"images/GAST/77575_Hepatic_hemangioma_US.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound of a hepatic hemangioma shows a homogenous, hyperechoic lesion with an etched border.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 77575 Version 3.0</div></div></div>"},"77576":{"type":"graphic_figure","displayName":"Cardiac anatomy PI","title":"Anatomy of the interior of the heart","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Anatomy of the interior of the heart</div><div class=\"cntnt\"><img style=\"width:536px; height:544px;\" src=\"images/PI/77576_Cardiac_anatomy_PI.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77576 Version 4.0</div></div></div>"},"77579":{"type":"graphic_table","displayName":"Physiologic Rx Malnutrition A","title":"Physiologic basis for treatment of severe malnutrition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic basis for treatment of severe malnutrition</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Affected organ or system</td> <td class=\"subtitle1\">Effects</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td>Cardiovascular system</td> <td> <p>Cardiac output and stroke volume are reduced</p> <p>Infusion of saline may cause an increase in venous pressure</p> <p>Any increase in blood volume can easily produce acute heart failure; any decrease will further compromise tissue perfusion</p> <p>Blood pressure is low</p> <p>Renal perfusion and circulation time are reduced</p> <p>Plasma volume is usually normal and red cell volume is reduced</p> </td> <td> <p>If the child appears dehydrated, give ReSoMal or F-75 diet; do not give fluids intravenously unless the child is in shock</p> <p>If there is evidence of congestive heart failure, restrict blood transfusion to 10 mL/kg and give a diuretic*</p> </td> </tr> <tr class=\"divider_top\"> <td>Liver</td> <td> <p>Synthesis of all proteins is reduced</p> <p>Abnormal metabolites of amino acids are produced</p> <p>Capacity of liver to take up, metabolize and excrete toxins is severely reduced</p> <p>Energy production from substrates such as galactose and fructose is much slower than normal</p> <p>Gluconeogenesis is reduced, which increases the risk of hypoglycaemia during infection</p> <p>Bile secretion is reduced</p> </td> <td> <p>Do not give the child large meals</p> <p>Ensure that the amount of protein given does not exceed the metabolic capacity of the liver, but is sufficient to support synthesis of proteins (1-2 g/kg per day)</p> <p>Reduce the dosage of drugs that depend on hepatic disposal or are hepatotoxic</p> <p>Ensure that sufficient carbohydrate is given to avoid the need for gluconeogenesis</p> <p>Do not give iron supplements, which may be dangerous because transferrin levels are reduced</p> </td> </tr> <tr class=\"divider_top\"> <td>Genitourinary system</td> <td> <p>Glomerular filtration is reduced</p> <p>Capacity of kidney to excrete excess acid or a water load is greatly reduced</p> <p>Urinary phosphate output is low</p> <p>Sodium excretion is reduced</p> <p>Urinary tract infection is common</p> </td> <td> <p>Prevent further tissue breakdown by treating any infections and providing adequate energy (80-100 kcal/kg or 336-420 kJ/kg per day)</p> <p>Do not give the child more protein than is required to maintain tissues</p> <p>Ensure that high-quality proteins are given, with balanced amino acids</p> <p>Avoid nutrients that give an acid load, such as magnesium chloride</p> <p>Restrict dietary sodium</p> <p>Ensure that water intake is sufficient but not excessive</p> </td> </tr> <tr class=\"divider_top\"> <td>Gastrointestinal system</td> <td> <p>Production of gastric acid is reduced</p> <p>Intestinal motility is reduced</p> <p>Pancreas is atrophied and production of digestive enzymes is reduced</p> <p>Small intestinal mucosa is atrophied; activities of digestive enzymes are reduced</p> <p>Absorption of nutrients is reduced when large amounts of food are eaten</p> </td> <td> <p>Give the child small, frequent feeds</p> <p>If absorption is poor, increase the frequency and reduce the size of each feed</p> <p>If there is malabsorption of fat, treatment with pancreatic enzymes may be useful</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Diuretics should not be given to reduce edema in malnourished children.</div><div class=\"graphic_reference\">Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &#169; 1999 World Health Organization.</div><div id=\"graphicVersion\">Graphic 77579 Version 3.0</div></div></div>"},"77580":{"type":"graphic_table","displayName":"Long-acting meds for ADHD in children","title":"Intermediate- and long-acting medications for children with attention deficit hyperactivity disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intermediate- and long-acting medications for children with attention deficit hyperactivity disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">United States trade name<br /> (generic availability)</td> <td class=\"subtitle1\">Description of release and duration of action</td> <td class=\"subtitle1\">Initial dose*</td> <td class=\"subtitle1\">Dose advancement</td> <td class=\"subtitle1\">Maximum dose<br /> (per day)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Methylphenidate</td> </tr> <tr> <td class=\"indent1\">Methylphenidate ER<br /> (10, 20 mg tablets)</td> <td>Metadate ER (generic available)</td> <td> <p>Delayed onset with continuous release over 3 to 8 hours. May require twice daily dosing and/or use with immediate-release methylphenidate.</p> <p>Tablet must be swallowed whole.</p> </td> <td>10 mg</td> <td>Increments of 10 mg per day every 3 to 7 days</td> <td> <p>&#8804;50 kg: 60 mg</p> &#62;50 kg: 100 mg<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"> <p>Methylphenidate ER chewable tablets</p> <p>(20 mg [scored], 30 mg [scored], 40 mg [not scored])</p> </td> <td>Quillichew ER</td> <td>Continuous release over 6 to 8 hours with duration of action up to 13 hours.</td> <td>20 mg</td> <td>Increments of 10 mg, 15 mg, or 20 mg per day every 7 days</td> <td>60 mg</td> </tr> <tr> <td class=\"indent1\"> <p>Methylphenidate&nbsp;XR-ODT</p> <p>(8.6, 17.3, 25.9 mg tablets as methylphenidate base [equivalent to 10, 20, 30 mg of methylphenidate hydrochloride])<sup>&#916;</sup></p> </td> <td>Cotempla XR-ODT&nbsp;</td> <td> <p>25% immediate-release and 75% extended-release for duration of action up to 12 hours.</p> <p>Whole tablet&nbsp;must be&nbsp;dissolved on tongue; should be taken&nbsp;consistently either with or without food<sup>&#9674;</sup>.</p> </td> <td>17.3 mg</td> <td>Increments of 8.6 to 17.3 mg per day every 7 days</td> <td>51.8 mg</td> </tr> <tr> <td class=\"indent1\"> <p>Methylphenidate ER</p> <p>(18, 27, 36, 54 mg tablets)&nbsp;</p> </td> <td>Concerta (generic available)</td> <td> <p>20% immediate-release and 80% continuous-release over 10 to 12 hours by osmotic delivery.</p> <p>Tablet must be swallowed whole.</p> </td> <td>18 mg&nbsp;</td> <td>Increments of 9 to 18 mg per dose every 3 to 7 days</td> <td> <p>&#60;13 years: 54 mg</p> <p>&#8805;13 years: 72 mg</p> </td> </tr> <tr> <td class=\"indent1\">Methylphenidate LA<br /> (10, 20, 30, 40 mg capsules)</td> <td>Ritalin LA (generic available except 10 mg)</td> <td> <p>50% immediate-release and 50% delayed-release over 8 to 12 hours (bimodal).</p> <p>Capsule may be swallowed whole or opened and contents sprinkled over spoonful of cold applesauce and swallowed immediately; capsule or contents should not be crushed or chewed.&nbsp;</p> </td> <td>10 or 20 mg</td> <td>Increments of 10 or 20 mg per dose every 3 to 7 days</td> <td> <p>&#8804;50 kg: 60 mg</p> &#62;50 kg: 100 mg<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Methylphenidate CD<br /> (10, 20, 30, 40, 50, 60 mg capsules)</td> <td>Metadate CD (generic available)</td> <td> <p>30% immediate-release and 70% delayed-release over 8 to 12 hours (bimodal).</p> <p>Capsule may be swallowed whole or opened and contents sprinkled over spoonful of cold applesauce and swallowed immediately; capsule or contents should not be crushed or chewed.</p> </td> <td>20 mg</td> <td>Increments of 10 mg per dose every 3 to 7 days</td> <td> <p>&#8804;50 kg: 60 mg</p> &#62;50 kg: 100 mg<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\"> <p>Methylphenidate XR&nbsp;</p> <p>(10, 15, 20, 30, 40, 50, 60 mg capsules)</p> </td> <td>Aptensio&nbsp;XR (generic available)</td> <td> <p>40% immediate release and 60% controlled release for duration of action of 12 hours.</p> <p>Capsule may be swallowed whole or opened and contents sprinkled over spoonful of cold applesauce and swallowed immediately; capsule or contents should not be crushed or chewed.</p> </td> <td>10 mg</td> <td>Increments of 10 mg every 7 days</td> <td>60 mg</td> </tr> <tr> <td class=\"indent1\"> <p>Methylphenidate XR oral suspension<br /> (5 mg/mL)</p> </td> <td>Quillivant XR</td> <td>20% immediate-release and 80% extended-release for duration of action up to 12 hours.</td> <td>20 mg</td> <td>Increments of 10 mg every 7 days</td> <td>60 mg</td> </tr> <tr> <td class=\"indent1\"> <p>Methylphenidate patch<sup>&#167;</sup></p> <p>(10, 15, 20, 30 mg patch)</p> </td> <td>Daytrana</td> <td>Onset 2 hours after application of patch and continuous release over&nbsp;9 to 12 hours.</td> <td>10 mg<sup>&#167;</sup></td> <td>Increments of 5 mg per dose every 3 to 7 days</td> <td>30 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Dexmethylphenidate</td> </tr> <tr> <td class=\"indent1\">Dexmethylphenidate XR<br /> (5, 10, 15, 20, 25, 30, 35, 40 mg capsules)</td> <td> <p>Focalin XR</p> <p>(generic available)</p> </td> <td> <p>50% immediate-release and 50% delayed-release over 10 to 12 hours (bimodal).</p> <p>Capsule may be swallowed whole or opened and contents sprinkled over spoonful of cold applesauce and swallowed immediately; capsule or contents should not be crushed or chewed.</p> </td> <td>5 mg</td> <td>Increments of 5 mg per dose every 3 to 7 days</td> <td>40 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Amphetamines</td> </tr> <tr> <td class=\"indent1\">Amphetamine-dextroamphetamine ER mixed salts<br /> (5, 10, 15, 20, 25, 30 mg capsules)<sup>&#165;</sup></td> <td>Adderall XR (generic available)</td> <td>Combination of immediate- and continuous-release over 8 to 10 hours. </td> <td>5 mg</td> <td>Increments of 5 mg per dose every 3 to 7 days</td> <td> <p>&#8804;50 kg: 40 mg</p> <p>&#62;50 kg: 60 mg<sup>&#135;</sup></p> </td> </tr> <tr> <td class=\"indent1\"> <p>Amphetamine-dextroamphetamine ER mixed salts(12.5, 25, 37.5, 50 mg capsules)<sup>&#165;&#134;</sup></p> </td> <td>Mydayis</td> <td> <p>Combination of immediate- and two different delayed-release beads for duration up to 16 hours.</p> <p>Capsule may be swallowed whole or sprinkled over a spoonful of cold applesauce and swallowed immediately; capsule or contents should not be crushed or chewed.</p> </td> <td>12.5 mg</td> <td>Increments of 12.5 mg every 7 days</td> <td> <p>13 through 17 years: 25 mg</p> <p>&#8805;18 years: 50 mg</p> </td> </tr> <tr> <td class=\"indent1\">Amphetamine&nbsp;ER (oral suspension 2.5 mg amphetamine as base per mL)<sup>&#165;</sup></td> <td>Dyanavel XR </td> <td> <p>Combination of immediate- and extended-release for duration of action up to 13 hours.</p> </td> <td>2.5 or 5 mg </td> <td>Increments of 2.5 to 10 mg per day every 4 to 7 days</td> <td>20 mg&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <p>Amphetamine ER (oral suspension 1.25 mg amphetamine as base per mL)<sup>&#165;</sup></p> </td> <td>Adzenys ER</td> <td>Combination of 50% immediate- and 50% extended-release; levels are comparable to amphetamine-dextroamphetamine ER mixed salts capsules when equivalent doses are used<sup>&#165;</sup>.</td> <td>6.3 mg&nbsp;</td> <td>Increments of 3.1 or 6.3 mg per day every 7 days</td> <td> <p>6 to 12 years: 18.8 mg</p> <p>&#8805;13 years: 12.5 mg</p> </td> </tr> <tr> <td class=\"indent1\">Amphetamine ER (ODT&nbsp;3.1, 6.3, 9.4, 12.5, 15.7, 18.8 mg as base)<sup>&#165;</sup></td> <td>Adzenys&nbsp;XR-ODT&nbsp;</td> <td> <p>Combination of 50% immediate- and 50% extended-release; levels are&nbsp;comparable to amphetamine-dextroamphetamine ER mixed salts capsules when equivalent doses are used<sup>&#165;</sup>.</p> </td> <td>6.3 mg</td> <td>Increments of 3.1 or 6.3 mg per day every 7 days</td> <td> <p>6 to 12 years: 18.8 mg</p> <p>&#8805;13 years: 12.5 mg</p> </td> </tr> <tr> <td class=\"indent1\">Dextroamphetamine SR<br /> (5, 10, 15 mg capsules)</td> <td>Generic extended release available (Dexedrine Spansule brand is no longer available)</td> <td>Combination of immediate- and continuous-release over 6 to 8 hours. May require dividing dose twice daily.</td> <td>5 mg</td> <td>Increments of 5 mg per day every 3 to 7 days</td> <td> <p>&#8804;50 kg: 40 mg</p> &#62;50 kg: 60 mg<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\">Lisdexamfetamine<br /> (10, 20, 30, 40, 50, 60, 70 mg capsules and&nbsp;10, 20, 30, 40, 50, 60 mg chewable tablets)</td> <td>Vyvanse</td> <td> <p>Prodrug converted to dextroamphetamine in bloodstream with an effect over approximately 10 hours.</p> <p>Capsule may be opened and dissolved in water or juice for immediate use.</p> <p>Chewable tablets must be chewed completely before swallowing.</p> </td> <td>20 mg</td> <td>Increments of 10 or 20 mg per day every 3 to 7 days</td> <td>70 mg</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Nonstimulants</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Selective norepinephrine reuptake inhibitor</td> </tr> <tr> <td class=\"indent2\">Atomoxetine<br /> (10, 18, 25, 40, 60, 80, 100 mg capsules)</td> <td>Strattera (generic available)</td> <td>At least 10 to 12 hours.</td> <td>0.5 mg/kg per day for minimum of 3 days</td> <td>Increase to 1.2 mg/kg per day after a minimum of 3 days (maximum 100 mg per day)</td> <td>Lesser or 1.4 mg/kg or 100 mg </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"6\">Alpha-2 adrenergic agonists</td> </tr> <tr> <td class=\"indent2\">Guanfacine ER**(1, 2, 3, 4 mg tablets)</td> <td>Intuniv (generic available)</td> <td>At least 10 to 12 hours.</td> <td>1 mg per day<sup>&#135;</sup></td> <td>Increments of 1 mg per day at no less than weekly intervals</td> <td> <p>&#8804;12 years: 4 mg</p> <p>&#62;12 years: 7 mg</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ER: extended release; XR: extended release; ODT: orally disintegrating tablet; LA: long-acting; CD: controlled dispense; SR: sustained release.<br />* Suggested doses for initiating treatment with long-acting stimulant medications for treatment of children aged ≥6 years.<br />¶ This maximum dose exceeds the US Food and Drug Administration (FDA)-approved maximum dose; careful monitoring for adverse effects is warranted.<br />Δ&nbsp;Cotempla XR-ODT strengths are expressed by the manufacturer as methylphenidate base. Most other methylphenidate product doses are expressed as methylphenidate hydrochloride salt. Cotempla XR-ODT dose needs to be converted to methylphenidate hydrochloride for comparison with other methylphenidate products.<br />◊ Although the prescribing information&nbsp;indicates that Cotempla XR-ODT&nbsp;should be taken consistently with or without food, we suggest that it be taken consistently with food – given the general stimulant effect of appetite suppression.<br />§ Patch is applied 2 hours before needed effect and worn for a total of 9 hours. Doses for the methylphenidate patch are not equivalent to those for the oral preparations.<br />¥&nbsp;Amphetamine&nbsp;ER oral suspension and ODT strengths reflect milligrams of amphetamine base, whereas amphetamine-dextroamphetamine ER capsule strengths reflect milligrams of mixed salts. These cannot be substituted on an mg-per-mg basis. <FONT color=black>For conversion, refer to separate table of dose equivalents of stimulants for ADHD available in UpToDate.</FONT><br />‡&nbsp;Doses above 40 mg per day total are rarely necessary and warrant close monitoring.<br />†&nbsp;Mydayis is not approved by the FDA for children &lt;13 years.<br />**&nbsp;Immediate-release form cannot be substituted mg-for-mg for ER form&nbsp;due to pharmacokinetic differences. Discontinuation requires dose tapering to prevent rebound increase in blood pressure.<FONT color=red><br /></FONT></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.</LI>&#xD;&#xA;<LI>Subcommittee on attention-deficit/hyperactivity disorder, Steering committee on quality improvement and management. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Supplemental information. Pediatrics 2011.</LI>&#xD;&#xA;<LI>Drugs for ADHD. Med Lett Drugs Ther 2015; 57:37.</LI>&#xD;&#xA;<LI>Wender EH. Managing stimulant medication for attention-deficit/hyperactivity disorder. Pediatr Rev 2001; 22:183.</LI></OL>Prepared with additional data from the US Food&nbsp;and Drug Administration approved product information, available at <A spellcheck=true href=\"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm\" target=_blank>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm</A> (accessed on September 19, 2017). </div><div id=\"graphicVersion\">Graphic 77580 Version 20.0</div></div></div>"},"77583":{"type":"graphic_picture","displayName":"Laser PRP for severe PDR","title":"Panretinal photocoagulation for severe proliferative diabetic retinopathy: Appearance on fundus photograph","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Panretinal photocoagulation for severe proliferative diabetic retinopathy: Appearance on fundus photograph</div><div class=\"cntnt\"><img style=\"width:396px; height:300px;\" src=\"images/ENDO/77583_Laser_PRP_for_severe_PDR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Color fundus photograph of the posterior portion of laser panretinal photocoagulation (PRP) for severe proliferative diabetic retinopathy with areas of neovascularization at the disc and elsewhere (NVD and NVE) as well as white ischemic retinal vessels, and displaying numerous laser burns outside the macula; the treatment would further continue in all quadrants to the midperiphery.</div><div id=\"graphicVersion\">Graphic 77583 Version 3.0</div></div></div>"},"77584":{"type":"graphic_figure","displayName":"Waist circumference measure","title":"Waist circumference measurement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Waist circumference measurement</div><div class=\"cntnt\"><img style=\"width:357px; height:468px;\" src=\"images/ENDO/77584_Waist_circumference_measure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measuring-tape position for waist (abdominal) circumference in adults. To measure waist circumference, locate the upper hip bone and the top of the right iliac crest. Place a measuring tape in a horizontal plane around the abdomen at the level of the iliac crest. Before reading the tape measure, ensure that the tape is snug, but does not compress the skin, and is parallel to the floor. The measurement is made at the end of a normal expiration.</div><div class=\"graphic_reference\">Reproduced from: National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart Lung and Blood Institute, Bethesda, MD, October 2000.</div><div id=\"graphicVersion\">Graphic 77584 Version 1.0</div></div></div>"},"77586":{"type":"graphic_picture","displayName":"Anterior ear lobe crease and posterior helical ear pits - BWS","title":"Anterior ear lobe crease and posterior helical ear pits in a patient with Beckwith-Wiedemann syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior ear lobe crease and posterior helical ear pits in a patient with Beckwith-Wiedemann syndrome</div><div class=\"cntnt\"><img style=\"width:442px; height:308px;\" src=\"images/ALLRG/77586_Ant_ear_lobe_crease_BWS.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77586 Version 1.0</div></div></div>"},"77587":{"type":"graphic_picture","displayName":"Deep morphea","title":"Deep morphea","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Deep morphea</div><div class=\"cntnt\"><img style=\"width:253px; height:432px;\" src=\"images/DERM/77587_Deep_morphea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The areas affected by deep morphea have a cobblestone appearance with subcutaneous atrophy.</div><div id=\"graphicVersion\">Graphic 77587 Version 2.0</div></div></div>"},"77589":{"type":"graphic_table","displayName":"PROSTQA probabilities of erection after radical prostatectomy","title":"PROSTQA model-predicted probabilities of men having functional erections suitable for intercourse two years after radical prostatectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PROSTQA model-predicted probabilities of men having functional erections suitable for intercourse two years after radical prostatectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Planned surgical technique</td> <td class=\"subtitle1\" rowspan=\"2\">Patient age, y</td> <td class=\"subtitle1\" rowspan=\"2\">Pretreatment PSA level, ng/mL</td> <td class=\"subtitle1\" colspan=\"3\">Predicted functional erections after treatment, percent (95% CI) (by pretreatment sexual HRQOL score)*</td> </tr> <tr> <td class=\"subtitle2\">67</td> <td class=\"subtitle2\">83</td> <td class=\"subtitle2\">100</td> </tr> <tr> <td rowspan=\"6\">Nerve-sparing</td> <td rowspan=\"2\">50</td> <td>&#8804;10</td> <td>35 (25-45)</td> <td>52 (43-61)</td> <td>70 (61-77)</td> </tr> <tr> <td>&#62;10</td> <td>18 (9-34)</td> <td>32 (18-49)</td> <td>50 (32-68)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">60</td> <td>&#8804;10</td> <td>23 (18-30)</td> <td>38 (33-44)</td> <td>57 (49-64)</td> </tr> <tr> <td>&#62;10</td> <td>11 (0-21)</td> <td>21 (12-34)</td> <td>36 (22-53)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">70</td> <td>&#8804;10</td> <td>15 (10-22)</td> <td>26 (19-35)</td> <td>43 (32-55)</td> </tr> <tr> <td>&#62;10</td> <td>7 (3-14)</td> <td>13 (7-24)</td> <td>24 (13-41)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"6\">Non&ndash;nerve-sparing</td> <td rowspan=\"2\">50</td> <td>&#8804;10</td> <td>13 (5-30)</td> <td>23 (9-46)</td> <td>39 (18-64)</td> </tr> <tr> <td>&#62;10</td> <td>6 (2-18)</td> <td>11 (4-31)</td> <td>21 (7-48)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">60</td> <td>&#8804;10</td> <td>8 (3-19)</td> <td>14 (6-32)</td> <td>27 (12-50)</td> </tr> <tr> <td>&#62;10</td> <td>3 (1-11)</td> <td>7 (2-19)</td> <td>13 (4-34)</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">70</td> <td>&#8804;10</td> <td>5 (2-12)</td> <td>9 (3-22)</td> <td>17 (7-37)</td> </tr> <tr> <td>&#62;10</td> <td>2 (1-7)</td> <td>4 (1-12)</td> <td>8 (3-23)</td> </tr> </tbody></table><html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">11</mso:Specialty>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=96076&amp;amp;Mode=Edit&quot;&gt;&lt;img alt=&quot;&quot; border=0 src=&quot;/_layouts/IMAGES/ICGEN.gif&quot;&gt;Edit Table&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n</head></div><div class=\"graphic_footnotes\">PROSTQA: Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; PSA: prostate-specific antigen; HRQOL: health-related quality of life.<br> * Specific values of pretreatment sexual functioning (Expanded Prostate Cancer Index Composite scores of 67, 83, and 100; range of 0-100, with a higher score representing better function) are tabulated to represent cohort distribution (25th, 50th, and 75th percentiles of scores among prostatectomy-treated patients) as well as to reflect a clinically relevant set of possible pretreatment sexual functioning. Across all treatment groups, these percentiles correspond to 358 patients (36 percent) with pretreatment sexual HRQOL scores of 67 or less, 441 (45 percent) with scores of 68-99, and 186 (19 percent) with scores of 100.</div><div class=\"graphic_reference\">Reproduced with permission from: Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205. Copyright © 2011 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77589 Version 11.0</div></div></div>"},"77590":{"type":"graphic_picture","displayName":"Paragonimiasis adult worm","title":"Paragonimiasis adult worm","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Paragonimiasis adult worm</div><div class=\"cntnt\"><img style=\"width:548px; height:237px;\" src=\"images/ID/77590_Paragonimiasis_adult_worm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Adult of <em>P. westermani</em>.<br />(B) Adult of <em>Paragonimus</em> spp, taken from a lung biopsy specimen stained with hematoxylin and eosin. Note the presence of the oral sucker. The species was not identified in this case.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Paragonimiasis. Available at: <a href=\"http://www.cdc.gov/dpdx/paragonimiasis/index.html\" target=\"_blank\">http://www.cdc.gov/dpdx/paragonimiasis/index.html</a>.</div><div id=\"graphicVersion\">Graphic 77590 Version 5.0</div></div></div>"},"77591":{"type":"graphic_figure","displayName":"Hypoxia in the renal medulla","title":"Hypoxia in the renal medulla","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypoxia in the renal medulla</div><div class=\"cntnt\"><img style=\"width:328px; height:176px;\" src=\"images/NEPH/77591_Hypoxia_in_the_renal_medull.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Development of medullary hypoxia due to the exchange of oxygen between the descending and ascending limbs of the vasa recta capillaries (straight arrows) and to oxygen consumption by the medullary cells (curved arrows). The net effect is that the PO2 falls to 5 to 10 mmHg in the inner medulla.</div><div class=\"graphic_reference\">From Brezis M, Rosen S, Silva P, Epstein FH, Kidney Int 1984; 26:375. Reprinted by permission from Kidney International.</div><div id=\"graphicVersion\">Graphic 77591 Version 1.0</div></div></div>"},"77593":{"type":"graphic_figure","displayName":"Lung volumes exercise COPD","title":"Dynamic changes in lung volumes during exercise in normal lungs and COPD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dynamic changes in lung volumes during exercise in normal lungs and COPD</div><div class=\"cntnt\"><img style=\"width:424px; height:240px;\" src=\"images/PULM/77593_Lung_volumes_exercise_COPD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic changes in lung volumes during exercise in normal lungs and COPD. Note that end-expiratory lung volume (EELV) remains relatively constant in normal lungs as minute ventilation increases. Tidal volume (VT) is able to expand, since inspiratory volume (IC) remains constant. In COPD, increases in EELV force VT closer to the total lung capacity (TLC) and IC is reduced even at rest. Dynamic hyperinflation further increases EELV and reduces IC as minute ventilation increases. VT is unable to expand and patients cannot achieve high minute ventilations before breathing becomes so restricted that patients have to stop activity.</div><div class=\"graphic_footnotes\">EELV: end-expiratory lung volume; VT: tidal volume; IC: inspiratory volume; TLC: total lung capacity; IRV: inspiratory reserve volume.</div><div class=\"graphic_reference\">Adapted with permission from: O'Donnell, DE, Revill, SM, Webb, KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:770.</div><div id=\"graphicVersion\">Graphic 77593 Version 1.0</div></div></div>"},"77595":{"type":"graphic_diagnosticimage","displayName":"Posterior scleritis in Cogans","title":"Severe posterior scleritis in Cogan's syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Severe posterior scleritis in Cogan's syndrome</div><div class=\"cntnt\"><img style=\"width:360px; height:264px;\" src=\"images/RHEUM/77595_Posterior_scleritis_in_Coga.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computerized tomography of the orbits shows thickening and enhancement of both posterior sclera in this patient with Cogan's syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: MacCallum RM, St. Clair EW, Haynes BF. Cogan's syndrome. In: Inflammatory Diseases of Blood Vessels. Hoffman GS, Weyand CM (Eds). Marcel Dekker, Inc, New York City 2002. Copyright © 2002 Marcel Dekker, Inc.</div><div id=\"graphicVersion\">Graphic 77595 Version 3.0</div></div></div>"},"77597":{"type":"graphic_diagnosticimage","displayName":"Radiograph osteitis pubis AP view","title":"Radiograph osteitis pubis anterior posterior view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph osteitis pubis anterior posterior view</div><div class=\"cntnt\"><img style=\"width:432px; height:267px;\" src=\"images/PC/77597_Osteitis_pubis_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Osteitis pubis. Plain AP radiograph. Rarefaction of the inferior pubic rami and symphysis pubis is a typical early radiographic sign.</div><div class=\"graphic_footnotes\">AP: anterior posterior. </div><div class=\"graphic_reference\">Reproduced with permission from: Knoeller SF, Uhl M, Herget GW. Osteitis pubis or osteomyelitis? A diagnostic and therapeutic challenge: Report of 9 cases and review of the literature. Acta Orthop Belg 2006; 72:541. Copyright &copy; 2006 Acta Orthopaedica Belgica.</div><div id=\"graphicVersion\">Graphic 77597 Version 6.0</div></div></div>"},"77598":{"type":"graphic_diagnosticimage","displayName":"Ascites cirrhosis CT","title":"Ascites","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ascites</div><div class=\"cntnt\"><img style=\"width:428px; height:288px;\" src=\"images/GAST/77598_Ascites_cirrhosis_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT scan shows a large volume of ascitic fluid surrounding a small shrunken cirrhotic liver. The fluid is of low attenuation and is free floating without septations or solid material.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 77598 Version 3.0</div></div></div>"},"77599":{"type":"graphic_table","displayName":"History in hypertension","title":"Important aspects of the history in the patient with hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in the patient with hypertension</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Duration of hypertension</td> </tr> <tr> <td class=\"indent1\">Last known normal blood pressure</td> </tr> <tr> <td class=\"indent1\">Course of the blood pressure</td> </tr> <tr> <td class=\"subtitle1_single\">Prior treatment of hypertension</td> </tr> <tr> <td class=\"indent1\">Drugs: types, doses, side effects</td> </tr> <tr> <td class=\"subtitle1_single\">Intake of agents that may cause hypertension</td> </tr> <tr> <td class=\"indent1\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"indent1\">Estrogens</td> </tr> <tr> <td class=\"indent1\">Adrenal steroids</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> </tr> <tr> <td class=\"indent1\">Sympathomimetics</td> </tr> <tr> <td class=\"indent1\">Excessive sodium</td> </tr> <tr> <td class=\"subtitle1_single\">Family history</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> </tr> <tr> <td class=\"indent1\">Premature cardiovascular disease or death</td> </tr> <tr> <td class=\"indent1\">Familial diseases: pheochromocytoma, renal disease, diabetes, gout</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms of secondary causes</td> </tr> <tr> <td class=\"indent1\">Muscle weakness</td> </tr> <tr> <td class=\"indent1\">Spells of tachycardia, sweating, tremor</td> </tr> <tr> <td class=\"indent1\">Thinning of the skin</td> </tr> <tr> <td class=\"indent1\">Flank pain</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms of target-organ damage</td> </tr> <tr> <td class=\"indent1\">Headaches</td> </tr> <tr> <td class=\"indent1\">Transient weakness or blindness</td> </tr> <tr> <td class=\"indent1\">Loss of visual acuity</td> </tr> <tr> <td class=\"indent1\">Chest pain</td> </tr> <tr> <td class=\"indent1\">Dyspnea</td> </tr> <tr> <td class=\"indent1\">Claudication</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Presence of other risk factors</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Diabetes</td> </tr> <tr> <td class=\"indent1\">Dyslipidemia</td> </tr> <tr> <td class=\"indent1\">Physical inactivity</td> </tr> <tr> <td class=\"subtitle1_single\">Dietary history</td> </tr> <tr> <td class=\"indent1\">Sodium</td> </tr> <tr> <td class=\"indent1\">Processed foods</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> </tr> <tr> <td class=\"indent1\">Saturated fats</td> </tr> <tr> <td class=\"subtitle1_single\">Psychosocial factors</td> </tr> <tr> <td class=\"indent1\">Family structure</td> </tr> <tr> <td class=\"indent1\">Work status</td> </tr> <tr> <td class=\"indent1\">Educational level</td> </tr> <tr> <td class=\"subtitle1_single\">Sexual function</td> </tr> <tr> <td class=\"subtitle1_single\">Features of sleep apnea</td> </tr> <tr> <td class=\"indent1\">Early morning headaches</td> </tr> <tr> <td class=\"indent1\">Daytime somnolence</td> </tr> <tr> <td class=\"indent1\">Loud snoring</td> </tr> <tr> <td class=\"indent1\">Erratic sleep</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77599 Version 6.0</div></div></div>"},"77600":{"type":"graphic_picture","displayName":"Rash in staphylococcal toxic shock syndrome","title":"Rash in staphylococcal toxic shock syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash in staphylococcal toxic shock syndrome</div><div class=\"cntnt\"><img style=\"width:386px; height:252px;\" src=\"images/ID/77600_Rash_in_toxic_shock_syndrom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous maculopapular eruption on the abdomen&nbsp;of a patient with staphylococcal toxic shock syndrome (TSS). The erythroderm of TSS can be subtle and resemble a sunburn.</div><div class=\"graphic_reference\">Courtesy of Charles V Sanders. The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995.</div><div class=\"contractual\"><br/><a href=\"http://www.lww.com/\">http://www.lww.com</a></div><div id=\"graphicVersion\">Graphic 77600 Version 5.0</div></div></div>"},"77601":{"type":"graphic_picture","displayName":"Skin lesions due to vancomycin hypersensitivity","title":"Skin lesions due to vancomycin hypersensitivity","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Skin lesions due to vancomycin hypersensitivity</div><div class=\"cntnt\"><img style=\"width:504px; height:164px;\" src=\"images/ID/77601_Vancomycin_allergy_skin_les.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photographs of erythematous macules, vesicles, tense bullae, and erosions on the left hand (A) and tense bullae and erosions on the dorsal surfaces of the feet (B) in a 63-year-old man with skin eruptions after vancomycin administration.</div><div class=\"graphic_reference\">Reproduced with permission from: Clin Infect Dis 2004; 38:398. Copyright © 2004 University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 77601 Version 3.0</div></div></div>"},"77602":{"type":"graphic_picture","displayName":"Chylous pericardial fluid","title":"Milky chylous pericardial fluid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Milky chylous pericardial fluid</div><div class=\"cntnt\"><img style=\"width:378px; height:250px;\" src=\"images/CARD/77602_Chylous_pericardial_fluid.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced by permission from Chan, RMT, Dodek. Arch Intern Med 1984; 144:1857.</div><div id=\"graphicVersion\">Graphic 77602 Version 2.0</div></div></div>"},"77603":{"type":"graphic_table","displayName":"Major causes of hyponatremia","title":"Major causes of hyponatremia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major causes of hyponatremia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Disorders in which ADH levels are elevated</td> </tr> <tr> <td class=\"sublist2_start\">Reduced effective arterial blood volume</td> </tr> <tr> <td class=\"sublist2\">True volume depletion</td> </tr> <tr> <td class=\"sublist2\">Heart failure</td> </tr> <tr> <td class=\"sublist2\">Cirrhosis</td> </tr> <tr> <td class=\"indent1\">Syndrome of inappropriate ADH secretion, including reset osmostat pattern</td> </tr> <tr> <td class=\"sublist2_start\">Hormonal changes</td> </tr> <tr> <td class=\"sublist2\">Adrenal insufficiency</td> </tr> <tr> <td class=\"sublist2\">Hypothyroidism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist2\">Pregnancy</td> </tr> <tr> <td class=\"subtitle1_single\">Disorders in which ADH levels may be appropriately suppressed</td> </tr> <tr> <td class=\"indent1\">Advanced renal failure</td> </tr> <tr> <td class=\"indent1\">Primary polydipsia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Beer drinker's potomania</td> </tr> <tr> <td class=\"subtitle1_single\">Hyponatremia with normal or elevated plasma osmolality</td> </tr> <tr> <td class=\"sublist2_start\">High plasma osmolality (effective osmols)</td> </tr> <tr> <td class=\"sublist2\">Hyperglycemia</td> </tr> <tr> <td class=\"sublist2\">Mannitol</td> </tr> <tr> <td class=\"sublist2_start\">High plasma osmolality (ineffective osmols)</td> </tr> <tr> <td class=\"sublist2\">Renal failure</td> </tr> <tr> <td class=\"sublist2\">Alcohol intoxication with an elevated serum alcohol concentration</td> </tr> <tr> <td class=\"sublist2_start\">Normal plasma osmolality</td> </tr> <tr> <td class=\"sublist2\">Pseudohyponatremia (laboratory artifact)</td> </tr> <tr> <td class=\"sublist3\">High triglycerides</td> </tr> <tr> <td class=\"sublist3\">Cholestatic and obstructive jaundice (lipoprotein-X)</td> </tr> <tr> <td class=\"sublist3\">Multiple myeloma</td> </tr> <tr> <td class=\"sublist2\">Absorption of irrigant solutions</td> </tr> <tr> <td class=\"sublist3\">Glycine</td> </tr> <tr> <td class=\"sublist3\">Sorbitol</td> </tr> <tr> <td class=\"sublist3\">Mannitol</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ADH: antidiuretic hormone.</div><div id=\"graphicVersion\">Graphic 77603 Version 7.0</div></div></div>"},"77604":{"type":"graphic_table","displayName":"Causes of acquired goiter in children","title":"Causes of acquired goiter in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of acquired goiter in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"sublist1_start\">Inflammatory causes</td> </tr> <tr> <td class=\"sublist1\">Chronic autoimmune (Hashimoto's) thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Subacute granulomatous thyroiditis</td> </tr> <tr> <td class=\"sublist1\">Acute suppurative thyroiditis</td> </tr> <tr> <td>Colloid goiter</td> </tr> <tr> <td>Iodine-deficiency goiter</td> </tr> <tr> <td class=\"sublist1_start\">Ingestion of goitrogens</td> </tr> <tr> <td class=\"sublist1\">Iodine</td> </tr> <tr> <td class=\"sublist1\">Lithium carbonate</td> </tr> <tr> <td class=\"sublist1\">Foodstuffs (cassava, millet)</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid infiltrative disease</td> </tr> <tr> <td class=\"sublist1\">Histiocytosis</td> </tr> <tr> <td class=\"sublist1\">Cystinosis</td> </tr> <tr> <td class=\"sublist1_start\">Toxic goiter</td> </tr> <tr> <td class=\"sublist1\">Graves' disease</td> </tr> <tr> <td class=\"sublist1\">Autonomously functioning thyroid adenoma</td> </tr> <tr> <td class=\"sublist2\">Activating mutations of the TSH receptor</td> </tr> <tr> <td class=\"sublist2\">Activating mutations of the G protein alpha subunit</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid cysts</td> </tr> <tr> <td class=\"sublist1\">Thyroglossal duct cysts</td> </tr> <tr> <td>Thyroid adenomas</td> </tr> <tr> <td class=\"sublist1_start\">Thyroid carcinoma</td> </tr> <tr> <td class=\"sublist1\">Papillary carcinoma</td> </tr> <tr> <td class=\"sublist1\">Follicular carcinoma</td> </tr> <tr> <td class=\"sublist1\">Medullary carcinoma</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77604 Version 2.0</div></div></div>"},"77605":{"type":"graphic_algorithm","displayName":"Approach dx ascites","title":"Differential diagnosis of ascites","html":"<div class=\"graphic\"><div style=\"width: 1322px\" class=\"figure\"><div class=\"ttl\">Differential diagnosis of ascites</div><div class=\"cntnt\"><img style=\"width:1302px; height:766px;\" src=\"images/GAST/77605_Approach_dx_ascites.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">WBC: white blood cell; RBC: red blood cell; PMN: polymorphonuclear leukocyte; TP: total protein; LDH: lactate dehydrogenase; SBP: spontaneous bacterial peritonitis.</div><div class=\"graphic_reference\">Modified with permission from: Sleisenger &amp; Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 7th Edition, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), WB Saunders Company 2002. Copyright &copy; 2002 WB Saunders Company.</div><div id=\"graphicVersion\">Graphic 77605 Version 3.0</div></div></div>"},"77606":{"type":"graphic_table","displayName":"TNM staging ampullary CA","title":"TNM staging for ampullary carcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">TNM staging for ampullary carcinoma</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Primary tumor (T)\n   </td>\n   </tr>\n   <tr>\n   <td>TX</td>\n   <td  colspan=\"3\">\n   Primary tumor cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>T0</td>\n   <td  colspan=\"3\">\n   No evidence of primary tumor\n   </td>\n   </tr>\n   <tr>\n   <td>Tis</td>\n   <td  colspan=\"3\">\n   Carcinoma in situ\n   </td>\n   </tr>\n   <tr>\n   <td>T1</td>\n   <td  colspan=\"3\">\n   Tumor limited to the ampulla of Vater or sphincter of Oddi\n   </td>\n   </tr>\n   <tr>\n   <td>T2</td>\n   <td  colspan=\"3\">\n   Tumor invades duodenal wall\n   </td>\n   </tr>\n   <tr>\n   <td>T3</td>\n   <td  colspan=\"3\">\n   Tumor invades pancreas\n   </td>\n   </tr>\n   <tr>\n   <td>T4</td>\n   <td  colspan=\"3\">\n   Tumor invades peripancreatic soft tissues or other adjacent organs or structures other than pancreas\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Regional lymph nodes (N)\n   </td>\n   </tr>\n   <tr>\n   <td>NX</td>\n   <td  colspan=\"3\">\n   Regional lymph nodes cannot be assessed\n   </td>\n   </tr>\n   <tr>\n   <td>N0</td>\n   <td  colspan=\"3\">\n   No regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>N1</td>\n   <td  colspan=\"3\">\n   Regional lymph node metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Distant metastasis (M)\n   </td>\n   </tr>\n   <tr>\n   <td>M0</td>\n   <td  colspan=\"3\">\n   No distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td>M1</td>\n   <td  colspan=\"3\">\n   Distant metastasis\n   </td>\n   </tr>\n   <tr>\n   <td  colspan=\"4\" class=\"subtitle1_single\">\n   Anatomic stage/prognostic groups\n   </td>\n   </tr>\n   <tr>\n   <td>Stage 0</td>\n   <td>Tis</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IA</td>\n   <td>T1</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IB</td>\n   <td>T2</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IIA</td>\n   <td>T3</td>\n   <td>N0</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   Stage IIB\n   </td>\n   <td>T1</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>T2</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>T3</td>\n   <td>N1</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage III</td>\n   <td>T4</td>\n   <td>Any N</td>\n   <td>M0</td>\n   </tr>\n   <tr>\n   <td>Stage IV</td>\n   <td>Any T</td>\n   <td>Any N</td>\n   <td>M1</td>\n   </tr>\n </table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">6.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/1/2010--These are in the AJCC folder and should be renewed annually for the life of the 7th Edition; this has been paid for 2010 (JD). The total fee of $&amp;quot;160.00&amp;quot;was originally charged to TNM_staging_adrenal_CA TNM_staging_ampullary_CA anal_cancer_TNM_stage anal_cancer_stage_group Anal_outcome_hist_AJCC TNM_stage_append_CA TNM_stage_append_carcinoid Surv_rates_appendix_CA TNM_staging_bone_tumors TNM_stage_breast_cancer Breast_reg_lymph_nodes 2002_TNM_breast_cancer Staging_cervical_cancer TNM_staging_colorec_CA CRC_tumor_regression_grade SEER_surv_adeno_colon SEER_surv_adeno_rectum Reg_nodes_colorec_CA CRC_resection_margin Staging_uterine_carcinoma Staging_uterine_sarcoma TNM_distal_cholangio TNM_staging_esoph_SCC TNM_staging_esoph_EGJ_adenoCA Esoph_CA_site T_stage_esophageal_cancer Staging_fallopian_cancer TNM_staging_gallbladder_CA OS_gallbladder_CA TNM_staging_GIST Dis_prog_gastric_GIST Dis_prog_small_int_GIST Staging_gest_trop_neoplas TNM_stage_hypopharynx TNM_small_bowel_cancer TNM_intrahep_cholangio SEER_surv_intrahep_cholang TNM_staging_RCC TNM_stage_larynx TNM_stage_oral_cavity TNM_staging_HCC 7th_TNM_lung_stage system Lung_CA staging_6th_TNM 7th_TNM_lung_CA_changes TNM_path_staging_mel_conj TNM_clin_staging_mel_conj Melanoma_7thTNM_stage_group Melanoma_7th_TNM_staging TNM_staging_muc_melanoma_HN Muc_melanoma_HN_stage_group Ciliary_choroid_thickness TNM_stage_uveal_melanoma TNM_stage_Merkel_cell_CA TNM_stage_sinonasal_sites TNM_stage_nasopharynx TNM_stage_gastric_carcinoid TNM_gastrointest_carcinoid TNM_amp_sm_bowel_carcinoid TNM_staging_CRC_carcinoid Surv_rates_GI_neuroendo Staging_ovar_prim_perit_ca TNM_panc_endo_exo_CA NCDB_no_surg_surv_panc NCDB_surg_surv_panc Prog_panc_neuroendo_tum TNM_staging_penile_cancer TNM_perihilar_cholangio TNM_stage_oropharynx TNM_stage_mesothelioma TNM_staging_prostate_CA TNM_group_prostate_CA TNM_staging_renal_pelvis TNM_stage_salivary_glands TNM_stage_sarcoma_orbit TNM_staging_soft_tis_sarc 2010_TNM_staging_STS TNM_stage_cutan_SCC 2010_TNM_staging_stomach_CA SEER_survival_gast_CA TMN_staging_testicular_CA Stage_group_testicular_CA TNM_staging_thyroid_cancer Urethral_CA_TNM_women TNM_stage_group_urethra Urethral_CA_TNM_men TNM_staging_bladder_CA Staging_vaginal_cancer Staging_vulvar_cancer</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=21301&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>TNM_staging_ampullary_CA.htm</title></head></div><div class=\"graphic_lgnd\">Note: cTNM is the clinical classification, pTNM is the pathologic classification.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.</div><div id=\"graphicVersion\">Graphic 77606 Version 12.0</div></div></div>"},"77607":{"type":"graphic_figure","displayName":"How to dilate cervix","title":"Cervical dilation","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Cervical dilation</div><div class=\"cntnt\"><img style=\"width:537px; height:414px;\" src=\"images/OBGYN/77607_How_to_dilate_cervix.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 77607 Version 1.0</div></div></div>"},"77608":{"type":"graphic_picture","displayName":"CR to cetuximab for intransit metastases of SCC of the skin","title":"Complete response to cetuximab for rapidly recurrent, in-transit metastases of squamous cell carcinoma of the skin","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Complete response to cetuximab for rapidly recurrent, in-transit metastases of squamous cell carcinoma of the skin</div><div class=\"cntnt\"><img style=\"width:582px; height:294px;\" src=\"images/ONC/77608_CR_cetuximab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 73-year-old man presented with rapidly recurrent, in-transit metastases of squamous cell carcinoma of the skin, both within and outside his surgery and radiation fields. These photographs document complete response to cetuximab. The following time points are illustrated: pretherapy (A), week 4 of treatment (B), and week 16 of treatment (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 2007; 143:889. Copyright &#169; 2007 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77608 Version 4.0</div></div></div>"},"77610":{"type":"graphic_table","displayName":"Volumes of hemodialysis lines based on patient weight","title":"Volumes of hemodialysis lines based on patient weight","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Volumes of hemodialysis lines based on patient weight</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Patient weight (kg)</td> <td class=\"subtitle1\">Venous (mL)</td> <td class=\"subtitle1\">Arterial (mL)</td> <td class=\"subtitle1\">Total (mL)</td> </tr> <tr> <td>Mini-neonatal</td> <td>&#60;6</td> <td>21</td> <td>8</td> <td>29</td> </tr> <tr> <td>Neonatal</td> <td>6 to 12</td> <td>22</td> <td>18</td> <td>40</td> </tr> <tr> <td>Pediatric</td> <td>&#62;12</td> <td>42</td> <td>30</td> <td>72</td> </tr> <tr> <td>Adult</td> <td>&#62;30</td> <td>70</td> <td>62</td> <td>132</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77610 Version 4.0</div></div></div>"},"77611":{"type":"graphic_picture","displayName":"Paintball purpura","title":"Purpura due to a paintball injury","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Purpura due to a paintball injury</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77611_Paintball_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An annular purpuric lesion developed on this patient after getting struck by a paintball.</div><div id=\"graphicVersion\">Graphic 77611 Version 2.0</div></div></div>"},"77612":{"type":"graphic_figure","displayName":"Radial artery puncture site","title":"Radial artery puncture site","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radial artery puncture site</div><div class=\"cntnt\"><img style=\"width:347px; height:595px;\" src=\"images/EM/77612_RadialarterypuncsitePR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The strongest radial pulse is typically located as shown.</div><div class=\"graphic_reference\">Reproduced with permission from: Torrey SB, Saladino RA. Arterial puncture and catheterization. In: Textbook of Pediatric Emergency Procedures, 2nd edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright © 2008 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77612 Version 6.0</div></div></div>"},"77613":{"type":"graphic_picture","displayName":"Contact dermatitis drug","title":"Contact dermatitis due to neomycin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contact dermatitis due to neomycin</div><div class=\"cntnt\"><img style=\"width:250px; height:409px;\" src=\"images/DERM/77613_Contact_dermatitis_drug.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This contact dermatitis is secondary to neomycin in ear drops.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart, HP. Goodheart's photoguide of common skin disorders, 2nd ed., Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &#169; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77613 Version 1.0</div></div></div>"},"77614":{"type":"graphic_picture","displayName":"Left vocal fold polyp B","title":"Left vocal fold polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Left vocal fold polyp</div><div class=\"cntnt\"><img style=\"width:360px; height:360px;\" src=\"images/PC/77614_Left_vocal_fold_polyp_B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Identified in an&nbsp;older adult&nbsp;woman with longstanding hoarseness. The polyp is large enough to ball valve into the subglottic airway with inspiration.</div><div id=\"graphicVersion\">Graphic 77614 Version 3.0</div></div></div>"},"77615":{"type":"graphic_picture","displayName":"Resisted wrist flexion","title":"Resisted wrist flexion","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Resisted wrist flexion</div><div class=\"cntnt\"><img style=\"width:456px; height:363px;\" src=\"images/EM/77615_Resisted_wrist_flexion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow flexed at 90 degrees, the forearm is firmly grasped. The patient is asked to make a &quot;light&quot; fist and to flex the wrist against the resistance of the examiner's second hand. As this maneuver is performed, the examiner should emphasize the relationship of the wrist motion to the aggravation of elbow pain. The diagnosis of medial epicondylitis is strongly suggested by local tenderness of the medial epicondyle plus elbow pain aggravated by resisted wrist flexion.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 77615 Version 2.0</div></div></div>"},"77616":{"type":"graphic_table","displayName":"Gas properties at altitude","title":"Hypobaric conditions at increasing altitude","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hypobaric conditions at increasing altitude</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Altitude, ft</td> <td class=\"subtitle1\">Barometric pressure, mmHg</td> <td class=\"subtitle1\">Atmospheric PO2, mmHg</td> <td class=\"subtitle1\">Tracheal PO2, mmHg</td> <td class=\"subtitle1\">Gas density*</td> <td class=\"subtitle1\">Gas volume<sup>&#182;</sup></td> </tr> <tr> <td>0 (sea level)</td> <td>760</td> <td>159</td> <td>149</td> <td>1</td> <td>1</td> </tr> <tr> <td>2000</td> <td>707</td> <td>148</td> <td>138</td> <td>-</td> <td>-</td> </tr> <tr> <td>4000</td> <td>656</td> <td>137</td> <td>128</td> <td>0.9</td> <td>1.1</td> </tr> <tr> <td>5000</td> <td>632</td> <td>132</td> <td>122</td> <td>0.8</td> <td>1.2</td> </tr> <tr> <td>8000</td> <td>564</td> <td>118</td> <td>108</td> <td>-</td> <td>1.4</td> </tr> <tr> <td>10,000</td> <td>523</td> <td>109</td> <td>100</td> <td>0.7</td> <td>1.5</td> </tr> <tr> <td>15,000</td> <td>428</td> <td>89</td> <td>80</td> <td>0.6</td> <td>1.9</td> </tr> <tr> <td>30,000</td> <td>226</td> <td>47</td> <td>38</td> <td>0.3</td> <td>4</td> </tr> <tr> <td>40,000</td> <td>141</td> <td>29</td> <td>20</td> <td>0.2</td> <td>7.6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Fall in ambient pressure and PO2 at increasing altitude during air travel in commercial airliners. Pressurization of the cabin limits the reduction in cabin pressure, thereby limiting the reduction in inspired PO2.</div><div class=\"graphic_footnotes\">* Ratio of density at altitude to density at sea level.<br />&para; Ratio of volume occupied by a fixed amount of gas at altitude to the volume occupied at sea level.</div><div class=\"graphic_reference\">Adapted from Gary H. J Respir Dis 1990; 11:484.</div><div id=\"graphicVersion\">Graphic 77616 Version 3.0</div></div></div>"},"77617":{"type":"graphic_diagnosticimage","displayName":"Mediastinal lymphoma PA and CT","title":"Mediastinal lymphoma","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Mediastinal lymphoma</div><div class=\"cntnt\"><img style=\"width:460px; height:250px;\" src=\"images/PULM/77617_Mediastinal_lymphoma_PA_and.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The PA chest radiograph (left panel) reveals a lobulated mass in the upper portion of the mediastinum (arrow). A CT scan obtained at the level of the great vessels (right panel) shows multiple enlarged lymph nodes in the anterior mediastinum.</div><div class=\"graphic_footnotes\">PA: posteroanterior; CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of William Travis, MD.</div><div id=\"graphicVersion\">Graphic 77617 Version 3.0</div></div></div>"},"77618":{"type":"graphic_picture","displayName":"Enlarged temporal artery","title":"Enlarged temporal artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enlarged temporal artery</div><div class=\"cntnt\"><img style=\"width:286px; height:181px;\" src=\"images/RHEUM/77618_Enlarged_temp_artery_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Visibly enlarged temporal artery in a patient with giant cell arteritis (arrows).</div><div class=\"graphic_reference\">Courtesy of Gene G Hunder, MD.</div><div id=\"graphicVersion\">Graphic 77618 Version 2.0</div></div></div>"},"77619":{"type":"graphic_table","displayName":"Scleritis and systemic diseases","title":"Systemic diseases associated with scleritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic diseases associated with scleritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Connective tissue diseases</td> </tr> <tr> <td>Rheumatoid arthritis</td> </tr> <tr> <td>Reactive arthritis</td> </tr> <tr> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Relapsing polychondritis</td> </tr> <tr> <td class=\"subtitle1_single\">Systemic vasculitides</td> </tr> <tr> <td>Granulomatosis with polyangiitis (Wegener's)</td> </tr> <tr> <td>Microscopic polyangitis</td> </tr> <tr> <td>Churg-Strauss syndrome</td> </tr> <tr> <td>Polyarteritis nodosa</td> </tr> <tr> <td>Cogan's syndrome</td> </tr> <tr> <td>Beh&#231;et's syndrome</td> </tr> <tr> <td>Urticarial vasculitis</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td>Syphilis</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Lyme disease</td> </tr> <tr> <td>Herpes zoster</td> </tr> <tr> <td>Aspergillis</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Inflammatory bowel disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77619 Version 4.0</div></div></div>"},"77620":{"type":"graphic_picture","displayName":"Urine sediment of a pt with atazanavir crystalluria","title":"Photomicrograph showing urine sediment of a patient with atazanavir crystalluria","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Photomicrograph showing urine sediment of a patient with atazanavir crystalluria</div><div class=\"cntnt\"><img style=\"width:396px; height:307px;\" src=\"images/NEPH/77620_Urine_sediment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine sediment of a patient with atazanavir crystalluria demonstrates a needle-shaped crystal with bright field microscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Izzedine H, M'rad MB, Bardier A, et al. Atazanavir crystal nephropathy. AIDS 2007; 21:2357. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77620 Version 12.0</div></div></div>"},"77621":{"type":"graphic_diagnosticimage","displayName":"Prenatal ultrasound renal agenesis","title":"Prenatal ultrasound bilateral renal agenesis with adrenals in the renal fossa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Prenatal ultrasound bilateral renal agenesis with adrenals in the renal fossa</div><div class=\"cntnt\"><img style=\"width:308px; height:340px;\" src=\"images/OBGYN/77621_Renal_agenesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral renal agenesis, adrenals in the renal fossas seen on transverse view (arrows).</div><div class=\"graphic_reference\">Courtesy of Tulin Ozcan, MD.</div><div id=\"graphicVersion\">Graphic 77621 Version 2.0</div></div></div>"},"77622":{"type":"graphic_figure","displayName":"Robotic laparoscopy ports","title":"Port sites for robotic-assisted laparoscopy in gynecology","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Port sites for robotic-assisted laparoscopy in gynecology</div><div class=\"cntnt\"><img style=\"width:520px; height:567px;\" src=\"images/OBGYN/77622_Robotic_laparoscopy_ports.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77622 Version 2.0</div></div></div>"},"77624":{"type":"graphic_picture","displayName":"Mild Hunter syndrome B","title":"Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mild mucopolysaccharidosis type II (MPS II, Hunter syndrome) B</div><div class=\"cntnt\"><img style=\"width:123px; height:367px;\" src=\"images/PEDS/77624_Mild_Hunter_syndrome_B_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild Hunter syndrome (MPS II) in a 12-year-old boy (lateral view).</div><div class=\"graphic_reference\">Courtesy of Ed Wraith, MD.</div><div id=\"graphicVersion\">Graphic 77624 Version 5.0</div></div></div>"},"77625":{"type":"graphic_figure","displayName":"Projected height B","title":"Estimating projected height using skeletal age","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Estimating projected height using skeletal age</div><div class=\"cntnt\"><img style=\"width:540px; height:703px;\" src=\"images/PEDS/77625_Projected_height_B.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Projected height for a child older than two years can be determined by extrapolating the child's growth along the current channel to the 18- to 20-year mark. For children with delayed or accelerated growth, using the skeletal age (bone age) rather than the chronologic age to determine the projected height channel provides more accurate assessment of projected height. In the example above, the 10-year-old boy has a skeletal age of 8 years; he is 49 inches tall (&lt;3<SUP>rd</SUP> percentile for chronologic age [point A], but 25<SUP>th</SUP> percentile for skeletal age [point B]). His projected height is the 25<SUP>th</SUP> percentile height for a 20-year-old (point C): 68 inches.</div><div class=\"graphic_reference\">From: National Health Center for Health Statistics in collaboration with the National Center for Chronic Disease Prevention and Health Promotion.</div><div id=\"graphicVersion\">Graphic 77625 Version 4.0</div></div></div>"},"77627":{"type":"graphic_figure","displayName":"Pathogenesis of Brucella","title":"Pathogenesis of <EM>Brucella</EM>","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of <EM>Brucella</EM></div><div class=\"cntnt\"><img style=\"width:574px; height:598px;\" src=\"images/ID/77627_Pathogenesis_brucella_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This drawing is a schematic representation of the major events in the pathogenesis of brucellosis and the host immune response. <STRONG>(1) </STRONG>Entry of <EM>Brucella </EM>into the host, phagocytosis by macrophages, and processing of <EM>Brucella</EM> antigen. <STRONG>(2)</STRONG> Stimulation of T lymphocytes to produce interferon (IFN)-gamma. <STRONG>(3)</STRONG> Induction by IFN-gamma of direct activity of T lymphocytes and macrophage induction against <EM>Brucella</EM>. <STRONG>(4) </STRONG>Induction by INF-gamma of natural killer cells to kill <EM>Brucella </EM>and induction of macrophage killing. <STRONG>(5) </STRONG>Inhibition of tumor necrosis factor (TNF)-alpha production, resulting in reduced killing by natural killer cells and macrophages. <STRONG>(6)</STRONG> Release of incompletely killed <EM>Brucella </EM>to infect other cells. <STRONG>(7)</STRONG> Production of antibodies by B lymphocytes. Important for diagnostic purposes but not for control of the disease.</div><div id=\"graphicVersion\">Graphic 77627 Version 6.0</div></div></div>"},"77628":{"type":"graphic_table","displayName":"Applications of PET","title":"Clinical applications of peritoneal equilibration test","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical applications of peritoneal equilibration test</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Peritoneal membrane transport classification</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Predict dialysis dose</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Choose peritoneal dialysis regimen</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Monitor peritoneal membrane function</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diagnose acute membrane injury</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diagnose causes of inadequate ultrafiltration</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diagnose causes of inadequate solute clearance</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Estimate D/P ratio of a solute at a particular time</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Diagnose early ultrafiltration failure</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Assess influence of systemic disease on peritoneal membrane function</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">D/P ratio: dialysate to plasma ratio.</div><div id=\"graphicVersion\">Graphic 77628 Version 1.0</div></div></div>"},"77630":{"type":"graphic_diagnosticimage","displayName":"MRI acute seizure","title":"Resolution and recurrence of increased T2 signal associated with focal status epilepticus after seven days of pentobarbital anesthesia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Resolution and recurrence of increased T2 signal associated with focal status epilepticus after seven days of pentobarbital anesthesia</div><div class=\"cntnt\"><img style=\"width:421px; height:422px;\" src=\"images/NEURO/77630_MRI_acute_seizure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient was a 12 year old girl who presented 14 days before with epilepsia partialis continua arising from the right hemisphere.<br />(A) Axial FLAIR MR image obtained on day 14 prior to anesthetic treatment.<br />(B) Axial FLAIR MR image obtained after seven days of pentobarbital anesthesia titrated to produce burst-suppression on continuous EEG monitoring. Note T2 signal changes have largely resolved.<br />(C) Axial FLAIR MR image obtained 7 days after anesthetics were discontinued and epilepsia partialis had recurred.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; FLAIR: fluid attenuated inversion recovery; EEG: electroencephalogram. </div><div class=\"graphic_reference\">Reproduced with permission from: Doherty, CP, Cole, AJ, Grant, PE, et al. Multimodal longitudinal imaging of focal status epilepticus. Can J Neurol Sci 2004; 31:276. Copyright &copy; Canadian Journal of Neurological Sciences.</div><div id=\"graphicVersion\">Graphic 77630 Version 4.0</div></div></div>"},"77633":{"type":"graphic_table","displayName":"Drugs affecting serum lipase values","title":"Drugs affecting serum lipase values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs affecting serum lipase values</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Increase</td> </tr> <tr> <td class=\"indent1\">Adrenocorticotropic hormone</td> </tr> <tr> <td class=\"indent1\">Ardeparin</td> </tr> <tr> <td class=\"indent1\">Cholinergics (eg, bethanechol)</td> </tr> <tr> <td class=\"indent1\">Fat emulsions</td> </tr> <tr> <td class=\"indent1\">Furosemide</td> </tr> <tr> <td class=\"indent1\">Indomethacin</td> </tr> <tr> <td class=\"indent1\">Methacholine</td> </tr> <tr> <td class=\"indent1\">Methylprednisolone</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> </tr> <tr> <td class=\"indent1\">Narcotics (eg, codeine)</td> </tr> <tr> <td class=\"indent1\">Oral contraceptives</td> </tr> <tr> <td class=\"indent1\">Pegaspargase</td> </tr> <tr> <td class=\"indent1\">Pentazocine</td> </tr> <tr> <td class=\"indent1\">Secretin</td> </tr> <tr> <td class=\"indent1\">Sulfisoxazole</td> </tr> <tr> <td class=\"indent1\">Thiazide diuretics</td> </tr> <tr> <td class=\"indent1\">Triprolidine/pseudophedrine</td> </tr> <tr> <td class=\"indent1\">Valproic acid</td> </tr> <tr> <td class=\"indent1\">Zalcitabine</td> </tr> <tr> <td class=\"subtitle1_single\">Decrease</td> </tr> <tr> <td class=\"indent1\">5-aminosalicylic acid</td> </tr> <tr> <td class=\"indent1\">Calcium ions</td> </tr> <tr> <td class=\"indent1\">Hydroxyurea</td> </tr> <tr> <td class=\"indent1\">Protamine</td> </tr> <tr> <td class=\"indent1\">Somatostatin</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77633 Version 3.0</div></div></div>"},"77634":{"type":"graphic_table","displayName":"Risk GI procedure conditions","title":"Condition-related risk of thromboembolic complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Condition-related risk of thromboembolic complications</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1_single\">High-risk conditions</td>\n  </tr>\n  <tr>\n    <td>Atrial fibrillation associated with valvular heart disease (including the presence of a mechanical valve)</td>\n  </tr>\n  <tr>\n    <td>Atrial fibrillation associated with congestive heart failure or a left ventricular ejection fraction of &#60;35 percent</td>\n  </tr>\n  <tr>\n    <td>Atrial fibrillation associated with a history of a thromboembolic event</td>\n  </tr>\n  <tr>\n    <td>Atrial fibrillation associated with hypertension, diabetes, or age &#62;75 years</td>\n  </tr>\n  <tr>\n    <td>Mechanical valves in the mitral position</td>\n  </tr>\n  <tr>\n    <td>Mechanical valves in patients who have had a prior thromboembolic event</td>\n  </tr>\n  <tr>\n    <td>Coronary stents placed within one year</td>\n  </tr>\n  <tr>\n    <td>Acute coronary syndrome</td>\n  </tr>\n  <tr>\n    <td>Nonstented percutaneous coronary intervention after myocardial infarction</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Low-risk conditions</td>\n  </tr>\n  <tr>\n    <td>Deep vein thrombosis</td>\n  </tr>\n  <tr>\n    <td>Chronic or paroxysmal atrial fibrillation that is not associated with valvular disease</td>\n  </tr>\n  <tr>\n    <td>Bioprosthetic valves</td>\n  </tr>\n  <tr>\n    <td>Mechanical valves in the aortic position</td>\n  </tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Original figure modified for this publication. Anderson MA, Ben-Menachem T, Gan SI, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77634 Version 2.0</div></div></div>"},"77635":{"type":"graphic_figure","displayName":"Rectal anastomosis exenteration","title":"Schematic representation of low rectal anastomosis during pelvic exenteration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic representation of low rectal anastomosis during pelvic exenteration</div><div class=\"cntnt\"><img style=\"width:447px; height:624px;\" src=\"images/OBGYN/77635_Rectal_anastomosis_exentera.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77635 Version 2.0</div></div></div>"},"77636":{"type":"graphic_table","displayName":"Rx relapsed refractory FL","title":"Treatment of relapsed or refractory follicular lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of relapsed or refractory follicular lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First relapse</td> </tr> <tr> <td class=\"indent1\">Observation*</td> </tr> <tr> <td class=\"indent1\">Clinical trial, if available</td> </tr> <tr> <td class=\"indent1\">Monoclonal antibody-based therapy (R)</td> </tr> <tr> <td class=\"indent1\">Chemotherapy with monoclonal antibody-based therapy (eg, R-CVP, R-CHOP, BR), depending on initial therapy</td> </tr> <tr> <td class=\"indent1\">High dose chemotherapy followed by autologous or allogeneic HCT</td> </tr> <tr> <td class=\"subtitle1_single\">Second or greater relapse</td> </tr> <tr> <td class=\"indent1\">Single agent or combination chemotherapy</td> </tr> <tr> <td class=\"indent1\">Monoclonal antibody-based therapy (R)</td> </tr> <tr> <td class=\"indent1\">Radioimmunotherapy<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">High dose chemotherapy followed by autologous or allogeneic HCT</td> </tr> <tr> <td class=\"subtitle1_single\">Widespread disease, multiple prior therapies, transformed disease</td> </tr> <tr> <td class=\"indent1\">Anthracycline-based combination chemotherapy (eg, CHOP) if not previously given</td> </tr> <tr> <td class=\"indent1\">Idelalisib</td> </tr> <tr> <td class=\"indent1\">Radioimmunotherapy<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Allogeneic or autologous HCT for chemoresponsive disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Participation in a clinical trial is always recommended as a first option for all patients with follicular lymphoma.</div><div class=\"graphic_footnotes\">R: rituximab; CVP: cyclophosphamide, vincristine, prednisone; CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; BR: bendamustine, rituximab; HCT: hematopoietic cell transplantation.<br />* <STRONG>Indications for treatment</STRONG> include presence of \"B\" symptoms, threatened end-organ function, cytopenias, massive tumor bulk, and/or rapid progression. Patients with none of these signs or symptoms may be observed without an adverse effect on overall survival or disease transformation.<br />¶ Radioimmunotherapy&nbsp;refers to&nbsp;treatment with Yttrium-90-labeled ibritumomab.</div><div id=\"graphicVersion\">Graphic 77636 Version 5.0</div></div></div>"},"77637":{"type":"graphic_diagnosticimage","displayName":"2D TTE apical four-chamber","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the apical four-chamber view","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the apical four-chamber view</div><div class=\"cntnt\"><img style=\"width:522px; height:170px;\" src=\"images/CARD/77637_Apical_4_chamber_TTE.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The apical four-chamber view from a transthoracic echocardiogram, recorded in systole, show the right (RV) and left (LV) ventricles, the right (RA) and left (LA) atria, the mitral valve (MV, and tricuspid valve (TV).</div><div class=\"graphic_reference\">Courtesy of Warren Manning, MD.</div><div id=\"graphicVersion\">Graphic 77637 Version 5.0</div></div></div>"},"77639":{"type":"graphic_figure","displayName":"Seasonal pattern Campy infxn","title":"Seasonal pattern of campylobacter enteritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Seasonal pattern of campylobacter enteritis</div><div class=\"cntnt\"><img style=\"width:429px; height:235px;\" src=\"images/ID/77639_Seasonal_pattern_Campy_infx.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seasonal distribution of campylobacter enteritis in England and Wales. Each time period was associated with over 100,000 infections but the seasonal pattern was constant: a sharp increase in incidence in early summer, a peak in mid-summer, and a gradual decline to baseline levels by winter.</div><div class=\"graphic_reference\">Data from the PHLS Communicable Disease Surveillance Centre, London.</div><div id=\"graphicVersion\">Graphic 77639 Version 1.0</div></div></div>"},"77640":{"type":"graphic_figure","displayName":"Schematic of echo findings in PH","title":"Representation of echocardiographic findings in severe pulmonary hypertension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Representation of echocardiographic findings in severe pulmonary hypertension</div><div class=\"cntnt\"><img style=\"width:420px; height:337px;\" src=\"images/CARD/77640_Echo_findings_in_PH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of two-dimensional and Doppler echocardiographic changes in severe pulmonary hypertension. The main findings are right ventricular enlargement (RVE), right ventricular hypertrophy (RVH), right atrial enlargement (RAE), functional tricuspid regurgitation (TR) with a high velocity regurgitant jet by Doppler (TR jet), and a mid-systolic notch on the pulmonary artery Doppler flow tracing (PA flow). The interventricular septum is shifted toward the left ventricular cavity, resulting in flattening of the ventricular septum particularly during systole; this flattening is most evident in the short-axis left ventricular cavity view (not shown).</div><div class=\"graphic_reference\">Adapted from: Otto C. Cardiomyopathies, hypertensive and pulmonary heart disease. In: Textbook of Clinical Echocardiography, Otto C, Pearlman AS (Eds), Saunders, Philadelphia, 1995.</div><div id=\"graphicVersion\">Graphic 77640 Version 4.0</div></div></div>"},"77642":{"type":"graphic_picture","displayName":"Cylindrical cell papilloma Light","title":"Cylindrical cell papilloma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cylindrical cell papilloma</div><div class=\"cntnt\"><img style=\"width:414px; height:244px;\" src=\"images/ONC/77642_Schneiderian_papilloma_Ligh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the characteristic eosinophilic columnar epithelium (black arrow) with microabcesses (black arrowheads).</div><div class=\"graphic_reference\">Courtesy of G Kenneth Haines, MD.</div><div id=\"graphicVersion\">Graphic 77642 Version 4.0</div></div></div>"},"77643":{"type":"graphic_figure","displayName":"Long bone venous drainage","title":"Venous drainage from marrow of long bone with intramedullary needle in place","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Venous drainage from marrow of long bone with intramedullary needle in place</div><div class=\"cntnt\"><img style=\"width:449px; height:282px;\" src=\"images/PEDS/77643_Long_bone_venous_drain_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The veins that drain the medullary sinuses of the long bones are supported by the bony matrix. They do not collapse in shock or hypovolemia.</div><div class=\"graphic_reference\">Reproduced with permission from: Barkin RM (Ed). Pediatric emergency medicine: Concepts and clinical practice, 2nd ed, Mosby, St. Louis, 1997. p.151. Copyright &#169; 1997 Mosby.</div><div id=\"graphicVersion\">Graphic 77643 Version 4.0</div></div></div>"},"77644":{"type":"graphic_table","displayName":"Warning signs for serious causes of back pain in children","title":"Warning signs of potentially serious causes of back pain in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Warning signs of potentially serious causes of back pain in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong><span class=\"subtitle1_single\">Clinical feature</span></strong></td> <td><strong>Potential significance</strong>&nbsp;</td> </tr> <tr> <td>Young age (particularly <span class=\"subtitle1_single\">younger</span> than four years)</td> <td>Increases concern for malignancy or infectious/inflammatory conditions (eg, osteomyelitis, discitis)&nbsp;</td> </tr> <tr> <td>Fever</td> <td>Spinal or paraspinal infection (eg, osteomyelitis, epidural abscess)</td> </tr> <tr> <td>Fever and weight loss</td> <td>Malignant tumors (eg, leukemia, lymphoma, Ewing sarcoma)</td> </tr> <tr> <td>Pain that is severe or constant, occurs at night, is progressive, or interferes with activity</td> <td>Spinal tumor, infection, nerve root compression</td> </tr> <tr> <td>Morning stiffness</td> <td>Inflammatory condition (eg, ankylosing spondylitis)</td> </tr> <tr> <td>Pain that radiates below the buttocks</td> <td>Nerve root compression or irritation of paraspinous structures</td> </tr> <tr> <td>Acute&nbsp; or repetitive trauma (particularly lumbar hyperextension)</td> <td>Spondylolysis, spondylolisthesis&nbsp;</td> </tr> <tr> <td>History of malignancy</td> <td>Spinal metastases</td> </tr> <tr> <td>History of exposure to tuberculosis</td> <td>Tuberculosis of the spine (Pott's disease)</td> </tr> <tr> <td>Abnormal neurologic findings: asymmetric reflexes, Babinski, low rectal tone, bowel or bladder symptoms</td> <td>Nerve root compression,&nbsp;epidural abscess, transverse myelitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77644 Version 4.0</div></div></div>"},"77645":{"type":"graphic_picture","displayName":"Oropharyngeal airway sizing","title":"Oropharyngeal airway sizing","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Oropharyngeal airway sizing</div><div class=\"cntnt\"><img style=\"width:473px; height:401px;\" src=\"images/EM/77645_Oropharyn_airway_sizing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A rough method for choosing the correct oropharyngeal airway (OPA) size is to hold the airway beside the patient's mandible, orienting it with the flange at the patient's mouth and the tip directed toward the angle of the mandible. The tip of an appropriately sized OPA should just reach the angle of the patient's mandible.</div><div id=\"graphicVersion\">Graphic 77645 Version 3.0</div></div></div>"},"77648":{"type":"graphic_table","displayName":"Rx bacterial vaginosis","title":"Treatment options for bacterial vaginosis (nonpregnant women)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment options for bacterial vaginosis (nonpregnant women)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Drugs of choice</td> </tr> <tr> <td class=\"indent1\">Metronidazole 500 mg oral twice daily for seven days <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Metronidazole gel 0.75 percent 5 g* (one full applicator) intravaginally once daily for five days <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Clindamycin 2 percent cream 5 g<sup>&#182;</sup> (one full applicator) intravaginally at bedtime for seven days</td> </tr> <tr> <td class=\"subtitle1_single\">Alternatives</td> </tr> <tr> <td class=\"indent1\">Clindamycin 300 mg orally twice daily for seven days <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Clindamycin ovule (vaginal suppository) 100 mg intravaginally once daily for three days <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Tinidazole 2 g orally for two days <strong>OR</strong></td> </tr> <tr> <td class=\"indent1\">Tinidazole 1 g orally once daily for five days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Although data are limited, metronidazole 750 mg extended release tablets once daily for seven days OR a single vaginal dose of clindamycin 2 percent bioadhesive cream (US trade name: Clindesse) 5 g<SUP>¶</SUP>, one full applicator, also appear to be effective.</div><div class=\"graphic_footnotes\">* 5 grams of metronidazole 0.75 percent vaginal gel contains 37.5 mg of metronidazole.<br />¶ 5 grams of clindamycin 2 percent vaginal cream contains 100 mg of clindamycin.</div><div class=\"graphic_reference\">Adapted from: Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1.</div><div id=\"graphicVersion\">Graphic 77648 Version 12.0</div></div></div>"},"77650":{"type":"graphic_diagnosticimage","displayName":"2D TTE Anteriorly angulated 2-chamber view","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from an anteriorly angulated two-chamber view","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from an anteriorly angulated two-chamber view</div><div class=\"cntnt\"><img style=\"width:283px; height:268px;\" src=\"images/CARD/77650_Angulation_two_chamber_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In some patients anterior angulation of the two chamber view affords the best view of the geometry of the left ventricular outflow tract. This advantage is especially true in hypertrophic cardiomyopathy.</div><div id=\"graphicVersion\">Graphic 77650 Version 3.0</div></div></div>"},"77651":{"type":"graphic_table","displayName":"FDA safe use guidelines","title":"FDA guidelines for safe use of contact lenses","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">FDA guidelines for safe use of contact lenses</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t    <td>&#8226; Always wash your hands before handling contact lenses to reduce the chance of getting an infection.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Remove the lenses immediately and consult your eye care professional if your eyes become red, irritated, or your vision changes.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Always follow the directions of your eye care professional and all labeling instruction for proper use of contact lenses and lens care products.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Use contact lens products and solutions recommended by your eye care professional.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Do not use contact lens solutions that have gone beyond the expiration or discard date.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Rub and rinse your contact lenses as directed by your eye care professional.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Clean and disinfect your lenses properly following all labeling instructions provided with your lens care products.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Do not \"top-off\" the solutions in your case. Always discard all of the left over contact lens solution after each use. Never reuse any lens solution.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Never use non-sterile water (distilled water, tap water or any homemade saline solution). Exposure of contact lenses to water has been associated with Acanthamoeba keratitis, a corneal infection that is resistant to treatment and cure.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Do not put your lenses in your mouth to wet them. Saliva is not a sterile solution.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Clean, rinse and air-dry your lens case each time lenses are removed. You may want to flip over your lens case while air drying so excess solution may drain out of the case. Contact lens cases can be a source of bacterial growth.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Replace your contact lens storage case every 3 to 6 months.</td>\n\t  </tr>\n\t  <tr>\n\t    <td>&#8226; Do not transfer contact lens solutions into smaller travel size containers. This can affect the sterility of the solution which can lead to an eye infection. Transferring solutions into smaller size containers may also leave consumers open to accidentally using a solution not intended for the eyes.</td>\n\t  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: US Food and Drug Administration, www.fda.gov/cdrh/contactlenses/lenslist.html.</div><div id=\"graphicVersion\">Graphic 77651 Version 1.0</div></div></div>"},"77653":{"type":"graphic_diagnosticimage","displayName":"Pulm AVM PA gram II","title":"Arteriovenous malformation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Arteriovenous malformation</div><div class=\"cntnt\"><img style=\"width:360px; height:427px;\" src=\"images/PULM/77653_Pulm_AVM_PA_gram_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pulmonary arteriogram shows a complex arteriovenous malformation in the lingula with early venous drainage.</div><div class=\"graphic_reference\">Courtesy of Paul Stark, MD.</div><div id=\"graphicVersion\">Graphic 77653 Version 2.0</div></div></div>"},"77654":{"type":"graphic_picture","displayName":"Cicatricial pemphigoid - gingiva","title":"Cicatricial pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cicatricial pemphigoid</div><div class=\"cntnt\"><img style=\"width:432px; height:322px;\" src=\"images/DERM/77654_Cicatricial_pemph_gingiva.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions are present on the gingiva in this patient with cictricial pemphigoid.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77654 Version 3.0</div></div></div>"},"77655":{"type":"graphic_diagnosticimage","displayName":"Unresected fundus after gastric sleeve","title":"Unresected fundus after gastric sleeve (dumbbell sleeve)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Unresected fundus after gastric sleeve (dumbbell sleeve)</div><div class=\"cntnt\"><img style=\"width:432px; height:429px;\" src=\"images/SURG/77655_Unresec_fundus_gastr_sleeve.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dumbbell shaped sleeve with large fundus.</div><div id=\"graphicVersion\">Graphic 77655 Version 5.0</div></div></div>"},"77656":{"type":"graphic_picture","displayName":"Central line dilator","title":"Insertion of soft tissue dilator for central venous catheter placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Insertion of soft tissue dilator for central venous catheter placement</div><div class=\"cntnt\"><img style=\"width:432px; height:273px;\" src=\"images/EM/77656_Central_line_dilator.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The soft tissue dilator is advanced over the guidewire using a corkscrew motion. Mild resistance is normal. The dilator does NOT need to be advanced its entire length, but only to the anticipated depth of the vessel.</div><div class=\"graphic_reference\">UpToDate acknowledges the invaluable assistance of the University of Massacusetts Medical School, Department of Anatomy and Department of Emergency Medicine, including Thomas Ellis, MD and Jean Marcelin, MD, for the photographs of central venous catheter placement.</div><div id=\"graphicVersion\">Graphic 77656 Version 2.0</div></div></div>"},"77659":{"type":"graphic_diagnosticimage","displayName":"MRI MTS T2","title":"T2-weighted MR image showing left-sided mesial temporal sclerosis in a round hippocampal variant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T2-weighted MR image showing left-sided mesial temporal sclerosis in a round hippocampal variant</div><div class=\"cntnt\"><img style=\"width:360px; height:378px;\" src=\"images/NEURO/77659_MRI_MTS_T2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the decreased volume and abnormal increased T2 signal of the hippocampus (arrow) and atrophy of the left temporal lobe, including the white matter.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 77659 Version 4.0</div></div></div>"},"77660":{"type":"graphic_table","displayName":"Volume of fetal blood samples and collection tubes for lab tests","title":"Volume of fetal blood samples and collection tubes for laboratory studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Volume of fetal blood samples and collection tubes for laboratory studies</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Test</td>\n<td class=\"subtitle1\">Tube content</td>\n<td class=\"subtitle1\">Sample volume, mL</td>\n</tr>\n<tr>\n<td>Complete blood count</td>\n<td>EDTA</td>\n<td>0.3</td>\n</tr>\n<tr>\n<td>Reticulocyte count</td>\n<td>EDTA</td>\n<td>0.3</td>\n</tr>\n<tr>\n<td>Kleihauer-Betke</td>\n<td>EDTA</td>\n<td>0.5</td>\n</tr>\n<tr>\n<td>Coagulation studies</td>\n<td>Citrate</td>\n<td>1.8</td>\n</tr>\n<tr>\n<td>Blood group typing</td>\n<td>Dry</td>\n<td>0.5</td>\n</tr>\n<tr>\n<td>Direct/indirect Coombs</td>\n<td>Dry</td>\n<td>0.5</td>\n</tr>\n<tr>\n<td>Total and specific IgM</td>\n<td>Dry</td>\n<td>0.5</td>\n</tr>\n<tr>\n<td>Serum chemistry</td>\n<td>Dry</td>\n<td>0.5</td>\n</tr>\n<tr>\n<td>Molecular biology analysis</td>\n<td>Sodium heparin</td>\n<td>3.0</td>\n</tr>\n<tr>\n<td>Polymerase chain reaction</td>\n<td>EDTA</td>\n<td>0.5</td>\n</tr>\n<tr>\n<td>Blood gas analysis</td>\n<td>Heparinized syringe</td>\n<td>0.3</td>\n</tr>\n<tr>\n<td>Karyotype or fluorescence in situ hybridization</td>\n<td>Sodium heparin</td>\n<td>1.0</td>\n</tr>\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77660 Version 2.0</div></div></div>"},"77661":{"type":"graphic_picture","displayName":"Gemistocytic astrocytoma Light","title":"Gemistocytic astrocytoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gemistocytic astrocytoma</div><div class=\"cntnt\"><img style=\"width:378px; height:259px;\" src=\"images/ONC/77661_Gemistocytic_astrocytoma_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of gemistocytic astrocytoma. The emistocytic cells are exceptionally large and densely packed with a globoid appearance (arrows).</div><div class=\"graphic_reference\">Courtesy of Thomas Smith, MD, University of Massachusetts.</div><div id=\"graphicVersion\">Graphic 77661 Version 1.0</div></div></div>"},"77662":{"type":"graphic_figure","displayName":"Automated DNA sequencing","title":"Automated DNA sequencing","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Automated DNA sequencing</div><div class=\"cntnt\"><img style=\"width:485px; height:195px;\" src=\"images/PC/77662_Fluorescent_DNA_sequencing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This representation of automated DNA sequencing shows how this technique can be used to detect mutations and other changes in DNA sequence. DNA is amplified in the presence of primers and chain terminators. Either the primers or the terminators are fluorescently labeled, with a different color fluorescence for each base. The automated sequencer uses a laser to excite the DNA containing these fluorescently labeled nucleotides and produces a color-coded intensity profile. In this example, guanine (G) is purple, adenine (A) is green, thymine (T) is red, and cytosine (C) is blue. The sequence can be read from the color of the peaks.</div><div id=\"graphicVersion\">Graphic 77662 Version 2.0</div></div></div>"},"77663":{"type":"graphic_figure","displayName":"Paraphimosis forcep technique","title":"Forceps traction techniques for reduction of paraphimosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Forceps traction techniques for reduction of paraphimosis</div><div class=\"cntnt\"><img style=\"width:440px; height:327px;\" src=\"images/EM/77663_Paraphim_forcep_technique.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A)&nbsp;Non-crushing Babcock forceps can be placed in each of four quadrants of the swollen foreskin, followed by continuous, gentle, symmetrical traction until reduction of the foreskin has occurred. <br />(B) Alternatively, after topical or infiltrated local anesthesia is performed at the site of sharp Adson forceps application, one tine of the Adson forceps is placed under the constricting band and one on the superficial skin. A secure grasp is obtained and constant, steady traction is applied distally until reduction of the band over the glans occurs. This technique can be modified by using two forceps at the 9 and 3 o'clock positions.</div><div id=\"graphicVersion\">Graphic 77663 Version 7.0</div></div></div>"},"77664":{"type":"graphic_figure","displayName":"Substrate use in exercise","title":"Metabolic substrate utilization during exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Metabolic substrate utilization during exercise</div><div class=\"cntnt\"><img style=\"width:409px; height:214px;\" src=\"images/ENDO/77664_Substrate_use_in_exercise.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Substrate utilization during prolonged exercise in normal subjects. Muscle glycogen breakdown is important initially but stores are rapidly depleted. Glucose (derived from circulating glucose and hepatic glycogenolysis and gluconeogenesis) and free fatty acids (FFA) then become increasingly important. However, the fall in plasma glucose concentration reduces the secretion of insulin and raises that of counterregulatory hormones (such as epinephrine and norepinephrine). As a result, prolonged exercise is associated with a gradual fall in utilization of glucose and increase in that of FFA.</div><div id=\"graphicVersion\">Graphic 77664 Version 1.0</div></div></div>"},"77666":{"type":"graphic_picture","displayName":"Esophageal adenocarcinoma retroflexed CPC","title":"Endoscopic view of an esophageal adenocarcinoma extending into the gastric cardia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic view of an esophageal adenocarcinoma extending into the gastric cardia</div><div class=\"cntnt\"><img style=\"width:252px; height:255px;\" src=\"images/GAST/77666_Esoph_adenoca_retroflex_CPC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroflexed endoscopic view of this esophageal adenocarcinoma mass extending into the gastric cardia.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD and Douglas Pleskow, MD.</div><div id=\"graphicVersion\">Graphic 77666 Version 4.0</div></div></div>"},"77671":{"type":"graphic_picture","displayName":"Pulmonary KS high","title":"Pulmonary Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pulmonary Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:403px; height:262px;\" src=\"images/PULM/77671_Pulmonary_KS_high.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power photomicrograph shows a perivenular infiltrate of Kaposi sarcoma with a mixture of spindle cells, inflammatory cells, and ectatic vascular spaces.</div><div class=\"graphic_reference\">From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.</div><div id=\"graphicVersion\">Graphic 77671 Version 2.0</div></div></div>"},"77672":{"type":"graphic_picture","displayName":"Subacromial palpation with extension","title":"Subacromial palpation with extension","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Subacromial palpation with extension</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/EM/77672_Subacromial_palpation_ext.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Stephen M Simons, MD.</div><div id=\"graphicVersion\">Graphic 77672 Version 1.0</div></div></div>"},"77673":{"type":"graphic_figure","displayName":"Dermoscopic structures 1","title":"Criteria for melanocytic neoplasms and their histopathologic correlation<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Criteria for melanocytic neoplasms and their histopathologic correlation<sup>[1-3]</sup></div><div class=\"cntnt\"><img style=\"width:596px; height:837px;\" src=\"images/DERM/77673_Dermoscopicstruct1edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">List continued in figure \"Dermoscopic structures most commonly seen in melanocytic neoplasms and their histopathologic correlation.\"</div><div class=\"graphic_footnotes\">DEJ: dermo-epidermal junction.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48:679.</li>&#xD;&#xA;    <li>Braun RP, Rabinovitz HS, Oliviero M, et al. Dermoscopy of pigmented skin lesions. J Am Acad Dermatol 2005; 52:109.</li>&#xD;&#xA;    <li>Pehamberger H, Steiner A, Wolff K. In vivo epiluminescence microscopy of pigmented skin lesions. I. Pattern analysis of pigmented skin lesions. J Am Acad Dermatol 1987; 17:571.</li>&#xD;&#xA;    <li>Jaimes N, Marghoob AA, Rabinovitz H, et al. Clinical and dermoscopic characteristics of melanomas on nonfacial chronically sun-damaged skin. J Am Acad Dermatol 2015; 72:1027.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Drs. Ashfaq Marghoob and Natalia Jaimes.</div><div id=\"graphicVersion\">Graphic 77673 Version 9.0</div></div></div>"},"77674":{"type":"graphic_picture","displayName":"Gonorrhea and penile discharge","title":"Penile discharge in gonorrhea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Penile discharge in gonorrhea</div><div class=\"cntnt\"><img style=\"width:504px; height:304px;\" src=\"images/DERM/77674_Gonorrhea_penile_discharge.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acute gonorrhea. A purulent discharge emanates from the urethra.</div><div class=\"graphic_reference\">Reproduced with permission from: Rubin E, Farber JL. Pathology, 3rd ed, Lippincott Williams &amp; Wilkins, Philadelphia 1999. Copyright &#169; 1999 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77674 Version 1.0</div></div></div>"},"77675":{"type":"graphic_picture","displayName":"Borrelia lonestari","title":"B. lonestari","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">B. lonestari</div><div class=\"cntnt\"><img style=\"width:324px; height:243px;\" src=\"images/ID/77675_Borrelia_lonestari.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photomicrograph of Borrelia lonestari growing in tissue culture using ISE6 tick tissue culture (Giemsa stain).</div><div class=\"graphic_reference\">Courtesy of Susan Little, DVM.</div><div id=\"graphicVersion\">Graphic 77675 Version 1.0</div></div></div>"},"77676":{"type":"graphic_table","displayName":"Hand-hygiene technique","title":"Hand-hygiene technique","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hand-hygiene technique</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>When decontaminating hands with an alcohol-based hand rub, apply product to palm of one hand and rub hands together, covering all surfaces of hands and fingers, until hands are dry. Follow the manufacturer's recommendations regarding the volume of product to use.</td> </tr> <tr> <td>When washing hands with soap and water, wet hands first with water, apply an amount of product recommended by the manufacturer to hands, and rub hands together vigorously for at least&nbsp;20 seconds, covering all surfaces of the hands and fingers. Rinse hands with water and dry thoroughly with a disposable towel. Use towel to turn off the faucet.</td> </tr> <tr> <td>Liquid, bar, leaflet, or powdered forms of plain soap are acceptable when washing hands with soap and water. When bar soap is used, small bars of soap and soap racks that facilitate drainage should be used.</td> </tr> <tr> <td>Multiple-use cloth towels of the hanging or roll type are not recommended for use in health care settings.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report 2002; 51(RR-16):1.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. When &amp; How to Wash Your Hands. Available at: <A href=\"http://www.cdc.gov/handwashing/when-how-handwashing.html\">http://www.cdc.gov/handwashing/when-how-handwashing.html</A> (Accessed on September 15, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 77676 Version 6.0</div></div></div>"},"77679":{"type":"graphic_diagnosticimage","displayName":"MRI brain sagging","title":"MRI of brain sagging with low cerebrospinal fluid pressure headache","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">MRI of brain sagging with low cerebrospinal fluid pressure headache</div><div class=\"cntnt\"><img style=\"width:516px; height:262px;\" src=\"images/NEURO/77679_MRI_brain_sagging.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain MRI of a patient with low CSF pressure headache (spontaneous intracranial hypotension). Noncontrast T1-weighted sagittal images were obtained before (A) and after (B) treatment. There is crowding and pointing of the cerebellar tonsils at the foramen magnum mimicking a Chiari 1 malformation on the first study (arrow, image A). In addition, there is sagging of the brain resulting in inferior displacement of the floor of the third ventricle (arrowhead, image A) as well as loss of CSF space in the suprasellar cistern. These findings have resolved on MRI six months later after treatment (B), which included draining of associated subdural collections.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 77679 Version 3.0</div></div></div>"},"77680":{"type":"graphic_picture","displayName":"Extramammary Paget disease2","title":"Extramammary Paget disease of the vulva-2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extramammary Paget disease of the vulva-2</div><div class=\"cntnt\"><img style=\"width:400px; height:300px;\" src=\"images/OBGYN/77680_Extramammary_Paget_disease2.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 77680 Version 1.0</div></div></div>"},"77681":{"type":"graphic_picture","displayName":"Reticulated pigmented anomaly of the flexures","title":"Reticulated pigmented anomaly of the flexures (Dowling-Degos disease)","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Reticulated pigmented anomaly of the flexures (Dowling-Degos disease)</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77681_Retic_pig_anomaly_flexures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A reticulated, hyperpigmented plaque is present perianally.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77681 Version 3.0</div></div></div>"},"77682":{"type":"graphic_picture","displayName":"Lead line gums","title":"Lead line in the gums of a patient with occupational lead poisoning","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lead line in the gums of a patient with occupational lead poisoning</div><div class=\"cntnt\"><img style=\"width:392px; height:260px;\" src=\"images/HEME/77682_Lead_line_gums.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows a &quot;lead line&quot; in the region between the teeth and gingiva of a patient with lead poisoning due to occupational exposure (automobile radiator repair). The dark areas (arrows) represent deposition of insoluble lead following interaction with sulfur-containing metabolites produced by bacteria in these gingival pockets.</div><div class=\"graphic_reference\">Photograph provided by Stephen A Landaw, MD, PhD.</div><div id=\"graphicVersion\">Graphic 77682 Version 2.0</div></div></div>"},"77687":{"type":"graphic_figure","displayName":"Anatomy of the ureters - female pelvis","title":"Anatomy of the ureters - female pelvis, cross sectional view","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Anatomy of the ureters - female pelvis, cross sectional view</div><div class=\"cntnt\"><img style=\"width:511px; height:463px;\" src=\"images/SURG/77687_Ureters-female-sup-view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts the relationship of the ureter to the pelvic anatomy in the female, in a cross sectional view.</div><div id=\"graphicVersion\">Graphic 77687 Version 3.0</div></div></div>"},"77688":{"type":"graphic_picture","displayName":"Disseminated herpes zoster","title":"Disseminated herpes zoster","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Disseminated herpes zoster</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/DERM/77688_Diss_Herpes_Zoster_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The multiple vesicles and crusts of herpes zoster are not limited to a dermatome.</div><div class=\"graphic_reference\">Reproduced with permission from: Herbert A Hochman, MD. Originally published in&#160;Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003.</div><div id=\"graphicVersion\">Graphic 77688 Version 1.0</div></div></div>"},"77689":{"type":"graphic_table","displayName":"Exercise test endpoints","title":"Exercise test endpoints","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Exercise test endpoints</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Patient-determined endpoints</td> </tr> <tr> <td class=\"indent1\">Patient wants to stop</td> </tr> <tr> <td class=\"indent1\">Significant chest discomfort</td> </tr> <tr> <td class=\"indent1\">Marked fatigue or severe dyspnea</td> </tr> <tr> <td class=\"indent1\">Other limiting symptoms (dizziness, leg cramps, joint discomfort, etc)</td> </tr> <tr> <td class=\"subtitle1_single\">Provider-determined endpoints</td> </tr> <tr> <td class=\"indent1\">Patient does not look well (eg, ataxia, confusion, pallor, cyanosis, etc)</td> </tr> <tr> <td class=\"indent1\">Exertional hypotension (systolic BP below standing systolic BP measured at rest prior to test)</td> </tr> <tr> <td class=\"indent1\">Systolic BP &#62;250 mmHg</td> </tr> <tr> <td class=\"indent1\">Diastolic BP &#62;120 mmHg</td> </tr> <tr> <td class=\"indent1\">ECG endpoints</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Marked ST segment depression </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>New bundle branch block which cannot be distinguished from ventricular tachycardia </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>New high grade (ie, Mobitz 2 or complete) AV block </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ventricular tachycardia or fibrillation </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Increasing ventricular ectopy (premature beats, couplets or nonsustained ventricular tachycardia), especially if ischemia present </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Onset of supraventricular tachyarrhythmias </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Equipment failure</td> </tr> <tr> <td class=\"subtitle1_single\">Protocol-determined endpoints (submaximal tests)</td> </tr> <tr> <td class=\"indent1\">Heart rate determined (eg, 120 to 140 bpm)</td> </tr> <tr> <td class=\"indent1\">Workload determined (eg, 5 METs)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BP: blood pressure; ECG: electrocardiogram; AV: atrioventricular; MET: metabolic equivalent.</div><div id=\"graphicVersion\">Graphic 77689 Version 7.0</div></div></div>"},"77690":{"type":"graphic_diagnosticimage","displayName":"Battery versus coin lateral radiograph","title":"Battery versus coin ingestion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Battery versus coin ingestion</div><div class=\"cntnt\"><img style=\"width:370px; height:257px;\" src=\"images/PEDS/77690_Battery_vs_coin_lateral.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlarged radiographic comparison between a camera battery (left) and coin (right) demonstrates the subtle, but characteristic differences of these esophageal foreign bodies. The bilaminar structure of the battery gives a \"step off\" appearance on the lateral view, whereas the coin has sharp, crisp edges.</div><div class=\"graphic_reference\">Courtesy of Barbara Specter, MD.</div><div id=\"graphicVersion\">Graphic 77690 Version 3.0</div></div></div>"},"77698":{"type":"graphic_picture","displayName":"Micrograph ganglioneuroma","title":"Micrograph ganglioneuroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Micrograph ganglioneuroma</div><div class=\"cntnt\"><img style=\"width:297px; height:494px;\" src=\"images/NEURO/77698_Micrographganglioneuroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Photomicrograph of a tumor that was removed from the L2-3 nerve root. The spindle cells and collagenous background resemble neurofibroma. However, several multinucleated, dysplastic ganglion cells can be seen interspersed amidst the neurofibromatous background (arrows). Therefore, this tumor would be considered a ganglioneuroma. H&amp;E, x100. <br />(B) A higher-power view of a focal cluster of dysplastic ganglion cells (arrows). H&amp;E, x600.</div><div class=\"graphic_reference\">Courtesy of John E Donahue, MD.</div><div id=\"graphicVersion\">Graphic 77698 Version 3.0</div></div></div>"},"77699":{"type":"graphic_picture","displayName":"Congential HSV 2","title":"Congenital herpes simplex viral disease-2","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital herpes simplex viral disease-2</div><div class=\"cntnt\"><img style=\"width:396px; height:269px;\" src=\"images/OBGYN/77699_Congenital_HSV_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatic herpes simplex viral infection with infected cell in center.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 77699 Version 1.0</div></div></div>"},"77701":{"type":"graphic_diagnosticimage","displayName":"Calcaneus avulsion fracture","title":"Calcaneal apophyseal fracture","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Calcaneal apophyseal fracture</div><div class=\"cntnt\"><img style=\"width:478px; height:190px;\" src=\"images/EM/77701_Calcaneusavulsionfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) True avulsion injury of an inferior segment of the calcaneal apophysis, which was treated in a cast for comfort. <br />(B) Uninjured side shows normal apophyseal segmentation.</div><div class=\"graphic_reference\">Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright © 2006 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77701 Version 12.0</div></div></div>"},"77702":{"type":"graphic_diagnosticimage","displayName":"Open midshaft forearm fracture","title":"Open midshaft forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Open midshaft forearm fracture</div><div class=\"cntnt\"><img style=\"width:229px; height:587px;\" src=\"images/EM/77702_Openmidshaftfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 13-year-old girl with open forearm fracture.<br />Top Panels: AP and lateral x-rays; note extrusion of ulna on lateral view.<br />Bottom Panels: After irrigation and debridement and flexible nail internal fixation; note the Penrose drain in the ulnar wound.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: Mehlman CT, Wall EJ. Injuries to the shafts of the radius and ulna. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 77702 Version 14.0</div></div></div>"},"77703":{"type":"graphic_table","displayName":"WHO ovarian tumor classific","title":"WHO classification of tumors of the ovary*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">WHO classification of tumors of the ovary*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Epithelial tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Serous tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign <ul> <li>Serous cystadenoma </li> <li>Serous adenofibroma </li> <li>Serous surface papilloma </li> </ul> </li> <li>Borderline <ul> <li>Serous borderline tumor/atypical proliferative serous tumor </li> <li>Serous borderline tumor &ndash; micropapillary variant/noninvasive low-grade serous carcinoma </li> </ul> </li> <li>Malignant <ul> <li>Low-grade serous carcinoma </li> <li>High-grade serous carcinoma </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Mucinous tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign <ul> <li>Mucinous cystadenoma </li> <li>Mucinous adenofibroma </li> </ul> </li> <li>Borderline <ul> <li>Mucinous borderline tumor/atypical proliferative mucinous tumor </li> </ul> </li> <li>Malignant <ul> <li>Mucinous carcinoma </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Endometrioid tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign <ul> <li>Endometriotic cyst </li> <li>Endometrioid cystadenoma </li> <li>Endometrioid adenofibroma </li> </ul> </li> <li>Borderline <ul> <li>Endometrioid borderline tumor/atypical proliferative endometrioid tumor </li> </ul> </li> <li>Malignant <ul> <li>Endometrioid carcinoma </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Clear cell tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign <ul> <li>Clear cell cystadenoma </li> <li>Clear cell adenofibroma </li> </ul> </li> <li>Borderline <ul> <li>Clear cell borderline tumor/atypical proliferative clear cell tumor </li> </ul> </li> <li>Malignant <ul> <li>Clear cell carcinoma </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Brenner tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign <ul> <li>Brenner tumor </li> </ul> </li> <li>Borderline <ul> <li>Borderline Brenner tumor/atypical proliferative Brenner tumor </li> </ul> </li> <li>Malignant <ul> <li>Malignant Brenner tumor </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Seromucinous tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Benign <ul> <li>Seromucinous cystadenoma </li> <li>Seromucinous adenofibroma </li> </ul> </li> <li>Borderline <ul> <li>Seromucinous borderline tumor/atypical proliferative seromucinous tumor </li> </ul> </li> <li>Malignant <ul> <li>Seromucinous carcinoma </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2_single\">Undifferentiated carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Mesenchymal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Low-grade endometrioid stromal sarcoma </li> <li>High-grade endometrioid stromal sarcoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mixed epithelial and mesenchymal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adenosarcoma </li> <li>Carcinosarcoma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Sex cord-stromal tumors</td> </tr> <tr> <td class=\"subtitle2_single\">Pure stromal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Fibroma </li> <li>Cellular fibroma </li> <li>Thecoma </li> <li>Luteinized thecoma associated with sclerosing peritonitis </li> <li>Fibrosarcoma </li> <li>Sclerosing stromal tumor </li> <li>Signet-ring stromal tumor </li> <li>Microcystic stromal tumor </li> <li>Leydig cell tumor </li> <li>Steroid cell tumor </li> <li>Steroid cell tumor, malignant </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Pure sex cord tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adult granulosa cell tumor </li> <li>Juvenile granulosa cell tumor </li> <li>Sertoli cell tumor </li> <li>Sex cord tumor with annular tubules </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Mixed sex cord-stromal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Sertoli-Leydig cell tumor <ul> <li>Well-differentiated </li> <li>Moderately differentiated <ul> <li>With heterologous elements </li> </ul> </li> <li>Poorly differentiated <ul> <li>With heterologous elements </li> </ul> </li> <li>Retiform <ul> <li>With heterologous elements </li> </ul> </li> <li>Sex cord-stromal tumors, NOS </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Germ cell tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Dysgerminoma </li> <li>Yolk sac tumor </li> <li>Embryonal carcinoma </li> <li>Nongestational choriocarcinoma </li> <li>Mature teratoma </li> <li>Immature teratoma </li> <li>Mixed germ cell tumor </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Monodermal teratoma and somatic-type tumors arising from a dermoid cyst</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Struma ovarii, benign </li> <li>Struma ovarii, malignant </li> <li>Carcinoid <ul> <li>Strumal carcinoid </li> <li>Mucinous carcinoid </li> </ul> </li> <li>Neuroectodermal-type tumors </li> <li>Sebaceous tumors <ul> <li>Sebaceous adenoma </li> <li>Sebaceous carcinoma </li> </ul> </li> <li>Other rare monodermal teratomas </li> <li>Carcinomas <ul> <li>Squamous cell carcinoma </li> <li>Others </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Germ cell-sex cord-stromal tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Gonadoblastoma, including gonadoblastoma with malignant germ cell tumor </li> <li>Mixed germ cell-sex cord-stromal tumor, unclassified </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Tumors of rete ovarii <ul> <li>Adenoma of rete ovarii </li> <li>Adenocarcinoma of rete ovarii </li> </ul> </li> <li>Wolffian tumor </li> <li>Small cell carcinoma, hypercalcaemic type </li> <li>Small cell carcinoma, pulmonary type </li> <li>Wilms tumor </li> <li>Paraganglioma </li> <li>Solid pseudopapillary neoplasm </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Mesothelial tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Adenomatoid tumor </li> <li>Mesothelioma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Soft tissue tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Myxoma </li> <li>Others </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Tumor-like lesions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Follicle cyst </li> <li>Corpus luteum cyst </li> <li>Large solitary luteinized follicle cyst </li> <li>Hyperreactio luteinalis </li> <li>Pregnancy luteoma </li> <li>Stromal hyperplasia </li> <li>Stromal hyperthecosis </li> <li>Fibromatosis </li> <li>Massive oedema </li> <li>Leydig cell hyperplasia </li> <li>Others </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Lymphoid and myeloid tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Lymphomas </li> <li>Plasmacytoma </li> <li>Myeloid neoplasms </li> </ul> </td> </tr> <tr> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\"><strong>Secondary tumors</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; NOS: not otherwise specified.<br />* The classification is modified from the previous WHO classification of tumors, taking into account changes in our understanding of these lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: Kurman RJ, Carcangiu ML, Herrington S, Young RH. World Health Organization Classification of Tumours of the Female Reproductive Organs. IARC, Lyon, 2014. Copyright © 2014.</div><div id=\"graphicVersion\">Graphic 77703 Version 5.0</div></div></div>"},"77704":{"type":"graphic_figure","displayName":"Iron chelating agents","title":"Iron chelating agents","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Iron chelating agents</div><div class=\"cntnt\"><img style=\"width:451px; height:189px;\" src=\"images/HEME/77704_Iron_chelating_agents.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three general classes of agents capable of chelating iron are shown here. In order to perform this function, the chelating molecule(s) must complex with all of the iron atom's six available coordination sites, as shown. Bidentate chelating agents are capable of providing two such links per molecule; thus, three molecules are required to chelate one atom of iron. Similarly, two tridentate molecules and only one hexadentate molecule are required to accomplish the same purpose.</div><div class=\"graphic_reference\">Reproduced with permission from: Cohen A, Porter J. Transfusion and chelation therapy in thalassemia and sickle cell anemia. In: Disorders of hemoglobin: Genetics, Pathophysiology, and Clinical Management, Bunn HF, Steinberg MH, Forget BG (Eds), Cambridge University Press, Cambridge 2001. p.979. Copyright © 2001 Cambridge University Press.</div><div id=\"graphicVersion\">Graphic 77704 Version 2.0</div></div></div>"},"77705":{"type":"graphic_figure","displayName":"Effects of decreased cerebral blood flow","title":"Effects of decreased cerebral blood flow on vital brain functions","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Effects of decreased cerebral blood flow on vital brain functions</div><div class=\"cntnt\"><img style=\"width:491px; height:338px;\" src=\"images/NEURO/77705_Effects_dec_cerebral_blood.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Mounzer Kassab.</div><div id=\"graphicVersion\">Graphic 77705 Version 2.0</div></div></div>"},"77706":{"type":"graphic_figure","displayName":"T-tubule alterations and muscle weakness in myotonic dystrophy","title":"T-tubule alterations and muscle weakness in myotonic dystrophy","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">T-tubule alterations and muscle weakness in myotonic dystrophy</div><div class=\"cntnt\"><img style=\"width:598px; height:470px;\" src=\"images/NEURO/77706_T_tubule_alteration.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Model of T-tubule alterations and muscle weakness in myotonic dystrophic patients. In DM, expanded CUG or CCUG repeats sequester MBNL1 within intranuclear aggregates, resulting in decrease levels of free MBNL1 available to regulate alternative splicing. Consequently, the exon 11 of BIN1 pre-mRNA, which is normally included in adult skeletal muscle, is skipped in DM patients and results in expression of a fetal isoform of BIN1 unable to bind to PtdIns5P and to tubulate membranes, leading to misorganization of the T-tubule network and alteration of the excitation-contraction (E-C) coupling.</div><div class=\"graphic_reference\">Reproduced with permission from: Fugier C, Klein AF, Hammer C, et al. Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med 2011; 17:720. Copyright &#169; 2011 The Authors.</div><div id=\"graphicVersion\">Graphic 77706 Version 1.0</div></div></div>"},"77707":{"type":"graphic_diagnosticimage","displayName":"Omphalocele and cystic hygroma","title":"Ultrasound image showing omphalocele and cystic hygroma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound image showing omphalocele and cystic hygroma</div><div class=\"cntnt\"><img style=\"width:278px; height:186px;\" src=\"images/OBGYN/77707_US_omphalocele_cyst_hygroma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal view of a fetus with trisomy 18 at 12 weeks of gestation with an omphalocele and cystic hygroma.</div><div class=\"graphic_reference\">Courtesy of Ana Monteagudo, MD.</div><div id=\"graphicVersion\">Graphic 77707 Version 4.0</div></div></div>"},"77708":{"type":"graphic_picture","displayName":"Aplasia cutis congenita trunk","title":"Aplasia cutis congenita","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Aplasia cutis congenita</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77708_Aplasia_cutis_congenita.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, partially healed skin defect involving the trunk in an infant with aplasia cutis congenita.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77708 Version 2.0</div></div></div>"},"77709":{"type":"graphic_table","displayName":"Epidermolysis bullosa simplex variants","title":"Genotypic and phenotypic variants of epidermolysis bullosa simplex (epidermolytic)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Genotypic and phenotypic variants of epidermolysis bullosa simplex (epidermolytic)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Site of cleavage within the epidermis</td> <td class=\"subtitle1\">Subtypes</td> <td class=\"subtitle1\">Inheritance<br /> Mutated gene<br /> Targeted gene product</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"> <p><strong>Suprabasal</strong></p> (cytolysis of suprabasal keratinocytes; intact blisters usually not clinically evident; keratinocytes form numerous interdigitating cellular protrusions; only few desmosomal remnants present)</td> <td>Acantholytic EBS (EBS-acanth)</td> <td> <ul> <li>Autosomal recessive </li> <li><em>DSP</em>, <em>JUP</em> </li> <li>Desmoplakin (absent), plakoglobin (absent) </li> </ul> </td> <td> <ul> <li>Five cases of lethal acantholytic epidermolysis bullosa due to mutations in <em>DSP</em> and one due to <em>JUP</em> have been described<sup>[1-5]</sup> </li> <li>Generalized skin fragility with rapidly progressive epidermolysis and large sheets of detached skin with superficial erosions at birth; skin detachment on hands and feet in a glove and stocking pattern; complete disruption of the epidermal barrier without intact blisters or vesicles; no excessive granulation tissue </li> <li>Universal alopecia (complete absence of scalp hair, eyebrows, eyelashes despite discrete follicular openings on scalp), nail loss, and neonatal teeth </li> <li>Involvement of oropharynx, gastrointestinal, genitourinary, and respiratory tract with extensive suprabasal acantholytic separation </li> <li>Demise in neonatal period<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td>Skin fragility syndromes <ul> <li>Desmoplakin deficiency (EBS-desmoplakin; skin fragility-woolly hair syndrome) </li> <li>Plakoglobin deficiency (EBS-plakoglobin; skin fragility-plakoglobin deficiency) </li> <li>Plakophilin deficiency (EBS-plakophilin; skin fragility-ectodermal dysplasia syndrome) </li> </ul> </td> <td> <ul> <li>Autosomal recessive </li> <li><em>DSP</em>, <em>JUP</em>, <em>PKP1</em> </li> <li>Desmoplakin (reduced), plakoglobin (reduced), plakophilin-1 (absent or reduced) </li> </ul> </td> <td> <ul> <li>Generalized skin fragility with trauma-induced and spontaneous superficial erosions from birth; palmoplantar keratoderma with painful, often disabling fissures (walking, bearing weight); nail dystrophy; alopecia </li> <li>Chronic cheilitis, perioral scale, perioral and lingual fissures </li> <li>Blepharitis, astigmatism </li> <li>Persistent abnormal hair (hypotrichosis, loss of eyelashes, complete alopecia; woolly hair) </li> <li>Esophageal strictures, constipation </li> <li>Growth retardation (usually below the third centile for height and weight) </li> <li>Variable clinical features include scattered scale-crust on the trunk and limbs, follicular hyperkeratosis, inflammatory scaly plaques in flexures, perianal erythema and erosions, pruritus; reduced sweating; dental caries; recurrent systemic infections; chronic diarrhea </li> </ul> </td> </tr> <tr> <td>EBS superficialis</td> <td> <ul> <li>Unknown</li> </ul> </td> <td> <ul> <li>Blistering between stratum corneum and granulosum </li> <li>Superficial erosions with scarring and milia formation from birth or early infancy<sup>[6]</sup> </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\">Acral peeling skin syndrome<sup>[7]</sup></td> <td class=\"divider_bottom\"> <ul> <li>Autosomal recessive </li> <li><em>TGM5</em> </li> <li>Transglutaminase-5 </li> </ul> </td> <td class=\"divider_bottom\"> <ul> <li>Superficial painless skin peeling (volar and dorsal aspects of hands, feet; elbows, knees) </li> <li>Acral blisters, erosions at birth/since infancy; pruritus aggravated by heat, sweating, humidity, mechanical trauma, exposure to water </li> <li>Spontaneous healing with residual erythema, burning sensation, pruritus, and hyperpigmentation </li> <li>No scarring or atrophy </li> </ul> </td> </tr> <tr> <td rowspan=\"12\"> <p><strong>Basal</strong></p> (cytolysis of basal keratinocytes)</td> <td>EBS, localized (EBS-loc, former Weber-Cockayne)</td> <td> <ul> <li>Autosomal dominant </li> <li><em>KRT5</em>, <em>KRT14</em> </li> <li>Keratin 5, keratin 14 </li> </ul> </td> <td> <ul> <li>Most common EBS subtype </li> <li>Mainly limited, regional involvement of palms and soles </li> <li>Clinical onset usually during infancy or, rarely, early adulthood </li> <li>Extracutaneous manifestations (other than clinically insignificant blisters within oral cavity during early childhood) rare<sup>[8]</sup> </li> </ul> </td> </tr> <tr> <td>EBS, generalized severe (former Dowling-Meara)</td> <td> <ul> <li>Autosomal dominant </li> <li><em>KRT5</em>, <em>KRT14</em> </li> <li>Keratin 5, keratin 14 </li> </ul> </td> <td> <ul> <li>Generalized, peculiar herpetiform distribution (arcuate grouping) of blisters from birth (typically and best seen when patients have relatively milder disease activity<sup>[9]</sup>) </li> <li>Atrophic scarring, milia formation, confluent palmoplantar hyperkeratosis, nail manifestations </li> <li>Often mucosal involvement </li> </ul> </td> </tr> <tr> <td>EBS, generalized intermediate (includes former Koebner)</td> <td> <ul> <li>Autosomal dominant </li> <li><em>KRT5</em>, <em>KRT14</em>, <em>EXPH5</em>, <em>DYS</em>, <em>KLHL24</em> </li> <li>Keratin 5, keratin 14, exophilin 5, dystonin, Kelch-like family member 24 </li> </ul> </td> <td> <ul> <li>Widespread but less severe form that usually presents at birth </li> <li>Rarely eye involvement </li> </ul> </td> </tr> <tr> <td>EBS-MP (EBS with mottled pigmentation)</td> <td> <ul> <li>Autosomal dominant </li> <li><em>KRT5</em> </li> <li>Keratin 5 </li> </ul> </td> <td> <ul> <li>Skin blistering with reticulate brown skin pigmentation, keratoderma, nail dystrophy </li> <li>Pigmentary lesions usually present in early childhood, but may become less distinctive or even imperceptible by adult life<sup>[9]</sup> </li> </ul> </td> </tr> <tr> <td>EBS, migratory circinate</td> <td> <ul> <li>Autosomal dominant </li> <li><em>KRT5</em> </li> <li>Keratin 5 </li> </ul> </td> <td> <ul> <li>Blistering lesions on hands, legs, and feet from birth </li> <li>Annular migratory erythema with vesicles and crusts at the advancing edge </li> <li>Brown postinflammatory hyperpigmentation </li> <li>Improves in the first few years of life </li> </ul> </td> </tr> <tr> <td>EBS with muscular dystrophy</td> <td> <ul> <li>Autosomal recessive </li> <li><em>PLEC1</em> </li> <li>Plectin </li> </ul> </td> <td> <ul> <li>Generalized blistering from birth </li> <li>Atrophic scarring, milia formation, nail dystrophy and loss </li> <li>Granulation tissue formation and stenosis within respiratory tract </li> <li>Muscular dystrophy may either be present on or shortly after birth in a child with severe generalized skin involvement (usually appearing as \"floppy\" babies who are unable to easily lift their arms and legs), or, in others, may arise insidiously in later childhood or adulthood; this variant harbors a higher mortality rate from muscle involvement<sup>[8]</sup> </li> </ul> </td> </tr> <tr> <td>EBS with pyloric atresia</td> <td> <ul> <li>Autosomal recessive </li> <li><em>PLEC1</em>, <em>ITGA6</em>, <em>ITGB4</em> </li> <li>Plectin, integrin-alpha-6, integrin-beta-4 </li> </ul> </td> <td> <ul> <li>Gestational hydramnion </li> <li>Generalized blistering of variable severity from birth, atrophic scarring<sup>[10-12]</sup> </li> <li>Association with aplasia cutis congenita<sup>[13]</sup> </li> <li>Mucosal involvement (protein losing enteropathy, diarrhea) </li> <li>Enamel hypoplasia, caries </li> <li>Anemia, growth retardation, contractures, cryptorchidism, high mortality </li> </ul> </td> </tr> <tr> <td>EBS, autosomal recessive K14</td> <td> <ul> <li>Autosomal recessive </li> <li><em>KRT14</em><sup>[14]</sup> </li> <li>Keratin 14 </li> </ul> </td> <td> <ul> <li>Generalized blistering from birth (frequently anogenital), ichthyosiform plaques; rarely milia formation or atrophic scarring </li> <li>Involvement of oral cavity (caries) and genitourinary tract </li> <li>Growth retardation, constipation </li> </ul> </td> </tr> <tr> <td>EBS, Ogna type</td> <td> <ul> <li>Autosomal dominant </li> <li><em>PLEC1</em> </li> <li>Plectin </li> </ul> </td> <td> <ul> <li>Hemorrhagic blisters at predominantly acral sites from birth </li> <li>Onychogryphosis (markedly curved and deformed nails resembling ram's horns)<sup>[9]</sup> </li> </ul> </td> </tr> <tr> <td>EBS, autosomal recessive-exophilin 5 deficiency</td> <td> <ul> <li>Autosomal recessive </li> <li><em>EXPH5</em> </li> <li>Exophilin-5 (Rab27B GTPase effector protein Slac2-b) </li> </ul> </td> <td> <ul> <li>First described in three siblings born to first cousin parents<sup>[15]</sup> </li> <li>Disrupted keratinocyte adhesion within the lower epidermis with prominent skin fragility at birth </li> <li>Generalized trauma-induced, occasionally spontaneous scale, partly hemorrhagic crusts and intermittent skin blistering/erosions; bruising </li> <li>Healing with slightly atrophic scars and mild pigmentary mottling </li> <li>No involvement of mucous membranes, nails, and hair </li> <li>Symptomatic improvement within the first years of life with occasional small blisters, erosions, linear crusts at sites of mechanical trauma as the main feature </li> </ul> </td> </tr> <tr> <td>EBS, autosomal recessive-BP230 deficiency</td> <td> <ul> <li>Autosomal recessive </li> <li><em>DST</em>/<em>BPAG1-e</em> </li> <li>Dystonin/coiled coil domain of epithelial isoform of bullous pemphigoid antigen-1 (BPAG1-e) </li> </ul> </td> <td> <ul> <li>Only one reported case<sup>[14]</sup> </li> <li>Generalized, lifelong but relatively mild trauma-induced and spontaneous blistering (ankles, feet) </li> <li>Skin peeling; erosions, hemorrhage </li> <li>Nail dystrophy; normal hair growth </li> <li>Healing with postinflammatory hypo- and hyperpigmentation </li> <li>No scarring, milia formation, or mucosal blistering </li> <li>Episodes of collapse; recurrent bilateral headaches, transient episodes of arm numbness and weakness reported in index patient may represent manifestation of concomitant neurologic diagnosis of CADASIL syndrome </li> </ul> </td> </tr> <tr> <td>Recessive EBS due to stabilizing mutations in the ubiquitin ligase enzyme that processes <em>KRT14</em><sup>[16-18]</sup></td> <td> <ul> <li>Autosomal recessive </li> <li><em>KLHL-24</em> </li> <li>Kelch-like family member 24 </li> </ul> </td> <td> <ul> <li>Twenty-six cases in three reports from China, Israel, and the United Kingdom </li> <li>Quite marked birth traumas, especially the lower limbs </li> <li>Early involvement of trunk and arms </li> <li>Heal with subtle atrophic scarring </li> <li>Nail defects </li> <li>Oral ulceration </li> <li>Not much dyspigmentation </li> <li>Transient milia </li> <li>Alopecia &#177; </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBS: epidermolysis bullosa simplex; CADASIL: cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Jonkman MF, Pasmooij AM, Pasmans SG, et al. Loss of desmoplakin tail causes lethal acantholytic Epidermolysis bullosa. Am J HumGenet 2005; 77:653.</LI>&#xD;&#xA;<LI>Hobbs RP, Han SY, van der Zwaag PA, et al. Insights from a desmoplakin mutation identified in lethal acantholytic epidermolysis bullosa. J Invest Dermatol 2010; 130:2680.</LI>&#xD;&#xA;<LI>Kim SJ, Ko JM, Shin SH, et al. Korean Monozygotic Twins with Lethal Acantholytic Epidermolysis Bullosa Caused by Two Novel DSP Mutations. Ann Clin Lab Sci 2017; 47:213.</LI>&#xD;&#xA;<LI>Bolling MC, Veenstra MJ, Jonkman MF, et al. Lethal acantholytic epidermolysis bullosa due to a novel homozygous deletion in DSP: Expanding the phenotype and implications for desmoplakin function in skin and heart. Br J Dermatol 2010; 162:1388. </LI>&#xD;&#xA;<LI>Pigors M, Kiritsi D, Krümpelmann S, et al. Lack of plakoglobin leads to lethal congenital epidermolysis bullosa: a novel clinico-genetic entity. Hum Mol Genet 2011; 20:1811.</LI>&#xD;&#xA;<LI>Fine JD, Johnson L, Wright T. Epidermolysis bullosa simplex superficialis. A new variant of epidermolysis bullosa characterized by subcorneal skin cleavage mimicking peeling skin syndrome. Arch Dermatol 1989; 125:633. </LI>&#xD;&#xA;<LI>Kiritsi D, Cosgarea I, Franzke CW, et al. Acral peeling skin syndrome with TGM5 gene mutations may resemble epidermolysis bullosa simplex in young individuals. J Invest Dermatol 2010; 130:1741.</LI>&#xD;&#xA;<LI>Lanschuetzer CM, Fine JD. Classification and molecular basis of hereditary epidermolysis. In: Life with Epidermolysis Bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy, Fine JD, Hintner H (Eds), Springer, Vienna, New York 2008. p.6.</LI>&#xD;&#xA;<LI>Fine JD. General cutaneous manifestations. In: Life with Epidermolysis Bullosa (EB): Etiology, diagnosis, multidisciplinary care and therapy, Fine JD, Hintner H (Eds), Springer, Vienna, New York 2008. p.99.</LI>&#xD;&#xA;<LI>Mellerio JE, Pulkkinen L, McMillan JR, et al. Pyloric atresia-junctional epidermolysis bullosa syndrome: Mutations in the integrin beta4 gene (ITGB4) in two unrelated patients with mild disease. Br J Dermatol 1998; 139:862.</LI>&#xD;&#xA;<LI>Nakano A, Pulkkinen L, Murrell D, et al. Epidermolysis bullosa with congenital pyloric atresia: novel mutations in the beta 4 integrin gene (ITGB4) and genotype/phenotype correlations. Pediatr Res 2001; 49:618.</LI>&#xD;&#xA;<LI>Pulkkinen L, Kim DU, Uitto J. Epidermolysis bullosa with pyloric atresia: Novel mutations in the beta4 integrin gene (ITGB4). Am J Pathol 1998; 152:157.</LI>&#xD;&#xA;<LI>Maman E, Maor E, Kachko L, Carmi R. Epidermolysis bullosa, pyloric atresia, aplasia cutis congenita: Histopathological delineation of an autosomal recessive disease. Am J Med Genet 1998; 78:127.</LI>&#xD;&#xA;<LI>Groves RW, Liu L, Dopping-Hepenstal PJ, et al. A homozygous nonsense mutation within the dystonin gene coding for the coiled-coil domain of the epithelial isoform of BPAG1 underlies a new subtype of autosomal recessive epidermolysis bullosa simplex. J Invest Dermatol 2010; 130:1551.</LI>&#xD;&#xA;<LI>McGrath JA, Stone KL, Begum R, et al. Germline Mutation in EXPH5 Implicates the Rab27B Effector Protein Slac2-b in Inherited Skin Fragility. Am J Hum Genet 2012; 91:1115.</LI>&#xD;&#xA;<LI>He Y, Maier K, Leppert J, et al. Monoallelic mutations in the translation initiation codon of KLHL24 cause skin fragility. Am J Hum Genet 2016; 99:1395.</LI>&#xD;&#xA;<LI>Lin Z, Li S, Feng C, et al. Stabilizing mutations of KLHL24 ubiquitin ligase cause loss of keratin 14 and human skin fragility. Nat Genet 2016; 48:1508.</LI>&#xD;&#xA;<LI>Lee JYW, Liu L, Hsu CK, et al. Mutations in KLHL24 Add to the Molecular Heterogeneity of Epidermolysis Bullosa Simplex. J Invest Dermatol 2017; 137:1378.</LI></OL></div><div id=\"graphicVersion\">Graphic 77709 Version 10.0</div></div></div>"},"77710":{"type":"graphic_table","displayName":"Disease sites in BL","title":"Disease sites at presentation in endemic and sporadic Burkitt lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disease sites at presentation in endemic and sporadic Burkitt lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n    <tbody>\r\n        <tr>\r\n            <td class=\"subtitle1\" rowspan=\"2\">Site</td>\r\n            <td class=\"subtitle1\" colspan=\"2\">Patients with involvement<br />\r\n            (percent)</td>\r\n        </tr>\r\n        <tr>\r\n            <td class=\"subtitle2\">Endemic</td>\r\n            <td class=\"subtitle2\">Sporadic</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Abdomen</td>\r\n            <td class=\"centered\">58</td>\r\n            <td class=\"centered\">91</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Pleural effusion</td>\r\n            <td class=\"centered\">3</td>\r\n            <td class=\"centered\">19</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Bone marrow</td>\r\n            <td class=\"centered\">7</td>\r\n            <td class=\"centered\">20</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Peripheral nodes</td>\r\n            <td class=\"centered\">9</td>\r\n            <td class=\"centered\">13</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Bone</td>\r\n            <td class=\"centered\">8</td>\r\n            <td class=\"centered\">9</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Central nervous system</td>\r\n            <td class=\"centered\">19</td>\r\n            <td class=\"centered\">14</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Paraspinal</td>\r\n            <td class=\"centered\">17</td>\r\n            <td class=\"centered\">2</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Testis</td>\r\n            <td class=\"centered\">2</td>\r\n            <td class=\"centered\">6</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Pharynx</td>\r\n            <td class=\"centered\">0</td>\r\n            <td class=\"centered\">10</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Jaw</td>\r\n            <td class=\"centered\">58</td>\r\n            <td class=\"centered\">7</td>\r\n        </tr>\r\n        <tr>\r\n            <td>Orbit</td>\r\n            <td class=\"centered\">11</td>\r\n            <td class=\"centered\">1</td>\r\n        </tr>\r\n    </tbody>\r\n</table></div><div class=\"graphic_reference\">Reproduced with permission from: Gascoyne RD, Magrath IT, Sehn L. Burkitt lymphoma. In: Non-Hodgkin Lymphomas, 2nd ed, Armitage JO, Mauch PM, Harris NL, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77710 Version 6.0</div></div></div>"},"77712":{"type":"graphic_picture","displayName":"Leukemic infiltrate","title":"Leukemic cells in the vitreous of a boy with relapse of acute lymphoblastic leukemia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Leukemic cells in the vitreous of a boy with relapse of acute lymphoblastic leukemia</div><div class=\"cntnt\"><img style=\"width:288px; height:247px;\" src=\"images/PEDS/77712_Leukemic_infiltrate.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tasman, W, Jaeger, E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2e. Lippincott Williams &amp; Wilkins, 2001. Copyright &#169;2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77712 Version 1.0</div></div></div>"},"77716":{"type":"graphic_diagnosticimage","displayName":"Oblique view tibial plateau fracture","title":"Oblique view tibial plateau fracture","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Oblique view tibial plateau fracture</div><div class=\"cntnt\"><img style=\"width:540px; height:338px;\" src=\"images/EM/77716_Oblique_view_tibial_plateau.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two oblique radiographs of the same knee demonstrate the usefulness of these views in cases of suspected fracture. The fracture of the lateral tibial plateau appears as a curvilinear area of radiolucency in one obllique view (left panel), while the same fracture is less easily appreciated on the other view (right panel, arrows).</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 77716 Version 2.0</div></div></div>"},"77717":{"type":"graphic_table","displayName":"Kings College criteria","title":"King's College Hospital criteria for liver transplantation in acute liver failure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">King's College Hospital criteria for liver transplantation in acute liver failure</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1_single\">\n   Acetaminophen-induced disease\n   </td>\n   </tr>\n   <tr>\n   <td>Arterial pH &#60;7.3 (irrespective of the grade of encephalopathy)</td>\n   </tr>\n   <tr>\n   <td><strong>OR</strong></td>\n   </tr>\n   <tr>\n   <td>Grade III or IV encephalopathy AND</td>\n   </tr>\n   <tr>\n   <td>Prothrombin time &#62;100 seconds AND</td>\n   </tr>\n   <tr>\n   <td>Serum creatinine &#62;3.4mg/dL (301 &#181;mol/L)</td>\n   </tr>\n   <tr>\n   <td  class=\"subtitle1_single\">\n   All other causes of acute liver failure\n   </td>\n   </tr>\n   <tr>\n   <td>Prothrombin time &#62;100 seconds (irrespective of the grade of encephalopathy)</td>\n   </tr>\n   <tr>\n   <td><strong>OR</strong></td>\n   </tr>\n   <tr>\n   <td>Any <strong>three</strong> of the following variables (irrespective of the grade of encephalopathy)</td>\n   </tr>\n   <tr>\n   <td>1. Age &#60;10 years or &#62;40 years</td>\n   </tr>\n   <tr>\n   <td>2. Etiology: non-A, non-B hepatitis, halothane hepatitis, idiosyncratic drug reactions</td>\n   </tr>\n   <tr>\n   <td>3. Duration of jaundice before onset of encephalopathy &#62;7 days</td>\n   </tr>\n   <tr>\n   <td>4. Prothrombin time &#62;50 seconds</td>\n   </tr>\n   <tr>\n   <td>5. Serum bilirubin &#62;18 mg/dL (308 &#181;mol/L)</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: O'Grady JG, Alexander GJM, Hayllar KM, et al. Gastroenterology 1989; 97:439.</div><div id=\"graphicVersion\">Graphic 77717 Version 2.0</div></div></div>"},"77718":{"type":"graphic_table","displayName":"Caries periodontitis treatment","title":"Antimicrobial regimens for the prevention of dental caries and the treatment of periodontal disease in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial regimens for the prevention of dental caries and the treatment of periodontal disease in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Clinical entity </td> <td class=\"subtitle1\">Common causative organisms </td> <td class=\"subtitle1\">Antimicrobial regimens </td> </tr> <tr> <td class=\"subtitle2_left\" rowspan=\"3\">Supragingival dental plaque and dental caries prevention </td> <td rowspan=\"3\"><em>Streptococcus mutans</em>, other streptococci, <em>Actinomyces</em> spp </td> <td>Fluoride-containing toothpaste (sodium fluoride, 1.1 percent or stannous fluoride, 0.4 percent)&nbsp;two or&nbsp;three times daily <strong>AND/OR</strong></td> </tr> <tr> <td>Fluoride-containing varnishes (sodium fluoride, 5 percent) applied&nbsp;three or&nbsp;four times yearly <strong>AND/OR</strong></td> </tr> <tr> <td>Chlorhexidine, 0.12 percent oral rinse</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gingivitis </td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Acute simple gingivitis </td> <td rowspan=\"4\">Streptococci, <em>Actinomyces</em> spp, spirochetes </td> <td>Penicillin G 2 to 4 MU IV every&nbsp;four to&nbsp;six hours (OR penicillin V 500 mg every&nbsp;six to&nbsp;eight hours), <strong>PLUS</strong> metronidazole 500 mg PO every&nbsp;eight hours <strong>OR</strong></td> </tr> <tr> <td>Amoxicillin-clavulanate 875 mg PO every 12 hours or 500 mg PO every&nbsp;eight hours <strong>OR</strong></td> </tr> <tr> <td>Ampicillin-sulbactam 1.5 to&nbsp;3 g IV every six&nbsp;hours <strong>OR</strong></td> </tr> <tr> <td>Clindamycin 450 mg PO or 600 mg IV every&nbsp;six to&nbsp;eight hours</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Ulcerative or acute necrotizing ulcerative gingivitis </td> <td rowspan=\"4\"><em>Prevotella intermedia</em>, <em>Fusobacterium</em> spp, <em>Tannerella forsythia</em>, <em>Treponema denticoli</em>, other oral spirochetes </td> <td>Metronidazole 500 mg PO or IV every&nbsp;eight hours <strong>OR</strong></td> </tr> <tr> <td>Amoxicillin-clavulanate 875 mg PO every 12 hours or 500 mg PO every&nbsp;eight hours <strong>OR</strong></td> </tr> <tr> <td>Ampicillin-sulbactam 1.5 to 3 g IV every&nbsp;six hours <strong>OR</strong></td> </tr> <tr> <td>Clindamycin 450 mg PO or 600 mg IV every&nbsp;six to&nbsp;eight hours</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Periodontitis </td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Early onset, \"aggressive\" or \"localized juvenile\" periodontitis </td> <td rowspan=\"2\"><em>Actinobacillus actinomycetemcomitans</em>, <em>Porphyromonas gingivalis</em>, <em>Treponema denticola</em>, <em>Prevotella intermedia</em> </td> <td>Doxycycline 200 mg PO or IV every 12 hours (only in patients&nbsp;eight years of age or older) <strong>OR</strong></td> </tr> <tr> <td>Metronidazole 500 mg PO or IV every&nbsp;eight hours</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Adult periodontitis </td> <td rowspan=\"2\"><em>Treponema denticoli</em>, other oral spirochetes, <em>Porphyromonas gingivalis</em>, <em>Prevotella intermedia</em>, <em>Tannerella forsythia</em> </td> <td>Topical minocycline microspheres (Aristin&#174;) <strong>OR</strong></td> </tr> <tr> <td>Topical doxycycline hyclate periodontal extended-release liquid (Atridox&#174;)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">IV: intravenous; MU: million units; PO: by mouth.</div><div id=\"graphicVersion\">Graphic 77718 Version 5.0</div></div></div>"},"77719":{"type":"graphic_table","displayName":"Clinical series of miliary TB","title":"Major clinical series of miliary tuberculosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major clinical series of miliary tuberculosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">First author, year</td> <td class=\"subtitle1\">Years included</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Inclusion criteria</td> <td class=\"subtitle1\"># of patients</td> <td class=\"subtitle1\">Percent male</td> <td class=\"subtitle1\">Race, percent</td> </tr> <tr> <td>Maartens, 1990 </td> <td>1978 to 1987</td> <td>Groote Schuur Hospital (community-based teaching hospital in South Africa)</td> <td>Miliary pattern on CXR plus MTB on culture from any site; or biopsy or autopsy evidence of miliary organ involvement with TB</td> <td>109</td> <td>51</td> <td>African, 45, mixed, 49, white, 6</td> </tr> <tr> <td>Kim, 1990 </td> <td>1975 to 1988</td> <td>Duke University Medical Center and Durham VA Hospital Durham, North Carolina</td> <td>Discharge diagnosis of disseminated or miliary TB</td> <td>38</td> <td>50</td> <td>African-American, 50*</td> </tr> <tr> <td rowspan=\"4\">Gelb, 1973 </td> <td rowspan=\"4\">1960 to 1970</td> <td rowspan=\"4\">UCLA Hospital Los Angeles, California</td> <td>Miliary pattern on CXR and one or more:</td> <td rowspan=\"4\">109</td> <td rowspan=\"4\">59</td> <td rowspan=\"4\">African-American, 81</td> </tr> <tr> <td>1. MTB on culture</td> </tr> <tr> <td>2. Biopsy or autopsy showing caseating granulomas with AFB</td> </tr> <tr> <td>3. Clinical presentation and response consistent with TB</td> </tr> <tr> <td>Munt, 1971 </td> <td>1954 to 1970</td> <td>Sanitorium drawing from eastern part of North Carolina</td> <td>\"Acute, diffuse pulmonary and extra-pulmonary dissemination of TB, usually associated with a miliary pattern on CXR, with either MTB by culture or response to TB therapy\"</td> <td>69</td> <td>65</td> <td>African-American, 87</td> </tr> <tr> <td>Proudfoot, 1969</td> <td>1954 to 1967</td> <td>Edinburgh, Scotland</td> <td>\"Adults diagnosed in Edinburgh as having disseminated TB\"</td> <td>40</td> <td>40</td> <td>Non-British, &#60;1</td> </tr> <tr> <td>Biehl, 1957 </td> <td>1951 to 1956</td> <td>Cincinatti General (city teaching hospital Cincinatti, Ohio)</td> <td>Bacteriologic or pathologic diagnosis of miliary tuberculosis or probable diagnosis with response to therapy</td> <td>68</td> <td>69</td> <td>African-American, 23</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CXR: chest radiograph; MTB: <EM>Mycobacterium tuberculosis</EM>; TB: tuberculosis; AFB: acid-fast bacilli.</div><div class=\"graphic_footnotes\">* Excluding VA population.</div><div class=\"graphic_reference\">Courtesy of Nesli Basgoz, MD.</div><div id=\"graphicVersion\">Graphic 77719 Version 3.0</div></div></div>"},"77720":{"type":"graphic_movie","displayName":"Laryngomalacia video","title":"Laryngomalacia video","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Laryngomalacia video</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77720_laryngomconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:360px; height:316px;\" src=\"images/CARD/77720_laryngom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexible laryngoscopy of laryngomalacia. Note the omega-shaped epiglottis and the collapse of the supraglottic structures during inspiration.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP, FACS.</div><div id=\"graphicVersion\">Graphic 77720 Version 3.0</div></div></div>"},"77721":{"type":"graphic_diagnosticimage","displayName":"Cystic renal cell carcinoma CT","title":"CT scan demonstrating cystic renal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT scan demonstrating cystic renal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:304px; height:288px;\" src=\"images/NEPH/77721_Cystic_renal_cell_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single axial contrast-enhanced CT scan through the right kidney demonstrates a large, multiloculated cystic mass containing irregular septations.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 77721 Version 4.0</div></div></div>"},"77723":{"type":"graphic_picture","displayName":"Leukocytoclastic vasculitis with ulcer","title":"Cutaneous small vessel vasculitis with ulcer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Cutaneous small vessel vasculitis with ulcer</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/77723_Leukocytoclastic_vasc_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small ulcer and areas of hyperpigmentation are present in this patient with cutaneous small vessel vasculitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77723 Version 3.0</div></div></div>"},"77724":{"type":"graphic_table","displayName":"Gene defects causing SCID","title":"Gene defects causing severe combined immunodeficiency","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gene defects causing severe combined immunodeficiency</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">T-B+ SCID</td> </tr> <tr> <td><em>IL-2R common gamma chain</em></td> <td><em>IL2RG</em></td> </tr> <tr> <td><em>Janus kinase 3</em></td> <td><em>JAK3</em></td> </tr> <tr> <td><em>IL-7Ra chain</em></td> <td><em>IL7RA</em></td> </tr> <tr> <td>IL-2Ra chain (CD25) deficiency</td> <td><em>IL2R</em></td> </tr> <tr> <td>CD45 (protein tyrosine phosphatase, receptor type, C)</td> <td><em>PTPRC</em></td> </tr> <tr> <td>CD3 delta</td> <td><em>CD3D</em></td> </tr> <tr> <td>CD3 epsilon</td> <td><em>CD3E</em></td> </tr> <tr> <td>CD3 zeta</td> <td><em>CD3Z</em></td> </tr> <tr> <td>Coronin 1A</td> <td><em>CORO1A</em></td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">T-B- SCID</td> </tr> <tr> <td><em>Recombinase activating genes 1 and 2</em></td> <td><em>RAG1/RAG2</em></td> </tr> <tr> <td><em>DNA cross-link repair enzyme 1C (Artemis)</em></td> <td><em>DCLRE1C</em></td> </tr> <tr> <td>DNA-dependent protein kinase</td> <td><em>PRKDC</em></td> </tr> <tr> <td>Adenylate kinase 2 (reticular dysgenesis)</td> <td><em>AK2</em></td> </tr> <tr> <td><em>Adenosine deaminase</em></td> <td><em>ADA</em></td> </tr> <tr> <td>DNA ligase IV</td> <td><em>LIG4</em></td> </tr> <tr> <td>Nonhomologous end-joining protein 1 (Cernunnos)</td> <td><em>NHEJ1</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The defects listed in <em>italics</em> are the most common forms of SCID.</div><div class=\"graphic_footnotes\">SCID: severe combined immunodeficiency; IL-2R: interleukin-2 receptor; IL-7Ra: interleukin-7 receptor alpha; IL-2Ra: interleukin-2 receptor alpha; CD: cluster of differentiation.</div><div id=\"graphicVersion\">Graphic 77724 Version 11.0</div></div></div>"},"77725":{"type":"graphic_picture","displayName":"Types of tenaculum","title":"Tenaculums","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tenaculums</div><div class=\"cntnt\"><img style=\"width:404px; height:288px;\" src=\"images/OBGYN/77725_Types_of_tenaculum.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Beirer tenaculum. (B) Single tooth tenaculum.</div><div class=\"graphic_reference\">Courtesy of William J Mann, Jr, MD.</div><div id=\"graphicVersion\">Graphic 77725 Version 2.0</div></div></div>"},"77726":{"type":"graphic_figure","displayName":"Cross-reactivity among related food allergens","title":"Approximate rates of clinical cross-reactivity among related food allergens","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Approximate rates of clinical cross-reactivity among related food allergens</div><div class=\"cntnt\"><img style=\"width:470px; height:374px;\" src=\"images/ALLRG/77726_Cross_X_similar_foods_aller.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Legumes (family Fabaceae or Leguminosae) include peanut, soy, and various beans, peas, lentils, and lupins. Tree nuts include almond, Brazil nut, cashew, hazelnut, macadamia, pecan, pine nut, pistachio, and walnut. Crustaceae include crab, lobster, and shrimp. Foods in the Rosaceae family include apple, pear, quince, apricot, plum, cherry, raspberry, loquat, strawberry, and almond. Gourds (family Cucurbitaceae) include squash, pumpkin, zucchini, and cucumber. Foods that cross-react with latex include avocado, banana, chestnut, kiwi, peach, tomato, white potato, and bell pepper.</div><div class=\"graphic_footnotes\">CMA: cow's milk allergy; OAS: oral allergy syndrome (food-pollen syndrome).</div><div id=\"graphicVersion\">Graphic 77726 Version 5.0</div></div></div>"},"77728":{"type":"graphic_waveform","displayName":"Multifocal atrial tach tutorial","title":"Multifocal atrial tachycardia","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multifocal atrial tachycardia</div><div class=\"cntnt\"><img style=\"width:279px; height:119px;\" src=\"images/CARD/77728_Multifocal_atrial_tach_tuto.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multifocal atrial tachycardia is similar to a wandering atrial pacemaker, except that the heart rate is rapid (greater than 100 beats per minute). There is great variability of the P wave morphology and axis, the PR intervals, and the cycle lengths of the QRS complexes. The QRS complexes are unchanged and are similar to sinus rhythm since ventricular activation is normal.</div><div id=\"graphicVersion\">Graphic 77728 Version 2.0</div></div><div style=\"width: 456px\" class=\"figure\"><div class=\"ttl\">Sinus rhythm</div><div class=\"cntnt\"><img style=\"width:456px; height:103px;\" src=\"images/CARD/69872_Sinus_rhythm_tutorial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.</div><div id=\"graphicVersion\">Graphic 69872 Version 2.0</div></div></div>"},"77731":{"type":"graphic_diagnosticimage","displayName":"2D TTE Subcostal abdominal aorta","title":"Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing the abdominal aorta","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Two-dimensional transthoracic echocardiogram (2D TTE) from the subcostal view showing the abdominal aorta</div><div class=\"cntnt\"><img style=\"width:380px; height:246px;\" src=\"images/CARD/77731_Subcostal_abdominal_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The abdominal aorta (Ab Ao) can be seen in subcostal long (panel A) and short axis (panel B) views. The neural canal (NC) is seen through the intervertegral disc in this thin patient.</div><div id=\"graphicVersion\">Graphic 77731 Version 3.0</div></div></div>"},"77732":{"type":"graphic_figure","displayName":"MELD three month survival","title":"Estimated 3-month survival as a function of the MELD score in patients with cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 499px\" class=\"figure\"><div class=\"ttl\">Estimated 3-month survival as a function of the MELD score in patients with cirrhosis</div><div class=\"cntnt\"><img style=\"width:479px; height:315px;\" src=\"images/GAST/77732_MELD_three_month_survival.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MELD: model for end-stage liver disease.</div><div class=\"graphic_reference\">Adapted from: Wiesner, R, Edwards, E, Freeman, R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91.</div><div id=\"graphicVersion\">Graphic 77732 Version 3.0</div></div></div>"},"77733":{"type":"graphic_picture","displayName":"Buruli ulcer thigh","title":"Buruli ulcer located on the thigh","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Buruli ulcer located on the thigh</div><div class=\"cntnt\"><img style=\"width:425px; height:371px;\" src=\"images/ID/77733_Buruli_ulcer_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Undermined lesion with necrotic debris in the right thigh of a seven-year-old girl.</div><div class=\"graphic_reference\">Courtesy of Tjip S van der Werf, MD.</div><div id=\"graphicVersion\">Graphic 77733 Version 2.0</div></div></div>"},"77734":{"type":"graphic_picture","displayName":"Coagulase test","title":"Tube test for free coagulase activity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tube test for free coagulase activity</div><div class=\"cntnt\"><img style=\"width:357px; height:240px;\" src=\"images/ID/77734_Coagulase_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When <EM>Staphylococcus aureus</EM>, which produces coagulase, is incubated in plasma, a visible fibrin clot is formed (lower tube). Coagulase-negative organisms (top tube) do not form this complex.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 77734 Version 3.0</div></div></div>"},"77735":{"type":"graphic_diagnosticimage","displayName":"HHV-6 encephalitis MRI 3","title":"MRI findings of HHV-6 encephalitis in hematopoietic cell transplant recipients","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">MRI findings of HHV-6 encephalitis in hematopoietic cell transplant recipients</div><div class=\"cntnt\"><img style=\"width:520px; height:400px;\" src=\"images/ID/77735_HHV-6_encephalitis_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging of the brain for the&nbsp;four patients who developed limbic encephalitis, showing axial images at the level of the basal ganglia. Arrows indicate signal hyperintensities in the region of the hippocampus. Shown are T2-weighted imaging (A) and diffusion imaging (B) for patient 1 on day +21 after stem cell transplantation (SCT), 6 days after onset of neurological symptoms. (C) T2-weighted fluid attenuated inversion recovery imaging for patient 2 on day +24 after SCT, on the day of onset of neurological symptoms. (D) T2-weighted imaging for patient 3 on day +40 after SCT, 20 days after onset of neurological symptoms. (E) T2-weighted imaging for patient 4 on day +43 after SCT, 10 days after onset of neurological symptoms.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; HHV-6: human herpesvirus 6.</div><div class=\"graphic_reference\">Reproduced with permission from: Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: Incidence and clinical significance. J Infect Dis 2006; 193:68. Copyright ©2006 University of Chicago Press.</div><div class=\"contractual\"><br/><a href=\"http://www.journals.uchicago.edu/\">http://www.journals.uchicago.edu/</a></div><div id=\"graphicVersion\">Graphic 77735 Version 6.0</div></div></div>"},"77736":{"type":"graphic_picture","displayName":"Mixed flora peritoneal fluid","title":"Mixed flora in peritoneal fluid from a ruptured viscus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed flora in peritoneal fluid from a ruptured viscus</div><div class=\"cntnt\"><img style=\"width:360px; height:240px;\" src=\"images/ID/77736_Mixedfloraperitonealflui.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of peritoneal fluid (x1000) shows several different organisms, including gram-positive cocci in chains, gram-positive rods, plump enteric gram-negative bacilli, and thinner gram-negative rods. Mixed fecal flora grew from this specimen.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 77736 Version 3.0</div></div></div>"},"77738":{"type":"graphic_figure","displayName":"Tracheomalacia FV loop","title":"Flow-volume loop classic for tracheomalacia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Flow-volume loop classic for tracheomalacia</div><div class=\"cntnt\"><img style=\"width:302px; height:352px;\" src=\"images/PULM/77738_Tracheomalacia_FV_loop.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Maximal expiratory flow declines rapidly after a sharp peak associated with the collapse of central airways as a result of negative transmural pressure.</div><div class=\"graphic_reference\">Courtesy of Carl O'Donnell.</div><div id=\"graphicVersion\">Graphic 77738 Version 1.0</div></div></div>"},"77739":{"type":"graphic_algorithm","displayName":"Stress and coronary thrombosis","title":"Relationship between stress and coronary thrombosis","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Relationship between stress and coronary thrombosis</div><div class=\"cntnt\"><img style=\"width:549px; height:352px;\" src=\"images/CARD/77739_Stress_and_coronary_thrombo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hypothetical model by which daily activities such as mental stress may trigger coronary thrombosis and precipitate an acute coronary syndrome such as unstable angina or a myocardial infarction.</div><div class=\"graphic_reference\">Redrawn from Muller, JE, Abela, GS, Nesto, RW, et al. J Am Coll Cardiol 1994; 23:809.</div><div id=\"graphicVersion\">Graphic 77739 Version 2.0</div></div></div>"},"77740":{"type":"graphic_picture","displayName":"Stand on one foot","title":"Balance exercise: Stand on one foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Balance exercise: Stand on one foot</div><div class=\"cntnt\"><img style=\"width:369px; height:297px;\" src=\"images/PC/77740_Stand_on_one_foot_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">You can do this exercise while waiting for the bus or standing in line at the grocery. For an added challenge, you can modify the exercise to improve your balance.   <OL>  <LI>Stand on one foot behind a sturdy chair, holding on for balance. </LI>  <LI>Hold position for up to 10 seconds. </LI>  <LI>Repeat 10 to 15 times. </LI>  <LI>Repeat 10 to 15 times with other leg. </LI>  <LI>Repeat 10 to 15 more times with each leg. </LI></OL></div><div class=\"graphic_reference\">Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: http://go4life.niapublications.org (Accessed December 2, 2011).</div><div id=\"graphicVersion\">Graphic 77740 Version 3.0</div></div></div>"},"77742":{"type":"graphic_figure","displayName":"Development human B cells","title":"Development of human B cells","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Development of human B cells</div><div class=\"cntnt\"><img style=\"width:497px; height:262px;\" src=\"images/ALLRG/77742_Development_human_B_cells.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stem cells develop into immature and mature B cells. Following appropriate activation, B lymphocytes rearrange their immunoglobulin genes to switch from IgM to IgG, IgA, or IgE. B cells eventually differentiate into plasma cells, which will produce various isotypes of antibodies. When developmental defects occur, immunodeficiency, such as common variable immunodeficiency (CVID), selective IgM deficiency (sIgMD), and selective IgA deficiency (sIgAD) appear.</div><div class=\"graphic_footnotes\">µ: mu; IgM: immunoglobulin M; IgD: immunoglobulin D; IgG: immunoglobulin G; IgA: immunoglobulin A; IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 77742 Version 4.0</div></div></div>"},"77745":{"type":"graphic_picture","displayName":"Diffuse panbronchiolitis Light","title":"Diffuse panbronchiolitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diffuse panbronchiolitis</div><div class=\"cntnt\"><img style=\"width:360px; height:245px;\" src=\"images/PULM/77745_Diffuse_panbronchiolitis_Li.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse panbronchiolitis involving a respiratory bronchiole which appears filled with necrotic debris and neutrophils. This small airway is surrounded by an intense lymphoplasmacytic inflammatory infiltrate (hematoxylin and eosin stain).</div><div class=\"graphic_reference\">Courtesy of Talmadge E King, Jr, MD.</div><div id=\"graphicVersion\">Graphic 77745 Version 1.0</div></div></div>"},"77746":{"type":"graphic_table","displayName":"Normal heart rates","title":"Normal heart rates in adults based on age and sex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal heart rates in adults based on age and sex</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Age (years)</td> <td class=\"subtitle1\" colspan=\"9\">HR (beats per minute)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\">All</td> <td class=\"subtitle2\" colspan=\"3\">Male</td> <td class=\"subtitle2\" colspan=\"3\">Female</td> </tr> <tr> <td class=\"subtitle3\">N</td> <td class=\"subtitle3\">Mean</td> <td class=\"subtitle3\">1%-99%</td> <td class=\"subtitle3\">N</td> <td class=\"subtitle3\">Mean</td> <td class=\"subtitle3\">1%-99%</td> <td class=\"subtitle3\">N</td> <td class=\"subtitle3\">Mean</td> <td class=\"subtitle3\">1%-99%</td> </tr> <tr> <td class=\"centered\">20-29</td> <td class=\"centered\">6086</td> <td class=\"centered\">67</td> <td class=\"centered\">43-98</td> <td class=\"centered\">3127</td> <td class=\"centered\">64</td> <td class=\"centered\">42-99</td> <td class=\"centered\">2959</td> <td class=\"centered\">69</td> <td class=\"centered\">46-99</td> </tr> <tr> <td class=\"centered\">30-39</td> <td class=\"centered\">9569</td> <td class=\"centered\">69</td> <td class=\"centered\">46-100</td> <td class=\"centered\">4605</td> <td class=\"centered\">67</td> <td class=\"centered\">44-99</td> <td class=\"centered\">4964</td> <td class=\"centered\">70</td> <td class=\"centered\">48-100</td> </tr> <tr> <td class=\"centered\">40-49</td> <td class=\"centered\">15,392</td> <td class=\"centered\">69</td> <td class=\"centered\">46-101</td> <td class=\"centered\">7104</td> <td class=\"centered\">68</td> <td class=\"centered\">45-101</td> <td class=\"centered\">8288</td> <td class=\"centered\">70</td> <td class=\"centered\">48-102</td> </tr> <tr> <td class=\"centered\">50-59</td> <td class=\"centered\">18,578</td> <td class=\"centered\">68</td> <td class=\"centered\">46-102</td> <td class=\"centered\">9936</td> <td class=\"centered\">68</td> <td class=\"centered\">45-102</td> <td class=\"centered\">8642</td> <td class=\"centered\">69</td> <td class=\"centered\">47-102</td> </tr> <tr> <td class=\"centered\">60-69</td> <td class=\"centered\">16,585</td> <td class=\"centered\">67</td> <td class=\"centered\">44-102</td> <td class=\"centered\">9457</td> <td class=\"centered\">65</td> <td class=\"centered\">42-102</td> <td class=\"centered\">7128</td> <td class=\"centered\">68</td> <td class=\"centered\">46-101</td> </tr> <tr> <td class=\"centered\">70-79</td> <td class=\"centered\">8432</td> <td class=\"centered\">65</td> <td class=\"centered\">43-101</td> <td class=\"centered\">4509</td> <td class=\"centered\">64</td> <td class=\"centered\">42-102</td> <td class=\"centered\">3923</td> <td class=\"centered\">67</td> <td class=\"centered\">44-101</td> </tr> <tr> <td class=\"centered\">80-89</td> <td class=\"centered\">2259</td> <td class=\"centered\">65</td> <td class=\"centered\">44-101</td> <td class=\"centered\">1001</td> <td class=\"centered\">63</td> <td class=\"centered\">41-98</td> <td class=\"centered\">1258</td> <td class=\"centered\">67</td> <td class=\"centered\">46-102</td> </tr> <tr> <td class=\"centered\">90-99</td> <td class=\"centered\">119</td> <td class=\"centered\">70</td> <td class=\"centered\">43-146</td> <td class=\"centered\">58</td> <td class=\"centered\">64</td> <td class=\"centered\">43-95</td> <td class=\"centered\">81</td> <td class=\"centered\">72</td> <td class=\"centered\">44-147</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Normal heart rate values (with range from 1st to 99th percentile) for heart rate (beats/minute) in&nbsp;77,276 healthy adults according to age and gender.</div><div class=\"graphic_footnotes\">%: percent; HR: heart rate.</div><div class=\"graphic_reference\">Data from: Mason JW, Ramseth DJ, Chanter DO, et al. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 2007; 40:228.</div><div id=\"graphicVersion\">Graphic 77746 Version 4.0</div></div></div>"},"77747":{"type":"graphic_picture","displayName":"Occluded TIPS with fistula","title":"Occluded TIPS","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Occluded TIPS</div><div class=\"cntnt\"><img style=\"width:250px; height:310px;\" src=\"images/GAST/77747_Occluded_TIPS_with_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Occlusion of a transjugular intrahepatic portosystemic shunt (TIPS) with a fistula between the stent and the biliary ducts.</div><div class=\"graphic_reference\">Courtesy of Arun Sanyal, MD.</div><div id=\"graphicVersion\">Graphic 77747 Version 2.0</div></div></div>"},"77749":{"type":"graphic_figure","displayName":"Atrial septal embryology","title":"Development of the atrial septum","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Development of the atrial septum</div><div class=\"cntnt\"><img style=\"width:543px; height:629px;\" src=\"images/CARD/77749_Atrialseptalembryology.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77749 Version 3.0</div></div></div>"},"77752":{"type":"graphic_movie","displayName":"Ruptured papillary muscle post myocardial infarction long axis","title":"Ruptured papillary muscle after a myocardial infarction","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ruptured papillary muscle after a myocardial infarction</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77752_papmuscrconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:287px; height:431px;\" src=\"images/CARD/77752_papmuscr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Long axis view from a two-dimensional echocardiogram shows a flail anterior mitral valve leaflet resulting in mitral regurgitation. Part of the papillary muscle is attached to the leaflet, seen as an echodense mobile mass.</div><div id=\"graphicVersion\">Graphic 77752 Version 3.0</div></div></div>"},"77753":{"type":"graphic_table","displayName":"Characteristics of major noncardiac causes of chest pain","title":"Characteristics of major noncardiac causes of chest pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of major noncardiac causes of chest pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Duration of pain</td> <td class=\"subtitle1\">Character of pain</td> </tr> <tr> <td>Gastroesophageal reflux</td> <td>5 to 60 minutes</td> <td>Visceral, substernal, worse with recumbency, no radiation, relief with food, antacids</td> </tr> <tr> <td>Esophageal spasm</td> <td>5 to 60 minutes</td> <td>Visceral, spontaneous, substernal, associated with cold liquids, relief with nitroglycerin</td> </tr> <tr> <td>Peptic ulcer</td> <td>Hours</td> <td>Visceral, burning, epigastric, relief with food, antacids, normal ECG</td> </tr> <tr> <td>Biliary disease</td> <td>Hours</td> <td>Visceral, epigastric, interscapular colic, occurs after meals</td> </tr> <tr> <td>Cervical disc</td> <td>Variable</td> <td>Superficial, positional, arm, neck</td> </tr> <tr> <td>Musculoskeletal</td> <td>Variable</td> <td>Superficial, positional, worse with movement, local tenderness</td> </tr> <tr> <td>Hyperventilation</td> <td>2 to 3 minutes</td> <td>Visceral, substernal, tachypneic, anxious</td> </tr> <tr> <td>Thyroiditis</td> <td>Persistent</td> <td>Aggravated by swallowing, neck, throat tenderness</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Excludes pain above the neck or below the umbilicus.</div><div class=\"graphic_footnotes\">ECG: electrocardiogram.<br /></div><div id=\"graphicVersion\">Graphic 77753 Version 3.0</div></div></div>"},"77755":{"type":"graphic_table","displayName":"GAD-7 anxiety scale","title":"GAD-7 anxiety scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">GAD-7 anxiety scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Not at all</td> <td class=\"subtitle1\">Several days</td> <td class=\"subtitle1\">More than half the days</td> <td class=\"subtitle1\">Nearly every day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Over the last&nbsp;two weeks, how often have you been bothered by the following problems?</td> </tr> <tr> <td class=\"indent1\">1. Feeling nervous, anxious, or on edge</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">2. Not being able to stop or control worrying</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">3. Worrying too much about different things</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">4. Trouble relaxing</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">5. Being so restless that it is hard to sit still</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">6. Becoming easily annoyed or irritable</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">7. Feeling afraid as if something awful might happen</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"><strong>Total score</strong>*<sup>&#182;</sup> _____ =</td> <td class=\"centered\">Add Columns</td> <td class=\"centered\">_____ +</td> <td class=\"centered\">_____ +</td> <td class=\"centered\">_____</td> </tr> <tr> <td colspan=\"5\">If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?</td> </tr> <tr> <td class=\"indent1\"><strong>Circle one</strong></td> <td class=\"centered\">Not difficult at all</td> <td class=\"centered\">Somewhat difficult</td> <td class=\"centered\">Very difficult</td> <td class=\"centered\">Extremely difficult</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Score: 5 to 9 = mild anxiety; 10 to 14 = moderate anxiety; 15 to 21 = severe anxiety.<br />¶ This is a form that can be printed out and filled out by hand rather than a calculator that can be filled in online.</div><div class=\"graphic_reference\">Adapted and reproduced with permission from: Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092. Copyright © 2006 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77755 Version 21.0</div></div></div>"},"77757":{"type":"graphic_table","displayName":"Specialized cath techniques","title":"Specialized cardiac catheterization techniques","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Specialized cardiac catheterization techniques</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td>Transseptal puncture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Direct left ventricular puncture</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Dual hi-fidelity micromanometer catheters</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Multiple arterial access</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Long sheaths/double lumen catheters</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Endomyocardial biopsy</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Pericardial pressure/drainage</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Transcoronary pressure/flow velocity</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Intraarterial/intracardiac ultrasound imaging</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Indication dilution curves</td>\n\n    </tr>\n\n  </tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77757 Version 1.0</div></div></div>"},"77758":{"type":"graphic_table","displayName":"Pneumococcal vaccines and antibody testing","title":"Pneumococcal vaccines and antibody testing for conjugate and pure pneumococcal polysaccharides","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pneumococcal vaccines and antibody testing for conjugate and pure pneumococcal polysaccharides</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Serotypes</td> <td class=\"subtitle1\" colspan=\"3\">Vaccines</td> </tr> <tr> <td class=\"subtitle2\">PPV-23</td> <td class=\"subtitle2\">PCV-13</td> <td class=\"subtitle2\">PCV-7</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">6A</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">6B</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">7F</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">9N</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">9V</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">10A</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">11A</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">12F</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">14</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">15B</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">17F</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">18C</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">19A</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">19F</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">20</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">22F</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">23F</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"centered\">33F</td> <td class=\"centered\"><strong>X</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The serotypes that are present only in the polysaccharide vaccine are shown in bold (ie, 2, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22, and 33F).&nbsp;The PCV-7 is being phased out in favor of the PCV-13 in many countries.</div><div class=\"graphic_footnotes\">PPV-23: 23-valent pneumococcal polysaccharide vaccine; PCV-13: 13-valent pneumococcal conjugate vaccine; PCV-7: 7-valent pneumococcal conjugate vaccine.</div><div class=\"graphic_reference\">Courtesy of Ricardo Sorensen, MD.</div><div id=\"graphicVersion\">Graphic 77758 Version 8.0</div></div></div>"},"77759":{"type":"graphic_table","displayName":"Antithrombotic Rx in MVP","title":"ACC/AHA guideline summary: Antithrombotic therapy in symptomatic patients with mitral valve prolapse (MVP)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ACC/AHA guideline summary: Antithrombotic therapy in symptomatic patients with mitral valve prolapse (MVP)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Class I - There is evidence and/or general agreement that antithrombotic therapy with aspirin or warfarin is indicated in patients with MVP in the following settings</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Aspirin (75 to 325 mg/day) for:</td> </tr> <tr> <td class=\"sublist2\">1. Cerebral transient ischemic attacks.</td> </tr> <tr> <td class=\"sublist2\">2. In patients under age 65 for atrial fibrillation in the absence of mitral regurgitation, hypertension, or heart failure, all of which are risk factors for thromboembolism.</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Warfarin for:</td> </tr> <tr> <td class=\"sublist2\">1. Atrial fibrillation in patients &#8805;65 years of age or those with a murmur of mitral regurgitation, hypertension, or a history of heart failure.</td> </tr> <tr> <td class=\"sublist2\">2. In patients with a history of stroke who have mitral regurgitation, atrial fibrillation, or left atrial thrombus.</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIa - The weight of evidence or opinion is in favor of the usefulness of aspirin or warfarin in patients with MVP in the following settings</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Aspirin (75 to 325 mg/day) for:</td> </tr> <tr> <td class=\"sublist2\">1. A history of stroke in the absence of mitral regurgitation, atrial fibrillation, left atrial thrombus, or, on echocardiography, thickening (&#8805;5 mm) or redundancy of the mitral valve leaflets.</td> </tr> <tr> <td class=\"sublist2\">2. A history of stroke if there are contraindications to warfarin therapy.</td> </tr> <tr> <td class=\"sublist1_start\">&#8226; Warfarin for:</td> </tr> <tr> <td class=\"sublist2\">1. A history of stroke in the absence of mitral regurgitation, atrial fibrillation, or left atrial thrombus if echocardiography shows thickening (&#8805;5 mm) and/or redundancy of the mitral valve leaflets.</td> </tr> <tr> <td class=\"sublist2\">2. Cerebral transient ischemic attacks despite aspirin therapy.</td> </tr> <tr> <td class=\"subtitle1_single\">Class IIb - The weight of evidence or opinion is less well established for the usefulness of aspirin in patients with MS in the following setting</td> </tr> <tr> <td>&#8226; Aspirin (75 to 325 mg/day) in patients in sinus rhythm who have high risk findings of mitral valve prolapse on echocardiography.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.</div><div id=\"graphicVersion\">Graphic 77759 Version 3.0</div></div></div>"},"77760":{"type":"graphic_diagnosticimage","displayName":"Melioidosis encephalitis","title":"Brain magnetic resonance imaging in melioidosis encephalitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Brain magnetic resonance imaging in melioidosis encephalitis</div><div class=\"cntnt\"><img style=\"width:387px; height:263px;\" src=\"images/ID/77760_Melioidosis_encephalitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melioidosis involving the brain usually presents as a brainstem encephalitis as visible here on MRI.</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Bart Currie, FRACP.</div><div id=\"graphicVersion\">Graphic 77760 Version 5.0</div></div></div>"},"77762":{"type":"graphic_movie","displayName":"Normal mitral valve M-mode","title":"Normal M-mode echocardiogram","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal M-mode echocardiogram</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77762_mmodenorconv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:241px;\" src=\"images/CARD/77762_mmodenor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The echocardiogram was obtained from the left ventricular chamber at the level of the mitral valve, as shown by the cursor in the 2D image. Shown are the right ventricle, interventricular septum, the left ventricle and the motion of the anterior and posterior leaflets of the mitral which are normal.</div><div id=\"graphicVersion\">Graphic 77762 Version 4.0</div></div></div>"},"77767":{"type":"graphic_figure","displayName":"Death in tuberous sclerosis","title":"Mortality in tuberous sclerosis","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Mortality in tuberous sclerosis</div><div class=\"cntnt\"><img style=\"width:560px; height:260px;\" src=\"images/PULM/77767_Death_in_tuberous_sclerosis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Distribution of the causes of death and ages of patients at the time of death for tuberous sclerosis complex.</div><div class=\"graphic_reference\">Redrawn from Shepherd, CW, Gomez, MR, Lie, JT, Crowson, CS, Mayo Clin Proc 1991; 66:792.</div><div id=\"graphicVersion\">Graphic 77767 Version 1.0</div></div></div>"},"77768":{"type":"graphic_algorithm","displayName":"Protocol for prevention of fire ant stings","title":"Protocol for prevention of fire ant stings in health care facilities in fire ant endemic areas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Protocol for prevention of fire ant stings in health care facilities in fire ant endemic areas</div><div class=\"cntnt\"><img style=\"width:434px; height:546px;\" src=\"images/ALLRG/77768_Prevention_fire_ant_stings.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Not all ants inside health care facilities are fire ants. To be on the safe side, the patient should be removed until the pest control service has investigated.</div><div class=\"graphic_reference\">Reproduced with permission from: Goddard J, Jarrat J, deShazo RD. Recommendations for prevention and management of fire ant infestation of health care facilities. South Med J 2002; 95:627. Copyright © 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77768 Version 11.0</div></div></div>"},"77769":{"type":"graphic_diagnosticimage","displayName":"Budd Chiari CT","title":"Budd-Chiari syndrome on computed tomography scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Budd-Chiari syndrome on computed tomography scan</div><div class=\"cntnt\"><img style=\"width:370px; height:299px;\" src=\"images/GAST/77769_Budd_Chiari_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan through the liver of a 17-year-old male with new onset abdominal distension shows a mottled appearance to the underperfused liver with collapsed portal veins, ascites (small arrows), and extensive retroperitoneal varices (large arrow). Note also the enlarged caudate lobe of the liver (large arrowhead) and the collapsed small inferior vena cava (small arrowhead). These are all characteristic imaging features of the Budd-Chiari syndrome.</div><div class=\"graphic_reference\">Courtesy of Jonathan Kruskal, MD.</div><div id=\"graphicVersion\">Graphic 77769 Version 3.0</div></div></div>"},"77773":{"type":"graphic_table","displayName":"Clinical features of psychogenic nonepileptic seizures","title":"More common features distinguishing epileptic seizures and psychogenic nonepileptic seizures*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">More common features distinguishing epileptic seizures and psychogenic nonepileptic seizures*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sign</td> <td class=\"subtitle1\">Epileptic</td> <td class=\"subtitle1\">PNES</td> </tr> <tr> <td>Duration</td> <td>Usually brief, less than 1-2 minutes</td> <td>Usually longer than 2 minutes</td> </tr> <tr> <td>Eyes</td> <td>Eyes usually open during event</td> <td> <p>Eyes often closed</p> Forced eye closure suggests PNES</td> </tr> <tr> <td>Motor activity</td> <td> <p>Stereotyped</p> <p>Synchronized</p> Build, progress</td> <td> <p>Variable</p> <p>Forward pelvic thrusting, rolling side to side, opisthotonus</p> Wax and wane</td> </tr> <tr> <td>Vocalization</td> <td>Uncommon, especially during convulsion</td> <td>May occur</td> </tr> <tr> <td>Prolonged ictal atonia</td> <td>Very rare</td> <td>May occur</td> </tr> <tr> <td>Incontinence</td> <td>Common in convulsive seizures</td> <td>Less common</td> </tr> <tr> <td>Autonomic signs</td> <td>Cyanosis, tachycardia common with major convulsion</td> <td>Uncommon</td> </tr> <tr> <td>Postictal symptoms</td> <td> <p>Usually confused, drowsy</p> Headache common</td> <td> <p>May rapidly awaken and reorient</p> Headache rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* No single feature is sensitive or specific for epileptic versus psychogenic nonepileptic seizures.</div><div id=\"graphicVersion\">Graphic 77773 Version 3.0</div></div></div>"},"77774":{"type":"graphic_diagnosticimage","displayName":"Doppler pulmonary vein MR","title":"Continuous wave Doppler from the pulmonary vein in mitral regurgitation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Continuous wave Doppler from the pulmonary vein in mitral regurgitation</div><div class=\"cntnt\"><img style=\"width:387px; height:259px;\" src=\"images/CARD/77774_Doppler_pulmonary_vein_AR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The systolic flow, which is normally dominant, is depressed and the retrograde flow at the time of atrial contraction, which is normally less than the transmitral A wave, is exaggerated.</div><div id=\"graphicVersion\">Graphic 77774 Version 4.0</div></div></div>"},"77775":{"type":"graphic_diagnosticimage","displayName":"Right ventricular cardiac output","title":"Right ventricular cardiac output","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Right ventricular cardiac output</div><div class=\"cntnt\"><img style=\"width:586px; height:387px;\" src=\"images/CARD/77775_Right_vent_cardiac_output.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pulse-wave Doppler signal through the pulmonary valve gives a velocity over time, which is integrated to get the velocity time integral (VTI), a measure of right ventricular stroke distance and a proxy for right ventricular cardiac output.</div><div id=\"graphicVersion\">Graphic 77775 Version 2.0</div></div></div>"},"77776":{"type":"graphic_picture","displayName":"Cheilitis PI","title":"Cheilitis","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Cheilitis</div><div class=\"cntnt\"><img style=\"width:584px; height:223px;\" src=\"images/PI/77776_Cheilitis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cheilitis means inflammation of the lips. There are different types of cheilitis. Photo A shows &quot;actinic&quot; cheilitis, which causes the lips to be red and scaly. Photo B shows &quot;angular&quot; cheilitis, which causes cracking and redness in the corners of the mouth.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77776 Version 4.0</div></div></div>"},"77780":{"type":"graphic_table","displayName":"Med guide antidepressants","title":"2007 Revised Medication Guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">2007 Revised Medication Guide</div><div class=\"cntnt\"><table  cellspacing=\"0\">\r\n \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"2\">\r\n  \r\n   Medication Guide\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"2\">\r\n  \r\n   Antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  colspan=\"2\">\r\n  \r\n   Read the Medication Guide that comes with you or your family member's antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. <strong>Talk to your, or your family member's, healthcare provider about:</strong>\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; All risks and benefits of treatment with antidepressant medicines\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; All treatment choices for depression or other serious mental illness\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle1_single\" colspan=\"2\">\r\n  \r\n   What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults when the medicine is first started.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is first started or when the dose is changed.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   4. Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Thoughts about suicide or dying\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Trouble sleeping (insomnia)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Attempts to commit suicide\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; New or worse irritability</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; New or worse depression\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Acting aggressive, being angry, or violent</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; New or worse anxiety\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Acting on dangerous impulses</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Feeling very agitated or restless\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; An extreme increase in activity and talking (mania)</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\">\r\n  \r\n   &#8226; Panic attacks\r\n  \r\n   </td>\r\n  \r\n   <td>&#8226; Other unusual changes in behavior or mood</td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"subtitle2_single\" colspan=\"2\">\r\n  \r\n   5. What else do I need to know about antidepressant medicines?\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Never stop an antidepressant medicine without first talking to a healthcare provider.</strong> Stopping an antidepressant medicine suddenly can cause other symptoms.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Antidepressants are medicines used to treat depression and other illnesses.</strong> It is important to discuss all the risks of treating depression and also the risks of not treating it. Patients and their families or other caregivers should discuss all treatment choices with the healthcare provider, not just the use of antidepressants.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Antidepressant medicines have other side effects.</strong> Talk to the healthcare provider about the side effects of the medicine prescribed for you or your family member.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Antidepressant medicines can interact with other medicines.</strong> Know all of the medicines that you or your family member takes. Keep a list of all medicines to show the healthcare provider. Do not start new medicines without first checking with your healthcare provider.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n  \r\n   <tr>\r\n  \r\n   <td  class=\"indent2\" colspan=\"2\">\r\n  \r\n   &#8226; <strong>Not all antidepressant medicines prescribed for children are FDA approved for use in children.</strong> Talk to your child's healthcare provider for more information.\r\n  \r\n   </td>\r\n  \r\n   </tr>\r\n </table></div><div class=\"graphic_lgnd\">This Medication Guide has been approved by the US Food and Drug Administration for all antidepressants.<br>Revised 2007.</div><div class=\"graphic_reference\">Data from: US Food and Drug Administration, Center for Drug Evaluation and Research. Medication Guide for Antidepressant Drugs. Available at: www.fda.gov/Cder/drug/antidepressants (Accessed on August 1, 2008).</div><div id=\"graphicVersion\">Graphic 77780 Version 1.0</div></div></div>"},"77781":{"type":"graphic_table","displayName":"Periop endocrine agents","title":"Perioperative management of endocrine agents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Perioperative management of endocrine agents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name or class of drug</td> <td class=\"subtitle1\">Clinical considerations</td> <td class=\"subtitle1\">Recommended strategy for surgery with brief NPO state</td> <td class=\"subtitle1\">Recommended strategy for surgery with prolonged NPO state</td> </tr> <tr> <td>Oral contraceptives</td> <td>Continuation may increase risk of venous thromboembolism. Stopping can result in unwanted pregnancies.</td> <td> <p>Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism.</p> <p>Stop&nbsp;four to six&nbsp;weeks before surgery for procedures with high risk for thromboembolism. Instruct on alternate forms of contraception and obtain serum pregnancy test immediately before surgery.</p> </td> <td> <p>Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism.</p> <p>Stop&nbsp;four to six&nbsp;weeks before surgery for procedures with high risk for thromboembolism. Instruct on alternate forms of contraception and obtain serum pregnancy test immediately before surgery.</p> </td> </tr> <tr> <td>Hormone replacement therapy</td> <td>Continuation may increase risk of venous thromboembolism.</td> <td> <p>Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism.</p> <p>When possible, stop&nbsp;four to six&nbsp;weeks before surgery for procedures with high risk for thromboembolism. Resume when period of elevated risk has resolved.</p> </td> <td> <p>Continue up to and including the day of surgery for procedures with low to moderate risk of venous thromboembolism.</p> <p>When possible, stop&nbsp;four to six&nbsp;weeks before surgery for procedures with high risk for thromboembolism. Resume when tolerating oral medications and period of elevated risk has resolved.</p> </td> </tr> <tr> <td>Selective estrogen receptor modulators (SERMs)</td> <td>Continuation may increase risk of venous thromboembolism.</td> <td>Continue for surgeries with low risk of venous thromboembolism and discontinue for surgeries with moderate to high risk for venous thromboembolism. When stopped, should be stopped at least&nbsp;four to six&nbsp;weeks prior to surgery. When SERMs are used for breast cancer treatment, consult oncologist.</td> <td>Continue up to and including the day of surgery for procedures with low risk of venous thromboembolism. Stop&nbsp;four to six&nbsp;weeks before surgery for procedures with moderate to high risk for thromboembolism. Resume when tolerating oral medications. When SERMs are used for breast cancer treatment, consult oncologist.</td> </tr> <tr> <td>Oral hypoglycemics and insulin</td> <td colspan=\"3\">Refer to the UpToDate topic on perioperative management of diabetes mellitus.</td> </tr> <tr> <td>Glucocorticoids</td> <td colspan=\"3\">Refer to the UpToDate topic on the surgical patient taking glucocorticoids.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NPO: nil per os (nothing by mouth).</div><div id=\"graphicVersion\">Graphic 77781 Version 7.0</div></div></div>"},"77782":{"type":"graphic_picture","displayName":"Suspicious mass","title":"Suspicious mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Suspicious mass</div><div class=\"cntnt\"><img style=\"width:427px; height:527px;\" src=\"images/PC/77782_Suspicious_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spiculation from cancer in three different cases. In Panel A, a small irregular nodule is seen with spiculated margins. In Panel B, the cancer is not seen as a mass lesion but extensive distortion is seen. In Panel C, an ill defined, irregular nodule is seen with speculations extending far beyond the index nodule (arrows).</div><div id=\"graphicVersion\">Graphic 77782 Version 1.0</div></div></div>"},"77787":{"type":"graphic_table","displayName":"Secondary causes","title":"Secondary causes of resistant hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Secondary causes of resistant hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1_single\">Common</td>\n  </tr>\n  <tr>\n    <td>Obstructive sleep apnea</td>\n  </tr>\n  <tr>\n    <td>Renal parenchymal disease</td>\n  </tr>\n  <tr>\n    <td>Primary aldosteronism</td>\n  </tr>\n  <tr>\n    <td>Renal artery stenosis</td>\n  </tr>\n  <tr>\n    <td class=\"subtitle1_single\">Uncommon</td>\n  </tr>\n  <tr>\n    <td>Pheochromocytoma</td>\n  </tr>\n  <tr>\n    <td>Cushing's disease</td>\n  </tr>\n  <tr>\n    <td>Hyperparathyroidism</td>\n  </tr>\n  <tr>\n    <td>Aortic coarctation</td>\n  </tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">9.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">12/1/2009--Requested permission (JD). 1/27/2010--Permission granted; figures to Terrence; invoice to Jo (JD). The total fee of $&amp;quot;100.00&amp;quot;was originally charged to Agents_that _increase_BP Secondary_causes Diagnosis_and_treatment</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=39679&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Secondary_causes.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from: Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment: A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403. Copyright © 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77787 Version 9.0</div></div></div>"},"77791":{"type":"graphic_picture","displayName":"Lymphomatoid papulosis","title":"Lymphomatoid papulosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid papulosis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/77791_Lymphomatoid_papulosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflammatory papules are present on the trunk. Some lesions have overlying crust.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77791 Version 4.0</div></div></div>"},"77792":{"type":"graphic_table","displayName":"Modalities photoepilation","title":"Modalities for photoepilation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modalities for photoepilation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">System</td> <td class=\"subtitle1\">Skin types*</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages</td> </tr> <tr> <td>1064 nm Nd-YAG</td> <td>I-VI</td> <td>Good for darker skin types</td> <td> <ul> <li>Pain </li> <li>Possible folliculitis</li> </ul> </td> </tr> <tr> <td>755 nm alexandrite</td> <td>I-III</td> <td>Good for lighter hair</td> <td> <ul> <li>Pain </li> <li>Possible folliculitis</li> </ul> </td> </tr> <tr> <td>810 nm diode</td> <td>I-V</td> <td>Good for darker skin types</td> <td> <ul> <li>Pain </li> <li>Possible folliculitis</li> </ul> </td> </tr> <tr> <td>IPL<sup>&#182;</sup></td> <td>I-IV</td> <td>Less expensive system to purchase</td> <td> <ul> <li>May not be as effective as laser systems</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Fitzpatrick skin types: &#xD;&#xA;<UL>&#xD;&#xA;<LI>I - always burns, never tans;</LI>&#xD;&#xA;<LI>II - always burns, sometimes tans;</LI>&#xD;&#xA;<LI>III - sometimes burns, always tans;</LI>&#xD;&#xA;<LI>IV - rarely burns, always tans;</LI>&#xD;&#xA;<LI>V - moderately pigmented;</LI>&#xD;&#xA;<LI>VI - darkly pigmented.</LI></UL>¶ Intense pulsed light.</div><div id=\"graphicVersion\">Graphic 77792 Version 2.0</div></div></div>"},"77793":{"type":"graphic_picture","displayName":"Paper wasp nest","title":"Paper wasp nest","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Paper wasp nest</div><div class=\"cntnt\"><img style=\"width:504px; height:424px;\" src=\"images/ALLRG/77793_Paper_wasp_nest.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.</div><div id=\"graphicVersion\">Graphic 77793 Version 1.0</div></div></div>"},"77794":{"type":"graphic_picture","displayName":"Fundic gland polyps CPC Light","title":"Fundic gland polyp","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Fundic gland polyp</div><div class=\"cntnt\"><img style=\"width:362px; height:506px;\" src=\"images/GAST/77794_Fundic_gland_polyps_CPC_Lig.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biopsy of a gastric nodule in the fundus showing the classic appearance of a fundic gland polyp. At low power (upper panel), there are variably dilated glands with an unremarkable surface/foveolar zone. At high power (lower panel), the dilated glands (asterisks) are lined by the cells indigenous to corpus mucosa. Normal corpus glands are shown (arrows).</div><div class=\"graphic_reference\">Courtesy of Donald Antonioli, MD.</div><div id=\"graphicVersion\">Graphic 77794 Version 1.0</div></div></div>"},"77795":{"type":"graphic_picture","displayName":"Ileal carcinoid Light","title":"Ileal carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Ileal carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:528px; height:195px;\" src=\"images/GAST/77795_Ileal_carcinoid_Light.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low (left panel) and high power (right panel) histology of an ileal carcinoid tumor. The high power magnification demonstrates nests of uniform small cells and an absence of mitoses.</div><div class=\"graphic_reference\">Courtesy of Dr. Saint Aufranc.</div><div id=\"graphicVersion\">Graphic 77795 Version 1.0</div></div></div>"},"77796":{"type":"graphic_table","displayName":"High fiber foods","title":"High fiber foods","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">High fiber foods</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Fiber (grams)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Cereal (&#189; cup serving)</td> </tr> <tr> <td class=\"indent1\">Fiber One</td> <td class=\"centered\">13</td> </tr> <tr> <td class=\"indent1\">100% Bran</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">All Bran</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">Bran Buds</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"indent1\">Kashi Go Lean</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Kellogg's Complete Bran Flakes</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Grape Nuts</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"indent1\">Raisin Bran*</td> <td class=\"centered\">3 to 5</td> </tr> <tr> <td class=\"indent1\">Cracklin' Oat Bran*</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">100% Whole Grain Wheat Chex</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Fruit and Fibre</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Great Grains</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Frosted Mini Wheats</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Kellogg's Low Fat Granola</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Cheerios</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Wheaties</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Instant oatmeal</td> <td class=\"centered\">2<sup>&#182;</sup><sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Fruit</td> </tr> <tr> <td class=\"indent1\">Pear (one)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Strawberries (1 cup)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Apple (one, with skin)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Dried fruits (eg, raisins) (3 Tablespoons)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Papaya (one)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Peach (fresh)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Plums (two)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Mango</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Nectarine</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Avocado (&#189; medium)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tomato (one medium)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vegetables (cooked unless indicated)</td> </tr> <tr> <td class=\"indent1\">Pinto, kidney, black, lima beans (&#189; cup)</td> <td class=\"centered\">4 to 7</td> </tr> <tr> <td class=\"indent1\">Sweet potato (1 medium)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Lentils (&#189; cup)</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Jicama (&#189; raw)</td> <td class=\"centered\">3 to 4</td> </tr> <tr> <td class=\"indent1\">Baked potato with skin (medium)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Corn (&#189; cup)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Peas (&#189; cup)</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Broccoli (&#189; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cabbage (&#189; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Spinach (&#189; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Cauliflower (&#190; cup)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Carrots (1 medium raw, or &#189; cup cooked)</td> <td class=\"centered\">2<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* These cereals are also high in sugar (15 to 20 grams/serving).<br />¶ These foods contain relatively small amounts of fiber, but may still be helpful to provide a portion of the child's fiber intake.<br />Δ Reflects insoluble fiber, which is the most relevant type of fiber for prevention and treatment of constipation. Soluble fiber has different health benefits. Some \"high fiber\" forms of instant oatmeal contain up to 10 grams of fiber. However, most of this additional fiber is soluble, which may not be as valuable as insoluble fiber for prevention and treatment of constipation.</div><div id=\"graphicVersion\">Graphic 77796 Version 5.0</div></div></div>"},"77798":{"type":"graphic_table","displayName":"MPM II","title":"Mortality prediction model II (MPM II)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mortality prediction model II (MPM II)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Variable</td> <td class=\"subtitle1\">Response</td> <td class=\"subtitle1\">Points</td> </tr> <tr class=\"divider_bottom\"> <td>Patient age*</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Medical or unscheduled surgical admission?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cardiopulmonary resuscitation prior to admission?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Coma (Glasgow coma scale 3-5)?</p> (Does not include patients whose coma is due to overdose or who received neuromuscular blocking agents)</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Heart rate &#8805;150 bpm?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Systolic blood pressure &#8804;90 mmHg?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Mechanical ventilation?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Acute renal failure?</p> (Does not include pre-renal azotemia)</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cardiac dysrhythmias?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cerebrovascular accident?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Intracranial mass effect?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Gastrointestinal bleeding?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Metastatic carcinoma?</p> (Distant metastases only; does not include local lymph node involvement)</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cirrhosis?</td> <td>Yes</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No</td> <td>0</td> </tr> <tr> <td rowspan=\"2\"> <p>Chronic renal insufficiency?</p> (Creatinine &#62;2 mg/dL chronically)</td> <td>Yes</td> <td>1</td> </tr> <tr> <td>No</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patient age does not receive points when calculating the severity score; however, it is used in the formula to calculate predicted mortality.</div><div class=\"graphic_reference\">Data from: Lemeshow, S, Teres, D, Klar, J, et al. Mortality probability models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993; 270:2478.</div><div id=\"graphicVersion\">Graphic 77798 Version 2.0</div></div></div>"},"77800":{"type":"graphic_figure","displayName":"Indirect inguinal hernia sac TEP dissection","title":"Indirect inguinal hernia sac TEP dissection","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Indirect inguinal hernia sac TEP dissection</div><div class=\"cntnt\"><img style=\"width:500px; height:436px;\" src=\"images/SURG/77800_TEP_hernia_sac_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure&nbsp;shows an indirect hernia viewed from within the extraperitoneal space.&nbsp;After gently pulling the hernia sac from the inguinal canal&nbsp;into the abdomen, the end of the hernia sac can be identified and&nbsp;bluntly dissected from the cord structures.</div><div class=\"graphic_footnotes\">TEP: total extraperitoneal hernia repair.</div><div class=\"graphic_reference\">Reproduced with permission from: Jones DB, Maithel SK, Schneider BE. Atlas of minimally invasive surgery. Ciné-Med, Woodbury, CT 2006. Copyright © 2006 Ciné-Med, Inc.</div><div id=\"graphicVersion\">Graphic 77800 Version 11.0</div></div></div>"},"77801":{"type":"graphic_picture","displayName":"Mild episcleritis","title":"Mild episcleritis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Mild episcleritis</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/77801_Episcleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77801 Version 5.0</div></div></div>"},"77805":{"type":"graphic_picture","displayName":"Congenital dermal melanocytosis - Mongolian spots","title":"Congenital dermal melanocytosis (Mongolian spots)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Congenital dermal melanocytosis (Mongolian spots)</div><div class=\"cntnt\"><img style=\"width:435px; height:504px;\" src=\"images/PEDS/77805_Mongolian_spots.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple gray-blue patches on the back and buttocks of an infant.</div><div class=\"graphic_reference\">Courtesy of the Yale Dermatology Residents' Slide Collection.</div><div id=\"graphicVersion\">Graphic 77805 Version 3.0</div></div></div>"},"77807":{"type":"graphic_table","displayName":"Assessment of the red eye","title":"Assessment of the red eye","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Assessment of the red eye</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Acuity</td> <td class=\"subtitle1\">Foreign body sensation</td> <td class=\"subtitle1\">Photophobia</td> <td class=\"subtitle1\">Discharge</td> <td class=\"subtitle1\">Cardinal feature</td> <td class=\"subtitle1\">Treat/refer</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Lids/lashes</td> </tr> <tr> <td class=\"indent1\">Stye/hordeoleum</td> <td>Nl</td> <td>-</td> <td>-</td> <td>None</td> <td>Tender</td> <td>Treat</td> </tr> <tr> <td class=\"indent1\">Chalazion</td> <td>Nl</td> <td>-</td> <td>-</td> <td>None</td> <td>Nontender</td> <td>Treat</td> </tr> <tr> <td class=\"indent1\">Blepharitis</td> <td>Nl</td> <td>-</td> <td>-</td> <td>Dry crusting</td> <td>Chronic</td> <td>Treat</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Conjunctiva</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"7\">Conjunctivitis</td> </tr> <tr> <td class=\"sublist2\">Bacterial</td> <td class=\"sublist_other\">Nl</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">Mucopurulent</td> <td class=\"sublist_other\">Discharge all day</td> <td class=\"sublist_other\">Treat</td> </tr> <tr> <td class=\"sublist2_start\">Viral</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">&nbsp;</td> <td class=\"sublist_other_start\">Mucoserous</td> <td class=\"sublist_other_start\">None/URI</td> <td class=\"sublist_other_start\">Treat</td> </tr> <tr> <td class=\"sublist2\">Allergic</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">Mucoserous</td> <td class=\"sublist_other\">Itching</td> <td class=\"sublist_other\">Treat</td> </tr> <tr> <td class=\"sublist2\">Non-specific (toxic or dry eye syndrome)</td> <td class=\"sublist_other\">Nl</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">-</td> <td class=\"sublist_other\">Watery</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Episcleritis/scleritis</td> <td>Nl</td> <td>-</td> <td>-</td> <td>None</td> <td>Sectoral injection, dull ache</td> <td>Treat</td> </tr> <tr> <td class=\"indent1\">Subconjunctival hemorrhage</td> <td>Nl</td> <td>-</td> <td>-</td> <td>None</td> <td>Extravasated &nbsp;blood</td> <td>Treat</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Cornea</td> </tr> <tr> <td class=\"indent1\">Abrasion</td> <td>Nl or down</td> <td>+</td> <td>+</td> <td>Watery</td> <td>History/trauma defect revealed by fluorescein</td> <td>Treat</td> </tr> <tr> <td class=\"indent1\">Contact lens overwear</td> <td>Nl or down</td> <td>+</td> <td>+</td> <td>Watery</td> <td>History</td> <td>Treat</td> </tr> <tr> <td class=\"indent1\">Foreign body</td> <td>Nl or down</td> <td>+</td> <td>+</td> <td>Mucoserous</td> <td>History/trauma</td> <td>Treat initially by attempt to remove by irrigation or swab; refer if still present after 24 hr</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"7\">Infectious keratitis</td> </tr> <tr> <td class=\"sublist2\">Bacterial</td> <td class=\"sublist_other\">Nl or down</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">Muco-purulent</td> <td class=\"sublist_other\">White spot on cornea spots stains w/fluorescein</td> <td class=\"sublist_other\">Refer, same day/ emergent</td> </tr> <tr> <td class=\"sublist2\">Viral</td> <td class=\"sublist_other\">Nl or down</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">+</td> <td class=\"sublist_other\">Watery</td> <td class=\"sublist_other\">Gray, branching opacity dendrite; dendrite revealed w/fluorescein</td> <td class=\"sublist_other\">Refer, 1 to 2 days/ urgent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Anterior chamber/iris</td> </tr> <tr> <td class=\"indent1\">Iritis</td> <td>Nl or down</td> <td>-</td> <td>+</td> <td>None/watery</td> <td>Miotic pupil</td> <td>Refer, 1 to 2 days/urgent</td> </tr> <tr> <td class=\"indent1\">Hyphema</td> <td>Nl or down</td> <td>-</td> <td>+/-</td> <td>None/watery</td> <td>RBC \"level\"</td> <td>Refer, same day/emergent</td> </tr> <tr> <td class=\"indent1\">Hypopyon</td> <td>Nl or down</td> <td>-</td> <td>+/-</td> <td>None/purulent</td> <td>WBC \"level\"</td> <td>Refer, same day/emergent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Iris/lens</td> </tr> <tr> <td class=\"indent1\">Angle closure</td> <td>Nl or down</td> <td>-</td> <td>+/-</td> <td>None/watery</td> <td>Fixed, mid-dilated pupil</td> <td>Refer, same day/emergent</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77807 Version 2.0</div></div></div>"},"77809":{"type":"graphic_figure","displayName":"Transperineal fistula repair2","title":"Transverse transperineal approach to a rectovaginal fistula located at the sphincter complex","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transverse transperineal approach to a rectovaginal fistula located at the sphincter complex</div><div class=\"cntnt\"><img style=\"width:410px; height:438px;\" src=\"images/OBGYN/77809_Transperineal_fistula_rep1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dissection above and lateral to the fistula tract is carried out using sharp dissection.</div><div id=\"graphicVersion\">Graphic 77809 Version 1.0</div></div></div>"},"77812":{"type":"graphic_diagnosticimage","displayName":"Sinus CT scan of a patient with AFRS","title":"Sinus computed tomography scan of a patient with allergic fungal rhinosinusitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus&nbsp;computed tomography&nbsp;scan of a patient with allergic fungal rhinosinusitis</div><div class=\"cntnt\"><img style=\"width:288px; height:355px;\" src=\"images/ALLRG/77812_AFRSCT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sinus computed tomography scan of a patient with arrows showing complete opacification of both anterior ethmoid and maxillary sinuses and hyperdensities within these same areas.</div><div class=\"graphic_reference\">Courtesy of Daniel L&nbsp;Hamilos, MD.</div><div id=\"graphicVersion\">Graphic 77812 Version 9.0</div></div></div>"},"77814":{"type":"graphic_table","displayName":"Arterial calcium stimulation insulinoma","title":"Arterial calcium stimulation with hepatic venous sampling for insulinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Arterial calcium stimulation with hepatic venous sampling for insulinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Artery</td> <td class=\"subtitle1\">Time, seconds</td> <td class=\"subtitle1\">Serum hepatic vein insulin, microU/mL (pmol/L)</td> </tr> <tr> <td rowspan=\"4\">Superior mesenteric</td> <td>0</td> <td>41 (284)</td> </tr> <tr> <td>20</td> <td>65 (451)</td> </tr> <tr> <td>40</td> <td>333 (2313)</td> </tr> <tr> <td>60</td> <td>441 (3063)</td> </tr> <tr> <td rowspan=\"4\">Gastroduodenal</td> <td>0</td> <td>30 (208)</td> </tr> <tr> <td>20</td> <td>42 (292)</td> </tr> <tr> <td>40</td> <td>38 (264)</td> </tr> <tr> <td>60</td> <td>36 (250)</td> </tr> <tr> <td rowspan=\"4\">Splenic</td> <td>0</td> <td>31 (215)</td> </tr> <tr> <td>20</td> <td>26 (180)</td> </tr> <tr> <td>40</td> <td>26 (180)</td> </tr> <tr> <td>60</td> <td>31 (215)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Intraarterial injection of calcium, an insulin secretagogue in insulinoma patients but not normal subjects, and changes in hepatic venous serum insulin concentrations in a patient with suspected insulinoma. The hepatic venous serum insulin concentration increased 10-fold after superior mesenteric artery injection, 1.4-fold after the gastroduodenal artery injection, and did not change after the splenic artery injection. An insulinoma was removed from the uncinate process.</div><div id=\"graphicVersion\">Graphic 77814 Version 4.0</div></div></div>"},"77816":{"type":"graphic_algorithm","displayName":"Classification tree dx FMF1","title":"Classification tree using the detailed criteria for the diagnosis of familial mediterranean fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classification tree using the detailed criteria for the diagnosis of familial mediterranean fever</div><div class=\"cntnt\"><img style=\"width:433px; height:373px;\" src=\"images/GAST/77816_Classification_tree_dx_FMF1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent.</div><div class=\"graphic_reference\">Adapted from: Livneh A, Langevitz P, Zemer D, et al. Arthritis Rheum 1997; 40:1879.</div><div id=\"graphicVersion\">Graphic 77816 Version 4.0</div></div></div>"},"77817":{"type":"graphic_picture","displayName":"Corneal abrasion","title":"Corneal abrasion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Corneal abrasion</div><div class=\"cntnt\"><img style=\"width:318px; height:222px;\" src=\"images/PC/77817_Cornealabrasion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear green stain in the central cornea.</div><div class=\"graphic_reference\">Reproduced with permission from: Trobe JD, Hackel RE. Field Guide to the Eyes. Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright © 2002 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77817 Version 10.0</div></div></div>"},"77818":{"type":"graphic_picture","displayName":"Partial nail avulsion","title":"Removal of a lateral wedge of toenail in a partial avulsion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Removal of a lateral wedge of toenail in a partial avulsion</div><div class=\"cntnt\"><img style=\"width:382px; height:268px;\" src=\"images/PC/77818_Partialnailavulsion.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Krull EA. Surgery of the nail. In: Dermatology, 3rd ed, Moschella SL, Hurley HJ (Eds), WB Saunders, Philadelphia 1992. p.2407. Reproduced with permission from Atlas of Office Procedures 1999; 2:97. Copyright 1999 WB Saunders.</div><div id=\"graphicVersion\">Graphic 77818 Version 3.0</div></div></div>"},"77820":{"type":"graphic_figure","displayName":"Prednisone in nocturnal asthma","title":"Timing of prednisone dosing in nocturnal asthma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Timing of prednisone dosing in nocturnal asthma</div><div class=\"cntnt\"><img style=\"width:513px; height:240px;\" src=\"images/PULM/77820_Prednisone_in_nocturnal_ast.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Effect of the timing of the prednisone dose on the percent overnight fall in FEV1. Compared to placebo, only the 3 pm dose reduced the fall in FEV1.</div><div class=\"graphic_reference\">Redrawn from Beam, WR, Weiner, DE, Martin, RJ, Am Rev Respir Dis 1992; 146:1524.</div><div id=\"graphicVersion\">Graphic 77820 Version 1.0</div></div></div>"},"77821":{"type":"graphic_table","displayName":"Differential dx Sjögren's syndrome","title":"Differential diagnosis of the manifestations of Sjögren's syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of the manifestations of Sj&ouml;gren's syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Dry eyes</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Aqueous-deficient form</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lacrimal gland inflammation </li> </ul> </td> <td> <p>Sarcoidosis</p> <p>Lymphoma</p> <p>IgG4-related disease</p> <p>Graft-versus-host disease</p> HCV infection</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Lacrimal gland duct obstruction </li> </ul> </td> <td> <p>Trachoma</p> <p>Stevens-Johnson syndrome</p> Ocular cicatricial pemphigoid</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Age-related glandular fibrosis </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Reflex hyposecretion secondary to ocular sensory loss </li> </ul> </td> <td> <p>Corneal surgery (eg, laser-assisted in situ keratomileusis [LASIK])</p> <p>Chronic contact lens wear</p> Diabetes mellitus</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Idiopathic<sup>[1]</sup> </li> </ul> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Medications </li> </ul> </td> <td>Tricyclic and other antidepressants; antihistamines</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Evaporative form</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Meibomian gland dysfunction </li> </ul> </td> <td> <p>Acne rosacea</p> <p>Seborrheic dermatitis</p> <p>Atopic dermatitis</p> <p>Isotretinoin therapy</p> Menopause</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Impaired lid closure </li> </ul> </td> <td>Thyroid ophthalmopathy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Low blink rate </li> </ul> </td> <td> <p>Parkinson's disease</p> Working at a computer monitor<sup>[2,3]</sup></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ocular surface disorders </li> </ul> </td> <td> <p>Vitamin A deficiency<sup>[4-6]</sup></p> <p>Topical drugs and preservatives</p> <p>Contact lens wear</p> Allergic conjunctivitis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Dry mouth</td> </tr> <tr> <td class=\"indent1\">Drugs</td> <td> <p>Antidepressants</p> <p>Antihistamines</p> <p>Anticholinergics</p> <p>Diuretics</p> Neuroleptics</td> </tr> <tr> <td class=\"indent1\">Systemic diseases</td> <td> <p>Amyloidosis</p> <p>Sarcoidosis</p> <p>HIV and HCV infection</p> Uncontrolled diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Psychogenic</td> <td>Anxiety</td> </tr> <tr> <td class=\"indent1\">Radiation therapy</td> <td> <p>External beam for head and neck cancers</p> Iodine-131 for thyroid cancer</td> </tr> <tr> <td class=\"indent1\">Dehydration</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Salivary gland enlargement</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Usually unilateral</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute </li> </ul> </td> <td> <p>Bacterial infection</p> <p>Actinomycosis<sup>[7]</sup></p> Obstruction</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic </li> </ul> </td> <td> <p>Chronic sialadenitis</p> Primary neoplasm (adenoma, adenocarcinoma, lymphoma, mixed salivary gland tumors)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Usually bilateral</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Acute </li> </ul> </td> <td>Acute viral infections (EBV, mumps, CMV, coxsackie A)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Chronic </li> </ul> </td> <td> <p>Chronic viral infections (HIV, HCV)</p> <p>IgG4-related sialadenitis</p> <p>Amyloidosis</p> <p>Granulomatous diseases (sarcoidosis, tuberculosis)<sup>[8,9]</sup></p> <p>HIV infection</p> <p>Hyperlipidemia</p> <p>Diabetes mellitus<sup>[10]</sup></p> <p>Alcoholism<sup>[10]</sup></p> <p>Malnutrition</p> <p>Acromegaly<sup>[11,12]</sup></p> Anorexia and bulimia<sup>[13,14]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG4: immunoglobulin 4; HCV: hepatitis C virus; HIV: human immunodeficiency virus; EBV: Epstein-Barr virus; CMV: cytomegalovirus.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj&ouml;gren's Syndrome International Registry. Am J Ophthalmol 2010; 149:405.</li>&#xD;&#xA;    <li>Wolkoff P, N&oslash;jgaard JK, Franck C, Skov P. The modern office environment desiccates the eyes? Indoor Air 2006; 16:258.</li>&#xD;&#xA;    <li>Sheedy JE, Gowrisankaran S, Hayes JR. Blink rate decreases with eyelid squint. Optom Vis Sci 2005; 82:905.</li>&#xD;&#xA;    <li>Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 2006; 25:900.</li>&#xD;&#xA;    <li>Bowman SJ. Collaborative research into outcome measures in Sj&ouml;gren's syndrome. Update on disease assessment. Scand J Rheumatol Suppl 2002; 116:23.</li>&#xD;&#xA;    <li>Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci 2006; 47:3293.</li>&#xD;&#xA;    <li>Hensher R, Bowerman J. Actinomycosis of the parotid gland. Br J Oral Maxillofac Surg 1985; 23:128.</li>&#xD;&#xA;    <li>Janmeja AK, Das SK, Kochhar S, Handa U. Tuberculosis of the parotid gland. Indian J Chest Dis Allied Sci 2003; 45:67.</li>&#xD;&#xA;    <li>Ramos-Casals M, Brito-Zer&oacute;n P, Garc&iacute;a-Carrasco M, Font J. Sarcoidosis or Sj&ouml;gren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore) 2004; 83:85.</li>&#xD;&#xA;    <li>Kim D, Uy C, Mandel L. Sialosis of unknown origin. N Y State Dent J 1998; 64:38.</li>&#xD;&#xA;    <li>Manetti L, Bogazzi F, Brogioni S, et al. Submandibular salivary gland volume is increased in patients with acromegaly. Clin Endocrinol (Oxf) 2002; 57:97.</li>&#xD;&#xA;    <li>Thomson JA, McCrossan J, Mason DK. Salivary gland enlargement in acromegaly. Clin Endocrinol (Oxf) 1974; 3:1.</li>&#xD;&#xA;    <li>Buchanan JA, Fortune F. Bilateral parotid enlargement as a presenting feature of bulimia nervosa in a post-adolescent male. Postgrad Med J 1994; 70:27.</li>&#xD;&#xA;    <li>Vavrina J, M&uuml;ller W, Gebbers JO. Enlargement of salivary glands in bulimia. J Laryngol Otol 1994; 108:516.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75.</div><div id=\"graphicVersion\">Graphic 77821 Version 3.0</div></div></div>"},"77822":{"type":"graphic_picture","displayName":"Dermatomyositis - upper back","title":"Dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermatomyositis</div><div class=\"cntnt\"><img style=\"width:432px; height:324px;\" src=\"images/DERM/77822_Dermatomyositis_upper_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Confluent, violaceous erythema is present on the posterior neck, upper back, and shoulders. This presentation is often referred to as the \"shawl sign\" of dermatomyositis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77822 Version 4.0</div></div></div>"},"77824":{"type":"graphic_picture","displayName":"Renal biopsy","title":"Light micrograph of kidney biopsy with atazanavir crystals within tubular lumen and renal parenchyma","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Light micrograph of kidney biopsy with atazanavir crystals within tubular lumen and renal parenchyma</div><div class=\"cntnt\"><img style=\"width:514px; height:205px;\" src=\"images/NEPH/77824_Renal_biopsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal biopsy from a patient treated with atazanavir demonstrates crystals within the tubular lumen and renal parenchyma. <br />(A) Needle-shaped atazanavir crystals within the tubular lumen.<br />(B) Atazanavir crystals within the renal parenchyma associated with granuloma formation.</div><div class=\"graphic_reference\">Reproduced with permission from: Izzedine H, M'rad MB, Bardier A, et al. Atazanavir crystal nephropathy. AIDS 2007; 21:2357. Copyright © 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77824 Version 12.0</div></div></div>"},"77825":{"type":"graphic_table","displayName":"Causes of painful ophthalmoplegia","title":"Causes of painful ophthalmoplegia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of painful ophthalmoplegia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\">(1) Trauma:</td> </tr> <tr> <td class=\"subtitle2_left\">(2) Vascular:</td> </tr> <tr> <td class=\"indent1\">Intracavernous carotid artery aneurysm</td> </tr> <tr> <td class=\"indent1\">Posterior cerebral artery aneurysm</td> </tr> <tr> <td class=\"indent1\">Carotid-cavernous fistula</td> </tr> <tr> <td class=\"indent1\">Carotid-cavernous thrombosis</td> </tr> <tr> <td class=\"indent1\">Posterior communicating artery aneurysm</td> </tr> <tr> <td class=\"indent1\">Internal carotid artery dissection</td> </tr> <tr> <td class=\"subtitle2_left\">(3) Neoplasm:</td> </tr> <tr> <td class=\"subtitle3_single\">Primary intracranial tumour</td> </tr> <tr> <td class=\"indent2\">Pituitary adenoma</td> </tr> <tr> <td class=\"indent2\">Meningioma</td> </tr> <tr> <td class=\"indent2\">Craniopharyngioma, others</td> </tr> <tr> <td class=\"subtitle3_single\">Primary cranial tumour</td> </tr> <tr> <td class=\"indent2\">Chordoma, others</td> </tr> <tr> <td class=\"subtitle3_single\">Local metastases</td> </tr> <tr> <td class=\"indent2\">Nasopharyngeal tumour</td> </tr> <tr> <td class=\"indent2\">Squamous cell carcinoma</td> </tr> <tr> <td class=\"subtitle3_single\">Distant metastases</td> </tr> <tr> <td class=\"indent2\">Lymphoma</td> </tr> <tr> <td class=\"indent2\">Multiple myeloma</td> </tr> <tr> <td class=\"indent2\">Carcinomatous metastases</td> </tr> <tr> <td class=\"subtitle2_left\">(4) Inflammation, infection:</td> </tr> <tr> <td class=\"subtitle3_single\">Bacterial</td> </tr> <tr> <td class=\"indent2\">Contiguous sinusitis</td> </tr> <tr> <td class=\"indent2\">Mucocele (sphenoid sinus)</td> </tr> <tr> <td class=\"indent2\">Periostitis</td> </tr> <tr> <td class=\"indent2\">Abcess</td> </tr> <tr> <td class=\"subtitle3_single\">Viral</td> </tr> <tr> <td class=\"indent2\">Herpes zoster</td> </tr> <tr> <td class=\"subtitle3_single\">Fungal</td> </tr> <tr> <td class=\"indent2\">Mucormycosis, Actinomycosis</td> </tr> <tr> <td class=\"subtitle3_single\">Spirochetal</td> </tr> <tr> <td class=\"indent2\">Treponema pallidum</td> </tr> <tr> <td class=\"subtitle3_single\">Mycobacterial</td> </tr> <tr> <td class=\"indent2\">Mycobacterium tuberculosis</td> </tr> <tr> <td class=\"subtitle3_single\">Others</td> </tr> <tr> <td class=\"indent2\">Sarcoidosis</td> </tr> <tr> <td class=\"indent2\">Wegener's granulomatosis</td> </tr> <tr> <td class=\"indent2\">Eosinophilic granuloma</td> </tr> <tr> <td class=\"indent2\">Tolosa-Hunt syndrome</td> </tr> <tr> <td class=\"indent2\">Orbital pseudotumor</td> </tr> <tr> <td class=\"subtitle2_left\">(5) Miscellaneous:</td> </tr> <tr> <td class=\"indent1\">Diabetic ophthalmoplegia</td> </tr> <tr> <td class=\"indent1\">Ophthalmoplegic migraine</td> </tr> <tr> <td class=\"indent1\">Giant cell arteritis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Kline LB, Hoyt WF. The Tolosa-Hunt syndrome. J Neurol Neurosurg Psychiatry 2001; 71:577.</div><div id=\"graphicVersion\">Graphic 77825 Version 3.0</div></div></div>"},"77826":{"type":"graphic_table","displayName":"Obsessions and compulsions in pregnancy or postpartum","title":"Obsessions and compulsions in pregnancy or postpartum","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obsessions and compulsions in pregnancy or postpartum</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   &nbsp;\n   </td>\n   <td  class=\"subtitle1\">\n   Obsessions\n   </td>\n   <td  class=\"subtitle1\">\n   Associated compulsions\n   </td>\n   </tr>\n   <tr>\n   <td  rowspan=\"3\">\n   <strong>Pregnancy</strong>\n   </td>\n   <td>Fear of fetal death</td>\n   <td>Checking for fetal movements</td>\n   </tr>\n   <tr>\n   <td>Fear of contaminating the fetus by toxic agents</td>\n   <td>Excessive washing and cleaning</td>\n   </tr>\n   <tr>\n   <td>Aggressive obsessions towards fetus</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td  rowspan=\"5\">\n   <strong>Postpartum</strong>\n   </td>\n   <td>Fear of intentional or accidental harm to the infant (including sexual abuse)</td>\n   <td>Avoidant behavior (eg, avoiding knives, infant)</td>\n   </tr>\n   <tr>\n   <td>Fear of misplacing the baby</td>\n   <td>Compulsive checking of the infant (eg, at night)</td>\n   </tr>\n   <tr>\n   <td>Intense fear of Sudden Infant Death Syndrome</td>\n   <td>&nbsp;</td>\n   </tr>\n   <tr>\n   <td>Fear of contaminating the infant</td>\n   <td>Excessive washing and cleaning</td>\n   </tr>\n   <tr>\n   <td>Fear of criticism of mothering skills</td>\n   <td>&nbsp;</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">1. Wenzel, A, et al. The occurrence of panic and obsessive compulsive symptoms in women with postpartum dysphoria: A prospective study. Archives of Women's Mental Health 2001; 4:5.<br>2. Uguz, F, Akman, C, Kaya, N, Cilli, AS. Postpartum-onset obsessive-compulsive disorder: incidence, clinical features, and related factors. J Clin Psychiatry 2007; 68:132.<br>3. Wisner, KL, Peindl, KS, Gigliotti, T, Hanusa, BH. Obsessions and compulsions in women with postpartum depression. J Clin Psychiatry 1999; 60:176.<br>4. Labad, J, Menchon, JM, Alonso, P, et al. Female reproductive cycle and obsessive-compulsive disorder. J Clin Psychiatry 2005; 66:428.<br>5. Brockington, IF, Macdonald, E, Wainscott, G. Anxiety, obsessions and morbid preoccupations in pregnancy and the puerperium. Arch Womens Ment Health 2006; 9:253.<br>6. Sichel, DA, Cohen, LS, Dimmock, JA, Rosenbaum, JF. Postpartum obsessive compulsive disorder: a case series. J Clin Psychiatry 1993; 54:156.<br>7. Jennings, KD, Ross, S, Popper, S, Elmore, M. Thoughts of harming infants in depressed and nondepressed mothers. J Affect Disord 1999; 54:21.<br>8. Abramowitz, JS, et al. The cognitive mediation of obsessive-compulsive symptoms: a longitudinal study. J Anxiety Disord 2007; 21:91.<br>9. Buttolph, M. Obsessive-compulsive disorders in pregnancy and childbirth, in Obsessive Compulsive Disorders, Theory and Management, 2nd Ed, Jenike, M, Baer, L, Minichiello, WE (Eds), Yearbook Medical Publishers, Chicago 1990.<br>10. Sichel, DA, Cohen, LS, Rosenbaum, JF, Driscoll, J. Postpartum onset of obsessive-compulsive disorder. Psychosomatics 1993; 34:277.</div><div id=\"graphicVersion\">Graphic 77826 Version 2.0</div></div></div>"},"77827":{"type":"graphic_table","displayName":"Evaluation of child IBD","title":"Evaluation of the child with suspected inflammatory bowel disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of the child with suspected inflammatory bowel disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History</td> </tr> <tr> <td class=\"indent1\">Abdominal pain, appetite</td> </tr> <tr> <td class=\"indent1\">Stool frequency, consistency, rectal bleeding, nocturnal diarrhea</td> </tr> <tr> <td class=\"indent1\">Family history: relatives with inflammatory bowel disease, familial growth patterns</td> </tr> <tr> <td class=\"indent1\">Previous growth data*</td> </tr> <tr> <td class=\"indent1\">School attendance and daily activity</td> </tr> <tr> <td class=\"indent1\">Psychosocial history, including impact upon daily life of patient and parent(s)</td> </tr> <tr> <td class=\"subtitle1_single\">Physical examination</td> </tr> <tr> <td class=\"indent1\">Height and weight, evaluating for trends and growth velocity*</td> </tr> <tr> <td class=\"indent1\">Abdominal examination: tenderness, mass</td> </tr> <tr> <td class=\"indent1\">Rectal examination: evaluate for perianal disease and occult blood</td> </tr> <tr> <td class=\"indent1\">Rash, arthritis, clubbing, oral lesions</td> </tr> <tr> <td class=\"indent1\">Sexual maturity staging (Tanner stage)*</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory tests</td> </tr> <tr> <td class=\"indent1\">CBC with differential count, platelets, ESR, C-reactive protein</td> </tr> <tr> <td class=\"indent1\">Serum total protein, albumin</td> </tr> <tr> <td class=\"indent1\">ALT, AST, GGTP (to assess for hepatobiliary disease, including primary sclerosing cholangitis)</td> </tr> <tr> <td class=\"indent1\">Stool guaiac (hemoccult), leukocytes, calprotectin; urine analysis</td> </tr> <tr> <td class=\"indent1\">Stool bacterial culture, smears for ova and parasite, C. difficile toxin assay</td> </tr> <tr> <td class=\"indent1\">Tuberculosis screening (tuberculin skin test)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Titers for varicella and measles; HBV serologies<sup>&#916;</sup>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Additional tests as indicated, depending upon clinical findings: <ul class=\"decimal_heading\"> <li>To further characterize the type of inflammatory bowel disease: P-ANCA, ASCA<sup>&#9674; </sup></li> <li>To investigate other causes of diarrhea: lactose/glucose hydrogen breath test for lactose intolerance/bacterial overgrowth, 72-hour fecal fat quantitation, and stool alpha-1-antitrypsin </li> <li>If poor nutrition is suspected: serum iron, calcium, magnesium, folate, vitamins A, E, B12, and zinc* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Radiographic studies</td> </tr> <tr> <td class=\"indent1\">For localization of small bowel disease, one of the following:<sup>&#167; </sup> <ul class=\"decimal_heading\"> <li>MRE</li> <li>UGI/SBFT </li> <li>Abdominal CT with oral contrast </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Additional tests as indicated, depending upon clinical findings: bone age*, abdominal plain films, fistulogram, ultrasound or HMPAO-labeled white blood cell scan</td> </tr> <tr> <td class=\"subtitle1_single\">Endoscopic studies</td> </tr> <tr> <td class=\"indent1\">Colonoscopy (including ileoscopy) with biopsies</td> </tr> <tr> <td class=\"indent1\">Upper endoscopy with biopsies</td> </tr> <tr> <td class=\"indent1\">Additional procedures as indicated: <ul class=\"decimal_heading\"> <li>Video capsule endoscopy if more information on small bowel involvement is needed </li> <li>MRCP or ERCP if sclerosing cholangitis is suspected </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; ESR: erythrocyte sedimentation rate; ALT: alanine aminotransferase; AST: aspartate aminotransferase;&nbsp;GGTP: gamma glutaryl transpeptidase; C. difficile: clostridium difficile; HBV: hepatitis B virus; P-ANCA: perinuclear antineutrophil cytoplasmic antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies; MRE: magnetic resonance enterography; UGI/SBFT: upper&nbsp;gastrointestinal series with small bowel follow-through; CT: computerized tomography; HMPAO: hexamethylpropyleneamine oxime; MRCP: magnetic resonance cholangiopancreatography; ERCP: endoscopic retrograde cholangiopancreatography.<br />* For a more detailed discussion of nutritional issues, refer to UpToDate topic review on growth failure in children with inflammatory bowel disease (IBD).<br />Δ Before beginning treatment with immunosuppressing medications (especially infliximab and other tumor necrosis factor antibodies), patients should be tested for latent tuberculosis infection. In addition, immunization status should be carefully reviewed and brought up to date, including measurement of titers for varicella and measles, and HBV serologies. Live viral vaccines should not be given to patients with high-level immunosuppression. <br />◊ ASCA and P-ANCA have modest accuracy for distinguishing ulcerative colitis from Crohn disease. Additional testing for other antibodies such as anti-OmpC (outer membrane porin C) increases the sensitivity for IBD diagnosis and severity, but does not help to categorize children with indeterminate colitis.&nbsp;<br />§ For a discussion of the selection of imaging techniques, refer to the UpToDate topic on diagnosis of&nbsp;inflammatory bowel disease&nbsp;in children.</div><div class=\"graphic_reference\">Modified with permission from: Shashidhar H, Integlia MJ, Grand RJ. Clinical manifestations of pediatric inflammatory bowel disease. In: Inflammatory Bowel Disease, Kirsner JB (Ed), WB Saunders, Philadelphia 2000. Copyright &copy; 2000 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 77827 Version 9.0</div></div></div>"},"77828":{"type":"graphic_figure","displayName":"Pocketing","title":"Pocketing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pocketing</div><div class=\"cntnt\"><img style=\"width:432px; height:510px;\" src=\"images/PEDS/77828_Pocketing.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ends of the piercing jewelry are embedded into the skin, leaving the middle of the shank exposed, as depicted above.</div><div id=\"graphicVersion\">Graphic 77828 Version 3.0</div></div></div>"},"77829":{"type":"graphic_picture","displayName":"Phytophotodermatitis 1","title":"Phytophotodermatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phytophotodermatitis</div><div class=\"cntnt\"><img style=\"width:385px; height:432px;\" src=\"images/DERM/77829_Phytophotodermatitis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous linear streaks that subsequently became hyperpigmented occurred on the trunk of this 14-year-old male who was exposed to the sun after squeezing limes during a Carribean vacation.</div><div class=\"graphic_reference\">Copyright © Bernard Cohen, MD, Dermatlas; http://www.dermatlas.org.</div><div id=\"graphicVersion\">Graphic 77829 Version 6.0</div></div></div>"},"77830":{"type":"graphic_picture","displayName":"Mallet finger photo","title":"Mallet finger","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mallet finger</div><div class=\"cntnt\"><img style=\"width:432px; height:334px;\" src=\"images/EM/77830_Mallet_finger_photo.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 77830 Version 1.0</div></div></div>"},"77831":{"type":"graphic_figure","displayName":"Vertebral anterior wedge fracture","title":"Anterior wedge fracture of the cervical spine","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anterior wedge fracture of the cervical spine</div><div class=\"cntnt\"><img style=\"width:371px; height:441px;\" src=\"images/EM/77831_Verteb_ant_wedge_fx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77831 Version 4.0</div></div></div>"},"77832":{"type":"graphic_table","displayName":"Definitions of sensitivity, specificity, PPV, and NPV","title":"Definitions of sensitivity, specificity, and positive and negative predictive values","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Definitions of sensitivity, specificity, and positive and negative predictive values</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Disease present</td> <td class=\"subtitle1\">Disease absent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test positive</strong></td> <td class=\"centered\"><strong>A</strong></td> <td class=\"centered\"><strong>B</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Test negative</strong></td> <td class=\"centered\"><strong>C</strong></td> <td class=\"centered\"><strong>D</strong></td> </tr> <tr> <td colspan=\"3\">Sensitivity = A &#247; (A + C)</td> </tr> <tr> <td colspan=\"3\">Specificity = D &#247; (B + D)</td> </tr> <tr> <td colspan=\"3\">Positive predictive value = A &#247; (A + B)</td> </tr> <tr> <td colspan=\"3\">Negative predictive value = D &#247; (C + D)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77832 Version 3.0</div></div></div>"},"77833":{"type":"graphic_figure","displayName":"Exposing rectovaginal fistula","title":"Repair of a small rectovaginal fistula through a transvaginal approach","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Repair of a small rectovaginal fistula through a transvaginal approach</div><div class=\"cntnt\"><img style=\"width:340px; height:415px;\" src=\"images/OBGYN/77833_Exposing_rectovaginal_fistu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The surgeon places the nondominant index finger into the rectum to demonstrate the fistula.</div><div id=\"graphicVersion\">Graphic 77833 Version 1.0</div></div></div>"},"77834":{"type":"graphic_table","displayName":"Features of bleeding disorders","title":"Clinical manifestations of bleeding disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of bleeding disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Bleeding symptoms</td> <td class=\"subtitle1\" colspan=\"2\">Bleeding disorder</td> </tr> <tr> <td class=\"subtitle2\">Platelet defects (qualitative or quantitative)</td> <td class=\"subtitle2\">Clotting factor deficiencies (eg,&nbsp;factor VIII or factor IX deficiencies)</td> </tr> <tr> <td class=\"subtitle2_left\">Overview of bleeding events</td> <td class=\"subtitle2_left\"> <p>Mucocutaneous bleeding<br /> &nbsp;&nbsp;&nbsp; (oral cavity, nasal, gastrointestinal, and genitourinary sites)</p> </td> <td class=\"subtitle2_left\">Deep tissue bleeding<br /> &nbsp;&nbsp;&nbsp; (including joints and muscles)</td> </tr> <tr> <td class=\"indent1\">Excessive bleeding after minor cuts</td> <td>Yes</td> <td>Not usually</td> </tr> <tr> <td class=\"indent1\">Petechiae</td> <td>Common</td> <td>Uncommon</td> </tr> <tr> <td class=\"indent1\">Ecchymoses</td> <td>Generally small and superficial; may be significant, depending upon the defect or degree of thrombocytopenia</td> <td>May develop large subcutaneous and soft tissue hematomas</td> </tr> <tr> <td class=\"indent1\">Hemarthroses, muscle hematomas</td> <td>Uncommon</td> <td>Common in severe deficiency states or in association with injury in those with mild to moderate deficiency states</td> </tr> <tr> <td class=\"indent1\">Bleeding with invasive procedures, including surgery</td> <td>Often immediate, with degree of bleeding dependent upon the severity of the defect, ranging from none (eg, mild degrees of thrombocytopenia or mild platelet function defect) to mild to severe (eg, Glanzmann thrombasthenia)</td> <td>May be associated either with procedural bleeding or delayed bleeding, depending upon the type and severity of the defect</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77834 Version 10.0</div></div></div>"},"77837":{"type":"graphic_picture","displayName":"Hand splint","title":"Hand splint","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hand splint</div><div class=\"cntnt\"><img style=\"width:360px; height:540px;\" src=\"images/SURG/77837_Hand_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Splint immobilization of an infected hand protects the affected area, limits opening of tissue planes restricting the spread of infection, and decreases pain. Splinting in a position of function can help protect against flexion contractures, reduce stiffness, and hasten rehabilitation. This illustrates a volar splint used to maintain the hand in a functional position.</div><div id=\"graphicVersion\">Graphic 77837 Version 2.0</div></div></div>"},"77838":{"type":"graphic_table","displayName":"BARC definition for bleeding","title":"Bleeding Academic Research Consortium definition for bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bleeding Academic Research Consortium definition for bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Type 0</td> </tr> <tr> <td class=\"indent1\">No bleeding</td> </tr> <tr> <td class=\"subtitle1_single\">Type 1</td> </tr> <tr> <td class=\"indent1\">Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization, or treatment by a health care professional; may include episodes leading to self-discontinuation of medical therapy by the patient without consulting a health care professional</td> </tr> <tr> <td class=\"subtitle1_single\">Type 2</td> </tr> <tr> <td class=\"indent1\">Any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, or 5 but does meet at least one of the following criteria: (1) requiring nonsurgical, medical intervention by a health care professional, (2) leading to hospitalization or increased level of care, or (3) prompting evaluation</td> </tr> <tr> <td class=\"subtitle1_single\">Type 3</td> </tr> <tr> <td class=\"subtitle2_single\">Type 3a</td> </tr> <tr> <td class=\"indent1\">Overt bleeding plus hemoglobin drop of 3 to &#60;5 g/dL* (provided hemoglobin drop is related to bleed)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Any transfusion with overt bleeding</td> </tr> <tr> <td class=\"subtitle2_single\">Type 3b</td> </tr> <tr> <td class=\"indent1\">Overt bleeding plus hemoglobin drop &#8805;5 g/dL* (provided hemoglobin drop is related to bleed)</td> </tr> <tr> <td class=\"indent1\">Cardiac tamponade</td> </tr> <tr> <td class=\"indent1\">Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bleeding requiring intravenous vasoactive agents</td> </tr> <tr> <td class=\"subtitle2_single\">Type 3c</td> </tr> <tr> <td class=\"indent1\">Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal)</td> </tr> <tr> <td class=\"indent1\">Subcategories confirmed by autopsy or imaging or lumbar puncture</td> </tr> <tr> <td class=\"indent1\">Intraocular bleed compromising vision</td> </tr> <tr> <td class=\"subtitle1_single\">Type 4: CABG-related bleeding</td> </tr> <tr> <td class=\"indent1\">Perioperative intracranial bleeding within 48 hours</td> </tr> <tr> <td class=\"indent1\">Reoperation after closure of sternotomy for the purpose of controlling bleeding</td> </tr> <tr> <td class=\"indent1\">Transfusion of &#8805;5&nbsp;units whole blood or packed red blood cells within a 48-hour period<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Chest tube output &#8805;2 L within a 24-hour period</td> </tr> <tr> <td class=\"subtitle1_single\">Type 5: Fatal bleeding</td> </tr> <tr> <td class=\"subtitle2_single\">Type 5a</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious</td> </tr> <tr> <td class=\"subtitle2_single\">Type 5b</td> </tr> <tr> <td class=\"indent1\">Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">CABG indicates coronary artery bypass graft. Platelet tranfusions should be recorded and reported but are not included in these definitions until further information is obtatined about the relationship to oucomes. If a CABG-related bleed is not adjudicated as at least a type 3 severity event, it will be classified as not a bleeding event. If a bleeding event occurs with a clear temporal relationship to CABG (ie, within a 48-h time frame) but does not meet type 4 severity criteria, it will be classified as not a bleeding event.</div><div class=\"graphic_footnotes\">CABG: coronary artery bypass graft.<br />* Corrected for transfusion (1 U packed red blood cells or 1 U whole blood = 1 g/dL hemoglobin).<br />¶ Cell saver products are not counted.</div><div class=\"graphic_reference\">Reproduced with permission from: Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123:2736. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77838 Version 7.0</div></div></div>"},"77839":{"type":"graphic_diagnosticimage","displayName":"Radiation field stage II HL","title":"Involved-field radiation for a patient with stage II Hodgkin lymphoma","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Involved-field radiation for a patient with stage II Hodgkin lymphoma</div><div class=\"cntnt\"><img style=\"width:503px; height:253px;\" src=\"images/HEME/77839_RadiatfieldstgIIHL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with stage II Hodgkin lymphoma extensively involving the right neck and with a solitary node in the left neck. The gross tumor volume (PET + disease) is displayed in red; the clinical treated volume (involved lymph node regions) is displayed in green.</div><div class=\"graphic_footnotes\">PET: positron emission tomography. </div><div class=\"graphic_reference\">Reproduced with permission from: Yahalom J, Hoppe RT, Mauch PM. Principles and Techniques of Radiation Therapy for Hodgkin Lymphoma. In: Hodgkin Lymphoma, 2nd ed, Hoppe RT, Mauch PT, Armitage JO, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 77839 Version 8.0</div></div></div>"},"77841":{"type":"graphic_table","displayName":"Therapeutic levels common drugs","title":"Commonly available serum quantitative levels","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Commonly available serum quantitative levels</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Drug or toxin</td> <td class=\"subtitle1\">Toxic level</td> </tr> <tr> <td>Acetaminophen</td> <td>&#62;150 mg/L&nbsp;at 4 hours (if later, plot on nomogram)</td> </tr> <tr> <td>Salicylate</td> <td>&#62;30 mg/dL or 300 mg/L</td> </tr> <tr> <td>Theophylline</td> <td>&#62;20 mcmol/L</td> </tr> <tr> <td>Phenobarbital</td> <td>&#62;50 mg/L</td> </tr> <tr> <td>Carbamazepine</td> <td>&#62;12 mg/L</td> </tr> <tr> <td>Phenytoin</td> <td>&#62;20 mg/L</td> </tr> <tr> <td>Valproic acid</td> <td>&#62;150 mg/L</td> </tr> <tr> <td>Digoxin</td> <td>&#62;2.0 ng/L (distribution takes approx. 6 hours)</td> </tr> <tr> <td>Ethanol</td> <td>&#62;100 mg/dL</td> </tr> <tr> <td>Ethylene glycol</td> <td>&#62;20 mg/dL</td> </tr> <tr> <td>Methanol</td> <td>&#62;20 mg/dL</td> </tr> <tr> <td>Carboxyhemoglobin</td> <td>&#62;10 percent</td> </tr> <tr> <td>Methemoglobin</td> <td>&#62;15 percent</td> </tr> <tr> <td>Lithium</td> <td>&#62;2.0 meq/L</td> </tr> <tr> <td>Iron</td> <td>&#62;500 mcg/dL</td> </tr> <tr> <td>Lead</td> <td>&#62;25 mg/dL</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77841 Version 2.0</div></div></div>"},"77842":{"type":"graphic_table","displayName":"High vs low voltage injury","title":"Comparison among lightning, high-voltage, and low-voltage electrical injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison among lightning, high-voltage, and low-voltage electrical injuries</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Lightning</td>\n\n      <td class=\"subtitle1\">High voltage</td>\n\n      <td class=\"subtitle1\">Low voltage</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Voltage, V</td>\n\n      <td>&#62;30 x 10 6</td>\n\n      <td>&#62;1,000</td>\n\n      <td>&#60;600</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Current,\nA</td>\n\n      <td>&#62;200,000</td>\n\n      <td>&#60;1,000</td>\n\n      <td>&#60;240</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Duration</td>\n\n      <td>Instantaneous</td>\n\n      <td>Brief</td>\n\n      <td>Prolonged</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Type of current </td>\n\n      <td>DC</td>\n\n      <td>DC or AC</td>\n\n      <td>Mostly AC</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Cardiac arrest</td>\n\n      <td>Asystole</td>\n\n      <td>Ventricular fibrillation</td>\n\n      <td>Ventricular fibrillation</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Respiratory arrest</td>\n\n      <td>Direct CNS injury</td>\n\n      <td>Indirect trauma or tetanic contraction of respiratory\nmuscles</td>\n\n      <td>Tetanic contractions of respiratory muscles</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Muscles\ncontraction</td>\n\n      <td>Single</td>\n\n      <td>Single (DC); Tetanic (AC)</td>\n\n      <td>Tetanic</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Burns</td>\n\n      <td>Rare, superficial</td>\n\n      <td>Common, deep</td>\n\n      <td>Usually superficial</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Rhabdomyolysis</td>\n\n      <td>Uncommon</td>\n\n      <td>Very common</td>\n\n      <td>Common</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Blunt injury (cause)</td>\n\n      <td>Blast effect (shock wave)</td>\n\n      <td>Fall (muscle contraction)</td>\n\n      <td>Fall (uncommon)</td>\n\n    </tr>\n\n    <tr>\n\n      <td>Acute mortality</td>\n\n      <td>Very high</td>\n\n      <td>Moderate</td>\n\n      <td> Low</td>\n\n    </tr>\n\n\n  </tbody>\n</table></div><div class=\"graphic_footnotes\">DC: direct current; AC: alternating current; CNS: central nervous system.</div><div class=\"graphic_reference\">Reproduced with permission from: Koumbourlis, AC. Electrical injuries. Crit Care Med 2002; 30:S425. Copyright &#169; 2002 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 77842 Version 1.0</div></div></div>"},"77845":{"type":"graphic_picture","displayName":"TTO2 patient photo","title":"TTO2 patient photo","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">TTO2 patient photo</div><div class=\"cntnt\"><img style=\"width:360px; height:273px;\" src=\"images/PULM/77845_TTO2_patient_photo.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77845 Version 2.0</div></div></div>"},"77846":{"type":"graphic_picture","displayName":"Burkhalter-type splint for metacarpal fractures","title":"Burkhalter-type splint for metacarpal fractures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Burkhalter-type splint for metacarpal fractures</div><div class=\"cntnt\"><img style=\"width:360px; height:270px;\" src=\"images/EM/77846_Burkhalter_splint_for_MC_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plaster splint applied with 30 degrees extension at wrist, 90 degrees flexion of&nbsp;MCP joints. On the volar aspect, the splint material extends to the MCP joint; dorsally, the material extends to the PIP joints&nbsp;to block extension.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal; PIP: proximal interphalangeal.</div><div class=\"graphic_reference\">Courtesy of Kevin Burroughs, MD.</div><div id=\"graphicVersion\">Graphic 77846 Version 5.0</div></div></div>"},"77847":{"type":"graphic_table","displayName":"Methods to improve compliance","title":"General guidelines to improve patient adherence to antihypertensive therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General guidelines to improve patient adherence to antihypertensive therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\"> <p>Be aware of the problem and be alert to signs of patient nonadherence including missed appointments and no or minimal response to antihypertensive medications.</p> Recognize that lifestyle patterns and habits such as high-salt diets or excessive alcohol use can blunt antihypertensive responses.</td> </tr> <tr class=\"divider_bottom\"> <td style=\"font-size:1.2em;\"><strong>Establish the goal of therapy: To achieve goal blood pressure with minimal or no side effects</strong></td> </tr> <tr> <td style=\"font-size:1.2em;\"><strong>Educate the patient about the disease and its treatment</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Involve the patient in decision-making on medications and lifestyle changes. </li> <li>Encourage family support. </li> </ul> </td> </tr> <tr> <td style=\"font-size:1.2em;\"><strong>Maintain contact with the patient</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Encourage visits and telephone calls or electronic communications to allied health personnel. </li> <li>Engage the pharmacist in monitoring the response to and adherence with therapy. </li> <li>Give feedback to the patient on home blood pressure readings during office visits and between office visits, especially in patients with uncontrolled hypertension. </li> <li>Ask about adherence in a nonjudgmental manner and explore if any medication doses are missed. </li> <li>Acknowledge that medications can be expensive and have unwanted side effects. </li> <li>Make contact with patients who do not return for scheduled appointments. </li> </ul> </td> </tr> <tr> <td style=\"font-size:1.2em;\"><strong>Keep care inexpensive and simple</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Do the least workup needed to rule out secondary causes. </li> <li>Obtain follow-up laboratory data only yearly unless indicated more often. </li> <li>Use home blood pressure readings. </li> <li>Use nondrug, no-cost therapies. </li> <li>Use the fewest daily doses of drugs needed; use single-pill combinations when possible and work with a pharmacy that consolidates refills for patients taking multiple prescription medications. </li> <li>Tailor medication to daily routines. </li> <li>Use generic drugs. </li> <li>Ask the patient to provide list of preferred drugs from insurance. </li> <li>Have a pharmacist suggest low-cost alternatives.* </li> <li>Use pill box(es), blister-packaging, or electronic reminders (eg, smartphone app). </li> </ul> </td> </tr> <tr> <td style=\"font-size:1.2em;\"><strong>Prescribe according to pharmacologic principles</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Add one drug at a time, although it is sometimes appropriate to begin treatment with a single-pill combination. </li> <li>Use longer-acting drugs with less peak-trough blood pressure-lowering variation. </li> <li>Use moderately dosed combinations to minimize side effects (eg, ACE inhibitor&nbsp;or ARB with low-dose diuretic and/or amlodipine). </li> </ul> </td> </tr> <tr> <td style=\"font-size:1.2em;\"><strong>Other</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Start with small doses, aiming for 5 to 10 mmHg reductions at each step. </li> <li>Have medication taken immediately upon awakening in the morning or after 4 am if patient awakens to void. </li> <li>Titrate gradually, particularly beta blockers. </li> <li>Be willing to stop unsuccessful therapy and try a different approach, especially in patients already taking multiple antihypertensive medications. </li> <li>Anticipate side effects. </li> <li>Adjust therapy to ameliorate side effects that do not spontaneously disappear. </li> <li>Continue to add effective and tolerated drugs, stepwise and in sufficient doses, to achieve the goal of therapy.<br /> Have a case manager, pharmacist, or nurse identify and suggest solutions to barriers to adherence. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE inhibitor: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.<br />* For a comprehensive list of cost-lowering strategies for patients, refer to UpToDate patient information topics on reducing the costs of medicines: Beyond the basics.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Morgado MP, Morgado SR, Mendes LC, et al. Pharmacist interventions to enhance blood pressure control and adherence to antihypertensive therapy: Review and meta-analysis. Am J Health Syst Pharm 2011; 68:241.</LI>&#xD;&#xA;<LI>Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012; 157:785.</LI></OL></div><div id=\"graphicVersion\">Graphic 77847 Version 8.0</div></div></div>"},"77848":{"type":"graphic_diagnosticimage","displayName":"Microcystic type3 CPAM","title":"Microcystic Type III CPAM at 24 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Microcystic Type III CPAM at 24 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:478px; height:428px;\" src=\"images/OBGYN/77848_Microcystic_type3_CPAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial (A) and coronal (B) ultrasounds demonstrate a solid appearing echogenic mass in the left lower lobe causing mild displacement of the heart to the right. Oblique (C) T2w magnetic resonance images confirm the finding of a high signal mass in the left lower lobe. No arterial feeder and no hydrops were seen.</div><div class=\"graphic_reference\">Courtesy of Dorothy I Bulas, MD.</div><div id=\"graphicVersion\">Graphic 77848 Version 3.0</div></div></div>"},"77850":{"type":"graphic_table","displayName":"2002 TNM staging stomach CA","title":"American Joint Committee on Cancer staging for gastric cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Joint Committee on Cancer staging for gastric cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Tumor (T) stage </td> </tr> <tr> <td>TX</td> <td colspan=\"3\">Primary tumor cannot be assessed </td> </tr> <tr> <td>T0</td> <td colspan=\"3\">No evidence of primary tumor </td> </tr> <tr> <td>T1s</td> <td colspan=\"3\">Carcinoma in situ: intraepithelial tumor without invasion of the lamina propia </td> </tr> <tr> <td>T1</td> <td colspan=\"3\">Tumor invades lamina propria or submucosa </td> </tr> <tr> <td class=\"sublist1_start\">T2 </td> <td class=\"sublist_other_start\" colspan=\"3\">Tumor invades muscularis propria or subserosa </td> </tr> <tr> <td class=\"sublist1\">T2a </td> <td class=\"sublist_other\" colspan=\"3\">Tumor invades muscularis propria </td> </tr> <tr> <td class=\"sublist1\">T2b </td> <td class=\"sublist_other\" colspan=\"3\">Tumor invades subserosa </td> </tr> <tr> <td>T3</td> <td colspan=\"3\">Tumor penetrates serosa (visceral peritoneum) without invasion of adjacent structures* </td> </tr> <tr> <td>T4</td> <td colspan=\"3\">Tumor invades adjacent structures* </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Nodal (N) stage </td> </tr> <tr> <td>NX</td> <td colspan=\"3\">Regional lymph node(s) cannot be assessed </td> </tr> <tr> <td>N0</td> <td colspan=\"3\">No regional lymph node metastasis </td> </tr> <tr> <td>N1</td> <td colspan=\"3\">Metastasis in 1 to 6 regional lymph nodes </td> </tr> <tr> <td>N2</td> <td colspan=\"3\">Metastasis in 7 to 15 regional lymph nodes </td> </tr> <tr> <td>N3</td> <td colspan=\"3\">Metastasis in more than 15 regional lymph nodes </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Metastasis (M) stage </td> </tr> <tr> <td>Mx</td> <td colspan=\"3\">Presence of distant metastasis cannot be assessed </td> </tr> <tr> <td>M0</td> <td colspan=\"3\">No distant metastasis </td> </tr> <tr> <td>M1</td> <td colspan=\"3\">Distant metastasis </td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Stage grouping </td> </tr> <tr> <td>Stage 0</td> <td>Tis</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage 1A</td> <td>T1</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"2\">Stage 1B </td> <td>T1</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T2a/b</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage II </td> <td>T1</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T2a/b</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N0</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IIIA </td> <td>T2a/b</td> <td>N2</td> <td>M0</td> </tr> <tr> <td>T3</td> <td>N1</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N0</td> <td>M0</td> </tr> <tr> <td>Stage IIIB</td> <td>T3</td> <td>N2</td> <td>M0</td> </tr> <tr> <td rowspan=\"3\">Stage IV </td> <td>T1-3</td> <td>N3</td> <td>M0</td> </tr> <tr> <td>T4</td> <td>N1-3</td> <td>M0</td> </tr> <tr> <td>Any T</td> <td>Any N</td> <td>M1</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The adjacent structures of the stomach include the spleen, transverse colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, kidney, small intestine, and retroperitoneum. Intramural extension to the duodenum or esophagus is classified by the depth of the greatest invasion in any of these sites, including the stomach.</div><div class=\"graphic_reference\">Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) published by Springer-Verlag New York, Inc.</div><div id=\"graphicVersion\">Graphic 77850 Version 2.0</div></div></div>"},"77852":{"type":"graphic_algorithm","displayName":"Tyrosine degradation","title":"Tyrosine degradation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tyrosine degradation</div><div class=\"cntnt\"><img style=\"width:372px; height:388px;\" src=\"images/PEDS/77852_Tyrosine_degradation.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><span class=blue>(1)</span> Tyrosinemia type II - corneal ulcers, hyperkeratosis, occasional mental retardation<br><span class=blue>(2)</span> Tyrosinemia type III - possible mental retardation<br><span class=blue>(3)</span> Alkaptonuria - ochronosis, black urine<br><span class=blue>(4)</span> Maleylacetoacetate isomerase deficiency - phenotype?<br><span class=blue>(5)</span> Tyrosinemia type I - liver failure, renal damage</div><div class=\"graphic_footnotes\">TAT: tyrosine aminotransferase; 4-OHPPD: 4-hydroxy phenylpyruvate dioxygenase; HGD: homogentisic acid dioxygenase; MAI: maleylacetoacetate isomerase; FAH: fumarylacetoacetate hydrolase.</div><div class=\"graphic_reference\">Courtesy of Markus Grompe, MD.</div><div id=\"graphicVersion\">Graphic 77852 Version 4.0</div></div></div>"},"77853":{"type":"graphic_picture","displayName":"Slit lamp beam height","title":"Slit lamp beam height","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Slit lamp beam height</div><div class=\"cntnt\"><img style=\"width:360px; height:480px;\" src=\"images/EM/77853_Slit_lamp_beam_height.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adjust slit lamp beam for a tall, narrow vertical beam of white light.</div><div id=\"graphicVersion\">Graphic 77853 Version 2.0</div></div></div>"},"77854":{"type":"graphic_table","displayName":"Features hypothalamic obesity","title":"Clinical features of hypothalamic obesity due to tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of hypothalamic obesity due to tumors</div><div class=\"cntnt\"><table cellspacing=\"0\">\n\n  <tbody>\n\n\n    <tr>\n\n      <td class=\"subtitle1\">&nbsp;</td>\n\n      <td class=\"subtitle1\">Number</td>\n\n      <td class=\"subtitle1\">Percent</td>\n\n    </tr>\n\n    <tr>\n\n      <td class=\"subtitle2_left\">Total patients studied</td>\n\n      <td>77</td>\n\n      <td>&nbsp;</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">Pressure symptoms</td>\n      \n      \n    </tr>\n    <tr>\n\n      <td class=\"indent1\">Headache</td>\n\n      <td>50</td>\n\n      <td>65</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1\">Impaired vision</td>\n      <td>49</td>\n      <td>64</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Endocrine symptoms</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Impaired reproductive function</td>\n\n      <td>39</td>\n\n      <td>52</td>\n\n    </tr>\n\n    <tr>\n      <td class=\"indent1\">Diabetes insipidus</td>\n      <td>24</td>\n      <td>31</td>\n    </tr>\n    <tr>\n      <td class=\"indent1\">Impaired growth</td>\n      <td>7</td>\n      <td>9</td>\n    </tr>\n    <tr>\n\n      <td colspan=\"3\" rowspan=\"1\" class=\"subtitle2_left\">Neurologic and physiologic symptoms</td>\n\n      \n\n      \n\n    </tr>\n\n    <tr>\n\n      <td class=\"indent1\">Convulsions</td>\n\n      <td>5</td>\n\n      <td>6</td>\n\n    </tr>\n    <tr>\n      <td class=\"indent1\">Somnolence</td>\n      <td>28</td>\n      <td>36 </td>\n    </tr>\n    <tr>\n      <td class=\"indent1\">Behavioral changes</td>\n      <td>15</td>\n      <td>19</td>\n    </tr>\n\n  </tbody>\n</table>\n\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">4.00000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=14766&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Features_hypothalamic_obesi.htm</title></head></div><div class=\"graphic_reference\">Adapted from: Bray GA, Gallagher TF. Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine 1975; 54:301.</div><div id=\"graphicVersion\">Graphic 77854 Version 2.0</div></div></div>"},"77855":{"type":"graphic_table","displayName":"Monitoring pheo and PHPT in RET mutation carriers","title":"Clinical monitoring for pheochromocytoma and hyperparathyroidism in carriers of a mutation in the <EM>RET </EM>gene","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical monitoring for pheochromocytoma and hyperparathyroidism in carriers of a mutation in the <EM>RET </EM>gene</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"3\">&nbsp;</td> <td class=\"subtitle1_single\">Pheochromocytoma*</td> <td class=\"subtitle1_single\">Hyperparathyroidism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Risk</td> <td class=\"subtitle2_left\"><em>RET </em>codon mutation</td> <td class=\"subtitle2_left\">Recommended age&nbsp;to begin annual&nbsp;screening for pheochromocytoma<sup>&#182;</sup></td> <td class=\"subtitle2_left\">Recommended age&nbsp;to begin annual&nbsp;screening for hyperparathyroidism<sup>&#916;</sup></td> </tr> <tr> <td colspan=\"2\">Highest</td> <td>918</td> <td>11 years</td> <td>Not applicable</td> </tr> <tr> <td colspan=\"2\">High</td> <td>634, 883</td> <td>11 years</td> <td>11 years</td> </tr> <tr> <td colspan=\"2\">Moderate</td> <td>533, 609, 611, 618, 620, 630, 666, 768, 790, 804, 891, 912</td> <td>16 years</td> <td>16 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEN2: multiple endocrine neoplasia type 2; MTC: medullary thyroid cancer; CT: computed tomography; MRI: magnetic resonance imaging; PTH: parathyroid hormone.<br />* Patients with MEN2 and a diagnosis of MTC (regardless of age) must have pheochromocytoma excluded prior to thyroidectomy.<br />¶ Screening test: free plasma metanephrines or normetanephrines, or 24-hour urinary metanephrines and normetanephrines. If biochemical results positive, adrenal imaging with CT or MRI.<br />Δ Screening test: serum calcium and, if elevated, PTH.</div><div class=\"graphic_reference\">Data from: Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.</div><div id=\"graphicVersion\">Graphic 77855 Version 7.0</div></div></div>"},"77856":{"type":"graphic_figure","displayName":"GI peptide regulation of cell function","title":"Mechanisms by which gastrointestinal peptides regulate and influence cell function","html":"<div class=\"graphic\"><div style=\"width: 759px\" class=\"figure\"><div class=\"ttl\">Mechanisms by which gastrointestinal peptides regulate and influence cell function</div><div class=\"cntnt\"><img style=\"width:739px; height:531px;\" src=\"images/GAST/77856_GI_pptd_cll_fnct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Bohorquez DV, Liddle RA. Gastrointestinal Hormones and Neurotransmitters. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 10th ed, Feldman M, Friedman LS, Brandt LJ (Eds), Saunders, Philadelphia 1998. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77856 Version 2.0</div></div></div>"},"77857":{"type":"graphic_figure","displayName":"Hymenectomy","title":"Hymenectomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Hymenectomy</div><div class=\"cntnt\"><img style=\"width:538px; height:333px;\" src=\"images/OBGYN/77857_Hymenectomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77857 Version 2.0</div></div></div>"},"77858":{"type":"graphic_algorithm","displayName":"Joint drainage bacterial arthritis","title":"Approach to joint drainage for management of nongonococcal bacterial arthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Approach to joint drainage for management of nongonococcal bacterial arthritis</div><div class=\"cntnt\"><img style=\"width:328px; height:238px;\" src=\"images/RHEUM/77858_Rxbctrlarthrts.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77858 Version 6.0</div></div></div>"},"77859":{"type":"graphic_picture","displayName":"Lap hernia still B","title":"Lap hernia still B","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lap hernia still B</div><div class=\"cntnt\"><img style=\"width:416px; height:332px;\" src=\"images/SURG/77859_Lap_hernia_still_B.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77859 Version 3.0</div></div></div>"},"77861":{"type":"graphic_picture","displayName":"Infected bulla","title":"Infected bulla in paraseptal emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Infected bulla in paraseptal emphysema</div><div class=\"cntnt\"><img style=\"width:396px; height:331px;\" src=\"images/PULM/77861_Infected_bulla_final.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left upper lobe cavity with a moderately thick wall, representing an infected bulla in a patient with marked paraseptal emphysema.</div><div id=\"graphicVersion\">Graphic 77861 Version 3.0</div></div></div>"},"77862":{"type":"graphic_picture","displayName":"Acne sinus tract","title":"Acne sinus tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Acne sinus tract</div><div class=\"cntnt\"><img style=\"width:318px; height:351px;\" src=\"images/DERM/77862_Acne_sinus_tract.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple sinus tracts in an adolescent male with severe nodular acne.</div><div id=\"graphicVersion\">Graphic 77862 Version 1.0</div></div></div>"},"77863":{"type":"graphic_picture","displayName":"Angioid streaks","title":"Angioid streaks","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Angioid streaks</div><div class=\"cntnt\"><img style=\"width:432px; height:338px;\" src=\"images/DERM/77863_Angioid_streaks.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical angioid streaks in fundus of patient with pseudoxanthoma elasticum.</div><div class=\"graphic_reference\">Reproduced with permission from: Gold, DH, Weingeist, TA. Color Atlas of the Eye in Systemic Disease. Lippincott Williams &amp; Wilkins, Baltimore 2001. Copyright &#169; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77863 Version 1.0</div></div></div>"},"77865":{"type":"graphic_table","displayName":"Common cold treatments in pregnancy 4","title":"Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Agents used to treat the common cold and its symptoms, their efficacy and their safety in pregnancy, continued</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Effect in randomly controlled trial<br /> (not pregnant)</td> <td class=\"subtitle1\">Pregnancy data</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Decongestants</td> </tr> <tr> <td class=\"indent1\"> <p>Intranasal:</p> <p>Oxymetazoline</p> <p>Xylometazoline</p> Pheniramine</td> <td rowspan=\"2\"> <p>Short-lived mild relief of obstruction with single use. No evidence of sustained effects.</p> <p>Spray decongestants associated with rebound effects upon withdrawal.</p> </td> <td rowspan=\"2\"> <p>Most commonly used decongestants are in need of further study before they can be definitively considered safe in pregnancy. Present data is variable but these agents probably represent a low risk.</p> <p>Oxymetazoline is the preferred intranasal agent, but use for mild symptoms should be discouraged in pregnancy. No clear human teratogenic effect and no effect on uterine blood flow in the setting of normal nasal mucosa but concerns exist about its possible effects on uterine blood flow in the setting of overuse, inflamed nasal mucosa and in cases were poor placental perfusion is already suspected.</p> <p>Pseudoephedrine should be avoided in the first trimester. Two studies have suggested an increased risk of gastroschisis. Later in pregnancy, it is probably the preferred oral agent among the oral decongestants. This agent is less likely to raise blood pressure than the other oral decongestants.</p> <p>Ephedrine is teratogenic in chicks even at small doses. There is no evidence of human teratogenesis, but data are limited.</p> Phenylephrine has been associated with a wide range of congenital anomalies in humans and dramatic effects on uterine blood flow in sheep. This agent should be avoided at all stages of pregnancy. The uterine vessels are maximally dilated and have only alpha-adrenergic receptors. The alpha-adrenergic stimulant phenylephrine will cause constriction of these vessels, resulting in reduced uterine blood flow, fetal hypoxia, and subsequent bradycardia.</td> </tr> <tr> <td class=\"indent1\"> <p>Oral:</p> <p>Pseudoephedrine</p> <p>Ephedrine</p> Phenylephrine</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77865 Version 8.0</div></div></div>"},"77867":{"type":"graphic_waveform","displayName":"Atrioventricular reentrant tachycardia","title":"Atrioventricular reentrant tachycardia","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Atrioventricular reentrant tachycardia</div><div class=\"cntnt\"><img style=\"width:467px; height:106px;\" src=\"images/PEDS/77867_AVreentranttachycardia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrioventricular reentrant tachycardia breaking to sinus rhythm with Wolff-Parkinson-White syndrome.</div><div id=\"graphicVersion\">Graphic 77867 Version 3.0</div></div></div>"},"77869":{"type":"graphic_diagnosticimage","displayName":"Chondrocalcinosis in HH","title":"Knee chondrocalcinosis in hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee chondrocalcinosis in hemochromatosis</div><div class=\"cntnt\"><img style=\"width:396px; height:213px;\" src=\"images/RHEUM/77869_Chondrocalcinosis_in_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serial knee radiographs, separated by 11 years, from a patient with hereditary hemochromatosis. During this time there has been progressive chondrocalcinosis without the development of either joint space narrowing or secondary degenerative arthritis.</div><div class=\"graphic_reference\">Courtesy of John S Axford, BSc, MD, FRCP.</div><div id=\"graphicVersion\">Graphic 77869 Version 2.0</div></div></div>"},"77870":{"type":"graphic_diagnosticimage","displayName":"Cavernous hemangioma MRI","title":"Cavernous hepatic hemangioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cavernous hepatic hemangioma</div><div class=\"cntnt\"><img style=\"width:319px; height:320px;\" src=\"images/GAST/77870_Cavernous_hemangioma_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance (MR)&nbsp;imaging of a cavernous hemangioma in an asymptomatic 52-year-old man. Panel A: Heavily T2-weighted MR image shows the masses (arrows) as very high signal intensity. Panels B-D: Dynamic T1-weighted gradient-echo MR images before (B), during the arterial-phase of gadolinium chelate-enhancement (C), and during the portal phase of enhancement (D) show initial nodular peripheral enhancement (arrowheads) that starts to fill in the hemangiomas (arrows).</div><div class=\"graphic_reference\">Courtesy of Eric Outwater, MD.</div><div id=\"graphicVersion\">Graphic 77870 Version 4.0</div></div></div>"},"77871":{"type":"graphic_table","displayName":"Relative risk complication","title":"Relative risk of complication using tacrolimus versus cyclosporine after liver transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Relative risk of complication using tacrolimus versus cyclosporine after liver transplantation</div><div class=\"cntnt\"><table  cellspacing=\"0\">\n   <tr>\n   <td  class=\"subtitle1\">\n   Parameter - tacrolimus versus cyclosporine\n   </td>\n   <td  class=\"subtitle1\">\n   RR\n   </td>\n   <td  class=\"subtitle1\">\n   95% CI\n   </td>\n   </tr>\n   <tr>\n   <td>One-year mortality</td>\n   <td>0.85</td>\n   <td>0.73-0.99</td>\n   </tr>\n   <tr>\n   <td>One-year graft loss</td>\n   <td>0.73</td>\n   <td>0.61-0.86</td>\n   </tr>\n   <tr>\n   <td>Acute rejection</td>\n   <td>0.81</td>\n   <td>0.75-0.88</td>\n   </tr>\n   <tr>\n   <td>Steroid-resistant rejection</td>\n   <td>0.54</td>\n   <td>0.47-0.74</td>\n   </tr>\n   <tr>\n   <td>Likely to change to another agent</td>\n   <td>0.57</td>\n   <td>0.49-0.66</td>\n   </tr>\n   <tr>\n   <td>De novo diabetes mellitus</td>\n   <td>1.38</td>\n   <td>1.01-1.86</td>\n   </tr>\n </table></div><div class=\"graphic_reference\">Data from: McAlister, VC, Haddad, E, Renouf, E, et al. Cyclosporine versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6:1578.</div><div id=\"graphicVersion\">Graphic 77871 Version 1.0</div></div></div>"},"77872":{"type":"graphic_table","displayName":"Prevalence of selected adverse reproductive outcomes in US","title":"Prevalence of selected adverse reproductive outcomes in the United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of selected adverse reproductive outcomes in the United States</div><div class=\"cntnt\"><table cellspacing=\"0\">\r\n \r\n <tr>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Outcome\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Percent\r\n \r\n </td>\r\n \r\n <td class=\"subtitle1\">\r\n \r\n Unit of measure\r\n \r\n </td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Infertility</td>\r\n \r\n <td>8-12</td>\r\n \r\n <td>Couples</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Recognized spontaneous abortion</td>\r\n \r\n <td>15-20</td>\r\n \r\n <td>Women or pregnancies</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Birth weight &#60;2500 g</td>\r\n \r\n <td>7-9</td>\r\n \r\n <td>Livebirths</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Preterm (&#8804;37 wks)</td>\r\n \r\n <td>11-13</td>\r\n \r\n <td>Livebirths</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Fetal death or stillbirth</td>\r\n \r\n <td>0.7-1</td>\r\n \r\n <td>Stillbirths and livebirths</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Infant death</td>\r\n \r\n <td>0.7</td>\r\n \r\n <td>Livebirths</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Birth defects (through 1 year of life)</td>\r\n \r\n <td>3</td>\r\n \r\n <td>Livebirths</td>\r\n \r\n </tr>\r\n \r\n <tr>\r\n \r\n <td>Chromosomal anomalies in livebirths</td>\r\n \r\n <td>0.2</td>\r\n \r\n <td>Livebirths</td>\r\n \r\n </tr>\r\n \r\n </table>\r\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\r\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\r\n<mso:Specialty msdt:dt=\"string\">19.0000000000000</mso:Specialty>\r\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\r\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=21630&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\r\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\r\n<title>Adverse_reproduct_outcomes.htm</title></head></div><div class=\"graphic_reference\">Modified from: Janssen S. Female reproductive toxicology. Current Occupational &amp; Environmental Medicine, 5th ed., Ladou J, Jarrison&nbsp;RJ (Eds),&nbsp;Lange Medical Books/ McGraw-Hill, New York 2014 and compiled from various sources.</div><div id=\"graphicVersion\">Graphic 77872 Version 3.0</div></div></div>"},"77874":{"type":"graphic_picture","displayName":"Pes planus","title":"Pes planus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pes planus</div><div class=\"cntnt\"><img style=\"width:394px; height:287px;\" src=\"images/RHEUM/77874_Pes_planus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examination for pes planus (flat feet) should be part of the evaluation of any patient with a rheumatologic complaint in the lower extremity. This condition is usually best viewed from the posterior. Eversion of the heels is also evident in this position.</div><div class=\"graphic_reference\">Reproduced with permission from Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.</div><div id=\"graphicVersion\">Graphic 77874 Version 2.0</div></div></div>"},"77875":{"type":"graphic_table","displayName":"Mushroom poisoning syndromes","title":"Mushroom poisoning syndromes: Symptoms, toxicity, and treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mushroom poisoning syndromes: Symptoms, toxicity, and treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"4\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" style=\"color: red;\" colspan=\"7\">We encourage consultation with a medical toxicologist for all patients with mushroom poisoning by calling the United States Poison Control Network at <span class=\"baec5a81-e4d6-4674-97f3-e9220f0136c1\" style=\"white-space: nowrap;\">1-800-222-1222<a href=\"#\" title=\"Call: 1-800-222-1222\"><img alt=\"\" title=\"Call: 1-800-222-1222\" style=\"overflow: hidden; cursor: hand; height: 16px; vertical-align: middle; white-space: nowrap; right: 0px; position: static !important; float: none; left: 0px; margin: 0px; display: inline; top: 0px; width: 16px; bottom: 0px;border: medium none;\" src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABAAAAAQCAYAAAAf8/9hAAABcklEQVR4XpXTPUvDUBTH4aR2c2hBQXGpTiIORhBcBOvgYKf0Awi+4Ggr1MVPIIrYdnEpShddHIyLi6AVXVxsRRDRwbi4KNgu4lCIv8i/i6QRDzycy+09555LqOl5nhEUptPoJe1iDHU8oYlrlDw79m4QEbSLPexzsIc8hDRm8YBjLpj4q8EgxQdab+MNd4ghhQ2adIc1+ORAFEnWWfTDRp7GDfImlsIavKALLuqoqMGUCs4wHtagiQ5uc8kDyCOBKlP1k78QNTOZnMXCQRxWsbjl6iuskV41SQG2Gj9rikvcR1WcgKFDBa1LOEUK56hqv8BUFV3SGWkVS9JQ6Dsv4wQ1DKMPORUvkm78BhdQMI1CTa5I0yrcwSFqFD+SZ7DQesIkCG5S/JpkHYERQRmuNsrZ7Grc+Ef8/Bcoslkfae8Wc7CUHZ++TuAEBj86pHntjaDKXllPy6PW/gkKFaThwp/K87N8hDcQTTKKFTioSxqB8Q2BNX5JtAljwgAAAABJRU5ErkJggg==\" /></a></span>, or accessing the World Health Organization's list of <a href=\"http://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" spellcheck=\"true\">international poison centers</a>. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1\">Mushroom poisoning syndrome</td> <td class=\"subtitle1\">Toxins</td> <td class=\"subtitle1\">Onset of symptoms</td> <td class=\"subtitle1\">Sites of toxicity</td> <td class=\"subtitle1\">Specific mushroom examples</td> <td class=\"subtitle1\">Treatment*</td> <td class=\"subtitle1\">Mortality</td> </tr> <tr class=\"divider_bottom\"> <td>Acute gastroenteritis without liver failure</td> <td>GI irritants</td> <td>&#60;6 hours (most within 3 hours)</td> <td>GI tract</td> <td> <p><em>Chlorophyllum molybdites</em></p> <p><em>Clitocybe nebularis</em></p> <em>Omphalates illudens</em></td> <td>Supportive care: IV fluid repletion as needed</td> <td>Mortality rare, symptoms typically resolve within 6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Hallucinogenic</td> <td>Psilocybin, psilocin</td> <td>30 minutes-2 hours</td> <td>CNS (hallucinogenic effects)</td> <td> <p><em>Psilocybe cubensis</em></p> <p><em>P. mexicana</em></p> <p><em>Conocybe cyanopus</em></p> <p><em>Gymnopilus aeruginosa</em></p> <em>Panaeolousfoenisecil</em></td> <td> <p>Benzodiazepines for agitation</p> Supportive care</td> <td>Mortality rare, symptoms typically resolve within 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>CNS excitation and depression (stupor, coma, delirium, agitation, hallucinations, and, in children, seizures)</td> <td>Ibotenic acid, muscimol</td> <td>30 minutes-2 hours</td> <td>CNS (depressant and excitatory effects)</td> <td> <p><em>Amanita muscaria</em></p> <p><em>A. pantherina</em></p> <em>A. gemmata</em></td> <td> <p>Benzodiazepines (eg, lorazepam 0.05 mg/kg, maximum dose 2-4 mg) for agitation</p> Supportive care</td> <td>Mortality rare, symptoms typically resolve within 6-24 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Cholinergic excess (vomiting, diarrhea, bradycardia, bronchorrhea, bronchospasm, salivation, tearing)</td> <td>Muscarine</td> <td>30 minutes-2 hours</td> <td>Autonomic nervous system (muscarinic receptors)</td> <td> <p><em>Clitocybe dealbata</em></p> <p><em>C. illudens</em></p> <p><em>Inocybe fastigiata</em></p> <em>Boletus calopus</em></td> <td> <p>Atropine (0.02 mg/kg IV, minimum dose 0.1 mg, maximum dose 1 mg) OR</p> <p>Glycopyrrolate (10 mcg/kg, maximum dose 0.2 mg)</p> <p>Repeat anticholinergic agent as needed until bronchial secretions have dried</p> Supportive care: IV fluid resuscitation of vomiting and diarrhea, inhaled albuterol and ipratropium bromide for bronchospasm</td> <td>Mortality rare, symptoms typically resolve within 12 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Disulfuram-like reaction (flushing, headache, tachycardia, chest pain, anxiety)</td> <td>Coprine</td> <td>30 minutes-2 hours</td> <td>Inhibition of aldehyde-dehydrogenase enzyme leading to increased blood aldehyde</td> <td> <p><em>Coprinus atramentarius</em></p> <em>Clitocybe clavipes</em></td> <td>Supportive care</td> <td>Mortality rare, symptoms typically resolve within 6 hours</td> </tr> <tr class=\"divider_bottom\"> <td>Gastroenteritis and delayed onset renal failure</td> <td>Allenic norleucine</td> <td> <p>30 minutes-3 hours (GI toxicity)</p> 12-24 hours (renal toxicity)</td> <td> <p>Kidney</p> GI tract</td> <td><em>Amanita smithiana</em></td> <td> <p>Supportive care: As for renal insufficiency</p> Hemodialysis</td> <td>Mortality rare, full recovery of renal function in most patients</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed liver toxicity and delayed gastroenteritis</td> <td>Cyclopeptides: <ul class=\"decimal_heading\"> <li>Amatoxins </li> <li>Phallotoxins </li> </ul> </td> <td>6-24 hours<sup>&#182;</sup></td> <td> <p>GI tract</p> <p>Liver</p> Kidney</td> <td> <p><em>Amanita phalloides</em></p> <p><em>A. virosa</em></p> <p><em>A. verna</em></p> <p><em>A. bisporigera</em></p> <p><em>Galerina autumnalis</em></p> <p><em>G. marginata</em></p> <p><em>G. venenata</em></p> <em>Lepiota helveola</em></td> <td> <p>Multiple dose activated charcoal</p> <p>IV Silibinin<sup>&#916;</sup></p> <p>IV N-acetylcysteine<sup>&#916;</sup></p> <p>IV cimetidine<sup>&#916;</sup></p> <p>IV vitamin C<sup>&#916;</sup></p> <p>Supportive care: IV fluid resuscitation for hypovolemia; supportive treatment of liver failure and hepatorenal syndrome<sup>&#9674;</sup></p> Liver transplant</td> <td>2-30%</td> </tr> <tr class=\"divider_bottom\"> <td>Seizures, delayed gastroenteritis and liver toxicity</td> <td>Gyromitrin</td> <td>4-10 hours</td> <td> <p>GI tract</p> <p>Central nervous system</p> <p>Liver</p> Blood</td> <td> <p><em>Gyromitra esculenta</em></p> <p><em>G.infula</em></p> <p><em>Sarcosphaera coronaria</em></p> <em>Cyathipodia macropus</em></td> <td> <p>Seizures: Benzodiazepines and pyridoxine (70 mg/kg IV, maximum dose: 5 grams)</p> <p>Methemoglobinemia: Methylene blue (1-2 mg/kg IV, slowly over 5 minutes for symptoms or methemoglobin level &#62;20%)</p> Supportive care: IV fluid resuscitation for delayed vomiting and diarrhea</td> <td>0-10%</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed renal failure</td> <td>Orellanine, orellinine, cortinarin</td> <td>3-20 days</td> <td>Kidney</td> <td> <p><em>Cortinarius orellanus</em></p> <p><em>C. speciosissinus</em></p> <p><em>Mycena pura</em></p> <em>Omphalatus orarius</em></td> <td> <p>Supportive care: As for renal insufficiency</p> <p>Hemodialysis</p> Renal transplant</td> <td>Rare, end-stage renal failure 11%, renal transplant 13%</td> </tr> <tr class=\"divider_bottom\"> <td>Delayed rhabdomyolysis</td> <td>Unknown</td> <td>24-72 hours</td> <td>Muscle</td> <td><em>Tricholoma equestre</em></td> <td> <p>Supportive care: IV fluid repletion and correction of hyperkalemia</p> Hemodialysis</td> <td>25%</td> </tr> <tr class=\"divider_bottom\"> <td>Erythromelalgia (burning extremity pain with erythema and edema, severe tactile pain)</td> <td>Acromelic acid</td> <td>&#62;24 hours</td> <td> <p>Peripheral nerves</p> Skin</td> <td><em>Clitocybe acromelalga</em></td> <td>Supportive care: Pain management</td> <td>Mortality rare, symptoms may last for months</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"7\">Delayed encephalopathy</td> </tr> <tr> <td class=\"sublist1\">Patients with renal failure</td> <td class=\"sublist_other\">Unknown</td> <td class=\"sublist_other\">&#62;24 hours to days</td> <td class=\"sublist_other\">Encephalopathy</td> <td class=\"sublist_other\"><em>Pleurocybella porrigens</em><sup>&#167;</sup></td> <td class=\"sublist_other\">Supportive care</td> <td class=\"sublist_other\">27%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Normal healthy patients</td> <td class=\"sublist_other\">Polyporic acid (causes violet colored urine)</td> <td class=\"sublist_other\">&#62;12 hours</td> <td class=\"sublist_other\">Encephalopathy, liver and renal toxicity</td> <td class=\"sublist_other\"><em>Hapalopilus rustilans</em></td> <td class=\"sublist_other\">Supportive care</td> <td class=\"sublist_other\">Rare</td> </tr> <tr class=\"divider_bottom\"> <td>Immune-mediate hemolytic anemia</td> <td>Antibodies to <em>Paxillus involutus</em></td> <td>Repeated ingestion of cooked mushroom</td> <td>Blood</td> <td><em>Paxillus involutus</em></td> <td>Supportive care: As for autoimmune hemolytic anemia. Renal insufficiency may occur.</td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td>Shiitake dermatitis</td> <td>Lentinan</td> <td>2 hours to 5 days after consumption of raw or undercooked shiitake mushrooms</td> <td>Skin</td> <td><em>Lentinula edodes</em></td> <td>For severe cases, antihistamines and systemic corticosteroids</td> <td>None</td> </tr> <tr> <td>Allergic bronchioalveolitis</td> <td>Allergic reaction to spores of <em>Lycoperdon </em>species</td> <td>&#60;6 hours</td> <td>Lungs</td> <td><em>Lycoperdon</em> species</td> <td> <p>Corticosteroids</p> Antifungal agents (eg, Amphotericin B)</td> <td>Rare</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; CNS: central nervous system;&nbsp;IV: intravenous.<br />* Supportive care of airway, breathing, circulation, and where appropriate, anticipation of liver or renal failure, seizures, hemolytic anemia, methemoglobinemia, and/or rhabdomyolysis are the mainstays of treatment for mushroom poisoning. Aggressive intravenous fluid resuscitation is often necessary for patients with severe vomiting and diarrhea. Refer to \"Management of mushroom poisoning\".<br />¶ Gastroenteritis may occur as early as six hours after consumption of mushrooms containing cyclopeptide toxins. Gastroenteritis may appear under six hours in patients who ingest other mushrooms along with cyclopeptide-containing species. Liver toxicity typically becomes apparent within 24-36 hours after ingestion.<br />Δ Although frequently recommended, these treatments are of uncertain benefit. If IV silibinin is not available, administration of high-dose IV penicillin G and oral silymarin or similar milk thistle product is suggested. Refer to UpToDate topics on management of amatoxin-containing mushroom poisoning. <br /><FONT class=lozenge>◊</FONT> For example, lactulose for encephalopathy, vitamin K and fresh frozen plasma for coagulopathy. Bridging lliver therapies such as molecular absorbent regenerating system, fractionated plasma separation and adsorption system, or therapeutic plasma exchange should be determined by a liver transplant service.<br />§ Mushroom commonly served in Japanese miso soup.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Goldfrank LR. Mushrooms. In: Goldfrank's Toxicologic Emergencies, 9th, Nelson LS, Lewin NA, Howland MA, et al (Eds), McGraw-Hill, New York 2011. p.1522.</li>&#xD;&#xA;    <li>Brent J, Palmer RB. Mushrooms. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th edition, Shannon MW, Borron SW, Burns MJ (Eds), Saunders Elsevier, Philadelphia, PA 2007. p.455.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 77875 Version 13.0</div></div></div>"},"77876":{"type":"graphic_table","displayName":"Morse Fall Scale","title":"Morse Fall Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Morse Fall Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Item</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td rowspan=\"2\"><strong>1. History of falling</strong></td> <td>No</td> <td>0</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Yes</td> <td>25</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>2. Secondary diagnosis</strong></td> <td>No</td> <td>0</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Yes</td> <td>15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">3. Ambulatory aid</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">None/bed rest/nurse assist</td> <td>0</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Crutches/cane/walker</td> <td>15</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Furniture</td> <td>30</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\"><strong>4. Intravenous therapy/saline lock</strong></td> <td>No</td> <td>0</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td>Yes</td> <td>20</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">5. Gait</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Normal/bed rest/wheelchair</td> <td>0</td> <td rowspan=\"3\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Weak</td> <td>10</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Impaired</td> <td>20</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"4\">6. Mental status</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Oriented to own ability</td> <td>0</td> <td rowspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Overestimates/forgets limitations</td> <td>15</td> </tr> <tr class=\"divider_top\"> <td colspan=\"2\">&nbsp;</td> <td><strong>Total</strong></td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Dr. Janice Morse. Copyright © 2011. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77876 Version 3.0</div></div></div>"},"77877":{"type":"graphic_figure","displayName":"Disconnected Roux-en-O misconstruction figure","title":"Disconnected Roux-en-O misconstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Disconnected Roux-en-O misconstruction</div><div class=\"cntnt\"><img style=\"width:419px; height:476px;\" src=\"images/SURG/77877_Disconnected-Roux-en-O.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure depicts a misconstruction of a Roux-en-Y gastric bypass with the &quot;O&quot; disconnected from the small bowel.</div><div id=\"graphicVersion\">Graphic 77877 Version 1.0</div></div></div>"},"77878":{"type":"graphic_figure","displayName":"Hypothalamic blood supply","title":"Vascular and neural connections between the hypothalamus and pituitary","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Vascular and neural connections between the hypothalamus and pituitary</div><div class=\"cntnt\"><img style=\"width:513px; height:310px;\" src=\"images/ENDO/77878_Hypothalamic_blood_supply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the vascular and neural connections of the hypothalamic-pituitary axis. The paraventricular nucleus neurons have terminals in the median eminence where their hormones are released directly into the primary capillary plexus, traverse the long portal veins in the pituitary stalk, and enter the secondary plexus in the anterior pituitary gland. The primary plexus, long portal venous system, and secondary plexus comprise the hypothalamic-hypophyseal portal venous system. In contrast, the axons of the supraoptic nucleus travel down the supraopticohypophyseal tract and release vasopressin and oxytocin directly in the posterior pituitary.</div><div class=\"graphic_reference\">Adapted from: Guillemin R, in: Neuroendocrinology, Krieger DT, Hughes JC (Eds), Sinauer Associates, Sunderland, MA, 1980, p. 45.</div><div id=\"graphicVersion\">Graphic 77878 Version 2.0</div></div></div>"},"77880":{"type":"graphic_table","displayName":"Risk of nausea and vomiting with emergency contraception","title":"Risk of nausea and vomiting with emergency contraception","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk of nausea and vomiting with emergency contraception</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n  <tr>\n    <td class=\"subtitle1\">&nbsp;</td>\n    <td class=\"subtitle1\">Percentage of women who experience nausea</td>\n    <td class=\"subtitle1\">Percentage of women who experience vomiting</td>\n  </tr>\n  <tr>\n    <td>Estradiol + levonorgestrel</td>\n    <td>43</td>\n    <td>16</td>\n  </tr>\n  <tr>\n    <td>Levonorgestrel (alone)</td>\n    <td>18</td>\n    <td>4</td>\n  </tr>\n\n</tbody>\n</table></div><div id=\"graphicVersion\">Graphic 77880 Version 3.0</div></div></div>"},"77881":{"type":"graphic_figure","displayName":"Uterine artery ligation","title":"Uterine artery ligation","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Uterine artery ligation</div><div class=\"cntnt\"><img style=\"width:457px; height:374px;\" src=\"images/OBGYN/77881_Uterine_artery_ligation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sutures are placed to ligate the ascending uterine artery and the anastomotic branch of the ovarian artery. The procedure should be performed on each side.</div><div id=\"graphicVersion\">Graphic 77881 Version 1.0</div></div></div>"},"77882":{"type":"graphic_picture","displayName":"Histology nevoid melanoma 2","title":"Nevoid melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevoid melanoma</div><div class=\"cntnt\"><img style=\"width:368px; height:520px;\" src=\"images/ONC/77882_Histology_nevoid_melanoma_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A: Medium power light photomicrograph of a nevoid melanoma, demonstrating striking hypercellularity and hyperchromasia in the dermal component. Panel B: High power light photomicrograph view of the same lesion. The neoplastic cells are hyperchromatic and pleomorphic. Note a readily observed mitosis in the center of the field (red arrow).</div><div class=\"graphic_reference\">Courtesy of Vincent Liu, MD and April Wang Armstrong, MD.</div><div id=\"graphicVersion\">Graphic 77882 Version 1.0</div></div></div>"},"77883":{"type":"graphic_picture","displayName":"Prostate adenoCA IHC staining","title":"Prostate tissue immunohistochemistry","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Prostate tissue immunohistochemistry</div><div class=\"cntnt\"><img style=\"width:483px; height:201px;\" src=\"images/ONC/77883_Prostate_adenoCA_IHC_staini.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power photomicrographs of serial tissue sections of the prostate gland, stained with hematoxylin and eosin (panel A), alpha-methylacyl-CoA racemase (AMACR/P504S) (panel B), and 34bE12 (panel C). The prostate adenocarcinoma stains positively for AMACR (brown stain) and negatively for 34bE12. In contrast, the peripheral benign glands adjacent to the cancer stain negatively for AMACR but positively for 34bE12.</div><div class=\"graphic_reference\">Courtesy of Ximing Yang, MD.</div><div id=\"graphicVersion\">Graphic 77883 Version 2.0</div></div></div>"},"77884":{"type":"graphic_picture","displayName":"Gottrons sign PI","title":"Gottron's sign in dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Gottron's sign in dermatomyositis</div><div class=\"cntnt\"><img style=\"width:229px; height:323px;\" src=\"images/PI/77884_Gottrons_sign_1_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows \"Gottron's&nbsp;sign\" (a red, scaly rash)&nbsp;on the fingers of&nbsp;a patient with dermatomyositis. Gottron's sign can mimic psoriasis.</div><div class=\"graphic_reference\">Courtesy of Marc Miller, MD.</div><div id=\"graphicVersion\">Graphic 77884 Version 2.0</div></div></div>"},"77885":{"type":"graphic_table","displayName":"Estimated global prevalence","title":"Estimated prevalence of fire-related burn injuries* in 2004, by World Health Organization region","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimated prevalence of fire-related burn injuries* in 2004, by World Health Organization region</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Africa</td> <td class=\"subtitle1\">The Americas</td> <td class=\"subtitle1\">EMR<sup>&#182;</sup></td> <td class=\"subtitle1\">Europe</td> <td class=\"subtitle1\">SEAR<sup>&#916;</sup></td> <td class=\"subtitle1\">WPR<sup>&#9674;</sup></td> <td class=\"subtitle1\">World</td> </tr> <tr> <td><strong>Population (000)</strong></td> <td>737,536</td> <td>874,380</td> <td>519,688</td> <td>883,311</td> <td>1,671,904</td> <td>1,738,457</td> <td>6,436,826</td> </tr> <tr> <td><strong>Burns (000)</strong></td> <td>17,733</td> <td>7850</td> <td>14,919</td> <td>15,668</td> <td>44,344</td> <td>15,531</td> <td>116,284</td> </tr> <tr> <td><strong>Prevalence rate</strong></td> <td>2.4</td> <td>0.9</td> <td>2.87</td> <td>1.77</td> <td>2.65</td> <td>8.93</td> <td>1.81</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes only burns covering 20 percent or more of total body surface area.<br />¶ Eastern Mediterranean region.<br />Δ Southeast Asia region.<br /><FONT class=lozenge>◊</FONT> Western Pacific region.</div><div class=\"graphic_reference\">Data from: World Health Organization. Disease and injury estimates for 2004. Morbidity and Mortality. Prevalence. Prevalence (000s) for selected causes, in WHO regions, estimates for 2004. www.who.int/healthinfo/global_burden_disease/estimates_regional/en/index.html.</div><div id=\"graphicVersion\">Graphic 77885 Version 3.0</div></div></div>"},"77887":{"type":"graphic_picture","displayName":"Systemic AL amyloidosis purpura","title":"Immunoglobulin light chain (AL) amyloidosis - periorbital purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Immunoglobulin light chain&nbsp;(AL) amyloidosis - periorbital purpura</div><div class=\"cntnt\"><img style=\"width:400px; height:533px;\" src=\"images/DERM/77887_Systemic_AL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple periorbital purpuric macules are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 77887 Version 5.0</div></div></div>"},"77888":{"type":"graphic_figure","displayName":"Surfaces of the diaphragm","title":"Surfaces of the diaphragm","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Surfaces of the diaphragm</div><div class=\"cntnt\"><img style=\"width:534px; height:719px;\" src=\"images/SURG/77888_Diaphragmatic-surfaces.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77888 Version 2.0</div></div></div>"},"77890":{"type":"graphic_picture","displayName":"Transbronchial needle","title":"Transbronchial needle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transbronchial needle</div><div class=\"cntnt\"><img style=\"width:450px; height:353px;\" src=\"images/PULM/77890_Transbronchial_needle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 19G transbronchial histology needle extending from its sheath.</div><div id=\"graphicVersion\">Graphic 77890 Version 1.0</div></div></div>"},"77891":{"type":"graphic_figure","displayName":"Supracondylar flexion fx","title":"Supracondylar flexion fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supracondylar flexion fracture</div><div class=\"cntnt\"><img style=\"width:396px; height:354px;\" src=\"images/EM/77891_Supracondylarflexionfx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexion mechanism. Flexion-type fractures usually result from a blow to the posterior aspect of the elbow. The obliquity of the fracture line may be opposite that of an extension type. The large blue arrows demonstrate the usual direction of displacement of the fragments.</div><div class=\"graphic_reference\">Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright © 2001 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77891 Version 12.0</div></div></div>"},"77892":{"type":"graphic_picture","displayName":"Table top test in diabetes","title":"Contractures in the metacarpophalangeal joints in diabetes mellitus: Table top test","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Contractures in the metacarpophalangeal joints in diabetes mellitus: Table top test</div><div class=\"cntnt\"><img style=\"width:435px; height:113px;\" src=\"images/ENDO/77892_Table_top_test_in_diabetes.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positive table top test in a patient with diabetes (left panel) and a negative test in a normal subject (right panel). The inability to flatten the palm against the surface of a table results from contractures in the metacarpophalangeal joints.</div><div class=\"graphic_reference\">Courtesy of Verna Wright, MD.</div><div id=\"graphicVersion\">Graphic 77892 Version 2.0</div></div></div>"},"77893":{"type":"graphic_figure","displayName":"Cancer incidence in females in more and less developed countries","title":"Cancer incidence in females in more and less developed countries*","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Cancer incidence in females in more and less developed countries*</div><div class=\"cntnt\"><img style=\"width:553px; height:449px;\" src=\"images/GAST/77893_Cancer_incid_women_edt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Comparison of the most common cancers in more and less developed countries in 2000.</div><div class=\"graphic_reference\">Reproduced with permission from: Stewart B, Kleihues P. World Cancer Report,&nbsp;IARC Press, Lyon 2003. Copyright © 2003 IARC Press.</div><div id=\"graphicVersion\">Graphic 77893 Version 13.0</div></div></div>"},"77895":{"type":"graphic_table","displayName":"Oligosymptomatic celiac disease","title":"Clinical and laboratory findings in 82 oligosymptomatic Italian children with celiac disease detected by screening","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical and laboratory findings in 82 oligosymptomatic Italian children with celiac disease detected by screening</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n<td class=\"subtitle1\">Symptom</td>\n<td class=\"subtitle1\">Percent</td>\n</tr>\n<tr>\n<td colspan=\"2\" class=\"sublist1_start\">Iron deficiency</td>\n</tr>\n<tr>\n<td class=\"sublist1\">With anemia</td>\n<td class=\"sublist_other\">29</td>\n</tr>\n<tr>\n<td class=\"sublist1\">Without anemia</td>\n<td class=\"sublist_other\">27</td>\n</tr>\n<tr>\n<td>Recurrent abdominal pain</td>\n<td>24</td>\n</tr>\n<tr>\n<td>Mood changes</td>\n<td>17</td>\n</tr>\n<tr>\n<td>Recurrent aphthous stomatitis</td>\n<td>11</td>\n</tr>\n<tr>\n<td>Poor appetite</td>\n<td>10</td>\n</tr>\n<tr>\n<td>Recurrent diarrhea</td>\n<td>9</td>\n</tr>\n<tr>\n<td>Short stature</td>\n<td>7</td>\n</tr>\n<tr>\n<td>Abdominal distention</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Constipation</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Pubertal delay</td>\n<td>2</td>\n</tr>\n<tr>\n<td>Hypoalbuminemia</td>\n<td>2</td>\n</tr>\n</tbody>\n</table></div><div class=\"graphic_reference\">Data from: Catassi C, Fabiani E, R&#228;tsch IM, et al. The coeliac iceberg in Italy: a multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr 1996; 412(Suppl):29.</div><div id=\"graphicVersion\">Graphic 77895 Version 2.0</div></div></div>"},"77899":{"type":"graphic_figure","displayName":"Calculation valve area AS","title":"Calculation of aortic valve area in aortic stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Calculation of aortic valve area in aortic stenosis</div><div class=\"cntnt\"><img style=\"width:278px; height:462px;\" src=\"images/CARD/77899_CalculationvalveareaAS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left ventricular outflow tract (LVOT) diameter (red line), measured just under the aortic valve, is obtained from the long axis parasternal view (panel A); the diameter is 1.5 cm and the area 1.8 cm<SUP>2</SUP>. Using the apical four-chamber view, the Doppler sample volume in the LVOT is obtained from a position that approximates the locus from which the diameter of the LVOT had been measured (panel B). Another approach uses the continuous wave Doppler, sampling the jet across the stenotic aortic valve in the apical four-chamber view (panel C); the peak velocity is 4.7 m/s, yielding a peak gradient of 88 mmHg, a mean gradient of 45 mmHg, a flow velocity integral (VTI) of 100 cm, and a valve area of 0.27 cm<SUP>2</SUP>. With the Doppler probe over the right parasternal window, the stenotic jet shows a peak velocity of 5.4 m/s, a peak gradient of 117 mmHg, a VTI of 129 cm, and a valve area of 0.21 cm<SUP>2</SUP>.</div><div id=\"graphicVersion\">Graphic 77899 Version 2.0</div></div></div>"},"77900":{"type":"graphic_movie","displayName":"Pericardial effusion without tamponade 4 chamber view","title":"Pericardial effusion","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pericardial effusion</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77900_4chpeff1conv.mp4\" style=\"width:320px;height:256px\"></div><img style=\"width:320px; height:240px;\" src=\"images/CARD/77900_4chpeff1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical four chamber view from a two-dimensional echocardiogram shows a moderate pericardial effusion (PE) surrounding the right atrium (RA), right ventricle (RV), and left ventricle (LV), but not the left atrium (LA). RA motion is exaggerated, but the chamber is not compressed. At cardiac catheterization, the patient had normal hemodynamics.</div><div class=\"graphic_reference\">Courtesy of Ralph Shabetai, MD.</div><div id=\"graphicVersion\">Graphic 77900 Version 2.0</div></div></div>"},"77902":{"type":"graphic_picture","displayName":"Chorioamnionitis 3","title":"Chorioamnionitis 3","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">Chorioamnionitis 3</div><div class=\"cntnt\"><img style=\"width:469px; height:648px;\" src=\"images/OBGYN/77902_Chorioamnionitis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gross photograph of the umbilical cord and fetal surface of the placenta illustrating yellow, opaque membranous surfaces characteristic of inflammation from chorioamnionitis.</div><div class=\"graphic_reference\">Courtesy of Drucilla J Roberts, MD.</div><div id=\"graphicVersion\">Graphic 77902 Version 2.0</div></div></div>"},"77903":{"type":"graphic_picture","displayName":"Atrophy breast tissue menopause","title":"Atrophy of breast tissue in menopause","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Atrophy of breast tissue in menopause</div><div class=\"cntnt\"><img style=\"width:551px; height:240px;\" src=\"images/ONC/77903_Atrophy_breast_tissue_menop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A section of breast tissue from a postmenopausal woman demonstrating atrophy of the glandular tissues. The stroma is composed primarily of adiopose tissue.</div><div class=\"graphic_footnotes\">A: lower lower view of an atrophic lobule; B: higher-power view of an atrophic lobule.</div><div class=\"graphic_reference\">Reproduced with permission from: Schnitt, SJ. Normal anatomy and development, In: Atlas of Breast Cancer, Hayes, DF (Ed). Harcourt Publishers Ltd. 2000, p.3.4. Copyright &#169; 2000 Mosby.</div><div id=\"graphicVersion\">Graphic 77903 Version 1.0</div></div></div>"},"77904":{"type":"graphic_diagnosticimage","displayName":"Melanoma pleural metastases","title":"Thoracic metastases from melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Thoracic metastases from melanoma</div><div class=\"cntnt\"><img style=\"width:335px; height:239px;\" src=\"images/ONC/77904_Melanoma_pleural_metastases.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT image shows extensive pleural metastases from melanoma with an associated soft tissue mass involving the right chest wall.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Kevin Donohoe, MD.</div><div id=\"graphicVersion\">Graphic 77904 Version 3.0</div></div></div>"},"77905":{"type":"graphic_picture","displayName":"Nasolabial folds","title":"Nasolabial folds","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Nasolabial folds</div><div class=\"cntnt\"><img style=\"width:502px; height:302px;\" src=\"images/DERM/77905_Nasolabial_folds_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lines extending from the lateral nasal alae to the lateral mouth are nasolabial folds.</div><div id=\"graphicVersion\">Graphic 77905 Version 3.0</div></div></div>"},"77906":{"type":"graphic_algorithm","displayName":"External ear pediatric algorithm","title":"External ear causes of ear pain in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">External ear causes of ear pain in children</div><div class=\"cntnt\"><img style=\"width:404px; height:469px;\" src=\"images/EM/77906_External_ear_algorithm.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77906 Version 3.0</div></div></div>"},"77907":{"type":"graphic_figure","displayName":"IJ central line mid","title":"Central approach to the internal jugular vein","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Central approach to the internal jugular vein</div><div class=\"cntnt\"><img style=\"width:542px; height:469px;\" src=\"images/EM/77907_IJ_central_line_mid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central approach to cannulation of the internal jugular vein is most common. Insert the needle at the apex of the angle formed by the two heads of the sternocleidomastoid, lateral to the carotid artery pulsation, at an angle approximately 30 degrees from the skin. Direct the needle towards the ipsilateral nipple. Blood is usually aspirated within 2.5 cm of insertion. If blood is not aspirated while advancing, slowly withdraw the needle. Aspiration often occurs as the needle is pulled back.</div><div id=\"graphicVersion\">Graphic 77907 Version 2.0</div></div></div>"},"77909":{"type":"graphic_table","displayName":"Chromosomal abnormalities","title":"Recurring chromosomal abnormalities in adults with myelodysplastic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Recurring chromosomal abnormalities in adults with myelodysplastic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"18%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup span=\"2\" width=\"7%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Chromosome abnormality</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\" colspan=\"2\">Involved genes*</td> <td class=\"subtitle1\">Consequence</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"11\"><strong>MDS unbalanced</strong></td> <td>+8</td> <td>10%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&ndash;7/del(7q)</td> <td>10% </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>del(5q)</td> <td>10% </td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>del(20q)</td> <td>5 to 8%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>&ndash;Y</td> <td>5%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>i(17p)</td> <td>3 to 5%</td> <td>TP53</td> <td>&nbsp;</td> <td>Loss of function</td> </tr> <tr> <td>&ndash;13/del(13q)</td> <td>3%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>del(11q)</td> <td>3%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>del(12p)/t(12p)</td> <td>3%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>del(9q)</td> <td>1 to 2%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>idic(X)(q13)</td> <td>1 to 2%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Balanced</strong></td> <td>t(1;3)(p36.3;q21.3)</td> <td>1%</td> <td>PRDM16</td> <td>MECOM</td> <td>Deregulation of PRDM16 - transcriptional activation?</td> </tr> <tr> <td>t(2;11)(p21;q23.3)/t(11q23.3)</td> <td>1%</td> <td>&nbsp;</td> <td>KMT2A</td> <td>KMT2A fusion protein - altered transcriptional regulation</td> </tr> <tr> <td>inv(3)(q21.3q26.2)</td> <td>1%</td> <td>&nbsp;</td> <td>MECOM</td> <td>Overexpression of MECOM - altered transcriptional regulation</td> </tr> <tr class=\"divider_bottom\"> <td>t(6;9)(p23.3;q34.1)</td> <td>1%</td> <td>DEK</td> <td>NUP214</td> <td>Fusion protein - nuclear pore protein</td> </tr> <tr> <td rowspan=\"6\"><strong>Therapy-related MDS</strong></td> <td>&ndash;7/del(7q)</td> <td>50%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>del(5q)</td> <td>40 to 45%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>dic(5;17)(q11.1-13;p11.1-13)</td> <td>5%</td> <td>&nbsp;</td> <td>TP53</td> <td>Loss of function, DNA damage response</td> </tr> <tr> <td>der(1;7)(q10;p10)</td> <td>3%</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>t(3;21)(q26.2;q22.1)</td> <td>2%</td> <td>MECOM</td> <td>RUNX1</td> <td>Loss of RUNX1, overexpression of MECOM - altered transcriptional regulation</td> </tr> <tr> <td>t(11;16)(q23.3;p13.3)/t(11q23)</td> <td>3%</td> <td>KMT2A</td> <td>CREBBP</td> <td>KMT2A fusion protein - altered transcriptional regulation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Genes are listed in order of citation in the karyotype, eg, for the t(11;16),&nbsp;KMT2A is at 11q23.3 and CREBBP at 16p13.3.</div><div class=\"graphic_reference\">Source: Vardiman, JW, Brunning, RD, Arber, DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: WHO classification of tumors of hematopoietic and lymphoid tissues, Swerdlow, SH, Campo, E, Harris, NL, et al. (Eds), WHO Press, 2008.<br />Modified with additional data from:<br /><OL>&#xD;&#xA;<LI>Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.</LI></OL></div><div id=\"graphicVersion\">Graphic 77909 Version 5.0</div></div></div>"},"77910":{"type":"graphic_figure","displayName":"Stem cell properties","title":"Stem cell properties","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Stem cell properties</div><div class=\"cntnt\"><img style=\"width:525px; height:302px;\" src=\"images/HEME/77910_Stem_cell_properties_edt2.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic view of some general properties and assays for the heterogeneous cells that compromise the stem cell and progenitor cell compartments. As indicated, cells capable of permanently reconstituting in vivo hematopoiesis are separable from cells that give rise to day 12 CFU-S, but the precise developmental stage of in vitro long-term culture initiating cells (LTC- IC), cobblestone area forming cells (CAFC), CFU-blast and high proliferative potential colony forming cells (HPP-CFC) is not established. In the progenitor compartment, mixed colonies of almost all lineage combinations have been described.</div><div id=\"graphicVersion\">Graphic 77910 Version 4.0</div></div></div>"},"77911":{"type":"graphic_table","displayName":"Noninfectious causes cervical lymphadenopathy in children","title":"Noninfectious causes of cervical lymphadenopathy in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noninfectious causes of cervical lymphadenopathy in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Possible associated clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Lymphoma or leukemia</td> <td>Persistent, or progressive, nontender cervical or generalized lymphadenopathy; constitutional symptoms (eg, fever, weight loss, fatigue)</td> </tr> <tr> <td class=\"indent1\">Neuroblastoma</td> <td>Constitutional symptoms (fever, weight loss); abdominal mass; GI symptoms; proptosis; periorbital ecchymoses; Horner syndrome; opsoclonus myoclonus ataxia; palpable subcutaneous nodules; bone pain; hypertension; unilateral nasal obstruction</td> </tr> <tr> <td class=\"indent1\">Rhabdomyosarcoma</td> <td>Localized, painless, enlarging mass; proptosis; ophthalmoplegia; nasal, aural, or sinus obstruction (without drainage)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thyroid cancer</td> <td>History of external radiation to the head and neck; hoarseness; dysphagia; medullary thyroid cancer may be associated with multiple endocrine neoplasias</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Collagen vascular disease</td> </tr> <tr> <td class=\"indent1\">Juvenile idiopathic arthritis</td> <td>Arthritis/arthralgia; fever; rash; other systemic involvement (eg, hepatosplenomegaly, pericarditis, etc)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systemic lupus erythematosus</td> <td>Arthritis/arthralgia; hematologic abnormalities (anemia, leukopenia, lymphopenia, thrombocytopenia); malar rash; oral ulcers; fever; renal disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Drugs</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> <td>Seizure disorder</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Carbamazepine</td> <td>Seizure disorder</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Kawasaki disease</td> <td>Fever; rash; nonexudative conjunctivitis; enanthem; swelling of hands and feet</td> </tr> <tr> <td class=\"indent1\">PFAPA</td> <td>Recurrent fevers; aphthous stomatitis; pharyngitis; and adenitis</td> </tr> <tr> <td class=\"indent1\">Kikuchi disease</td> <td>Fever; rash; systemic symptoms (fatigue, weight loss); leukopenia; anemia; usually occurs in young women</td> </tr> <tr> <td class=\"indent1\">Langerhans cell histiocytosis</td> <td>Lytic bone lesions; rash (papular or eczematous); oral lesions (mass, gingivitis, ulcers, loose teeth); diabetes insipidus</td> </tr> <tr> <td class=\"indent1\">Hemophagocytic lymphohistiocytosis</td> <td>Hepatomegaly; rash; neurologic findings (seizures, mental status changes); anemia; thrombocytopenia; most frequent at age &#60;10 months, but may occur in older children</td> </tr> <tr> <td class=\"indent1\">Castleman disease</td> <td>Lymph nodes may be &#62;4 cm (1.6 inches); may have systemic symptoms (fever, night sweats, malaise); hepatosplenomegaly; anemia, thrombocytosis</td> </tr> <tr> <td class=\"indent1\">Kimura disease</td> <td>Painless subcutaneous masses in head and neck; eosinophilia; increased IgE</td> </tr> <tr> <td class=\"indent1\">Postvaccination</td> <td>Recent history of immunization (particularly diphtheria-tetanus-pertussis, polio, or typhoid fever vaccine)</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td>Extensive enlargement of cervical nodes; facial eruption (flat-topped papules); weight loss; lethargy; fatigue, cough; bone lesions (eg, cystic or sclerotic focal lesions, osteopenia, osteoporosis)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis syndrome; IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 77911 Version 11.0</div></div></div>"},"77912":{"type":"graphic_picture","displayName":"Kissing nevus","title":"Kissing nevus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kissing nevus</div><div class=\"cntnt\"><img style=\"width:407px; height:250px;\" src=\"images/PC/77912_Kissing_nevus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The nevus includes both the upper and lower eyelids.</div><div class=\"graphic_reference\">With permission from Slomovits, TL (Ed), Basic and clinical science courses section, American Academy of Ophthalmology, San Francisco 1996.</div><div id=\"graphicVersion\">Graphic 77912 Version 1.0</div></div></div>"},"77915":{"type":"graphic_table","displayName":"Recommended phenylalanine limits in patients with PKU","title":"Treatment recommendations for phenylalanine concentrations (micromol/L) in patients with phenylketonuria (PKU) in the United States and selected European countries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment recommendations for phenylalanine concentrations (micromol/L) in patients with phenylketonuria (PKU) in the United States and selected European countries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">United Kingdom</td> <td class=\"subtitle1\">Germany</td> <td class=\"subtitle1\">France</td> <td class=\"subtitle1\">United States</td> </tr> <tr> <td>Birth*</td> <td>&#62;400</td> <td>&#62;600</td> <td>&#62;600</td> <td>&#62;360<sup>[1]</sup></td> </tr> <tr> <td>Infant to 10 years</td> <td>120 to 360</td> <td>40 to 240</td> <td>120 to 360</td> <td>120 to 360</td> </tr> <tr> <td>10 to 12 years</td> <td>&#60;480</td> <td>&#60;600</td> <td>&#60;900</td> <td>120 to 360</td> </tr> <tr> <td>12 to 20 years</td> <td>&#60;480</td> <td>&#60;600</td> <td>&#60;900</td> <td>120 to 360<sup>[1]</sup></td> </tr> <tr> <td>&#62;20 years</td> <td>&#60;700</td> <td>&#60;1200</td> <td>&#60;900</td> <td>120 to 360<sup>&#182;[1]</sup></td> </tr> <tr> <td>Prior to conception and during pregnancy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>120 to 360</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Newborn screening phenylalanine concentration at which treatment is initiated.<br />¶ Per published guidelines<SUP innerHtml>[1]</SUP>, although difficult to achieve in clinical practice.</div><div class=\"graphic_reference\">Reference:<br /><OL>&#xD;&#xA;<LI>Singh RH, Rohr F, Frazier D, et al. Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genet Med 2014; 16:121.</LI></OL>Modified with permission from: MacLeod EL, Ney DM. Nutritional management of phenylketonuria. Ann Nestle 2010; 68:58. Copyright © 2010 S. Karger AG, Basel. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77915 Version 6.0</div></div></div>"},"77916":{"type":"graphic_picture","displayName":"Glaucoma view PI","title":"How glaucoma affects vision","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">How glaucoma affects vision</div><div class=\"cntnt\"><img style=\"width:514px; height:227px;\" src=\"images/PI/77916_Glaucoma_view_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glaucoma damages how well you see at the edges. It can cause &quot;tunnel vision.&quot;</div><div class=\"graphic_reference\">Reproduced from: the National Eye Institute. Available at: <a href=\"http://www.nei.nih.gov/health/examples/\" target=\"_blank\">http://www.nei.nih.gov/health/examples/</a>.</div><div id=\"graphicVersion\">Graphic 77916 Version 2.0</div></div></div>"},"77918":{"type":"graphic_figure","displayName":"Bisphosphonate chem struc","title":"Basic bisphosphonate chemical structure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Basic bisphosphonate chemical structure</div><div class=\"cntnt\"><img style=\"width:295px; height:199px;\" src=\"images/ONC/77918_Bisphosphonatechemstruc.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two phosphonate (PO<SUB>3</SUB>) groups covalently linked to carbon (C) determine both the name \"bisphosphonate\" and the function. Bisphosphonates differ from each other at the two side chains,&nbsp;R<SUB innerHtml>1</SUB> and R<SUB>2</SUB>, which determine their chemical properties and pharmacokinetics.</div><div id=\"graphicVersion\">Graphic 77918 Version 2.0</div></div></div>"},"77919":{"type":"graphic_table","displayName":"Paraneoplastic antibodies and syndromes","title":"Paraneoplastic antibodies<SUP>*</SUP>, syndromes, and associated cancers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Paraneoplastic antibodies<SUP>*</SUP>, syndromes, and associated cancers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibody</td> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Associated cancers</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Well-characterized paraneoplastic antibodies<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Anti-Hu (ANNA-1)</td> <td>Encephalomyelitis including cortical, limbic, and brainstem encephalitis; cerebellar degeneration; myelitis; sensory neuronopathy; and/or autonomic dysfunction</td> <td>SCLC, other</td> </tr> <tr> <td class=\"indent1\">Anti-Yo (PCA-1)</td> <td>Cerebellar degeneration</td> <td>Gynecologic, breast</td> </tr> <tr> <td class=\"indent1\">Anti-Ri (ANNA-2)</td> <td>Cerebellar degeneration, brainstem encephalitis, opsoclonus-myoclonus</td> <td>Breast, gynecologic, SCLC</td> </tr> <tr> <td class=\"indent1\">Anti-Tr (DNER)</td> <td>Cerebellar degeneration</td> <td>Hodgkin lymphoma</td> </tr> <tr> <td class=\"indent1\">Anti-CV2/CRMP5</td> <td>Encephalomyelitis, cerebellar degeneration, chorea, peripheral neuropathy</td> <td>SCLC, thymoma, other</td> </tr> <tr> <td class=\"indent1\">Anti-Ma proteins<sup>&#916;</sup> (Ma1, Ma2)</td> <td>Limbic, hypothalamic, brainstem encephalomyelitis (infrequently cerebellar degeneration)</td> <td>Testicular germ cell tumors, lung cancer, other solid tumors</td> </tr> <tr> <td class=\"indent1\">Anti-VGCC<sup>&#9674;</sup>&nbsp;</td> <td>Cerebellar degeneration&nbsp;</td> <td>SCLC&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anti-amphiphysin</td> <td>Stiff-person syndrome, encephalomyelitis</td> <td>Breast, lung cancer</td> </tr> <tr> <td class=\"indent1\">Anti-PCA-2&nbsp;(MAP1B)</td> <td>Peripheral neuropathy, cerebellar ataxia, encephalopathy&nbsp;</td> <td>SCLC&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anti-recoverin<sup>&#167;</sup></td> <td>Cancer-associated retinopathy</td> <td>SCLC</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anti-bipolar cells of the retina<sup>&#165;</sup></td> <td>Melanoma-associated retinopathy</td> <td>Melanoma</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Partially characterized paraneoplastic antibodies<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">Anti-Zic 4</td> <td>Cerebellar degeneration</td> <td>SCLC</td> </tr> <tr> <td class=\"indent1\">Anti-ANNA-3</td> <td>Sensory neuronopathy, encephalomyelitis</td> <td>No tumor or Hodgkin lymphoma</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANNA: antinuclear-nuclear antibody; SCLC: small cell lung cancer; PCA: Purkinje cell antibody; DNER: Delta/Notch-like epidermal growth factor-related receptor; VGCC: voltage-gated calcium channel.<br />* Antibodies that are almost exclusively found in patients with cancer and neurologic symptoms.<br />¶&nbsp;Well-characterized antibodies are those directed against antigens whose molecular identity is known, or that have been identified by several investigators.<SUP>[1]</SUP><br />Δ&nbsp;Antibodies to Ma2: younger than 45 years, usually men with testicular germ cell tumors; older than 45, men or women with lung cancer and less frequently other tumors. Ma1 antibodies often associated with tumors other than germ cell neoplasms and confer a worse prognosis, with more prominent brainstem and cerebellar dysfunction.<br />◊&nbsp;The identification of these antibodies in a patient with cerebellar dysfunction indicates paraneoplasia, almost always associated with an SCLC. These antibodies are also found in patients with Lambert-Eaton myasthenic syndrome, in which only approximately 50% of patients have cancer.<br />§&nbsp;Other antibodies reported in a few or isolated cases include antibodies to tubby-like protein and the photoreceptor-specific nuclear receptor.<br />¥&nbsp;Target antigens include transducin-b, rhodopsin, and arrestin, among others.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75:1135.</LI></OL></div><div id=\"graphicVersion\">Graphic 77919 Version 17.0</div></div></div>"},"77920":{"type":"graphic_figure","displayName":"Bone mass lifeline","title":"Schematic representation of bone mass changes with age","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Schematic representation of bone mass changes with age</div><div class=\"cntnt\"><img style=\"width:487px; height:397px;\" src=\"images/PEDS/77920_Bone_mass_lifeline.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic&nbsp;representation of the bone mass life-line in individuals who achieve their full genetic potential for skeletal mass (red) and in those who do not (blue). The magnitude of the difference between curves is not intended to be to scale. Along the bottom of the graph are several factors known to be of particular importance.</div><div class=\"graphic_reference\">Data from Robert P. Heaney, 1999.</div><div id=\"graphicVersion\">Graphic 77920 Version 2.0</div></div></div>"},"77921":{"type":"graphic_picture","displayName":"Nevus of Ota","title":"Nevus of Ota (oculodermal melanocytosis, nevus fuscocaeruleus ophthalmomaxillaris)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Nevus of Ota (oculodermal melanocytosis, nevus fuscocaeruleus ophthalmomaxillaris)</div><div class=\"cntnt\"><img style=\"width:396px; height:391px;\" src=\"images/PEDS/77921_Nevus_of_Ota.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mottled blue-black patch in the left periorbital area, with involvement of the conjunctiva and sclera of the left eye.</div><div class=\"graphic_reference\">Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.</div><div id=\"graphicVersion\">Graphic 77921 Version 1.0</div></div></div>"},"77922":{"type":"graphic_table","displayName":"Homesickness prevention for hospitalized children","title":"Homesickness-prevention strategies for parents of hospitalized children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Homesickness-prevention strategies for parents of hospitalized children</div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n\t<tr>\n\t\t\t\t\t<td>1. Homesickness is normal. Almost all children feel a bit sad and nervous when they are separated from home and loved ones. No matter how turbulent your child's life has been lately, he or she is likely to miss many things about home during this hospitalization. One way that parents can help children deal with this distress is to reassure them that missing home is normal.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>2. Talk with your child honestly about when and why he or she is being hospitalized. Although the honest truth may be upsetting or surprising to some children, coping with the reality of their situation now prevents uncomfortable surprises later. Children who feel \"tricked\" into hospitalization lose confidence in the reliability of their caregivers and therapists, which increases homesickness.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>3. To help your child feel \"at home\" in the hospital, the staff may give your child a tour of the unit. Staff members can explain the daily routine on the unit and answer any questions that you or your child might have. This orientation, along with photographs, calendars, schedules, and introductions to other children, will help your child feel more comfortable.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>4. Although you may have some mixed feelings about your child's hospitalization, try not to convey those feelings to your child. If you talk about your mixed feelings, you may increase your child's own doubts about the value of hospitalization. Instead, give your child a consistent, positive message about why he or she is here. Help your child understand the value of this hospital stay.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>5. Often, it is impossible for staff to predict your child's exact discharge date. This date depends on many factors, some of which are constantly changing. Although this uncertainty is hard for families, it is even harder when an exact date does not work out as planned. The disappointment of a postponed discharge date can make children quite homesick. Therefore, instead of focusing on a particular date, ask the staff to estimate a range of dates, and be honest with your child that no one knows the exact discharge date yet.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>6. Sometimes, children in the hospital get confused about time. Your child might even forget when you visited the last time or when you said you would come back for a visit. This confusion can make homesickness worse. To help your child keep track of your visits, draw or buy a simple calendar and write your plans down. Try your best to be on time for the visits and telephone calls that you plan.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td>7. Frequent visits and telephone calls help ease children's homesickness. Of course, you have other commitments, but try to visit as often as possible. Avoid canceling visits at the last moment, which is particularly upsetting to children. If you cannot visit, be sure to call and talk with your child on the telephone.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1_start\">8. Despite all of your efforts and all of the staff's efforts to make children feel comfortable, many of them still feel homesick in the hospital. Fortunately, many children can help themselves feel better by doing one of the things below. You and the hospital staff should share these techniques with your child:</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">a. Do a fun activity to forget about missing home. Play a game with a friend, watch television, listen to music, or read a book.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">b. Do something to feel closer to home. Write a letter, talk on the telephone, or look at a family picture.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">c. Think about the good side of being in the hospital. There are kids to play with and staff to help you. Being in the hospital will help you get better.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">d. Keep a positive attitude. Staff members can answer your questions and teach you a lot about dealing with your problems.</td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">e. Remind yourself that you will be home soon. Hospitalizations do not last forever. </td>\n\t\t\t\t</tr>\n\t\t\t\t<tr>\n\t\t\t\t\t<td class=\"sublist1\">f. Talk with someone who can make you feel better, such as your doctor or one of the other staff members.</td>\n\t\t\t\t</tr>\n\n</tbody>\n</table>\n\r\n\r\n<html xmlns:mso=\"urn:schemas-microsoft-com:office:office\" xmlns:msdt=\"uuid:C2F41010-65B3-11d1-A29F-00AA00C14882\"><head>\n<!--[if gte mso 9]><xml>\n<mso:CustomDocumentProperties>\n<mso:Specialty msdt:dt=\"string\">13.0000000000000</mso:Specialty>\n<mso:Media_Type msdt:dt=\"string\">Table</mso:Media_Type>\n<mso:Media_Notes msdt:dt=\"string\">4/5/2007 - Perm was granted to the author before when he submitted his new topic. to Terrence to make.mt 4/21/2008--Requested renewal (JD). 5/21/2008--Permission granted with Dr. Walton's signature (JD). 6/6/2009--Permission granted via Rightslink, awaiting formal invoice (JD). 7/6/2009--Formal invoice received, to Catherine for payment (JD). 5/14/2010--Renewal granted via Rightslink on behalf of Dr. Walton (JD).</mso:Media_Notes>\n<mso:Edit_Table msdt:dt=\"string\">&lt;a href=&quot;/Graphics/Pages/TableEditor.aspx?SPID=54719&amp;amp;Mode=Edit&quot;&gt;&lt;/a&gt;</mso:Edit_Table>\n</mso:CustomDocumentProperties>\n</xml><![endif]-->\n<title>Parents_homesick_prevention.htm</title></head></div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 119, Pages 192-201, Copyright © 2007 by the AAP.</div><div id=\"graphicVersion\">Graphic 77922 Version 14.0</div></div></div>"},"77924":{"type":"graphic_picture","displayName":"Urticarial vasculitis III","title":"Urticarial vasculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticarial vasculitis</div><div class=\"cntnt\"><img style=\"width:333px; height:504px;\" src=\"images/ALLRG/77924_UV_lesions_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Discrete and confluent urticarial patches with unusual annular and semi-annular features.</div><div id=\"graphicVersion\">Graphic 77924 Version 3.0</div></div></div>"},"77929":{"type":"graphic_algorithm","displayName":"Pacemaker algorithm sinus node dysfunction","title":"Selection of pacemaker systems for patients with sinus node dysfunction","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Selection of pacemaker systems for patients with sinus node dysfunction</div><div class=\"cntnt\"><img style=\"width:557px; height:452px;\" src=\"images/CARD/77929_Pacemakers_sick_sinus.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Decisions are illustrated by diamonds. Shaded boxes indicate type of pacemaker.</div><div class=\"graphic_footnotes\">AV: atrioventricular.</div><div class=\"graphic_reference\">Reproduced with permission from: Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008; 51(21):e1-e62. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright © 2008 Elsevier Inc.</div><div id=\"graphicVersion\">Graphic 77929 Version 4.0</div></div></div>"},"77930":{"type":"graphic_table","displayName":"Effects of OA PI","title":"Effects of osteoarthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of osteoarthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Age when symptoms start</td> </tr> <tr> <td>Usually after 40</td> </tr> <tr> <td class=\"subtitle1_single\">Commonly affected body parts</td> </tr> <tr> <td>Neck and lower back</td> </tr> <tr> <td>Joint at the base of the thumb</td> </tr> <tr> <td>Knuckles in the middle and near the tip of the fingers</td> </tr> <tr> <td>Hip</td> </tr> <tr> <td>Knee</td> </tr> <tr> <td>Joint in the foot, above the heel</td> </tr> <tr> <td>Knuckle at the base of the big toe</td> </tr> <tr> <td class=\"subtitle1_single\">Less commonly affected body parts</td> </tr> <tr> <td>Shoulder</td> </tr> <tr> <td>Wrist</td> </tr> <tr> <td>Elbow</td> </tr> <tr> <td>Knuckles at the base of the fingers</td> </tr> <tr> <td class=\"subtitle1_single\">Symptoms</td> </tr> <tr> <td>Pain</td> </tr> <tr> <td>Stiffness</td> </tr> <tr> <td>Crackling or clicking sounds in the joints</td> </tr> <tr> <td>Extra bone growth (for example, knuckles that look swollen or knobby)</td> </tr> <tr> <td>Decreased range of motion</td> </tr> <tr> <td>Problems with the alignment of certain joints</td> </tr> <tr> <td>Tenderness to the touch</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77930 Version 1.0</div></div></div>"},"77932":{"type":"graphic_figure","displayName":"Hip internal rotation","title":"Evaluation of internal rotation of the hips","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Evaluation of internal rotation of the hips</div><div class=\"cntnt\"><img style=\"width:464px; height:326px;\" src=\"images/EM/77932_Hip_internal_rotation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Evaluation of internal rotation of the hips is performed with the child in the prone position and with the knees flexed; the ankles and feet are then rotated away from the body to compare the amount of internal rotation in the symptomatic versus the asymptomatic hip. The pelvis must be kept flat on the examining table; otherwise, asymmetry of internal rotation may not be appreciated.</div><div id=\"graphicVersion\">Graphic 77932 Version 1.0</div></div></div>"},"77933":{"type":"graphic_table","displayName":"Differential diagnosis of viral CNS infection","title":"Potentially treatable diseases mimicking viral CNS infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potentially treatable diseases mimicking viral CNS infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Infectious</td> </tr> <tr> <td>Tuberculosis</td> </tr> <tr> <td>Partially treated bacterial meningitis</td> </tr> <tr> <td>Listeria meningitis (occasionally)</td> </tr> <tr> <td>Spirochetal infection (syphilis, Lyme disease, leptospirosis)</td> </tr> <tr> <td>Rocky Mountain spotted fever</td> </tr> <tr> <td>Fungal infection (cryptococcosis, coccidioidomycosis, histoplasmosis)</td> </tr> <tr> <td>Mycoplasma pneumoniae</td> </tr> <tr> <td>Parameningeal infection (brain abscess, epidural or subdural abscess)</td> </tr> <tr> <td>Amebic infection</td> </tr> <tr> <td>Trypanosomiasis</td> </tr> <tr> <td>Toxoplasmosis</td> </tr> <tr> <td>Cerebral malaria (<em>Plasmodium falciparum</em>)</td> </tr> <tr> <td>Disseminated cat-scratch disease (<em>Bartonella henselae</em>)</td> </tr> <tr> <td>Whipple's Disease (<em>Tropheryma whipplei</em>)</td> </tr> <tr> <td>Legionellosis</td> </tr> <tr> <td class=\"subtitle1_single\">Noninfectious</td> </tr> <tr> <td>Tumor (meningeal or parenchymal)</td> </tr> <tr> <td>Dural venous sinus thrombosis</td> </tr> <tr> <td>Sarcoidosis</td> </tr> <tr> <td>Cerebral vasculitis</td> </tr> <tr> <td>Behcet syndrome</td> </tr> <tr> <td class=\"sublist1_start\">Drug-induced meningitis</td> </tr> <tr> <td class=\"sublist1\">Nonsteroidal antiinflammatory drugs</td> </tr> <tr> <td class=\"sublist1\">Sulfa drugs </td> </tr> <tr> <td class=\"sublist1\">Antithymocyte globulin</td> </tr> <tr> <td class=\"sublist1\">Intravenous immune globulin</td> </tr> <tr> <td>Migrainous syndromes with pleocytosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 77933 Version 3.0</div></div></div>"},"77934":{"type":"graphic_picture","displayName":"Normal vaginal flora","title":"Normal vaginal flora","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal vaginal flora</div><div class=\"cntnt\"><img style=\"width:367px; height:240px;\" src=\"images/ID/77934_Normalvaginalflora.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gram stain of vaginal swab under high-power magnification (x1000) showing mixed bacterial Gram stain morphology consistent with normal vaginal flora.</div><div class=\"graphic_reference\">Courtesy of Harriet Provine.</div><div id=\"graphicVersion\">Graphic 77934 Version 3.0</div></div></div>"},"77935":{"type":"graphic_table","displayName":"Thin smear malaria dx","title":"Clues to species diagnosis via thin smear","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clues to species diagnosis via thin smear</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\"><em>P. falciparum</em></td> <td class=\"subtitle1\"><em>P. vivax</em></td> <td class=\"subtitle1\"><em>P. ovale</em></td> <td class=\"subtitle1\"><em>P. malariae</em></td> </tr> <tr> <td>Size of RBCs</td> <td>Normal size (sometimes distorted and crenated)</td> <td>Enlarged</td> <td>Enlarged and usually oval in shape (with fimbriated ends)</td> <td>Normal size</td> </tr> <tr> <td>Number of parasites per RBC</td> <td>May be multiple</td> <td>Usually one</td> <td>Usually one</td> <td>Usually one</td> </tr> <tr> <td>Typical form of trophozoite</td> <td>Rings</td> <td>Amoeboid, often fragmented</td> <td>Compact and regular</td> <td>Compact</td> </tr> <tr> <td>Other characteristics</td> <td>Banana-shaped gametocytes; black pigment in RBCs; schizonts rare</td> <td>Schuffner's granules; often see gametocytes and schizonts</td> <td>Schuffner's granules; often see gametocytes and schizonts</td> <td>Often see gametocytes and schizonts</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div id=\"graphicVersion\">Graphic 77935 Version 2.0</div></div></div>"},"77938":{"type":"graphic_diagnosticimage","displayName":"Ultrasound showing hydronephrosis","title":"Ultrasound showing hydronephrosis","html":"<div class=\"graphic normal\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ultrasound showing hydronephrosis</div><div class=\"cntnt\"><img style=\"width:375px; height:253px;\" src=\"images/NEPH/77938_Ultrasonography_in_obstruct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal ultrasonogram showing hydronephrosis due to urinary tract obstruction. The collecting structures (CS) are distended by fluid, rather than being closely bunched together as in the normal kidney. This study was performed in a renal transplant.</div><div id=\"graphicVersion\">Graphic 77938 Version 6.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal renal ultrasound</div><div class=\"cntnt\"><img style=\"width:378px; height:249px;\" src=\"images/NEPH/63842_Normal_renal_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal renal ultrasonogram showing the renal outline and the normal width of the renal parenchyma (RP) which is represented by the black area between the renal capsule and, in white, the collecting system (CS). The collecting system structures are closely bunched together.</div><div id=\"graphicVersion\">Graphic 63842 Version 1.0</div></div></div>"},"77939":{"type":"graphic_diagnosticimage","displayName":"T3 esophageal cancer EUS","title":"T3 esophageal cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">T3 esophageal cancer</div><div class=\"cntnt\"><img style=\"width:449px; height:404px;\" src=\"images/GAST/77939_T3_esophageal_cancer_EUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic ultrasound image showing stage T3 esophageal cancer.</div><div class=\"graphic_reference\">Courtesy of John R Saltzman, MD.</div><div id=\"graphicVersion\">Graphic 77939 Version 2.0</div></div></div>"},"77941":{"type":"graphic_figure","displayName":"Schematic anatomic locations accessory pathways","title":"Schematic showing anatomic locations of accessory pathways as they cross the AV junction","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Schematic showing anatomic locations of accessory pathways as they cross the AV junction</div><div class=\"cntnt\"><img style=\"width:490px; height:322px;\" src=\"images/CARD/77941_Schematic_AV_junctions.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The atrioventricular (AV) valve plane of the heart is viewed from the cardiac apex. The tricuspid valve is on the left in this figure and the mitral valve on the right; the coronary sinus, which provides the venous drainage of the heart, passes posterior to the mitral valve and empties into the right atrium above the tricuspid valve. All AV bypass tracts cross the AV valve plane; their locations are named with respect to this orientation (eg, an anteroseptal bypass tract crosses the AV valve plane from atrium to ventricle in the region marked &quot;anteroseptal&quot; in the figure, at approximately 10 to 11 o'clock with respect to the mitral valve ring).</div><div class=\"graphic_reference\">Reproduced with permission from: Cosio FG, Anderson RH, Becker A, et al. Living anatomy of the atrioventricular junctions. A guide to electrophysiological Statement from the Cardiac Nomenclature Study Group, Working Group of Arrythmias, European Society of Cardiology, and the Task Force on Cardiac Nomenclature from NASPE. North American Society of Pacing and Electrophysiology. Eur Heart J 1999; 20:1068. Copyright © 1999 European Society of Cardiology.</div><div id=\"graphicVersion\">Graphic 77941 Version 3.0</div></div></div>"},"77943":{"type":"graphic_figure","displayName":"Cardiac catheterization PI","title":"Cardiac catheterization","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Cardiac catheterization</div><div class=\"cntnt\"><img style=\"width:524px; height:676px;\" src=\"images/PI/77943_Cardiac_catheterization_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For a cardiac catheterization, your doctor will make a very small cut in the top, inner part of your leg, or just above your hand. He or she will put a thin plastic tube, called a \"catheter,\" in a blood vessel which is just below the cut. Then he or she will move the tube through your blood vessels to your heart. When the tube is in place, your doctor can do different tests. Most people have a test called \"coronary angiography.\" For this test, your doctor will inject a dye that creates pictures to show if your heart arteries are clogged.</div><div id=\"graphicVersion\">Graphic 77943 Version 5.0</div></div></div>"},"77944":{"type":"graphic_table","displayName":"Vancouver and ILAR criteria for juvenile psoriatic arthritis","title":"Vancouver and ILAR criteria for juvenile psoriatic arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Vancouver and ILAR criteria for juvenile psoriatic arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Vancouver</td> <td class=\"subtitle1\">ILAR (Edmonton revision)</td> </tr> <tr> <td class=\"sublist1_start\" rowspan=\"5\"><strong>Inclusion criteria</strong></td> <td class=\"sublist1_start\">Arthritis plus psoriasis or arthritis plus at least two of the following:</td> <td class=\"sublist1_start\">Arthritis plus psoriasis or arthritis plus at least two of the following:</td> </tr> <tr> <td class=\"sublist1\">Dactylitis</td> <td class=\"sublist1\">Dactylitis</td> </tr> <tr> <td class=\"sublist1\">Nail pits</td> <td class=\"sublist1\">Nail pits or onycholysis</td> </tr> <tr> <td class=\"sublist1\">FHx of psoriasis in a first- or second-degree relative</td> <td class=\"sublist1\">FHx of psoriasis in a first-degree relative</td> </tr> <tr> <td class=\"sublist1\">Psoriasis-like rash</td> <td class=\"sublist1\">&nbsp;</td> </tr> <tr class=\"divider_top\"> <td><strong>Exclusion criteria</strong></td> <td>None</td> <td> <ol> <li>Arthritis in an HLA-B27-positive male beginning after the sixth birthday </li> <li>AS, ERA, sacroiliitis with IBD, reactive arthritis, or acute anterior uveitis, or a history of one of these disorders in a first-degree relative </li> <li>The presence of IgM RF on at least two occasions at least three months apart </li> <li>The presence of systemic JIA in a patient </li> <li>Arthritis fulfilling&nbsp;two JIA categories </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For both criteria sets, arthritis must be of unknown etiology, begin before the 16<SUP>th</SUP> birthday, and persist for at least six weeks. Under the Vancouver criteria, \"definite\" disease is arthritis plus psoriasis or arthritis plus three minor criteria, while \"probable\" disease is arthritis plus two minor criteria.</div><div class=\"graphic_footnotes\">ILAR: International League of Associations for Rheumatology; FHx: family history; AS: ankylosing spondylitis; ERA: enthesitis-related arthritis; IBD: inflammatory bowel disease; JIA: juvenile idiopathic arthritis; RF: rheumatoid factor.</div><div class=\"graphic_reference\">Reproduced from: Nigrovic PA, Sundel RP, Petty RE. Juvenile psoriatic arthritis. In: Textbook of Pediatric Rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Saunders, Philadelphia 2011. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 77944 Version 4.0</div></div></div>"},"77945":{"type":"graphic_figure","displayName":"Hormone levels reproductive age","title":"Hormone levels: Older and younger reproductive age","html":"<div class=\"graphic\"><div style=\"width: 754px\" class=\"figure\"><div class=\"ttl\">Hormone levels: Older and younger reproductive age</div><div class=\"cntnt\"><img style=\"width:734px; height:440px;\" src=\"images/ENDO/77945_Inhibins.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean daily levels of gonadotropins, sex steroids, and inhibins in older (ages 35 to 46 years; n = 21), shown in orange, and younger women (ages 20 to 34 years; n = 23), shown in blue.</div><div class=\"graphic_footnotes\">FSH: follicle-stimulating hormone; LH: luteinizing hormone.</div><div class=\"graphic_reference\">Adapted from: Welt CK, McNicholl DJ, Taylor AE, Hall JE. Female reproductive aging is marked by decreased secretion of dimeric inhibin. J Clin Endocrinol Metab 1999; 84:105.</div><div id=\"graphicVersion\">Graphic 77945 Version 5.0</div></div></div>"},"77946":{"type":"graphic_diagnosticimage","displayName":"Abnormal pancreaticobiliary junction I","title":"Abnormal pancreaticobiliary junction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Abnormal pancreaticobiliary junction</div><div class=\"cntnt\"><img style=\"width:266px; height:382px;\" src=\"images/GAST/77946_Anomalous_pancbil_junc_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography (ERCP) demonstrating an abnormal pancreaticobiliary junction in a child with recurrent abdominal pain and pancreatitis. Note the long, dilated common channel (thick arrow) containing a stone (thin arrow). The patient also has pancreas divisum.</div><div class=\"graphic_reference\">Courtesy of Mark Topazian, MD.</div><div id=\"graphicVersion\">Graphic 77946 Version 5.0</div></div></div>"},"77947":{"type":"graphic_figure","displayName":"LV mass LVEF outcome","title":"Left ventricular mass is an independent predictor of mortality","html":"<div class=\"graphic\"><div style=\"width: 517px\" class=\"figure\"><div class=\"ttl\">Left ventricular mass is an independent predictor of mortality</div><div class=\"cntnt\"><img style=\"width:497px; height:294px;\" src=\"images/CARD/77947_LVmassLVEFoutcome.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the SOLVD trials of 1172 patients with left ventricular (LV) dysfunction, Kaplan-Meier survival curves demonstrate that increased LV mass ≥298 g is an independent risk factor for all-cause mortality (p = 0.0014); a one standard deviation increase in LV mass is associated with a 17 percent increased risk of death. An LV ejection fraction (LVEF) ≥35 percent, however, is protective in those with LV mass ≥298 g.</div><div class=\"graphic_reference\">Data from Quinones MA, Greenberg BH, Kopelen HA, et al, for the SOLVD Investigators. J Am Coll Cardiol 2000; 35:1237.</div><div id=\"graphicVersion\">Graphic 77947 Version 3.0</div></div></div>"},"77948":{"type":"graphic_figure","displayName":"Auto PEEP and hyperinflation","title":"Auto-PEEP and dynamic hyperinflation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Auto-PEEP and dynamic hyperinflation</div><div class=\"cntnt\"><img style=\"width:444px; height:298px;\" src=\"images/PULM/77948_Auto_PEEP_and_hyperinflatio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This diagram shows the presence of auto-PEEP and dynamic hyperinflation with and without expiratory flow limitation. The diagram on the left displays the circumstance of expiratory flow limitation as reflected in proximal airway collapse (&quot;choke point&quot;). In the diagram on the right, expiratory flow limitation has not taken place although the patient manifests auto-PEEP and dynamic pulmonary hyperinflation as a function of increased expiratory resistance from the endotracheal tube, exhalation valve, and bacteria filter. The application of PEEP in the patient with expiratory flow limitation would be expected to improve expiratory airflow. However, in conditions without the presence of expiratory limitation, the application of PEEP would potentially worsen dynamic hyperinflation and increase the risk of barotrauma.</div><div class=\"graphic_footnotes\">PEEP: positive end-expiratory pressure.</div><div class=\"graphic_reference\">Adapted from Puritan-Bennett 1994, Form AA-1888.</div><div id=\"graphicVersion\">Graphic 77948 Version 2.0</div></div></div>"},"77950":{"type":"graphic_figure","displayName":"Tender points in fibromyalgia","title":"Tender points in fibromyalgia","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Tender points in fibromyalgia</div><div class=\"cntnt\"><img style=\"width:520px; height:312px;\" src=\"images/RHEUM/77950_Tender_points_in_fibromyalg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The 18 \"tender points\" important for the diagnosis of fibromyalgia. Note the bilateral symmetry of the labeled regions. Tenderness on palpation of at least 11 of these sites in a patient with at least a three-month history of diffuse musculoskeletal pain is recommended as a diagnostic standard for fibromyalgia.</div><div class=\"graphic_reference\">Adapted from: Goldenberg DL. Diagnostic and therapeutic challenges of fibromyalgia.&nbsp;Hosp Pract (Off Ed) 1989; 24:39.</div><div id=\"graphicVersion\">Graphic 77950 Version 3.0</div></div></div>"},"77951":{"type":"graphic_picture","displayName":"Endoscopic image of a transampullary covered metal stent","title":"Endoscopic image of a transampullary covered metal stent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endoscopic image of a transampullary covered metal stent</div><div class=\"cntnt\"><img style=\"width:360px; height:355px;\" src=\"images/GAST/77951_Endo_covered_metal_stent.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic post-deployment image of a fully covered metal stent.</div><div class=\"graphic_reference\">Courtesy of Douglas G. Adler, MD, FACS, FASGE.</div><div id=\"graphicVersion\">Graphic 77951 Version 1.0</div></div></div>"},"77953":{"type":"graphic_figure","displayName":"VF bilateral HH","title":"Bilateral homonymous hemianopias","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Bilateral homonymous hemianopias</div><div class=\"cntnt\"><img style=\"width:504px; height:426px;\" src=\"images/NEURO/77953_VF_bilateral_HH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Humphrey visual field (24-2) showing bilateral homonymous hemianopias; there is a complete right homonymous hemianopia and an incomplete congruous left homonymous hemianopia. This patient had bilateral occipital infarctions.</div><div id=\"graphicVersion\">Graphic 77953 Version 1.0</div></div></div>"},"77954":{"type":"graphic_table","displayName":"Percent nodal metastases","title":"Percentage of nodal metastases as a function of location and tumor size<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Percentage of nodal metastases as a function of location and tumor size<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\">\n<tbody>\n\n<tr>\n    <td class=\"subtitle1\">&nbsp;</td>\n    <td class=\"subtitle1\">T1</td>\n    <td class=\"subtitle1\">T2</td>\n    <td class=\"subtitle1\">T3</td>\n    <td class=\"subtitle1\">T4</td>\n  </tr>\n  <tr>\n    <td>Pyriform sinus</td>\n    <td>38 to 91</td>\n    <td>67 to 83</td>\n    <td>69 to 80</td>\n    <td>60 to 98</td>\n  </tr>\n  <tr>\n    <td>Pharyngeal wall</td>\n    <td>33 to 70</td>\n    <td>31 to 79</td>\n    <td>47 to 85</td>\n    <td>70 to 82</td>\n  </tr>\n  <tr>\n    <td>Postcricoid space</td>\n    <td>6</td>\n    <td>17</td>\n    <td>38</td>\n    <td>50</td>\n  </tr>\n\n</tbody>\n</table></div><div class=\"graphic_reference\">1. McGavran MH, Bauer WC, Spjut HJ, Ogura JH. Carcinoma of the Pyriform Sinus: the Results of Radical Surgery. Arch Otolaryngol 1963; 78:826.</div><div id=\"graphicVersion\">Graphic 77954 Version 1.0</div></div></div>"},"77955":{"type":"graphic_picture","displayName":"Towel stretch PI","title":"Towel stretch","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Towel stretch</div><div class=\"cntnt\"><img style=\"width:311px; height:323px;\" src=\"images/PI/77955_Towel_stretch_PI_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hold a 3-foot-long towel in both hands behind your back in the horizontal position. Then use your good arm to pull the towel so that your affected arm moves toward your lower back. You can also hold the towel at an angle (as shown) to do this exercise. Repeat this stretch 10 to 20 times.</div><div class=\"graphic_reference\">Courtesy of Bruce C Anderson, MD.</div><div id=\"graphicVersion\">Graphic 77955 Version 5.0</div></div></div>"},"77957":{"type":"graphic_diagnosticimage","displayName":"Osteomyelitis soft tissue","title":"Early osteomyelitis in a 6-year-old with fever and ankle pain","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Early osteomyelitis in a 6-year-old with fever and ankle pain</div><div class=\"cntnt\"><img style=\"width:426px; height:499px;\" src=\"images/PEDS/77957_Osteomyelitis_soft_tissue.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A) Plain radiographs of the ankle demonstrate deep soft tissue swelling inferior to the medial malleolus. B) A technetium 99m bone scan shows increased uptake in the distal tibia in the blood flow and bone uptake (four hour) phases.</div><div class=\"graphic_reference\">Courtesy of Marvin B Harper, MD.</div><div id=\"graphicVersion\">Graphic 77957 Version 2.0</div></div></div>"},"77959":{"type":"graphic_diagnosticimage","displayName":"Stone related cystic duct leak","title":"Stone-related cystic duct stump leak after cholecystectomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Stone-related cystic duct stump leak after cholecystectomy</div><div class=\"cntnt\"><img style=\"width:266px; height:378px;\" src=\"images/GAST/77959_Stone_related_cystic_duct_l.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic retrograde cholangiopancreatography demonstrates an incomplete cholecystectomy and cystic duct leak with retained common bile duct stones.</div><div class=\"graphic_reference\">Courtesy of Michael J Bourke, MBBS, FRACP.</div><div id=\"graphicVersion\">Graphic 77959 Version 4.0</div></div></div>"},"77960":{"type":"graphic_figure","displayName":"Single drug in whites","title":"Antihypertensive response to different drugs in whites","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Antihypertensive response to different drugs in whites</div><div class=\"cntnt\"><img style=\"width:474px; height:229px;\" src=\"images/NEPH/77960_Single_drug_in_whites.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Response rates to single drug therapy for hypertension in whites under the age of 60. There were no significant differences in response, except that hydrochlorothiazide (HCTZ) appeared to be least effective. A response was defined as a diastolic pressure below 90 mmHg at the end of the titration phase and below 95 mmHg at one year. The pattern of response was similar but the success rate for each drug was reduced by five to 15 percent if goal diastolic pressure were less than 90 mmHg at one year. There were between 30 and 39 patients in each group.</div><div class=\"graphic_reference\">Data from Materson, BJ, Reda, DJ, Cushman, WC, et al, N Engl J Med 1993; 328:914. Correction and additional data: Am J Hypertens 1995; 8:189.</div><div id=\"graphicVersion\">Graphic 77960 Version 2.0</div></div></div>"},"77962":{"type":"graphic_movie","displayName":"Aortic regurgitation as heard at the lower left sternal border","title":"Phonocardiogram of aortic regurgitation as heard at the lower left sternal border ","html":"<div class=\"graphic normal\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Phonocardiogram of aortic regurgitation as heard at the lower left sternal border </div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/77962_aorllsbconv.mp4\" style=\"width:458px;height:468px\"></div><img style=\"width:448px; height:256px;\" src=\"images/CARD/77962_aorllsb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Carotid artery pulse tracing and phonocardiogram of aortic regurgitation as heard at the fourth left intercostal space. S1 (mitral and tricuspid valve closure) is followed by a short midsystolic ejection murmur resulting from the large stroke volume seen in aortic regurgitation. Following S2 (aortic and pulmonic valve closure), there is a holodiastolic blowing murmur of aortic regurgitation (AR).</div><div class=\"graphic_reference\">Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.</div><div id=\"graphicVersion\">Graphic 77962 Version 5.0</div></div></div>"},"77963":{"type":"graphic_figure","displayName":"Systolic BP in type 2 diabetes","title":"Lower systolic blood pressure (BP) is associated with fewer complications in patients with type 2 diabetes","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lower systolic blood pressure (BP) is associated with fewer complications in patients with type 2 diabetes</div><div class=\"cntnt\"><img style=\"width:383px; height:281px;\" src=\"images/NEPH/77963_Systolic_BP_in_type_2_diabe.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Among 3642 patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study (UKPDS), there was an inverse correlation between the updated mean systolic blood pressure and the aggregate end point for any complication related to diabetes (myocardial infarction, sudden death, angina, stroke, renal failure, lower extremity amputation or death from peripheral vascular disease, death from hyperglycemia or hypoglycemia, heart failure, vitreous hemorrhage, retinal photocoagulation, and cataract extraction). The lowest risk occurred at a systolic pressure below 120 mmHg. The values, adjusted for age, sex, and ethnic group, are expressed for white men aged 50 to 54 years at diagnosis with a mean duration of diabetes of ten years.</div><div class=\"graphic_reference\">Data from Adler AI, Stratton IM, Neil HA, et al. BMJ 2000; 321:412.</div><div id=\"graphicVersion\">Graphic 77963 Version 4.0</div></div></div>"},"77964":{"type":"graphic_diagnosticimage","displayName":"3D-ultrasound of complete cleft lip","title":"3D-ultrasound of complete cleft lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">3D-ultrasound of complete cleft lip</div><div class=\"cntnt\"><img style=\"width:330px; height:350px;\" src=\"images/OBGYN/77964_3D_comp_cleft_lip_and_palat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rendered three-dimensional image of an early second trimester fetal face. The image demonstrates a unilateral complete cleft lip.</div><div class=\"graphic_reference\">Courtesy of Thomas Shipp, MD.</div><div id=\"graphicVersion\">Graphic 77964 Version 3.0</div></div></div>"},"77965":{"type":"graphic_diagnosticimage","displayName":"Amyloidosis of small bowel UGI","title":"Amyloidosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Amyloidosis</div><div class=\"cntnt\"><img style=\"width:271px; height:288px;\" src=\"images/GAST/77965_Amyloidosis_of_small_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper gastrointestinal series showing nonspecific dilatation of small bowel loops (arrow) with a stricture in the duodenal loop (arrowhead) in a patient with secondary amyloidosis.</div><div class=\"graphic_reference\">Reproduced with permission from Malagelada JR, Camilleri M, Stanghellini V. Manometric Diagnosis of Gastrointestinal Motility Disorders. Thieme Medical Publishers, New York 1986.</div><div id=\"graphicVersion\">Graphic 77965 Version 3.0</div></div></div>"},"77966":{"type":"graphic_diagnosticimage","displayName":"Linear EUS normal anatomy","title":"Linear endoscopic ultrasound normal anatomy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Linear endoscopic ultrasound normal anatomy</div><div class=\"cntnt\"><img style=\"width:432px; height:336px;\" src=\"images/GAST/77966_Linear_EUS_normal_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal anatomy of target region as demonstrated by linear endosonography.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery.</div><div class=\"graphic_reference\">Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.</div><div id=\"graphicVersion\">Graphic 77966 Version 11.0</div></div></div>"},"77967":{"type":"graphic_picture","displayName":"Tissue core Gross","title":"Tissue core","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Tissue core</div><div class=\"cntnt\"><img style=\"width:478px; height:473px;\" src=\"images/GAST/77967_Tissue_core_Gross.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of a tissue core (arrow) obtained by a trucut biopsy.</div><div class=\"graphic_reference\">Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.</div><div id=\"graphicVersion\">Graphic 77967 Version 1.0</div></div></div>"},"77968":{"type":"graphic_figure","displayName":"Survival MUD transplant CML","title":"Survival in chronic myeloid leukemia after matched unrelated donor transplantation","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Survival in chronic myeloid leukemia after matched unrelated donor transplantation</div><div class=\"cntnt\"><img style=\"width:458px; height:290px;\" src=\"images/HEME/77968_Survival_MUD_transplant_CML.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph shows the probability of survival versus years after matched unrelated donor (MUD) hematopoietic cell transplantation for patients transplanted within the first year after diagnosis of chronic myelogenous leukemia (CML). Survival data is shown in red for those &lt;21 years of age at the time of transplant, in blue for those 21 to 36, in green for those 37 to 50, and in red for those &gt;50.</div><div class=\"graphic_reference\">Data from Hansen, JA, et al. N Engl J Med 1998; 338:962.</div><div id=\"graphicVersion\">Graphic 77968 Version 2.0</div></div></div>"},"77971":{"type":"graphic_figure","displayName":"Person having an echo PI","title":"Transthoracic echocardiogram (echo)","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiogram (echo)</div><div class=\"cntnt\"><img style=\"width:508px; height:486px;\" src=\"images/PI/77971_EchoPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows a person getting an echocardiogram (or \"echo\"). To do an echo, a doctor or nurse puts some gel on a person's chest. He or she presses a thick wand (called a \"transducer\") against the chest and moves it around. An echo uses sound waves to create images of the heart that appear on a computer screen. A test called an electrocardiogram (ECG) is done during an echo. For an ECG, patches (called \"electrodes\") are stuck to a person's chest. Wires run from the patches to a machine that records the electrical activity of the heart.</div><div id=\"graphicVersion\">Graphic 77971 Version 4.0</div></div></div>"},"77972":{"type":"graphic_figure","displayName":"Wound healing schematic","title":"Wound healing schematic","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Wound healing schematic</div><div class=\"cntnt\"><img style=\"width:569px; height:549px;\" src=\"images/SURG/77972_Wound_healing_schematic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of wound healing processes.</div><div class=\"graphic_footnotes\">ADP: adenosine diphosphate; TXA2: thromboxane A2; TGF: transforming growth factor; PDGF: platelet-derived growth factor; PF4: platelet factor 4; TNF-&#945;: tumor necrosis factor &#945;; FGF: fibroblast growth factor; PAF: platelet-activating factor; KGF: keratinocyte growth factor.</div><div class=\"graphic_reference\">Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery Scientific Principles and Practice, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &#169; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 77972 Version 1.0</div></div></div>"},"77974":{"type":"graphic_diagnosticimage","displayName":"AP view midshaft femur fracture with intramedullary rod","title":"AP view of midshaft femur fracture with intramedullary rod","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">AP view of midshaft femur fracture with intramedullary rod</div><div class=\"cntnt\"><img style=\"width:241px; height:360px;\" src=\"images/EM/77974_Femur_fx_IM_rod.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">According to many orthopedic sources, standard treatment of a femoral shaft fracture is an antegrade reamed intramedullary nail, shown in the radiograph above. This technique enables rigid fixation and is associated with a 98 to 99% union rate.</div><div class=\"graphic_footnotes\">AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Thomas J Mezzanotte, MD.</div><div id=\"graphicVersion\">Graphic 77974 Version 4.0</div></div></div>"},"77975":{"type":"graphic_figure","displayName":"Lead time bias","title":"How lead time affects survival time after screening","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">How lead time affects survival time after screening</div><div class=\"cntnt\"><img style=\"width:453px; height:230px;\" src=\"images/PC/77975_Leadtimebias.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded areas indicate length of survival after diagnosis (Dx).</div><div class=\"graphic_footnotes\">O: onset of disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials, 5th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 77975 Version 11.0</div></div></div>"},"77977":{"type":"graphic_waveform","displayName":"COPD pressure flow muscle","title":"COPD pressure, flow, and muscle tracings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">COPD pressure, flow, and muscle tracings</div><div class=\"cntnt\"><img style=\"width:438px; height:537px;\" src=\"images/PULM/77977_COPD_pressure_flow_muscle.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recordings of flow, airway pressure (Paw), and transversus abdominis electromyography in a critically ill patient with COPD who is receiving pressure support of 20 cm H<SUB>2</SUB>O. The onset of expiratory muscle activity (vertical dotted line) occurred when mechanical inflation was only partially completed, indicating that the patient was \"fighting the ventilator\".</div><div class=\"graphic_reference\">Reproduced with permission from: Parthasarathy S, Jubran A, Tobin MJ. Am J Respir Crit Care Med 1998; 158:1471. Copyright ©1998 American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 77977 Version 3.0</div></div></div>"},"77978":{"type":"graphic_diagnosticimage","displayName":"TB tracheal stenosis CXR","title":"Tuberculosis tracheobronchial stenosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tuberculosis tracheobronchial stenosis</div><div class=\"cntnt\"><img style=\"width:382px; height:360px;\" src=\"images/PULM/77978_TB_tracheal_stenosis_CXR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph demonstrates total collapse of right lung, narrowing of the lower trachea, complete occlusion of right mainstem bronchus, and marked hyperexpansion of the left lung, which crosses the midline towards the right hemithorax.</div><div id=\"graphicVersion\">Graphic 77978 Version 2.0</div></div></div>"},"77979":{"type":"graphic_diagnosticimage","displayName":"DISH radiograph lumbar spine","title":"Lumbar spine in diffuse idiopathic skeletal hyperostosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lumbar spine in diffuse idiopathic skeletal hyperostosis</div><div class=\"cntnt\"><img style=\"width:448px; height:373px;\" src=\"images/RHEUM/77979_DISHradiographlumbarspin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral (left) and anteroposterior (right) views of the lumbar spine in a patient with DISH. The changes are more extensive than usual. Radiolucent areas anterior to L3 and L4 (arrows) represent the space between the vertebral body and the ossified anterior longitudinal ligament. There is remarkable preservation of disc height despite the individual's age (93 years).</div><div class=\"graphic_footnotes\">DISH: diffuse idiopathic skeletal hyperostosis.</div><div class=\"graphic_reference\">Courtesy of John Esdaile, MD.</div><div id=\"graphicVersion\">Graphic 77979 Version 3.0</div></div></div>"},"77980":{"type":"graphic_figure","displayName":"Germinal center","title":"Diagram of a germinal center","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagram of a germinal center</div><div class=\"cntnt\"><img style=\"width:418px; height:403px;\" src=\"images/RHEUM/77980_Germinal_center.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Germinal centers are organized into several \"compartments,\" each devoted to particular processes in the generation of an antibody response. The dark zone contains many rapidly dividing B cells called centroblasts, which do not express surface immunoglobulin. These cells continually give rise to centrocytes, nondividing cells which have regained surface&nbsp;immunoglobulin, which migrate into the basal light zone. If they contact their specific antigen, they enter the apical light zone, otherwise they die. The mechanisms determining whether cells will become memory cells or antibody-producing cells (plasma cells) may operate within the apical light zone.</div><div class=\"graphic_reference\">Reproduced with permission from Bona C, Bonilla F. B Cells and Humoral Immunity. In: Textbook of Immunology,&nbsp;2nd ed, Harwood Academic Publishers 1996. Page 38, figure 2-20. Original source: Liu et al. Germinal centers in T cell-dependent antibody responses. Immunology Today 1992; 13:17.</div><div id=\"graphicVersion\">Graphic 77980 Version 3.0</div></div></div>"},"77982":{"type":"graphic_table","displayName":"Sources of vitamin D PI","title":"Selected food sources of vitamin D","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected food sources of vitamin D</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Food</td> <td class=\"subtitle1\">International units per serving</td> </tr> <tr> <td>Cod liver oil, 1 tablespoon (15 mL)</td> <td>1360</td> </tr> <tr> <td>Salmon (sockeye), cooked, 3 ounces (85 g)</td> <td>794</td> </tr> <tr> <td>Mushrooms that have been exposed to ultraviolet light to increase vitamin D, 3 ounces (85 g) (not yet commonly available)</td> <td>400</td> </tr> <tr> <td>Mackerel, cooked, 3 ounces (85 g)</td> <td>388</td> </tr> <tr> <td>Tuna fish, canned in water, drained, 3 ounces (85 g)</td> <td>154</td> </tr> <tr> <td>Milk, nonfat, reduced fat, and whole, vitamin D-fortified, 8 ounces (240 mL)</td> <td>115 to 124</td> </tr> <tr> <td>Orange juice fortified with vitamin D, 8 ounces (240 mL) (check product labels, as amount of added vitamin D varies)</td> <td>100</td> </tr> <tr> <td>Yogurt, fortified with 20 percent of the DV for vitamin D, 6 ounces (180 mL) (more heavily fortified yogurts provide more of the DV)</td> <td>80</td> </tr> <tr> <td>Margarine, fortified, 1 tablespoon (15 g)</td> <td>60</td> </tr> <tr> <td>Sardines, canned in oil, drained, 2 sardines</td> <td>46</td> </tr> <tr> <td>Liver, beef, cooked, 3.5 ounces (100 g)</td> <td>46</td> </tr> <tr> <td>Ready-to-eat cereal, fortified with 10 percent of the DV for vitamin D, 6 to 8 ounces (227 g) (more heavily fortified cereals might provide more of the DV)</td> <td>40</td> </tr> <tr> <td>Egg, 1 whole (vitamin D is found in yolk)</td> <td>25</td> </tr> <tr> <td>Cheese, Swiss, 1 ounce (29 g)</td> <td>6</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">In the United States, reference values are listed on food labels as a percentage of DVs (%DV), based on a 2000 calorie daily energy intake.</div><div class=\"graphic_footnotes\">DV: daily value; %: percent.</div><div class=\"graphic_reference\">US Department of Agriculture, Agricultural Research Service. USDA Nutrient Database for Standard Reference, Release 22, 2009.</div><div id=\"graphicVersion\">Graphic 77982 Version 6.0</div></div></div>"},"77983":{"type":"graphic_table","displayName":"Erythema multiforme and SJS-TEN skin findings","title":"Cutaneous findings in severe bullous erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cutaneous findings in severe bullous erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis&nbsp;</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Bullous erythema multiforme</td> </tr> <tr> <td>Detachment less than 10 percent of BSA <strong>plus</strong></td> </tr> <tr> <td>Typical targets <strong>or</strong></td> </tr> <tr> <td>Raised, atypical targets</td> </tr> <tr> <td class=\"subtitle1_single\">Stevens-Johnson syndrome</td> </tr> <tr> <td>Detachment less than 10 percent of BSA <strong>plus</strong></td> </tr> <tr> <td>Widespread macules <strong>or</strong></td> </tr> <tr> <td>Flat, atypical targets</td> </tr> <tr> <td class=\"subtitle1_single\">Overlap Stevens-Johnson syndrome/toxic epidermal necrolysis</td> </tr> <tr> <td>Detachment between 10 and 30 percent of BSA <strong>plus</strong></td> </tr> <tr> <td>Widespread macules <strong>or</strong></td> </tr> <tr> <td>Flat, atypical targets</td> </tr> <tr> <td class=\"subtitle1_single\">Toxic epidermal necrolysis</td> </tr> <tr> <td class=\"subtitle2_single\">With spots or without blisters</td> </tr> <tr> <td class=\"indent1\">Detachment of greater than 30 percent of BSA <strong>plus</strong></td> </tr> <tr> <td class=\"indent1\">Widespread macules <strong>or</strong></td> </tr> <tr> <td class=\"indent1\">Flat, atypical targets </td> </tr> <tr> <td class=\"subtitle2_single\">Without spots</td> </tr> <tr> <td class=\"indent1\">Detachment greater than 10 percent of BSA with large epidermal sheets <strong>and</strong></td> </tr> <tr> <td class=\"indent1\">Without any macules or targets</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BSA: body surface area.</div><div class=\"graphic_reference\">Adapted from Bastuji-Garin S, Rzany B, Stern R, et al. Arch Dermatol 1993; 129:92.</div><div id=\"graphicVersion\">Graphic 77983 Version 4.0</div></div></div>"},"77985":{"type":"graphic_table","displayName":"Frequency of mutant alleles","title":"Summary of the frequency of mutant alleles in 227 North Americans with galactosemia (each patient has two alleles)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of the frequency of mutant alleles in 227 North Americans with galactosemia (each patient has two alleles)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Mutant alleles</td> <td class=\"subtitle1\">Caucasian</td> <td class=\"subtitle1\">Hispanic</td> <td class=\"subtitle1\">African American</td> </tr> <tr> <td>Q188R</td> <td>257 (64%)</td> <td>24 (50%)</td> <td>22 (21%)</td> </tr> <tr> <td>S135L</td> <td>6 (1.5%)</td> <td>-</td> <td>49 (47%)</td> </tr> <tr> <td>N314D</td> <td>4 (1%)</td> <td>-</td> <td>-</td> </tr> <tr> <td>Other</td> <td>135 (33.5%)</td> <td>24 (50%)</td> <td>33 (32%)</td> </tr> <tr class=\"divider_top\"> <td><strong>Total alleles</strong></td> <td><strong>402</strong></td> <td><strong>48</strong></td> <td><strong>104</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">While certain alleles are common, a significant portion are rare or unidentified.</div><div class=\"graphic_reference\">Reproduced with permission from: Wong LJ, Xu YK, Wang BT, et al. Am J Hum Genet 1996; 59:A296. Copyright © 1996 The University of Chicago Press.</div><div id=\"graphicVersion\">Graphic 77985 Version 6.0</div></div></div>"},"77986":{"type":"graphic_picture","displayName":"Cellulitis with venous insufficiency","title":"Cellulitis with venous insufficiency","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cellulitis with venous insufficiency</div><div class=\"cntnt\"><img style=\"width:236px; height:288px;\" src=\"images/PC/77986_Cellulitis_venous_insuffici.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bilateral venous insufficiency, as demonstrated by edema, venous flairs, and pigment changes on the left leg. The right leg also shows massive pitting edema (thumb mark at arrow) and red inflamed skin, suggesting the presence of cellulitis.</div><div class=\"graphic_reference\">Courtesy of Patrick C Alguire, MD.</div><div id=\"graphicVersion\">Graphic 77986 Version 2.0</div></div></div>"},"77987":{"type":"graphic_table","displayName":"Virologic response to treatment","title":"Virologic response to treatment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Virologic response to treatment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Time</td> <td class=\"subtitle1\">Expectation</td> <td class=\"subtitle1\">Reference</td> </tr> <tr> <td>1 week</td> <td>VL decrease by 0.75 to 1 log10 copies/mL</td> <td>Poulis, 2001</td> </tr> <tr> <td rowspan=\"2\">4 weeks</td> <td rowspan=\"2\">VL decrease by 1.5 to 2 log10 copies/mL to &#60;5000 copies/mL</td> <td>Ghani, 2002</td> </tr> <tr> <td>Maggiolo, 2000</td> </tr> <tr> <td>8-16 weeks</td> <td>&#60;500 copies/mL</td> <td>Demeter, 2001</td> </tr> <tr> <td>16-24 weeks</td> <td>&#60;50 copies/mL</td> <td>Yeni, 2002</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">VL: viral load.</div><div id=\"graphicVersion\">Graphic 77987 Version 3.0</div></div></div>"},"77988":{"type":"graphic_figure","displayName":"Spread odontogenic infection","title":"Routes of spread of odontogenic orofacial infections","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Routes of spread of odontogenic orofacial infections</div><div class=\"cntnt\"><img style=\"width:188px; height:378px;\" src=\"images/ID/77988_Spread_odontogenic_infectio.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spread occurs along planes of least resistance. <br />Top panel: Coronal section in the region of the first molar teeth: (a) maxillary antrum; (b) nasal cavity; (c) palatal plate; (d) sublingual space (above the mylohyoid muscle); (e) submandibular space (below the mylohyoid muscle); (f) intraoral presentation with infection spreading through the buccal plates inside the attachment of the buccinator muscle; (g) extraoral presentation to buccal space with infection spreading through the buccal plates outside the attachment of the buccinator muscle. <br />Bottom panel: Lingual aspect of the mandible: (a) apices of the involved tooth above the myohyoid muscle, with spread of infection to the sublingual space; (b) apices of involved tooth below the mylohyoid muscle, with spread of infection into the submandibular space.</div><div class=\"graphic_reference\">Reproduced with permission from Chow AW, Roser SM, Brady FA, Ann Intern Med 1978; 88:392.</div><div id=\"graphicVersion\">Graphic 77988 Version 3.0</div></div></div>"},"77990":{"type":"graphic_picture","displayName":"Hidradenitis suppurativa","title":"Hidradenitis suppurativa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hidradenitis suppurativa</div><div class=\"cntnt\"><img style=\"width:257px; height:397px;\" src=\"images/OBGYN/77990_Hidradentitis_suppurativa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comedones and bridged scars in a flexure.</div><div class=\"graphic_reference\">Reproduced with permission from: Ridley CM, Neill SM (Eds), The Vulva, 2nd ed, Blackwell Science, Oxford, 1999, p.141.</div><div id=\"graphicVersion\">Graphic 77990 Version 4.0</div></div></div>"},"77991":{"type":"graphic_picture","displayName":"Congenital lobar emphysema histology section","title":"Histology section in congenital lobar emphysema","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histology section in congenital lobar emphysema</div><div class=\"cntnt\"><img style=\"width:264px; height:387px;\" src=\"images/PEDS/77991_CLE_histology_section.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology section from&nbsp;a two-year-old girl with congenital lobar emphysema. The junction of the affected and unaffected lobules is shown. In the affected region (lower portion), airspaces and terminal bronchioles are enlarged; their walls are normal and resemble those in the adjacent uninvolved lobules.</div><div class=\"graphic_reference\">Courtesy of Claire Langston, MD, and Christopher Oermann, MD.</div><div id=\"graphicVersion\">Graphic 77991 Version 2.0</div></div></div>"},"77992":{"type":"graphic_waveform","displayName":"Intermediate case 13 answer","title":"Hypercalcemia","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hypercalcemia</div><div class=\"cntnt\"><img style=\"width:540px; height:331px;\" src=\"images/CARD/77992_Intermediate_case_13_answer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shortened QT interval in hypercalcemia that results from shortening of the duration of the ventricular action potential. (Hypocalcemia has the opposite effect.) Note how the T waves appear to take off directly from the end of the QRS due to abbreviation of the ST segment. The slight J point elevation in leads V1 to V3 may also be seen with hypercalcemia in the absence of ischemia.</div><div class=\"graphic_reference\">Courtesy of Ary Goldberger, MD.</div><div id=\"graphicVersion\">Graphic 77992 Version 2.0</div></div></div>"},"77993":{"type":"graphic_waveform","displayName":"Advanced case 9","title":"Advanced case 9","html":"<div class=\"graphic normal\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Advanced case 9</div><div class=\"cntnt\"><img style=\"width:540px; height:87px;\" src=\"images/CARD/77993_Advanced_case_9.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 77993 Version 2.0</div></div><div style=\"width: 450px\" class=\"figure\"><div class=\"ttl\">Normal rhythm strip</div><div class=\"cntnt\"><img style=\"width:432px; height:165px;\" src=\"images/CARD/59022_Normal_rhythm_strip.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.</div><div class=\"graphic_reference\">Courtesy of Morton F Arnsdorf, MD.</div><div id=\"graphicVersion\">Graphic 59022 Version 3.0</div></div></div>"},"77994":{"type":"graphic_table","displayName":"SSI eligibility children","title":"Information required for Supplemental Security Income determination in children with chronic illness","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Information required for Supplemental Security Income determination in children with chronic illness</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Diagnosis and tests listed in the Social Security Administration's childhood \"<a href=\"https://www.ssa.gov/disability/professionals/bluebook/listing-impairments.htm\" spellcheck=\"true\" target=\"_blank\">Listing of Impairments</a>\" for children (Part B)</td> </tr> <tr> <td>Medical history of the child for the previous 12 months</td> </tr> <tr> <td>Complete, detailed, clinical findings (eg, results of physical, intelligence, developmental, and mental status examinations)</td> </tr> <tr> <td>Complete, detailed laboratory findings (eg, blood pressure, radiographs)</td> </tr> <tr> <td>Specific diagnosis (statement of disease or injury based upon signs and symptoms)</td> </tr> <tr> <td>Review of treatment(s) prescribed and description of response and prognosis</td> </tr> <tr> <td>The probable duration of the impairment</td> </tr> <tr> <td>An assessment of the child's physical or mental abilities to function independently, appropriately, and effectively in an age-appropriate manner and to perform age-appropriate daily activities</td> </tr> <tr> <td>The nature and limiting effects of the impairment(s) on the child's ability to function independently, appropriately, and effectively in an age-appropriate manner and to perform age-appropriate daily activities</td> </tr> <tr> <td>School documents, reports, or information indicating the child's need for special education services and deviations from age-appropriate performance in the school setting</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Council on Children With Disabilities. From the American Academy of Pediatrics: Policy statements--Supplemental Security Income (SSI) for children and youth with disabilities. Pediatrics 2009; 124:1702.</div><div id=\"graphicVersion\">Graphic 77994 Version 3.0</div></div></div>"},"77995":{"type":"graphic_table","displayName":"Timing first exam for ROP","title":"Timing of first eye examination for retinopathy of prematurity based upon gestational age at birth*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of first eye examination for retinopathy of prematurity based upon gestational age at birth*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age at birth<br /> (weeks)</td> <td class=\"subtitle1\">Chronologic age at initial examination<br /> (weeks)</td> </tr> <tr> <td class=\"centered\">22<sup>&#182;</sup></td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"centered\">23<sup>&#182;</sup></td> <td class=\"centered\">7</td> </tr> <tr> <td class=\"centered\">24</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"centered\">25</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"centered\">26</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">27-30</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"centered\">31-32<sup>&#916;</sup></td> <td class=\"centered\">4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The above schedule detects prethreshold ROP with 99 percent confidence, usually well before any required treatment.<br />¶ Because of the small numbers of survivors in these gestational categories, this guideline should be considered tentative rather than evidence based.<br />Δ If necessary.</div><div id=\"graphicVersion\">Graphic 77995 Version 4.0</div></div></div>"},"77996":{"type":"graphic_picture","displayName":"Traumatic retinal detachment","title":"Traumatic retinal detachment","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traumatic retinal detachment</div><div class=\"cntnt\"><img style=\"width:369px; height:277px;\" src=\"images/PC/77996_Traumatic_retinal_detachmen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Wide field fundus photograph of an inferotemporal retinal detachment. Note the corrugated appearance of the retina inferotemporally. The focus of the photograph is on the elevated, undulating retinal detachment and thus the optic nerve is out of focus.</div><div class=\"graphic_reference\">Reproduced with permission from: Ryan SJ, Langmore SE, Hinton D, Ogden TE. The Retina, 3rd ed, Volume 3: Surgical Retina, Mosby-Year Book, Inc., St. Louis 2001. Copyright &#169; 2001 Elsevier Science.</div><div id=\"graphicVersion\">Graphic 77996 Version 2.0</div></div></div>"},"77997":{"type":"graphic_figure","displayName":"Heart rate and O2 at exercise","title":"Heart rate and oxygen consumption during exercise","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Heart rate and oxygen consumption during exercise</div><div class=\"cntnt\"><img style=\"width:422px; height:322px;\" src=\"images/PULM/77997_Heart_rate_and_O2_at_exerci.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the heart rate - oxygen uptake (VO<sub>2</sub>) relationship during incremental exercise in normal (red circles) and well-trained individuals (blue squares).</div><div id=\"graphicVersion\">Graphic 77997 Version 2.0</div></div></div>"},"77998":{"type":"graphic_diagnosticimage","displayName":"Fixation of proximal humerus fracture","title":"Surgical fixation of a proximal humerus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Surgical fixation of a proximal humerus fracture</div><div class=\"cntnt\"><img style=\"width:324px; height:350px;\" src=\"images/EM/77998_Fixation_prox_humerus_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This postoperative anteroposterior radiograph shows the result of an open reduction and internal fixation of a displaced proximal humerus fracture. Preoperatively, this&nbsp;injury was&nbsp;categorized as \"two-part\" fracture using the Neer classification system.</div><div class=\"graphic_reference\">Courtesy of Rebecca Bassett, MD.</div><div id=\"graphicVersion\">Graphic 77998 Version 3.0</div></div></div>"},"77999":{"type":"graphic_figure","displayName":"Syndesmosis (interosseous ligament)","title":"Syndesmosis (interosseous ligament)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Syndesmosis (interosseous ligament)</div><div class=\"cntnt\"><img style=\"width:433px; height:632px;\" src=\"images/EM/77999_Syndesmosis_edt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior view of the tibia and fibula. The interosseous ligament is a thick osseofascial membrane that runs the length of the tibia and fibula and terminates distally in the thicker syndesmosis.</div><div id=\"graphicVersion\">Graphic 77999 Version 4.0</div></div></div>"}};